assay_tissue,src_id,assay_type,description,src_assay_id,assay_cell_type,tid,bao_format,assay_organism,chembl_id,assay_test_type,assay_tax_id,tissue_id,assay_category,relationship_type,curated_by,doc_id,confidence_score,cell_id,assay_id,assay_subcellular_fraction,assay_strain,variant_id
,1.0,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,12052.0,BAO_0000019,,CHEMBL615117,,,,,H,Autocuration,11087.0,8.0,,1.0,,,
,1.0,F,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,22226.0,BAO_0000219,,CHEMBL615118,,,,,U,Autocuration,684.0,0.0,,2.0,,,
,1.0,B,,,,22226.0,BAO_0000019,,CHEMBL615119,,,,,U,Autocuration,15453.0,0.0,,3.0,,,
,1.0,B,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,104729.0,BAO_0000249,Bos taurus,CHEMBL615120,,9913.0,,,H,Autocuration,17841.0,4.0,,4.0,,,
,1.0,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615121,,9606.0,,,N,Intermediate,17430.0,1.0,163.0,5.0,,,
,1.0,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615122,,9606.0,,,N,Intermediate,17430.0,1.0,163.0,6.0,,,
,1.0,F,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,143B,80001.0,BAO_0000219,Mus musculus,CHEMBL615123,,10090.0,,,N,Intermediate,13799.0,1.0,163.0,7.0,,,
,1.0,F,In vitro cell cytotoxicity was determined against 143B cell line,,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615124,,9606.0,,,N,Expert,17774.0,1.0,163.0,8.0,,,
,1.0,F,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615125,,9606.0,,,N,Intermediate,3801.0,1.0,163.0,9.0,,,
,1.0,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615126,,9606.0,,,N,Intermediate,17430.0,1.0,163.0,10.0,,,
,1.0,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615127,,9606.0,,,N,Intermediate,17430.0,1.0,163.0,11.0,,,
,1.0,F,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,143B,80001.0,BAO_0000219,Homo sapiens,CHEMBL615128,,9606.0,,,N,Expert,17774.0,1.0,163.0,12.0,,,
,1.0,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185.0,BAO_0000218,Staphylococcus aureus,CHEMBL857900,,1280.0,,,N,Intermediate,11324.0,1.0,,13.0,,,
,1.0,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185.0,BAO_0000218,Staphylococcus aureus,CHEMBL615129,,1280.0,,,N,Intermediate,11324.0,1.0,,14.0,,,
,1.0,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185.0,BAO_0000218,Staphylococcus aureus,CHEMBL615130,,1280.0,,,N,Intermediate,11324.0,1.0,,15.0,,,
,1.0,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,50185.0,BAO_0000218,Staphylococcus aureus,CHEMBL615131,,1280.0,,,N,Intermediate,11324.0,1.0,,16.0,,,
,1.0,A,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,100122.0,BAO_0000357,Rattus norvegicus,CHEMBL884521,,10116.0,,,D,Expert,11347.0,9.0,,17.0,,,
,1.0,B,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,12054.0,BAO_0000357,,CHEMBL615132,,,,,H,Autocuration,16474.0,8.0,,18.0,,,
,1.0,B,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,12054.0,BAO_0000019,,CHEMBL615133,,,,,H,Autocuration,10091.0,8.0,,19.0,,,
,1.0,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054.0,BAO_0000357,,CHEMBL615134,,,,,H,Autocuration,16474.0,8.0,,20.0,,,
,1.0,B,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,12054.0,BAO_0000357,,CHEMBL615135,,,,,H,Autocuration,16474.0,8.0,,21.0,,,
,1.0,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,12054.0,BAO_0000357,,CHEMBL615136,,,,,H,Autocuration,16474.0,8.0,,22.0,,,
,1.0,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054.0,BAO_0000357,,CHEMBL615137,,,,,H,Autocuration,16474.0,8.0,,23.0,,,
,1.0,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,12054.0,BAO_0000357,,CHEMBL615138,,,,,H,Autocuration,16474.0,8.0,,24.0,,,
,1.0,B,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,22226.0,BAO_0000219,,CHEMBL836324,,,,,U,Autocuration,14352.0,0.0,,25.0,,,
,1.0,B,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,12054.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL615139,,9986.0,,,H,Autocuration,5646.0,8.0,,26.0,,,
,1.0,B,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,12054.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL615140,,9986.0,,,H,Autocuration,5646.0,8.0,,27.0,,,
,1.0,B,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,12426.0,BAO_0000219,,CHEMBL615141,,,,,H,Autocuration,10997.0,8.0,,28.0,,,
,1.0,B,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,12054.0,BAO_0000357,soya bean,CHEMBL615142,,3847.0,,,H,Autocuration,6309.0,8.0,,29.0,,,
,1.0,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,12054.0,BAO_0000357,Glycine max,CHEMBL615143,,3847.0,,,H,Autocuration,167.0,8.0,,30.0,,,
,1.0,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,12054.0,BAO_0000357,Glycine max,CHEMBL615144,,3847.0,,,H,Autocuration,167.0,8.0,,31.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,12054.0,BAO_0000357,Glycine max,CHEMBL872867,,3847.0,,,H,Autocuration,11087.0,8.0,,32.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,12054.0,BAO_0000357,Glycine max,CHEMBL615145,,3847.0,,,H,Autocuration,11087.0,8.0,,33.0,,,
,1.0,B,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054.0,BAO_0000357,Glycine max,CHEMBL615146,,3847.0,,,H,Autocuration,13622.0,8.0,,34.0,,,
,1.0,B,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,12054.0,BAO_0000357,Glycine max,CHEMBL615147,,3847.0,,,H,Autocuration,13622.0,8.0,,35.0,,,
,1.0,A,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615148,,10116.0,,,U,Autocuration,11347.0,0.0,,36.0,,,
,1.0,B,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,22226.0,BAO_0000019,Escherichia coli,CHEMBL615149,,562.0,,,U,Autocuration,5926.0,0.0,,37.0,,,
,1.0,B,Dissociation constant with dimeric 16S rRNA RNA construct B,,,22226.0,BAO_0000019,,CHEMBL615150,,,,,U,Autocuration,4567.0,0.0,,38.0,,,
,1.0,B,Dissociation constant towards 16S rRNA construct A,,,22222.0,BAO_0000225,,CHEMBL615151,,,,,M,Intermediate,3782.0,3.0,,39.0,,,
,1.0,B,Dissociation constant towards 16S rRNA construct B,,,22222.0,BAO_0000225,,CHEMBL615152,,,,,M,Intermediate,3782.0,3.0,,40.0,,,
,1.0,B,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,100263.0,BAO_0000225,Escherichia coli,CHEMBL615153,,562.0,,,M,Expert,4466.0,3.0,,41.0,,,
,1.0,B,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,100263.0,BAO_0000225,Escherichia coli,CHEMBL615154,,562.0,,,M,Expert,6592.0,3.0,,42.0,,,
,1.0,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053.0,BAO_0000019,,CHEMBL615155,,,,,H,Autocuration,898.0,8.0,,43.0,,,
,1.0,B,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053.0,BAO_0000019,,CHEMBL615156,,,,,H,Autocuration,898.0,8.0,,44.0,,,
,1.0,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001.0,BAO_0000019,Homo sapiens,CHEMBL615157,,9606.0,,,H,Autocuration,13163.0,8.0,,45.0,,,
,1.0,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,20001.0,BAO_0000019,Homo sapiens,CHEMBL615158,,9606.0,,,H,Autocuration,13163.0,8.0,,46.0,,,
,1.0,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971.0,BAO_0000019,Rattus norvegicus,CHEMBL615159,,10116.0,,,D,Expert,10691.0,9.0,,47.0,,,
,1.0,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,12971.0,BAO_0000019,Rattus norvegicus,CHEMBL615172,,10116.0,,,D,Expert,10691.0,9.0,,48.0,,,
,1.0,B,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971.0,BAO_0000019,Rattus norvegicus,CHEMBL615173,,10116.0,,,D,Expert,10691.0,9.0,,49.0,,,
,1.0,B,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,12971.0,BAO_0000019,Rattus norvegicus,CHEMBL615174,,10116.0,,,D,Expert,10691.0,9.0,,50.0,,,
,1.0,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,13053.0,BAO_0000019,,CHEMBL884518,,,,,H,Autocuration,898.0,8.0,,51.0,,,
,1.0,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,11512.0,BAO_0000357,,CHEMBL615175,,,,,H,Autocuration,912.0,8.0,,52.0,,,
,1.0,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,11512.0,BAO_0000357,,CHEMBL615176,,,,,H,Autocuration,912.0,8.0,,53.0,,,
,1.0,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,11512.0,BAO_0000357,,CHEMBL615177,,,,,H,Autocuration,912.0,8.0,,54.0,,,
,1.0,B,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,104740.0,BAO_0000249,Rattus norvegicus,CHEMBL615178,,10116.0,,,D,Autocuration,15103.0,5.0,,55.0,Membranes,,
,1.0,F,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615179,,9606.0,,,N,Intermediate,5116.0,1.0,506.0,56.0,,,
,1.0,F,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Oocytes,104835.0,BAO_0000219,Rattus norvegicus,CHEMBL615180,,10116.0,,,D,Autocuration,14578.0,7.0,,57.0,,,
,1.0,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Oocytes,104821.0,BAO_0000219,Rattus norvegicus,CHEMBL615181,,10116.0,,,D,Autocuration,14578.0,7.0,,58.0,,,
,1.0,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Oocytes,104848.0,BAO_0000219,Rattus norvegicus,CHEMBL615182,,10116.0,,,D,Autocuration,14578.0,7.0,,59.0,,,
,1.0,F,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615183,,9606.0,,,N,Expert,4787.0,1.0,506.0,60.0,,,
,1.0,F,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615184,,9606.0,,,N,Intermediate,4787.0,1.0,506.0,61.0,,,
,1.0,F,Cytotoxic activity against human ovarian cancer (1A9) cell line,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615185,,9606.0,,,N,Intermediate,3547.0,1.0,506.0,62.0,,,
,1.0,F,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615186,,9606.0,,,N,Intermediate,3547.0,1.0,506.0,63.0,,,
,1.0,F,Effective dose of compound against replication of 1A9 cell line was evaluated,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615187,,9606.0,,,N,Intermediate,6726.0,1.0,506.0,64.0,,,
,1.0,F,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL885343,,9606.0,,,N,Expert,3455.0,1.0,506.0,65.0,,,
,1.0,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615188,,9606.0,,,N,Intermediate,5726.0,1.0,506.0,66.0,,,
,1.0,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615189,,9606.0,,,N,Intermediate,5726.0,1.0,506.0,67.0,,,
,1.0,F,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615190,,9606.0,,,N,Intermediate,5726.0,1.0,506.0,68.0,,,
,1.0,F,Inhibitory activity against Taxol resistant 1A9 cell lines,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615191,,9606.0,,,N,Intermediate,3395.0,1.0,506.0,69.0,,,
,1.0,F,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615192,,9606.0,,,N,Expert,3415.0,1.0,506.0,70.0,,,
,1.0,F,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL827083,,9606.0,,,N,Expert,3415.0,1.0,506.0,71.0,,,
,1.0,F,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615193,,9606.0,,,N,Expert,17099.0,1.0,506.0,72.0,,,
,1.0,F,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615194,,9606.0,,,N,Intermediate,17099.0,1.0,506.0,73.0,,,
,1.0,F,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615195,,9606.0,,,N,Intermediate,17099.0,1.0,506.0,74.0,,,
,1.0,F,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,1A9,80002.0,BAO_0000219,Homo sapiens,CHEMBL615196,,9606.0,,,N,Intermediate,17099.0,1.0,506.0,75.0,,,
,1.0,F,Inhibitory concentration against Jurkat cells,,Jurkat,81072.0,BAO_0000219,Homo sapiens,CHEMBL615197,,9606.0,,,N,Intermediate,17721.0,1.0,503.0,76.0,,,
,1.0,F,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL615198,,,,,U,Intermediate,1229.0,0.0,,77.0,,,
,1.0,A,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,100121.0,BAO_0000357,Rattus norvegicus,CHEMBL615199,,10116.0,,,D,Expert,11347.0,9.0,,78.0,,,
,1.0,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231.0,BAO_0000357,,CHEMBL615200,,,,,H,Expert,17117.0,8.0,,79.0,,,
,1.0,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,11231.0,BAO_0000357,,CHEMBL615201,,,,,H,Expert,17117.0,8.0,,80.0,,,
,1.0,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,11231.0,BAO_0000357,,CHEMBL615202,,,,,H,Expert,17117.0,8.0,,81.0,,,
,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,11231.0,BAO_0000251,Candida albicans,CHEMBL615203,,5476.0,,,H,Autocuration,11375.0,8.0,,82.0,Microsomes,,
,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,11231.0,BAO_0000251,Candida albicans,CHEMBL615204,,5476.0,,,H,Autocuration,11375.0,8.0,,83.0,Microsomes,,
,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,11231.0,BAO_0000251,Saccharomyces cerevisiae,CHEMBL615205,,4932.0,,,H,Autocuration,11375.0,8.0,,84.0,Microsomes,,
,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,11231.0,BAO_0000251,Saccharomyces cerevisiae,CHEMBL615206,,4932.0,,,H,Autocuration,11375.0,8.0,,85.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,12083.0,BAO_0000251,Sus scrofa,CHEMBL615207,,9823.0,2107.0,,H,Autocuration,11375.0,8.0,,86.0,Microsomes,,
,1.0,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,11231.0,BAO_0000019,Rattus norvegicus,CHEMBL827084,,10116.0,,,H,Autocuration,791.0,8.0,,87.0,,,
,1.0,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,11231.0,BAO_0000019,Rattus norvegicus,CHEMBL615208,,10116.0,,,H,Autocuration,791.0,8.0,,88.0,,,
,1.0,B,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,11231.0,BAO_0000019,Rattus norvegicus,CHEMBL615209,,10116.0,,,H,Autocuration,791.0,8.0,,89.0,,,
Liver,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,12083.0,BAO_0000251,Rattus norvegicus,CHEMBL615210,,10116.0,2107.0,,D,Autocuration,11375.0,9.0,,90.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,12083.0,BAO_0000251,Rattus norvegicus,CHEMBL615211,,10116.0,2107.0,,D,Autocuration,11375.0,9.0,,91.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,12083.0,BAO_0000251,Rattus norvegicus,CHEMBL615212,,10116.0,2107.0,,D,Autocuration,153.0,9.0,,92.0,Microsomes,,
,1.0,B,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,11377.0,BAO_0000357,,CHEMBL615213,,,,,H,Expert,8269.0,8.0,,93.0,,,
,1.0,B,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,11377.0,BAO_0000357,,CHEMBL615273,,,,,H,Expert,8269.0,8.0,,94.0,,,
,1.0,F,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615274,,9606.0,,,N,Expert,17653.0,1.0,726.0,95.0,,,
,1.0,F,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615275,,9606.0,,,N,Intermediate,14277.0,1.0,726.0,96.0,,,
,1.0,F,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615276,,9606.0,,,N,Intermediate,1717.0,1.0,726.0,97.0,,,
,1.0,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615277,,9606.0,,,N,Intermediate,14091.0,1.0,726.0,98.0,,,
,1.0,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615326,,9606.0,,,N,Intermediate,14091.0,1.0,726.0,99.0,,,
,1.0,F,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,50606.0,BAO_0000218,Hepatitis B virus,CHEMBL883130,,10407.0,,,N,Expert,17653.0,1.0,,100.0,,,
,1.0,F,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL884519,,9606.0,,,N,Intermediate,13105.0,1.0,726.0,101.0,,,
,1.0,F,Concentration required to inhibit 50% of 2.2.15 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615327,,9606.0,,,N,Intermediate,1717.0,1.0,726.0,102.0,,,
,1.0,A,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615328,,9606.0,,,N,Intermediate,13105.0,1.0,726.0,103.0,,,
,1.0,F,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615329,,9606.0,,,N,Intermediate,13600.0,1.0,,104.0,,,
,1.0,F,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615330,,9606.0,,,N,Intermediate,13467.0,1.0,,105.0,,,
,1.0,F,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,2.2.15,50606.0,BAO_0000218,Hepatitis B virus,CHEMBL615331,,10407.0,,,N,Expert,17477.0,1.0,,106.0,,,
,1.0,F,In vitro anti-HBV activity in 2.2.15 cells,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615332,,9606.0,,,N,Intermediate,1593.0,1.0,,107.0,,,
,1.0,F,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615333,,9606.0,,,N,Intermediate,1593.0,1.0,,108.0,,,
,1.0,F,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615334,,9606.0,,,N,Intermediate,15089.0,1.0,,109.0,,,
,1.0,F,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615335,,9606.0,,,N,Intermediate,15089.0,1.0,,110.0,,,
,1.0,F,Cytotoxicity in 2.2.15 cells,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615336,,9606.0,,,N,Intermediate,1593.0,1.0,,111.0,,,
,1.0,F,Cytotoxicity in 2.2.15 cells; Not determined,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615337,,9606.0,,,N,Intermediate,1593.0,1.0,,112.0,,,
,1.0,F,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615338,,9606.0,,,N,Intermediate,13600.0,1.0,,113.0,,,
,1.0,F,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615339,,9606.0,,,N,Intermediate,13467.0,1.0,,114.0,,,
,1.0,F,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,2.2.15,50587.0,BAO_0000218,Homo sapiens,CHEMBL615340,,9606.0,,,N,Intermediate,13467.0,1.0,,115.0,,,
,1.0,F,Antiviral activity against HBV was determined in 2.215 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615341,,9606.0,,,N,Intermediate,14764.0,1.0,726.0,116.0,,,
,1.0,B,Inhibition of 20-HETE synthesis in human renal microsomes,,,22226.0,BAO_0000251,Homo sapiens,CHEMBL615342,,9606.0,,,U,Autocuration,6531.0,0.0,,117.0,Microsomes,,
,1.0,B,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,22226.0,BAO_0000019,,CHEMBL615343,,,,,U,Autocuration,17322.0,0.0,,118.0,,,
,1.0,F,Inhibitory concentration against 2008 (ovarian) cells,,2008,80612.0,BAO_0000219,Homo sapiens,CHEMBL615344,,9606.0,,,N,Intermediate,17072.0,1.0,388.0,119.0,,,
,1.0,F,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,2008,80612.0,BAO_0000219,Homo sapiens,CHEMBL615345,,9606.0,,,N,Intermediate,16936.0,1.0,388.0,120.0,,,
,1.0,F,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,2008,80612.0,BAO_0000219,Homo sapiens,CHEMBL615346,,9606.0,,,N,Intermediate,16936.0,1.0,388.0,121.0,,,
,1.0,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,2008,80612.0,BAO_0000219,Homo sapiens,CHEMBL615347,,9606.0,,,N,Intermediate,17146.0,1.0,388.0,122.0,,,
,1.0,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,2008,80612.0,BAO_0000219,Homo sapiens,CHEMBL615348,,9606.0,,,N,Intermediate,17146.0,1.0,388.0,123.0,,,
,1.0,F,In vitro inhibition of 2008/R ovarian cancer cell line,,2008/R,80613.0,BAO_0000219,Homo sapiens,CHEMBL827085,,9606.0,,,N,Intermediate,10797.0,1.0,561.0,124.0,,,
,1.0,F,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,2008/R,80613.0,BAO_0000219,Homo sapiens,CHEMBL615349,,9606.0,,,N,Intermediate,10797.0,1.0,561.0,125.0,,,
,1.0,F,In vitro inhibition of 2008/S ovarian cancer cell line,,2008/S,80614.0,BAO_0000219,Homo sapiens,CHEMBL615350,,9606.0,,,N,Intermediate,10797.0,1.0,389.0,126.0,,,
,1.0,F,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,2008/S,80614.0,BAO_0000219,Homo sapiens,CHEMBL615351,,9606.0,,,N,Intermediate,10797.0,1.0,389.0,127.0,,,
,1.0,B,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,100256.0,BAO_0000220,Homo sapiens,CHEMBL615352,,9606.0,,,S,Expert,4823.0,2.0,,128.0,,,
,1.0,B,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,100256.0,BAO_0000220,Homo sapiens,CHEMBL615353,,9606.0,,,S,Intermediate,12912.0,2.0,,129.0,,,
,1.0,B,Inhibition of chymotrypsin-like activity of 20S proteasome,,,100256.0,BAO_0000220,,CHEMBL615354,,,,,S,Expert,2957.0,2.0,,130.0,,,
,1.0,B,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,100256.0,BAO_0000220,,CHEMBL615355,,,,,S,Expert,2957.0,2.0,,131.0,,,
,1.0,B,Inhibitory activity against 20S proteosome,,,100256.0,BAO_0000220,,CHEMBL615356,,,,,S,Intermediate,3260.0,2.0,,132.0,,,
,1.0,B,Compound was tested for inhibitory activity against tryptase,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615357,,9606.0,,,U,Autocuration,3451.0,0.0,,133.0,,,
,1.0,F,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL615358,,9606.0,,,N,Intermediate,13885.0,1.0,726.0,134.0,,,
,1.0,F,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,HepG2,81020.0,BAO_0000219,Homo sapiens,CHEMBL827086,,9606.0,,,N,Intermediate,13885.0,1.0,726.0,135.0,,,
,1.0,B,Compound was tested for the inhibition of Alpha-glucosidase,,,22226.0,BAO_0000019,,CHEMBL615359,,,,,U,Autocuration,3676.0,0.0,,136.0,,,
,1.0,B,Inhibitory concentration against human neutrophil elastase (HNE),,,235.0,BAO_0000357,,CHEMBL615360,,,,,H,Autocuration,6043.0,8.0,,137.0,,,
Heart,1.0,F,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615361,,10116.0,948.0,,U,Autocuration,11140.0,0.0,,138.0,,,
,1.0,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640.0,BAO_0000019,,CHEMBL615362,,,,,H,Autocuration,10543.0,8.0,,139.0,,,
,1.0,F,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640.0,BAO_0000019,,CHEMBL615363,,,,,H,Expert,10543.0,8.0,,140.0,,,
,1.0,B,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640.0,BAO_0000357,,CHEMBL615364,,,,,H,Autocuration,10543.0,8.0,,141.0,,,
,1.0,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,19640.0,BAO_0000019,,CHEMBL615365,,,,,H,Expert,10543.0,8.0,,142.0,,,
,1.0,F,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,P338,80360.0,BAO_0000219,Mus musculus,CHEMBL615366,,10090.0,,,N,Intermediate,11365.0,1.0,524.0,143.0,,,
,1.0,F,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,P338,80360.0,BAO_0000219,Mus musculus,CHEMBL615367,,10090.0,,,N,Intermediate,11365.0,1.0,524.0,144.0,,,
,1.0,F,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,PBL,80384.0,BAO_0000219,Homo sapiens,CHEMBL615368,,9606.0,,,N,Intermediate,11803.0,1.0,554.0,145.0,,,
,1.0,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,22226.0,BAO_0000019,Ovis aries,CHEMBL615369,,9940.0,,,U,Autocuration,11803.0,0.0,,146.0,,,
,1.0,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,22226.0,BAO_0000019,Ovis aries,CHEMBL615370,,9940.0,,,U,Autocuration,11803.0,0.0,,147.0,,,
,1.0,B,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,191.0,BAO_0000357,,CHEMBL615673,,,,,H,Autocuration,12278.0,8.0,,148.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615674,,9606.0,,,U,Autocuration,8249.0,0.0,,149.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615675,,9606.0,,,U,Autocuration,8249.0,0.0,,150.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,CCRF-CEM,22226.0,BAO_0000219,Homo sapiens,CHEMBL615676,,9606.0,,,U,Autocuration,8249.0,0.0,635.0,151.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,CCRF-CEM,22226.0,BAO_0000219,Homo sapiens,CHEMBL615677,,9606.0,,,U,Autocuration,8249.0,0.0,635.0,152.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,CCRF-CEM,22226.0,BAO_0000219,Homo sapiens,CHEMBL615678,,9606.0,,,U,Autocuration,8249.0,0.0,635.0,153.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,CCRF-CEM,22226.0,BAO_0000219,Homo sapiens,CHEMBL615679,,9606.0,,,U,Autocuration,8249.0,0.0,635.0,154.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615680,,9606.0,,,U,Autocuration,8249.0,0.0,,155.0,,,
,1.0,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615681,,9606.0,,,U,Autocuration,8249.0,0.0,,156.0,,,
,1.0,B,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,104290.0,BAO_0000249,,CHEMBL857972,,,,,H,Autocuration,16992.0,6.0,,157.0,,,
,1.0,F,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,50264.0,BAO_0000218,Streptococcus pyogenes,CHEMBL857899,,1314.0,,,N,Intermediate,10543.0,1.0,,158.0,,,
,1.0,F,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,50527.0,BAO_0000218,Human herpesvirus 3,CHEMBL615371,,10335.0,,,N,Intermediate,17833.0,1.0,,159.0,,,
,1.0,F,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,HEL,50527.0,BAO_0000218,vericilla zoster virus,CHEMBL615372,,10335.0,,,N,Expert,17290.0,1.0,468.0,160.0,,,
,1.0,F,Antiviral activity against 07/1 strain of VZV; ND: No data,,,50527.0,BAO_0000218,vericilla zoster virus,CHEMBL615373,,10335.0,,,N,Intermediate,17290.0,1.0,,161.0,,,
,1.0,F,Antiviral activity against 07/1 strain of VZV; ND=No data,,,50527.0,BAO_0000218,vericilla zoster virus,CHEMBL615374,,10335.0,,,N,Intermediate,17290.0,1.0,,162.0,,,
,1.0,F,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,50145.0,BAO_0000218,escherichia cloac,CHEMBL615375,,561.0,,,N,Intermediate,10932.0,1.0,,163.0,,,
,1.0,B,Ratio of Ki at A2 to Ki at A1 receptors,,,22226.0,BAO_0000019,,CHEMBL615376,,,,,U,Autocuration,9707.0,0.0,,164.0,,,
,1.0,B,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,11143.0,BAO_0000249,Candida albicans,CHEMBL615377,,5476.0,,,H,Expert,2346.0,8.0,,165.0,,,
,1.0,B,"Inhibition of 1,3-beta-glucan synthase",,,18077.0,BAO_0000357,Candida glabrata CBS 138,CHEMBL615378,,284593.0,,,H,Expert,2205.0,8.0,,166.0,,,
,1.0,F,Inhibition of growth of 1-87 human tumor cell line,,1-87 tumor cell line,80609.0,BAO_0000219,Homo sapiens,CHEMBL615379,,9606.0,,,N,Intermediate,11900.0,1.0,832.0,167.0,,,
,1.0,B,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL615380,,10116.0,,,D,Expert,14864.0,9.0,,168.0,,,
,1.0,B,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,100171.0,BAO_0000357,Glycine max,CHEMBL615381,,3847.0,,,D,Autocuration,16474.0,9.0,,169.0,,,
,1.0,B,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,100171.0,BAO_0000357,Glycine max,CHEMBL615382,,3847.0,,,D,Autocuration,16474.0,9.0,,170.0,,,
,1.0,B,% inhibition against soybean 1-lipoxygenase (SLO),,,100171.0,BAO_0000357,Glycine max,CHEMBL615383,,3847.0,,,D,Autocuration,16474.0,9.0,,171.0,,,
,1.0,B,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,100171.0,BAO_0000357,Glycine max,CHEMBL615384,,3847.0,,,D,Autocuration,16474.0,9.0,,172.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,100171.0,BAO_0000357,Glycine max,CHEMBL615385,,3847.0,,,D,Autocuration,3094.0,9.0,,173.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,100171.0,BAO_0000357,Glycine max,CHEMBL615386,,3847.0,,,D,Autocuration,3094.0,9.0,,174.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,100171.0,BAO_0000357,Glycine max,CHEMBL615387,,3847.0,,,D,Autocuration,3094.0,9.0,,175.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,100171.0,BAO_0000357,Glycine max,CHEMBL615388,,3847.0,,,D,Autocuration,3094.0,9.0,,176.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,100171.0,BAO_0000357,Glycine max,CHEMBL615214,,3847.0,,,D,Autocuration,3094.0,9.0,,177.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,100171.0,BAO_0000357,Glycine max,CHEMBL827087,,3847.0,,,D,Autocuration,3094.0,9.0,,178.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,100171.0,BAO_0000357,Glycine max,CHEMBL615215,,3847.0,,,D,Autocuration,3094.0,9.0,,179.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,100171.0,BAO_0000357,Glycine max,CHEMBL615216,,3847.0,,,D,Autocuration,3094.0,9.0,,180.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,100171.0,BAO_0000357,Glycine max,CHEMBL615217,,3847.0,,,D,Autocuration,3094.0,9.0,,181.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,100171.0,BAO_0000357,Glycine max,CHEMBL615218,,3847.0,,,D,Autocuration,3094.0,9.0,,182.0,,,
,1.0,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,100171.0,BAO_0000357,Glycine max,CHEMBL615219,,3847.0,,,D,Autocuration,3094.0,9.0,,183.0,,,
,1.0,B,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,22226.0,BAO_0000019,Mus musculus,CHEMBL615220,,10090.0,,,U,Autocuration,10413.0,0.0,,184.0,,,
,1.0,F,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,C3H 10T1/2,80049.0,BAO_0000219,Mus musculus,CHEMBL615221,,10090.0,,,N,Intermediate,16929.0,1.0,294.0,185.0,,,
,1.0,F,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL615222,,,,,U,Intermediate,1229.0,0.0,,186.0,,,
,1.0,B,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11489.0,BAO_0000357,,CHEMBL615223,,,,,H,Autocuration,16587.0,8.0,,187.0,,,
,1.0,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,11862.0,BAO_0000357,,CHEMBL615224,,,,,H,Autocuration,16587.0,8.0,,188.0,,,
,1.0,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,11862.0,BAO_0000357,,CHEMBL615225,,,,,H,Autocuration,16587.0,8.0,,189.0,,,
,1.0,B,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,11489.0,BAO_0000357,,CHEMBL615226,,,,,H,Autocuration,16587.0,8.0,,190.0,,,
,1.0,B,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,11862.0,BAO_0000357,,CHEMBL615227,,,,,H,Autocuration,16587.0,8.0,,191.0,,,
,1.0,F,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,12347.0,BAO_0000019,Bos taurus,CHEMBL615228,,9913.0,,,D,Expert,8058.0,9.0,,192.0,,,
,1.0,B,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,100120.0,BAO_0000357,Rattus norvegicus,CHEMBL615229,,10116.0,,,D,Expert,9065.0,9.0,,193.0,,,
Adrenal gland,1.0,B,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,100120.0,BAO_0000357,Rattus norvegicus,CHEMBL615230,,10116.0,2369.0,,D,Expert,8865.0,9.0,,194.0,,,
,1.0,B,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120.0,BAO_0000357,Rattus norvegicus,CHEMBL615231,,10116.0,,,D,Expert,9066.0,9.0,,195.0,,,
,1.0,B,Inhibition of rat adrenal 11-beta-hydroxylase,,,100120.0,BAO_0000357,Rattus norvegicus,CHEMBL884520,,10116.0,,,D,Expert,8394.0,9.0,,196.0,,,
,1.0,B,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,100120.0,BAO_0000357,Rattus norvegicus,CHEMBL615232,,10116.0,,,D,Expert,8394.0,9.0,,197.0,,,
,1.0,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,10328.0,BAO_0000019,,CHEMBL615233,,,,,H,Autocuration,6431.0,8.0,,198.0,,,
,1.0,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490.0,BAO_0000357,,CHEMBL827088,,,,,H,Autocuration,6431.0,8.0,,199.0,,,
,1.0,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,11490.0,BAO_0000357,,CHEMBL615234,,,,,H,Autocuration,6431.0,8.0,,200.0,,,
,1.0,F,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,11134.0,BAO_0000019,,CHEMBL615235,,,,,H,Autocuration,9295.0,8.0,,201.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052.0,BAO_0000019,,CHEMBL615236,,,,,H,Autocuration,10193.0,8.0,,202.0,,,
,1.0,B,Compound was tested in vitro for inhibition of 12-LO human platelet,,,11134.0,BAO_0000019,,CHEMBL615237,,,,,H,Autocuration,13622.0,8.0,,203.0,,,
,1.0,F,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134.0,BAO_0000019,,CHEMBL615238,,,,,H,Autocuration,12079.0,8.0,,204.0,,,
,1.0,B,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,11134.0,BAO_0000019,,CHEMBL615239,,,,,H,Autocuration,13622.0,8.0,,205.0,,,
,1.0,F,Inhibitory concentration against human platelet 12-lipoxygenase,,,11134.0,BAO_0000019,Homo sapiens,CHEMBL615240,,9606.0,,,D,Autocuration,12079.0,9.0,,206.0,,,
,1.0,B,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,11835.0,BAO_0000019,,CHEMBL615241,,,,,H,Expert,13500.0,8.0,,207.0,,,
,1.0,B,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,11601.0,BAO_0000357,,CHEMBL615242,,,,,H,Expert,13723.0,8.0,,208.0,,,
,1.0,B,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,11134.0,BAO_0000019,,CHEMBL615243,,,,,H,Autocuration,16474.0,8.0,,209.0,,,
,1.0,B,Inhibitory activity against human platelet 12-lipoxygenase,,,11134.0,BAO_0000019,,CHEMBL615244,,,,,H,Autocuration,1630.0,8.0,,210.0,,,
,1.0,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,11134.0,BAO_0000019,,CHEMBL615245,,,,,H,Autocuration,167.0,8.0,,211.0,,,
,1.0,B,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,11134.0,BAO_0000019,,CHEMBL615246,,,,,H,Autocuration,16474.0,8.0,,212.0,,,
,1.0,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,11134.0,BAO_0000019,,CHEMBL615247,,,,,H,Autocuration,167.0,8.0,,213.0,,,
,1.0,B,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,11134.0,BAO_0000019,,CHEMBL615248,,,,,H,Autocuration,16474.0,8.0,,214.0,,,
,1.0,B,Inhibitory activity towards porcine 12-lipoxygenase,,,11601.0,BAO_0000357,,CHEMBL615249,,,,,H,Autocuration,10091.0,8.0,,215.0,,,
,1.0,B,Tested for inhibition against porcine 12-LO,,,11601.0,BAO_0000357,,CHEMBL615250,,,,,H,Autocuration,11966.0,8.0,,216.0,,,
,1.0,B,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,12052.0,BAO_0000019,,CHEMBL615251,,,,,H,Autocuration,951.0,8.0,,217.0,,,
,1.0,B,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,12052.0,BAO_0000019,,CHEMBL615252,,,,,H,Autocuration,10997.0,8.0,,218.0,,,
,1.0,B,In vitro inhibition of rat platelet 12-lipoxygenase,,,12052.0,BAO_0000019,,CHEMBL828340,,,,,H,Expert,10193.0,8.0,,219.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052.0,BAO_0000019,,CHEMBL615253,,,,,H,Autocuration,10193.0,8.0,,220.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,12052.0,BAO_0000019,,CHEMBL615254,,,,,H,Autocuration,10193.0,8.0,,221.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,12052.0,BAO_0000019,,CHEMBL615255,,,,,H,Autocuration,10193.0,8.0,,222.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,12052.0,BAO_0000019,,CHEMBL615256,,,,,H,Autocuration,10193.0,8.0,,223.0,,,
,1.0,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,12052.0,BAO_0000019,,CHEMBL615257,,,,,H,Autocuration,10193.0,8.0,,224.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,12052.0,BAO_0000019,,CHEMBL615258,,,,,H,Autocuration,11087.0,8.0,,225.0,,,
,1.0,F,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615259,,9606.0,,,N,Intermediate,15569.0,1.0,621.0,226.0,,,
,1.0,F,In vitro antitumor activity against 41M cell line.,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615260,,9606.0,,,N,Expert,12989.0,1.0,621.0,227.0,,,
,1.0,F,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615261,,9606.0,,,N,Intermediate,16745.0,1.0,621.0,228.0,,,
,1.0,F,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615262,,9606.0,,,N,Intermediate,15569.0,1.0,621.0,229.0,,,
,1.0,F,In vitro antitumor activity against 41McisR cell line.,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615263,,9606.0,,,N,Expert,12989.0,1.0,621.0,230.0,,,
,1.0,F,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL838393,,9606.0,,,N,Expert,12989.0,1.0,621.0,231.0,,,
,1.0,F,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,41M,80007.0,BAO_0000219,Homo sapiens,CHEMBL615264,,9606.0,,,N,Intermediate,16745.0,1.0,621.0,232.0,,,
,1.0,B,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,84.0,BAO_0000357,Homo sapiens,CHEMBL615265,,9606.0,,,D,Expert,6210.0,9.0,,233.0,,,
,1.0,B,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68.0,BAO_0000357,Homo sapiens,CHEMBL615266,,9606.0,,,D,Expert,6210.0,9.0,,234.0,,,
,1.0,B,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,68.0,BAO_0000357,,CHEMBL615267,,,,,H,Expert,6226.0,8.0,,235.0,,,
,1.0,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201.0,BAO_0000357,,CHEMBL615268,,,,,H,Expert,17855.0,8.0,,236.0,,,
,1.0,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,10201.0,BAO_0000357,,CHEMBL615269,,,,,H,Expert,17855.0,8.0,,237.0,,,
,1.0,B,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,10201.0,BAO_0000357,,CHEMBL615270,,,,,H,Expert,17855.0,8.0,,238.0,,,
,1.0,B,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220.0,BAO_0000357,,CHEMBL615271,,,,,H,Autocuration,10413.0,8.0,,239.0,,,
,1.0,B,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303.0,BAO_0000357,Escherichia coli,CHEMBL615272,,562.0,,,H,Autocuration,10413.0,8.0,,240.0,,,
,1.0,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,11303.0,BAO_0000357,Escherichia coli,CHEMBL615103,,562.0,,,H,Autocuration,10413.0,8.0,,241.0,,,
,1.0,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,11303.0,BAO_0000357,Escherichia coli,CHEMBL615104,,562.0,,,H,Autocuration,10413.0,8.0,,242.0,,,
,1.0,B,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,12220.0,BAO_0000357,,CHEMBL615105,,,,,H,Autocuration,10413.0,8.0,,243.0,,,
,1.0,B,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,12220.0,BAO_0000357,,CHEMBL872866,,,,,H,Autocuration,10413.0,8.0,,244.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303.0,BAO_0000357,Sus scrofa,CHEMBL615106,,9823.0,,,H,Autocuration,7587.0,8.0,,245.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615107,,9823.0,,,H,Autocuration,7587.0,8.0,,246.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,11303.0,BAO_0000357,Sus scrofa,CHEMBL615108,,9823.0,,,H,Autocuration,7587.0,8.0,,247.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,11303.0,BAO_0000357,Sus scrofa,CHEMBL615109,,9823.0,,,H,Autocuration,7587.0,8.0,,248.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303.0,BAO_0000357,Sus scrofa,CHEMBL615110,,9823.0,,,H,Autocuration,7587.0,8.0,,249.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL840105,,9823.0,,,H,Autocuration,7587.0,8.0,,250.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615111,,9823.0,,,H,Autocuration,7587.0,8.0,,251.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615112,,9823.0,,,H,Autocuration,7587.0,8.0,,252.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615113,,9823.0,,,H,Autocuration,7587.0,8.0,,253.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615114,,9823.0,,,H,Autocuration,7587.0,8.0,,254.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,11303.0,BAO_0000357,Sus scrofa,CHEMBL615115,,9823.0,,,H,Autocuration,7587.0,8.0,,255.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,11303.0,BAO_0000019,Sus scrofa,CHEMBL615116,,9823.0,,,H,Autocuration,7587.0,8.0,,256.0,,,
,1.0,B,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,11303.0,BAO_0000357,,CHEMBL615698,,,,,H,Autocuration,7323.0,8.0,,257.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,22226.0,BAO_0000019,Sus scrofa,CHEMBL615699,,9823.0,,,U,Autocuration,7587.0,0.0,,258.0,,,
,1.0,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,22226.0,BAO_0000019,Sus scrofa,CHEMBL615700,,9823.0,,,U,Autocuration,7587.0,0.0,,259.0,,,
,1.0,B,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,100249.0,BAO_0000357,Saccharomyces cerevisiae,CHEMBL615701,,4932.0,,,H,Expert,13750.0,8.0,,260.0,,,
,1.0,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615702,,10116.0,,,U,Autocuration,7662.0,0.0,,261.0,,,
,1.0,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615703,,10116.0,,,U,Autocuration,7662.0,0.0,,262.0,,,
,1.0,B,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615704,,10116.0,,,U,Autocuration,7662.0,0.0,,263.0,,,
,1.0,F,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698.0,BAO_0000019,,CHEMBL615705,,,,,H,Autocuration,12211.0,6.0,,264.0,,,
,1.0,F,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,104698.0,BAO_0000019,,CHEMBL615706,,,,,H,Autocuration,12211.0,6.0,,265.0,,,
Ileum,1.0,F,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL615707,,10141.0,2116.0,,D,Intermediate,12211.0,9.0,,266.0,,,
,1.0,F,Stimulatory activity of intragastric pressure was tested in the rat,,,10623.0,BAO_0000019,,CHEMBL615708,,,,,H,Expert,12211.0,8.0,,267.0,,,
,1.0,B,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,121.0,BAO_0000357,,CHEMBL615709,,,,,H,Autocuration,15453.0,8.0,,268.0,,,
,1.0,F,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615710,,10116.0,,,U,Autocuration,11884.0,0.0,,269.0,,,
,1.0,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,12688.0,BAO_0000019,,CHEMBL615711,,,,,H,Autocuration,7185.0,8.0,,270.0,,,
,1.0,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,121.0,BAO_0000357,Homo sapiens,CHEMBL615712,,9606.0,,,D,Expert,6876.0,9.0,,271.0,,,
,1.0,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,121.0,BAO_0000357,Homo sapiens,CHEMBL836325,,9606.0,,,D,Expert,6876.0,9.0,,272.0,,,
,1.0,F,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,12198.0,BAO_0000019,,CHEMBL615713,,,,,H,Autocuration,11863.0,8.0,,273.0,,,
,1.0,B,Inhibition constant of high-affinity 5-HT uptake,,,12198.0,BAO_0000357,,CHEMBL615714,,,,,H,Autocuration,11863.0,8.0,,274.0,,,
,1.0,F,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,12198.0,BAO_0000019,,CHEMBL615715,,,,,H,Autocuration,11863.0,8.0,,275.0,,,
,1.0,F,Maximum rate was determined for high affinity transport of 5-HT,,,12198.0,BAO_0000019,,CHEMBL615716,,,,,H,Autocuration,11863.0,8.0,,276.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-HT uptake,,,104714.0,BAO_0000019,,CHEMBL615717,,,,,H,Autocuration,4639.0,4.0,,277.0,,,
,1.0,B,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,10577.0,BAO_0000019,,CHEMBL881818,,,,,H,Expert,15796.0,8.0,,278.0,,,
,1.0,B,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,105.0,BAO_0000357,Bos taurus,CHEMBL884540,,9913.0,,,H,Expert,15796.0,8.0,,279.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,104744.0,BAO_0000224,Rattus norvegicus,CHEMBL615718,,10116.0,,,D,Autocuration,12801.0,5.0,,280.0,,,
,1.0,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,104744.0,BAO_0000224,,CHEMBL615719,,,,,H,Autocuration,12801.0,4.0,,281.0,,,
,1.0,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,104744.0,BAO_0000249,,CHEMBL615720,,,,,H,Autocuration,12120.0,4.0,,282.0,Membranes,,
,1.0,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,104744.0,BAO_0000249,,CHEMBL615721,,,,,H,Autocuration,12120.0,4.0,,283.0,Membranes,,
,1.0,B,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744.0,BAO_0000019,,CHEMBL615722,,,,,H,Autocuration,11963.0,4.0,,284.0,,,
,1.0,F,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,51.0,BAO_0000019,,CHEMBL615723,,,,,H,Autocuration,11701.0,8.0,,285.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615724,,,10000000.0,,H,Autocuration,9995.0,8.0,,286.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615725,,,10000000.0,,H,Autocuration,9995.0,8.0,,287.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615726,,,10000000.0,,H,Autocuration,9995.0,8.0,,288.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,10576.0,BAO_0000218,,CHEMBL615727,In vivo,,,,H,Autocuration,16394.0,8.0,,289.0,,,
,1.0,F,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL615728,,10141.0,,,D,Intermediate,11574.0,9.0,,290.0,,,
,1.0,B,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,279.0,BAO_0000219,,CHEMBL857971,,,,,H,Autocuration,15779.0,8.0,449.0,291.0,,,
,1.0,B,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL615729,,,,,H,Autocuration,15363.0,8.0,,292.0,,,
,1.0,F,Efficacy against 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL615730,,10116.0,,,D,Expert,15363.0,9.0,,293.0,,,
,1.0,F,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,12687.0,BAO_0000019,,CHEMBL615731,,,,,H,Expert,15329.0,8.0,,294.0,,,
,1.0,F,Relative potency towards 5-HT2A receptor of rat tail artery,,,12687.0,BAO_0000019,,CHEMBL615732,,,,,H,Expert,15329.0,8.0,,295.0,,,
,1.0,F,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687.0,BAO_0000019,,CHEMBL615733,,,,,H,Expert,15329.0,8.0,,296.0,,,
,1.0,F,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,12687.0,BAO_0000019,,CHEMBL615734,,,,,H,Expert,15329.0,8.0,,297.0,,,
,1.0,F,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,12687.0,BAO_0000019,,CHEMBL615735,,,,,H,Autocuration,15329.0,8.0,,298.0,,,
,1.0,F,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,12687.0,BAO_0000019,,CHEMBL615736,,,,,H,Expert,15329.0,8.0,,299.0,,,
Ileum,1.0,F,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL615737,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,300.0,,,
Ileum,1.0,F,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL615738,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,301.0,,,
Ileum,1.0,F,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL615739,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,302.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,10623.0,BAO_0000357,,CHEMBL615278,,,,,H,Autocuration,12092.0,8.0,,303.0,,,
,1.0,F,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623.0,BAO_0000019,Rattus norvegicus,CHEMBL615279,,10116.0,,,D,Expert,1317.0,9.0,,304.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL615280,,,,,H,Expert,12409.0,8.0,,305.0,,,
,1.0,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,22226.0,BAO_0000019,Gallus gallus,CHEMBL615281,,9031.0,,,U,Autocuration,11126.0,0.0,,306.0,,,
,1.0,F,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615282,,9606.0,,,U,Autocuration,11126.0,0.0,,307.0,,,
,1.0,F,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615283,,9606.0,,,U,Autocuration,11126.0,0.0,,308.0,,,
,1.0,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,HL-60,80156.0,BAO_0000219,Homo sapiens,CHEMBL615284,,9606.0,,,N,Autocuration,11126.0,1.0,649.0,309.0,,,
,1.0,B,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615285,,9606.0,,,U,Autocuration,11126.0,0.0,,310.0,,,
,1.0,B,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615286,,9606.0,,,U,Autocuration,11126.0,0.0,,311.0,,,
,1.0,B,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Oocytes,104703.0,BAO_0000219,Homo sapiens,CHEMBL615287,,9606.0,,,D,Autocuration,17807.0,7.0,,312.0,,,
,1.0,F,Chymotryptic inhibitory activity against 26S proteasome,,,100256.0,BAO_0000220,,CHEMBL615288,,,,,S,Intermediate,16575.0,2.0,,313.0,,,
,1.0,B,Inhibitory activity against 26S proteasome degradation of IkB,,,100256.0,BAO_0000220,,CHEMBL615289,,,,,S,Intermediate,15407.0,2.0,,314.0,,,
,1.0,F,In vitro inhibition of 2780/DOX ovarian cancer cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL615290,,9606.0,,,N,Intermediate,10797.0,1.0,478.0,315.0,,,
,1.0,F,In vitro inhibition of 2780/S ovarian cancer cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL884522,,9606.0,,,N,Intermediate,10797.0,1.0,478.0,316.0,,,
,1.0,F,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615291,,9606.0,,,U,Autocuration,3469.0,0.0,,317.0,,,
,1.0,B,Association constant for binding to AATT 28-mer AATT hairpin,,,22222.0,BAO_0000225,,CHEMBL615292,,,,,M,Intermediate,16037.0,3.0,,318.0,,,
,1.0,B,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,22222.0,BAO_0000225,,CHEMBL615293,,,,,M,Intermediate,16037.0,3.0,,319.0,,,
,1.0,B,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222.0,BAO_0000225,,CHEMBL615294,,,,,M,Intermediate,16037.0,3.0,,320.0,,,
,1.0,B,Reaction Rate Parameter for 28-mer AATT hairpin,,,22222.0,BAO_0000225,,CHEMBL615295,,,,,M,Intermediate,16037.0,3.0,,321.0,,,
,1.0,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,22226.0,BAO_0000019,Homo sapiens,CHEMBL825021,,9606.0,,,U,Autocuration,16524.0,0.0,,322.0,,,
,1.0,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615296,,9606.0,,,U,Autocuration,16524.0,0.0,,323.0,,,
,1.0,F,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615297,,9606.0,,,U,Autocuration,16524.0,0.0,,324.0,,,
,1.0,F,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,22226.0,BAO_0000019,Cricetulus griseus,CHEMBL615298,,10029.0,,,U,Autocuration,16758.0,0.0,,325.0,,,
,1.0,F,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,22226.0,BAO_0000019,Cricetulus griseus,CHEMBL615299,,10029.0,,,U,Autocuration,16758.0,0.0,,326.0,,,
,1.0,F,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,22226.0,BAO_0000019,Cricetulus griseus,CHEMBL615300,,10029.0,,,U,Autocuration,16758.0,0.0,,327.0,,,
,1.0,B,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,241.0,BAO_0000357,,CHEMBL615301,,,,,H,Autocuration,14360.0,8.0,,328.0,,,
,1.0,B,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,241.0,BAO_0000357,Homo sapiens,CHEMBL615302,,9606.0,,,D,Expert,14360.0,9.0,,329.0,,,
,1.0,B,Selectivity ratio of ID50 in liver and heart,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615303,,10116.0,,,U,Autocuration,9964.0,0.0,,330.0,,,
,1.0,B,"Selectivity, ratio of relative ID50 in liver and heart",,,12132.0,BAO_0000019,,CHEMBL615304,,,,,H,Autocuration,9964.0,8.0,,331.0,,,
,1.0,B,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,12132.0,BAO_0000019,,CHEMBL615305,,,,,H,Autocuration,9964.0,8.0,,332.0,,,
,1.0,B,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000218,,CHEMBL615306,,,,,H,Autocuration,9964.0,8.0,,333.0,,,
,1.0,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000218,,CHEMBL615307,,,,,H,Autocuration,9964.0,8.0,,334.0,,,
,1.0,B,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000218,,CHEMBL615308,In vivo,,,,H,Autocuration,9964.0,8.0,,335.0,,,
,1.0,F,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000218,,CHEMBL615309,In vivo,,,,H,Autocuration,9964.0,8.0,,336.0,,,
,1.0,B,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,22226.0,BAO_0000019,,CHEMBL615310,,,,,U,Autocuration,9964.0,0.0,,337.0,,,
,1.0,B,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,12132.0,BAO_0000019,,CHEMBL615311,,,,,H,Autocuration,9964.0,8.0,,338.0,,,
,1.0,B,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615312,,9606.0,,,U,Autocuration,9964.0,0.0,,339.0,,,
,1.0,B,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132.0,BAO_0000019,,CHEMBL615313,,,,,H,Autocuration,9964.0,8.0,,340.0,,,
,1.0,F,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,12132.0,BAO_0000019,,CHEMBL615314,,,,,H,Autocuration,9964.0,8.0,,341.0,,,
,1.0,B,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000019,,CHEMBL615315,,,,,H,Autocuration,9964.0,8.0,,342.0,,,
,1.0,B,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615316,,10116.0,,,U,Autocuration,9964.0,0.0,,343.0,,,
,1.0,B,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,12132.0,BAO_0000218,,CHEMBL615317,In vivo,,,,H,Autocuration,9964.0,8.0,,344.0,,,
,1.0,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000218,,CHEMBL615318,,,,,H,Autocuration,9964.0,8.0,,345.0,,,
,1.0,B,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615319,,10116.0,,,U,Autocuration,9964.0,0.0,,346.0,,,
,1.0,B,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000019,,CHEMBL615320,,,,,H,Autocuration,9964.0,8.0,,347.0,,,
,1.0,F,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,12132.0,BAO_0000019,,CHEMBL615321,,,,,H,Autocuration,9964.0,8.0,,348.0,,,
,1.0,B,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615322,,10116.0,,,U,Autocuration,3796.0,0.0,,349.0,,,
,1.0,B,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690.0,BAO_0000357,Escherichia coli,CHEMBL615323,,562.0,,,H,Autocuration,4251.0,8.0,,350.0,,,
,1.0,B,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,19690.0,BAO_0000357,Escherichia coli,CHEMBL615407,,562.0,,,H,Autocuration,4251.0,8.0,,351.0,,,
,1.0,B,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690.0,BAO_0000357,Escherichia coli,CHEMBL857267,,562.0,,,H,Autocuration,4251.0,8.0,,352.0,,,
,1.0,B,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,19690.0,BAO_0000357,Escherichia coli,CHEMBL615408,,562.0,,,H,Autocuration,4251.0,8.0,,353.0,,,
,1.0,B,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,19690.0,BAO_0000357,,CHEMBL615409,,,,,H,Autocuration,166.0,8.0,,354.0,,,
,1.0,B,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,19690.0,BAO_0000357,,CHEMBL615410,,,,,H,Autocuration,17861.0,8.0,,355.0,,,
,1.0,B,Inhibition constant against 3-dehydroquinate synthase,,,19690.0,BAO_0000357,,CHEMBL615411,,,,,H,Autocuration,166.0,8.0,,356.0,,,
,1.0,B,Association rate constant against 3-dehydroquinate synthase,,,19690.0,BAO_0000357,,CHEMBL615412,,,,,H,Autocuration,166.0,8.0,,357.0,,,
,1.0,B,Rate constant against 3-dehydroquinate synthase,,,19690.0,BAO_0000357,,CHEMBL615413,,,,,H,Autocuration,166.0,8.0,,358.0,,,
,1.0,B,Inhibitory activity against fuc-TVII,,,22226.0,BAO_0000019,,CHEMBL615414,,,,,U,Autocuration,3548.0,0.0,,359.0,,,
Liver,1.0,B,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615415,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,360.0,Microsomes,,
Liver,1.0,B,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615416,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,361.0,Microsomes,,
Liver,1.0,B,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615417,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,362.0,Microsomes,,
Liver,1.0,B,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615418,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,363.0,Microsomes,,
Liver,1.0,B,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615419,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,364.0,Microsomes,,
Liver,1.0,B,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615420,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,365.0,Microsomes,,
Liver,1.0,B,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615421,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,366.0,Microsomes,,
Liver,1.0,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615422,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,367.0,Microsomes,,
Liver,1.0,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615423,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,368.0,Microsomes,,
Liver,1.0,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL872868,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,369.0,Microsomes,,
Liver,1.0,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,12236.0,BAO_0000251,Rattus norvegicus,CHEMBL615424,,10116.0,2107.0,,D,Autocuration,9877.0,9.0,,370.0,Microsomes,,
,1.0,B,Inhibitory activity against 3-phosphoglycerate kinase.,,,104832.0,BAO_0000224,,CHEMBL825022,,,,,H,Autocuration,3003.0,4.0,,371.0,,,
,1.0,B,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,104832.0,BAO_0000224,,CHEMBL615425,,,,,H,Autocuration,3003.0,4.0,,372.0,,,
,1.0,B,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,104832.0,BAO_0000224,,CHEMBL615426,,,,,H,Autocuration,3003.0,4.0,,373.0,,,
,1.0,B,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,10612.0,BAO_0000357,Homo sapiens,CHEMBL615427,,9606.0,,,D,Expert,17185.0,9.0,,374.0,,,
,1.0,F,Cytotoxicity on 3677 melanoma cells,,3677 melanoma cell line,80616.0,BAO_0000219,Homo sapiens,CHEMBL615428,,9606.0,,,N,Intermediate,6072.0,1.0,844.0,375.0,,,
,1.0,F,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,3677 melanoma cell line,80616.0,BAO_0000219,Homo sapiens,CHEMBL615429,,9606.0,,,N,Intermediate,6072.0,1.0,844.0,376.0,,,
,1.0,F,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,MC-38,80617.0,BAO_0000219,Mus musculus,CHEMBL615430,,10090.0,,,N,Intermediate,5018.0,1.0,700.0,377.0,,,
,1.0,F,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615431,,9606.0,,,U,Intermediate,2852.0,0.0,,378.0,,,
,1.0,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,B16,22226.0,BAO_0000218,,CHEMBL615432,,,,,U,Autocuration,8663.0,0.0,798.0,379.0,,,
,1.0,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,B16,22226.0,BAO_0000218,,CHEMBL615433,,,,,U,Autocuration,8663.0,0.0,798.0,380.0,,,
,1.0,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,12464.0,BAO_0000019,Human rhinovirus 14,CHEMBL615434,,12131.0,,,D,Expert,3245.0,9.0,,381.0,,,
,1.0,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,50085.0,BAO_0000218,Human rhinovirus sp.,CHEMBL615435,,169066.0,,,N,Intermediate,3245.0,1.0,,382.0,,,
,1.0,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,50679.0,BAO_0000218,human rhinovirus type 14,CHEMBL615436,,169066.0,,,N,Intermediate,3877.0,1.0,,383.0,,,
,1.0,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,50679.0,BAO_0000218,human rhinovirus type 14,CHEMBL615437,,169066.0,,,N,Intermediate,3877.0,1.0,,384.0,,,
,1.0,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464.0,BAO_0000019,Human rhinovirus 14,CHEMBL615438,,12131.0,,,D,Expert,5861.0,9.0,,385.0,,,
,1.0,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464.0,BAO_0000019,Human rhinovirus 14,CHEMBL615439,,12131.0,,,D,Expert,5861.0,9.0,,386.0,,,
,1.0,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,12464.0,BAO_0000019,Human rhinovirus 14,CHEMBL615440,,12131.0,,,D,Expert,5861.0,9.0,,387.0,,,
,1.0,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,12464.0,BAO_0000019,Human rhinovirus 14,CHEMBL615441,,12131.0,,,D,Expert,5861.0,9.0,,388.0,,,
,1.0,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,50665.0,BAO_0000218,Enterovirus,CHEMBL615641,,12059.0,,,N,Intermediate,13748.0,1.0,,389.0,,,
,1.0,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,50665.0,BAO_0000218,Enterovirus,CHEMBL872065,,12059.0,,,N,Intermediate,13748.0,1.0,,390.0,,,
,1.0,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,50665.0,BAO_0000218,Enterovirus,CHEMBL825023,,12059.0,,,N,Intermediate,13748.0,1.0,,391.0,,,
,1.0,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,50665.0,BAO_0000218,Enterovirus,CHEMBL615642,,12059.0,,,N,Intermediate,13748.0,1.0,,392.0,,,
,1.0,B,Inhibition of human rhinovirus 3C protease,,,12464.0,BAO_0000357,Human rhinovirus B,CHEMBL615643,,147712.0,,,H,Expert,13748.0,8.0,,393.0,,,
,1.0,B,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL615644,,9606.0,,,U,Autocuration,17699.0,0.0,,394.0,,,
,1.0,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615645,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,395.0,,,
,1.0,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615646,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,396.0,,,
,1.0,F,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615647,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,397.0,,,
,1.0,F,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615648,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,398.0,,,
,1.0,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615649,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,399.0,,,
,1.0,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,3EM 37,80619.0,BAO_0000218,Mus musculus,CHEMBL615650,,10090.0,,,N,Intermediate,7145.0,1.0,833.0,400.0,,,
,1.0,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,3LL cell line,80620.0,BAO_0000218,Mus musculus,CHEMBL615651,,10090.0,,,N,Intermediate,5325.0,1.0,847.0,401.0,,,
,1.0,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,3LL cell line,80620.0,BAO_0000218,Mus musculus,CHEMBL615652,,10090.0,,,N,Intermediate,5325.0,1.0,847.0,402.0,,,
,1.0,F,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,3LL cell line,80620.0,BAO_0000218,Mus musculus,CHEMBL615653,,10090.0,,,N,Expert,5325.0,1.0,847.0,403.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615654,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,404.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615655,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,405.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL825024,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,406.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615656,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,407.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615657,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,408.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615658,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,409.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615659,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,410.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615660,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,411.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615661,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,412.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615662,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,413.0,,,
,1.0,F,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615663,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,414.0,,,
,1.0,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615664,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,415.0,,,
,1.0,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615665,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,416.0,,,
,1.0,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615666,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,417.0,,,
,1.0,F,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615667,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,418.0,,,
,1.0,F,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615668,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,419.0,,,
,1.0,F,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615669,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,420.0,,,
,1.0,F,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615670,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,421.0,,,
,1.0,F,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL836739,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,422.0,,,
,1.0,F,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615671,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,423.0,,,
,1.0,F,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615672,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,424.0,,,
,1.0,F,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615791,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,425.0,,,
,1.0,F,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615792,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,426.0,,,
,1.0,F,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615793,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,427.0,,,
,1.0,F,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615794,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,428.0,,,
,1.0,F,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,3LL cell line,80620.0,BAO_0000219,Mus musculus,CHEMBL615795,,10090.0,,,N,Intermediate,16169.0,1.0,847.0,429.0,,,
,1.0,F,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,3LLD122,80621.0,BAO_0000219,Homo sapiens,CHEMBL615590,,9606.0,,,N,Intermediate,15547.0,1.0,971.0,430.0,,,
,1.0,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,22226.0,BAO_0000218,,CHEMBL615591,,,,,U,Autocuration,8663.0,0.0,,431.0,,,
,1.0,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,22226.0,BAO_0000218,,CHEMBL615592,,,,,U,Autocuration,8663.0,0.0,,432.0,,,
,1.0,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,22226.0,BAO_0000218,,CHEMBL615593,,,,,U,Autocuration,8663.0,0.0,,433.0,,,
,1.0,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,22226.0,BAO_0000218,,CHEMBL615594,,,,,U,Autocuration,8663.0,0.0,,434.0,,,
,1.0,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615595,,10090.0,,,N,Intermediate,4504.0,1.0,723.0,435.0,,,
,1.0,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615596,,10090.0,,,N,Intermediate,4504.0,1.0,723.0,436.0,,,
,1.0,F,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,NIH3T3,11169.0,BAO_0000219,,CHEMBL615597,,,,,H,Expert,12695.0,8.0,723.0,437.0,,,
,1.0,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615598,,10090.0,,,N,Intermediate,12695.0,1.0,723.0,438.0,,,
,1.0,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615599,,10090.0,,,N,Intermediate,12695.0,1.0,723.0,439.0,,,
,1.0,F,Effective dose against murine 3T3 fibroblasts cells,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615600,,10090.0,,,N,Expert,17642.0,1.0,723.0,440.0,,,
,1.0,F,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615601,,10090.0,,,N,Expert,17642.0,1.0,723.0,441.0,,,
,1.0,F,Cytotoxic effect on 3T3 cells,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615602,,10090.0,,,N,Expert,12340.0,1.0,723.0,442.0,,,
,1.0,F,Cytotoxic effect on 3T3 cells,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615603,,10090.0,,,N,Expert,12340.0,1.0,723.0,443.0,,,
,1.0,F,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615604,,10090.0,,,N,Intermediate,12716.0,1.0,723.0,444.0,,,
,1.0,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615605,,10090.0,,,N,Intermediate,6277.0,1.0,723.0,445.0,,,
,1.0,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615606,,10090.0,,,N,Intermediate,6277.0,1.0,723.0,446.0,,,
,1.0,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL884526,,10090.0,,,N,Expert,6277.0,1.0,723.0,447.0,,,
,1.0,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615607,,10090.0,,,N,Expert,6277.0,1.0,723.0,448.0,,,
,1.0,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615608,,10090.0,,,N,Intermediate,6277.0,1.0,723.0,449.0,,,
,1.0,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615609,,10090.0,,,N,Expert,6277.0,1.0,723.0,450.0,,,
,1.0,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615682,,10090.0,,,N,Expert,6277.0,1.0,723.0,451.0,,,
,1.0,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615683,,10090.0,,,N,Intermediate,6277.0,1.0,723.0,452.0,,,
,1.0,F,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,NIH3T3,80951.0,BAO_0000218,Mus musculus,CHEMBL615684,,10090.0,,,N,Expert,17780.0,1.0,723.0,453.0,,,
,1.0,F,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,104860.0,BAO_0000219,Mus musculus,CHEMBL615685,,10090.0,,,D,Autocuration,12751.0,7.0,,454.0,,,
,1.0,F,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615686,,10090.0,,,N,Expert,12380.0,1.0,723.0,455.0,,,
,1.0,F,Inhibitory activity against 3T3 cell line,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615687,,10090.0,,,N,Intermediate,14892.0,1.0,723.0,456.0,,,
,1.0,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL884523,,10090.0,,,N,Intermediate,12695.0,1.0,723.0,457.0,,,
,1.0,F,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,11169.0,BAO_0000019,,CHEMBL615688,,,,,H,Expert,12695.0,8.0,,458.0,,,
,1.0,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615689,,10090.0,,,N,Intermediate,12695.0,1.0,723.0,459.0,,,
,1.0,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615690,,10090.0,,,N,Intermediate,12695.0,1.0,723.0,460.0,,,
,1.0,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,11169.0,BAO_0000019,,CHEMBL615691,,,,,H,Expert,12695.0,8.0,,461.0,,,
,1.0,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,11169.0,BAO_0000019,,CHEMBL615692,,,,,H,Expert,12695.0,8.0,,462.0,,,
,1.0,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615693,,10090.0,,,N,Intermediate,6277.0,1.0,723.0,463.0,,,
,1.0,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615324,,10090.0,,,N,Expert,6277.0,1.0,723.0,464.0,,,
,1.0,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,NIH3T3,9.0,BAO_0000219,Homo sapiens,CHEMBL615325,,9606.0,,,D,Expert,4959.0,9.0,723.0,465.0,,,
,1.0,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,NIH3T3,9.0,BAO_0000219,Homo sapiens,CHEMBL615490,,9606.0,,,D,Expert,4959.0,9.0,723.0,466.0,,,
,1.0,F,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,NIH3T3,188.0,BAO_0000219,Homo sapiens,CHEMBL615491,,9606.0,,,D,Expert,4959.0,9.0,723.0,467.0,,,
,1.0,F,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,NIH3T3,188.0,BAO_0000219,Homo sapiens,CHEMBL615492,,9606.0,,,D,Expert,4959.0,9.0,723.0,468.0,,,
,1.0,F,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615493,,10090.0,,,N,Intermediate,12082.0,1.0,723.0,469.0,,,
,1.0,F,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615494,,10090.0,,,N,Intermediate,12082.0,1.0,723.0,470.0,,,
,1.0,F,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615495,,10090.0,,,N,Intermediate,12082.0,1.0,723.0,471.0,,,
,1.0,F,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615496,,10090.0,,,N,Intermediate,12082.0,1.0,723.0,472.0,,,
,1.0,F,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615497,,10090.0,,,N,Intermediate,2643.0,1.0,723.0,473.0,,,
,1.0,F,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615498,,10090.0,,,N,Expert,11926.0,1.0,723.0,474.0,,,
,1.0,A,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615499,,10090.0,,,N,Intermediate,15204.0,1.0,723.0,475.0,,,
,1.0,F,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL835522,,10090.0,,,N,Expert,15992.0,1.0,723.0,476.0,,,
,1.0,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615500,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,477.0,,,
,1.0,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615501,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,478.0,,,
,1.0,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615502,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,479.0,,,
,1.0,F,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615503,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,480.0,,,
,1.0,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615504,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,481.0,,,
,1.0,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615505,,10090.0,,,N,Intermediate,16279.0,1.0,723.0,482.0,,,
,1.0,F,Inhibition of swiss 3T3 mouse fibroblast proliferation,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615506,,10090.0,,,N,Expert,12831.0,1.0,723.0,483.0,,,
,1.0,F,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,NIH3T3,80951.0,BAO_0000219,Mus musculus,CHEMBL615507,,10090.0,,,N,Intermediate,13497.0,1.0,723.0,484.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615508,,,,,N,Intermediate,13715.0,1.0,620.0,485.0,,,
,1.0,F,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615509,,10090.0,,,N,Intermediate,13618.0,1.0,620.0,486.0,,,
,1.0,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615510,,10090.0,,,N,Intermediate,11902.0,1.0,620.0,487.0,,,
,1.0,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615511,,10090.0,,,N,Intermediate,11902.0,1.0,620.0,488.0,,,
,1.0,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615512,,10090.0,,,N,Intermediate,11902.0,1.0,620.0,489.0,,,
,1.0,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,3T3-L1,80006.0,BAO_0000218,Mus musculus,CHEMBL615513,,10090.0,,,N,Intermediate,14840.0,1.0,620.0,490.0,,,
,1.0,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,3T3-L1,80006.0,BAO_0000218,Mus musculus,CHEMBL615514,,10090.0,,,N,Intermediate,14840.0,1.0,620.0,491.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615515,,,,,N,Intermediate,13715.0,1.0,620.0,492.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615516,,,,,N,Intermediate,13715.0,1.0,620.0,493.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615517,,,,,N,Intermediate,13715.0,1.0,620.0,494.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615518,,,,,N,Intermediate,13715.0,1.0,620.0,495.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615519,,,,,N,Intermediate,13715.0,1.0,620.0,496.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615520,,,,,N,Intermediate,13715.0,1.0,620.0,497.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615521,,,,,N,Intermediate,13715.0,1.0,620.0,498.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615522,,,,,N,Intermediate,13715.0,1.0,620.0,499.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615523,,,,,N,Intermediate,13715.0,1.0,620.0,500.0,,,
,1.0,F,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615524,,,,,N,Expert,13715.0,1.0,620.0,501.0,,,
,1.0,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615525,,,,,N,Expert,13715.0,1.0,620.0,502.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615526,,,,,N,Intermediate,13715.0,1.0,620.0,503.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615527,,,,,N,Intermediate,13715.0,1.0,620.0,504.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615528,,,,,N,Intermediate,13715.0,1.0,620.0,505.0,,,
,1.0,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615529,,,,,N,Expert,13715.0,1.0,620.0,506.0,,,
,1.0,F,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615530,,,,,N,Expert,13715.0,1.0,620.0,507.0,,,
,1.0,F,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615531,,,,,N,Expert,13715.0,1.0,620.0,508.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615532,,,,,N,Intermediate,13715.0,1.0,620.0,509.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615533,,,,,N,Intermediate,13715.0,1.0,620.0,510.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,3T3-L1,80006.0,BAO_0000219,,CHEMBL615534,,,,,N,Intermediate,13715.0,1.0,620.0,511.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615535,,,,,N,Intermediate,13715.0,1.0,620.0,512.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615536,,,,,N,Intermediate,13715.0,1.0,620.0,513.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615537,,,,,N,Intermediate,13715.0,1.0,620.0,514.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL615538,,,,,N,Intermediate,13715.0,1.0,620.0,515.0,,,
,1.0,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,3T3-L1,80006.0,BAO_0000218,,CHEMBL836166,,,,,N,Intermediate,13715.0,1.0,620.0,516.0,,,
,1.0,F,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,3T3-L1,11214.0,BAO_0000219,,CHEMBL615539,,,,,H,Expert,6411.0,8.0,620.0,517.0,,,
,1.0,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615540,,10090.0,,,N,Intermediate,6411.0,1.0,620.0,518.0,,,
,1.0,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,3T3-L1,11214.0,BAO_0000219,,CHEMBL615541,,,,,H,Expert,6411.0,8.0,620.0,519.0,,,
,1.0,F,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615542,,10090.0,,,N,Expert,3966.0,1.0,620.0,520.0,,,
,1.0,F,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615543,,10090.0,,,N,Intermediate,3966.0,1.0,620.0,521.0,,,
,1.0,F,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615544,,10090.0,,,N,Expert,15556.0,1.0,620.0,522.0,,,
,1.0,F,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615545,,10090.0,,,N,Expert,5845.0,1.0,620.0,523.0,,,
,1.0,F,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615546,,10090.0,,,N,Expert,14422.0,1.0,620.0,524.0,,,
,1.0,F,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615547,,10090.0,,,N,Expert,5845.0,1.0,620.0,525.0,,,
,1.0,F,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615548,,10090.0,,,N,Expert,14508.0,1.0,620.0,526.0,,,
,1.0,F,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615549,,10090.0,,,N,Expert,14508.0,1.0,620.0,527.0,,,
,1.0,F,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,3T3-L1,80006.0,BAO_0000219,Mus musculus,CHEMBL615550,,10090.0,,,N,Expert,14508.0,1.0,620.0,528.0,,,
,1.0,F,Inhibitory activity against rat fibroblast (3Y1) cell line,,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615551,,10116.0,,,N,Intermediate,6349.0,1.0,1118.0,529.0,,,
,1.0,F,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615552,,10116.0,,,N,Expert,15899.0,1.0,1118.0,530.0,,,
,1.0,F,Cytotoxicity in 3Y1 cells.,,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615553,,10116.0,,,N,Expert,15899.0,1.0,1118.0,531.0,,,
,1.0,F,Cytostatic effect in 3Y1 cells.,,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615554,,10116.0,,,N,Expert,15899.0,1.0,1118.0,532.0,,,
,1.0,F,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615555,,10116.0,,,N,Intermediate,15899.0,1.0,1118.0,533.0,,,
,1.0,F,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,3Y1 cell line,80622.0,BAO_0000219,Rattus norvegicus,CHEMBL615556,,10116.0,,,N,Expert,17038.0,1.0,1118.0,534.0,,,
,1.0,B,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,22226.0,BAO_0000019,,CHEMBL615557,,,,,U,Autocuration,12421.0,0.0,,535.0,,,
,1.0,B,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226.0,BAO_0000019,,CHEMBL615558,,,,,U,Autocuration,12947.0,0.0,,536.0,,,
,1.0,B,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,22226.0,BAO_0000019,,CHEMBL872066,,,,,U,Autocuration,12947.0,0.0,,537.0,,,
,1.0,B,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,11607.0,BAO_0000019,Sus scrofa,CHEMBL615559,,9823.0,,,D,Expert,4896.0,9.0,,538.0,,,
,1.0,B,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,11607.0,BAO_0000019,,CHEMBL615560,,,,,H,Autocuration,6148.0,8.0,,539.0,,,
,1.0,B,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,11607.0,BAO_0000019,,CHEMBL615561,,,,,H,Autocuration,16432.0,8.0,,540.0,,,
,1.0,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,11607.0,BAO_0000019,,CHEMBL857062,,,,,H,Expert,4978.0,8.0,,541.0,,,
,1.0,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,11607.0,BAO_0000019,,CHEMBL615562,,,,,H,Expert,4978.0,8.0,,542.0,,,
,1.0,B,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,11607.0,BAO_0000019,,CHEMBL615563,,,,,H,Autocuration,3723.0,8.0,,543.0,,,
,1.0,B,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,11607.0,BAO_0000357,,CHEMBL615564,,,,,H,Autocuration,3518.0,8.0,,544.0,,,
,1.0,B,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,11607.0,BAO_0000019,,CHEMBL615565,,,,,H,Autocuration,4164.0,8.0,,545.0,,,
,1.0,B,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,11607.0,BAO_0000019,,CHEMBL615566,,,,,H,Autocuration,3518.0,8.0,,546.0,,,
,1.0,B,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,11607.0,BAO_0000019,Sus scrofa,CHEMBL615567,,9823.0,,,D,Expert,4164.0,9.0,,547.0,,,
,1.0,B,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,11607.0,BAO_0000019,,CHEMBL615568,,,,,H,Autocuration,3518.0,8.0,,548.0,,,
,1.0,B,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,11607.0,BAO_0000357,,CHEMBL615569,,,,,H,Autocuration,3518.0,8.0,,549.0,,,
,1.0,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,11607.0,BAO_0000019,,CHEMBL615570,,,,,H,Autocuration,4978.0,8.0,,550.0,,,
,1.0,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,11607.0,BAO_0000019,,CHEMBL615571,,,,,H,Autocuration,4978.0,8.0,,551.0,,,
,1.0,B,Binding affinity against melatonin (MT1) receptor (pC1),,,104733.0,BAO_0000224,,CHEMBL615572,,,,,H,Autocuration,6455.0,4.0,,552.0,,,
,1.0,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,22226.0,BAO_0000019,,CHEMBL615573,,,,,U,Autocuration,2222.0,0.0,,553.0,,,
,1.0,B,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,22226.0,BAO_0000019,,CHEMBL615574,,,,,U,Autocuration,13020.0,0.0,,554.0,,,
,1.0,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,22226.0,BAO_0000019,,CHEMBL615575,,,,,U,Autocuration,13021.0,0.0,,555.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,10619.0,BAO_0000357,,CHEMBL615576,,,,,H,Autocuration,14532.0,8.0,,556.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,10619.0,BAO_0000357,,CHEMBL615577,,,,,H,Autocuration,14118.0,8.0,,557.0,,,
Hippocampus,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,51.0,BAO_0000221,,CHEMBL615578,,,10000000.0,,H,Autocuration,11884.0,8.0,,558.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615579,,,,,H,Expert,13969.0,8.0,,559.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615580,,,,,H,Expert,13392.0,8.0,,560.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,51.0,BAO_0000019,,CHEMBL615581,,,,,H,Expert,14430.0,8.0,,561.0,,,
Hippocampus,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615582,,,10000000.0,,H,Autocuration,12248.0,8.0,,562.0,,,
Hippocampus,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615583,,,10000000.0,,H,Autocuration,12249.0,8.0,,563.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615584,,,10000000.0,,H,Autocuration,9995.0,8.0,,564.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL833691,,,10000000.0,,H,Autocuration,9995.0,8.0,,565.0,,,
Hippocampus,1.0,B,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615585,,,10000000.0,,H,Autocuration,9995.0,8.0,,566.0,,,
Hippocampus,1.0,B,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615586,,,10000000.0,,H,Autocuration,9995.0,8.0,,567.0,,,
Hippocampus,1.0,B,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL884524,,,10000000.0,,H,Autocuration,9995.0,8.0,,568.0,,,
Hippocampus,1.0,B,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615587,,,10000000.0,,H,Autocuration,12249.0,8.0,,569.0,,,
Hippocampus,1.0,B,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,51.0,BAO_0000221,,CHEMBL615588,,,10000000.0,,H,Autocuration,11799.0,8.0,,570.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL615589,,10116.0,,,D,Expert,14331.0,9.0,,571.0,Membranes,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,51.0,BAO_0000221,Bos taurus,CHEMBL615442,,9913.0,10000000.0,,H,Expert,11884.0,8.0,,572.0,,,
Hippocampus,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,51.0,BAO_0000221,,CHEMBL615443,,,10000000.0,,H,Autocuration,14331.0,8.0,,573.0,,,
Hippocampus,1.0,B,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615444,,,10000000.0,,H,Autocuration,11701.0,8.0,,574.0,,,
Hippocampus,1.0,B,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,51.0,BAO_0000221,,CHEMBL615445,,,10000000.0,,H,Expert,11701.0,8.0,,575.0,,,
Hippocampus,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615446,,,10000000.0,,H,Autocuration,12248.0,8.0,,576.0,,,
,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615447,,,,,H,Autocuration,12248.0,8.0,449.0,577.0,,,
Hippocampus,1.0,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615448,,,10000000.0,,H,Expert,12248.0,8.0,,578.0,,,
Hippocampus,1.0,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615449,,,10000000.0,,H,Expert,12249.0,8.0,,579.0,,,
,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615450,,,,,H,Autocuration,12248.0,8.0,449.0,580.0,,,
Hippocampus,1.0,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,51.0,BAO_0000221,,CHEMBL615451,,,10000000.0,,H,Expert,11799.0,8.0,,581.0,,,
,1.0,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51.0,BAO_0000357,,CHEMBL615452,,,,,H,Autocuration,634.0,8.0,,582.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615453,,,10000000.0,,H,Autocuration,9995.0,8.0,,583.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615454,,,10000000.0,,H,Autocuration,9995.0,8.0,,584.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615455,,,10000000.0,,H,Autocuration,9995.0,8.0,,585.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615456,,,10000000.0,,H,Autocuration,9995.0,8.0,,586.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615457,,,10000000.0,,H,Autocuration,9995.0,8.0,,587.0,,,
Hippocampus,1.0,B,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,51.0,BAO_0000218,,CHEMBL615458,,,10000000.0,,H,Expert,12210.0,8.0,,588.0,,,
Hippocampus,1.0,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL615459,,,10000000.0,,H,Expert,13311.0,8.0,,589.0,,,
,1.0,B,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615460,,9606.0,,,D,Expert,2331.0,9.0,449.0,590.0,,,
,1.0,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,51.0,BAO_0000019,Cavia porcellus,CHEMBL615461,,10141.0,,,H,Autocuration,1375.0,8.0,,591.0,,,
,1.0,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,51.0,BAO_0000019,Cavia porcellus,CHEMBL615462,,10141.0,,,H,Autocuration,1375.0,8.0,,592.0,,,
Hippocampus,1.0,F,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615463,,10141.0,10000000.0,,H,Autocuration,11574.0,8.0,,593.0,,,
Ileum,1.0,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615464,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,594.0,,,
Ileum,1.0,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615465,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,595.0,,,
Ileum,1.0,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615466,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,596.0,,,
Ileum,1.0,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615467,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,597.0,,,
Ileum,1.0,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615468,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,598.0,,,
Ileum,1.0,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,51.0,BAO_0000221,Cavia porcellus,CHEMBL615469,,10141.0,2116.0,,H,Autocuration,12867.0,8.0,,599.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Cavia porcellus,CHEMBL615470,,10141.0,,,H,Autocuration,11574.0,8.0,,600.0,,,
,1.0,B,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Cavia porcellus,CHEMBL615471,,10141.0,,,H,Autocuration,13114.0,8.0,,601.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Cavia porcellus,CHEMBL615472,,10141.0,,,H,Autocuration,13181.0,8.0,,602.0,,,
Hippocampus,1.0,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,106.0,BAO_0000221,Cavia porcellus,CHEMBL883242,,10141.0,10000000.0,,H,Autocuration,10639.0,8.0,,603.0,,,
Hippocampus,1.0,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,106.0,BAO_0000221,Cavia porcellus,CHEMBL615473,,10141.0,10000000.0,,H,Autocuration,10639.0,8.0,,604.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHO,11863.0,BAO_0000218,Cricetulus griseus,CHEMBL615474,,10029.0,,,H,Autocuration,11883.0,8.0,449.0,605.0,,,
,1.0,B,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615475,,,,,H,Autocuration,17785.0,8.0,,606.0,,,
,1.0,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,HeLa,51.0,BAO_0000219,,CHEMBL615476,,,,,H,Autocuration,1558.0,8.0,308.0,607.0,,,
,1.0,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,HeLa,51.0,BAO_0000219,,CHEMBL615477,,,,,H,Autocuration,1558.0,8.0,308.0,608.0,,,
,1.0,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL615478,,,,,H,Autocuration,15740.0,8.0,,609.0,,,
,1.0,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615160,,,,,H,Autocuration,17624.0,8.0,449.0,610.0,,,
,1.0,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615161,,,,,H,Expert,17624.0,8.0,449.0,611.0,,,
,1.0,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,CHO,51.0,BAO_0000219,,CHEMBL615162,,,,,H,Autocuration,17624.0,8.0,449.0,612.0,,,
,1.0,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,CHO,51.0,BAO_0000219,,CHEMBL615163,,,,,H,Autocuration,17624.0,8.0,449.0,613.0,,,
,1.0,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615164,,,,,H,Expert,17624.0,8.0,449.0,614.0,,,
,1.0,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615165,,,,,H,Expert,17624.0,8.0,449.0,615.0,,,
,1.0,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,CHO,51.0,BAO_0000219,,CHEMBL615166,,,,,H,Autocuration,17624.0,8.0,449.0,616.0,,,
,1.0,F,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,51.0,BAO_0000219,,CHEMBL615167,,,,,H,Autocuration,14256.0,8.0,,617.0,,,
,1.0,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL615168,,9606.0,,,D,Expert,3445.0,9.0,308.0,618.0,,,
,1.0,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL615169,,9606.0,,,D,Expert,3445.0,9.0,308.0,619.0,,,
,1.0,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615170,,9606.0,,,D,Expert,17200.0,9.0,449.0,620.0,,,
,1.0,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615171,,9606.0,,,D,Expert,17200.0,9.0,449.0,621.0,,,
,1.0,F,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL615694,,,,,H,Autocuration,15180.0,8.0,,622.0,,,
,1.0,F,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL615695,,,,,H,Autocuration,15180.0,8.0,,623.0,,,
,1.0,F,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51.0,BAO_0000019,,CHEMBL615696,,,,,H,Autocuration,16026.0,8.0,,624.0,,,
,1.0,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615697,,,,,H,Autocuration,2759.0,8.0,449.0,625.0,,,
,1.0,F,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL859410,,9606.0,,,D,Expert,2759.0,9.0,449.0,626.0,,,
,1.0,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHO,51.0,BAO_0000219,,CHEMBL615841,,,,,H,Autocuration,2759.0,8.0,449.0,627.0,,,
,1.0,F,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615842,,9606.0,,,D,Expert,2759.0,9.0,449.0,628.0,,,
,1.0,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL835003,,,,,H,Autocuration,2759.0,8.0,449.0,629.0,,,
,1.0,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,CHO,51.0,BAO_0000219,,CHEMBL615843,,,,,H,Autocuration,2759.0,8.0,449.0,630.0,,,
,1.0,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615979,,9606.0,,,D,Expert,2759.0,9.0,449.0,631.0,,,
,1.0,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHO,51.0,BAO_0000219,,CHEMBL615980,,,,,H,Autocuration,2759.0,8.0,449.0,632.0,,,
,1.0,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615981,,9606.0,,,D,Expert,2759.0,9.0,449.0,633.0,,,
,1.0,F,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,51.0,BAO_0000019,Homo sapiens,CHEMBL615982,,9606.0,,,D,Expert,3445.0,9.0,,634.0,,,
,1.0,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51.0,BAO_0000019,Homo sapiens,CHEMBL615983,,9606.0,,,D,Expert,5272.0,9.0,,635.0,,,
,1.0,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,51.0,BAO_0000019,Homo sapiens,CHEMBL615984,,9606.0,,,D,Expert,5272.0,9.0,,636.0,,,
,1.0,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,51.0,BAO_0000019,Homo sapiens,CHEMBL615985,,9606.0,,,D,Expert,5272.0,9.0,,637.0,,,
,1.0,F,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615986,,,,,H,Autocuration,17624.0,8.0,449.0,638.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615987,,,,,H,Autocuration,17624.0,8.0,449.0,639.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHO,51.0,BAO_0000219,,CHEMBL615988,,,,,H,Autocuration,17624.0,8.0,449.0,640.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615989,,,,,H,Expert,17624.0,8.0,449.0,641.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHO,51.0,BAO_0000219,,CHEMBL615990,,,,,H,Autocuration,17624.0,8.0,449.0,642.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,CHO,51.0,BAO_0000219,,CHEMBL615991,,,,,H,Autocuration,17624.0,8.0,449.0,643.0,,,
,1.0,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51.0,BAO_0000219,,CHEMBL615992,,,,,H,Autocuration,17624.0,8.0,449.0,644.0,,,
,1.0,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHO,51.0,BAO_0000219,,CHEMBL615993,,,,,H,Autocuration,17624.0,8.0,449.0,645.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51.0,BAO_0000219,,CHEMBL615994,,,,,H,Expert,17624.0,8.0,449.0,646.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,CHO,51.0,BAO_0000219,,CHEMBL615995,,,,,H,Autocuration,17624.0,8.0,449.0,647.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHO,51.0,BAO_0000219,,CHEMBL615996,,,,,H,Autocuration,17624.0,8.0,449.0,648.0,,,
,1.0,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHO,51.0,BAO_0000219,,CHEMBL615997,,,,,H,Autocuration,17624.0,8.0,449.0,649.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51.0,BAO_0000019,,CHEMBL615998,,,,,H,Autocuration,6563.0,8.0,,650.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51.0,BAO_0000019,,CHEMBL615999,,,,,H,Autocuration,6563.0,8.0,,651.0,,,
,1.0,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51.0,BAO_0000019,,CHEMBL616000,,,,,H,Autocuration,6563.0,8.0,,652.0,,,
,1.0,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51.0,BAO_0000219,,CHEMBL616001,,,,,H,Autocuration,17296.0,8.0,722.0,653.0,,,
,1.0,F,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616002,,9606.0,,,D,Expert,6876.0,9.0,,654.0,,,
,1.0,F,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,51.0,BAO_0000019,,CHEMBL616003,,,,,H,Expert,6876.0,8.0,,655.0,,,
,1.0,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616004,,9606.0,,,D,Expert,5272.0,9.0,,656.0,,,
,1.0,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616005,,9606.0,,,D,Expert,5272.0,9.0,,657.0,,,
,1.0,F,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51.0,BAO_0000019,,CHEMBL616006,,,,,H,Autocuration,5548.0,8.0,,658.0,,,
,1.0,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,51.0,BAO_0000019,,CHEMBL616007,,,,,H,Expert,5548.0,8.0,,659.0,,,
,1.0,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51.0,BAO_0000019,,CHEMBL616008,,,,,H,Autocuration,5548.0,8.0,,660.0,,,
,1.0,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,51.0,BAO_0000019,,CHEMBL616009,,,,,H,Autocuration,5548.0,8.0,,661.0,,,
,1.0,F,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,51.0,BAO_0000019,,CHEMBL616010,,,,,H,Expert,5929.0,8.0,,662.0,,,
,1.0,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616011,,9606.0,,,D,Expert,5929.0,9.0,,663.0,,,
,1.0,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,51.0,BAO_0000019,Homo sapiens,CHEMBL615740,,9606.0,,,D,Expert,5929.0,9.0,,664.0,,,
,1.0,F,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,51.0,BAO_0000019,,CHEMBL615741,,,,,H,Autocuration,16245.0,8.0,,665.0,,,
,1.0,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51.0,BAO_0000019,,CHEMBL615742,,,,,H,Expert,5640.0,8.0,,666.0,,,
,1.0,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,51.0,BAO_0000019,,CHEMBL615743,,,,,H,Autocuration,5640.0,8.0,,667.0,,,
,1.0,F,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,CHO,51.0,BAO_0000219,,CHEMBL615744,,,,,H,Autocuration,14509.0,8.0,449.0,668.0,,,
,1.0,F,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,CHO,51.0,BAO_0000219,,CHEMBL615745,,,,,H,Expert,14509.0,8.0,449.0,669.0,,,
,1.0,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51.0,BAO_0000357,,CHEMBL615746,,,,,H,Autocuration,15331.0,8.0,,670.0,,,
,1.0,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,51.0,BAO_0000357,,CHEMBL615747,,,,,H,Autocuration,15331.0,8.0,,671.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51.0,BAO_0000019,,CHEMBL615748,,,,,H,Autocuration,6563.0,8.0,,672.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,51.0,BAO_0000019,,CHEMBL615749,,,,,H,Autocuration,6563.0,8.0,,673.0,,,
,1.0,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,51.0,BAO_0000019,,CHEMBL615750,,,,,H,Autocuration,6563.0,8.0,,674.0,,,
,1.0,F,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616259,,9606.0,,,D,Expert,6563.0,9.0,,675.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51.0,BAO_0000019,,CHEMBL616260,,,,,H,Autocuration,6563.0,8.0,,676.0,,,
,1.0,F,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616261,,9606.0,,,D,Expert,5272.0,9.0,,677.0,,,
,1.0,F,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616262,,9606.0,,,D,Expert,5272.0,9.0,,678.0,,,
,1.0,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616263,,9606.0,,,D,Expert,5272.0,9.0,,679.0,,,
,1.0,F,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616264,,9606.0,,,D,Expert,5272.0,9.0,,680.0,,,
,1.0,F,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616265,,9606.0,,,D,Expert,5272.0,9.0,,681.0,,,
,1.0,F,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616266,,9606.0,,,D,Expert,5272.0,9.0,,682.0,,,
,1.0,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616267,,9606.0,,,D,Expert,5272.0,9.0,,683.0,,,
,1.0,F,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616268,,9606.0,,,D,Expert,5272.0,9.0,,684.0,,,
,1.0,B,Inhibition of human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616269,,9606.0,,,D,Expert,16146.0,9.0,,685.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL884528,,,,,H,Autocuration,17624.0,8.0,449.0,686.0,,,
,1.0,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,HEK293,105.0,BAO_0000219,,CHEMBL616270,,,,,D,Expert,13706.0,9.0,722.0,687.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL616271,,,,,H,Autocuration,15250.0,8.0,449.0,688.0,,,
,1.0,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL616272,,,,,H,Autocuration,17624.0,8.0,449.0,689.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,51.0,BAO_0000357,,CHEMBL616273,,,,,H,Expert,6861.0,8.0,,690.0,,,
,1.0,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616274,,9606.0,,,D,Expert,17200.0,9.0,,691.0,,,
,1.0,B,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL616275,,,,,H,Autocuration,17624.0,8.0,449.0,692.0,,,
,1.0,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL616276,,,,,H,Autocuration,17624.0,8.0,449.0,693.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616277,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,694.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616278,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,695.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616279,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,696.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616280,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,697.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616281,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,698.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616282,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,699.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616283,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,700.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616284,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,701.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616285,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,702.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616286,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,703.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616287,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,704.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616288,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,705.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL616289,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,706.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615610,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,707.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615611,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,708.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615612,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,709.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615613,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,710.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615614,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,711.0,,,
,1.0,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,22226.0,BAO_0000218,Rattus norvegicus,CHEMBL615615,In vivo,10116.0,,,U,Autocuration,12058.0,0.0,,712.0,,,
,1.0,B,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,105093.0,BAO_0000019,,CHEMBL615616,,,,,H,Autocuration,11440.0,4.0,,713.0,,,
Hypothalamus,1.0,B,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,11923.0,BAO_0000249,,CHEMBL615617,,,1898.0,,H,Autocuration,6238.0,8.0,,714.0,,,
,1.0,B,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,10577.0,BAO_0000019,,CHEMBL615618,,,,,H,Autocuration,10046.0,8.0,,715.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,10577.0,BAO_0000019,,CHEMBL615619,,,,,H,Autocuration,10046.0,8.0,,716.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,10577.0,BAO_0000019,,CHEMBL615620,,,,,H,Expert,10046.0,8.0,,717.0,,,
,1.0,B,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,55.0,BAO_0000357,,CHEMBL615621,,,,,H,Autocuration,167.0,8.0,,718.0,,,
,1.0,B,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,55.0,BAO_0000357,,CHEMBL615622,,,,,H,Autocuration,167.0,8.0,,719.0,,,
,1.0,F,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,12166.0,BAO_0000019,,CHEMBL615623,,,,,H,Autocuration,11520.0,8.0,,720.0,,,
,1.0,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166.0,BAO_0000019,,CHEMBL615624,,,,,H,Autocuration,11520.0,8.0,,721.0,,,
,1.0,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166.0,BAO_0000019,,CHEMBL615625,,,,,H,Autocuration,11520.0,8.0,,722.0,,,
,1.0,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,12166.0,BAO_0000019,,CHEMBL767045,,,,,H,Autocuration,11520.0,8.0,,723.0,,,
,1.0,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL615626,,10141.0,,,H,Autocuration,135.0,8.0,,724.0,,,
,1.0,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL615627,,10141.0,,,H,Autocuration,135.0,8.0,,725.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL615628,,10141.0,,,H,Autocuration,11311.0,8.0,,726.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL615629,,10141.0,,,H,Autocuration,10193.0,8.0,,727.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,55.0,BAO_0000357,Homo sapiens,CHEMBL615630,,9606.0,,,D,Expert,12281.0,9.0,,728.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,55.0,BAO_0000219,,CHEMBL615631,,,,,H,Autocuration,11311.0,8.0,,729.0,,,
,1.0,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087.0,BAO_0000218,,CHEMBL615632,,,,,H,Autocuration,12576.0,8.0,,730.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,17087.0,BAO_0000357,,CHEMBL615633,,,,,H,Autocuration,12281.0,8.0,,731.0,,,
,1.0,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,17087.0,BAO_0000218,,CHEMBL615634,,,,,H,Autocuration,12576.0,8.0,,732.0,,,
,1.0,B,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,55.0,BAO_0000019,Sus scrofa,CHEMBL615635,,9823.0,,,H,Expert,11089.0,8.0,,733.0,,,
,1.0,B,In vitro inhibition of rat 5-Lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL615636,,,,,H,Expert,11006.0,8.0,,734.0,,,
,1.0,B,Inhibitory activity against 5-Lipoxygenase,,,12166.0,BAO_0000357,Rattus norvegicus,CHEMBL615637,,10116.0,,,D,Expert,11481.0,9.0,,735.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL615638,,,,,H,Expert,10864.0,8.0,702.0,736.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL615639,,,,,H,Autocuration,3595.0,8.0,702.0,737.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,RBL-1,12166.0,BAO_0000219,,CHEMBL615640,,,,,H,Autocuration,11311.0,8.0,702.0,738.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,12166.0,BAO_0000019,,CHEMBL615796,,,,,H,Autocuration,11311.0,8.0,,739.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,12166.0,BAO_0000219,,CHEMBL615845,,,,,H,Autocuration,11311.0,8.0,,740.0,,,
,1.0,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166.0,BAO_0000357,,CHEMBL615846,,,,,H,Autocuration,11006.0,8.0,,741.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL615847,,,,,H,Autocuration,3595.0,8.0,702.0,742.0,,,
,1.0,B,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL615848,,,,,H,Autocuration,11311.0,8.0,,743.0,,,
,1.0,B,Ratio of IC50 against 5-LO and COX,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615849,,10116.0,,,U,Autocuration,11481.0,0.0,,744.0,,,
,1.0,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,12166.0,BAO_0000357,,CHEMBL615850,,,,,H,Autocuration,11006.0,8.0,,745.0,,,
,1.0,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,12166.0,BAO_0000357,,CHEMBL615851,,,,,H,Autocuration,11006.0,8.0,,746.0,,,
,1.0,B,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,12166.0,BAO_0000219,,CHEMBL615852,,,,,H,Autocuration,11311.0,8.0,,747.0,,,
,1.0,F,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,12166.0,BAO_0000019,,CHEMBL615853,,,,,H,Autocuration,11006.0,8.0,,748.0,,,
Prostate gland,1.0,B,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,120.0,BAO_0000357,,CHEMBL884527,,,2367.0,,H,Autocuration,4288.0,8.0,,749.0,,,
,1.0,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,22226.0,BAO_0000019,Columba livia,CHEMBL872871,,8932.0,,,U,Autocuration,7587.0,0.0,,750.0,,,
,1.0,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,22226.0,BAO_0000019,Columba livia,CHEMBL615854,,8932.0,,,U,Autocuration,7587.0,0.0,,751.0,,,
,1.0,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,22226.0,BAO_0000019,Columba livia,CHEMBL767046,,8932.0,,,U,Autocuration,7587.0,0.0,,752.0,,,
,1.0,B,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,10732.0,BAO_0000357,,CHEMBL615855,,,,,H,Autocuration,11249.0,8.0,,753.0,,,
,1.0,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,12198.0,BAO_0000019,Rattus norvegicus,CHEMBL615856,,10116.0,,,D,Expert,8003.0,9.0,,754.0,,,
,1.0,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198.0,BAO_0000019,Rattus norvegicus,CHEMBL615857,,10116.0,,,D,Expert,8003.0,9.0,,755.0,,,
,1.0,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,12198.0,BAO_0000019,Rattus norvegicus,CHEMBL615858,,10116.0,,,D,Expert,8003.0,9.0,,756.0,,,
Hippocampus,1.0,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10576.0,BAO_0000221,,CHEMBL615859,,,10000000.0,,H,Expert,12416.0,8.0,,757.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,51.0,BAO_0000357,,CHEMBL615860,,,,,H,Autocuration,16293.0,8.0,,758.0,,,
,1.0,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL615861,,9986.0,,,U,Autocuration,13047.0,0.0,,759.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,22226.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL615862,,9986.0,,,U,Autocuration,13047.0,0.0,,760.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,22226.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL615863,,9986.0,,,U,Autocuration,13047.0,0.0,,761.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,22226.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL615864,,9986.0,,,U,Autocuration,13047.0,0.0,,762.0,,,
Hippocampus,1.0,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744.0,BAO_0000221,,CHEMBL615865,,,10000000.0,,H,Autocuration,10085.0,4.0,,763.0,,,
Hippocampus,1.0,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744.0,BAO_0000221,,CHEMBL615866,,,10000000.0,,H,Autocuration,10085.0,4.0,,764.0,,,
Hippocampus,1.0,B,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,104744.0,BAO_0000221,,CHEMBL615867,,,10000000.0,,H,Autocuration,10085.0,4.0,,765.0,,,
,1.0,B,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,104744.0,BAO_0000249,,CHEMBL615868,,,,,H,Autocuration,9841.0,4.0,,766.0,Membranes,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,104744.0,BAO_0000249,Rattus norvegicus,CHEMBL615869,,10116.0,,,D,Autocuration,8822.0,5.0,,767.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,104744.0,BAO_0000019,Rattus norvegicus,CHEMBL615870,,10116.0,,,D,Autocuration,9806.0,5.0,,768.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,104744.0,BAO_0000019,Rattus norvegicus,CHEMBL615871,,10116.0,,,D,Autocuration,9806.0,5.0,,769.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,104744.0,BAO_0000224,,CHEMBL615872,,,,,H,Autocuration,8868.0,4.0,,770.0,,,
Hippocampus,1.0,B,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,104744.0,BAO_0000221,,CHEMBL833492,,,10000000.0,,H,Autocuration,9036.0,4.0,,771.0,,,
Hippocampus,1.0,B,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,104744.0,BAO_0000221,,CHEMBL615873,,,10000000.0,,H,Autocuration,11374.0,4.0,,772.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,104744.0,BAO_0000224,,CHEMBL615479,,,,,H,Autocuration,10881.0,4.0,,773.0,,,
,1.0,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,104744.0,BAO_0000019,,CHEMBL615480,,,,,H,Autocuration,8822.0,4.0,,774.0,,,
,1.0,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,104744.0,BAO_0000249,Rattus norvegicus,CHEMBL615481,,10116.0,,,D,Autocuration,9806.0,5.0,,775.0,,,
,1.0,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744.0,BAO_0000019,,CHEMBL872869,,,,,H,Autocuration,15463.0,4.0,,776.0,,,
,1.0,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744.0,BAO_0000019,,CHEMBL615482,,,,,H,Autocuration,15463.0,4.0,,777.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744.0,BAO_0000221,,CHEMBL615483,,,955.0,,H,Autocuration,14542.0,4.0,,778.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744.0,BAO_0000221,,CHEMBL615484,,,955.0,,H,Autocuration,14542.0,4.0,,779.0,,,
,1.0,B,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,104744.0,BAO_0000019,,CHEMBL615485,,,,,H,Autocuration,8569.0,4.0,,780.0,,,
,1.0,B,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,104744.0,BAO_0000224,Rattus norvegicus,CHEMBL615486,,10116.0,,,D,Autocuration,10062.0,5.0,,781.0,,,
,1.0,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,104744.0,BAO_0000224,,CHEMBL615487,,,,,H,Autocuration,4771.0,4.0,,782.0,,,
,1.0,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744.0,BAO_0000224,,CHEMBL615488,,,,,H,Autocuration,10062.0,4.0,,783.0,,,
,1.0,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744.0,BAO_0000224,,CHEMBL615489,,,,,H,Autocuration,10062.0,4.0,,784.0,,,
,1.0,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,104744.0,BAO_0000224,,CHEMBL615389,,,,,H,Autocuration,10062.0,4.0,,785.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744.0,BAO_0000019,,CHEMBL615390,,,,,H,Autocuration,15463.0,4.0,,786.0,,,
,1.0,B,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,104744.0,BAO_0000019,,CHEMBL615391,,,,,H,Autocuration,15463.0,4.0,,787.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,104744.0,BAO_0000224,,CHEMBL615392,,,,,H,Autocuration,9098.0,4.0,,788.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1 receptor,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615393,,10116.0,,,U,Autocuration,3070.0,0.0,,789.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,104744.0,BAO_0000221,,CHEMBL615394,,,955.0,,H,Autocuration,14542.0,4.0,,790.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,104744.0,BAO_0000221,,CHEMBL615395,,,955.0,,H,Autocuration,14542.0,4.0,,791.0,,,
,1.0,B,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,104744.0,BAO_0000224,,CHEMBL615396,,,,,H,Autocuration,6398.0,4.0,,792.0,,,
Brain,1.0,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,104744.0,BAO_0000221,,CHEMBL615397,,,955.0,,H,Autocuration,1344.0,4.0,,793.0,,,
,1.0,B,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,104744.0,BAO_0000019,,CHEMBL615398,,,,,H,Autocuration,11963.0,4.0,,794.0,,,
,1.0,B,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615399,,10116.0,,,U,Autocuration,8908.0,0.0,,795.0,,,
,1.0,B,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,104744.0,BAO_0000019,,CHEMBL615400,,,,,H,Autocuration,9098.0,4.0,,796.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,104744.0,BAO_0000019,Rattus norvegicus,CHEMBL615401,,10116.0,,,D,Autocuration,8841.0,5.0,,797.0,,,
,1.0,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL615402,,10116.0,,,U,Autocuration,8814.0,0.0,,798.0,,,
,1.0,B,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,104744.0,BAO_0000019,,CHEMBL615403,,,,,H,Autocuration,11752.0,4.0,,799.0,,,
Brain,1.0,B,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,104744.0,BAO_0000221,,CHEMBL615404,,,955.0,,H,Autocuration,11642.0,4.0,,800.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,104744.0,BAO_0000019,,CHEMBL615781,,,,,H,Autocuration,11642.0,4.0,,801.0,,,
Brain,1.0,B,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,104744.0,BAO_0000220,,CHEMBL615782,,,955.0,,H,Autocuration,9231.0,4.0,,802.0,,,
Brain,1.0,B,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,104744.0,BAO_0000221,,CHEMBL615783,,,955.0,,H,Autocuration,11351.0,4.0,,803.0,,,
,1.0,B,Compound was tested for binding affinity against 5-HT1 receptor,,,22226.0,BAO_0000019,,CHEMBL873481,,,,,U,Autocuration,4639.0,0.0,,804.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,22226.0,BAO_0000019,,CHEMBL615784,,,,,U,Autocuration,1205.0,0.0,,805.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576.0,BAO_0000357,,CHEMBL615785,,,,,H,Expert,10025.0,8.0,,806.0,,,
,1.0,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576.0,BAO_0000249,,CHEMBL615786,,,,,H,Autocuration,13241.0,8.0,,807.0,,,
,1.0,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576.0,BAO_0000218,,CHEMBL615787,In vivo,,,,H,Autocuration,16245.0,8.0,,808.0,,,
,1.0,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576.0,BAO_0000218,,CHEMBL615788,In vivo,,,,H,Autocuration,16245.0,8.0,,809.0,,,
,1.0,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,,CHEMBL767044,,,,,H,Autocuration,12438.0,8.0,,810.0,,,
,1.0,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,10576.0,BAO_0000218,,CHEMBL615789,In vivo,,,,H,Autocuration,16245.0,8.0,,811.0,,,
,1.0,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,10576.0,BAO_0000218,,CHEMBL615790,In vivo,,,,H,Autocuration,16245.0,8.0,,812.0,,,
,1.0,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,10576.0,BAO_0000019,,CHEMBL615813,,,,,H,Autocuration,15740.0,8.0,,813.0,,,
,1.0,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,10576.0,BAO_0000219,,CHEMBL615814,,,,,H,Autocuration,15535.0,8.0,,814.0,,,
,1.0,F,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,51.0,BAO_0000219,,CHEMBL615815,,,,,H,Expert,15535.0,8.0,,815.0,,,
,1.0,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,10576.0,BAO_0000219,,CHEMBL615816,,,,,H,Autocuration,15535.0,8.0,,816.0,,,
,1.0,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,10576.0,BAO_0000249,,CHEMBL615817,,,,,H,Expert,9888.0,8.0,,817.0,,,
Hippocampus,1.0,B,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,10576.0,BAO_0000221,,CHEMBL615818,,,10000000.0,,H,Autocuration,10085.0,8.0,,818.0,,,
Hippocampus,1.0,B,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,10576.0,BAO_0000221,,CHEMBL615819,,,10000000.0,,H,Autocuration,10085.0,8.0,,819.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,10576.0,BAO_0000249,,CHEMBL615820,,,,,H,Expert,17331.0,8.0,,820.0,Membranes,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615821,,10116.0,10000000.0,,D,Expert,10845.0,9.0,,821.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615822,,10116.0,10000000.0,,D,Expert,10845.0,9.0,,822.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL615823,,,10000000.0,,H,Expert,10845.0,8.0,,823.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615824,,10116.0,10000000.0,,D,Expert,10845.0,9.0,,824.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615825,,10116.0,10000000.0,,D,Expert,10845.0,9.0,,825.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000357,,CHEMBL615826,,,,,H,Expert,13730.0,8.0,,826.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000249,,CHEMBL615827,,,,,H,Expert,13508.0,8.0,,827.0,,,
Hippocampus,1.0,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000249,,CHEMBL615828,,,10000000.0,,H,Expert,13508.0,8.0,,828.0,,,
Hippocampus,1.0,B,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615829,,,10000000.0,,H,Expert,12073.0,8.0,,829.0,,,
Hippocampus,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL615830,,,10000000.0,,H,Autocuration,4671.0,8.0,,830.0,,,
Hippocampus,1.0,B,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,10576.0,BAO_0000221,,CHEMBL615831,,,10000000.0,,H,Expert,13631.0,8.0,,831.0,,,
,1.0,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL615832,,,,,H,Autocuration,12438.0,8.0,,832.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,10576.0,BAO_0000019,,CHEMBL615833,,,,,H,Autocuration,10483.0,8.0,,833.0,,,
Hippocampus,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL615834,,,10000000.0,,H,Autocuration,10483.0,8.0,,834.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,10576.0,BAO_0000249,,CHEMBL615835,,,,,H,Intermediate,12352.0,8.0,,835.0,,,
Hippocampus,1.0,B,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,10576.0,BAO_0000249,,CHEMBL615836,,,10000000.0,,H,Autocuration,14732.0,8.0,,836.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL615837,,10116.0,,,D,Expert,11049.0,9.0,,837.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL615838,,10116.0,,,D,Expert,11049.0,9.0,,838.0,,,
,1.0,B,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,10576.0,BAO_0000249,,CHEMBL615839,,,,,H,Expert,13657.0,8.0,,839.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,10576.0,BAO_0000019,,CHEMBL884525,,,,,H,Autocuration,11473.0,8.0,,840.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576.0,BAO_0000249,,CHEMBL615840,,,,,H,Autocuration,2014.0,8.0,,841.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615405,,,10000000.0,,H,Expert,3086.0,8.0,,842.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10576.0,BAO_0000019,,CHEMBL615406,,,,,H,Expert,15854.0,8.0,,843.0,,,
Hippocampus,1.0,B,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10576.0,BAO_0000221,,CHEMBL615900,,,10000000.0,,H,Expert,10922.0,8.0,,844.0,,,
Hippocampus,1.0,B,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,10576.0,BAO_0000221,,CHEMBL615901,,,10000000.0,,H,Expert,13346.0,8.0,,845.0,,,
,1.0,B,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,10576.0,BAO_0000357,,CHEMBL615902,,,,,H,Expert,15311.0,8.0,,846.0,,,
Hippocampus,1.0,B,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10576.0,BAO_0000221,,CHEMBL615903,,,10000000.0,,H,Autocuration,10922.0,8.0,,847.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,10576.0,BAO_0000357,,CHEMBL615904,,,,,H,Autocuration,10025.0,8.0,,848.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,10576.0,BAO_0000357,,CHEMBL615905,,,,,H,Expert,10025.0,8.0,,849.0,,,
,1.0,B,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576.0,BAO_0000019,,CHEMBL615906,,,,,H,Autocuration,9742.0,8.0,,850.0,,,
,1.0,F,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576.0,BAO_0000019,,CHEMBL615907,,,,,H,Autocuration,9742.0,8.0,,851.0,,,
,1.0,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576.0,BAO_0000019,,CHEMBL615908,,,,,H,Expert,12304.0,8.0,,852.0,,,
Hippocampus,1.0,B,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615909,,,10000000.0,,H,Autocuration,15789.0,8.0,,853.0,,,
,1.0,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,10576.0,BAO_0000019,,CHEMBL615910,,,,,H,Autocuration,9912.0,8.0,,854.0,,,
,1.0,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,10576.0,BAO_0000019,,CHEMBL615911,,,,,H,Autocuration,9912.0,8.0,,855.0,,,
,1.0,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,10576.0,BAO_0000019,,CHEMBL615912,,,,,H,Autocuration,9912.0,8.0,,856.0,,,
,1.0,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000019,,CHEMBL615913,,,,,H,Expert,16693.0,8.0,,857.0,,,
,1.0,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000357,,CHEMBL615914,,,,,H,Expert,13276.0,8.0,,858.0,,,
Hippocampus,1.0,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10576.0,BAO_0000221,,CHEMBL615915,,,10000000.0,,H,Autocuration,12678.0,8.0,,859.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,10576.0,BAO_0000357,,CHEMBL615916,,,,,H,Autocuration,11825.0,8.0,,860.0,,,
,1.0,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,10576.0,BAO_0000357,,CHEMBL615917,,,,,H,Expert,12443.0,8.0,,861.0,,,
,1.0,B,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL615918,,,,,H,Expert,13830.0,8.0,,862.0,,,
Hippocampus,1.0,B,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,10576.0,BAO_0000249,,CHEMBL615919,,,10000000.0,,H,Expert,14286.0,8.0,,863.0,,,
Hippocampus,1.0,B,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615920,,10116.0,10000000.0,,D,Expert,14356.0,9.0,,864.0,,,
,1.0,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL615921,,,,,H,Autocuration,15306.0,8.0,,865.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,10576.0,BAO_0000357,,CHEMBL615922,,,,,H,Expert,15306.0,8.0,,866.0,,,
,1.0,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL881290,,10116.0,,,D,Expert,16616.0,9.0,,867.0,,,
Hippocampus,1.0,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,10576.0,BAO_0000221,,CHEMBL615923,,,10000000.0,,H,Autocuration,3651.0,8.0,,868.0,,,
Hippocampus,1.0,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615924,,,10000000.0,,H,Autocuration,14331.0,8.0,,869.0,,,
Hippocampus,1.0,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615925,,,10000000.0,,H,Autocuration,14331.0,8.0,,870.0,,,
,1.0,B,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL615926,,10116.0,,,D,Expert,14178.0,9.0,,871.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL615927,,10116.0,,,D,Expert,10639.0,9.0,,872.0,,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL615928,,,10000000.0,,H,Autocuration,12306.0,8.0,,873.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL615929,,10116.0,,,D,Expert,1348.0,9.0,,874.0,,,
Hippocampus,1.0,B,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615930,,,10000000.0,,H,Autocuration,13605.0,8.0,,875.0,,,
,1.0,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615931,,,,,H,Autocuration,17624.0,8.0,449.0,876.0,,,
,1.0,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615932,,,,,H,Autocuration,17624.0,8.0,449.0,877.0,,,
,1.0,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615933,,,,,H,Autocuration,17624.0,8.0,449.0,878.0,,,
,1.0,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615934,,,,,H,Autocuration,15267.0,8.0,,879.0,,,
,1.0,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,51.0,BAO_0000357,,CHEMBL615935,,,,,H,Autocuration,16532.0,8.0,,880.0,,,
,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,51.0,BAO_0000019,,CHEMBL615936,,,,,H,Autocuration,6563.0,8.0,,881.0,,,
,1.0,B,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,CHO,51.0,BAO_0000219,,CHEMBL615937,,,,,H,Autocuration,4751.0,8.0,449.0,882.0,,,
,1.0,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615938,,,,,H,Autocuration,15463.0,8.0,,883.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,51.0,BAO_0000357,,CHEMBL615797,,,,,H,Autocuration,3805.0,8.0,,884.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615798,,,,,H,Autocuration,5640.0,8.0,,885.0,,,
,1.0,B,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,51.0,BAO_0000357,,CHEMBL872870,,,,,H,Autocuration,6563.0,8.0,,886.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,51.0,BAO_0000357,,CHEMBL615799,,,,,H,Autocuration,5548.0,8.0,,887.0,,,
,1.0,B,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615800,,,,,H,Autocuration,6347.0,8.0,,888.0,,,
,1.0,F,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51.0,BAO_0000219,,CHEMBL615801,,,,,H,Autocuration,17296.0,8.0,722.0,889.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,51.0,BAO_0000019,,CHEMBL615802,,,,,H,Autocuration,13047.0,8.0,,890.0,,,
,1.0,B,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,51.0,BAO_0000357,,CHEMBL615803,,,,,H,Autocuration,15740.0,8.0,,891.0,,,
,1.0,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,51.0,BAO_0000019,,CHEMBL835002,,,,,H,Expert,5640.0,8.0,,892.0,,,
,1.0,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,51.0,BAO_0000019,,CHEMBL615804,,,,,H,Autocuration,5640.0,8.0,,893.0,,,
,1.0,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,HeLa,51.0,BAO_0000219,,CHEMBL615805,,,,,H,Expert,17211.0,8.0,308.0,894.0,,,
,1.0,B,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL615806,,,,,H,Autocuration,4751.0,8.0,449.0,895.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL615807,,9606.0,,,D,Expert,6491.0,9.0,,896.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,51.0,BAO_0000357,,CHEMBL615808,,,,,H,Autocuration,4707.0,8.0,,897.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL615809,,9606.0,,,D,Expert,13910.0,9.0,,898.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,HeLa,51.0,BAO_0000219,,CHEMBL615810,,,,,H,Autocuration,16190.0,8.0,308.0,899.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615811,,,,,H,Autocuration,16633.0,8.0,,900.0,,,
,1.0,B,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615812,,,,,H,Autocuration,11898.0,8.0,449.0,901.0,,,
,1.0,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL615751,,,,,H,Autocuration,11898.0,8.0,449.0,902.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615752,,,,,H,Autocuration,14331.0,8.0,,903.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,CHO,51.0,BAO_0000219,,CHEMBL615753,,,,,H,Expert,17624.0,8.0,449.0,904.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,CHO,51.0,BAO_0000219,,CHEMBL615754,,,,,H,Autocuration,17624.0,8.0,449.0,905.0,,,
,1.0,B,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615755,,,,,H,Autocuration,3307.0,8.0,,906.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615756,,9606.0,,,D,Expert,6563.0,9.0,449.0,907.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000019,,CHEMBL615757,,,,,H,Autocuration,14165.0,8.0,,908.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL615758,,,,,H,Autocuration,5732.0,8.0,,909.0,,,
,1.0,B,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51.0,BAO_0000357,,CHEMBL615759,,,,,H,Expert,13366.0,8.0,,910.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615760,,,,,H,Autocuration,17626.0,8.0,,911.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,HeLa,51.0,BAO_0000219,,CHEMBL615761,,,,,H,Expert,6588.0,8.0,308.0,912.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,51.0,BAO_0000357,,CHEMBL872104,,,,,H,Autocuration,16209.0,8.0,,913.0,,,
,1.0,B,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615762,,,,,H,Autocuration,15463.0,8.0,,914.0,,,
,1.0,B,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615763,,,,,H,Autocuration,15463.0,8.0,,915.0,,,
,1.0,B,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,51.0,BAO_0000357,,CHEMBL615764,,,,,H,Autocuration,14770.0,8.0,,916.0,,,
,1.0,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,Cell line,51.0,BAO_0000219,,CHEMBL615765,,,,,H,Autocuration,16245.0,8.0,1167.0,917.0,,,
,1.0,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,51.0,BAO_0000019,,CHEMBL615766,,,,,H,Autocuration,16245.0,8.0,,918.0,,,
,1.0,B,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615767,,,,,H,Autocuration,5548.0,8.0,,919.0,,,
,1.0,B,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615768,,,,,H,Expert,5548.0,8.0,,920.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615769,,,,,H,Autocuration,5548.0,8.0,,921.0,,,
,1.0,B,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,51.0,BAO_0000357,,CHEMBL615770,,,,,H,Expert,6876.0,8.0,,922.0,,,
,1.0,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615771,,,,,H,Autocuration,2598.0,8.0,,923.0,,,
,1.0,B,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,51.0,BAO_0000357,,CHEMBL615772,,,,,H,Expert,17785.0,8.0,,924.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL615773,,,,,H,Autocuration,6013.0,8.0,,925.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615774,,,,,H,Expert,5929.0,8.0,,926.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615775,,,,,H,Autocuration,16633.0,8.0,,927.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL615776,,,,,H,Autocuration,1558.0,8.0,,928.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL615777,,,,,H,Expert,16026.0,8.0,,929.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,51.0,BAO_0000219,,CHEMBL615778,,,,,H,Autocuration,12469.0,8.0,,930.0,,,
,1.0,B,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51.0,BAO_0000357,Homo sapiens,CHEMBL615779,,9606.0,,,D,Expert,15874.0,9.0,,931.0,,,
,1.0,B,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,51.0,BAO_0000357,,CHEMBL615780,,,,,H,Autocuration,15874.0,8.0,,932.0,,,
,1.0,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616298,,,,,H,Autocuration,3935.0,8.0,,933.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616299,,,,,H,Autocuration,15818.0,8.0,,934.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,CHO-K1,51.0,BAO_0000219,,CHEMBL616300,,,,,H,Autocuration,13706.0,8.0,485.0,935.0,,,
,1.0,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,CHO-K1,51.0,BAO_0000219,,CHEMBL616301,,,,,H,Expert,13729.0,8.0,485.0,936.0,,,
,1.0,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL616302,,,,,H,Autocuration,15413.0,8.0,,937.0,,,
,1.0,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,51.0,BAO_0000019,,CHEMBL616117,,,,,H,Autocuration,15413.0,8.0,,938.0,,,
,1.0,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,51.0,BAO_0000019,,CHEMBL616118,,,,,H,Autocuration,15413.0,8.0,,939.0,,,
,1.0,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,51.0,BAO_0000019,,CHEMBL616119,,,,,H,Autocuration,15413.0,8.0,,940.0,,,
,1.0,B,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616120,,9606.0,,,D,Expert,3445.0,9.0,308.0,941.0,,,
,1.0,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616121,,,,,H,Autocuration,15740.0,8.0,,942.0,,,
,1.0,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,51.0,BAO_0000357,,CHEMBL616122,,,,,H,Autocuration,15740.0,8.0,,943.0,,,
,1.0,B,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616123,,,,,H,Autocuration,17626.0,8.0,,944.0,,,
,1.0,B,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616124,,9606.0,,,D,Expert,4234.0,9.0,,945.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,51.0,BAO_0000357,,CHEMBL616125,,,,,H,Expert,5640.0,8.0,,946.0,,,
,1.0,B,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,51.0,BAO_0000357,Rattus norvegicus,CHEMBL616126,,10116.0,,,H,Expert,5272.0,8.0,,947.0,,,
,1.0,B,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,CHO,51.0,BAO_0000219,,CHEMBL616127,,,,,H,Autocuration,4622.0,8.0,449.0,948.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL616128,,,,,H,Expert,17085.0,8.0,,949.0,,,
,1.0,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,51.0,BAO_0000357,,CHEMBL616129,,,,,H,Autocuration,3025.0,8.0,,950.0,,,
,1.0,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616130,,,,,H,Expert,15315.0,8.0,,951.0,,,
,1.0,B,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,51.0,BAO_0000357,,CHEMBL616131,,,,,H,Autocuration,15267.0,8.0,,952.0,,,
,1.0,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,HeLa,51.0,BAO_0000219,,CHEMBL616132,,,,,H,Autocuration,17158.0,8.0,308.0,953.0,,,
,1.0,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616133,,9606.0,,,D,Expert,14214.0,9.0,308.0,954.0,,,
,1.0,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL616134,,,,,H,Autocuration,17133.0,8.0,,955.0,,,
,1.0,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,51.0,BAO_0000357,,CHEMBL616135,,,,,H,Autocuration,16532.0,8.0,,956.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616136,,9606.0,,,D,Expert,2391.0,9.0,,957.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,51.0,BAO_0000019,,CHEMBL616137,,,,,H,Autocuration,14447.0,8.0,,958.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,51.0,BAO_0000019,,CHEMBL872105,,,,,H,Autocuration,14447.0,8.0,,959.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,51.0,BAO_0000357,,CHEMBL616138,,,,,H,Autocuration,15086.0,8.0,,960.0,,,
,1.0,B,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616139,,9606.0,,,D,Expert,13051.0,9.0,,961.0,,,
,1.0,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,51.0,BAO_0000019,,CHEMBL616140,,,,,H,Autocuration,16026.0,8.0,,962.0,,,
,1.0,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,51.0,BAO_0000019,,CHEMBL616141,,,,,H,Expert,17085.0,8.0,,963.0,,,
,1.0,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL616142,,,,,H,Autocuration,17133.0,8.0,,964.0,,,
,1.0,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,51.0,BAO_0000357,,CHEMBL616143,,,,,H,Autocuration,17133.0,8.0,,965.0,,,
,1.0,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51.0,BAO_0000219,,CHEMBL616144,,,,,H,Autocuration,17211.0,8.0,308.0,966.0,,,
,1.0,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,HeLa,51.0,BAO_0000219,,CHEMBL616145,,,,,H,Autocuration,17211.0,8.0,308.0,967.0,,,
,1.0,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51.0,BAO_0000219,,CHEMBL616012,,,,,H,Autocuration,17211.0,8.0,308.0,968.0,,,
,1.0,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,HeLa,51.0,BAO_0000219,,CHEMBL616013,,,,,H,Autocuration,17211.0,8.0,308.0,969.0,,,
,1.0,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51.0,BAO_0000019,,CHEMBL616014,,,,,H,Autocuration,16394.0,8.0,,970.0,,,
,1.0,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51.0,BAO_0000019,,CHEMBL616015,,,,,H,Autocuration,16394.0,8.0,,971.0,,,
,1.0,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,51.0,BAO_0000019,,CHEMBL616016,,,,,H,Autocuration,16394.0,8.0,,972.0,,,
,1.0,F,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,51.0,BAO_0000218,,CHEMBL616017,In vivo,,,,H,Autocuration,16394.0,8.0,,973.0,,,
,1.0,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,51.0,BAO_0000019,,CHEMBL616018,,,,,H,Autocuration,16394.0,8.0,,974.0,,,
,1.0,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,51.0,BAO_0000019,,CHEMBL616019,,,,,H,Autocuration,15740.0,8.0,,975.0,,,
,1.0,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,51.0,BAO_0000019,,CHEMBL616020,,,,,H,Autocuration,15740.0,8.0,,976.0,,,
,1.0,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL858018,,,,,H,Autocuration,15740.0,8.0,,977.0,,,
,1.0,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51.0,BAO_0000219,,CHEMBL616021,,,,,H,Autocuration,17296.0,8.0,722.0,978.0,,,
,1.0,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,51.0,BAO_0000019,,CHEMBL616022,,,,,H,Expert,5640.0,8.0,,979.0,,,
,1.0,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,51.0,BAO_0000019,,CHEMBL616023,,,,,H,Autocuration,5640.0,8.0,,980.0,,,
,1.0,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,51.0,BAO_0000019,,CHEMBL616024,,,,,H,Autocuration,5640.0,8.0,,981.0,,,
,1.0,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,51.0,BAO_0000019,,CHEMBL616025,,,,,H,Autocuration,5640.0,8.0,,982.0,,,
,1.0,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHO,51.0,BAO_0000219,,CHEMBL616026,,,,,H,Autocuration,2759.0,8.0,449.0,983.0,,,
,1.0,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,51.0,BAO_0000019,,CHEMBL616027,,,,,H,Autocuration,16394.0,8.0,,984.0,,,
,1.0,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,51.0,BAO_0000019,Homo sapiens,CHEMBL616028,,9606.0,,,D,Expert,16394.0,9.0,,985.0,,,
,1.0,F,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616029,,9606.0,,,D,Expert,3445.0,9.0,,986.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,CHO,51.0,BAO_0000219,,CHEMBL616030,,,,,H,Expert,4316.0,8.0,449.0,987.0,,,
,1.0,B,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,51.0,BAO_0000019,,CHEMBL616031,,,,,H,Expert,4316.0,8.0,,988.0,,,
,1.0,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616032,,9606.0,,,D,Expert,15180.0,9.0,,989.0,,,
,1.0,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,51.0,BAO_0000019,Homo sapiens,CHEMBL616033,,9606.0,,,D,Expert,15180.0,9.0,,990.0,,,
,1.0,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51.0,BAO_0000019,,CHEMBL616034,,,,,H,Autocuration,15042.0,8.0,,991.0,,,
,1.0,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51.0,BAO_0000019,,CHEMBL616035,,,,,H,Autocuration,15042.0,8.0,,992.0,,,
,1.0,F,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL616036,,,,,H,Autocuration,15042.0,8.0,,993.0,,,
,1.0,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51.0,BAO_0000019,,CHEMBL616037,,,,,H,Autocuration,15042.0,8.0,,994.0,,,
,1.0,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51.0,BAO_0000019,,CHEMBL616038,,,,,H,Autocuration,15042.0,8.0,,995.0,,,
,1.0,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,51.0,BAO_0000019,,CHEMBL616039,,,,,H,Autocuration,15042.0,8.0,,996.0,,,
,1.0,F,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL616040,,,,,H,Autocuration,15042.0,8.0,,997.0,,,
,1.0,F,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616041,,9606.0,,,D,Expert,15180.0,9.0,308.0,998.0,,,
,1.0,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616042,,9606.0,,,D,Expert,15180.0,9.0,308.0,999.0,,,
,1.0,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616043,,9606.0,,,D,Expert,15180.0,9.0,308.0,1000.0,,,
,1.0,F,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,51.0,BAO_0000019,,CHEMBL616044,,,,,H,Autocuration,16245.0,8.0,,1001.0,,,
,1.0,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51.0,BAO_0000019,,CHEMBL616045,,,,,H,Autocuration,16026.0,8.0,,1002.0,,,
,1.0,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,HEK293,51.0,BAO_0000219,,CHEMBL616046,,,,,H,Autocuration,17296.0,8.0,722.0,1003.0,,,
,1.0,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHO,51.0,BAO_0000219,,CHEMBL616047,,,,,H,Autocuration,2759.0,8.0,449.0,1004.0,,,
,1.0,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL616048,,,,,H,Autocuration,2759.0,8.0,449.0,1005.0,,,
,1.0,F,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL616049,,9606.0,,,D,Expert,2759.0,9.0,449.0,1006.0,,,
,1.0,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHO,51.0,BAO_0000219,,CHEMBL616050,,,,,H,Autocuration,2759.0,8.0,449.0,1007.0,,,
,1.0,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,51.0,BAO_0000219,,CHEMBL616051,,,,,H,Expert,15419.0,8.0,,1008.0,,,
,1.0,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,51.0,BAO_0000219,,CHEMBL616212,,,,,H,Autocuration,15419.0,8.0,,1009.0,,,
,1.0,F,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,51.0,BAO_0000019,,CHEMBL616213,,,,,H,Autocuration,16026.0,8.0,,1010.0,,,
,1.0,B,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,51.0,BAO_0000219,,CHEMBL616214,In vitro,,,,H,Expert,1414.0,8.0,,1011.0,,,
,1.0,B,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,51.0,BAO_0000219,,CHEMBL616215,In vitro,,,,H,Expert,1414.0,8.0,,1012.0,,,
,1.0,B,Binding activity radioligand.,,,51.0,BAO_0000357,,CHEMBL616216,,,,,H,Autocuration,12861.0,8.0,,1013.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,51.0,BAO_0000019,,CHEMBL616217,,,,,H,Autocuration,12861.0,8.0,,1014.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616218,,,,,H,Autocuration,5104.0,8.0,,1015.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616219,,,,,H,Autocuration,5105.0,8.0,,1016.0,,,
,1.0,B,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616220,,,,,H,Autocuration,16312.0,8.0,,1017.0,,,
,1.0,B,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL833493,,9606.0,,,D,Expert,15180.0,9.0,,1018.0,,,
,1.0,B,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616221,,,,,H,Autocuration,5033.0,8.0,,1019.0,,,
,1.0,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL616222,,9606.0,,,D,Expert,16909.0,9.0,449.0,1020.0,,,
,1.0,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,,CHEMBL616223,,,,,H,Autocuration,2590.0,8.0,,1021.0,,,
,1.0,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,51.0,BAO_0000019,,CHEMBL616224,,,,,H,Autocuration,2590.0,8.0,,1022.0,,,
,1.0,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,51.0,BAO_0000019,,CHEMBL616225,,,,,H,Expert,16394.0,8.0,,1023.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,HEK293,51.0,BAO_0000219,Homo sapiens,CHEMBL616226,,9606.0,,,D,Expert,4540.0,9.0,722.0,1024.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,HEK293,51.0,BAO_0000219,,CHEMBL616227,,,,,H,Autocuration,17296.0,8.0,722.0,1025.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,HEK293,51.0,BAO_0000219,,CHEMBL616228,,,,,H,Autocuration,17296.0,8.0,722.0,1026.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,HEK293,51.0,BAO_0000219,,CHEMBL616229,,,,,H,Autocuration,15779.0,8.0,722.0,1027.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,HEK293,51.0,BAO_0000219,,CHEMBL616230,,,,,H,Autocuration,15779.0,8.0,722.0,1028.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,HEK293,51.0,BAO_0000219,,CHEMBL616231,,,,,H,Autocuration,15779.0,8.0,722.0,1029.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL616232,,,,,H,Autocuration,6166.0,8.0,,1030.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,HEK293,51.0,BAO_0000219,,CHEMBL616233,,,,,H,Autocuration,15779.0,8.0,722.0,1031.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,HEK293,51.0,BAO_0000219,,CHEMBL857973,,,,,H,Autocuration,4199.0,8.0,722.0,1032.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,51.0,BAO_0000219,,CHEMBL616234,,,,,H,Autocuration,15316.0,8.0,,1033.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616235,,,,,H,Autocuration,14875.0,8.0,,1034.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,HeLa,51.0,BAO_0000219,,CHEMBL616236,,,,,H,Expert,14727.0,8.0,308.0,1035.0,,,
,1.0,B,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,51.0,BAO_0000019,,CHEMBL616237,,,,,H,Expert,14727.0,8.0,,1036.0,,,
,1.0,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,HEK293,51.0,BAO_0000219,,CHEMBL616238,,,,,H,Autocuration,15146.0,8.0,722.0,1037.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,HEK293,51.0,BAO_0000219,,CHEMBL616239,,,,,H,Autocuration,5213.0,8.0,722.0,1038.0,,,
,1.0,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,51.0,BAO_0000219,,CHEMBL616240,,,,,H,Autocuration,16429.0,8.0,,1039.0,,,
,1.0,B,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,HeLa,51.0,BAO_0000219,Homo sapiens,CHEMBL616241,,9606.0,,,D,Expert,15042.0,9.0,308.0,1040.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,HEK293,51.0,BAO_0000219,,CHEMBL616242,,,,,H,Autocuration,14818.0,8.0,722.0,1041.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,HEK293,51.0,BAO_0000219,,CHEMBL616243,,,,,H,Autocuration,4829.0,8.0,722.0,1042.0,,,
,1.0,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616244,,,,,D,Expert,17200.0,9.0,,1043.0,,,
,1.0,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616245,,9606.0,,,D,Autocuration,13051.0,9.0,,1044.0,,,
,1.0,B,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,106.0,BAO_0000357,,CHEMBL616246,,,,,H,Autocuration,5486.0,8.0,,1045.0,,,
,1.0,B,Binding affinity against 5-HT1D receptor,,,105.0,BAO_0000357,,CHEMBL616247,,,,,H,Autocuration,5254.0,8.0,,1046.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,105.0,BAO_0000357,,CHEMBL616248,,,,,H,Autocuration,5254.0,8.0,,1047.0,,,
,1.0,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,107.0,BAO_0000357,,CHEMBL616249,,,,,H,Autocuration,15331.0,8.0,,1048.0,,,
,1.0,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576.0,BAO_0000357,Homo sapiens,CHEMBL616250,,9606.0,,,H,Autocuration,13506.0,8.0,,1049.0,,,
,1.0,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616251,,,,,H,Autocuration,15267.0,8.0,,1050.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,11863.0,BAO_0000218,,CHEMBL616252,In vivo,,,,H,Autocuration,16616.0,8.0,,1051.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,11863.0,BAO_0000218,,CHEMBL616253,In vivo,,,,H,Autocuration,16616.0,8.0,,1052.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,11863.0,BAO_0000218,,CHEMBL616254,In vivo,,,,H,Autocuration,16616.0,8.0,,1053.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL616255,,10090.0,,,D,Expert,16616.0,9.0,,1054.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL832872,,10090.0,,,D,Expert,16616.0,9.0,,1055.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL616256,,10090.0,,,D,Expert,16616.0,9.0,,1056.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL616257,,10090.0,,,D,Expert,16616.0,9.0,,1057.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL616258,,10090.0,,,D,Expert,16616.0,9.0,,1058.0,,,
,1.0,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,11863.0,BAO_0000218,Mus musculus,CHEMBL616384,,10090.0,,,D,Expert,16616.0,9.0,,1059.0,,,
Hippocampus,1.0,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,11863.0,BAO_0000221,,CHEMBL616385,,,10000000.0,,H,Autocuration,10297.0,8.0,,1060.0,,,
,1.0,B,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,11863.0,BAO_0000357,,CHEMBL616386,,,,,H,Expert,13704.0,8.0,,1061.0,,,
Hippocampus,1.0,B,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,11863.0,BAO_0000221,Mus musculus,CHEMBL616387,,10090.0,10000000.0,,D,Expert,10297.0,9.0,,1062.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,11863.0,BAO_0000221,,CHEMBL616388,,,10000000.0,,H,Autocuration,10297.0,8.0,,1063.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,11863.0,BAO_0000221,Mus musculus,CHEMBL616389,,10090.0,10000000.0,,D,Expert,10297.0,9.0,,1064.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,11863.0,BAO_0000221,,CHEMBL616390,,,10000000.0,,H,Autocuration,10297.0,8.0,,1065.0,,,
,1.0,B,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,11863.0,BAO_0000357,,CHEMBL616391,,,,,H,Autocuration,217.0,8.0,,1066.0,,,
Hippocampus,1.0,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,11863.0,BAO_0000221,Mus musculus,CHEMBL616392,,10090.0,10000000.0,,D,Expert,10297.0,9.0,,1067.0,,,
,1.0,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Sus scrofa,CHEMBL616393,,9823.0,,,H,Autocuration,4921.0,8.0,,1068.0,,,
,1.0,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,51.0,BAO_0000357,Sus scrofa,CHEMBL616394,,9823.0,,,H,Autocuration,4921.0,8.0,,1069.0,,,
,1.0,B,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616395,,9823.0,,,H,Autocuration,4996.0,8.0,,1070.0,,,
,1.0,B,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,51.0,BAO_0000357,Sus scrofa,CHEMBL616396,,9823.0,,,H,Autocuration,12918.0,8.0,,1071.0,,,
,1.0,B,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51.0,BAO_0000019,Sus scrofa,CHEMBL872907,,9823.0,,,H,Autocuration,5333.0,8.0,,1072.0,,,
,1.0,B,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616397,,9823.0,,,H,Autocuration,4437.0,8.0,,1073.0,,,
,1.0,B,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616398,,9823.0,,,H,Autocuration,1742.0,8.0,,1074.0,,,
,1.0,B,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,Sus scrofa,CHEMBL616399,,9823.0,,,H,Expert,16688.0,8.0,,1075.0,,,
,1.0,B,Binding activity radioligand.,,,51.0,BAO_0000357,Sus scrofa,CHEMBL857065,,9823.0,,,H,Autocuration,12861.0,8.0,,1076.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616400,,9823.0,,,H,Expert,12861.0,8.0,,1077.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616401,,9823.0,,,H,Autocuration,12861.0,8.0,,1078.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,10624.0,BAO_0000019,,CHEMBL616402,,,,,H,Expert,12490.0,8.0,,1079.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616403,,9823.0,,,H,Expert,11828.0,8.0,,1080.0,,,
Hippocampus,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,51.0,BAO_0000221,Sus scrofa,CHEMBL616404,,9823.0,10000000.0,,H,Autocuration,11866.0,8.0,,1081.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,51.0,BAO_0000249,Sus scrofa,CHEMBL616405,,9823.0,,,H,Autocuration,12827.0,8.0,,1082.0,,,
,1.0,B,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616406,,9823.0,,,H,Autocuration,12918.0,8.0,,1083.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,51.0,BAO_0000019,Sus scrofa,CHEMBL616407,,9823.0,,,H,Expert,12919.0,8.0,,1084.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,51.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616408,,9986.0,,,H,Autocuration,13047.0,8.0,,1085.0,,,
,1.0,B,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616409,,10116.0,,,D,Expert,15796.0,9.0,,1086.0,,,
Hippocampus,1.0,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616410,,10116.0,10000000.0,,D,Expert,3651.0,9.0,,1087.0,,,
,1.0,B,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,10576.0,BAO_0000357,,CHEMBL616411,,,,,H,Autocuration,188.0,8.0,,1088.0,,,
,1.0,F,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616412,,10116.0,,,D,Expert,16616.0,9.0,,1089.0,Membranes,,
Hippocampus,1.0,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616413,,10116.0,10000000.0,,D,Expert,16616.0,9.0,,1090.0,Membranes,,
Hippocampus,1.0,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616414,,,10000000.0,,H,Autocuration,12306.0,8.0,,1091.0,,,
Hippocampus,1.0,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616415,,10116.0,10000000.0,,D,Expert,17167.0,9.0,,1092.0,,,
,1.0,B,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,10576.0,BAO_0000019,,CHEMBL616416,,,,,H,Autocuration,14776.0,8.0,,1093.0,,,
,1.0,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,10576.0,BAO_0000357,,CHEMBL616417,,,,,H,Expert,12158.0,8.0,,1094.0,,,
,1.0,B,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,10576.0,BAO_0000357,,CHEMBL616418,,,,,H,Autocuration,13481.0,8.0,,1095.0,,,
,1.0,B,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,10576.0,BAO_0000219,,CHEMBL616419,In vitro,,,,H,Autocuration,13427.0,8.0,,1096.0,,,
,1.0,B,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616420,,,,,H,Autocuration,10210.0,8.0,,1097.0,,,
,1.0,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576.0,BAO_0000249,,CHEMBL616421,,,,,H,Autocuration,10205.0,8.0,,1098.0,Membranes,,
,1.0,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,10576.0,BAO_0000249,,CHEMBL616422,,,,,H,Autocuration,10205.0,8.0,,1099.0,Membranes,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,10576.0,BAO_0000249,,CHEMBL616423,,,,,H,Expert,10205.0,8.0,,1100.0,Membranes,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616424,,10116.0,,,D,Expert,12280.0,9.0,,1101.0,,,
,1.0,B,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616425,,,,,H,Expert,17386.0,8.0,,1102.0,,,
,1.0,B,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,10576.0,BAO_0000357,,CHEMBL616426,,,,,H,Expert,13654.0,8.0,,1103.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,10576.0,BAO_0000221,,CHEMBL616427,,,10000000.0,,H,Autocuration,14423.0,8.0,,1104.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,10576.0,BAO_0000221,,CHEMBL616428,,,10000000.0,,H,Autocuration,15412.0,8.0,,1105.0,,,
Hippocampus,1.0,B,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616290,,,10000000.0,,H,Autocuration,12073.0,8.0,,1106.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616052,,10116.0,,,D,Expert,4101.0,9.0,,1107.0,,,
,1.0,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616053,,,,,H,Autocuration,10062.0,8.0,,1108.0,,,
,1.0,B,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000249,,CHEMBL616054,,,,,H,Autocuration,6238.0,8.0,,1109.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616055,,,,,H,Autocuration,16273.0,8.0,,1110.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,10576.0,BAO_0000357,,CHEMBL616056,,,,,H,Autocuration,11139.0,8.0,,1111.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576.0,BAO_0000019,,CHEMBL616057,,,,,H,Expert,16796.0,8.0,,1112.0,,,
Brain,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616058,,10116.0,955.0,,D,Expert,9548.0,9.0,,1113.0,,,
Brain,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576.0,BAO_0000221,,CHEMBL616059,,,955.0,,H,Autocuration,10381.0,8.0,,1114.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000249,,CHEMBL616060,,,,,H,Autocuration,13408.0,8.0,,1115.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616061,,10116.0,10000000.0,,D,Expert,13825.0,9.0,,1116.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,10576.0,BAO_0000221,,CHEMBL616062,,,10000000.0,,H,Expert,11147.0,8.0,,1117.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000249,,CHEMBL616063,,,,,H,Autocuration,10552.0,8.0,,1118.0,,,
Striatum,1.0,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,10576.0,BAO_0000249,,CHEMBL616064,,,2435.0,,H,Autocuration,10552.0,8.0,,1119.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616065,,10116.0,,,D,Expert,17136.0,9.0,,1120.0,Membranes,,
,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616066,,10116.0,,,D,Expert,5778.0,9.0,,1121.0,Membranes,,
Hippocampus,1.0,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616067,,,10000000.0,,H,Autocuration,13481.0,8.0,,1122.0,,,
Hippocampus,1.0,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,10576.0,BAO_0000221,,CHEMBL616068,,,10000000.0,,H,Autocuration,13481.0,8.0,,1123.0,,,
Hippocampus,1.0,B,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616069,,,10000000.0,,H,Intermediate,13630.0,8.0,,1124.0,,,
,1.0,B,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576.0,BAO_0000249,,CHEMBL616070,,,,,H,Expert,16245.0,8.0,,1125.0,,,
Hippocampus,1.0,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616071,,,10000000.0,,H,Autocuration,14509.0,8.0,,1126.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000221,,CHEMBL616072,,,10000000.0,,H,Expert,14509.0,8.0,,1127.0,,,
Hippocampus,1.0,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,10576.0,BAO_0000221,,CHEMBL616073,,,10000000.0,,H,Autocuration,14509.0,8.0,,1128.0,,,
Hippocampus,1.0,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,10576.0,BAO_0000221,,CHEMBL616074,,,10000000.0,,H,Autocuration,14509.0,8.0,,1129.0,,,
,1.0,B,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,10576.0,BAO_0000019,,CHEMBL616075,,,,,H,Expert,14256.0,8.0,,1130.0,,,
,1.0,B,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616076,,,,,H,Autocuration,11139.0,8.0,,1131.0,,,
,1.0,B,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616077,,10116.0,,,D,Expert,11047.0,9.0,,1132.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616078,,10116.0,,,D,Expert,11047.0,9.0,,1133.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616079,,10116.0,,,D,Expert,11047.0,9.0,,1134.0,,,
,1.0,B,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHO-K1,10576.0,BAO_0000219,Rattus norvegicus,CHEMBL616080,,10116.0,,,D,Expert,2395.0,9.0,485.0,1135.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616081,,,,,H,Autocuration,9699.0,8.0,,1136.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616082,,10116.0,10000000.0,,D,Expert,12028.0,9.0,,1137.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,10576.0,BAO_0000221,,CHEMBL616083,,,10000000.0,,H,Autocuration,12028.0,8.0,,1138.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576.0,BAO_0000019,,CHEMBL616084,,,,,H,Autocuration,5815.0,8.0,,1139.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,10576.0,BAO_0000019,,CHEMBL616085,,,,,H,Expert,16616.0,8.0,,1140.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,10576.0,BAO_0000019,,CHEMBL616086,,,,,H,Autocuration,5815.0,8.0,,1141.0,,,
Hippocampus,1.0,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,10576.0,BAO_0000221,,CHEMBL616087,,,10000000.0,,H,Autocuration,2761.0,8.0,,1142.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,10576.0,BAO_0000357,,CHEMBL616088,,,,,H,Expert,13133.0,8.0,,1143.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,10576.0,BAO_0000019,,CHEMBL616089,,,,,H,Autocuration,10444.0,8.0,,1144.0,,,
,1.0,B,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616090,,10116.0,,,D,Expert,13278.0,9.0,,1145.0,,,
,1.0,B,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616091,,,,,H,Autocuration,15874.0,8.0,,1146.0,,,
Striatum,1.0,B,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,10576.0,BAO_0000249,,CHEMBL616092,,,2435.0,,H,Autocuration,10552.0,8.0,,1147.0,Membranes,,
,1.0,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,10576.0,BAO_0000357,,CHEMBL616093,,,,,H,Autocuration,11130.0,8.0,,1148.0,,,
,1.0,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,10576.0,BAO_0000218,,CHEMBL616094,In vivo,,,,H,Autocuration,11130.0,8.0,,1149.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,10576.0,BAO_0000221,,CHEMBL616095,,,955.0,,H,Autocuration,14542.0,8.0,,1150.0,,,
,1.0,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616096,,10116.0,,,D,Expert,13670.0,9.0,,1151.0,,,
,1.0,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,10576.0,BAO_0000249,,CHEMBL616097,,,,,H,Expert,9888.0,8.0,,1152.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616098,,10116.0,,,D,Expert,3678.0,9.0,,1153.0,Membranes,,
Hippocampus,1.0,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616099,,,10000000.0,,H,Autocuration,11332.0,8.0,,1154.0,,,
Hippocampus,1.0,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616100,,,10000000.0,,H,Autocuration,11332.0,8.0,,1155.0,,,
,1.0,B,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616101,,,,,H,Expert,1185.0,8.0,,1156.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,10576.0,BAO_0000249,,CHEMBL616102,,,,,H,Expert,2014.0,8.0,,1157.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616103,,,,,H,Autocuration,1185.0,8.0,,1158.0,,,
,1.0,B,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,10576.0,BAO_0000019,,CHEMBL616104,,,,,H,Expert,14429.0,8.0,,1159.0,,,
,1.0,B,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,10576.0,BAO_0000019,,CHEMBL616105,,,,,H,Expert,16288.0,8.0,,1160.0,,,
,1.0,B,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616106,,10116.0,,,D,Expert,5432.0,9.0,,1161.0,,,
,1.0,B,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,10576.0,BAO_0000019,,CHEMBL616107,,,,,H,Autocuration,14429.0,8.0,,1162.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,10576.0,BAO_0000357,,CHEMBL616108,,,,,H,Expert,13672.0,8.0,,1163.0,,,
Hippocampus,1.0,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576.0,BAO_0000221,,CHEMBL616109,,,10000000.0,,H,Expert,11296.0,8.0,,1164.0,,,
,1.0,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,10576.0,BAO_0000357,,CHEMBL616110,,,,,H,Autocuration,11296.0,8.0,,1165.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,CHO,10576.0,BAO_0000219,,CHEMBL616111,,,,,H,Expert,14749.0,8.0,449.0,1166.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,10576.0,BAO_0000019,,CHEMBL616112,,,,,H,Expert,15086.0,8.0,,1167.0,,,
Hippocampus,1.0,B,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,10576.0,BAO_0000221,,CHEMBL616113,,,10000000.0,,H,Autocuration,13462.0,8.0,,1168.0,,,
,1.0,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,,CHEMBL616114,,,,,H,Autocuration,15363.0,8.0,,1169.0,,,
,1.0,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,,CHEMBL616115,,,,,H,Autocuration,15363.0,8.0,,1170.0,,,
,1.0,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616116,,,,,H,Autocuration,10796.0,8.0,,1171.0,,,
Brain,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL615844,,,955.0,,H,Expert,12816.0,8.0,,1172.0,,,
Hippocampus,1.0,B,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,,CHEMBL615939,,,10000000.0,,H,Expert,13542.0,8.0,,1173.0,,,
,1.0,B,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,10576.0,BAO_0000019,,CHEMBL615940,,,,,H,Expert,13308.0,8.0,,1174.0,,,
Hippocampus,1.0,B,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,10576.0,BAO_0000221,,CHEMBL615941,,,10000000.0,,H,Expert,13541.0,8.0,,1175.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,10576.0,BAO_0000221,,CHEMBL615942,,,10000000.0,,H,Autocuration,10058.0,8.0,,1176.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL615943,,,10000000.0,,H,Autocuration,10058.0,8.0,,1177.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,10576.0,BAO_0000221,,CHEMBL615944,,,10000000.0,,H,Autocuration,10058.0,8.0,,1178.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,10576.0,BAO_0000221,,CHEMBL615945,,,10000000.0,,H,Autocuration,10058.0,8.0,,1179.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,10576.0,BAO_0000221,,CHEMBL615946,,,10000000.0,,H,Autocuration,10058.0,8.0,,1180.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,10576.0,BAO_0000221,,CHEMBL615947,,,10000000.0,,H,Autocuration,10058.0,8.0,,1181.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,10576.0,BAO_0000221,,CHEMBL615948,,,10000000.0,,H,Autocuration,10058.0,8.0,,1182.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,10576.0,BAO_0000221,,CHEMBL615949,,,10000000.0,,H,Autocuration,10058.0,8.0,,1183.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,10576.0,BAO_0000221,,CHEMBL615950,,,10000000.0,,H,Autocuration,10058.0,8.0,,1184.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,10576.0,BAO_0000221,,CHEMBL615951,,,10000000.0,,H,Autocuration,10058.0,8.0,,1185.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,10576.0,BAO_0000221,,CHEMBL615952,,,10000000.0,,H,Autocuration,10058.0,8.0,,1186.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,10576.0,BAO_0000221,,CHEMBL615953,,,10000000.0,,H,Autocuration,10058.0,8.0,,1187.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,10576.0,BAO_0000221,,CHEMBL615954,,,10000000.0,,H,Autocuration,10058.0,8.0,,1188.0,,,
Hippocampus,1.0,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL615955,,10116.0,10000000.0,,D,Expert,10058.0,9.0,,1189.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,10576.0,BAO_0000221,,CHEMBL615956,,,10000000.0,,H,Autocuration,10058.0,8.0,,1190.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,10576.0,BAO_0000221,,CHEMBL615957,,,10000000.0,,H,Autocuration,10058.0,8.0,,1191.0,,,
,1.0,B,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,10576.0,BAO_0000019,,CHEMBL615958,,,,,H,Expert,12879.0,8.0,,1192.0,,,
,1.0,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,10576.0,BAO_0000019,,CHEMBL615959,,,,,H,Expert,11964.0,8.0,,1193.0,,,
,1.0,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,10576.0,BAO_0000019,,CHEMBL615960,,,,,H,Autocuration,11964.0,8.0,,1194.0,,,
,1.0,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,10576.0,BAO_0000019,,CHEMBL615961,,,,,H,Autocuration,11964.0,8.0,,1195.0,,,
Brain,1.0,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,10576.0,BAO_0000221,,CHEMBL615962,,,955.0,,H,Expert,9548.0,8.0,,1196.0,,,
,1.0,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,10576.0,BAO_0000019,,CHEMBL615963,,,,,H,Expert,9098.0,8.0,,1197.0,,,
,1.0,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,10576.0,BAO_0000019,,CHEMBL615964,,,,,H,Autocuration,9098.0,8.0,,1198.0,,,
,1.0,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,10576.0,BAO_0000019,,CHEMBL615965,,,,,H,Autocuration,9098.0,8.0,,1199.0,,,
,1.0,B,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,CHO,10576.0,BAO_0000219,,CHEMBL615966,,,,,H,Expert,13248.0,8.0,449.0,1200.0,,,
,1.0,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,10576.0,BAO_0000249,,CHEMBL615967,,,,,H,Expert,3147.0,8.0,,1201.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000019,,CHEMBL615968,,,,,H,Expert,13949.0,8.0,,1202.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHO,10576.0,BAO_0000218,,CHEMBL615969,,,,,H,Autocuration,11883.0,8.0,449.0,1203.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,10576.0,BAO_0000218,,CHEMBL615970,,,,,H,Autocuration,11883.0,8.0,,1204.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL615971,,10116.0,,,D,Expert,11883.0,9.0,,1205.0,,,
,1.0,B,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10576.0,BAO_0000249,,CHEMBL615972,,,,,H,Expert,15535.0,8.0,,1206.0,Membranes,,
,1.0,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,10576.0,BAO_0000249,,CHEMBL615973,,,,,H,Autocuration,15535.0,8.0,,1207.0,,,
,1.0,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,10576.0,BAO_0000249,,CHEMBL615974,,,,,H,Autocuration,15535.0,8.0,,1208.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL615975,,9606.0,,,D,Expert,16372.0,9.0,449.0,1209.0,,,
,1.0,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,10576.0,BAO_0000249,,CHEMBL615976,,,,,H,Expert,14608.0,8.0,,1210.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL872106,,10116.0,10000000.0,,D,Expert,4795.0,9.0,,1211.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000357,,CHEMBL615977,,,,,H,Autocuration,13863.0,8.0,,1212.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,10576.0,BAO_0000357,,CHEMBL615978,,,,,H,Autocuration,13863.0,8.0,,1213.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,10576.0,BAO_0000357,,CHEMBL616166,,,,,H,Autocuration,13863.0,8.0,,1214.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,10576.0,BAO_0000357,,CHEMBL616167,,,,,H,Autocuration,13863.0,8.0,,1215.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,10576.0,BAO_0000357,,CHEMBL616168,,,,,H,Autocuration,13863.0,8.0,,1216.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,10576.0,BAO_0000357,,CHEMBL616169,,,,,H,Autocuration,13863.0,8.0,,1217.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,10576.0,BAO_0000357,,CHEMBL616170,,,,,H,Autocuration,13863.0,8.0,,1218.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,10576.0,BAO_0000357,,CHEMBL616171,,,,,H,Autocuration,13863.0,8.0,,1219.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,10576.0,BAO_0000357,,CHEMBL616172,,,,,H,Autocuration,13863.0,8.0,,1220.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,10576.0,BAO_0000357,,CHEMBL616173,,,,,H,Autocuration,13863.0,8.0,,1221.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,10576.0,BAO_0000357,,CHEMBL616174,,,,,H,Autocuration,13863.0,8.0,,1222.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,10576.0,BAO_0000357,,CHEMBL616175,,,,,H,Autocuration,13863.0,8.0,,1223.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,10576.0,BAO_0000357,,CHEMBL616176,,,,,H,Autocuration,13863.0,8.0,,1224.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,10576.0,BAO_0000357,,CHEMBL616177,,,,,H,Autocuration,13863.0,8.0,,1225.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,10576.0,BAO_0000357,,CHEMBL616178,,,,,H,Autocuration,13863.0,8.0,,1226.0,,,
,1.0,B,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,10576.0,BAO_0000019,,CHEMBL616179,,,,,H,Autocuration,9742.0,8.0,,1227.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616180,,,,,H,Autocuration,12073.0,8.0,,1228.0,,,
,1.0,B,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616181,,,,,H,Autocuration,4101.0,8.0,,1229.0,,,
,1.0,B,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,10576.0,BAO_0000019,,CHEMBL616182,,,,,H,Autocuration,15360.0,8.0,,1230.0,,,
Hippocampus,1.0,B,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,,CHEMBL616183,,,10000000.0,,H,Autocuration,11576.0,8.0,,1231.0,,,
,1.0,B,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,10576.0,BAO_0000019,,CHEMBL615874,,,,,H,Expert,5834.0,8.0,,1232.0,,,
,1.0,B,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHO-K1,10576.0,BAO_0000219,Rattus norvegicus,CHEMBL615875,,10116.0,,,D,Expert,2395.0,9.0,485.0,1233.0,,,
,1.0,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,10576.0,BAO_0000019,,CHEMBL615876,,,,,H,Autocuration,1375.0,8.0,,1234.0,,,
,1.0,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,10576.0,BAO_0000019,,CHEMBL615877,,,,,H,Autocuration,1375.0,8.0,,1235.0,,,
,1.0,B,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,10576.0,BAO_0000357,,CHEMBL615878,,,,,H,Autocuration,3967.0,8.0,,1236.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,10576.0,BAO_0000357,,CHEMBL615879,,,,,H,Expert,12884.0,8.0,,1237.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,10576.0,BAO_0000357,,CHEMBL615880,,,,,H,Expert,2343.0,8.0,,1238.0,,,
,1.0,B,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576.0,BAO_0000019,,CHEMBL615881,,,,,H,Autocuration,11511.0,8.0,,1239.0,,,
,1.0,B,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL615882,,10116.0,,,D,Expert,11511.0,9.0,,1240.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,10576.0,BAO_0000218,,CHEMBL615883,In vivo,,,,H,Autocuration,16394.0,8.0,,1241.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,10576.0,BAO_0000218,,CHEMBL615884,In vivo,,,,H,Autocuration,16394.0,8.0,,1242.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,10576.0,BAO_0000218,,CHEMBL615885,In vivo,,,,H,Autocuration,16394.0,8.0,,1243.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,10576.0,BAO_0000218,,CHEMBL615886,In vivo,,,,H,Autocuration,16394.0,8.0,,1244.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,10576.0,BAO_0000218,,CHEMBL615887,In vivo,,,,H,Autocuration,16394.0,8.0,,1245.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,10576.0,BAO_0000218,,CHEMBL615888,In vivo,,,,H,Autocuration,16394.0,8.0,,1246.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,10576.0,BAO_0000218,,CHEMBL615889,In vivo,,,,H,Autocuration,16394.0,8.0,,1247.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,10576.0,BAO_0000218,,CHEMBL615890,In vivo,,,,H,Autocuration,16394.0,8.0,,1248.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,10576.0,BAO_0000218,,CHEMBL615891,In vivo,,,,H,Autocuration,16394.0,8.0,,1249.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,10576.0,BAO_0000218,,CHEMBL615892,In vivo,,,,H,Autocuration,16394.0,8.0,,1250.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,10576.0,BAO_0000218,,CHEMBL615893,In vivo,,,,H,Autocuration,16394.0,8.0,,1251.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,10576.0,BAO_0000218,,CHEMBL615894,In vivo,,,,H,Autocuration,16394.0,8.0,,1252.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,10576.0,BAO_0000218,,CHEMBL615895,In vivo,,,,H,Autocuration,16394.0,8.0,,1253.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,10576.0,BAO_0000218,,CHEMBL615896,In vivo,,,,H,Autocuration,16394.0,8.0,,1254.0,,,
,1.0,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,10576.0,BAO_0000218,,CHEMBL615897,In vivo,,,,H,Autocuration,16394.0,8.0,,1255.0,,,
,1.0,F,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL615898,,10116.0,,,D,Expert,16616.0,9.0,,1256.0,Membranes,,
,1.0,B,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,10576.0,BAO_0000019,,CHEMBL615899,,,,,H,Autocuration,16796.0,8.0,,1257.0,,,
,1.0,B,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,10576.0,BAO_0000019,,CHEMBL616291,,,,,H,Autocuration,16796.0,8.0,,1258.0,,,
,1.0,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,10576.0,BAO_0000357,,CHEMBL616292,,,,,H,Autocuration,15629.0,8.0,,1259.0,,,
,1.0,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,10576.0,BAO_0000249,,CHEMBL616293,,,,,H,Autocuration,13241.0,8.0,,1260.0,,,
Hippocampus,1.0,B,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616294,,,10000000.0,,H,Expert,12073.0,8.0,,1261.0,,,
Hippocampus,1.0,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,10576.0,BAO_0000249,,CHEMBL616295,,,10000000.0,,H,Autocuration,14286.0,8.0,,1262.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,10576.0,BAO_0000221,,CHEMBL616296,,,955.0,,H,Autocuration,14542.0,8.0,,1263.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616297,,,,,H,Autocuration,13630.0,8.0,,1264.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616605,,,,,H,Autocuration,13630.0,8.0,,1265.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616606,,,,,H,Autocuration,13630.0,8.0,,1266.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576.0,BAO_0000019,,CHEMBL616607,,,,,H,Autocuration,13630.0,8.0,,1267.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,10576.0,BAO_0000019,,CHEMBL616608,,,,,H,Expert,13630.0,8.0,,1268.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616609,,,,,H,Autocuration,13630.0,8.0,,1269.0,,,
,1.0,F,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616610,,10116.0,,,D,Expert,13630.0,9.0,,1270.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616611,,,,,H,Autocuration,13630.0,8.0,,1271.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616612,,,,,H,Expert,13630.0,8.0,,1272.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616613,,,,,H,Autocuration,13630.0,8.0,,1273.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,10576.0,BAO_0000019,,CHEMBL616614,,,,,H,Expert,13630.0,8.0,,1274.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616615,,,,,H,Autocuration,13630.0,8.0,,1275.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576.0,BAO_0000019,,CHEMBL616616,,,,,H,Expert,13630.0,8.0,,1276.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616617,,,,,H,Autocuration,13630.0,8.0,,1277.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616618,,,,,H,Autocuration,13630.0,8.0,,1278.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616619,,,,,H,Autocuration,13630.0,8.0,,1279.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616620,,,,,H,Expert,13630.0,8.0,,1280.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616621,,,,,H,Expert,13630.0,8.0,,1281.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,10576.0,BAO_0000019,,CHEMBL616622,,,,,H,Autocuration,13630.0,8.0,,1282.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,10576.0,BAO_0000019,,CHEMBL616146,,,,,H,Expert,13630.0,8.0,,1283.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL832873,,,,,H,Autocuration,13630.0,8.0,,1284.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,10576.0,BAO_0000019,,CHEMBL616147,,,,,H,Autocuration,13630.0,8.0,,1285.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL872872,,,,,H,Autocuration,13630.0,8.0,,1286.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,10576.0,BAO_0000019,,CHEMBL616148,,,,,H,Autocuration,13630.0,8.0,,1287.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,10576.0,BAO_0000221,,CHEMBL616149,,,10000000.0,,H,Autocuration,9783.0,8.0,,1288.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,10576.0,BAO_0000221,,CHEMBL616150,,,10000000.0,,H,Expert,9783.0,8.0,,1289.0,,,
,1.0,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616151,,10116.0,,,D,Expert,14331.0,9.0,,1290.0,Membranes,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,10576.0,BAO_0000221,,CHEMBL872873,,,10000000.0,,H,Expert,15260.0,8.0,,1291.0,,,
Hippocampus,1.0,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,10576.0,BAO_0000221,,CHEMBL616670,,,10000000.0,,H,Autocuration,15260.0,8.0,,1292.0,,,
Hippocampus,1.0,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,10576.0,BAO_0000221,,CHEMBL616671,,,10000000.0,,H,Autocuration,15260.0,8.0,,1293.0,,,
,1.0,F,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL884861,,10116.0,,,D,Expert,16616.0,9.0,,1294.0,,,
,1.0,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616672,,,,,H,Autocuration,15629.0,8.0,,1295.0,,,
,1.0,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576.0,BAO_0000019,,CHEMBL616673,,,,,H,Autocuration,15086.0,8.0,,1296.0,,,
,1.0,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000019,,CHEMBL616674,,,,,H,Expert,5717.0,8.0,,1297.0,,,
,1.0,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616675,,,,,H,Autocuration,12652.0,8.0,,1298.0,,,
Hippocampus,1.0,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,10576.0,BAO_0000221,,CHEMBL616676,,,10000000.0,,H,Autocuration,14608.0,8.0,,1299.0,,,
Hippocampus,1.0,B,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616677,,,10000000.0,,H,Autocuration,12306.0,8.0,,1300.0,,,
Hippocampus,1.0,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616678,,,10000000.0,,H,Autocuration,12306.0,8.0,,1301.0,,,
,1.0,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616679,,10116.0,,,D,Expert,15247.0,9.0,,1302.0,,,
Hippocampus,1.0,B,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,10576.0,BAO_0000221,,CHEMBL616680,,,10000000.0,,H,Expert,17529.0,8.0,,1303.0,,,
Hippocampus,1.0,B,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616681,,,10000000.0,,H,Autocuration,14826.0,8.0,,1304.0,,,
Hippocampus,1.0,B,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616682,,,10000000.0,,H,Autocuration,14826.0,8.0,,1305.0,,,
Hippocampus,1.0,B,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,,CHEMBL616683,,,10000000.0,,H,Autocuration,13241.0,8.0,,1306.0,,,
Hippocampus,1.0,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,,CHEMBL616684,,,10000000.0,,H,Autocuration,14093.0,8.0,,1307.0,,,
Hippocampus,1.0,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,10576.0,BAO_0000221,,CHEMBL616685,,,10000000.0,,H,Autocuration,14093.0,8.0,,1308.0,,,
Brain,1.0,B,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,10576.0,BAO_0000221,,CHEMBL616686,,,955.0,,H,Autocuration,14442.0,8.0,,1309.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576.0,BAO_0000357,,CHEMBL616687,,,,,H,Autocuration,9919.0,8.0,,1310.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1A receptor site,,,10576.0,BAO_0000357,,CHEMBL616688,,,,,H,Autocuration,9919.0,8.0,,1311.0,,,
Hippocampus,1.0,B,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,10576.0,BAO_0000221,,CHEMBL616689,,,10000000.0,,H,Autocuration,11440.0,8.0,,1312.0,,,
,1.0,B,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616690,,,,,H,Autocuration,11257.0,8.0,,1313.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,10576.0,BAO_0000357,,CHEMBL616691,,,,,H,Expert,10330.0,8.0,,1314.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616692,,10116.0,10000000.0,,D,Expert,17331.0,9.0,,1315.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,10576.0,BAO_0000249,,CHEMBL616693,,,,,H,Expert,16567.0,8.0,,1316.0,,,
,1.0,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616694,,10116.0,,,D,Expert,12058.0,9.0,,1317.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,10576.0,BAO_0000221,,CHEMBL616695,,,10000000.0,,H,Autocuration,9699.0,8.0,,1318.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,10576.0,BAO_0000357,,CHEMBL616696,,,,,H,Autocuration,9547.0,8.0,,1319.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,10576.0,BAO_0000357,,CHEMBL616697,,,,,H,Autocuration,10330.0,8.0,,1320.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616698,,,,,H,Autocuration,14331.0,8.0,,1321.0,,,
,1.0,B,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616949,,10116.0,,,D,Expert,14060.0,9.0,,1322.0,,,
Hippocampus,1.0,B,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616950,,,10000000.0,,H,Autocuration,14744.0,8.0,,1323.0,,,
,1.0,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,10576.0,BAO_0000357,,CHEMBL832875,,,,,H,Autocuration,13506.0,8.0,,1324.0,,,
Brain,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576.0,BAO_0000221,,CHEMBL616951,,,955.0,,H,Expert,10862.0,8.0,,1325.0,,,
Brain,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576.0,BAO_0000221,,CHEMBL616952,,,955.0,,H,Expert,10862.0,8.0,,1326.0,,,
,1.0,B,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,10576.0,BAO_0000357,,CHEMBL616953,,,,,H,Expert,10062.0,8.0,,1327.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,10576.0,BAO_0000357,,CHEMBL616954,,,,,H,Autocuration,12073.0,8.0,,1328.0,,,
,1.0,B,GTPgammaS radioligand binding assay,,,106.0,BAO_0000357,,CHEMBL616955,,,,,H,Autocuration,14875.0,8.0,,1329.0,,,
,1.0,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106.0,BAO_0000357,,CHEMBL616956,,,,,H,Autocuration,2391.0,8.0,,1330.0,,,
,1.0,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,106.0,BAO_0000019,,CHEMBL616957,,,,,H,Autocuration,2391.0,8.0,,1331.0,,,
,1.0,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,106.0,BAO_0000019,,CHEMBL616958,,,,,H,Autocuration,2391.0,8.0,,1332.0,,,
,1.0,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616959,,,,,H,Autocuration,2391.0,8.0,,1333.0,,,
,1.0,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,106.0,BAO_0000357,,CHEMBL616960,,,,,H,Autocuration,2391.0,8.0,,1334.0,,,
,1.0,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,106.0,BAO_0000019,,CHEMBL616961,,,,,H,Autocuration,2391.0,8.0,,1335.0,,,
,1.0,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,HeLa,106.0,BAO_0000219,,CHEMBL616962,,,,,H,Expert,17211.0,8.0,308.0,1336.0,,,
,1.0,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,HeLa,106.0,BAO_0000219,,CHEMBL616963,,,,,H,Autocuration,17211.0,8.0,308.0,1337.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616524,,9606.0,,,D,Expert,6491.0,9.0,,1338.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHO,106.0,BAO_0000219,,CHEMBL616525,,,,,H,Autocuration,16190.0,8.0,449.0,1339.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,106.0,BAO_0000019,,CHEMBL872908,,,,,H,Autocuration,14165.0,8.0,,1340.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,106.0,BAO_0000019,,CHEMBL616526,,,,,H,Autocuration,14165.0,8.0,,1341.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616527,,9606.0,,,D,Expert,4234.0,9.0,,1342.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,106.0,BAO_0000219,,CHEMBL616528,,,,,H,Expert,6328.0,8.0,,1343.0,,,
,1.0,B,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106.0,BAO_0000357,,CHEMBL616529,,,,,H,Autocuration,14770.0,8.0,,1344.0,,,
,1.0,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,106.0,BAO_0000357,,CHEMBL616530,,,,,H,Autocuration,2598.0,8.0,,1345.0,,,
,1.0,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616531,,,,,H,Expert,6897.0,8.0,,1346.0,,,
,1.0,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616532,,,,,H,Autocuration,6897.0,8.0,,1347.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616533,,,,,H,Autocuration,6013.0,8.0,,1348.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616534,,,,,H,Expert,5843.0,8.0,,1349.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,106.0,BAO_0000357,,CHEMBL616535,,,,,H,Expert,14454.0,8.0,,1350.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,106.0,BAO_0000357,,CHEMBL616536,,,,,H,Autocuration,16209.0,8.0,,1351.0,,,
,1.0,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616537,,,,,H,Autocuration,3935.0,8.0,,1352.0,,,
,1.0,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,CHO-K1,106.0,BAO_0000219,,CHEMBL616538,,,,,H,Expert,13729.0,8.0,485.0,1353.0,,,
,1.0,F,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000019,,CHEMBL616539,,,,,H,Expert,14251.0,8.0,,1354.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000019,,CHEMBL616540,,,,,H,Expert,17085.0,8.0,,1355.0,,,
,1.0,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,106.0,BAO_0000357,,CHEMBL616429,,,,,H,Autocuration,3025.0,8.0,,1356.0,,,
,1.0,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616430,,,,,H,Expert,15315.0,8.0,,1357.0,,,
,1.0,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,106.0,BAO_0000219,Homo sapiens,CHEMBL616431,,9606.0,,,D,Expert,14214.0,9.0,,1358.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616432,,9606.0,,,D,Expert,3804.0,9.0,,1359.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616433,,9606.0,,,D,Expert,2391.0,9.0,,1360.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616434,,9606.0,,,D,Expert,4175.0,9.0,,1361.0,,,
,1.0,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,CHO,106.0,BAO_0000219,,CHEMBL616435,,,,,H,Autocuration,17296.0,8.0,449.0,1362.0,,,
,1.0,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,106.0,BAO_0000019,,CHEMBL616436,,,,,H,Expert,17085.0,8.0,,1363.0,,,
,1.0,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,HeLa,106.0,BAO_0000219,,CHEMBL616437,,,,,H,Autocuration,17211.0,8.0,308.0,1364.0,,,
,1.0,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,HeLa,106.0,BAO_0000219,,CHEMBL616438,,,,,H,Autocuration,17211.0,8.0,308.0,1365.0,,,
,1.0,B,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,HeLa,106.0,BAO_0000219,,CHEMBL616439,,,,,H,Autocuration,17211.0,8.0,308.0,1366.0,,,
,1.0,B,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616440,,9606.0,,,D,Expert,15926.0,9.0,,1367.0,,,
,1.0,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,CHO-K1,106.0,BAO_0000219,,CHEMBL616441,,,,,H,Autocuration,16312.0,8.0,485.0,1368.0,,,
,1.0,B,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,106.0,BAO_0000357,,CHEMBL616442,,,,,H,Expert,5843.0,8.0,,1369.0,,,
,1.0,B,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,106.0,BAO_0000357,,CHEMBL616443,,,,,H,Autocuration,5843.0,8.0,,1370.0,,,
,1.0,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,CHO-K1,106.0,BAO_0000219,,CHEMBL616444,,,,,H,Expert,16312.0,8.0,485.0,1371.0,,,
,1.0,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616445,,9606.0,,,D,Expert,15926.0,9.0,,1372.0,,,
,1.0,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616446,,9606.0,,,D,Expert,15926.0,9.0,,1373.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHO,106.0,BAO_0000219,Homo sapiens,CHEMBL616447,,9606.0,,,D,Expert,4540.0,9.0,449.0,1374.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,106.0,BAO_0000357,,CHEMBL616448,,,,,H,Autocuration,6166.0,8.0,,1375.0,,,
,1.0,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,CHO,106.0,BAO_0000219,,CHEMBL616449,,,,,H,Autocuration,17296.0,8.0,449.0,1376.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,CHO,106.0,BAO_0000219,,CHEMBL616450,,,,,H,Autocuration,17296.0,8.0,449.0,1377.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,CHO,106.0,BAO_0000219,,CHEMBL857974,,,,,H,Autocuration,17296.0,8.0,449.0,1378.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,106.0,BAO_0000219,,CHEMBL616451,,,,,H,Autocuration,15779.0,8.0,449.0,1379.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,106.0,BAO_0000219,,CHEMBL616452,,,,,H,Autocuration,15779.0,8.0,449.0,1380.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHO,106.0,BAO_0000219,,CHEMBL616453,,,,,H,Autocuration,15779.0,8.0,449.0,1381.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,106.0,BAO_0000219,,CHEMBL616454,,,,,H,Autocuration,4199.0,8.0,449.0,1382.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616455,,9606.0,,,D,Expert,14875.0,9.0,,1383.0,,,
,1.0,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHO,106.0,BAO_0000219,,CHEMBL616456,,,,,H,Autocuration,15146.0,8.0,449.0,1384.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,106.0,BAO_0000357,,CHEMBL616457,,,,,H,Autocuration,5213.0,8.0,,1385.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHO,106.0,BAO_0000219,,CHEMBL616458,,,,,H,Autocuration,14818.0,8.0,449.0,1386.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,106.0,BAO_0000219,,CHEMBL616459,,,,,H,Autocuration,4829.0,8.0,449.0,1387.0,,,
,1.0,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,106.0,BAO_0000019,,CHEMBL616460,,,,,H,Expert,14454.0,8.0,,1388.0,,,
,1.0,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,106.0,BAO_0000019,,CHEMBL616461,,,,,H,Expert,14454.0,8.0,,1389.0,,,
,1.0,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHO,106.0,BAO_0000219,,CHEMBL616462,,,,,H,Autocuration,14875.0,8.0,449.0,1390.0,,,
,1.0,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHO,106.0,BAO_0000219,,CHEMBL616463,,,,,H,Autocuration,14875.0,8.0,449.0,1391.0,,,
,1.0,F,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,105.0,BAO_0000019,,CHEMBL616464,,,,,H,Autocuration,15250.0,8.0,,1392.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,CHO,105.0,BAO_0000219,,CHEMBL616465,,,,,H,Autocuration,15250.0,8.0,449.0,1393.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,17105.0,BAO_0000357,,CHEMBL832874,,,,,H,Autocuration,15086.0,8.0,,1394.0,,,
,1.0,F,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616184,,9986.0,,,H,Autocuration,3025.0,8.0,,1395.0,,,
,1.0,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616185,,9986.0,,,H,Autocuration,14998.0,8.0,,1396.0,,,
,1.0,B,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616186,,9986.0,,,H,Intermediate,14998.0,8.0,,1397.0,,,
,1.0,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616187,,9986.0,,,H,Autocuration,14998.0,8.0,,1398.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,10577.0,BAO_0000357,,CHEMBL616188,,,,,H,Expert,13969.0,8.0,,1399.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL873475,,,,,D,Intermediate,13392.0,9.0,,1400.0,,,
Striatum,1.0,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,10577.0,BAO_0000019,Rattus norvegicus,CHEMBL616189,,10116.0,2435.0,,D,Expert,3651.0,9.0,,1401.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577.0,BAO_0000357,,CHEMBL616190,,,,,H,Expert,10025.0,8.0,,1402.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,10576.0,BAO_0000357,,CHEMBL616191,,,,,H,Autocuration,13863.0,8.0,,1403.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,10576.0,BAO_0000357,,CHEMBL616192,,,,,H,Autocuration,13863.0,8.0,,1404.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,10576.0,BAO_0000357,,CHEMBL616193,,,,,H,Autocuration,13863.0,8.0,,1405.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,10576.0,BAO_0000357,,CHEMBL616194,,,,,H,Autocuration,13863.0,8.0,,1406.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,10576.0,BAO_0000357,,CHEMBL616195,,,,,H,Autocuration,13863.0,8.0,,1407.0,,,
,1.0,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,10576.0,BAO_0000357,,CHEMBL616196,,,,,H,Autocuration,13863.0,8.0,,1408.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,10576.0,BAO_0000249,,CHEMBL616197,,,10000000.0,,H,Autocuration,4622.0,8.0,,1409.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000019,,CHEMBL616198,,,,,H,Intermediate,14911.0,8.0,,1410.0,,,
Hippocampus,1.0,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10576.0,BAO_0000221,,CHEMBL616199,,,10000000.0,,H,Autocuration,12678.0,8.0,,1411.0,,,
Hippocampus,1.0,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,10576.0,BAO_0000221,,CHEMBL616200,,,10000000.0,,H,Expert,12678.0,8.0,,1412.0,,,
Hippocampus,1.0,B,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616201,,,10000000.0,,H,Expert,14235.0,8.0,,1413.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616202,,,10000000.0,,H,Expert,14949.0,8.0,,1414.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL616203,,,10000000.0,,H,Expert,14949.0,8.0,,1415.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,10576.0,BAO_0000221,,CHEMBL616204,,,10000000.0,,H,Expert,14949.0,8.0,,1416.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,10576.0,BAO_0000221,,CHEMBL616205,,,10000000.0,,H,Expert,14949.0,8.0,,1417.0,,,
Hippocampus,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,10576.0,BAO_0000221,,CHEMBL616206,,,10000000.0,,H,Expert,14949.0,8.0,,1418.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,10576.0,BAO_0000249,,CHEMBL616207,,,,,H,Expert,16118.0,8.0,,1419.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,10576.0,BAO_0000249,,CHEMBL616208,,,,,H,Autocuration,3268.0,8.0,,1420.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,10576.0,BAO_0000249,,CHEMBL616209,,,,,H,Autocuration,3268.0,8.0,,1421.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616210,,,,,H,Expert,16117.0,8.0,,1422.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,10576.0,BAO_0000221,,CHEMBL616211,,,10000000.0,,H,Expert,9783.0,8.0,,1423.0,,,
Hippocampus,1.0,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,10576.0,BAO_0000221,,CHEMBL616504,,,10000000.0,,H,Autocuration,9783.0,8.0,,1424.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616505,,10116.0,10000000.0,,D,Expert,14356.0,9.0,,1425.0,,,
,1.0,F,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000019,,CHEMBL616506,,,,,H,Autocuration,15740.0,8.0,,1426.0,,,
Hippocampus,1.0,B,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10576.0,BAO_0000221,,CHEMBL872107,,,10000000.0,,H,Autocuration,12306.0,8.0,,1427.0,,,
Hippocampus,1.0,B,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616507,,10116.0,10000000.0,,D,Expert,13348.0,9.0,,1428.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,10576.0,BAO_0000249,,CHEMBL616303,,,,,H,Autocuration,10394.0,8.0,,1429.0,,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,10576.0,BAO_0000221,,CHEMBL616304,,,10000000.0,,H,Autocuration,15260.0,8.0,,1430.0,,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576.0,BAO_0000221,,CHEMBL616305,,,10000000.0,,H,Expert,10046.0,8.0,,1431.0,,,
Hippocampus,1.0,F,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,,CHEMBL616306,,,10000000.0,,H,Intermediate,15260.0,8.0,,1432.0,,,
,1.0,B,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616307,,,,,H,Autocuration,12851.0,8.0,,1433.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL881829,,10116.0,10000000.0,,D,Expert,2148.0,9.0,,1434.0,,,
,1.0,B,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,10576.0,BAO_0000357,,CHEMBL616308,,,,,H,Expert,13134.0,8.0,,1435.0,,,
,1.0,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,10576.0,BAO_0000019,,CHEMBL616309,,,,,H,Autocuration,12462.0,8.0,,1436.0,,,
,1.0,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,10576.0,BAO_0000019,,CHEMBL616310,,,,,H,Expert,12462.0,8.0,,1437.0,,,
,1.0,B,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,CHO,10576.0,BAO_0000219,,CHEMBL616311,,,,,H,Autocuration,12462.0,8.0,449.0,1438.0,,,
,1.0,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000357,,CHEMBL616312,,,,,H,Expert,11933.0,8.0,,1439.0,,,
,1.0,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,10576.0,BAO_0000357,,CHEMBL616313,,,,,H,Autocuration,11933.0,8.0,,1440.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616314,,10116.0,10000000.0,,D,Expert,403.0,9.0,,1441.0,,,
Hippocampus,1.0,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616315,,,10000000.0,,H,Autocuration,15538.0,8.0,,1442.0,,,
Hippocampus,1.0,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,10576.0,BAO_0000221,,CHEMBL616567,,,10000000.0,,H,Autocuration,15538.0,8.0,,1443.0,,,
Hippocampus,1.0,B,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,10576.0,BAO_0000221,,CHEMBL616568,,,10000000.0,,H,Autocuration,15538.0,8.0,,1444.0,,,
,1.0,B,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,10576.0,BAO_0000019,,CHEMBL616569,,,,,H,Intermediate,12464.0,8.0,,1445.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,10576.0,BAO_0000357,,CHEMBL616570,,,,,H,Expert,1455.0,8.0,,1446.0,,,
,1.0,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,10576.0,BAO_0000357,,CHEMBL616571,,,,,H,Autocuration,12652.0,8.0,,1447.0,,,
Hippocampus,1.0,B,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,10576.0,BAO_0000221,,CHEMBL616572,,,10000000.0,,H,Autocuration,12639.0,8.0,,1448.0,,,
,1.0,B,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,10576.0,BAO_0000249,,CHEMBL616573,,,,,H,Expert,13949.0,8.0,,1449.0,,,
,1.0,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616574,,10116.0,,,D,Expert,12463.0,9.0,,1450.0,,,
Hippocampus,1.0,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,10576.0,BAO_0000221,,CHEMBL616575,,,10000000.0,,H,Expert,14829.0,8.0,,1451.0,,,
Hippocampus,1.0,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,10576.0,BAO_0000221,,CHEMBL872108,,,10000000.0,,H,Autocuration,14829.0,8.0,,1452.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,10576.0,BAO_0000357,,CHEMBL616576,,,,,H,Autocuration,12092.0,8.0,,1453.0,,,
,1.0,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,10576.0,BAO_0000249,,CHEMBL616577,,,,,H,Autocuration,403.0,8.0,,1454.0,,,
,1.0,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,10576.0,BAO_0000249,,CHEMBL616578,,,,,H,Autocuration,403.0,8.0,,1455.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,10576.0,BAO_0000357,,CHEMBL616579,,,,,H,Expert,3967.0,8.0,,1456.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616580,,10116.0,,,D,Expert,12771.0,9.0,,1457.0,,,
,1.0,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,10576.0,BAO_0000019,,CHEMBL616581,,,,,H,Autocuration,15086.0,8.0,,1458.0,,,
Hippocampus,1.0,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616582,,,10000000.0,,H,Autocuration,14909.0,8.0,,1459.0,,,
Hippocampus,1.0,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616583,,,10000000.0,,H,Expert,14949.0,8.0,,1460.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616584,,10116.0,10000000.0,,D,Expert,2309.0,9.0,,1461.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616585,,,,,H,Expert,4170.0,8.0,,1462.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616586,,10116.0,10000000.0,,D,Expert,11642.0,9.0,,1463.0,,,
Hippocampus,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616587,,,10000000.0,,H,Autocuration,11642.0,8.0,,1464.0,,,
Hippocampus,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616588,,,10000000.0,,H,Autocuration,12953.0,8.0,,1465.0,,,
Hippocampus,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000221,,CHEMBL616589,,,10000000.0,,H,Autocuration,12953.0,8.0,,1466.0,,,
Hippocampus,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10576.0,BAO_0000221,,CHEMBL616590,,,10000000.0,,H,Expert,12953.0,8.0,,1467.0,,,
,1.0,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,CHO,10576.0,BAO_0000219,,CHEMBL616591,,,,,H,Expert,12903.0,8.0,449.0,1468.0,,,
,1.0,B,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616592,,,,,H,Expert,12536.0,8.0,,1469.0,,,
,1.0,B,The inhibition activity of 5-HT1A at 1 uM,,,10576.0,BAO_0000357,,CHEMBL616593,,,,,H,Autocuration,10058.0,8.0,,1470.0,,,
,1.0,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,CHO-K1,10576.0,BAO_0000219,,CHEMBL616594,,,,,H,Expert,12902.0,8.0,485.0,1471.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,10576.0,BAO_0000249,,CHEMBL616595,,,,,H,Expert,14057.0,8.0,,1472.0,,,
,1.0,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,10576.0,BAO_0000357,,CHEMBL616596,,,,,H,Autocuration,11296.0,8.0,,1473.0,,,
Hippocampus,1.0,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576.0,BAO_0000221,,CHEMBL616597,,,10000000.0,,H,Autocuration,11296.0,8.0,,1474.0,,,
Hippocampus,1.0,B,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10576.0,BAO_0000221,,CHEMBL616598,,,10000000.0,,H,Expert,11296.0,8.0,,1475.0,,,
,1.0,F,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616599,,10116.0,,,D,Expert,16616.0,9.0,,1476.0,Membranes,,
Hippocampus,1.0,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616600,,10116.0,10000000.0,,D,Expert,16616.0,9.0,,1477.0,Membranes,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,10576.0,BAO_0000019,,CHEMBL616601,,,,,H,Autocuration,16567.0,8.0,,1478.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,10576.0,BAO_0000019,,CHEMBL616602,,,,,H,Autocuration,16567.0,8.0,,1479.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,10576.0,BAO_0000019,,CHEMBL616603,,,,,H,Autocuration,16567.0,8.0,,1480.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,10576.0,BAO_0000019,,CHEMBL616604,,,,,H,Autocuration,16567.0,8.0,,1481.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,10576.0,BAO_0000249,,CHEMBL616316,,,,,H,Autocuration,17136.0,8.0,,1482.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,10576.0,BAO_0000249,,CHEMBL616317,,,,,H,Autocuration,17136.0,8.0,,1483.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616318,,10116.0,,,D,Expert,16616.0,9.0,,1484.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,10576.0,BAO_0000221,,CHEMBL616319,,,10000000.0,,H,Autocuration,17331.0,8.0,,1485.0,,,
Hippocampus,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,10576.0,BAO_0000221,,CHEMBL616320,,,10000000.0,,H,Autocuration,17331.0,8.0,,1486.0,,,
Hippocampus,1.0,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616321,,10116.0,10000000.0,,D,Expert,17167.0,9.0,,1487.0,,,
,1.0,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576.0,BAO_0000019,,CHEMBL616322,,,,,H,Autocuration,15740.0,8.0,,1488.0,,,
,1.0,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,10576.0,BAO_0000019,,CHEMBL616323,,,,,H,Autocuration,15740.0,8.0,,1489.0,,,
,1.0,B,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,10576.0,BAO_0000357,,CHEMBL616324,,,,,H,Autocuration,4671.0,8.0,,1490.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10576.0,BAO_0000221,,CHEMBL616325,,,10000000.0,,H,Autocuration,10058.0,8.0,,1491.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10576.0,BAO_0000221,,CHEMBL616326,,,10000000.0,,H,Autocuration,10058.0,8.0,,1492.0,,,
Hippocampus,1.0,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,10576.0,BAO_0000221,,CHEMBL616327,,,10000000.0,,H,Autocuration,10058.0,8.0,,1493.0,,,
,1.0,B,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616328,,,,,H,Autocuration,12073.0,8.0,,1494.0,,,
,1.0,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576.0,BAO_0000249,,CHEMBL858110,,,,,H,Autocuration,2759.0,8.0,,1495.0,,,
,1.0,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,10576.0,BAO_0000249,,CHEMBL616329,,,,,H,Autocuration,2759.0,8.0,,1496.0,,,
,1.0,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576.0,BAO_0000249,,CHEMBL616330,,,,,H,Autocuration,2759.0,8.0,,1497.0,,,
,1.0,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,10576.0,BAO_0000249,,CHEMBL616331,,,,,H,Autocuration,2759.0,8.0,,1498.0,,,
,1.0,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576.0,BAO_0000249,,CHEMBL616332,,,,,H,Autocuration,2759.0,8.0,,1499.0,,,
Brain,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10576.0,BAO_0000249,,CHEMBL857063,,,955.0,,H,Autocuration,9737.0,8.0,,1500.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,10576.0,BAO_0000019,,CHEMBL616333,,,,,H,Autocuration,9737.0,8.0,,1501.0,,,
,1.0,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,10576.0,BAO_0000019,,CHEMBL616334,,,,,H,Expert,5717.0,8.0,,1502.0,,,
Hippocampus,1.0,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616335,,,10000000.0,,H,Autocuration,12253.0,8.0,,1503.0,,,
,1.0,B,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,10576.0,BAO_0000019,,CHEMBL616336,,,,,H,Autocuration,14025.0,8.0,,1504.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,10576.0,BAO_0000249,,CHEMBL616337,,,,,H,Expert,10425.0,8.0,,1505.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,10576.0,BAO_0000019,,CHEMBL616338,,,,,H,Autocuration,14998.0,8.0,,1506.0,,,
Hippocampus,1.0,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,10576.0,BAO_0000221,,CHEMBL616339,,,10000000.0,,H,Autocuration,13694.0,8.0,,1507.0,,,
Hippocampus,1.0,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,10576.0,BAO_0000221,,CHEMBL616340,,,10000000.0,,H,Autocuration,13694.0,8.0,,1508.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,10576.0,BAO_0000357,,CHEMBL616341,,,,,H,Autocuration,4342.0,8.0,,1509.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,Rattus norvegicus,CHEMBL616342,,10116.0,,,D,Expert,12936.0,9.0,,1510.0,,,
,1.0,B,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,10576.0,BAO_0000019,Rattus norvegicus,CHEMBL616343,,10116.0,,,D,Expert,13144.0,9.0,,1511.0,,,
,1.0,B,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,10576.0,BAO_0000019,,CHEMBL616344,,,,,H,Expert,13343.0,8.0,,1512.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000357,,CHEMBL616345,,,,,H,Expert,12132.0,8.0,,1513.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,10576.0,BAO_0000019,,CHEMBL616346,,,,,H,Expert,15419.0,8.0,,1514.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10576.0,BAO_0000221,,CHEMBL616347,,,10000000.0,,H,Autocuration,1479.0,8.0,,1515.0,,,
,1.0,B,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,10576.0,BAO_0000019,,CHEMBL616348,,,,,H,Expert,14287.0,8.0,,1516.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,,10576.0,BAO_0000357,,CHEMBL616349,,,,,H,Expert,13116.0,8.0,,1517.0,,,
,1.0,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,10576.0,BAO_0000249,Rattus norvegicus,CHEMBL616152,,10116.0,,,D,Expert,2759.0,9.0,,1518.0,Membranes,,
,1.0,B,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,10576.0,BAO_0000249,,CHEMBL616153,,,,,H,Autocuration,2759.0,8.0,,1519.0,,,
,1.0,B,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,10576.0,BAO_0000019,,CHEMBL616154,,,,,H,Expert,14748.0,8.0,,1520.0,,,
,1.0,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,10576.0,BAO_0000019,,CHEMBL616155,,,,,H,Autocuration,12304.0,8.0,,1521.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616156,,10116.0,10000000.0,,D,Expert,12409.0,9.0,,1522.0,,,
Hippocampus,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,10576.0,BAO_0000221,Rattus norvegicus,CHEMBL616157,,10116.0,10000000.0,,D,Expert,12409.0,9.0,,1523.0,,,
Hippocampus,1.0,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,10576.0,BAO_0000221,,CHEMBL616158,,,10000000.0,,H,Autocuration,13267.0,8.0,,1524.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,10576.0,BAO_0000357,,CHEMBL616159,,,,,H,Autocuration,15194.0,8.0,,1525.0,,,
,1.0,B,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,10576.0,BAO_0000357,,CHEMBL616160,,,,,H,Expert,14256.0,8.0,,1526.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,10576.0,BAO_0000019,,CHEMBL616161,,,,,H,Autocuration,16567.0,8.0,,1527.0,,,
,1.0,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,10576.0,BAO_0000019,,CHEMBL616162,,,,,H,Autocuration,15740.0,8.0,,1528.0,,,
,1.0,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL616163,,10116.0,,,D,Expert,13278.0,9.0,,1529.0,,,
,1.0,B,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,10626.0,BAO_0000249,,CHEMBL616164,,,,,H,Expert,1970.0,8.0,,1530.0,Membranes,,
Brain,1.0,B,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,10576.0,BAO_0000221,,CHEMBL616165,,,955.0,,H,Autocuration,10034.0,8.0,,1531.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,51.0,BAO_0000019,Rattus norvegicus,CHEMBL616355,,10116.0,,,H,Autocuration,13348.0,8.0,,1532.0,,,
,1.0,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,10576.0,BAO_0000019,,CHEMBL616356,,,,,H,Autocuration,13630.0,8.0,,1533.0,,,
Brain,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,10576.0,BAO_0000221,,CHEMBL616357,,,955.0,,H,Autocuration,10862.0,8.0,,1534.0,,,
,1.0,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,10576.0,BAO_0000019,,CHEMBL616358,,,,,H,Autocuration,12058.0,8.0,,1535.0,,,
,1.0,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616359,,,,,H,Autocuration,4639.0,8.0,,1536.0,,,
,1.0,B,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,51.0,BAO_0000357,,CHEMBL616360,,,,,H,Expert,15453.0,8.0,,1537.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616361,,,,,H,Expert,4820.0,8.0,,1538.0,,,
,1.0,B,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616362,,,,,H,Autocuration,1089.0,8.0,,1539.0,,,
,1.0,B,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,51.0,BAO_0000249,,CHEMBL616363,,,,,H,Autocuration,386.0,8.0,,1540.0,Brain membranes,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,51.0,BAO_0000357,,CHEMBL616364,,,,,H,Autocuration,6011.0,8.0,,1541.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616365,,,,,H,Autocuration,5014.0,8.0,,1542.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000357,,CHEMBL616366,,,,,H,Expert,4402.0,8.0,,1543.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL872906,,,,,H,Expert,17066.0,8.0,,1544.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,51.0,BAO_0000357,,CHEMBL616367,,,,,H,Autocuration,17515.0,8.0,,1545.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616368,,,,,H,Autocuration,2474.0,8.0,,1546.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL616369,,,,,H,Autocuration,4775.0,8.0,,1547.0,,,
,1.0,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616370,,9606.0,,,D,Expert,14294.0,9.0,,1548.0,,,
,1.0,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,51.0,BAO_0000357,Homo sapiens,CHEMBL616371,,9606.0,,,D,Expert,14294.0,9.0,,1549.0,,,
,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,51.0,BAO_0000219,,CHEMBL616372,,,,,H,Autocuration,12249.0,8.0,449.0,1550.0,,,
,1.0,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,51.0,BAO_0000219,,CHEMBL616373,,,,,H,Expert,11376.0,8.0,,1551.0,,,
,1.0,B,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,51.0,BAO_0000218,,CHEMBL616374,In vivo,,,,H,Autocuration,2474.0,8.0,,1552.0,,,
Hippocampus,1.0,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,51.0,BAO_0000221,,CHEMBL616375,,,10000000.0,,H,Autocuration,13311.0,8.0,,1553.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL616376,,,,,H,Autocuration,4373.0,8.0,,1554.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,51.0,BAO_0000357,,CHEMBL857064,,,,,H,Expert,1633.0,8.0,,1555.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL616377,,,,,H,Autocuration,11866.0,8.0,,1556.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,51.0,BAO_0000357,,CHEMBL616378,,,,,H,Autocuration,4373.0,8.0,,1557.0,,,
,1.0,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,51.0,BAO_0000357,,CHEMBL616379,,,,,H,Autocuration,4687.0,8.0,,1558.0,,,
,1.0,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616380,,,,,H,Autocuration,16946.0,8.0,,1559.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,11863.0,BAO_0000357,,CHEMBL616381,,,,,H,Autocuration,13291.0,8.0,,1560.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616382,,,,,H,Autocuration,14159.0,8.0,,1561.0,,,
,1.0,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,11863.0,BAO_0000357,,CHEMBL616383,,,,,H,Autocuration,10812.0,8.0,,1562.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,CHO,11863.0,BAO_0000219,Mus musculus,CHEMBL616350,,10090.0,,,D,Expert,3032.0,9.0,449.0,1563.0,,,
,1.0,B,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616351,,,,,H,Autocuration,16655.0,8.0,,1564.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,11863.0,BAO_0000357,,CHEMBL616352,,,,,H,Autocuration,14532.0,8.0,,1565.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616353,,,,,H,Autocuration,13944.0,8.0,,1566.0,,,
,1.0,B,Binding affinity against serotonergic 5-HT1a receptor,,,11863.0,BAO_0000357,,CHEMBL616354,,,,,H,Autocuration,13033.0,8.0,,1567.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,11863.0,BAO_0000357,,CHEMBL616508,,,,,H,Autocuration,10321.0,8.0,,1568.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,Mus musculus,CHEMBL616559,,10090.0,,,D,Expert,2968.0,9.0,,1569.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616560,,,,,H,Autocuration,13964.0,8.0,,1570.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,11863.0,BAO_0000357,,CHEMBL616561,,,,,H,Autocuration,15527.0,8.0,,1571.0,,,
,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,11863.0,BAO_0000219,,CHEMBL616562,,,,,H,Autocuration,12248.0,8.0,449.0,1572.0,,,
,1.0,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHO,11863.0,BAO_0000219,,CHEMBL616563,,,,,H,Autocuration,12249.0,8.0,449.0,1573.0,,,
,1.0,B,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616564,,,,,H,Autocuration,15120.0,8.0,,1574.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,11863.0,BAO_0000357,,CHEMBL616565,,,,,H,Autocuration,13313.0,8.0,,1575.0,,,
,1.0,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000218,,CHEMBL616566,,,,,H,Autocuration,2613.0,8.0,,1576.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,11863.0,BAO_0000357,,CHEMBL616989,,,,,H,Autocuration,16700.0,8.0,,1577.0,,,
,1.0,B,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL857975,,,,,H,Autocuration,2201.0,8.0,,1578.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,Mus musculus,CHEMBL616990,,10090.0,,,D,Expert,1274.0,9.0,,1579.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,11863.0,BAO_0000357,,CHEMBL616991,,,,,H,Autocuration,1317.0,8.0,,1580.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616992,,,,,H,Autocuration,12146.0,8.0,,1581.0,,,
,1.0,B,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,11863.0,BAO_0000357,,CHEMBL616993,,,,,H,Autocuration,14059.0,8.0,,1582.0,,,
,1.0,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616994,,9986.0,,,H,Expert,14025.0,8.0,,1583.0,,,
,1.0,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616995,,9986.0,,,H,Autocuration,14025.0,8.0,,1584.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,HEK293,105571.0,BAO_0000219,Gorilla gorilla,CHEMBL616996,,9593.0,,,D,Intermediate,14447.0,9.0,722.0,1585.0,,,
,1.0,F,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106.0,BAO_0000218,Cavia porcellus,CHEMBL616997,In vivo,10141.0,,,H,Autocuration,3025.0,8.0,,1586.0,,,
,1.0,F,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,106.0,BAO_0000218,Cavia porcellus,CHEMBL616998,In vivo,10141.0,,,H,Autocuration,3025.0,8.0,,1587.0,,,
,1.0,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,106.0,BAO_0000019,Cavia porcellus,CHEMBL616999,,10141.0,,,H,Autocuration,15329.0,8.0,,1588.0,,,
,1.0,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,106.0,BAO_0000019,Cavia porcellus,CHEMBL617000,,10141.0,,,H,Autocuration,15329.0,8.0,,1589.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,106.0,BAO_0000019,Cavia porcellus,CHEMBL617001,,10141.0,,,H,Autocuration,15847.0,8.0,,1590.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,106.0,BAO_0000019,Cavia porcellus,CHEMBL858111,,10141.0,,,H,Autocuration,15847.0,8.0,,1591.0,,,
,1.0,F,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,106.0,BAO_0000019,,CHEMBL617002,,,,,H,Autocuration,14165.0,8.0,,1592.0,,,
,1.0,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,106.0,BAO_0000019,,CHEMBL617003,,,,,H,Autocuration,14214.0,8.0,,1593.0,,,
,1.0,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,106.0,BAO_0000019,,CHEMBL617004,,,,,H,Autocuration,14214.0,8.0,,1594.0,,,
,1.0,F,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,106.0,BAO_0000019,Homo sapiens,CHEMBL617005,,9606.0,,,D,Expert,14214.0,9.0,,1595.0,,,
,1.0,F,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,CHO-K1,106.0,BAO_0000219,Homo sapiens,CHEMBL616623,,9606.0,,,D,Expert,13729.0,9.0,485.0,1596.0,,,
,1.0,F,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,CHO,106.0,BAO_0000219,,CHEMBL616624,,,,,H,Autocuration,3025.0,8.0,449.0,1597.0,,,
,1.0,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL883243,,,,,H,Autocuration,2391.0,8.0,,1598.0,,,
,1.0,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,106.0,BAO_0000019,,CHEMBL616625,,,,,H,Autocuration,2391.0,8.0,,1599.0,,,
,1.0,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,CHO,106.0,BAO_0000219,,CHEMBL616626,,,,,H,Expert,14956.0,8.0,449.0,1600.0,,,
,1.0,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,CHO,106.0,BAO_0000219,,CHEMBL616627,,,,,H,Autocuration,2598.0,8.0,449.0,1601.0,,,
,1.0,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,CHO,106.0,BAO_0000219,,CHEMBL616628,,,,,H,Autocuration,2598.0,8.0,449.0,1602.0,,,
,1.0,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,CHO,106.0,BAO_0000219,,CHEMBL616629,,,,,H,Autocuration,2598.0,8.0,449.0,1603.0,,,
,1.0,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,CHO,106.0,BAO_0000219,,CHEMBL616630,,,,,H,Autocuration,2598.0,8.0,449.0,1604.0,,,
,1.0,F,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,106.0,BAO_0000019,,CHEMBL616631,,,,,H,Expert,14956.0,8.0,,1605.0,,,
,1.0,F,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,106.0,BAO_0000019,,CHEMBL616632,,,,,H,Autocuration,14956.0,8.0,,1606.0,,,
,1.0,B,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL616633,,9606.0,,,D,Expert,14214.0,9.0,,1607.0,,,
,1.0,B,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,CHO,106.0,BAO_0000219,,CHEMBL616634,,,,,H,Expert,3463.0,8.0,449.0,1608.0,,,
,1.0,B,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,106.0,BAO_0000357,,CHEMBL616635,,,,,H,Autocuration,15331.0,8.0,,1609.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,Homo sapiens,CHEMBL885358,,9606.0,,,D,Expert,16146.0,9.0,,1610.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHO,106.0,BAO_0000219,Homo sapiens,CHEMBL616636,,9606.0,,,D,Expert,14159.0,9.0,449.0,1611.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,CHO,106.0,BAO_0000219,,CHEMBL616637,,,,,H,Expert,14158.0,8.0,449.0,1612.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616638,,,,,H,Autocuration,14159.0,8.0,,1613.0,,,
,1.0,B,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHO,106.0,BAO_0000219,,CHEMBL616639,,,,,H,Expert,15250.0,8.0,449.0,1614.0,,,
,1.0,B,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHO,106.0,BAO_0000219,,CHEMBL616640,,,,,H,Expert,15250.0,8.0,449.0,1615.0,,,
,1.0,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHO,106.0,BAO_0000219,,CHEMBL616641,,,,,H,Expert,15331.0,8.0,449.0,1616.0,,,
,1.0,B,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,CHO,106.0,BAO_0000219,,CHEMBL616642,,,,,H,Expert,15332.0,8.0,449.0,1617.0,,,
,1.0,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHO,106.0,BAO_0000219,,CHEMBL616643,,,,,H,Expert,14956.0,8.0,449.0,1618.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,106.0,BAO_0000357,,CHEMBL616644,,,,,H,Autocuration,3805.0,8.0,,1619.0,,,
,1.0,B,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,106.0,BAO_0000357,,CHEMBL616645,,,,,H,Autocuration,14875.0,8.0,,1620.0,,,
,1.0,F,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616646,,9986.0,,,H,Autocuration,14454.0,8.0,,1621.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616647,,9986.0,,,H,Expert,14454.0,8.0,,1622.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,105.0,BAO_0000357,,CHEMBL616509,,,,,H,Autocuration,16288.0,8.0,,1623.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,105.0,BAO_0000357,,CHEMBL616510,,,,,H,Autocuration,16288.0,8.0,,1624.0,,,
,1.0,B,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616511,,,,,H,Autocuration,16312.0,8.0,,1625.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,105.0,BAO_0000357,Bos taurus,CHEMBL616512,,9913.0,,,H,Expert,1348.0,8.0,,1626.0,,,
,1.0,B,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,105.0,BAO_0000357,Bos taurus,CHEMBL616513,,9913.0,,,H,Autocuration,5834.0,8.0,,1627.0,,,
Striatum,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,105.0,BAO_0000019,Bos taurus,CHEMBL616514,,9913.0,2435.0,,H,Autocuration,13366.0,8.0,,1628.0,,,
,1.0,B,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,105.0,BAO_0000357,Bos taurus,CHEMBL616515,,9913.0,,,H,Expert,1414.0,8.0,,1629.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,105.0,BAO_0000019,Bos taurus,CHEMBL616516,,9913.0,,,H,Autocuration,14998.0,8.0,,1630.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616517,,9913.0,,,H,Autocuration,11473.0,8.0,,1631.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616518,,9913.0,,,H,Autocuration,11473.0,8.0,,1632.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616519,,9913.0,,,H,Autocuration,10639.0,8.0,,1633.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616520,,9913.0,,,H,Autocuration,10639.0,8.0,,1634.0,,,
,1.0,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616521,,9913.0,,,H,Autocuration,1375.0,8.0,,1635.0,,,
,1.0,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,105.0,BAO_0000357,Bos taurus,CHEMBL616522,,9913.0,,,H,Autocuration,1375.0,8.0,,1636.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105.0,BAO_0000357,Bos taurus,CHEMBL884531,,9913.0,,,H,Autocuration,16532.0,8.0,,1637.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,105.0,BAO_0000357,Bos taurus,CHEMBL616523,,9913.0,,,H,Autocuration,11147.0,8.0,,1638.0,,,
Striatum,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,105.0,BAO_0000019,Bos taurus,CHEMBL616731,,9913.0,2435.0,,H,Autocuration,13366.0,8.0,,1639.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,105.0,BAO_0000019,Bos taurus,CHEMBL616732,,9913.0,,,H,Autocuration,10444.0,8.0,,1640.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,105.0,BAO_0000357,Bos taurus,CHEMBL616733,,9913.0,,,H,Autocuration,16532.0,8.0,,1641.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,105.0,BAO_0000357,Bos taurus,CHEMBL616734,,9913.0,,,H,Autocuration,16532.0,8.0,,1642.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,105.0,BAO_0000249,Bos taurus,CHEMBL616735,,9913.0,,,H,Autocuration,12827.0,8.0,,1643.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,105.0,BAO_0000249,Bos taurus,CHEMBL616736,,9913.0,,,H,Autocuration,12827.0,8.0,,1644.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105.0,BAO_0000019,Bos taurus,CHEMBL616737,,9913.0,,,H,Expert,12919.0,8.0,,1645.0,,,
,1.0,B,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,105.0,BAO_0000019,Bos taurus,CHEMBL616738,,9913.0,,,H,Autocuration,14025.0,8.0,,1646.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105.0,BAO_0000019,Bos taurus,CHEMBL616739,,9913.0,,,H,Expert,12919.0,8.0,,1647.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105.0,BAO_0000019,Bos taurus,CHEMBL616740,,9913.0,,,H,Expert,12919.0,8.0,,1648.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,105.0,BAO_0000019,Bos taurus,CHEMBL616741,,9913.0,,,H,Expert,12919.0,8.0,,1649.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,HEK293,105.0,BAO_0000219,Gorilla gorilla,CHEMBL616742,,9593.0,,,H,Autocuration,14447.0,8.0,722.0,1650.0,,,
,1.0,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616743,,10141.0,,,D,Intermediate,1375.0,9.0,,1651.0,,,
,1.0,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616744,,10141.0,,,D,Intermediate,1375.0,9.0,,1652.0,,,
,1.0,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616745,,10141.0,,,D,Intermediate,12409.0,9.0,,1653.0,,,
,1.0,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616746,,10141.0,,,D,Intermediate,12409.0,9.0,,1654.0,,,
,1.0,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616747,,10141.0,,,D,Intermediate,12409.0,9.0,,1655.0,,,
,1.0,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616748,,10141.0,,,D,Intermediate,12409.0,9.0,,1656.0,,,
,1.0,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616648,,10141.0,,,D,Intermediate,12409.0,9.0,,1657.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,,105570.0,BAO_0000357,Cavia porcellus,CHEMBL616649,,10141.0,,,D,Intermediate,11574.0,9.0,,1658.0,,,
,1.0,B,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,105570.0,BAO_0000357,Cavia porcellus,CHEMBL616650,,10141.0,,,D,Intermediate,1558.0,9.0,,1659.0,,,
,1.0,F,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570.0,BAO_0000218,Cavia porcellus,CHEMBL616651,,10141.0,,,D,Intermediate,12409.0,9.0,,1660.0,,,
,1.0,F,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570.0,BAO_0000218,Cavia porcellus,CHEMBL616652,,10141.0,,,D,Intermediate,12409.0,9.0,,1661.0,,,
,1.0,F,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,105570.0,BAO_0000218,Cavia porcellus,CHEMBL616653,,10141.0,,,D,Intermediate,12409.0,9.0,,1662.0,,,
,1.0,F,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,105570.0,BAO_0000218,Cavia porcellus,CHEMBL616654,,10141.0,,,D,Intermediate,12409.0,9.0,,1663.0,,,
,1.0,B,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,105570.0,BAO_0000019,Cavia porcellus,CHEMBL616655,,10141.0,,,D,Intermediate,12253.0,9.0,,1664.0,,,
,1.0,B,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,105570.0,BAO_0000357,Cavia porcellus,CHEMBL616656,,10141.0,,,D,Intermediate,12936.0,9.0,,1665.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,105.0,BAO_0000019,Cavia porcellus,CHEMBL616657,,10141.0,,,H,Autocuration,13181.0,8.0,,1666.0,,,
Striatum,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,105570.0,BAO_0000357,Cavia porcellus,CHEMBL616658,,10141.0,2435.0,,D,Intermediate,12409.0,9.0,,1667.0,,,
,1.0,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,105570.0,BAO_0000357,Cavia porcellus,CHEMBL616659,,10141.0,,,D,Intermediate,10639.0,9.0,,1668.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,,51.0,BAO_0000357,,CHEMBL616660,,,,,H,Autocuration,5254.0,8.0,,1669.0,,,
,1.0,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,106.0,BAO_0000357,,CHEMBL616661,,,,,H,Autocuration,13051.0,8.0,,1670.0,,,
,1.0,F,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616662,,,,,H,Expert,3463.0,8.0,,1671.0,,,
,1.0,F,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616663,,,,,H,Autocuration,15315.0,8.0,,1672.0,,,
,1.0,F,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616664,,,,,H,Autocuration,6011.0,8.0,,1673.0,,,
,1.0,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL881820,,9606.0,,,D,Expert,14159.0,9.0,449.0,1674.0,,,
,1.0,F,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,CHO,105.0,BAO_0000219,,CHEMBL616665,,,,,H,Autocuration,14159.0,8.0,449.0,1675.0,,,
,1.0,B,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHO,105.0,BAO_0000219,,CHEMBL616666,,,,,H,Expert,15250.0,8.0,449.0,1676.0,,,
,1.0,B,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,CHO,105.0,BAO_0000219,,CHEMBL616667,,,,,H,Autocuration,15250.0,8.0,449.0,1677.0,,,
,1.0,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHO,105.0,BAO_0000219,,CHEMBL616668,,,,,H,Expert,15331.0,8.0,449.0,1678.0,,,
,1.0,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616669,,9606.0,,,D,Expert,15332.0,9.0,449.0,1679.0,,,
,1.0,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,CHO,105.0,BAO_0000219,,CHEMBL617040,,,,,H,Expert,15332.0,8.0,449.0,1680.0,,,
,1.0,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,CHO,105.0,BAO_0000219,,CHEMBL617041,,,,,H,Autocuration,3294.0,8.0,449.0,1681.0,,,
,1.0,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,CHO,105.0,BAO_0000219,,CHEMBL617042,,,,,H,Expert,14158.0,8.0,449.0,1682.0,,,
,1.0,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,CHO,105.0,BAO_0000219,,CHEMBL617043,,,,,H,Expert,14956.0,8.0,449.0,1683.0,,,
,1.0,F,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL617044,,,,,H,Autocuration,12469.0,8.0,,1684.0,,,
,1.0,F,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHO,105.0,BAO_0000219,,CHEMBL617045,,,,,H,Expert,3463.0,8.0,449.0,1685.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL617046,,9606.0,,,D,Expert,15250.0,9.0,449.0,1686.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL617047,,9606.0,,,D,Expert,15250.0,9.0,449.0,1687.0,,,
,1.0,F,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,105.0,BAO_0000019,,CHEMBL617048,,,,,H,Expert,14956.0,8.0,,1688.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,105.0,BAO_0000019,,CHEMBL616897,,,,,H,Autocuration,14159.0,8.0,,1689.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,105.0,BAO_0000019,Homo sapiens,CHEMBL616898,,9606.0,,,D,Expert,14159.0,9.0,,1690.0,,,
,1.0,F,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL858201,,9606.0,,,D,Expert,14499.0,9.0,449.0,1691.0,,,
,1.0,F,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616899,,,,,H,Autocuration,15315.0,8.0,,1692.0,,,
,1.0,B,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,105.0,BAO_0000219,,CHEMBL616900,In vitro,,,,H,Autocuration,3294.0,8.0,,1693.0,,,
,1.0,B,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,CHO,105.0,BAO_0000219,,CHEMBL616901,,,,,H,Expert,3463.0,8.0,449.0,1694.0,,,
,1.0,B,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,105.0,BAO_0000357,,CHEMBL616902,,,,,H,Autocuration,15331.0,8.0,,1695.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616903,,9606.0,,,D,Expert,14159.0,9.0,449.0,1696.0,,,
,1.0,B,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,CHO,105.0,BAO_0000219,,CHEMBL616904,,,,,H,Expert,14158.0,8.0,449.0,1697.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616905,,,,,H,Autocuration,14159.0,8.0,,1698.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHO,105.0,BAO_0000219,,CHEMBL616906,,,,,H,Expert,15250.0,8.0,449.0,1699.0,,,
,1.0,B,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105.0,BAO_0000219,,CHEMBL616907,,,,,H,Expert,15250.0,8.0,449.0,1700.0,,,
,1.0,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105.0,BAO_0000219,,CHEMBL616908,,,,,H,Expert,15331.0,8.0,449.0,1701.0,,,
,1.0,B,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616909,,9606.0,,,D,Expert,15332.0,9.0,449.0,1702.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616910,,9606.0,,,D,Expert,14499.0,9.0,449.0,1703.0,,,
,1.0,B,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHO,105.0,BAO_0000219,,CHEMBL616911,,,,,H,Expert,15332.0,8.0,449.0,1704.0,,,
,1.0,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHO,105.0,BAO_0000219,,CHEMBL616912,,,,,H,Expert,14956.0,8.0,449.0,1705.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,105.0,BAO_0000357,,CHEMBL616913,,,,,H,Autocuration,3805.0,8.0,,1706.0,,,
,1.0,B,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616914,,9606.0,,,D,Expert,6011.0,9.0,449.0,1707.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHO,105.0,BAO_0000219,,CHEMBL616915,,,,,H,Autocuration,16190.0,8.0,449.0,1708.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,105.0,BAO_0000019,,CHEMBL616916,,,,,H,Autocuration,14165.0,8.0,,1709.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616917,,9606.0,,,D,Expert,4234.0,9.0,,1710.0,,,
,1.0,B,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,105.0,BAO_0000357,,CHEMBL616918,,,,,H,Autocuration,15527.0,8.0,,1711.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,105.0,BAO_0000219,,CHEMBL616919,,,,,H,Expert,6328.0,8.0,,1712.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL616920,,,,,H,Autocuration,16209.0,8.0,,1713.0,,,
,1.0,B,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,105.0,BAO_0000357,,CHEMBL872914,,,,,H,Autocuration,14770.0,8.0,,1714.0,,,
,1.0,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,105.0,BAO_0000357,,CHEMBL616921,,,,,H,Autocuration,2598.0,8.0,,1715.0,,,
,1.0,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616922,,,,,H,Expert,6897.0,8.0,,1716.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616923,,,,,H,Autocuration,6013.0,8.0,,1717.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616924,,,,,H,Expert,5843.0,8.0,,1718.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,105.0,BAO_0000357,,CHEMBL875909,,,,,H,Expert,14454.0,8.0,,1719.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,105.0,BAO_0000357,,CHEMBL616925,,,,,H,Autocuration,14454.0,8.0,,1720.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,105.0,BAO_0000357,,CHEMBL616926,,,,,H,Autocuration,14454.0,8.0,,1721.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616927,,,,,H,Autocuration,15818.0,8.0,,1722.0,,,
,1.0,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,CHO-K1,105.0,BAO_0000219,,CHEMBL616928,,,,,H,Expert,13729.0,8.0,485.0,1723.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,105.0,BAO_0000219,Homo sapiens,CHEMBL616929,In vitro,9606.0,,,D,Expert,6011.0,9.0,,1724.0,,,
,1.0,B,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616930,,9606.0,,,D,Expert,4234.0,9.0,,1725.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616931,,,,,H,Expert,17085.0,8.0,,1726.0,,,
,1.0,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,105.0,BAO_0000357,,CHEMBL616932,,,,,H,Autocuration,3025.0,8.0,,1727.0,,,
,1.0,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616933,,,,,H,Expert,15315.0,8.0,,1728.0,,,
,1.0,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,105.0,BAO_0000219,Homo sapiens,CHEMBL616934,,9606.0,,,D,Expert,14214.0,9.0,,1729.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616935,,9606.0,,,D,Expert,3804.0,9.0,,1730.0,,,
,1.0,B,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,105.0,BAO_0000357,,CHEMBL616936,,,,,H,Autocuration,16700.0,8.0,,1731.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616937,,9606.0,,,D,Expert,2391.0,9.0,,1732.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616938,,9606.0,,,D,Expert,4175.0,9.0,,1733.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000019,,CHEMBL616939,,,,,H,Autocuration,17085.0,8.0,,1734.0,,,
,1.0,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,105.0,BAO_0000019,,CHEMBL616940,,,,,H,Expert,17085.0,8.0,,1735.0,,,
,1.0,B,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616941,,9606.0,,,D,Expert,15926.0,9.0,,1736.0,,,
,1.0,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,CHO-K1,105.0,BAO_0000219,,CHEMBL616942,,,,,H,Autocuration,16312.0,8.0,485.0,1737.0,,,
,1.0,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,CHO-K1,105.0,BAO_0000219,,CHEMBL616943,,,,,H,Autocuration,16312.0,8.0,485.0,1738.0,,,
,1.0,B,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,CHO,104802.0,BAO_0000219,,CHEMBL616944,,,,,H,Autocuration,14956.0,4.0,449.0,1739.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,105.0,BAO_0000019,,CHEMBL616945,,,,,H,Autocuration,3294.0,8.0,,1740.0,,,
,1.0,B,Binding activity radioligand.,,,105.0,BAO_0000357,,CHEMBL616946,,,,,H,Autocuration,12861.0,8.0,,1741.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,105.0,BAO_0000019,,CHEMBL616947,,,,,H,Autocuration,12861.0,8.0,,1742.0,,,
,1.0,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,CHO-K1,105.0,BAO_0000219,,CHEMBL616948,,,,,H,Expert,16312.0,8.0,485.0,1743.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616851,,,,,H,Autocuration,5104.0,8.0,,1744.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616852,,,,,H,Autocuration,5105.0,8.0,,1745.0,,,
,1.0,B,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616853,,,,,H,Autocuration,14499.0,8.0,,1746.0,,,
,1.0,B,Binding activity against human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616854,,9606.0,,,D,Expert,15926.0,9.0,,1747.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHO,105.0,BAO_0000219,Homo sapiens,CHEMBL616855,,9606.0,,,D,Expert,4540.0,9.0,449.0,1748.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,CHO,105.0,BAO_0000219,,CHEMBL616856,,,,,H,Autocuration,15779.0,8.0,449.0,1749.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,105.0,BAO_0000219,,CHEMBL616857,,,,,H,Autocuration,15779.0,8.0,449.0,1750.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL616858,,,,,H,Autocuration,6166.0,8.0,,1751.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,CHO,105.0,BAO_0000219,,CHEMBL616859,,,,,H,Autocuration,15779.0,8.0,449.0,1752.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,CHO,105.0,BAO_0000219,,CHEMBL616860,,,,,H,Autocuration,15779.0,8.0,449.0,1753.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,HEK293,105.0,BAO_0000219,,CHEMBL616861,,,,,H,Autocuration,17451.0,8.0,722.0,1754.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,HEK293,105.0,BAO_0000219,,CHEMBL616541,,,,,H,Autocuration,17451.0,8.0,722.0,1755.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,HEK293,105.0,BAO_0000219,,CHEMBL616542,,,,,H,Autocuration,17451.0,8.0,722.0,1756.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,105.0,BAO_0000219,,CHEMBL616543,,,,,H,Autocuration,4199.0,8.0,449.0,1757.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL616544,,9606.0,,,D,Expert,14875.0,9.0,,1758.0,,,
,1.0,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,CHO,105.0,BAO_0000219,,CHEMBL616545,,,,,H,Autocuration,15146.0,8.0,449.0,1759.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,105.0,BAO_0000357,,CHEMBL616546,,,,,H,Autocuration,5213.0,8.0,,1760.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,CHO,105.0,BAO_0000219,,CHEMBL616547,,,,,H,Autocuration,14818.0,8.0,449.0,1761.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,105.0,BAO_0000219,,CHEMBL616548,,,,,H,Autocuration,4829.0,8.0,449.0,1762.0,,,
,1.0,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,105.0,BAO_0000019,,CHEMBL616549,,,,,H,Expert,14454.0,8.0,,1763.0,,,
,1.0,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,105.0,BAO_0000019,,CHEMBL616550,,,,,H,Expert,14454.0,8.0,,1764.0,,,
,1.0,B,Binding affinity against 5-HT2C receptor,,,108.0,BAO_0000357,,CHEMBL857066,,,,,H,Autocuration,5254.0,8.0,,1765.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,,108.0,BAO_0000357,,CHEMBL616551,,,,,H,Autocuration,5254.0,8.0,,1766.0,,,
,1.0,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577.0,BAO_0000357,,CHEMBL616552,,,,,H,Autocuration,10639.0,8.0,,1767.0,,,
,1.0,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,10577.0,BAO_0000019,,CHEMBL832876,,,,,H,Autocuration,10639.0,8.0,,1768.0,,,
,1.0,B,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,10577.0,BAO_0000019,,CHEMBL616553,,,,,H,Expert,12352.0,8.0,,1769.0,,,
,1.0,B,Binding affinity towards 5-HT1B was determined,,,10577.0,BAO_0000357,,CHEMBL616554,,,,,H,Autocuration,9098.0,8.0,,1770.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,10577.0,BAO_0000019,,CHEMBL616555,,,,,H,Expert,14430.0,8.0,,1771.0,,,
,1.0,B,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,10577.0,BAO_0000019,,CHEMBL616556,,,,,H,Expert,13657.0,8.0,,1772.0,,,
,1.0,B,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,10577.0,BAO_0000019,,CHEMBL616557,,,,,H,Autocuration,13657.0,8.0,,1773.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10577.0,BAO_0000019,,CHEMBL616558,,,,,H,Expert,15854.0,8.0,,1774.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,10577.0,BAO_0000019,Rattus norvegicus,CHEMBL616749,,10116.0,,,D,Expert,10639.0,9.0,,1775.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,10577.0,BAO_0000357,,CHEMBL616750,,,,,H,Autocuration,10025.0,8.0,,1776.0,,,
,1.0,B,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,10577.0,BAO_0000357,,CHEMBL616751,,,,,H,Autocuration,10025.0,8.0,,1777.0,,,
,1.0,B,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577.0,BAO_0000249,,CHEMBL616752,,,,,H,Autocuration,14286.0,8.0,,1778.0,,,
Striatum,1.0,B,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,10577.0,BAO_0000019,,CHEMBL616753,,,2435.0,,H,Autocuration,3651.0,8.0,,1779.0,,,
,1.0,B,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,Rattus norvegicus,CHEMBL616754,,10116.0,,,D,Expert,14178.0,9.0,,1780.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,10577.0,BAO_0000019,,CHEMBL616755,,,,,H,Autocuration,10639.0,8.0,,1781.0,,,
Striatum,1.0,B,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,10577.0,BAO_0000019,,CHEMBL616756,,,2435.0,,H,Autocuration,13605.0,8.0,,1782.0,,,
Striatum,1.0,B,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,10577.0,BAO_0000019,,CHEMBL616757,,,2435.0,,H,Autocuration,5834.0,8.0,,1783.0,,,
Striatum,1.0,B,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,10577.0,BAO_0000357,,CHEMBL616758,,,2435.0,,H,Autocuration,10922.0,8.0,,1784.0,,,
,1.0,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,10577.0,BAO_0000249,,CHEMBL616759,,,,,H,Autocuration,14286.0,8.0,,1785.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,10577.0,BAO_0000357,,CHEMBL616760,,,,,H,Autocuration,11825.0,8.0,,1786.0,,,
Striatum,1.0,B,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,10577.0,BAO_0000019,,CHEMBL616761,,,2435.0,,H,Autocuration,14826.0,8.0,,1787.0,,,
Striatum,1.0,B,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,10577.0,BAO_0000019,,CHEMBL616762,,,2435.0,,H,Autocuration,9699.0,8.0,,1788.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,10577.0,BAO_0000019,,CHEMBL616763,,,,,H,Autocuration,14423.0,8.0,,1789.0,,,
,1.0,B,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,10577.0,BAO_0000357,,CHEMBL872909,,,,,H,Expert,10062.0,8.0,,1790.0,,,
,1.0,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL616764,,,,,H,Autocuration,10062.0,8.0,,1791.0,,,
,1.0,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,Rattus norvegicus,CHEMBL616765,,10116.0,,,D,Expert,12280.0,9.0,,1792.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,10577.0,BAO_0000357,,CHEMBL616766,,,2435.0,,H,Autocuration,15412.0,8.0,,1793.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,10577.0,BAO_0000357,,CHEMBL616767,,,2435.0,,H,Autocuration,15412.0,8.0,,1794.0,,,
,1.0,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL616768,,,,,H,Autocuration,10062.0,8.0,,1795.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577.0,BAO_0000357,,CHEMBL616769,,,,,H,Autocuration,11147.0,8.0,,1796.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,10577.0,BAO_0000019,,CHEMBL616770,,,,,H,Autocuration,9547.0,8.0,,1797.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,10577.0,BAO_0000019,,CHEMBL616771,,,,,H,Autocuration,10444.0,8.0,,1798.0,,,
Striatum,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,10577.0,BAO_0000019,,CHEMBL616772,,,2435.0,,H,Autocuration,12469.0,8.0,,1799.0,,,
,1.0,B,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,10577.0,BAO_0000019,,CHEMBL616773,,,,,H,Expert,9098.0,8.0,,1800.0,,,
,1.0,B,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,10577.0,BAO_0000019,,CHEMBL616774,,,,,H,Autocuration,9098.0,8.0,,1801.0,,,
,1.0,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL616775,,,,,H,Autocuration,9699.0,8.0,,1802.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10577.0,BAO_0000249,,CHEMBL616776,,,,,H,Autocuration,10394.0,8.0,,1803.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,10577.0,BAO_0000357,,CHEMBL616777,,,,,H,Autocuration,12092.0,8.0,,1804.0,,,
,1.0,B,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,10577.0,BAO_0000357,,CHEMBL616778,,,,,H,Autocuration,16700.0,8.0,,1805.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,10577.0,BAO_0000249,Rattus norvegicus,CHEMBL616779,,10116.0,,,D,Expert,403.0,9.0,,1806.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,Rattus norvegicus,CHEMBL616780,,10116.0,,,D,Expert,12771.0,9.0,,1807.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,10577.0,BAO_0000019,,CHEMBL616781,,,,,H,Autocuration,11642.0,8.0,,1808.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,10577.0,BAO_0000357,,CHEMBL616782,,,,,H,Autocuration,12953.0,8.0,,1809.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,10577.0,BAO_0000357,,CHEMBL616783,,,,,H,Autocuration,12953.0,8.0,,1810.0,,,
Striatum,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,10577.0,BAO_0000019,,CHEMBL616784,,,2435.0,,H,Expert,12953.0,8.0,,1811.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,10577.0,BAO_0000357,,CHEMBL616785,,,,,H,Autocuration,12953.0,8.0,,1812.0,,,
Brain,1.0,B,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10577.0,BAO_0000249,,CHEMBL857067,,,955.0,,H,Autocuration,9737.0,8.0,,1813.0,,,
,1.0,B,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,10577.0,BAO_0000019,,CHEMBL616786,,,,,H,Autocuration,9737.0,8.0,,1814.0,,,
Brain,1.0,B,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,10577.0,BAO_0000249,,CHEMBL616787,,,955.0,,H,Autocuration,9737.0,8.0,,1815.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,10577.0,BAO_0000357,,CHEMBL616788,,,,,H,Autocuration,12827.0,8.0,,1816.0,,,
,1.0,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL616789,,,,,H,Autocuration,5033.0,8.0,,1817.0,,,
,1.0,B,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,10577.0,BAO_0000019,Rattus norvegicus,CHEMBL616790,,10116.0,,,D,Expert,9786.0,9.0,,1818.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 1B receptor,,,10577.0,BAO_0000357,,CHEMBL616791,,,,,H,Expert,13116.0,8.0,,1819.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,10577.0,BAO_0000019,,CHEMBL616792,,,,,H,Autocuration,16429.0,8.0,,1820.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,10577.0,BAO_0000249,Rattus norvegicus,CHEMBL616793,,10116.0,,,D,Expert,12409.0,9.0,,1821.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,10577.0,BAO_0000357,,CHEMBL616794,,,,,H,Autocuration,15194.0,8.0,,1822.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,10577.0,BAO_0000357,,CHEMBL616795,,,,,H,Autocuration,15194.0,8.0,,1823.0,,,
,1.0,B,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,104686.0,BAO_0000019,,CHEMBL616796,,,,,H,Autocuration,5486.0,4.0,,1824.0,,,
,1.0,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616797,,,,,H,Autocuration,4639.0,8.0,,1825.0,,,
,1.0,B,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,106.0,BAO_0000249,,CHEMBL616798,,,,,H,Autocuration,386.0,8.0,,1826.0,Brain membranes,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,106.0,BAO_0000357,,CHEMBL616799,,,,,H,Autocuration,2474.0,8.0,,1827.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,106.0,BAO_0000357,,CHEMBL616800,,,,,H,Autocuration,6011.0,8.0,,1828.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616801,,,,,H,Autocuration,5014.0,8.0,,1829.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,106.0,BAO_0000357,,CHEMBL616802,,,,,H,Autocuration,17515.0,8.0,,1830.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,106.0,BAO_0000357,,CHEMBL616803,,,,,H,Autocuration,4373.0,8.0,,1831.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,106.0,BAO_0000357,,CHEMBL857068,,,,,H,Expert,1633.0,8.0,,1832.0,,,
,1.0,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,106.0,BAO_0000357,,CHEMBL616804,,,,,H,Autocuration,1633.0,8.0,,1833.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,106.0,BAO_0000357,,CHEMBL616805,,,,,H,Autocuration,4373.0,8.0,,1834.0,,,
,1.0,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616806,,,,,H,Autocuration,4687.0,8.0,,1835.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,,106.0,BAO_0000357,,CHEMBL616807,,,,,H,Autocuration,11574.0,8.0,,1836.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,106.0,BAO_0000357,,CHEMBL616808,,,,,H,Autocuration,10321.0,8.0,,1837.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,106.0,BAO_0000357,,CHEMBL616809,,,,,H,Autocuration,15527.0,8.0,,1838.0,,,
,1.0,B,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,106.0,BAO_0000357,,CHEMBL616810,,,,,H,Autocuration,17200.0,8.0,,1839.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,104802.0,BAO_0000224,,CHEMBL616811,,,,,H,Autocuration,14423.0,4.0,,1840.0,,,
,1.0,B,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,108.0,BAO_0000357,Bos taurus,CHEMBL616812,,9913.0,,,H,Autocuration,5834.0,8.0,,1841.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616813,,9823.0,,,H,Autocuration,11473.0,8.0,,1842.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616814,,9823.0,,,H,Autocuration,11473.0,8.0,,1843.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616815,,9823.0,,,H,Autocuration,10639.0,8.0,,1844.0,,,
,1.0,B,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616816,,9823.0,,,H,Autocuration,10639.0,8.0,,1845.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616817,,9823.0,,,H,Autocuration,14331.0,8.0,,1846.0,,,
,1.0,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616818,,9823.0,,,H,Autocuration,10796.0,8.0,,1847.0,,,
,1.0,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616819,,9823.0,,,H,Expert,9098.0,8.0,,1848.0,,,
,1.0,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616820,,9823.0,,,H,Expert,14331.0,8.0,,1849.0,,,
,1.0,B,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,108.0,BAO_0000019,Sus scrofa,CHEMBL616821,,9823.0,,,H,Expert,11828.0,8.0,,1850.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,108.0,BAO_0000357,Sus scrofa,CHEMBL616822,,9823.0,,,H,Autocuration,11866.0,8.0,,1851.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,108.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616823,,9986.0,,,H,Autocuration,13047.0,8.0,,1852.0,,,
,1.0,B,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616824,,10116.0,,,D,Autocuration,188.0,9.0,,1853.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616825,,10116.0,,,D,Autocuration,11825.0,9.0,,1854.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616826,,10116.0,,,D,Autocuration,11825.0,9.0,,1855.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616827,,10116.0,,,D,Expert,11624.0,9.0,,1856.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616828,,10116.0,,,D,Autocuration,11139.0,9.0,,1857.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616829,,10116.0,,,D,Autocuration,11147.0,9.0,,1858.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616830,,10116.0,,,D,Autocuration,10444.0,9.0,,1859.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616831,,10116.0,,,D,Expert,11624.0,9.0,,1860.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616832,,10116.0,,,D,Autocuration,11662.0,9.0,,1861.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616833,,10116.0,,,D,Autocuration,11662.0,9.0,,1862.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616834,,10116.0,,,D,Expert,11662.0,9.0,,1863.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL829595,,10116.0,,,D,Autocuration,11662.0,9.0,,1864.0,,,
,1.0,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616835,,10116.0,,,D,Autocuration,9098.0,9.0,,1865.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,12689.0,BAO_0000249,Rattus norvegicus,CHEMBL872910,,10116.0,,,D,Autocuration,10394.0,9.0,,1866.0,,,
,1.0,B,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL616836,,,,,H,Expert,11933.0,8.0,,1867.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL616837,,10116.0,,,D,Autocuration,12092.0,9.0,,1868.0,,,
,1.0,B,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL616466,,10116.0,,,D,Autocuration,12253.0,9.0,,1869.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,HEK293,12689.0,BAO_0000219,Rattus norvegicus,CHEMBL616467,,10116.0,,,D,Autocuration,12253.0,9.0,722.0,1870.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,108.0,BAO_0000357,,CHEMBL616468,,,,,H,Autocuration,1558.0,8.0,,1871.0,,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL616469,,,,,H,Autocuration,2474.0,8.0,,1872.0,,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL616470,,,,,H,Autocuration,2474.0,8.0,,1873.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689.0,BAO_0000357,,CHEMBL616471,,,,,H,Autocuration,11574.0,8.0,,1874.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,12689.0,BAO_0000357,,CHEMBL616472,,,,,H,Autocuration,1558.0,8.0,,1875.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,,12689.0,BAO_0000357,,CHEMBL616473,,,,,H,Autocuration,13944.0,8.0,,1876.0,,,
,1.0,B,Binding affinity against serotonergic 5-HT1c receptor,,,12689.0,BAO_0000357,,CHEMBL616474,,,,,H,Autocuration,13033.0,8.0,,1877.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL616475,,,,,H,Autocuration,10321.0,8.0,,1878.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,12689.0,BAO_0000357,,CHEMBL616476,,,,,H,Autocuration,11866.0,8.0,,1879.0,,,
,1.0,B,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,105.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616477,,9986.0,,,H,Autocuration,14454.0,8.0,,1880.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,104686.0,BAO_0000224,,CHEMBL616478,,,,,H,Autocuration,11574.0,4.0,,1881.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,104686.0,BAO_0000224,,CHEMBL616479,,,,,H,Autocuration,11574.0,4.0,,1882.0,,,
,1.0,B,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,104686.0,BAO_0000019,,CHEMBL616480,,,,,H,Autocuration,13631.0,4.0,,1883.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL616481,,10116.0,,,D,Autocuration,9630.0,5.0,,1884.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,104686.0,BAO_0000249,Rattus norvegicus,CHEMBL616482,,10116.0,,,D,Autocuration,8822.0,5.0,,1885.0,,,
Brain,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,104686.0,BAO_0000221,Rattus norvegicus,CHEMBL884713,,10116.0,955.0,,D,Autocuration,9064.0,5.0,,1886.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,104686.0,BAO_0000224,,CHEMBL616483,,,,,H,Autocuration,8868.0,4.0,,1887.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,104686.0,BAO_0000224,,CHEMBL616484,,,,,H,Autocuration,9064.0,4.0,,1888.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,104686.0,BAO_0000019,,CHEMBL616485,,,,,H,Autocuration,9806.0,4.0,,1889.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686.0,BAO_0000224,,CHEMBL616486,,,,,H,Autocuration,9098.0,4.0,,1890.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,104686.0,BAO_0000224,,CHEMBL616487,,,,,H,Autocuration,8868.0,4.0,,1891.0,,,
,1.0,B,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686.0,BAO_0000224,,CHEMBL616488,,,,,H,Autocuration,12765.0,4.0,,1892.0,,,
,1.0,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000019,,CHEMBL616489,,,,,H,Autocuration,11049.0,4.0,,1893.0,,,
,1.0,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000019,,CHEMBL616490,,,,,H,Autocuration,11049.0,4.0,,1894.0,,,
,1.0,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,104686.0,BAO_0000019,,CHEMBL616491,,,,,H,Autocuration,11049.0,4.0,,1895.0,,,
,1.0,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,104686.0,BAO_0000019,,CHEMBL616492,,,,,H,Autocuration,11049.0,4.0,,1896.0,,,
,1.0,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000019,,CHEMBL616493,,,,,H,Autocuration,11049.0,4.0,,1897.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,104686.0,BAO_0000019,,CHEMBL616494,,,,,H,Autocuration,11473.0,4.0,,1898.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,104686.0,BAO_0000019,,CHEMBL616495,,,,,H,Autocuration,11473.0,4.0,,1899.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,104686.0,BAO_0000019,,CHEMBL616496,,,,,H,Autocuration,3086.0,4.0,,1900.0,,,
,1.0,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000019,,CHEMBL616497,,,,,H,Autocuration,11049.0,4.0,,1901.0,,,
,1.0,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000019,,CHEMBL616498,,,,,H,Autocuration,11049.0,4.0,,1902.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,104686.0,BAO_0000019,,CHEMBL616499,,,,,H,Autocuration,10639.0,4.0,,1903.0,,,
,1.0,B,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,104686.0,BAO_0000019,,CHEMBL616500,,,,,H,Autocuration,10922.0,4.0,,1904.0,,,
Brain,1.0,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,104686.0,BAO_0000221,Rattus norvegicus,CHEMBL616501,,10116.0,955.0,,D,Autocuration,9064.0,5.0,,1905.0,,,
Brain,1.0,B,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,104686.0,BAO_0000221,,CHEMBL616502,,,955.0,,H,Autocuration,10748.0,4.0,,1906.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686.0,BAO_0000249,,CHEMBL884529,,,,,H,Autocuration,11614.0,4.0,,1907.0,Membranes,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686.0,BAO_0000249,,CHEMBL616503,,,,,H,Autocuration,11615.0,4.0,,1908.0,Membranes,,
,1.0,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL616964,,,,,H,Autocuration,11615.0,4.0,,1909.0,,,
,1.0,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,104686.0,BAO_0000249,,CHEMBL616965,,,,,H,Autocuration,11614.0,4.0,,1910.0,Membranes,,
,1.0,B,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,104686.0,BAO_0000224,,CHEMBL616966,,,,,H,Autocuration,11702.0,4.0,,1911.0,,,
,1.0,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686.0,BAO_0000224,,CHEMBL616967,,,,,H,Autocuration,11702.0,4.0,,1912.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL616968,,10116.0,,,D,Autocuration,11702.0,5.0,,1913.0,,,
,1.0,B,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686.0,BAO_0000224,,CHEMBL616969,,,,,H,Autocuration,11702.0,4.0,,1914.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,104686.0,BAO_0000019,,CHEMBL884530,,,,,H,Autocuration,13346.0,4.0,,1915.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL616970,,,,,H,Autocuration,10025.0,4.0,,1916.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686.0,BAO_0000224,,CHEMBL616971,,,,,H,Autocuration,10025.0,4.0,,1917.0,,,
,1.0,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686.0,BAO_0000224,,CHEMBL616972,,,,,H,Autocuration,10025.0,4.0,,1918.0,,,
,1.0,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,104686.0,BAO_0000224,,CHEMBL616973,,,,,H,Autocuration,9036.0,4.0,,1919.0,,,
,1.0,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,104686.0,BAO_0000224,,CHEMBL616974,,,,,H,Autocuration,9036.0,4.0,,1920.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,104686.0,BAO_0000019,,CHEMBL616975,,,,,H,Autocuration,9161.0,4.0,,1921.0,,,
,1.0,B,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,104686.0,BAO_0000019,,CHEMBL616976,,,,,H,Autocuration,12304.0,4.0,,1922.0,,,
,1.0,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,104686.0,BAO_0000224,,CHEMBL616977,,,,,H,Autocuration,13276.0,4.0,,1923.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686.0,BAO_0000224,,CHEMBL616978,,,,,H,Autocuration,11825.0,4.0,,1924.0,,,
,1.0,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,104686.0,BAO_0000224,,CHEMBL616979,,,,,H,Autocuration,12443.0,4.0,,1925.0,,,
,1.0,B,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL616980,,,,,H,Autocuration,13830.0,4.0,,1926.0,,,
,1.0,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,104686.0,BAO_0000249,,CHEMBL616981,,,,,H,Autocuration,9592.0,4.0,,1927.0,Membranes,,
,1.0,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,104686.0,BAO_0000249,,CHEMBL616982,,,,,H,Autocuration,9592.0,4.0,,1928.0,Membranes,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,104686.0,BAO_0000224,,CHEMBL616983,,,,,H,Autocuration,10881.0,4.0,,1929.0,,,
,1.0,B,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,104686.0,BAO_0000019,,CHEMBL616984,,,,,H,Autocuration,13605.0,4.0,,1930.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL616985,,10116.0,,,D,Autocuration,11624.0,5.0,,1931.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686.0,BAO_0000224,,CHEMBL616986,,,,,H,Autocuration,4101.0,4.0,,1932.0,,,
,1.0,B,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,104686.0,BAO_0000224,,CHEMBL616987,,,,,H,Autocuration,4101.0,4.0,,1933.0,,,
,1.0,B,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,104686.0,BAO_0000019,,CHEMBL616988,,,,,H,Autocuration,15360.0,4.0,,1934.0,,,
,1.0,B,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686.0,BAO_0000019,,CHEMBL617243,,,,,H,Autocuration,11576.0,4.0,,1935.0,,,
,1.0,B,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,104686.0,BAO_0000019,,CHEMBL617244,,,,,H,Autocuration,5834.0,4.0,,1936.0,,,
,1.0,B,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686.0,BAO_0000219,Rattus norvegicus,CHEMBL617245,,10116.0,,,D,Autocuration,2395.0,5.0,485.0,1937.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,104686.0,BAO_0000249,,CHEMBL617246,,,,,H,Autocuration,11965.0,4.0,,1938.0,Membranes,,
,1.0,B,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,104686.0,BAO_0000224,,CHEMBL617546,,,,,H,Autocuration,3967.0,4.0,,1939.0,,,
,1.0,B,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,104686.0,BAO_0000249,,CHEMBL617547,,,,,H,Autocuration,11130.0,4.0,,1940.0,Brain membranes,,
,1.0,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686.0,BAO_0000219,,CHEMBL617548,In vitro,,,,H,Autocuration,13427.0,4.0,,1941.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617549,,,,,H,Autocuration,9443.0,4.0,,1942.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686.0,BAO_0000224,,CHEMBL617550,,,,,H,Autocuration,9443.0,4.0,,1943.0,,,
,1.0,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,104686.0,BAO_0000224,,CHEMBL617551,,,,,H,Autocuration,11825.0,4.0,,1944.0,,,
,1.0,B,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,104686.0,BAO_0000249,,CHEMBL617552,,,,,H,Autocuration,12120.0,4.0,,1945.0,Membranes,,
,1.0,B,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,104686.0,BAO_0000249,,CHEMBL617553,,,,,H,Autocuration,12120.0,4.0,,1946.0,Membranes,,
Thoracic aorta,1.0,F,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,104686.0,BAO_0000019,,CHEMBL617554,,,1515.0,,H,Autocuration,11963.0,4.0,,1947.0,,,
,1.0,B,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,,CHEMBL617555,,,,,H,Autocuration,9069.0,4.0,,1948.0,,,
,1.0,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686.0,BAO_0000224,,CHEMBL617556,,,,,H,Autocuration,8868.0,4.0,,1949.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,10624.0,BAO_0000357,,CHEMBL617557,,,,,H,Autocuration,17200.0,8.0,,1950.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,10624.0,BAO_0000357,,CHEMBL617558,,,,,H,Autocuration,17200.0,8.0,,1951.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,17106.0,BAO_0000357,,CHEMBL617559,,,,,H,Expert,13969.0,8.0,,1952.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1D receptor,,,17106.0,BAO_0000357,,CHEMBL617560,,,,,D,Expert,13392.0,9.0,,1953.0,,,
,1.0,B,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106.0,BAO_0000249,,CHEMBL617561,,,,,H,Autocuration,1742.0,8.0,,1954.0,,,
,1.0,B,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106.0,BAO_0000249,,CHEMBL617562,,,,,H,Autocuration,1742.0,8.0,,1955.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,17106.0,BAO_0000357,,CHEMBL617563,,,2435.0,,H,Autocuration,14331.0,8.0,,1956.0,,,
,1.0,F,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,17106.0,BAO_0000019,,CHEMBL617564,,,,,H,Autocuration,12861.0,8.0,,1957.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,17106.0,BAO_0000019,,CHEMBL617565,,,,,H,Expert,12861.0,8.0,,1958.0,,,
,1.0,B,Binding activity radioligand.,,,17106.0,BAO_0000357,,CHEMBL856076,,,,,H,Autocuration,12861.0,8.0,,1959.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,17106.0,BAO_0000019,,CHEMBL617566,,,,,H,Autocuration,12861.0,8.0,,1960.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106.0,BAO_0000019,,CHEMBL875911,,,,,H,Expert,12861.0,8.0,,1961.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,17106.0,BAO_0000019,,CHEMBL617567,,,,,H,Autocuration,12861.0,8.0,,1962.0,,,
,1.0,B,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,17106.0,BAO_0000249,,CHEMBL617568,,,,,H,Autocuration,675.0,8.0,,1963.0,,,
,1.0,B,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,17106.0,BAO_0000019,,CHEMBL617569,,,,,H,Expert,12490.0,8.0,,1964.0,,,
,1.0,B,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,17106.0,BAO_0000249,,CHEMBL617570,,,,,H,Expert,11828.0,8.0,,1965.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,17106.0,BAO_0000357,,CHEMBL617571,,,,,H,Autocuration,11866.0,8.0,,1966.0,,,
,1.0,B,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,105.0,BAO_0000357,Sus scrofa,CHEMBL617572,,9823.0,,,H,Autocuration,773.0,8.0,,1967.0,,,
,1.0,B,The compound was tested for intrinsic activity against 5-HT1D receptor,,,105.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL617573,,9986.0,,,H,Expert,13047.0,8.0,,1968.0,,,
,1.0,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,105.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617574,,9986.0,,,H,Autocuration,13047.0,8.0,,1969.0,,,
,1.0,B,The compound was tested for binding affinity against 5-HT1D receptor,,,105.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL617575,,9986.0,,,H,Expert,13047.0,8.0,,1970.0,,,
,1.0,B,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,10578.0,BAO_0000357,,CHEMBL617576,,,,,H,Autocuration,188.0,8.0,,1971.0,,,
,1.0,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,10578.0,BAO_0000019,,CHEMBL617577,,,,,H,Autocuration,10639.0,8.0,,1972.0,,,
,1.0,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,10578.0,BAO_0000019,,CHEMBL617578,,,,,H,Autocuration,12438.0,8.0,,1973.0,,,
,1.0,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,10578.0,BAO_0000357,,CHEMBL617579,,,,,H,Autocuration,12438.0,8.0,,1974.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,10578.0,BAO_0000019,,CHEMBL617580,,,,,H,Expert,15854.0,8.0,,1975.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,10578.0,BAO_0000249,,CHEMBL617581,,,,,H,Autocuration,10394.0,8.0,,1976.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,10578.0,BAO_0000357,,CHEMBL617582,,,,,H,Autocuration,12092.0,8.0,,1977.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,10578.0,BAO_0000019,,CHEMBL617583,,,,,H,Expert,3389.0,8.0,,1978.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,105.0,BAO_0000357,,CHEMBL617584,,,,,H,Autocuration,6011.0,8.0,,1979.0,,,
,1.0,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL617585,,,,,H,Autocuration,4639.0,8.0,,1980.0,,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL875912,,,,,H,Autocuration,2474.0,8.0,,1981.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL617586,,,,,H,Autocuration,5014.0,8.0,,1982.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,105.0,BAO_0000357,,CHEMBL617587,,,,,H,Autocuration,17515.0,8.0,,1983.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,105.0,BAO_0000357,,CHEMBL617588,,,,,H,Autocuration,11866.0,8.0,,1984.0,,,
,1.0,B,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL857980,,,,,H,Autocuration,4687.0,8.0,,1985.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,,CHEMBL617589,,,,,H,Autocuration,12146.0,8.0,,1986.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL617590,,,,,H,Autocuration,10321.0,8.0,,1987.0,,,
,1.0,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,HEK293,105.0,BAO_0000219,,CHEMBL617591,,,,,H,Autocuration,13267.0,8.0,722.0,1988.0,,,
,1.0,B,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,105.0,BAO_0000357,Homo sapiens,CHEMBL617592,,9606.0,,,D,Expert,1274.0,9.0,,1989.0,,,
,1.0,B,,,,105.0,BAO_0000357,,CHEMBL617593,,,,,H,Autocuration,15250.0,8.0,,1990.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,106.0,BAO_0000219,,CHEMBL617594,,,,,H,Autocuration,13706.0,8.0,485.0,1991.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,105.0,BAO_0000219,,CHEMBL617595,,,,,H,Autocuration,13706.0,8.0,485.0,1992.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,HEK293,105.0,BAO_0000219,,CHEMBL617596,,,,,H,Autocuration,13706.0,8.0,722.0,1993.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,HEK293,105.0,BAO_0000219,,CHEMBL617597,,,,,H,Autocuration,13706.0,8.0,722.0,1994.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,105.0,BAO_0000019,,CHEMBL617598,,,,,H,Autocuration,13047.0,8.0,,1995.0,,,
,1.0,B,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,105.0,BAO_0000357,,CHEMBL872916,,,,,H,Autocuration,13366.0,8.0,,1996.0,,,
,1.0,B,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,105.0,BAO_0000357,,CHEMBL617599,,,,,H,Expert,13366.0,8.0,,1997.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,105.0,BAO_0000357,,CHEMBL617091,,,,,H,Autocuration,1558.0,8.0,,1998.0,,,
,1.0,B,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,CHO-K1,105.0,BAO_0000219,,CHEMBL617092,,,,,H,Expert,12902.0,8.0,485.0,1999.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHO-K1,105.0,BAO_0000219,,CHEMBL617093,,,,,H,Autocuration,13706.0,8.0,485.0,2000.0,,,
,1.0,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,105.0,BAO_0000019,,CHEMBL617094,,,,,H,Autocuration,13706.0,8.0,,2001.0,,,
,1.0,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,105.0,BAO_0000019,,CHEMBL617095,,,,,H,Autocuration,13706.0,8.0,,2002.0,,,
,1.0,F,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105.0,BAO_0000019,,CHEMBL617096,,,,,H,Autocuration,14251.0,8.0,,2003.0,,,
,1.0,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105.0,BAO_0000019,,CHEMBL617097,,,,,H,Autocuration,14251.0,8.0,,2004.0,,,
,1.0,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,105.0,BAO_0000019,,CHEMBL617098,,,,,H,Autocuration,14251.0,8.0,,2005.0,,,
,1.0,B,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL617301,,,,,H,Autocuration,13313.0,8.0,,2006.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL617302,,,,,H,Autocuration,13313.0,8.0,,2007.0,,,
,1.0,B,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617303,,,,,H,Autocuration,13366.0,8.0,,2008.0,,,
,1.0,B,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617304,,,,,H,Expert,13051.0,8.0,,2009.0,,,
,1.0,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,105.0,BAO_0000219,,CHEMBL617305,,,,,H,Expert,12903.0,8.0,449.0,2010.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,105.0,BAO_0000219,Homo sapiens,CHEMBL617306,,9606.0,,,D,Autocuration,12469.0,9.0,,2011.0,,,
,1.0,B,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,17106.0,BAO_0000357,,CHEMBL617307,,,,,H,Autocuration,5619.0,8.0,,2012.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,105.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617308,,9986.0,,,H,Autocuration,13047.0,8.0,,2013.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617309,,,,,H,Autocuration,16633.0,8.0,,2014.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617310,,,,,H,Autocuration,16633.0,8.0,,2015.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617311,,,,,H,Autocuration,16633.0,8.0,,2016.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,105.0,BAO_0000357,,CHEMBL617312,,,,,H,Autocuration,16633.0,8.0,,2017.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617313,,,,,H,Autocuration,3269.0,8.0,,2018.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,105.0,BAO_0000357,,CHEMBL617314,,,,,H,Expert,12409.0,8.0,,2019.0,,,
,1.0,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106.0,BAO_0000019,,CHEMBL617315,,,,,H,Autocuration,13706.0,8.0,,2020.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,HEK293,106.0,BAO_0000219,,CHEMBL617316,,,,,H,Autocuration,13706.0,8.0,722.0,2021.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,HEK293,106.0,BAO_0000219,,CHEMBL617317,,,,,H,Autocuration,13706.0,8.0,722.0,2022.0,,,
,1.0,B,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,106.0,BAO_0000219,,CHEMBL617318,,,,,H,Autocuration,12903.0,8.0,449.0,2023.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,106.0,BAO_0000019,,CHEMBL617319,,,,,H,Autocuration,13047.0,8.0,,2024.0,,,
,1.0,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106.0,BAO_0000357,,CHEMBL617320,,,,,D,Expert,13366.0,9.0,,2025.0,,,
,1.0,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106.0,BAO_0000357,,CHEMBL617321,,,,,D,Expert,13366.0,9.0,,2026.0,,,
,1.0,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,106.0,BAO_0000357,,CHEMBL617322,,,,,D,Expert,13366.0,9.0,,2027.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,106.0,BAO_0000357,,CHEMBL616862,,,,,H,Autocuration,13366.0,8.0,,2028.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,106.0,BAO_0000357,,CHEMBL616863,,,,,H,Autocuration,13366.0,8.0,,2029.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,CHO,106.0,BAO_0000219,,CHEMBL616864,,,,,H,Autocuration,12469.0,8.0,449.0,2030.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,CHO-K1,106.0,BAO_0000219,,CHEMBL616865,,,,,H,Autocuration,13706.0,8.0,485.0,2031.0,,,
,1.0,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,CHO-K1,106.0,BAO_0000219,,CHEMBL616866,,,,,H,Autocuration,13706.0,8.0,485.0,2032.0,,,
,1.0,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,106.0,BAO_0000019,,CHEMBL616867,,,,,H,Autocuration,13706.0,8.0,,2033.0,,,
,1.0,B,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,CHO-K1,106.0,BAO_0000219,,CHEMBL616868,,,,,H,Expert,12902.0,8.0,485.0,2034.0,,,
,1.0,B,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,105.0,BAO_0000357,,CHEMBL616869,,,,,H,Expert,13051.0,8.0,,2035.0,,,
,1.0,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHO,106.0,BAO_0000219,,CHEMBL616870,,,,,H,Expert,12903.0,8.0,449.0,2036.0,,,
,1.0,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,CHO-K1,105.0,BAO_0000219,,CHEMBL616871,,,,,H,Autocuration,1558.0,8.0,485.0,2037.0,,,
,1.0,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,CHO-K1,105.0,BAO_0000219,,CHEMBL616872,,,,,H,Autocuration,1558.0,8.0,485.0,2038.0,,,
,1.0,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,CHO-K1,105.0,BAO_0000219,,CHEMBL616873,,,,,H,Autocuration,1558.0,8.0,485.0,2039.0,,,
,1.0,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,CHO-K1,105.0,BAO_0000219,,CHEMBL616838,,,,,H,Autocuration,1558.0,8.0,485.0,2040.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,105.0,BAO_0000357,,CHEMBL616839,,,,,H,Autocuration,1558.0,8.0,,2041.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,106.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL616840,,9986.0,,,H,Autocuration,13047.0,8.0,,2042.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL616841,,,,,H,Autocuration,13313.0,8.0,,2043.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,105.0,BAO_0000357,,CHEMBL616842,,,,,H,Autocuration,13313.0,8.0,,2044.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,105.0,BAO_0000357,,CHEMBL857976,,,,,H,Expert,12409.0,8.0,,2045.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,CHO,10618.0,BAO_0000219,,CHEMBL616843,,,,,H,Autocuration,15250.0,8.0,449.0,2046.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,10618.0,BAO_0000357,Homo sapiens,CHEMBL616844,,9606.0,,,D,Expert,1348.0,9.0,,2047.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,10618.0,BAO_0000357,,CHEMBL616845,,,,,H,Autocuration,1348.0,8.0,,2048.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,Homo sapiens,CHEMBL616846,,9606.0,,,D,Expert,4234.0,9.0,,2049.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,10618.0,BAO_0000357,,CHEMBL616847,,,,,H,Autocuration,16209.0,8.0,,2050.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,10618.0,BAO_0000019,,CHEMBL616848,,,,,H,Autocuration,10444.0,8.0,,2051.0,,,
,1.0,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,,CHEMBL616849,,,,,H,Autocuration,3935.0,8.0,,2052.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,,CHEMBL872911,,,,,H,Autocuration,15818.0,8.0,,2053.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000019,,CHEMBL616850,,,,,H,Autocuration,17085.0,8.0,,2054.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,CHO,10618.0,BAO_0000219,Homo sapiens,CHEMBL616699,,9606.0,,,D,Expert,12936.0,9.0,449.0,2055.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,10618.0,BAO_0000357,,CHEMBL616700,,,,,H,Autocuration,6166.0,8.0,,2056.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,10618.0,BAO_0000219,,CHEMBL616701,,,,,H,Autocuration,15779.0,8.0,449.0,2057.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,CHO,10618.0,BAO_0000219,,CHEMBL616702,,,,,H,Autocuration,15779.0,8.0,449.0,2058.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHO,10618.0,BAO_0000219,,CHEMBL616703,,,,,H,Autocuration,15779.0,8.0,449.0,2059.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,10618.0,BAO_0000357,,CHEMBL616704,,,,,H,Autocuration,13181.0,8.0,,2060.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,CHO,10618.0,BAO_0000219,,CHEMBL616705,,,,,H,Autocuration,4199.0,8.0,449.0,2061.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,,CHEMBL616706,,,,,H,Autocuration,14875.0,8.0,,2062.0,,,
,1.0,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,CHO,10618.0,BAO_0000219,,CHEMBL616707,,,,,H,Autocuration,15146.0,8.0,449.0,2063.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,10618.0,BAO_0000357,,CHEMBL616708,,,,,H,Autocuration,5213.0,8.0,,2064.0,,,
,1.0,B,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,10618.0,BAO_0000357,,CHEMBL616709,,,,,H,Autocuration,12146.0,8.0,,2065.0,,,
,1.0,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,CHO,10618.0,BAO_0000219,,CHEMBL616710,,,,,H,Autocuration,13267.0,8.0,449.0,2066.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,CHO,10618.0,BAO_0000219,,CHEMBL616711,,,,,H,Autocuration,14818.0,8.0,449.0,2067.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,10618.0,BAO_0000219,,CHEMBL616712,,,,,H,Autocuration,4829.0,8.0,449.0,2068.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,10618.0,BAO_0000357,,CHEMBL616713,,,,,H,Autocuration,4373.0,8.0,,2069.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,10618.0,BAO_0000357,,CHEMBL616714,,,,,H,Autocuration,4373.0,8.0,,2070.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,,CHEMBL616715,,,,,H,Autocuration,14159.0,8.0,,2071.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,10618.0,BAO_0000357,,CHEMBL616716,,,,,H,Autocuration,16633.0,8.0,,2072.0,,,
,1.0,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,279.0,BAO_0000019,,CHEMBL616717,,,,,H,Autocuration,17085.0,8.0,,2073.0,,,
,1.0,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,279.0,BAO_0000019,,CHEMBL616718,,,,,H,Expert,17085.0,8.0,,2074.0,,,
,1.0,F,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000019,,CHEMBL875905,,,,,H,Autocuration,16209.0,8.0,,2075.0,,,
,1.0,F,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000019,,CHEMBL616719,,,,,H,Autocuration,16209.0,8.0,,2076.0,,,
,1.0,F,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,279.0,BAO_0000019,,CHEMBL616720,,,,,H,Expert,17085.0,8.0,,2077.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL616721,,,,,H,Autocuration,14159.0,8.0,,2078.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,CHO,279.0,BAO_0000219,,CHEMBL616722,,,,,H,Autocuration,15250.0,8.0,449.0,2079.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,279.0,BAO_0000357,,CHEMBL616723,,,,,H,Autocuration,3805.0,8.0,,2080.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,CHO,279.0,BAO_0000219,,CHEMBL616724,,,,,H,Autocuration,16190.0,8.0,449.0,2081.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,279.0,BAO_0000357,,CHEMBL616725,,,,,H,Autocuration,16190.0,8.0,,2082.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL616726,,,,,H,Autocuration,16209.0,8.0,,2083.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,279.0,BAO_0000357,,CHEMBL616727,,,,,H,Autocuration,16209.0,8.0,,2084.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,279.0,BAO_0000357,,CHEMBL616728,,,,,H,Autocuration,16209.0,8.0,,2085.0,,,
,1.0,B,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL616729,,,,,H,Autocuration,6866.0,8.0,,2086.0,,,
,1.0,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000019,,CHEMBL616730,,,,,H,Expert,17085.0,8.0,,2087.0,,,
,1.0,B,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL617125,,,,,H,Autocuration,16312.0,8.0,,2088.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,279.0,BAO_0000357,,CHEMBL857977,,,,,H,Autocuration,6166.0,8.0,,2089.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHO,279.0,BAO_0000219,,CHEMBL617126,,,,,H,Autocuration,15779.0,8.0,449.0,2090.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,CHO,279.0,BAO_0000219,,CHEMBL617127,,,,,H,Autocuration,4199.0,8.0,449.0,2091.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL617128,,,,,H,Autocuration,14875.0,8.0,,2092.0,,,
,1.0,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,CHO,279.0,BAO_0000219,,CHEMBL617129,,,,,H,Autocuration,15146.0,8.0,449.0,2093.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,279.0,BAO_0000357,,CHEMBL617130,,,,,H,Autocuration,5213.0,8.0,,2094.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,CHO,279.0,BAO_0000219,,CHEMBL617131,,,,,H,Autocuration,14818.0,8.0,449.0,2095.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,279.0,BAO_0000219,,CHEMBL617132,,,,,H,Autocuration,4829.0,8.0,449.0,2096.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHO,279.0,BAO_0000219,,CHEMBL617133,,,,,H,Autocuration,4829.0,8.0,449.0,2097.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,279.0,BAO_0000357,,CHEMBL617134,,,,,H,Autocuration,4373.0,8.0,,2098.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,279.0,BAO_0000357,,CHEMBL617135,,,,,H,Autocuration,4373.0,8.0,,2099.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,279.0,BAO_0000357,,CHEMBL617136,,,,,H,Autocuration,5014.0,8.0,,2100.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,104686.0,BAO_0000019,,CHEMBL617137,,,,,H,Autocuration,11662.0,4.0,,2101.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686.0,BAO_0000019,,CHEMBL617138,,,,,H,Autocuration,11662.0,4.0,,2102.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686.0,BAO_0000019,,CHEMBL617139,,,,,H,Autocuration,11662.0,4.0,,2103.0,,,
,1.0,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617140,,,,,H,Autocuration,14093.0,8.0,,2104.0,,,
,1.0,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,104686.0,BAO_0000218,,CHEMBL617141,In vivo,,,,H,Autocuration,11200.0,4.0,,2105.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL858112,,,,,H,Autocuration,11200.0,4.0,,2106.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,17005.0,BAO_0000019,,CHEMBL617142,,,,,H,Intermediate,12352.0,8.0,,2107.0,,,
,1.0,B,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,22226.0,BAO_0000019,Bos taurus,CHEMBL617143,,9913.0,,,U,Autocuration,13657.0,0.0,,2108.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,22226.0,BAO_0000019,Bos taurus,CHEMBL617144,,9913.0,,,U,Autocuration,14331.0,0.0,,2109.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,22226.0,BAO_0000019,Bos taurus,CHEMBL617145,,9913.0,,,U,Autocuration,14331.0,0.0,,2110.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,22226.0,BAO_0000019,,CHEMBL617146,,,,,U,Autocuration,14331.0,0.0,,2111.0,,,
,1.0,B,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,104784.0,BAO_0000019,Cavia porcellus,CHEMBL617147,,10141.0,,,H,Autocuration,12685.0,4.0,,2112.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,104784.0,BAO_0000019,Cavia porcellus,CHEMBL617148,,10141.0,,,H,Autocuration,14389.0,4.0,,2113.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,104784.0,BAO_0000019,Cavia porcellus,CHEMBL617149,,10141.0,,,H,Autocuration,14386.0,4.0,,2114.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,104784.0,BAO_0000224,,CHEMBL617150,,,,,H,Autocuration,5732.0,4.0,,2115.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104784.0,BAO_0000224,,CHEMBL617151,,,,,H,Autocuration,16293.0,4.0,,2116.0,,,
,1.0,B,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617201,,,,,H,Autocuration,2078.0,4.0,,2117.0,,,
,1.0,B,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,10209.0,BAO_0000357,,CHEMBL617202,,,,,H,Autocuration,5486.0,8.0,,2118.0,,,
,1.0,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826.0,BAO_0000218,,CHEMBL617203,In vivo,,,,H,Autocuration,11820.0,4.0,,2119.0,,,
,1.0,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826.0,BAO_0000019,,CHEMBL617204,,,,,H,Autocuration,10297.0,4.0,,2120.0,,,
,1.0,B,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,104826.0,BAO_0000224,,CHEMBL617205,,,,,H,Autocuration,13704.0,4.0,,2121.0,,,
,1.0,B,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,104826.0,BAO_0000019,Mus musculus,CHEMBL617206,,10090.0,,,D,Autocuration,10297.0,5.0,,2122.0,,,
,1.0,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,104826.0,BAO_0000218,,CHEMBL617207,In vivo,,,,H,Autocuration,11820.0,4.0,,2123.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,104826.0,BAO_0000019,Mus musculus,CHEMBL617208,,10090.0,,,D,Autocuration,10297.0,5.0,,2124.0,,,
,1.0,B,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,104826.0,BAO_0000224,,CHEMBL617209,,,,,H,Autocuration,11555.0,4.0,,2125.0,,,
,1.0,B,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,104826.0,BAO_0000224,,CHEMBL617210,,,,,H,Autocuration,11555.0,4.0,,2126.0,,,
,1.0,B,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,104826.0,BAO_0000224,,CHEMBL617211,,,,,H,Autocuration,11555.0,4.0,,2127.0,,,
,1.0,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,104826.0,BAO_0000019,Mus musculus,CHEMBL617212,,10090.0,,,D,Autocuration,10297.0,5.0,,2128.0,,,
,1.0,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,104784.0,BAO_0000224,Sus scrofa,CHEMBL617213,,9823.0,,,H,Autocuration,16688.0,4.0,,2129.0,,,
,1.0,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,104784.0,BAO_0000224,Sus scrofa,CHEMBL617214,,9823.0,,,H,Autocuration,16688.0,4.0,,2130.0,,,
,1.0,B,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226.0,BAO_0000221,,CHEMBL617215,,,,,U,Autocuration,5333.0,0.0,,2131.0,,,
,1.0,B,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,22226.0,BAO_0000221,,CHEMBL617216,,,,,U,Autocuration,4437.0,0.0,,2132.0,,,
,1.0,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000357,Sus scrofa,CHEMBL617217,,9823.0,,,H,Autocuration,5033.0,8.0,,2133.0,,,
,1.0,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,,CHEMBL617218,,,,,H,Autocuration,15267.0,4.0,,2134.0,,,
,1.0,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,,CHEMBL872913,,,,,H,Autocuration,15267.0,4.0,,2135.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,104826.0,BAO_0000019,,CHEMBL617219,,,,,H,Autocuration,11820.0,4.0,,2136.0,,,
,1.0,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL873482,,,,,H,Autocuration,9069.0,4.0,,2137.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617220,,10116.0,,,D,Autocuration,9162.0,5.0,,2138.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,104686.0,BAO_0000019,,CHEMBL617221,,,,,H,Autocuration,9162.0,4.0,,2139.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,104686.0,BAO_0000019,,CHEMBL617222,,,,,H,Autocuration,9162.0,4.0,,2140.0,,,
,1.0,F,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,104686.0,BAO_0000019,,CHEMBL875906,,,,,H,Autocuration,10428.0,4.0,,2141.0,,,
,1.0,B,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,104686.0,BAO_0000019,,CHEMBL617223,,,,,H,Autocuration,9628.0,4.0,,2142.0,,,
,1.0,B,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617224,,,,,H,Autocuration,12704.0,4.0,,2143.0,,,
,1.0,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617225,,10116.0,,,D,Autocuration,15453.0,5.0,,2144.0,,,
,1.0,B,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,104686.0,BAO_0000224,,CHEMBL617226,,,,,H,Autocuration,188.0,4.0,,2145.0,,,
,1.0,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,104686.0,BAO_0000224,,CHEMBL617227,,,,,H,Autocuration,10349.0,4.0,,2146.0,,,
,1.0,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,104686.0,BAO_0000224,,CHEMBL617228,,,,,H,Autocuration,10349.0,4.0,,2147.0,,,
,1.0,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,104686.0,BAO_0000224,,CHEMBL617229,,,,,H,Autocuration,8868.0,4.0,,2148.0,,,
,1.0,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,104686.0,BAO_0000224,,CHEMBL617230,,,,,H,Autocuration,10025.0,4.0,,2149.0,,,
,1.0,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,104686.0,BAO_0000224,,CHEMBL617231,,,,,H,Autocuration,10025.0,4.0,,2150.0,,,
,1.0,B,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,104686.0,BAO_0000224,,CHEMBL617232,,,,,H,Autocuration,11702.0,4.0,,2151.0,,,
,1.0,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617233,,,,,H,Autocuration,11702.0,4.0,,2152.0,,,
,1.0,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,104686.0,BAO_0000224,,CHEMBL617234,,,,,H,Autocuration,11702.0,4.0,,2153.0,,,
,1.0,F,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,104686.0,BAO_0000019,,CHEMBL617235,,,,,H,Autocuration,11702.0,4.0,,2154.0,,,
,1.0,F,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,104686.0,BAO_0000019,,CHEMBL617236,,,,,H,Autocuration,11702.0,4.0,,2155.0,,,
Hippocampus,1.0,B,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,104686.0,BAO_0000221,,CHEMBL617237,,,10000000.0,,H,Autocuration,10085.0,4.0,,2156.0,,,
Hippocampus,1.0,B,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,104686.0,BAO_0000221,,CHEMBL617238,,,10000000.0,,H,Autocuration,10085.0,4.0,,2157.0,,,
Brain,1.0,B,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,104686.0,BAO_0000221,Rattus norvegicus,CHEMBL617239,,10116.0,955.0,,D,Autocuration,9630.0,5.0,,2158.0,,,
,1.0,B,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,104686.0,BAO_0000019,,CHEMBL617240,,,,,H,Autocuration,11070.0,4.0,,2159.0,,,
,1.0,B,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686.0,BAO_0000249,,CHEMBL617241,,,,,H,Autocuration,9841.0,4.0,,2160.0,Membranes,,
,1.0,B,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,104686.0,BAO_0000249,,CHEMBL875907,,,,,H,Autocuration,9841.0,4.0,,2161.0,Membranes,,
,1.0,B,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,104686.0,BAO_0000019,,CHEMBL617242,,,,,H,Autocuration,13291.0,4.0,,2162.0,,,
,1.0,F,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,104686.0,BAO_0000019,,CHEMBL617152,,,,,H,Autocuration,10590.0,4.0,,2163.0,,,
Brain,1.0,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,104686.0,BAO_0000221,Rattus norvegicus,CHEMBL617153,,10116.0,955.0,,D,Autocuration,9064.0,5.0,,2164.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,104686.0,BAO_0000249,Rattus norvegicus,CHEMBL617154,,10116.0,,,D,Autocuration,12268.0,5.0,,2165.0,Membranes,,
Brain,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,104686.0,BAO_0000221,,CHEMBL617155,,,955.0,,H,Autocuration,13508.0,4.0,,2166.0,,,
,1.0,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686.0,BAO_0000019,,CHEMBL617156,,,,,H,Autocuration,11279.0,4.0,,2167.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL617157,,,,,H,Autocuration,11200.0,4.0,,2168.0,,,
,1.0,F,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL617158,,,,,H,Autocuration,11200.0,4.0,,2169.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686.0,BAO_0000019,,CHEMBL617159,,,,,H,Autocuration,11200.0,4.0,,2170.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,104686.0,BAO_0000019,,CHEMBL617160,,,,,H,Autocuration,11200.0,4.0,,2171.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL858113,,,,,H,Autocuration,11200.0,4.0,,2172.0,,,
Brain,1.0,B,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,104686.0,BAO_0000220,,CHEMBL617247,,,955.0,,H,Autocuration,9231.0,4.0,,2173.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686.0,BAO_0000019,,CHEMBL617248,,,,,H,Autocuration,9737.0,4.0,,2174.0,,,
Brain,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,104686.0,BAO_0000249,,CHEMBL617249,,,955.0,,H,Autocuration,9737.0,4.0,,2175.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,104686.0,BAO_0000019,,CHEMBL617250,,,,,H,Autocuration,9737.0,4.0,,2176.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,104686.0,BAO_0000019,,CHEMBL617251,,,,,H,Autocuration,9737.0,4.0,,2177.0,,,
,1.0,B,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617252,,10116.0,,,D,Autocuration,11828.0,5.0,,2178.0,,,
,1.0,B,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,104686.0,BAO_0000019,,CHEMBL617006,,,,,H,Autocuration,12253.0,4.0,,2179.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,104686.0,BAO_0000019,,CHEMBL617007,,,,,H,Autocuration,12253.0,4.0,,2180.0,,,
,1.0,F,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,104686.0,BAO_0000019,,CHEMBL617008,,,,,H,Autocuration,11279.0,4.0,,2181.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,104686.0,BAO_0000019,,CHEMBL617009,,,,,H,Autocuration,11866.0,4.0,,2182.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617010,,10116.0,,,D,Autocuration,14424.0,5.0,,2183.0,,,
,1.0,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL857978,,10116.0,,,D,Autocuration,15180.0,5.0,,2184.0,,,
,1.0,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617011,,10116.0,,,D,Autocuration,15180.0,5.0,,2185.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617012,,10116.0,,,D,Autocuration,9786.0,5.0,,2186.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,104686.0,BAO_0000224,,CHEMBL617013,,,,,H,Autocuration,12132.0,4.0,,2187.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,104686.0,BAO_0000249,,CHEMBL617014,,,,,H,Autocuration,5486.0,4.0,,2188.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,,CHEMBL617015,,,,,H,Autocuration,15316.0,4.0,,2189.0,,,
,1.0,B,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,104686.0,BAO_0000019,,CHEMBL617016,,,,,H,Autocuration,16429.0,4.0,,2190.0,,,
,1.0,B,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,104686.0,BAO_0000224,,CHEMBL617017,,,,,H,Autocuration,14617.0,4.0,,2191.0,,,
Brain,1.0,B,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,104686.0,BAO_0000221,,CHEMBL617018,,,955.0,,H,Autocuration,11351.0,4.0,,2192.0,,,
,1.0,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,104686.0,BAO_0000019,,CHEMBL617019,,,,,H,Autocuration,11279.0,4.0,,2193.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617020,,,,,H,Autocuration,9523.0,4.0,,2194.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617021,,,,,H,Autocuration,9523.0,4.0,,2195.0,,,
,1.0,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617022,,,,,H,Autocuration,9523.0,4.0,,2196.0,,,
,1.0,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617023,,,,,H,Autocuration,9523.0,4.0,,2197.0,,,
,1.0,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617024,,,,,H,Autocuration,9523.0,4.0,,2198.0,,,
,1.0,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,105075.0,BAO_0000019,,CHEMBL617025,,,,,H,Autocuration,9523.0,4.0,,2199.0,,,
,1.0,B,Hill coefficient of compound was determined,,,105075.0,BAO_0000224,,CHEMBL617026,,,,,H,Autocuration,9523.0,4.0,,2200.0,,,
,1.0,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,22226.0,BAO_0000019,,CHEMBL617027,,,,,U,Autocuration,4771.0,0.0,,2201.0,,,
,1.0,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617028,,10116.0,,,D,Autocuration,5033.0,5.0,,2202.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,12687.0,BAO_0000019,,CHEMBL617029,,,,,H,Expert,10845.0,8.0,,2203.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,12687.0,BAO_0000019,,CHEMBL875908,,,,,H,Expert,10845.0,8.0,,2204.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,12687.0,BAO_0000357,,CHEMBL617030,,,,,H,Autocuration,16288.0,8.0,,2205.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,12687.0,BAO_0000019,,CHEMBL617031,,,,,H,Autocuration,16288.0,8.0,,2206.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,12687.0,BAO_0000019,,CHEMBL617032,,,,,H,Autocuration,16190.0,8.0,,2207.0,,,
,1.0,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617033,,10116.0,,,D,Autocuration,12463.0,5.0,,2208.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,104686.0,BAO_0000224,,CHEMBL617034,,,,,H,Autocuration,9699.0,4.0,,2209.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,104686.0,BAO_0000224,,CHEMBL617035,,,,,H,Autocuration,9699.0,4.0,,2210.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686.0,BAO_0000019,,CHEMBL617036,,,,,H,Autocuration,11662.0,4.0,,2211.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617037,,,,,H,Autocuration,1205.0,4.0,,2212.0,,,
,1.0,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,22226.0,BAO_0000219,,CHEMBL617038,,,,,U,Autocuration,11376.0,0.0,,2213.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,104784.0,BAO_0000219,,CHEMBL617039,,,,,H,Autocuration,11376.0,4.0,,2214.0,,,
,1.0,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617161,,,,,H,Autocuration,4639.0,4.0,,2215.0,,,
,1.0,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617162,,,,,H,Autocuration,2222.0,4.0,,2216.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617163,,,,,H,Autocuration,1558.0,4.0,,2217.0,,,
,1.0,B,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617164,,,,,H,Autocuration,1089.0,4.0,,2218.0,,,
,1.0,B,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,104784.0,BAO_0000249,,CHEMBL617165,,,,,H,Autocuration,386.0,4.0,,2219.0,Brain membranes,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,104784.0,BAO_0000224,,CHEMBL617166,,,,,H,Autocuration,2474.0,4.0,,2220.0,,,
,1.0,B,Binding affinity towards 5-HT2 receptor,,,104784.0,BAO_0000224,,CHEMBL617167,,,,,H,Autocuration,17066.0,4.0,,2221.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL872912,,,,,H,Autocuration,959.0,4.0,,2222.0,,,
,1.0,B,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,104784.0,BAO_0000224,,CHEMBL617168,,,,,H,Autocuration,6398.0,4.0,,2223.0,,,
,1.0,B,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,104686.0,BAO_0000224,,CHEMBL617169,,,,,H,Autocuration,11889.0,4.0,,2224.0,,,
,1.0,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617170,,,,,H,Autocuration,4221.0,4.0,,2225.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,104784.0,BAO_0000224,,CHEMBL617171,,,,,H,Autocuration,11026.0,4.0,,2226.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,104784.0,BAO_0000224,,CHEMBL617172,,,,,H,Autocuration,11866.0,4.0,,2227.0,,,
,1.0,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617173,,,,,H,Autocuration,4221.0,4.0,,2228.0,,,
,1.0,B,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,22226.0,BAO_0000019,,CHEMBL617174,,,,,U,Autocuration,13950.0,0.0,,2229.0,,,
,1.0,B,5-hydroxytryptamine 2 receptor binding affinity,,,104784.0,BAO_0000224,,CHEMBL617175,,,,,H,Autocuration,1263.0,4.0,,2230.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,17005.0,BAO_0000357,,CHEMBL617176,,,,,H,Autocuration,13291.0,8.0,,2231.0,,,
,1.0,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,17005.0,BAO_0000357,,CHEMBL617177,,,,,H,Autocuration,10812.0,8.0,,2232.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784.0,BAO_0000224,,CHEMBL617178,,,,,H,Autocuration,13020.0,4.0,,2233.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,104784.0,BAO_0000224,,CHEMBL617179,,,,,H,Autocuration,13021.0,4.0,,2234.0,,,
,1.0,B,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,104784.0,BAO_0000224,,CHEMBL617180,,,,,H,Autocuration,13020.0,4.0,,2235.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,17005.0,BAO_0000357,,CHEMBL617181,,,,,H,Autocuration,14532.0,8.0,,2236.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000357,,CHEMBL617182,,,,,H,Autocuration,13944.0,8.0,,2237.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000357,,CHEMBL617183,,,,,H,Autocuration,14331.0,8.0,,2238.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,17005.0,BAO_0000357,,CHEMBL617184,,,,,H,Autocuration,14118.0,8.0,,2239.0,,,
,1.0,B,Binding affinity against serotonergic 5-HT2 receptor,,,17005.0,BAO_0000357,,CHEMBL617185,,,,,H,Autocuration,13033.0,8.0,,2240.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,17005.0,BAO_0000357,,CHEMBL617186,,,,,H,Autocuration,10321.0,8.0,,2241.0,,,
,1.0,B,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,17005.0,BAO_0000357,,CHEMBL617187,,,,,H,Autocuration,12918.0,8.0,,2242.0,,,
,1.0,B,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000357,,CHEMBL617188,,,,,H,Autocuration,15120.0,8.0,,2243.0,,,
,1.0,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000218,,CHEMBL617189,,,,,H,Autocuration,2613.0,8.0,,2244.0,,,
,1.0,B,Inhibitory activity against cloned human 5-HT2 receptor,,,104784.0,BAO_0000224,Homo sapiens,CHEMBL617190,,9606.0,,,D,Autocuration,13378.0,5.0,,2245.0,,,
,1.0,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,CHO,104784.0,BAO_0000219,Homo sapiens,CHEMBL617191,,9606.0,,,D,Autocuration,2331.0,5.0,449.0,2246.0,,,
,1.0,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,CHO,104784.0,BAO_0000219,Homo sapiens,CHEMBL617192,,9606.0,,,D,Autocuration,2331.0,5.0,449.0,2247.0,,,
,1.0,B,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,CHO,104784.0,BAO_0000219,Homo sapiens,CHEMBL617193,,9606.0,,,D,Autocuration,2331.0,5.0,449.0,2248.0,,,
,1.0,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,CHO,104784.0,BAO_0000219,Homo sapiens,CHEMBL617194,,9606.0,,,D,Autocuration,2331.0,5.0,449.0,2249.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104784.0,BAO_0000224,,CHEMBL617195,,,,,H,Autocuration,4170.0,4.0,,2250.0,,,
,1.0,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,104784.0,BAO_0000224,,CHEMBL881830,,,,,H,Autocuration,15453.0,4.0,,2251.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,17005.0,BAO_0000357,,CHEMBL617196,,,,,H,Autocuration,1479.0,8.0,,2252.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,104686.0,BAO_0000224,,CHEMBL617197,,,,,H,Autocuration,11139.0,4.0,,2253.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,17005.0,BAO_0000357,,CHEMBL617198,,,,,H,Expert,13969.0,8.0,,2254.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,17005.0,BAO_0000357,,CHEMBL873476,,,,,H,Expert,13392.0,8.0,,2255.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,17005.0,BAO_0000019,,CHEMBL617199,,,,,H,Expert,14430.0,8.0,,2256.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Cavia porcellus,CHEMBL617200,,10141.0,,,H,Autocuration,13181.0,8.0,,2257.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51.0,BAO_0000357,,CHEMBL617484,,,,,H,Autocuration,17200.0,8.0,,2258.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107.0,BAO_0000357,,CHEMBL617485,,,,,H,Autocuration,17200.0,8.0,,2259.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,51.0,BAO_0000357,,CHEMBL617486,,,,,H,Autocuration,17200.0,8.0,,2260.0,,,
,1.0,B,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,107.0,BAO_0000357,,CHEMBL858022,,,,,H,Autocuration,13463.0,8.0,,2261.0,,,
,1.0,B,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHO,107.0,BAO_0000219,,CHEMBL617049,,,,,H,Autocuration,6347.0,8.0,449.0,2262.0,,,
,1.0,F,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,107.0,BAO_0000219,Homo sapiens,CHEMBL617050,,9606.0,,,D,Expert,6857.0,9.0,449.0,2263.0,,,
,1.0,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107.0,BAO_0000219,,CHEMBL617051,,,,,H,Autocuration,4176.0,8.0,,2264.0,,,
,1.0,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,107.0,BAO_0000219,,CHEMBL617052,,,,,H,Autocuration,4176.0,8.0,,2265.0,,,
,1.0,F,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,107.0,BAO_0000219,,CHEMBL617053,,,,,H,Autocuration,4176.0,8.0,,2266.0,,,
,1.0,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,CHO,107.0,BAO_0000219,,CHEMBL617054,,,,,H,Autocuration,6347.0,8.0,449.0,2267.0,,,
,1.0,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,CHO,107.0,BAO_0000219,,CHEMBL617055,,,,,H,Autocuration,6347.0,8.0,449.0,2268.0,,,
,1.0,B,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,107.0,BAO_0000357,,CHEMBL882924,,,,,H,Autocuration,15331.0,8.0,,2269.0,,,
,1.0,B,Inhibition of human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617056,,9606.0,,,D,Expert,16146.0,9.0,,2270.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107.0,BAO_0000219,,CHEMBL617057,,,,,H,Autocuration,15250.0,8.0,449.0,2271.0,,,
,1.0,B,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,107.0,BAO_0000219,,CHEMBL617058,,,,,H,Expert,13631.0,8.0,,2272.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,107.0,BAO_0000357,,CHEMBL617059,,,,,H,Autocuration,3805.0,8.0,,2273.0,,,
,1.0,B,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,CHO,107.0,BAO_0000219,,CHEMBL617060,,,,,H,Autocuration,4011.0,8.0,449.0,2274.0,,,
,1.0,B,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,CHO,107.0,BAO_0000219,,CHEMBL617061,,,,,H,Expert,4012.0,8.0,449.0,2275.0,,,
,1.0,B,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,L929,107.0,BAO_0000219,,CHEMBL617062,,,,,H,Expert,6366.0,8.0,307.0,2276.0,,,
,1.0,B,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107.0,BAO_0000219,,CHEMBL617063,,,,,H,Expert,15949.0,8.0,449.0,2277.0,,,
,1.0,F,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,107.0,BAO_0000019,,CHEMBL617064,,,,,H,Autocuration,14093.0,8.0,,2278.0,,,
,1.0,F,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107.0,BAO_0000019,,CHEMBL617065,,,,,H,Autocuration,13481.0,8.0,,2279.0,,,
,1.0,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHO,107.0,BAO_0000219,,CHEMBL617066,,,,,H,Autocuration,6347.0,8.0,449.0,2280.0,,,
,1.0,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,CHO,107.0,BAO_0000219,,CHEMBL617067,,,,,H,Autocuration,6347.0,8.0,449.0,2281.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,107.0,BAO_0000019,,CHEMBL617068,,,,,H,Autocuration,14093.0,8.0,,2282.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,107.0,BAO_0000019,,CHEMBL617069,,,,,H,Autocuration,14093.0,8.0,,2283.0,,,
,1.0,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107.0,BAO_0000019,,CHEMBL617070,,,,,H,Autocuration,13481.0,8.0,,2284.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,107.0,BAO_0000357,,CHEMBL617071,,,,,H,Autocuration,14442.0,8.0,,2285.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,107.0,BAO_0000357,,CHEMBL872915,,,,,H,Autocuration,14442.0,8.0,,2286.0,,,
,1.0,B,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,107.0,BAO_0000357,,CHEMBL617072,,,,,H,Autocuration,14755.0,8.0,,2287.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,107.0,BAO_0000357,,CHEMBL617073,,,,,H,Autocuration,16441.0,8.0,,2288.0,,,
,1.0,B,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,107.0,BAO_0000357,,CHEMBL617074,,,,,H,Autocuration,14744.0,8.0,,2289.0,,,
,1.0,B,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,107.0,BAO_0000219,,CHEMBL617075,,,,,H,Expert,16659.0,8.0,449.0,2290.0,,,
,1.0,B,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617076,,,,,H,Autocuration,3307.0,8.0,,2291.0,,,
,1.0,B,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,107.0,BAO_0000019,Homo sapiens,CHEMBL617077,,9606.0,,,D,Expert,6857.0,9.0,,2292.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,107.0,BAO_0000357,,CHEMBL617078,,,,,H,Expert,5635.0,8.0,,2293.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617079,,9606.0,,,D,Expert,4234.0,9.0,,2294.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107.0,BAO_0000357,,CHEMBL617080,,,,,H,Autocuration,15527.0,8.0,,2295.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,CHO,107.0,BAO_0000219,,CHEMBL617081,,,,,H,Expert,6588.0,8.0,449.0,2296.0,,,
,1.0,B,Binding affinity towards human 5-HT2A receptor in BEK cells,,,107.0,BAO_0000219,,CHEMBL617082,,,,,H,Expert,13631.0,8.0,,2297.0,,,
,1.0,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617083,,,,,H,Autocuration,17723.0,8.0,,2298.0,,,
,1.0,B,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,107.0,BAO_0000357,,CHEMBL617084,,,,,H,Autocuration,14770.0,8.0,,2299.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617085,,9606.0,,,D,Expert,16293.0,9.0,,2300.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,107.0,BAO_0000357,,CHEMBL617086,,,,,H,Autocuration,16209.0,8.0,,2301.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,107.0,BAO_0000219,,CHEMBL617087,,,,,H,Autocuration,12469.0,8.0,,2302.0,,,
,1.0,B,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617088,,,,,H,Autocuration,15363.0,8.0,,2303.0,,,
,1.0,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617089,,,,,H,Autocuration,15363.0,8.0,,2304.0,,,
,1.0,B,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,107.0,BAO_0000019,,CHEMBL617090,,,,,H,Expert,16441.0,8.0,,2305.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,107.0,BAO_0000357,,CHEMBL617513,,,,,H,Autocuration,8.0,8.0,,2306.0,,,
,1.0,B,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL617514,,,,,H,Autocuration,4176.0,8.0,722.0,2307.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000019,,CHEMBL617515,,,,,H,Autocuration,17085.0,8.0,,2308.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107.0,BAO_0000357,,CHEMBL617516,,,,,H,Autocuration,17200.0,8.0,,2309.0,,,
,1.0,B,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617517,,9606.0,,,D,Expert,17200.0,9.0,,2310.0,,,
,1.0,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,CHO,107.0,BAO_0000219,Homo sapiens,CHEMBL617518,,9606.0,,,D,Expert,4013.0,9.0,449.0,2311.0,,,
,1.0,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617519,,,,,H,Autocuration,5088.0,8.0,,2312.0,,,
,1.0,B,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617520,,9606.0,,,D,Expert,5088.0,9.0,,2313.0,,,
,1.0,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,107.0,BAO_0000357,,CHEMBL617521,,,,,H,Autocuration,5088.0,8.0,,2314.0,,,
,1.0,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617522,,9606.0,,,D,Expert,5088.0,9.0,,2315.0,,,
,1.0,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,107.0,BAO_0000357,,CHEMBL617523,,,,,H,Autocuration,5088.0,8.0,,2316.0,,,
,1.0,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,107.0,BAO_0000357,,CHEMBL617524,,,,,H,Autocuration,5088.0,8.0,,2317.0,,,
,1.0,B,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,104686.0,BAO_0000019,,CHEMBL617525,,,,,H,Autocuration,9786.0,4.0,,2318.0,,,
,1.0,B,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617526,,10116.0,,,D,Autocuration,9205.0,5.0,,2319.0,,,
,1.0,B,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,104686.0,BAO_0000224,,CHEMBL617527,,,,,H,Autocuration,11257.0,4.0,,2320.0,,,
,1.0,B,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686.0,BAO_0000019,,CHEMBL617528,,,,,H,Autocuration,9362.0,4.0,,2321.0,,,
,1.0,B,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,104686.0,BAO_0000019,,CHEMBL617529,,,,,H,Autocuration,9362.0,4.0,,2322.0,,,
,1.0,B,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,104686.0,BAO_0000224,,CHEMBL617530,,,,,H,Autocuration,10590.0,4.0,,2323.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686.0,BAO_0000019,,CHEMBL617531,,,,,H,Autocuration,10468.0,4.0,,2324.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,104686.0,BAO_0000019,,CHEMBL617532,,,,,H,Autocuration,13050.0,4.0,,2325.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,104686.0,BAO_0000019,,CHEMBL617533,,,,,H,Autocuration,11624.0,4.0,,2326.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,104686.0,BAO_0000019,,CHEMBL617534,,,,,H,Autocuration,10468.0,4.0,,2327.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,104686.0,BAO_0000224,,CHEMBL617535,,,,,H,Autocuration,10330.0,4.0,,2328.0,,,
,1.0,B,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,104686.0,BAO_0000224,,CHEMBL617536,,,,,H,Autocuration,10062.0,4.0,,2329.0,,,
,1.0,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617537,,,,,H,Autocuration,11642.0,4.0,,2330.0,,,
,1.0,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617538,,,,,H,Autocuration,10062.0,4.0,,2331.0,,,
,1.0,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,104686.0,BAO_0000219,,CHEMBL617539,In vitro,,,,H,Autocuration,13427.0,4.0,,2332.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617540,,10116.0,,,D,Autocuration,12280.0,5.0,,2333.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617541,,10116.0,,,D,Autocuration,4101.0,5.0,,2334.0,,,
,1.0,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617542,,,,,H,Autocuration,10062.0,4.0,,2335.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,104686.0,BAO_0000224,,CHEMBL617543,,,,,H,Autocuration,11147.0,4.0,,2336.0,,,
,1.0,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686.0,BAO_0000219,Rattus norvegicus,CHEMBL617544,,10116.0,,,D,Autocuration,2395.0,5.0,485.0,2337.0,,,
,1.0,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHO-K1,104686.0,BAO_0000219,Rattus norvegicus,CHEMBL617545,,10116.0,,,D,Autocuration,2395.0,5.0,485.0,2338.0,,,
,1.0,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617413,,10116.0,,,D,Autocuration,9098.0,5.0,,2339.0,,,
,1.0,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,104686.0,BAO_0000019,,CHEMBL617414,,,,,H,Autocuration,9098.0,4.0,,2340.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617415,,10116.0,,,D,Autocuration,9098.0,5.0,,2341.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617416,,,,,H,Autocuration,9443.0,4.0,,2342.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,104686.0,BAO_0000224,,CHEMBL617417,,,,,H,Autocuration,9443.0,4.0,,2343.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,104686.0,BAO_0000019,,CHEMBL617418,,,,,H,Autocuration,9699.0,4.0,,2344.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,104686.0,BAO_0000019,,CHEMBL617419,,,,,H,Autocuration,9699.0,4.0,,2345.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,104686.0,BAO_0000224,,CHEMBL617420,,,,,H,Autocuration,9098.0,4.0,,2346.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617421,,10116.0,,,D,Autocuration,3070.0,5.0,,2347.0,,,
,1.0,B,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,104686.0,BAO_0000224,,CHEMBL617422,,,,,H,Autocuration,9547.0,4.0,,2348.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,104686.0,BAO_0000019,,CHEMBL617423,,,,,H,Autocuration,10444.0,4.0,,2349.0,,,
,1.0,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,104686.0,BAO_0000019,,CHEMBL617424,,,,,H,Autocuration,14617.0,4.0,,2350.0,,,
,1.0,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,104686.0,BAO_0000019,,CHEMBL617425,,,,,H,Autocuration,14617.0,4.0,,2351.0,,,
,1.0,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,104686.0,BAO_0000224,,CHEMBL617426,,,,,H,Autocuration,11130.0,4.0,,2352.0,,,
,1.0,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,104686.0,BAO_0000218,,CHEMBL617427,In vivo,,,,H,Autocuration,11130.0,4.0,,2353.0,,,
Brain,1.0,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,104686.0,BAO_0000221,,CHEMBL617428,,,955.0,,H,Autocuration,14542.0,4.0,,2354.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,104686.0,BAO_0000224,,CHEMBL617429,,,,,H,Autocuration,2797.0,4.0,,2355.0,,,
,1.0,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686.0,BAO_0000019,,CHEMBL617430,,,,,H,Autocuration,11332.0,4.0,,2356.0,,,
,1.0,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,104686.0,BAO_0000019,,CHEMBL617431,,,,,H,Autocuration,11332.0,4.0,,2357.0,,,
Frontal cortex,1.0,B,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,104686.0,BAO_0000019,,CHEMBL617432,,,1870.0,,H,Autocuration,10752.0,4.0,,2358.0,,,
,1.0,B,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617433,,,,,H,Autocuration,1185.0,4.0,,2359.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617434,,,,,H,Autocuration,1185.0,4.0,,2360.0,,,
,1.0,B,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617435,,10116.0,,,D,Autocuration,11624.0,5.0,,2361.0,,,
,1.0,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,104686.0,BAO_0000019,,CHEMBL617436,,,,,H,Autocuration,1344.0,4.0,,2362.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617437,,10116.0,2435.0,,D,Autocuration,15453.0,5.0,,2363.0,,,
,1.0,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,104686.0,BAO_0000019,,CHEMBL617438,,,,,H,Autocuration,11662.0,4.0,,2364.0,,,
,1.0,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,104686.0,BAO_0000019,,CHEMBL617439,,,,,H,Autocuration,11662.0,4.0,,2365.0,,,
,1.0,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617440,,,,,H,Autocuration,10796.0,4.0,,2366.0,,,
,1.0,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617441,,,,,H,Autocuration,9069.0,4.0,,2367.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL872918,,10116.0,,,D,Autocuration,8814.0,5.0,,2368.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,104686.0,BAO_0000019,Rattus norvegicus,CHEMBL617442,,10116.0,,,D,Autocuration,8908.0,5.0,,2369.0,,,
,1.0,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686.0,BAO_0000019,,CHEMBL617443,,,,,H,Autocuration,9098.0,4.0,,2370.0,,,
,1.0,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,104686.0,BAO_0000019,,CHEMBL617444,,,,,H,Autocuration,9098.0,4.0,,2371.0,,,
,1.0,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,104686.0,BAO_0000019,,CHEMBL617445,,,,,H,Autocuration,9098.0,4.0,,2372.0,,,
,1.0,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,104686.0,BAO_0000019,,CHEMBL617446,,,,,H,Autocuration,9098.0,4.0,,2373.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,104686.0,BAO_0000249,,CHEMBL617447,,,,,H,Autocuration,9098.0,4.0,,2374.0,,,
,1.0,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,104686.0,BAO_0000019,,CHEMBL617448,,,,,H,Autocuration,9098.0,4.0,,2375.0,,,
,1.0,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,104686.0,BAO_0000019,,CHEMBL617449,,,,,H,Autocuration,9098.0,4.0,,2376.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,104686.0,BAO_0000019,,CHEMBL617450,,,,,H,Autocuration,9161.0,4.0,,2377.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,104686.0,BAO_0000019,,CHEMBL617451,,,,,H,Autocuration,9161.0,4.0,,2378.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,104686.0,BAO_0000019,,CHEMBL617452,,,,,H,Autocuration,9161.0,4.0,,2379.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,104686.0,BAO_0000019,,CHEMBL617453,,,,,H,Autocuration,9161.0,4.0,,2380.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,104686.0,BAO_0000019,,CHEMBL617660,,,,,H,Autocuration,9161.0,4.0,,2381.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,104686.0,BAO_0000019,,CHEMBL617661,,,,,H,Autocuration,9161.0,4.0,,2382.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,104686.0,BAO_0000019,,CHEMBL617662,,,,,H,Autocuration,9161.0,4.0,,2383.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,104686.0,BAO_0000019,,CHEMBL872919,,,,,H,Autocuration,9161.0,4.0,,2384.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,104686.0,BAO_0000019,,CHEMBL617663,,,,,H,Autocuration,9161.0,4.0,,2385.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,104686.0,BAO_0000019,,CHEMBL617664,,,,,H,Autocuration,9161.0,4.0,,2386.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,104686.0,BAO_0000019,,CHEMBL617665,,,,,H,Autocuration,9161.0,4.0,,2387.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,104686.0,BAO_0000019,,CHEMBL617666,,,,,H,Autocuration,9161.0,4.0,,2388.0,,,
,1.0,B,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,104686.0,BAO_0000019,,CHEMBL617667,,,,,H,Autocuration,12094.0,4.0,,2389.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,104686.0,BAO_0000249,,CHEMBL617668,,,,,H,Autocuration,12018.0,4.0,,2390.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,104686.0,BAO_0000249,,CHEMBL617669,,,,,H,Autocuration,10394.0,4.0,,2391.0,,,
,1.0,B,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617670,,,,,H,Autocuration,15260.0,4.0,,2392.0,,,
,1.0,B,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617671,,10116.0,,,D,Autocuration,11624.0,5.0,,2393.0,,,
,1.0,B,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617672,,,,,H,Autocuration,13654.0,4.0,,2394.0,,,
,1.0,B,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,104686.0,BAO_0000019,,CHEMBL617673,,,,,H,Autocuration,9541.0,4.0,,2395.0,,,
,1.0,B,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,104686.0,BAO_0000224,,CHEMBL617674,,,,,H,Autocuration,11933.0,4.0,,2396.0,,,
,1.0,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,104686.0,BAO_0000019,,CHEMBL617675,,,,,H,Autocuration,15538.0,4.0,,2397.0,,,
,1.0,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,104686.0,BAO_0000019,,CHEMBL617676,,,,,H,Autocuration,15538.0,4.0,,2398.0,,,
,1.0,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,104686.0,BAO_0000019,,CHEMBL617677,,,,,H,Autocuration,15538.0,4.0,,2399.0,,,
,1.0,B,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000019,,CHEMBL617678,,,,,D,Autocuration,8841.0,5.0,,2400.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,104686.0,BAO_0000224,,CHEMBL617679,,,,,H,Autocuration,1455.0,4.0,,2401.0,,,
,1.0,B,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,104686.0,BAO_0000224,,CHEMBL617680,,,,,H,Autocuration,1455.0,4.0,,2402.0,,,
,1.0,B,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,104686.0,BAO_0000019,,CHEMBL617681,,,,,H,Autocuration,11752.0,4.0,,2403.0,,,
Brain,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,104686.0,BAO_0000221,,CHEMBL617682,,,955.0,,H,Autocuration,11642.0,4.0,,2404.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,104686.0,BAO_0000224,,CHEMBL617683,,,,,H,Autocuration,12092.0,4.0,,2405.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,104686.0,BAO_0000224,,CHEMBL617684,,,,,H,Autocuration,3967.0,4.0,,2406.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,Rattus norvegicus,CHEMBL617685,,10116.0,,,D,Autocuration,12771.0,5.0,,2407.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,104686.0,BAO_0000019,,CHEMBL617686,,,,,H,Autocuration,11642.0,4.0,,2408.0,,,
,1.0,B,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,104686.0,BAO_0000224,,CHEMBL617687,,,,,H,Autocuration,11628.0,4.0,,2409.0,,,
,1.0,B,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,104686.0,BAO_0000224,,CHEMBL617688,,,,,H,Autocuration,13654.0,4.0,,2410.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL617689,,,,,H,Autocuration,11200.0,4.0,,2411.0,,,
,1.0,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,104686.0,BAO_0000019,,CHEMBL617690,,,,,H,Autocuration,11200.0,4.0,,2412.0,,,
,1.0,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686.0,BAO_0000218,,CHEMBL617691,In vivo,,,,H,Autocuration,11200.0,4.0,,2413.0,,,
,1.0,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686.0,BAO_0000218,,CHEMBL617692,In vivo,,,,H,Autocuration,11200.0,4.0,,2414.0,,,
,1.0,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,104686.0,BAO_0000218,,CHEMBL617693,In vivo,,,,H,Autocuration,11200.0,4.0,,2415.0,,,
,1.0,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,104686.0,BAO_0000218,,CHEMBL617694,In vivo,,,,H,Autocuration,11200.0,4.0,,2416.0,,,
Brain,1.0,B,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,12687.0,BAO_0000221,,CHEMBL857985,,,955.0,,H,Expert,15436.0,8.0,,2417.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617695,,10116.0,,,D,Expert,15436.0,9.0,,2418.0,,,
,1.0,B,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,12687.0,BAO_0000019,,CHEMBL617696,,,,,H,Autocuration,14025.0,8.0,,2419.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,12687.0,BAO_0000357,,CHEMBL617697,,,,,H,Autocuration,4342.0,8.0,,2420.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617257,,10116.0,,,D,Expert,13735.0,9.0,,2421.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617258,,10116.0,,,D,Expert,5816.0,9.0,,2422.0,,,
,1.0,B,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,12687.0,BAO_0000019,,CHEMBL617259,,,,,H,Expert,14287.0,8.0,,2423.0,,,
,1.0,B,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,12687.0,BAO_0000357,,CHEMBL617260,,,,,H,Autocuration,15738.0,8.0,,2424.0,,,
,1.0,B,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617261,,10116.0,,,D,Expert,15738.0,9.0,,2425.0,,,
,1.0,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL617262,,,,,H,Autocuration,15026.0,8.0,,2426.0,,,
,1.0,B,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687.0,BAO_0000019,,CHEMBL617263,,,,,H,Expert,16647.0,8.0,,2427.0,,,
,1.0,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,12687.0,BAO_0000019,,CHEMBL617264,,,,,H,Autocuration,16647.0,8.0,,2428.0,,,
,1.0,B,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617265,,10116.0,,,D,Expert,13345.0,9.0,,2429.0,,,
,1.0,B,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000249,,CHEMBL617266,,,,,H,Autocuration,1543.0,8.0,,2430.0,Membranes,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,12687.0,BAO_0000019,,CHEMBL617267,,,,,H,Autocuration,12444.0,8.0,,2431.0,,,
,1.0,B,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,12687.0,BAO_0000019,,CHEMBL617268,,,,,H,Expert,16404.0,8.0,,2432.0,,,
,1.0,B,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHO,12687.0,BAO_0000219,,CHEMBL617269,,,,,H,Autocuration,16404.0,8.0,449.0,2433.0,,,
,1.0,B,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,12687.0,BAO_0000357,,CHEMBL617323,,,,,H,Expert,15577.0,8.0,,2434.0,,,
,1.0,B,Serotonergic activity of the compound.,,,12687.0,BAO_0000357,,CHEMBL617324,,,,,H,Autocuration,15577.0,8.0,,2435.0,,,
,1.0,B,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,12687.0,BAO_0000249,,CHEMBL617325,,,,,H,Autocuration,2495.0,8.0,,2436.0,,,
,1.0,B,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617326,,10116.0,,,D,Expert,15042.0,9.0,,2437.0,,,
,1.0,B,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,12687.0,BAO_0000249,,CHEMBL617327,,,,,H,Expert,15026.0,8.0,,2438.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617328,,10116.0,,,D,Expert,12919.0,9.0,,2439.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617329,,10116.0,,,D,Expert,12919.0,9.0,,2440.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617330,,10116.0,,,D,Expert,12919.0,9.0,,2441.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL617331,,,,,H,Autocuration,15194.0,8.0,,2442.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,12687.0,BAO_0000357,,CHEMBL617332,,,,,H,Autocuration,15194.0,8.0,,2443.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617333,,,,,H,Expert,4820.0,8.0,,2444.0,,,
,1.0,B,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,107.0,BAO_0000357,,CHEMBL617334,,,,,H,Autocuration,6736.0,8.0,,2445.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,107.0,BAO_0000357,,CHEMBL617335,,,,,H,Autocuration,5163.0,8.0,,2446.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,107.0,BAO_0000357,,CHEMBL617336,,,,,H,Autocuration,5163.0,8.0,,2447.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,107.0,BAO_0000357,,CHEMBL617337,,,,,H,Autocuration,6011.0,8.0,,2448.0,,,
,1.0,B,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617338,,9606.0,,,D,Expert,14294.0,9.0,,2449.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617339,,,,,H,Autocuration,5014.0,8.0,,2450.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617340,,,,,H,Expert,17066.0,8.0,,2451.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,107.0,BAO_0000357,,CHEMBL617341,,,,,H,Autocuration,17515.0,8.0,,2452.0,,,
,1.0,B,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617342,,,,,H,Expert,6736.0,8.0,,2453.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617343,,,,,H,Expert,5163.0,8.0,,2454.0,,,
,1.0,B,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,NIH3T3,107.0,BAO_0000219,,CHEMBL617344,,,,,H,Expert,16911.0,8.0,723.0,2455.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,107.0,BAO_0000357,,CHEMBL617345,,,,,H,Expert,6841.0,8.0,,2456.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,107.0,BAO_0000357,,CHEMBL617346,,,,,H,Expert,6119.0,8.0,,2457.0,,,
,1.0,B,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617347,,,,,H,Autocuration,3962.0,8.0,,2458.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,107.0,BAO_0000357,,CHEMBL617348,,,,,H,Autocuration,4373.0,8.0,,2459.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,107.0,BAO_0000357,,CHEMBL617349,,,,,H,Autocuration,4373.0,8.0,,2460.0,,,
,1.0,F,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000019,,CHEMBL617350,,,,,H,Autocuration,3962.0,8.0,,2461.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,107.0,BAO_0000357,,CHEMBL872339,,,,,H,Expert,1633.0,8.0,,2462.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,107.0,BAO_0000357,,CHEMBL617351,,,,,H,Autocuration,4373.0,8.0,,2463.0,,,
,1.0,B,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617352,,,,,H,Expert,6576.0,8.0,,2464.0,,,
,1.0,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617353,,,,,H,Autocuration,4687.0,8.0,,2465.0,,,
,1.0,B,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617354,,,,,H,Autocuration,16946.0,8.0,,2466.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617355,,,,,H,Autocuration,14159.0,8.0,,2467.0,,,
,1.0,B,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,CHO,107.0,BAO_0000219,Mus musculus,CHEMBL617356,,10090.0,,,H,Expert,3032.0,8.0,449.0,2468.0,,,
,1.0,B,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617357,,,,,H,Autocuration,16655.0,8.0,,2469.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617358,,,,,H,Autocuration,13964.0,8.0,,2470.0,,,
,1.0,B,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617359,,,,,H,Expert,16989.0,8.0,,2471.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,107.0,BAO_0000357,,CHEMBL617360,,,,,H,Autocuration,16117.0,8.0,,2472.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,107.0,BAO_0000357,,CHEMBL875913,,,,,H,Autocuration,16700.0,8.0,,2473.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617361,,,,,H,Autocuration,3269.0,8.0,,2474.0,,,
,1.0,B,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL617362,,9606.0,,,D,Expert,1274.0,9.0,,2475.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,107.0,BAO_0000357,,CHEMBL617363,,,,,H,Autocuration,1317.0,8.0,,2476.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617364,,,,,H,Autocuration,12146.0,8.0,,2477.0,,,
,1.0,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075.0,BAO_0000224,,CHEMBL617365,,,,,H,Autocuration,12652.0,4.0,,2478.0,,,
,1.0,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,105075.0,BAO_0000224,,CHEMBL617366,,,,,H,Autocuration,12652.0,4.0,,2479.0,,,
,1.0,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,105075.0,BAO_0000224,,CHEMBL617367,,,,,H,Autocuration,12652.0,4.0,,2480.0,,,
,1.0,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,105075.0,BAO_0000224,,CHEMBL617368,,,,,H,Autocuration,12652.0,4.0,,2481.0,,,
,1.0,B,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,107.0,BAO_0000357,,CHEMBL617369,,,,,H,Autocuration,16647.0,8.0,,2482.0,,,
,1.0,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617370,,9606.0,,,D,Expert,15851.0,9.0,722.0,2483.0,,,
,1.0,F,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,227.0,BAO_0000219,Homo sapiens,CHEMBL617371,,9606.0,,,D,Expert,6857.0,9.0,449.0,2484.0,,,
,1.0,B,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,227.0,BAO_0000357,,CHEMBL617372,,,,,H,Autocuration,3805.0,8.0,,2485.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,227.0,BAO_0000357,Homo sapiens,CHEMBL617373,,9606.0,,,D,Expert,6491.0,9.0,,2486.0,,,
,1.0,F,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,227.0,BAO_0000019,,CHEMBL617374,,,,,H,Autocuration,14093.0,8.0,,2487.0,,,
,1.0,F,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,227.0,BAO_0000019,,CHEMBL617375,,,,,H,Autocuration,13481.0,8.0,,2488.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,227.0,BAO_0000019,,CHEMBL617376,,,,,H,Autocuration,14093.0,8.0,,2489.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,227.0,BAO_0000019,,CHEMBL617377,,,,,H,Autocuration,14093.0,8.0,,2490.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,227.0,BAO_0000019,,CHEMBL617378,,,,,H,Autocuration,14093.0,8.0,,2491.0,,,
,1.0,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227.0,BAO_0000019,,CHEMBL617379,,,,,H,Autocuration,13481.0,8.0,,2492.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,227.0,BAO_0000357,,CHEMBL617380,,,,,H,Autocuration,14442.0,8.0,,2493.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,227.0,BAO_0000357,,CHEMBL617381,,,,,H,Autocuration,14442.0,8.0,,2494.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,227.0,BAO_0000357,,CHEMBL617382,,,,,H,Autocuration,14442.0,8.0,,2495.0,,,
,1.0,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617383,,,,,H,Autocuration,12369.0,8.0,,2496.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,107.0,BAO_0000357,,CHEMBL617384,,,,,H,Expert,12369.0,8.0,,2497.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,107.0,BAO_0000357,,CHEMBL617385,,,,,H,Expert,12369.0,8.0,,2498.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,107.0,BAO_0000019,,CHEMBL617386,,,,,H,Autocuration,14447.0,8.0,,2499.0,,,
,1.0,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,107.0,BAO_0000019,,CHEMBL617387,,,,,H,Autocuration,14447.0,8.0,,2500.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107.0,BAO_0000219,,CHEMBL617388,,,,,H,Autocuration,17451.0,8.0,723.0,2501.0,,,
,1.0,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,107.0,BAO_0000219,,CHEMBL617389,,,,,H,Autocuration,6857.0,8.0,449.0,2502.0,,,
,1.0,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,107.0,BAO_0000219,Homo sapiens,CHEMBL617390,,9606.0,,,D,Expert,6857.0,9.0,449.0,2503.0,,,
,1.0,B,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,104817.0,BAO_0000224,,CHEMBL617391,,,,,H,Autocuration,5635.0,4.0,,2504.0,,,
,1.0,B,Binding activity radioligand.,,,107.0,BAO_0000357,,CHEMBL617392,,,,,H,Autocuration,12861.0,8.0,,2505.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,107.0,BAO_0000019,,CHEMBL617393,,,,,H,Autocuration,12861.0,8.0,,2506.0,,,
,1.0,B,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,L929,107.0,BAO_0000219,,CHEMBL617394,,,,,H,Autocuration,5105.0,8.0,307.0,2507.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,L929,107.0,BAO_0000219,,CHEMBL617395,,,,,H,Expert,5104.0,8.0,307.0,2508.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,L929,107.0,BAO_0000219,,CHEMBL617396,,,,,H,Expert,5105.0,8.0,307.0,2509.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,L929,107.0,BAO_0000219,,CHEMBL617397,,,,,H,Autocuration,5105.0,8.0,307.0,2510.0,,,
,1.0,B,Binding affinity against 5-HT2A receptor,,,107.0,BAO_0000357,,CHEMBL617398,,,,,H,Autocuration,5254.0,8.0,,2511.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,,CHEMBL617399,,,,,H,Autocuration,5254.0,8.0,,2512.0,,,
,1.0,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL617400,,,,,H,Autocuration,13267.0,8.0,722.0,2513.0,,,
,1.0,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL617401,,,,,H,Autocuration,13267.0,8.0,722.0,2514.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL617402,,9606.0,,,D,Expert,14157.0,9.0,722.0,2515.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL617403,,9606.0,,,D,Expert,12936.0,9.0,722.0,2516.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,107.0,BAO_0000357,,CHEMBL617404,,,,,H,Expert,14068.0,8.0,,2517.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL857981,,9606.0,,,D,Expert,12936.0,9.0,722.0,2518.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL617405,,9606.0,,,D,Expert,12936.0,9.0,722.0,2519.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL617253,,9606.0,,,D,Expert,4540.0,9.0,722.0,2520.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,107.0,BAO_0000357,,CHEMBL617254,,,,,H,Expert,6166.0,8.0,,2521.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL617255,,,,,H,Autocuration,17296.0,8.0,722.0,2522.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL617256,,,,,H,Autocuration,17296.0,8.0,722.0,2523.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL616874,,,,,H,Autocuration,17296.0,8.0,722.0,2524.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL616875,,9606.0,,,D,Expert,15779.0,9.0,722.0,2525.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL616876,,,,,H,Expert,14391.0,8.0,722.0,2526.0,,,
,1.0,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,HEK293,107.0,BAO_0000219,,CHEMBL616877,,,,,H,Expert,15851.0,8.0,722.0,2527.0,,,
,1.0,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL616878,,9606.0,,,D,Expert,15851.0,9.0,722.0,2528.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,HEK293,107.0,BAO_0000219,,CHEMBL616879,,,,,H,Expert,3832.0,8.0,722.0,2529.0,,,
,1.0,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,HEK293,107.0,BAO_0000219,,CHEMBL616880,,,,,H,Expert,3833.0,8.0,722.0,2530.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,HEK293,107.0,BAO_0000219,Homo sapiens,CHEMBL616881,,9606.0,,,D,Expert,12936.0,9.0,722.0,2531.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,NIH3T3,107.0,BAO_0000219,,CHEMBL616882,,,,,H,Autocuration,17451.0,8.0,723.0,2532.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107.0,BAO_0000219,,CHEMBL616883,,,,,H,Autocuration,17451.0,8.0,723.0,2533.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,107.0,BAO_0000219,,CHEMBL616884,,,,,H,Autocuration,17451.0,8.0,723.0,2534.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL616885,,,,,H,Autocuration,4199.0,8.0,722.0,2535.0,,,
,1.0,B,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,CHO-K1,107.0,BAO_0000219,,CHEMBL616886,,,,,H,Autocuration,1883.0,8.0,485.0,2536.0,,,
,1.0,B,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,CHO-K1,107.0,BAO_0000219,,CHEMBL616887,,,,,H,Expert,1883.0,8.0,485.0,2537.0,,,
,1.0,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,107.0,BAO_0000357,Homo sapiens,CHEMBL616888,,9606.0,,,D,Expert,14875.0,9.0,,2538.0,,,
,1.0,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,HEK293,107.0,BAO_0000219,,CHEMBL616889,,,,,H,Autocuration,15146.0,8.0,722.0,2539.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,HEK293,107.0,BAO_0000219,,CHEMBL616890,,,,,H,Autocuration,5213.0,8.0,722.0,2540.0,,,
,1.0,B,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHO,107.0,BAO_0000219,Homo sapiens,CHEMBL616891,,9606.0,,,D,Expert,16404.0,9.0,449.0,2541.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,HEK293,107.0,BAO_0000219,,CHEMBL616892,,,,,H,Autocuration,14818.0,8.0,722.0,2542.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,HEK293,107.0,BAO_0000219,,CHEMBL616893,,,,,H,Autocuration,4829.0,8.0,722.0,2543.0,,,
,1.0,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,NIH3T3,10620.0,BAO_0000219,,CHEMBL616894,,,,,H,Autocuration,12652.0,8.0,723.0,2544.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,NIH3T3,107.0,BAO_0000219,,CHEMBL616895,,,,,H,Expert,4682.0,8.0,723.0,2545.0,,,
,1.0,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,10620.0,BAO_0000019,,CHEMBL616896,,,,,H,Autocuration,12652.0,8.0,,2546.0,,,
,1.0,B,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,10621.0,BAO_0000357,,CHEMBL617099,,,,,H,Autocuration,4921.0,8.0,,2547.0,,,
,1.0,B,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,10621.0,BAO_0000357,,CHEMBL617100,,,,,H,Autocuration,4921.0,8.0,,2548.0,,,
,1.0,B,Binding affinity against rabbit aorta 5-HT2A receptor,,,107.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL884532,,9986.0,,,H,Autocuration,16312.0,8.0,,2549.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,107.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL617101,,9986.0,,,H,Expert,14998.0,8.0,,2550.0,,,
,1.0,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,107.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL617102,,9986.0,,,H,Expert,14025.0,8.0,,2551.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,107.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617103,,9986.0,,,H,Autocuration,13047.0,8.0,,2552.0,,,
,1.0,B,The compound was tested for binding affinity against 5-HT2A receptor,,,107.0,BAO_0000357,Oryctolagus cuniculus,CHEMBL617104,,9986.0,,,H,Expert,13047.0,8.0,,2553.0,,,
,1.0,B,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,CHO-K1,10576.0,BAO_0000219,,CHEMBL857979,,,,,H,Autocuration,1883.0,8.0,485.0,2554.0,,,
,1.0,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,12687.0,BAO_0000019,,CHEMBL857502,,,,,H,Autocuration,13463.0,8.0,,2555.0,,,
,1.0,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687.0,BAO_0000019,,CHEMBL617105,,,,,H,Autocuration,13463.0,8.0,,2556.0,,,
Stomach,1.0,B,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,12687.0,BAO_0000019,,CHEMBL858021,,,945.0,,H,Autocuration,13463.0,8.0,,2557.0,,,
Stomach,1.0,B,Binding affinity for 5-HT 2A in rat stomach fundus,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL875910,,10116.0,945.0,,D,Expert,13463.0,9.0,,2558.0,,,
,1.0,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,12687.0,BAO_0000019,,CHEMBL617106,,,,,H,Autocuration,13463.0,8.0,,2559.0,,,
,1.0,B,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,NIH3T3,12687.0,BAO_0000219,,CHEMBL617107,,,,,H,Expert,16326.0,8.0,723.0,2560.0,,,
,1.0,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617108,,,,,H,Autocuration,14093.0,8.0,,2561.0,,,
,1.0,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617109,,,,,H,Autocuration,14093.0,8.0,,2562.0,,,
,1.0,B,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617110,,,,,H,Autocuration,15740.0,8.0,,2563.0,,,
,1.0,B,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,12687.0,BAO_0000357,,CHEMBL617111,,,,,H,Autocuration,16633.0,8.0,,2564.0,,,
,1.0,F,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617112,,10116.0,,,D,Expert,17200.0,9.0,,2565.0,,,
,1.0,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617113,,,,,H,Autocuration,17133.0,8.0,,2566.0,,,
,1.0,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617114,,,,,H,Autocuration,17133.0,8.0,,2567.0,,,
,1.0,B,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617115,,,,,H,Autocuration,17133.0,8.0,,2568.0,,,
,1.0,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687.0,BAO_0000219,,CHEMBL617116,,,,,H,Autocuration,17200.0,8.0,,2569.0,,,
,1.0,F,Efficacy at 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617117,,,,,H,Autocuration,15363.0,8.0,,2570.0,,,
,1.0,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687.0,BAO_0000357,,CHEMBL617118,,,,,H,Autocuration,17200.0,8.0,,2571.0,,,
,1.0,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617119,,10116.0,,,D,Expert,17200.0,9.0,,2572.0,,,
,1.0,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617120,,10116.0,,,D,Expert,17200.0,9.0,,2573.0,,,
,1.0,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687.0,BAO_0000219,Rattus norvegicus,CHEMBL617121,,10116.0,,,D,Expert,17200.0,9.0,,2574.0,,,
,1.0,F,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,12687.0,BAO_0000219,,CHEMBL617122,,,,,H,Autocuration,17200.0,8.0,,2575.0,,,
,1.0,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617123,,,,,H,Autocuration,17211.0,8.0,,2576.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,12687.0,BAO_0000019,,CHEMBL617124,,,,,H,Expert,17331.0,8.0,,2577.0,,,
,1.0,B,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,12687.0,BAO_0000249,,CHEMBL617600,,,,,H,Expert,13565.0,8.0,,2578.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL617601,,,,,H,Expert,13730.0,8.0,,2579.0,,,
,1.0,B,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,12687.0,BAO_0000019,,CHEMBL882923,,,,,H,Expert,12416.0,8.0,,2580.0,,,
,1.0,B,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617602,,,,,H,Autocuration,15295.0,8.0,,2581.0,,,
,1.0,B,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,12687.0,BAO_0000019,,CHEMBL617603,,,,,H,Autocuration,1742.0,8.0,,2582.0,,,
,1.0,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617604,,,,,H,Autocuration,15295.0,8.0,,2583.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL617605,,,,,H,Expert,14970.0,8.0,,2584.0,,,
,1.0,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL617606,,,,,H,Expert,16693.0,8.0,,2585.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617607,,10116.0,,,D,Expert,14776.0,9.0,,2586.0,,,
,1.0,B,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL617455,,,,,H,Autocuration,14286.0,8.0,,2587.0,,,
,1.0,B,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617456,,10116.0,,,D,Expert,17200.0,9.0,,2588.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,12687.0,BAO_0000357,,CHEMBL617457,,,,,H,Expert,15306.0,8.0,,2589.0,,,
,1.0,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617458,,10116.0,,,D,Expert,14178.0,9.0,,2590.0,,,
,1.0,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617459,,10116.0,,,D,Expert,14229.0,9.0,,2591.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,12687.0,BAO_0000357,,CHEMBL617460,,,,,H,Expert,12884.0,8.0,,2592.0,,,
,1.0,B,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,12687.0,BAO_0000357,,CHEMBL617461,,,,,H,Expert,13149.0,8.0,,2593.0,,,
,1.0,B,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617462,,10116.0,,,D,Expert,15295.0,9.0,,2594.0,,,
,1.0,B,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,12687.0,BAO_0000357,,CHEMBL617463,,,,,H,Autocuration,15740.0,8.0,,2595.0,,,
,1.0,B,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,12687.0,BAO_0000019,,CHEMBL617464,,,,,H,Autocuration,15185.0,8.0,,2596.0,,,
,1.0,B,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,12687.0,BAO_0000019,,CHEMBL617465,,,,,H,Autocuration,15185.0,8.0,,2597.0,,,
,1.0,B,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,12687.0,BAO_0000019,,CHEMBL617466,,,,,H,Expert,17529.0,8.0,,2598.0,,,
,1.0,B,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687.0,BAO_0000019,,CHEMBL617467,,,,,H,Autocuration,14826.0,8.0,,2599.0,,,
,1.0,B,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,12687.0,BAO_0000019,,CHEMBL617468,,,,,H,Expert,17211.0,8.0,,2600.0,,,
,1.0,B,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,12687.0,BAO_0000019,,CHEMBL617469,,,,,H,Autocuration,14826.0,8.0,,2601.0,,,
,1.0,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,,CHEMBL617470,,,,,H,Autocuration,14093.0,8.0,,2602.0,,,
,1.0,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,12687.0,BAO_0000019,,CHEMBL617471,,,,,H,Autocuration,14093.0,8.0,,2603.0,,,
,1.0,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,NIH3T3,12687.0,BAO_0000219,,CHEMBL617472,,,,,H,Expert,13246.0,8.0,723.0,2604.0,,,
,1.0,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,12687.0,BAO_0000357,,CHEMBL617473,,,,,H,Expert,13246.0,8.0,,2605.0,,,
,1.0,B,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617474,,10116.0,,,D,Expert,15436.0,9.0,,2606.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617475,,10116.0,,,D,Expert,15436.0,9.0,,2607.0,,,
Brain,1.0,B,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,12687.0,BAO_0000221,,CHEMBL617476,,,955.0,,H,Autocuration,14442.0,8.0,,2608.0,,,
,1.0,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617477,,,,,H,Expert,12457.0,8.0,,2609.0,,,
,1.0,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,NIH3T3,12687.0,BAO_0000219,,CHEMBL617478,,,,,H,Expert,12457.0,8.0,723.0,2610.0,,,
,1.0,F,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,12687.0,BAO_0000221,,CHEMBL617479,,,,,H,Autocuration,14755.0,8.0,,2611.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,12687.0,BAO_0000357,,CHEMBL617480,,,,,H,Autocuration,4707.0,8.0,,2612.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617481,,,,,H,Expert,13297.0,8.0,,2613.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,12687.0,BAO_0000019,,CHEMBL617482,,,,,H,Expert,17331.0,8.0,,2614.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL617483,,,,,H,Autocuration,4664.0,8.0,,2615.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687.0,BAO_0000357,,CHEMBL621528,,,,,H,Autocuration,16633.0,8.0,,2616.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,NIH3T3,12687.0,BAO_0000219,Rattus norvegicus,CHEMBL621529,,10116.0,,,D,Expert,4664.0,9.0,723.0,2617.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687.0,BAO_0000357,,CHEMBL621530,,,,,H,Expert,16133.0,8.0,,2618.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL621531,,,,,H,Expert,16133.0,8.0,,2619.0,,,
,1.0,B,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL621532,,10116.0,,,D,Expert,14060.0,9.0,,2620.0,,,
,1.0,B,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687.0,BAO_0000357,,CHEMBL621533,,,,,H,Expert,16326.0,8.0,,2621.0,,,
,1.0,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHO,12687.0,BAO_0000219,,CHEMBL621534,,,,,H,Expert,16659.0,8.0,449.0,2622.0,,,
,1.0,B,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,12687.0,BAO_0000019,,CHEMBL621535,,,,,H,Autocuration,14776.0,8.0,,2623.0,,,
,1.0,B,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,12687.0,BAO_0000357,,CHEMBL621536,,,,,H,Autocuration,13481.0,8.0,,2624.0,,,
,1.0,B,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL621537,,,,,H,Autocuration,17386.0,8.0,,2625.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL621538,,10116.0,,,D,Expert,6611.0,9.0,,2626.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,12687.0,BAO_0000019,,CHEMBL621539,,,,,H,Autocuration,14423.0,8.0,,2627.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,12687.0,BAO_0000019,,CHEMBL621540,,,,,H,Autocuration,15412.0,8.0,,2628.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,12687.0,BAO_0000019,,CHEMBL621541,,,,,H,Autocuration,15412.0,8.0,,2629.0,,,
,1.0,B,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL621542,,,,,H,Autocuration,6238.0,8.0,,2630.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,12687.0,BAO_0000357,,CHEMBL621543,,,,,H,Expert,6648.0,8.0,,2631.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL621544,,,,,H,Expert,5667.0,8.0,,2632.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL621545,,10116.0,,,D,Expert,6611.0,9.0,,2633.0,,,
,1.0,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL621546,,,,,H,Autocuration,13481.0,8.0,,2634.0,,,
,1.0,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,12687.0,BAO_0000357,,CHEMBL621547,,,,,H,Autocuration,13481.0,8.0,,2635.0,,,
,1.0,B,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,NIH3T3,12687.0,BAO_0000219,,CHEMBL618692,,,,,H,Expert,15558.0,8.0,723.0,2636.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL618693,,,,,H,Autocuration,6013.0,8.0,,2637.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,12687.0,BAO_0000357,,CHEMBL872922,,,,,H,Autocuration,16633.0,8.0,,2638.0,,,
,1.0,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,12687.0,BAO_0000357,,CHEMBL618694,,,,,H,Autocuration,6013.0,8.0,,2639.0,,,
,1.0,B,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL618695,,10116.0,,,D,Expert,6013.0,9.0,,2640.0,,,
,1.0,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,12687.0,BAO_0000357,,CHEMBL618696,,,,,H,Autocuration,6013.0,8.0,,2641.0,,,
,1.0,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,12687.0,BAO_0000357,,CHEMBL618697,,,,,H,Expert,6013.0,8.0,,2642.0,,,
,1.0,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,12687.0,BAO_0000357,,CHEMBL618892,,,,,H,Autocuration,6013.0,8.0,,2643.0,,,
,1.0,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL618893,,,,,H,Autocuration,6013.0,8.0,,2644.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL618894,,,,,H,Autocuration,16293.0,8.0,,2645.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,NIH3T3,12687.0,BAO_0000219,,CHEMBL618895,,,,,H,Expert,17175.0,8.0,723.0,2646.0,,,
,1.0,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL618896,,10116.0,,,D,Expert,13278.0,9.0,,2647.0,,,
Caudate-putamen,1.0,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,12687.0,BAO_0000019,,CHEMBL618897,,,5383.0,,H,Autocuration,3682.0,8.0,,2648.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,12687.0,BAO_0000357,,CHEMBL618898,,,,,H,Autocuration,2014.0,8.0,,2649.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,12687.0,BAO_0000357,,CHEMBL618899,,,,,H,Autocuration,2014.0,8.0,,2650.0,,,
,1.0,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,12687.0,BAO_0000357,,CHEMBL618900,,,,,H,Autocuration,4932.0,8.0,,2651.0,,,
,1.0,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,12687.0,BAO_0000019,,CHEMBL618901,,,,,H,Autocuration,4932.0,8.0,,2652.0,,,
,1.0,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL618902,,,,,H,Autocuration,3935.0,8.0,,2653.0,,,
Hippocampus,1.0,B,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000221,Rattus norvegicus,CHEMBL618903,,10116.0,10000000.0,,D,Expert,5432.0,9.0,,2654.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL618904,,,,,H,Autocuration,15818.0,8.0,,2655.0,,,
,1.0,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,12687.0,BAO_0000357,,CHEMBL618905,,,,,H,Autocuration,13672.0,8.0,,2656.0,,,
,1.0,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,12687.0,BAO_0000357,,CHEMBL618906,,,,,H,Autocuration,13672.0,8.0,,2657.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,NIH3T3,12687.0,BAO_0000219,,CHEMBL618907,,,,,H,Expert,14749.0,8.0,723.0,2658.0,,,
,1.0,B,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,12687.0,BAO_0000019,,CHEMBL618908,,,,,H,Autocuration,13462.0,8.0,,2659.0,,,
,1.0,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617909,,,,,H,Autocuration,15740.0,8.0,,2660.0,,,
,1.0,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,12687.0,BAO_0000019,,CHEMBL617910,,,,,H,Expert,16647.0,8.0,,2661.0,,,
Brain,1.0,B,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,12687.0,BAO_0000221,,CHEMBL617911,,,955.0,,H,Autocuration,13345.0,8.0,,2662.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL872923,,,,,H,Autocuration,16740.0,8.0,,2663.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL617912,,,,,H,Autocuration,16740.0,8.0,,2664.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617913,,10116.0,,,D,Expert,15535.0,9.0,,2665.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL617914,,,,,H,Expert,16740.0,8.0,,2666.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL617915,,,,,H,Autocuration,16740.0,8.0,,2667.0,,,
,1.0,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,12687.0,BAO_0000249,,CHEMBL617916,,,,,H,Autocuration,16740.0,8.0,,2668.0,,,
,1.0,B,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617917,,10116.0,,,D,Expert,4795.0,9.0,,2669.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,12687.0,BAO_0000019,,CHEMBL617918,,,,,H,Expert,8.0,8.0,,2670.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,12687.0,BAO_0000019,,CHEMBL617919,,,,,H,Autocuration,8.0,8.0,,2671.0,,,
,1.0,B,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617920,,10116.0,,,D,Expert,17200.0,9.0,,2672.0,,,
,1.0,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617921,,10116.0,,,D,Expert,2148.0,9.0,,2673.0,,,
,1.0,B,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,105102.0,BAO_0000224,Rattus norvegicus,CHEMBL617922,,10116.0,,,D,Expert,13345.0,5.0,,2674.0,,,
,1.0,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,12687.0,BAO_0000357,,CHEMBL617923,,,,,H,Autocuration,5088.0,8.0,,2675.0,,,
,1.0,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,12687.0,BAO_0000357,,CHEMBL617924,,,,,H,Autocuration,5088.0,8.0,,2676.0,,,
,1.0,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,12687.0,BAO_0000357,,CHEMBL617925,,,,,H,Autocuration,17133.0,8.0,,2677.0,,,
,1.0,B,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,12687.0,BAO_0000357,Rattus norvegicus,CHEMBL617926,,10116.0,,,D,Expert,17133.0,9.0,,2678.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,12687.0,BAO_0000357,,CHEMBL617927,,,,,H,Autocuration,16532.0,8.0,,2679.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,12687.0,BAO_0000357,,CHEMBL617928,,,,,H,Autocuration,15086.0,8.0,,2680.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617929,,10116.0,,,D,Expert,2309.0,9.0,,2681.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,12687.0,BAO_0000019,,CHEMBL617930,,,,,H,Expert,12953.0,8.0,,2682.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,12687.0,BAO_0000019,,CHEMBL617931,,,,,H,Autocuration,12953.0,8.0,,2683.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,12687.0,BAO_0000019,,CHEMBL617932,,,,,H,Autocuration,12953.0,8.0,,2684.0,,,
,1.0,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,CHO,12687.0,BAO_0000219,,CHEMBL617933,,,,,H,Autocuration,16659.0,8.0,449.0,2685.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687.0,BAO_0000019,,CHEMBL617934,,,,,H,Autocuration,16740.0,8.0,,2686.0,,,
,1.0,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,12687.0,BAO_0000019,,CHEMBL617935,,,,,H,Autocuration,16740.0,8.0,,2687.0,,,
,1.0,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,12687.0,BAO_0000357,,CHEMBL617936,,,,,H,Autocuration,17133.0,8.0,,2688.0,,,
,1.0,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,12687.0,BAO_0000019,,CHEMBL617937,,,,,H,Autocuration,17211.0,8.0,,2689.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,12687.0,BAO_0000019,,CHEMBL617938,,,,,H,Autocuration,17331.0,8.0,,2690.0,,,
,1.0,B,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,12687.0,BAO_0000218,,CHEMBL617939,,,,,H,Autocuration,16633.0,8.0,,2691.0,,,
,1.0,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,12687.0,BAO_0000218,,CHEMBL617940,,,,,H,Autocuration,16633.0,8.0,,2692.0,,,
,1.0,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,12687.0,BAO_0000218,,CHEMBL617941,,,,,H,Autocuration,16633.0,8.0,,2693.0,,,
,1.0,B,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,12687.0,BAO_0000357,,CHEMBL617942,,,,,H,Expert,15026.0,8.0,,2694.0,,,
,1.0,B,Ratio of pKi of 5-HT2A to that of D2 receptor,,,12687.0,BAO_0000357,,CHEMBL617943,,,,,H,Expert,15026.0,8.0,,2695.0,,,
,1.0,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093.0,BAO_0000224,,CHEMBL617944,,,,,H,Expert,16404.0,4.0,,2696.0,,,
,1.0,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,105093.0,BAO_0000224,,CHEMBL617945,,,,,H,Expert,16404.0,4.0,,2697.0,,,
,1.0,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,105075.0,BAO_0000224,,CHEMBL617946,,,,,H,Expert,16404.0,4.0,,2698.0,,,
,1.0,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,12687.0,BAO_0000357,,CHEMBL617947,,,,,H,Autocuration,16404.0,8.0,,2699.0,,,
,1.0,B,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,12687.0,BAO_0000357,,CHEMBL617948,,,,,H,Expert,16326.0,8.0,,2700.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,12687.0,BAO_0000019,,CHEMBL858116,,,,,H,Autocuration,15847.0,8.0,,2701.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,12687.0,BAO_0000019,,CHEMBL617949,,,,,H,Autocuration,15847.0,8.0,,2702.0,,,
,1.0,F,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,12687.0,BAO_0000019,,CHEMBL617950,,,,,H,Autocuration,15329.0,8.0,,2703.0,,,
Thoracic aorta,1.0,F,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,12687.0,BAO_0000019,,CHEMBL617951,,,1515.0,,H,Expert,16404.0,8.0,,2704.0,,,
Thoracic aorta,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,12687.0,BAO_0000019,,CHEMBL617952,,,1515.0,,H,Expert,16404.0,8.0,,2705.0,,,
Thoracic aorta,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,12687.0,BAO_0000019,,CHEMBL617953,,,1515.0,,H,Autocuration,16404.0,8.0,,2706.0,,,
,1.0,B,Binding activity radioligand.,,,12687.0,BAO_0000357,,CHEMBL617954,,,,,H,Autocuration,12861.0,8.0,,2707.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687.0,BAO_0000019,,CHEMBL617955,,,,,H,Expert,12861.0,8.0,,2708.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,12687.0,BAO_0000019,,CHEMBL857071,,,,,H,Autocuration,12861.0,8.0,,2709.0,,,
,1.0,B,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,12687.0,BAO_0000019,,CHEMBL617270,,,,,H,Expert,12490.0,8.0,,2710.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,N1E-115,12687.0,BAO_0000219,,CHEMBL617271,,,,,H,Autocuration,12827.0,8.0,339.0,2711.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,N1E-115,12687.0,BAO_0000219,,CHEMBL617272,,,,,H,Autocuration,12827.0,8.0,339.0,2712.0,,,
,1.0,B,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,12687.0,BAO_0000019,,CHEMBL617273,,,,,H,Autocuration,12918.0,8.0,,2713.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,12687.0,BAO_0000019,Rattus norvegicus,CHEMBL617274,,10116.0,,,D,Expert,12919.0,9.0,,2714.0,,,
,1.0,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617275,,,,,H,Autocuration,17723.0,8.0,,2715.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617276,,,,,H,Autocuration,6013.0,8.0,,2716.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617277,,,,,H,Autocuration,16293.0,8.0,,2717.0,,,
,1.0,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000019,,CHEMBL617278,,,,,H,Expert,3857.0,8.0,,2718.0,,,
,1.0,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,108.0,BAO_0000019,,CHEMBL617279,,,,,H,Expert,3857.0,8.0,,2719.0,,,
,1.0,B,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000019,,CHEMBL617280,,,,,H,Expert,3857.0,8.0,,2720.0,,,
,1.0,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617281,,,,,H,Autocuration,15363.0,8.0,,2721.0,,,
,1.0,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617282,,,,,H,Autocuration,15363.0,8.0,,2722.0,,,
,1.0,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,108.0,BAO_0000019,,CHEMBL617283,,,,,H,Expert,16441.0,8.0,,2723.0,,,
,1.0,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,108.0,BAO_0000019,,CHEMBL617284,,,,,H,Expert,16441.0,8.0,,2724.0,,,
,1.0,B,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617285,,,,,H,Autocuration,4176.0,8.0,722.0,2725.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000019,,CHEMBL617286,,,,,H,Autocuration,17085.0,8.0,,2726.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,108.0,BAO_0000357,Homo sapiens,CHEMBL617287,,9606.0,,,D,Expert,17200.0,9.0,,2727.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,108.0,BAO_0000357,,CHEMBL617288,,,,,H,Expert,5088.0,8.0,,2728.0,,,
,1.0,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,108.0,BAO_0000357,,CHEMBL617289,,,,,H,Autocuration,5088.0,8.0,,2729.0,,,
,1.0,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL872917,,,,,H,Autocuration,5088.0,8.0,,2730.0,,,
,1.0,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,108.0,BAO_0000357,,CHEMBL617290,,,,,H,Autocuration,5088.0,8.0,,2731.0,,,
,1.0,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108.0,BAO_0000219,,CHEMBL617291,,,,,H,Autocuration,16659.0,8.0,449.0,2732.0,,,
,1.0,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,CHO,108.0,BAO_0000219,,CHEMBL617292,,,,,H,Autocuration,16659.0,8.0,449.0,2733.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,NIH3T3,108.0,BAO_0000219,,CHEMBL617293,,,,,H,Autocuration,17451.0,8.0,723.0,2734.0,,,
,1.0,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,108.0,BAO_0000219,Homo sapiens,CHEMBL617294,,9606.0,,,D,Expert,6857.0,9.0,449.0,2735.0,,,
,1.0,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108.0,BAO_0000019,,CHEMBL617295,,,,,H,Expert,3857.0,8.0,,2736.0,,,
,1.0,B,Binding activity radioligand.,,,108.0,BAO_0000357,,CHEMBL617296,,,,,H,Autocuration,12861.0,8.0,,2737.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,108.0,BAO_0000019,,CHEMBL617297,,,,,H,Autocuration,12861.0,8.0,,2738.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,CHO,108.0,BAO_0000219,,CHEMBL617298,,,,,H,Expert,5104.0,8.0,449.0,2739.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,CHO,108.0,BAO_0000219,,CHEMBL617299,,,,,H,Expert,5105.0,8.0,449.0,2740.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,CHO,108.0,BAO_0000219,,CHEMBL617300,,,,,H,Autocuration,5105.0,8.0,449.0,2741.0,,,
,1.0,B,Binding affinity against 5-HT2C receptor,,,108.0,BAO_0000357,,CHEMBL617454,,,,,H,Autocuration,5254.0,8.0,,2742.0,,,
,1.0,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617505,,,,,H,Autocuration,13267.0,8.0,722.0,2743.0,,,
,1.0,B,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL617506,,9606.0,,,D,Expert,14157.0,9.0,722.0,2744.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL617507,,9606.0,,,D,Expert,12936.0,9.0,722.0,2745.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,108.0,BAO_0000357,,CHEMBL617508,,,,,H,Expert,14068.0,8.0,,2746.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL857982,,9606.0,,,D,Expert,12936.0,9.0,722.0,2747.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL617509,,9606.0,,,D,Expert,4540.0,9.0,722.0,2748.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL617510,,9606.0,,,D,Expert,4540.0,9.0,722.0,2749.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,108.0,BAO_0000357,,CHEMBL617511,,,,,H,Autocuration,6166.0,8.0,,2750.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617512,,,,,H,Autocuration,17296.0,8.0,722.0,2751.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617749,,,,,H,Autocuration,17296.0,8.0,722.0,2752.0,,,
,1.0,B,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,108.0,BAO_0000219,,CHEMBL617750,,,,,H,Autocuration,15779.0,8.0,722.0,2753.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,108.0,BAO_0000219,,CHEMBL617751,,,,,H,Autocuration,15779.0,8.0,722.0,2754.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617752,,,,,H,Expert,14391.0,8.0,722.0,2755.0,,,
,1.0,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,HEK293,108.0,BAO_0000219,,CHEMBL617753,,,,,H,Autocuration,15779.0,8.0,722.0,2756.0,,,
,1.0,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,HEK293,108.0,BAO_0000219,,CHEMBL617754,,,,,H,Expert,15851.0,8.0,722.0,2757.0,,,
,1.0,B,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,HEK293,108.0,BAO_0000219,Homo sapiens,CHEMBL617755,,9606.0,,,D,Expert,15851.0,9.0,722.0,2758.0,,,
,1.0,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,HEK293,108.0,BAO_0000219,,CHEMBL617756,,,,,H,Autocuration,15779.0,8.0,722.0,2759.0,,,
,1.0,B,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,HEK293,108.0,BAO_0000219,,CHEMBL617757,,,,,H,Expert,3832.0,8.0,722.0,2760.0,,,
,1.0,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,HEK293,108.0,BAO_0000219,,CHEMBL617758,,,,,H,Expert,3833.0,8.0,722.0,2761.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,NIH3T3,108.0,BAO_0000219,,CHEMBL617759,,,,,H,Autocuration,17451.0,8.0,723.0,2762.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617760,,,,,H,Autocuration,4199.0,8.0,722.0,2763.0,,,
,1.0,B,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,CHO-K1,108.0,BAO_0000219,,CHEMBL617761,,,,,H,Expert,1883.0,8.0,485.0,2764.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Homo sapiens,CHEMBL617762,,9606.0,,,D,Expert,4321.0,9.0,,2765.0,,,
,1.0,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617763,,,,,H,Autocuration,14875.0,8.0,,2766.0,,,
,1.0,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,HEK293,108.0,BAO_0000219,,CHEMBL857983,,,,,H,Autocuration,15146.0,8.0,722.0,2767.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,HEK293,108.0,BAO_0000219,,CHEMBL617764,,,,,H,Autocuration,5213.0,8.0,722.0,2768.0,,,
,1.0,B,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,HeLa,108.0,BAO_0000219,,CHEMBL617765,,,,,H,Autocuration,16404.0,8.0,308.0,2769.0,,,
,1.0,F,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,108.0,BAO_0000019,,CHEMBL617766,,,,,H,Autocuration,13267.0,8.0,,2770.0,,,
Hippocampus,1.0,F,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,108.0,BAO_0000221,,CHEMBL617767,,,10000000.0,,H,Autocuration,13267.0,8.0,,2771.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,HEK293,108.0,BAO_0000219,,CHEMBL617768,,,,,H,Autocuration,14818.0,8.0,722.0,2772.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,HEK293,108.0,BAO_0000219,,CHEMBL617769,,,,,H,Autocuration,4829.0,8.0,722.0,2773.0,,,
,1.0,B,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,11864.0,BAO_0000357,,CHEMBL858023,,,,,H,Autocuration,13463.0,8.0,,2774.0,,,
Stomach,1.0,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,11864.0,BAO_0000019,,CHEMBL617770,,,945.0,,H,Autocuration,13463.0,8.0,,2775.0,,,
Stomach,1.0,B,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,11864.0,BAO_0000019,,CHEMBL617771,,,945.0,,H,Autocuration,13463.0,8.0,,2776.0,,,
,1.0,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,A9,11864.0,BAO_0000219,,CHEMBL617772,,,,,H,Autocuration,12652.0,8.0,625.0,2777.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,NIH3T3,11864.0,BAO_0000219,,CHEMBL617773,,,,,H,Autocuration,4682.0,8.0,723.0,2778.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,NIH3T3,11864.0,BAO_0000219,,CHEMBL617850,,,,,H,Autocuration,4682.0,8.0,723.0,2779.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,NIH3T3,11864.0,BAO_0000219,,CHEMBL617851,,,,,H,Autocuration,4682.0,8.0,723.0,2780.0,,,
,1.0,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,11864.0,BAO_0000019,,CHEMBL617852,,,,,H,Autocuration,12652.0,8.0,,2781.0,,,
Stomach,1.0,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,12689.0,BAO_0000019,Mus musculus,CHEMBL858024,,10090.0,945.0,,H,Autocuration,13463.0,8.0,,2782.0,,,
Stomach,1.0,B,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL617853,,10116.0,945.0,,D,Expert,13463.0,9.0,,2783.0,,,
,1.0,B,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL617854,,,,,H,Expert,13969.0,8.0,,2784.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Sus scrofa,CHEMBL873477,,9823.0,,,H,Expert,13392.0,8.0,,2785.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617855,,,,,H,Expert,13392.0,8.0,,2786.0,,,
,1.0,B,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,108.0,BAO_0000019,,CHEMBL617856,,,,,H,Expert,14430.0,8.0,,2787.0,,,
,1.0,B,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,108.0,BAO_0000019,,CHEMBL617857,,,,,H,Autocuration,1742.0,8.0,,2788.0,,,
,1.0,B,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,108.0,BAO_0000249,,CHEMBL617858,,,,,H,Autocuration,14286.0,8.0,,2789.0,,,
,1.0,B,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617859,,,,,H,Autocuration,5619.0,8.0,,2790.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617860,,,,,H,Autocuration,15086.0,8.0,,2791.0,,,
,1.0,B,Binding activity radioligand.,,,108.0,BAO_0000357,,CHEMBL617861,,,,,H,Autocuration,12861.0,8.0,,2792.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,108.0,BAO_0000019,,CHEMBL617862,,,,,H,Expert,12861.0,8.0,,2793.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,108.0,BAO_0000019,,CHEMBL617863,,,,,H,Autocuration,12861.0,8.0,,2794.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,108.0,BAO_0000249,,CHEMBL617864,,,,,H,Autocuration,12827.0,8.0,,2795.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,108.0,BAO_0000249,,CHEMBL617649,,,,,H,Autocuration,12827.0,8.0,,2796.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108.0,BAO_0000019,Sus scrofa,CHEMBL617650,,9823.0,,,H,Expert,12919.0,8.0,,2797.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,108.0,BAO_0000019,Sus scrofa,CHEMBL617651,,9823.0,,,H,Expert,12919.0,8.0,,2798.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,108.0,BAO_0000357,Sus scrofa,CHEMBL617652,,9823.0,,,H,Autocuration,16429.0,8.0,,2799.0,,,
,1.0,B,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,108.0,BAO_0000019,Sus scrofa,CHEMBL857072,,9823.0,,,H,Autocuration,773.0,8.0,,2800.0,,,
,1.0,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Sus scrofa,CHEMBL617653,,9823.0,,,H,Autocuration,5033.0,8.0,,2801.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,12687.0,BAO_0000019,,CHEMBL617654,,,,,H,Autocuration,12861.0,8.0,,2802.0,,,
,1.0,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000019,,CHEMBL617655,,,,,H,Autocuration,14093.0,8.0,,2803.0,,,
,1.0,B,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL617656,,,,,H,Expert,14970.0,8.0,,2804.0,,,
,1.0,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL617657,,,,,H,Autocuration,14970.0,8.0,,2805.0,,,
,1.0,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,12689.0,BAO_0000357,,CHEMBL617658,,,,,H,Autocuration,14970.0,8.0,,2806.0,,,
,1.0,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL617659,,10116.0,,,D,Expert,14178.0,9.0,,2807.0,,,
,1.0,B,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL617838,,10116.0,,,D,Expert,14178.0,9.0,,2808.0,,,
,1.0,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,12689.0,BAO_0000249,Rattus norvegicus,CHEMBL617839,,10116.0,,,D,Expert,14229.0,9.0,,2809.0,Brain membranes,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,12689.0,BAO_0000357,,CHEMBL617840,,,,,H,Autocuration,16532.0,8.0,,2810.0,,,
,1.0,B,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,12689.0,BAO_0000019,,CHEMBL617841,,,,,H,Autocuration,14826.0,8.0,,2811.0,,,
,1.0,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,12689.0,BAO_0000019,,CHEMBL875915,,,,,H,Autocuration,17211.0,8.0,,2812.0,,,
,1.0,B,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,12689.0,BAO_0000219,,CHEMBL617842,In vitro,,,,H,Expert,17211.0,8.0,,2813.0,,,
,1.0,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,NIH3T3,12689.0,BAO_0000219,,CHEMBL617843,,,,,H,Expert,13246.0,8.0,723.0,2814.0,,,
,1.0,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,12689.0,BAO_0000357,,CHEMBL617844,,,,,H,Expert,13246.0,8.0,,2815.0,,,
,1.0,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL617845,,,,,H,Expert,12457.0,8.0,,2816.0,,,
,1.0,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,NIH3T3,12689.0,BAO_0000219,,CHEMBL617846,,,,,H,Expert,12457.0,8.0,723.0,2817.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,12689.0,BAO_0000357,,CHEMBL617847,,,,,H,Autocuration,4707.0,8.0,,2818.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL617848,,,,,H,Expert,13297.0,8.0,,2819.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689.0,BAO_0000357,,CHEMBL617849,,,,,H,Autocuration,16633.0,8.0,,2820.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL621507,,,,,H,Expert,16133.0,8.0,,2821.0,,,
,1.0,B,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,12689.0,BAO_0000357,,CHEMBL621508,,,,,H,Expert,16326.0,8.0,,2822.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,12689.0,BAO_0000019,,CHEMBL621509,,,,,H,Autocuration,14423.0,8.0,,2823.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,12689.0,BAO_0000019,,CHEMBL621510,,,,,H,Autocuration,15412.0,8.0,,2824.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,12689.0,BAO_0000019,,CHEMBL621511,,,,,H,Autocuration,15412.0,8.0,,2825.0,,,
,1.0,B,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,A9,12689.0,BAO_0000219,,CHEMBL621512,,,,,H,Expert,15558.0,8.0,625.0,2826.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,12689.0,BAO_0000357,,CHEMBL621513,,,,,H,Autocuration,16633.0,8.0,,2827.0,,,
,1.0,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,12689.0,BAO_0000357,,CHEMBL621514,,,,,H,Expert,6013.0,8.0,,2828.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,12689.0,BAO_0000219,,CHEMBL621515,In vitro,,,,H,Expert,17175.0,8.0,,2829.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,12689.0,BAO_0000219,,CHEMBL621516,,,,,H,Autocuration,12469.0,8.0,,2830.0,,,
Caudate-putamen,1.0,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,12689.0,BAO_0000019,,CHEMBL621517,,,5383.0,,H,Autocuration,3682.0,8.0,,2831.0,,,
,1.0,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,12689.0,BAO_0000357,,CHEMBL621518,,,,,H,Autocuration,4932.0,8.0,,2832.0,,,
,1.0,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,12689.0,BAO_0000019,,CHEMBL621519,,,,,H,Autocuration,4932.0,8.0,,2833.0,,,
,1.0,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL621520,,,,,H,Autocuration,3935.0,8.0,,2834.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL621521,,,,,H,Autocuration,15818.0,8.0,,2835.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL621522,,,,,H,Autocuration,15818.0,8.0,,2836.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,12689.0,BAO_0000219,,CHEMBL621523,,,,,H,Expert,14749.0,8.0,,2837.0,,,
,1.0,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL621524,,,,,H,Autocuration,15740.0,8.0,,2838.0,,,
,1.0,B,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,12689.0,BAO_0000357,Rattus norvegicus,CHEMBL621525,,10116.0,,,D,Expert,17133.0,9.0,,2839.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,12689.0,BAO_0000357,,CHEMBL872921,,,,,H,Autocuration,16532.0,8.0,,2840.0,,,
,1.0,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL621526,,,,,H,Autocuration,12369.0,8.0,,2841.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,12689.0,BAO_0000219,,CHEMBL621527,,,,,H,Expert,12369.0,8.0,,2842.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL617865,,10116.0,,,D,Expert,2309.0,9.0,,2843.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL617866,,,,,H,Autocuration,12953.0,8.0,,2844.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,12689.0,BAO_0000019,,CHEMBL617867,,,,,H,Autocuration,12953.0,8.0,,2845.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,12689.0,BAO_0000357,,CHEMBL617487,,,,,H,Autocuration,12953.0,8.0,,2846.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000357,,CHEMBL617488,,,,,H,Expert,12953.0,8.0,,2847.0,,,
,1.0,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,12689.0,BAO_0000357,,CHEMBL617489,,,,,H,Autocuration,17133.0,8.0,,2848.0,,,
,1.0,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,12689.0,BAO_0000019,,CHEMBL617490,,,,,H,Autocuration,17211.0,8.0,,2849.0,,,
,1.0,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,12689.0,BAO_0000019,,CHEMBL617491,,,,,H,Autocuration,17211.0,8.0,,2850.0,,,
,1.0,B,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,12689.0,BAO_0000019,,CHEMBL617492,,,,,H,Autocuration,14025.0,8.0,,2851.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,12689.0,BAO_0000019,,CHEMBL617493,,,,,H,Autocuration,14998.0,8.0,,2852.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,12689.0,BAO_0000357,,CHEMBL617494,,,,,H,Autocuration,4342.0,8.0,,2853.0,,,
,1.0,B,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,12689.0,BAO_0000019,Rattus norvegicus,CHEMBL617495,,10116.0,,,D,Expert,13735.0,9.0,,2854.0,,,
,1.0,B,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,12689.0,BAO_0000357,,CHEMBL617496,,,,,H,Autocuration,13181.0,8.0,,2855.0,,,
,1.0,B,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,CHO-K1,12689.0,BAO_0000219,,CHEMBL617497,,,,,H,Autocuration,1883.0,8.0,485.0,2856.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,12689.0,BAO_0000357,,CHEMBL617498,,,,,H,Autocuration,15194.0,8.0,,2857.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,12689.0,BAO_0000357,,CHEMBL617499,,,,,H,Autocuration,15194.0,8.0,,2858.0,,,
,1.0,F,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,12689.0,BAO_0000019,,CHEMBL617500,,,,,H,Autocuration,14579.0,8.0,,2859.0,,,
,1.0,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617501,,,,,H,Autocuration,4639.0,8.0,,2860.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617502,,,,,H,Expert,4820.0,8.0,,2861.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,227.0,BAO_0000357,,CHEMBL617503,,,,,H,Autocuration,14442.0,8.0,,2862.0,,,
,1.0,B,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,227.0,BAO_0000357,,CHEMBL617504,,,,,H,Autocuration,14755.0,8.0,,2863.0,,,
,1.0,B,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,227.0,BAO_0000357,,CHEMBL617406,,,,,H,Autocuration,14744.0,8.0,,2864.0,,,
,1.0,B,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,227.0,BAO_0000019,Homo sapiens,CHEMBL617407,,9606.0,,,D,Expert,6857.0,9.0,,2865.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,227.0,BAO_0000357,,CHEMBL617408,,,,,H,Autocuration,16209.0,8.0,,2866.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617409,,,,,H,Autocuration,15363.0,8.0,,2867.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617410,,,,,H,Autocuration,15363.0,8.0,,2868.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617411,,,,,H,Autocuration,15363.0,8.0,,2869.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000019,,CHEMBL617412,,,,,H,Autocuration,17085.0,8.0,,2870.0,,,
,1.0,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,227.0,BAO_0000357,Homo sapiens,CHEMBL617774,,9606.0,,,D,Expert,17200.0,9.0,,2871.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617775,,9606.0,,,D,Expert,15851.0,9.0,722.0,2872.0,,,
,1.0,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617776,,9606.0,,,D,Expert,15851.0,9.0,722.0,2873.0,,,
,1.0,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,227.0,BAO_0000219,Homo sapiens,CHEMBL617777,,9606.0,,,D,Expert,6857.0,9.0,449.0,2874.0,,,
,1.0,F,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHO,227.0,BAO_0000219,Homo sapiens,CHEMBL617778,,9606.0,,,D,Expert,6857.0,9.0,449.0,2875.0,,,
,1.0,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227.0,BAO_0000219,,CHEMBL617779,,,,,H,Autocuration,15779.0,8.0,722.0,2876.0,,,
,1.0,B,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,HEK293,227.0,BAO_0000219,,CHEMBL617780,,,,,H,Expert,15851.0,8.0,722.0,2877.0,,,
,1.0,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,HEK293,227.0,BAO_0000219,,CHEMBL617781,,,,,H,Autocuration,15779.0,8.0,722.0,2878.0,,,
,1.0,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617782,,9606.0,,,D,Expert,14157.0,9.0,722.0,2879.0,,,
,1.0,B,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617783,,9606.0,,,D,Expert,4540.0,9.0,722.0,2880.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,227.0,BAO_0000357,,CHEMBL617784,,,,,H,Autocuration,6166.0,8.0,,2881.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,HEK293,227.0,BAO_0000219,,CHEMBL617785,,,,,H,Autocuration,15779.0,8.0,722.0,2882.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,HEK293,227.0,BAO_0000219,,CHEMBL857984,,,,,H,Expert,14391.0,8.0,722.0,2883.0,,,
,1.0,B,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,HEK293,227.0,BAO_0000219,,CHEMBL617786,,,,,H,Expert,3832.0,8.0,722.0,2884.0,,,
,1.0,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,HEK293,227.0,BAO_0000219,,CHEMBL617787,,,,,H,Expert,3833.0,8.0,722.0,2885.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617788,,9606.0,,,D,Expert,15851.0,9.0,722.0,2886.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,HEK293,227.0,BAO_0000219,Homo sapiens,CHEMBL617789,,9606.0,,,D,Expert,15851.0,9.0,722.0,2887.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,HEK293,227.0,BAO_0000219,,CHEMBL617790,,,,,H,Autocuration,4199.0,8.0,722.0,2888.0,,,
,1.0,B,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,CHO-K1,227.0,BAO_0000219,,CHEMBL617791,,,,,H,Expert,1883.0,8.0,485.0,2889.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617608,,,,,H,Expert,4321.0,8.0,,2890.0,,,
,1.0,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,HEK293,227.0,BAO_0000219,,CHEMBL617609,,,,,H,Autocuration,15146.0,8.0,722.0,2891.0,,,
,1.0,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,HEK293,227.0,BAO_0000219,,CHEMBL617610,,,,,H,Autocuration,5213.0,8.0,722.0,2892.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,HEK293,227.0,BAO_0000219,,CHEMBL617611,,,,,H,Autocuration,14818.0,8.0,722.0,2893.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227.0,BAO_0000219,,CHEMBL617612,,,,,H,Autocuration,4829.0,8.0,722.0,2894.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,HEK293,227.0,BAO_0000219,,CHEMBL617613,,,,,H,Autocuration,4829.0,8.0,722.0,2895.0,,,
,1.0,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,227.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617614,,9986.0,,,H,Autocuration,14025.0,8.0,,2896.0,,,
Stomach,1.0,B,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,12688.0,BAO_0000019,,CHEMBL617615,,,945.0,,H,Expert,13463.0,8.0,,2897.0,,,
Stomach,1.0,B,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,12688.0,BAO_0000357,,CHEMBL858114,,,945.0,,H,Expert,7259.0,8.0,,2898.0,,,
Stomach,1.0,B,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,12688.0,BAO_0000357,,CHEMBL617616,,,945.0,,H,Autocuration,7259.0,8.0,,2899.0,,,
Stomach,1.0,F,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,12688.0,BAO_0000019,Rattus norvegicus,CHEMBL617617,,10116.0,945.0,,D,Expert,7185.0,9.0,,2900.0,,,
,1.0,F,Antagonistic against 5-hydroxytryptamine 2B receptor,,,12688.0,BAO_0000019,Rattus norvegicus,CHEMBL875914,,10116.0,,,D,Expert,7185.0,9.0,,2901.0,,,
Stomach,1.0,F,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,12688.0,BAO_0000019,,CHEMBL617618,,,945.0,,H,Autocuration,13267.0,8.0,,2902.0,,,
Stomach,1.0,B,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,12688.0,BAO_0000357,Rattus norvegicus,CHEMBL617619,,10116.0,945.0,,D,Expert,13735.0,9.0,,2903.0,,,
,1.0,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,12688.0,BAO_0000019,,CHEMBL617620,,,,,H,Autocuration,15738.0,8.0,,2904.0,,,
,1.0,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,12688.0,BAO_0000019,,CHEMBL617621,,,,,H,Autocuration,15738.0,8.0,,2905.0,,,
,1.0,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,12688.0,BAO_0000019,,CHEMBL617622,,,,,H,Autocuration,15738.0,8.0,,2906.0,,,
Stomach,1.0,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688.0,BAO_0000357,Rattus norvegicus,CHEMBL617623,,10116.0,945.0,,D,Expert,12936.0,9.0,,2907.0,,,
Stomach,1.0,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688.0,BAO_0000357,Rattus norvegicus,CHEMBL617624,,10116.0,945.0,,D,Expert,12936.0,9.0,,2908.0,,,
Stomach,1.0,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688.0,BAO_0000357,Rattus norvegicus,CHEMBL617625,,10116.0,945.0,,D,Expert,12936.0,9.0,,2909.0,,,
Stomach,1.0,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,12688.0,BAO_0000357,Rattus norvegicus,CHEMBL617626,,10116.0,945.0,,D,Expert,12936.0,9.0,,2910.0,,,
Stomach,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688.0,BAO_0000019,,CHEMBL617627,,,945.0,,H,Autocuration,16404.0,8.0,,2911.0,,,
Stomach,1.0,F,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688.0,BAO_0000019,,CHEMBL617628,,,945.0,,H,Expert,16404.0,8.0,,2912.0,,,
Stomach,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,12688.0,BAO_0000019,,CHEMBL617629,,,945.0,,H,Autocuration,16404.0,8.0,,2913.0,,,
Stomach,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,12688.0,BAO_0000019,,CHEMBL858115,,,945.0,,H,Autocuration,16404.0,8.0,,2914.0,,,
Stomach,1.0,F,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,12688.0,BAO_0000019,Rattus norvegicus,CHEMBL617630,,10116.0,945.0,,D,Expert,16404.0,9.0,,2915.0,,,
Thoracic aorta,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,12688.0,BAO_0000019,,CHEMBL617631,,,1515.0,,H,Autocuration,16404.0,8.0,,2916.0,,,
,1.0,B,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688.0,BAO_0000357,,CHEMBL617632,,,,,H,Autocuration,7483.0,8.0,,2917.0,,,
,1.0,B,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,12688.0,BAO_0000357,,CHEMBL617633,,,,,H,Expert,7483.0,8.0,,2918.0,,,
,1.0,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,12688.0,BAO_0000357,,CHEMBL617634,,,,,H,Autocuration,7483.0,8.0,,2919.0,,,
,1.0,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,12688.0,BAO_0000357,,CHEMBL617635,,,,,H,Autocuration,7483.0,8.0,,2920.0,,,
Stomach,1.0,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,12688.0,BAO_0000019,Rattus norvegicus,CHEMBL617637,,10116.0,945.0,,D,Autocuration,16404.0,9.0,,2922.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,,227.0,BAO_0000357,,CHEMBL617638,,,,,H,Autocuration,6347.0,8.0,,2923.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,227.0,BAO_0000357,,CHEMBL617639,,,,,H,Autocuration,4373.0,8.0,,2924.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,227.0,BAO_0000357,,CHEMBL617640,,,,,H,Autocuration,4373.0,8.0,,2925.0,,,
,1.0,B,Evaluated for the binding affinity to 5-HT 2B receptor,,,227.0,BAO_0000357,,CHEMBL617641,,,,,H,Autocuration,4687.0,8.0,,2926.0,,,
,1.0,B,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617642,,,,,H,Autocuration,16946.0,8.0,,2927.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617643,,,,,H,Autocuration,16633.0,8.0,,2928.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,227.0,BAO_0000357,,CHEMBL617644,,,,,H,Autocuration,16633.0,8.0,,2929.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,227.0,BAO_0000357,,CHEMBL617645,,,,,H,Autocuration,16633.0,8.0,,2930.0,,,
,1.0,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108.0,BAO_0000357,,CHEMBL617646,,,,,H,Expert,15026.0,8.0,,2931.0,,,
,1.0,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108.0,BAO_0000357,Bos taurus,CHEMBL617647,,9913.0,,,H,Autocuration,15738.0,8.0,,2932.0,,,
,1.0,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,108.0,BAO_0000357,Bos taurus,CHEMBL617648,,9913.0,,,H,Autocuration,15738.0,8.0,,2933.0,,,
,1.0,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,108.0,BAO_0000357,Bos taurus,CHEMBL617875,,9913.0,,,H,Autocuration,15738.0,8.0,,2934.0,,,
,1.0,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,108.0,BAO_0000357,Bos taurus,CHEMBL617876,,9913.0,,,H,Autocuration,15738.0,8.0,,2935.0,,,
,1.0,B,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,108.0,BAO_0000357,Bos taurus,CHEMBL617877,,9913.0,,,H,Expert,16404.0,8.0,,2936.0,,,
,1.0,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,108.0,BAO_0000357,Bos taurus,CHEMBL617878,,9913.0,,,H,Expert,15026.0,8.0,,2937.0,,,
,1.0,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,108.0,BAO_0000357,Bos taurus,CHEMBL617879,,9913.0,,,H,Autocuration,15738.0,8.0,,2938.0,,,
,1.0,B,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,108.0,BAO_0000019,Cavia porcellus,CHEMBL617880,,10141.0,,,H,Autocuration,16312.0,8.0,,2939.0,,,
Striatum,1.0,B,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617881,,10141.0,2435.0,,D,Intermediate,5486.0,9.0,,2940.0,,,
,1.0,B,Binding affinity against 5-HT1A receptor,,,51.0,BAO_0000357,,CHEMBL857073,,,,,H,Autocuration,5254.0,8.0,,2941.0,,,
,1.0,F,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,CHO,108.0,BAO_0000219,,CHEMBL617882,,,,,H,Expert,3857.0,8.0,449.0,2942.0,,,
,1.0,F,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,CHO,108.0,BAO_0000219,Homo sapiens,CHEMBL617883,,9606.0,,,D,Expert,6857.0,9.0,449.0,2943.0,,,
,1.0,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,108.0,BAO_0000219,,CHEMBL617884,,,,,H,Autocuration,4176.0,8.0,,2944.0,,,
,1.0,B,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,CHO,108.0,BAO_0000219,,CHEMBL617885,,,,,H,Autocuration,6347.0,8.0,449.0,2945.0,,,
,1.0,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,CHO,108.0,BAO_0000219,,CHEMBL617886,,,,,H,Autocuration,6347.0,8.0,449.0,2946.0,,,
,1.0,B,Inhibition of human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Homo sapiens,CHEMBL617887,,9606.0,,,D,Expert,16146.0,9.0,,2947.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,108.0,BAO_0000357,,CHEMBL617888,,,,,H,Autocuration,3805.0,8.0,,2948.0,,,
,1.0,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,108.0,BAO_0000019,,CHEMBL617889,,,,,H,Autocuration,3857.0,8.0,,2949.0,,,
,1.0,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL617890,,,,,H,Autocuration,5635.0,8.0,,2950.0,,,
,1.0,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108.0,BAO_0000357,,CHEMBL617891,,,,,H,Autocuration,5635.0,8.0,,2951.0,,,
,1.0,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,108.0,BAO_0000357,,CHEMBL617892,,,,,H,Autocuration,5635.0,8.0,,2952.0,,,
,1.0,B,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,CHO,108.0,BAO_0000219,,CHEMBL617893,,,,,H,Expert,4012.0,8.0,449.0,2953.0,,,
,1.0,B,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,CHO,108.0,BAO_0000219,,CHEMBL617894,,,,,H,Expert,6366.0,8.0,449.0,2954.0,,,
,1.0,B,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108.0,BAO_0000219,,CHEMBL617895,,,,,H,Expert,15949.0,8.0,449.0,2955.0,,,
,1.0,B,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,CHO,108.0,BAO_0000219,,CHEMBL617896,,,,,H,Autocuration,17211.0,8.0,449.0,2956.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,108.0,BAO_0000357,Homo sapiens,CHEMBL617897,,9606.0,,,D,Expert,6491.0,9.0,,2957.0,,,
,1.0,F,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,108.0,BAO_0000019,,CHEMBL617898,,,,,H,Autocuration,14093.0,8.0,,2958.0,,,
,1.0,F,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,108.0,BAO_0000019,,CHEMBL617899,,,,,H,Autocuration,13481.0,8.0,,2959.0,,,
,1.0,B,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,CHO,108.0,BAO_0000219,Rattus norvegicus,CHEMBL617900,,10116.0,,,H,Expert,6347.0,8.0,449.0,2960.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,108.0,BAO_0000019,,CHEMBL617901,,,,,H,Autocuration,14093.0,8.0,,2961.0,,,
,1.0,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,108.0,BAO_0000019,,CHEMBL617902,,,,,H,Autocuration,14093.0,8.0,,2962.0,,,
,1.0,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108.0,BAO_0000019,,CHEMBL617903,,,,,H,Autocuration,13481.0,8.0,,2963.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,108.0,BAO_0000357,,CHEMBL617904,,,,,H,Autocuration,14442.0,8.0,,2964.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL617905,,,,,H,Autocuration,14442.0,8.0,,2965.0,,,
,1.0,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,108.0,BAO_0000357,,CHEMBL617906,,,,,H,Autocuration,14442.0,8.0,,2966.0,,,
,1.0,B,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,108.0,BAO_0000357,,CHEMBL617907,,,,,H,Autocuration,14755.0,8.0,,2967.0,,,
,1.0,B,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,108.0,BAO_0000357,,CHEMBL617908,,,,,H,Autocuration,14744.0,8.0,,2968.0,,,
,1.0,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHO,108.0,BAO_0000219,,CHEMBL620617,,,,,H,Expert,16659.0,8.0,449.0,2969.0,,,
,1.0,B,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,108.0,BAO_0000019,Homo sapiens,CHEMBL620618,,9606.0,,,D,Expert,6857.0,9.0,,2970.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,108.0,BAO_0000357,,CHEMBL620619,,,,,H,Expert,5635.0,8.0,,2971.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Homo sapiens,CHEMBL620620,,9606.0,,,D,Expert,4234.0,9.0,,2972.0,,,
,1.0,B,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,108.0,BAO_0000357,,CHEMBL620621,,,,,H,Autocuration,16209.0,8.0,,2973.0,,,
,1.0,B,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,104698.0,BAO_0000249,Rattus norvegicus,CHEMBL872920,,10116.0,,,D,Autocuration,5778.0,7.0,,2974.0,Membranes,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,104698.0,BAO_0000223,,CHEMBL620622,,,,,H,Autocuration,5094.0,6.0,,2975.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL620623,,10116.0,,,D,Autocuration,809.0,7.0,,2976.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,104698.0,BAO_0000019,,CHEMBL620624,,,,,H,Autocuration,1578.0,6.0,,2977.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,104698.0,BAO_0000019,,CHEMBL620625,,,,,H,Autocuration,809.0,6.0,,2978.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,104698.0,BAO_0000219,,CHEMBL620626,,,,,H,Autocuration,12469.0,6.0,,2979.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,104698.0,BAO_0000019,,CHEMBL621307,,,,,H,Autocuration,14290.0,6.0,,2980.0,,,
,1.0,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,104698.0,BAO_0000019,,CHEMBL621308,,,,,H,Autocuration,14290.0,6.0,,2981.0,,,
,1.0,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,104698.0,BAO_0000223,,CHEMBL621309,,,,,H,Autocuration,10609.0,6.0,,2982.0,,,
,1.0,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,104698.0,BAO_0000223,,CHEMBL621310,,,,,H,Autocuration,10609.0,6.0,,2983.0,,,
,1.0,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,104698.0,BAO_0000223,,CHEMBL621311,,,,,H,Autocuration,10609.0,6.0,,2984.0,,,
,1.0,B,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698.0,BAO_0000249,,CHEMBL621502,,,,,H,Autocuration,15253.0,6.0,,2985.0,,,
,1.0,B,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,104698.0,BAO_0000249,,CHEMBL621503,,,,,H,Autocuration,15253.0,6.0,,2986.0,,,
,1.0,B,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,104698.0,BAO_0000249,,CHEMBL621504,,,,,H,Autocuration,11683.0,6.0,,2987.0,Membranes,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,,CHEMBL621505,,,,,H,Autocuration,12092.0,6.0,,2988.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698.0,BAO_0000019,,CHEMBL621506,,,,,H,Autocuration,1946.0,6.0,,2989.0,,,
,1.0,B,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,104698.0,BAO_0000223,,CHEMBL619781,,,,,H,Autocuration,11623.0,6.0,,2990.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,104698.0,BAO_0000223,,CHEMBL619782,,,,,H,Autocuration,11623.0,6.0,,2991.0,,,
,1.0,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,104698.0,BAO_0000019,,CHEMBL619783,,,,,H,Autocuration,14788.0,6.0,,2992.0,,,
,1.0,B,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL619784,,10116.0,,,D,Autocuration,5432.0,7.0,,2993.0,,,
,1.0,B,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698.0,BAO_0000249,,CHEMBL619785,,,,,H,Autocuration,14826.0,6.0,,2994.0,,,
,1.0,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,,CHEMBL619786,,,,,H,Autocuration,2222.0,6.0,,2995.0,,,
,1.0,B,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,104698.0,BAO_0000019,,CHEMBL619787,,,,,H,Autocuration,11963.0,6.0,,2996.0,,,
,1.0,B,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,104698.0,BAO_0000019,,CHEMBL872925,,,,,H,Autocuration,14145.0,6.0,,2997.0,,,
,1.0,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,104698.0,BAO_0000019,,CHEMBL619788,,,,,H,Autocuration,17819.0,6.0,,2998.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698.0,BAO_0000249,,CHEMBL619789,,,,,H,Autocuration,10394.0,6.0,,2999.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,104698.0,BAO_0000249,,CHEMBL619790,,,,,H,Autocuration,10394.0,6.0,,3000.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698.0,BAO_0000019,,CHEMBL619791,,,,,H,Autocuration,15034.0,6.0,,3001.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,104698.0,BAO_0000019,,CHEMBL619792,,,,,H,Autocuration,691.0,6.0,,3002.0,,,
,1.0,B,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,104698.0,BAO_0000249,,CHEMBL619793,,,,,H,Autocuration,12092.0,6.0,,3003.0,Membranes,,
,1.0,B,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL619794,,10116.0,,,D,Autocuration,11752.0,7.0,,3004.0,,,
Brain,1.0,B,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,104698.0,BAO_0000221,,CHEMBL619795,,,955.0,,H,Autocuration,11752.0,6.0,,3005.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,104698.0,BAO_0000019,,CHEMBL619796,,,,,H,Autocuration,301.0,6.0,,3006.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,104698.0,BAO_0000223,,CHEMBL620448,,,,,H,Autocuration,16532.0,6.0,,3007.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698.0,BAO_0000223,,CHEMBL620449,,,,,H,Autocuration,16532.0,6.0,,3008.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,104698.0,BAO_0000223,,CHEMBL620450,,,,,H,Autocuration,12092.0,6.0,,3009.0,,,
,1.0,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,104698.0,BAO_0000223,,CHEMBL620451,,,,,H,Autocuration,11684.0,6.0,,3010.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,104698.0,BAO_0000223,,CHEMBL620631,,,,,H,Autocuration,11684.0,6.0,,3011.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,104698.0,BAO_0000019,,CHEMBL620632,,,,,H,Autocuration,12953.0,6.0,,3012.0,,,
,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,104698.0,BAO_0000019,,CHEMBL620633,,,,,H,Autocuration,12953.0,6.0,,3013.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,104698.0,BAO_0000223,,CHEMBL620634,,,,,H,Autocuration,12953.0,6.0,,3014.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,104698.0,BAO_0000019,,CHEMBL620635,,,,,H,Autocuration,12861.0,6.0,,3015.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620636,In vivo,,,,H,Autocuration,11454.0,6.0,,3016.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620637,In vivo,,,,H,Autocuration,11454.0,6.0,,3017.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620638,In vivo,,,,H,Autocuration,11454.0,6.0,,3018.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620639,In vivo,,,,H,Autocuration,11454.0,6.0,,3019.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620640,In vivo,,,,H,Autocuration,11454.0,6.0,,3020.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620641,In vivo,,,,H,Autocuration,11454.0,6.0,,3021.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620642,In vivo,,,,H,Autocuration,11454.0,6.0,,3022.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620643,In vivo,,,,H,Autocuration,11454.0,6.0,,3023.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620644,In vivo,,,,H,Autocuration,11454.0,6.0,,3024.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620645,In vivo,,,,H,Autocuration,11454.0,6.0,,3025.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620646,In vivo,,,,H,Autocuration,11454.0,6.0,,3026.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620647,In vivo,,,,H,Autocuration,11454.0,6.0,,3027.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620648,In vivo,,,,H,Autocuration,11454.0,6.0,,3028.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620649,In vivo,,,,H,Autocuration,11454.0,6.0,,3029.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620650,In vivo,,,,H,Autocuration,11454.0,6.0,,3030.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620651,In vivo,,,,H,Autocuration,11454.0,6.0,,3031.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL872875,In vivo,,,,H,Autocuration,11454.0,6.0,,3032.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL620652,In vivo,,,,H,Autocuration,11454.0,6.0,,3033.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,104698.0,BAO_0000019,,CHEMBL620653,,,,,H,Autocuration,10609.0,6.0,,3034.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,104698.0,BAO_0000019,,CHEMBL857076,,,,,H,Autocuration,12861.0,6.0,,3035.0,,,
,1.0,B,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL620654,,10116.0,,,D,Autocuration,12861.0,7.0,,3036.0,,,
,1.0,B,Binding activity radioligand.,,,104698.0,BAO_0000223,,CHEMBL620655,,,,,H,Autocuration,12861.0,6.0,,3037.0,,,
,1.0,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,104698.0,BAO_0000249,,CHEMBL620656,,,,,H,Autocuration,10728.0,6.0,,3038.0,Brain membranes,,
,1.0,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,104698.0,BAO_0000249,,CHEMBL620657,,,,,H,Autocuration,10728.0,6.0,,3039.0,Brain membranes,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,108.0,BAO_0000357,,CHEMBL620658,,,,,H,Autocuration,5163.0,8.0,,3040.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,108.0,BAO_0000357,,CHEMBL620659,,,,,H,Autocuration,5163.0,8.0,,3041.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,108.0,BAO_0000357,,CHEMBL620660,,,,,H,Autocuration,6011.0,8.0,,3042.0,,,
,1.0,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620661,,,,,H,Autocuration,5014.0,8.0,,3043.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620662,,,,,H,Autocuration,5635.0,8.0,,3044.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620663,,,,,H,Expert,5163.0,8.0,,3045.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,108.0,BAO_0000357,,CHEMBL620664,,,,,H,Autocuration,6841.0,8.0,,3046.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,108.0,BAO_0000357,,CHEMBL620665,,,,,H,Expert,6119.0,8.0,,3047.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,108.0,BAO_0000357,,CHEMBL620666,,,,,H,Autocuration,4373.0,8.0,,3048.0,,,
,1.0,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,108.0,BAO_0000357,,CHEMBL620667,,,,,H,Autocuration,1633.0,8.0,,3049.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,108.0,BAO_0000357,,CHEMBL620668,,,,,H,Expert,1633.0,8.0,,3050.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,108.0,BAO_0000357,,CHEMBL620669,,,,,H,Autocuration,4373.0,8.0,,3051.0,,,
,1.0,B,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620670,,,,,H,Expert,6576.0,8.0,,3052.0,,,
,1.0,B,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620671,,,,,H,Autocuration,4687.0,8.0,,3053.0,,,
,1.0,B,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,108.0,BAO_0000357,,CHEMBL620672,,,,,H,Autocuration,12146.0,8.0,,3054.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,108.0,BAO_0000357,,CHEMBL620673,,,,,H,Autocuration,12146.0,8.0,,3055.0,,,
,1.0,B,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620674,,,,,H,Autocuration,16946.0,8.0,,3056.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL620675,,,,,H,Autocuration,14159.0,8.0,,3057.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,108.0,BAO_0000357,,CHEMBL620676,,,,,H,Autocuration,16700.0,8.0,,3058.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL621382,,,,,H,Autocuration,3269.0,8.0,,3059.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,Homo sapiens,CHEMBL621383,,9606.0,,,D,Expert,1274.0,9.0,,3060.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,108.0,BAO_0000357,,CHEMBL621384,,,,,H,Autocuration,1317.0,8.0,,3061.0,,,
,1.0,B,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,144.0,BAO_0000357,Bos taurus,CHEMBL621385,,9913.0,,,H,Autocuration,5834.0,8.0,,3062.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,144.0,BAO_0000357,Bos taurus,CHEMBL617989,,9913.0,,,H,Autocuration,11147.0,8.0,,3063.0,,,
,1.0,F,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617990,,10141.0,,,H,Expert,14145.0,4.0,,3064.0,,,
Ileum,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL875085,,10141.0,2116.0,,H,Autocuration,10561.0,4.0,,3065.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617991,,10141.0,,,H,Autocuration,15847.0,4.0,,3066.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617992,,10141.0,,,H,Autocuration,15847.0,4.0,,3067.0,,,
Ileum,1.0,B,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617993,,10141.0,2116.0,,H,Autocuration,10561.0,4.0,,3068.0,,,
Ileum,1.0,B,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617994,,10141.0,2116.0,,H,Autocuration,11454.0,4.0,,3069.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617995,,10141.0,,,H,Autocuration,4639.0,4.0,,3070.0,,,
,1.0,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617996,,10141.0,,,H,Autocuration,4639.0,4.0,,3071.0,,,
,1.0,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617997,,10141.0,,,H,Autocuration,4639.0,4.0,,3072.0,,,
,1.0,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617998,,10141.0,,,H,Autocuration,4639.0,4.0,,3073.0,,,
,1.0,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL617999,,10141.0,,,H,Autocuration,4639.0,4.0,,3074.0,,,
,1.0,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618000,,10141.0,,,H,Autocuration,4639.0,4.0,,3075.0,,,
Ileum,1.0,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617815,,10141.0,2116.0,,H,Autocuration,15253.0,4.0,,3076.0,,,
Ileum,1.0,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617816,,10141.0,2116.0,,H,Autocuration,15253.0,4.0,,3077.0,,,
Ileum,1.0,F,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617817,,10141.0,2116.0,,H,Autocuration,11963.0,4.0,,3078.0,,,
Ileum,1.0,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617818,,10141.0,2116.0,,H,Autocuration,1946.0,4.0,,3079.0,,,
Ileum,1.0,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617819,,10141.0,2116.0,,H,Autocuration,1946.0,4.0,,3080.0,,,
,1.0,B,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,104714.0,BAO_0000223,Cavia porcellus,CHEMBL617820,,10141.0,,,H,Autocuration,12045.0,4.0,,3081.0,,,
Ileum,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617821,,10141.0,2116.0,,H,Autocuration,1559.0,4.0,,3082.0,,,
Ileum,1.0,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617822,,10141.0,2116.0,,H,Autocuration,273.0,4.0,,3083.0,,,
Ileum,1.0,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617823,,10141.0,2116.0,,H,Autocuration,273.0,4.0,,3084.0,,,
Ileum,1.0,F,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617824,,10141.0,2116.0,,H,Autocuration,188.0,4.0,,3085.0,,,
Ileum,1.0,F,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617825,,10141.0,2116.0,,H,Autocuration,12919.0,4.0,,3086.0,,,
Ileum,1.0,F,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617826,,10141.0,2116.0,,H,Autocuration,12918.0,4.0,,3087.0,,,
Ileum,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617827,,10141.0,2116.0,,H,Autocuration,1559.0,4.0,,3088.0,,,
Ileum,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617828,,10141.0,2116.0,,H,Autocuration,273.0,4.0,,3089.0,,,
Ileum,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617829,,10141.0,2116.0,,H,Autocuration,1559.0,4.0,,3090.0,,,
Ileum,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617830,,10141.0,2116.0,,H,Autocuration,1559.0,4.0,,3091.0,,,
Ileum,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617831,,10141.0,2116.0,,H,Autocuration,1559.0,4.0,,3092.0,,,
Ileum,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,104714.0,BAO_0000221,Cavia porcellus,CHEMBL617832,,10141.0,2116.0,,H,Autocuration,14424.0,4.0,,3093.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,22226.0,BAO_0000019,Cavia porcellus,CHEMBL617833,,10141.0,,,U,Autocuration,13181.0,0.0,,3094.0,,,
,1.0,B,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,51.0,BAO_0000357,,CHEMBL617834,,,,,H,Autocuration,5486.0,8.0,,3095.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,104714.0,BAO_0000223,Homo sapiens,CHEMBL617835,,9606.0,,,D,Expert,6491.0,5.0,,3096.0,,,
,1.0,B,Binding affinity towards 5-HT3 receptor,,,104714.0,BAO_0000223,,CHEMBL617836,,,,,H,Autocuration,6013.0,4.0,,3097.0,,,
,1.0,B,Binding activity radioligand.,,,104714.0,BAO_0000223,,CHEMBL617837,,,,,H,Autocuration,12861.0,4.0,,3098.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,104714.0,BAO_0000019,,CHEMBL620392,,,,,H,Autocuration,12861.0,4.0,,3099.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL620393,,,,,H,Autocuration,5104.0,4.0,,3100.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL620394,,,,,H,Autocuration,5105.0,4.0,,3101.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,104714.0,BAO_0000223,,CHEMBL620395,,,,,H,Autocuration,5104.0,4.0,,3102.0,,,
,1.0,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,22226.0,BAO_0000019,,CHEMBL620396,,,,,U,Autocuration,3935.0,0.0,,3103.0,,,
,1.0,B,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,NG108-15,105030.0,BAO_0000219,,CHEMBL620582,,,,,H,Expert,13657.0,4.0,433.0,3104.0,,,
,1.0,B,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,105030.0,BAO_0000218,,CHEMBL620583,In vivo,,,,H,Autocuration,10369.0,4.0,,3105.0,,,
,1.0,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030.0,BAO_0000019,,CHEMBL620584,,,,,H,Autocuration,10369.0,4.0,,3106.0,,,
,1.0,B,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,105030.0,BAO_0000224,,CHEMBL620585,,,,,H,Autocuration,12918.0,4.0,,3107.0,,,
,1.0,B,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,105030.0,BAO_0000224,,CHEMBL620586,,,,,H,Autocuration,12918.0,4.0,,3108.0,,,
,1.0,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,105030.0,BAO_0000019,,CHEMBL620587,,,,,H,Autocuration,10369.0,4.0,,3109.0,,,
,1.0,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,105030.0,BAO_0000019,,CHEMBL620588,,,,,H,Autocuration,773.0,4.0,,3110.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor agonism in mouse,,,105030.0,BAO_0000218,,CHEMBL620589,,,,,H,Autocuration,12918.0,4.0,,3111.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,105030.0,BAO_0000219,,CHEMBL620590,,,,,H,Autocuration,10561.0,4.0,,3112.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030.0,BAO_0000019,,CHEMBL617956,,,,,H,Autocuration,12827.0,4.0,,3113.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,105030.0,BAO_0000019,,CHEMBL617957,,,,,H,Autocuration,12827.0,4.0,,3114.0,,,
,1.0,B,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,105030.0,BAO_0000224,,CHEMBL617958,,,,,H,Autocuration,12918.0,4.0,,3115.0,,,
,1.0,B,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030.0,BAO_0000219,,CHEMBL617959,,,,,H,Autocuration,273.0,4.0,,3116.0,,,
,1.0,B,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,105030.0,BAO_0000219,,CHEMBL617960,,,,,H,Autocuration,273.0,4.0,,3117.0,,,
,1.0,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,105030.0,BAO_0000224,,CHEMBL617961,,,,,H,Autocuration,10561.0,4.0,,3118.0,,,
,1.0,B,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,105030.0,BAO_0000219,,CHEMBL617962,In vitro,,,,H,Autocuration,5033.0,4.0,,3119.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,N1E-115,105030.0,BAO_0000219,,CHEMBL617963,,,,,H,Autocuration,16429.0,4.0,339.0,3120.0,,,
,1.0,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,11765.0,BAO_0000019,,CHEMBL617964,,,,,H,Autocuration,10322.0,8.0,,3121.0,,,
,1.0,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,11765.0,BAO_0000219,,CHEMBL617965,,,,,H,Autocuration,14331.0,8.0,,3122.0,,,
,1.0,B,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,10630.0,BAO_0000357,Mus musculus,CHEMBL617966,,10090.0,,,D,Autocuration,13462.0,9.0,,3123.0,,,
,1.0,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,17106.0,BAO_0000019,,CHEMBL857074,,,,,H,Autocuration,12861.0,8.0,,3124.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,Sus scrofa,CHEMBL617967,,9823.0,,,H,Autocuration,15086.0,8.0,,3125.0,,,
,1.0,B,Binding activity radioligand.,,,144.0,BAO_0000357,Sus scrofa,CHEMBL617968,,9823.0,,,H,Autocuration,12861.0,8.0,,3126.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,104714.0,BAO_0000223,Oryctolagus cuniculus,CHEMBL617969,,9986.0,,,H,Autocuration,10561.0,4.0,,3127.0,,,
,1.0,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,104714.0,BAO_0000223,Oryctolagus cuniculus,CHEMBL617970,,9986.0,,,H,Autocuration,10561.0,4.0,,3128.0,,,
,1.0,B,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,104714.0,BAO_0000223,Oryctolagus cuniculus,CHEMBL617971,,9986.0,,,H,Autocuration,10561.0,4.0,,3129.0,,,
,1.0,B,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617972,,9986.0,,,H,Autocuration,10561.0,4.0,,3130.0,,,
,1.0,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617973,,9986.0,,,H,Autocuration,273.0,4.0,,3131.0,,,
,1.0,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617974,,9986.0,,,H,Autocuration,273.0,4.0,,3132.0,,,
Ileum,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,104714.0,BAO_0000221,Oryctolagus cuniculus,CHEMBL617975,,9986.0,2116.0,,H,Autocuration,273.0,4.0,,3133.0,,,
,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617976,,9986.0,,,H,Autocuration,273.0,4.0,,3134.0,,,
,1.0,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617977,,9986.0,,,H,Autocuration,273.0,4.0,,3135.0,,,
,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617978,,9986.0,,,H,Autocuration,273.0,4.0,,3136.0,,,
,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,104714.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL617979,,9986.0,,,H,Autocuration,273.0,4.0,,3137.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,CHO,104714.0,BAO_0000219,Oryctolagus cuniculus,CHEMBL617980,,9986.0,,,H,Autocuration,13047.0,4.0,449.0,3138.0,,,
,1.0,B,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617981,,10116.0,,,D,Autocuration,1650.0,7.0,,3139.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,12020.0,BAO_0000019,,CHEMBL617982,,,,,H,Autocuration,16288.0,8.0,,3140.0,,,
,1.0,B,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,12020.0,BAO_0000357,,CHEMBL617983,,,,,H,Autocuration,16288.0,8.0,,3141.0,,,
,1.0,B,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617984,,10116.0,,,D,Autocuration,10254.0,7.0,,3142.0,,,
,1.0,B,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,104698.0,BAO_0000019,,CHEMBL617985,,,,,H,Autocuration,14532.0,6.0,,3143.0,,,
Heart,1.0,F,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,104698.0,BAO_0000218,,CHEMBL617986,In vivo,,948.0,,H,Autocuration,13392.0,6.0,,3144.0,,,
Heart,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,104698.0,BAO_0000019,,CHEMBL617987,,,948.0,,H,Autocuration,13392.0,6.0,,3145.0,,,
Heart,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,104698.0,BAO_0000019,,CHEMBL617988,,,948.0,,H,Autocuration,13392.0,6.0,,3146.0,,,
Heart,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,104698.0,BAO_0000019,,CHEMBL617792,,,948.0,,H,Autocuration,13392.0,6.0,,3147.0,,,
Heart,1.0,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,104698.0,BAO_0000019,,CHEMBL617793,,,948.0,,H,Autocuration,13392.0,6.0,,3148.0,,,
,1.0,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,104698.0,BAO_0000019,,CHEMBL617794,,,,,H,Autocuration,13392.0,6.0,,3149.0,,,
,1.0,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698.0,BAO_0000019,,CHEMBL617795,,,,,H,Autocuration,13392.0,6.0,,3150.0,,,
,1.0,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,104698.0,BAO_0000019,,CHEMBL617796,,,,,H,Autocuration,13392.0,6.0,,3151.0,,,
,1.0,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,104698.0,BAO_0000019,,CHEMBL617797,,,,,H,Autocuration,13392.0,6.0,,3152.0,,,
,1.0,F,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,104698.0,BAO_0000218,Rattus norvegicus,CHEMBL617798,In vivo,10116.0,,,D,Autocuration,1089.0,7.0,,3153.0,,,
,1.0,F,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,104698.0,BAO_0000218,,CHEMBL617799,In vivo,,,,H,Autocuration,1089.0,6.0,,3154.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,Rattus norvegicus,CHEMBL617800,In vivo,10116.0,,,D,Autocuration,11454.0,7.0,,3155.0,,,
,1.0,F,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617801,,10116.0,,,D,Autocuration,11454.0,7.0,,3156.0,,,
,1.0,F,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,104698.0,BAO_0000218,Rattus norvegicus,CHEMBL617802,In vivo,10116.0,,,D,Autocuration,12205.0,7.0,,3157.0,,,
,1.0,F,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617803,,10116.0,,,D,Autocuration,1089.0,7.0,,3158.0,,,
,1.0,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698.0,BAO_0000019,,CHEMBL617804,,,,,H,Autocuration,5094.0,6.0,,3159.0,,,
,1.0,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617805,,10116.0,,,D,Autocuration,2622.0,7.0,,3160.0,,,
,1.0,B,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,,CHEMBL617806,,,,,H,Autocuration,245.0,6.0,,3161.0,,,
,1.0,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,104698.0,BAO_0000019,,CHEMBL617807,,,,,H,Autocuration,14788.0,6.0,,3162.0,,,
,1.0,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,104698.0,BAO_0000019,,CHEMBL617808,,,,,H,Autocuration,14788.0,6.0,,3163.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,104698.0,BAO_0000249,,CHEMBL617809,,,,,H,Autocuration,3020.0,6.0,,3164.0,,,
,1.0,B,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,104698.0,BAO_0000019,,CHEMBL617810,,,,,H,Autocuration,1742.0,6.0,,3165.0,,,
Brain,1.0,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,104698.0,BAO_0000249,,CHEMBL617811,,,955.0,,H,Autocuration,17394.0,6.0,,3166.0,,,
Brain,1.0,B,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,104698.0,BAO_0000221,,CHEMBL617812,,,955.0,,H,Autocuration,17394.0,6.0,,3167.0,,,
,1.0,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698.0,BAO_0000249,,CHEMBL617813,,,,,H,Autocuration,17394.0,6.0,,3168.0,,,
,1.0,B,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,104698.0,BAO_0000249,,CHEMBL617814,,,,,H,Autocuration,14286.0,6.0,,3169.0,,,
,1.0,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,104698.0,BAO_0000019,,CHEMBL617698,,,,,H,Autocuration,14178.0,6.0,,3170.0,,,
,1.0,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617699,,10116.0,,,D,Autocuration,14178.0,7.0,,3171.0,,,
,1.0,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617700,,10116.0,,,D,Autocuration,14178.0,7.0,,3172.0,,,
,1.0,B,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL617701,,10116.0,,,D,Autocuration,14178.0,7.0,,3173.0,,,
,1.0,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,104698.0,BAO_0000019,,CHEMBL617702,,,,,H,Autocuration,15034.0,6.0,,3174.0,,,
,1.0,B,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,104698.0,BAO_0000249,,CHEMBL617703,,,,,H,Autocuration,1089.0,6.0,,3175.0,Membranes,,
,1.0,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617704,,10116.0,,,D,Autocuration,1089.0,7.0,,3176.0,,,
,1.0,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,104698.0,BAO_0000223,,CHEMBL617705,,,,,H,Autocuration,16532.0,6.0,,3177.0,,,
,1.0,B,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL617706,,10116.0,,,D,Autocuration,12801.0,7.0,,3178.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,NG108-15,104698.0,BAO_0000219,,CHEMBL617707,,,,,H,Autocuration,15194.0,6.0,433.0,3179.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,NG108-15,104698.0,BAO_0000219,,CHEMBL617708,,,,,H,Autocuration,15194.0,6.0,433.0,3180.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,104698.0,BAO_0000019,,CHEMBL617709,,,,,H,Autocuration,15194.0,6.0,,3181.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,104698.0,BAO_0000019,,CHEMBL617710,,,,,H,Autocuration,15194.0,6.0,,3182.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,104698.0,BAO_0000019,,CHEMBL882925,,,,,H,Autocuration,15194.0,6.0,,3183.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,104698.0,BAO_0000019,,CHEMBL617711,,,,,H,Autocuration,15194.0,6.0,,3184.0,,,
,1.0,F,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,104698.0,BAO_0000019,,CHEMBL617712,,,,,H,Autocuration,10610.0,6.0,,3185.0,,,
,1.0,F,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL617713,,10116.0,,,D,Autocuration,10355.0,7.0,,3186.0,,,
,1.0,F,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,104698.0,BAO_0000019,,CHEMBL617714,,,,,H,Autocuration,691.0,6.0,,3187.0,,,
,1.0,F,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,104698.0,BAO_0000218,,CHEMBL617715,,,,,H,Autocuration,10611.0,6.0,,3188.0,,,
,1.0,F,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,104698.0,BAO_0000218,,CHEMBL617716,In vivo,,,,H,Autocuration,12801.0,6.0,,3189.0,,,
,1.0,F,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,104698.0,BAO_0000218,,CHEMBL617717,,,,,H,Autocuration,10609.0,6.0,,3190.0,,,
,1.0,F,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617718,In vivo,,,,H,Autocuration,11454.0,6.0,,3191.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617719,In vivo,,,,H,Autocuration,11454.0,6.0,,3192.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,104698.0,BAO_0000218,,CHEMBL617720,In vivo,,,,H,Autocuration,11454.0,6.0,,3193.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,Rattus norvegicus,CHEMBL617721,In vivo,10116.0,,,D,Autocuration,11454.0,7.0,,3194.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617722,In vivo,,,,H,Autocuration,11454.0,6.0,,3195.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,104698.0,BAO_0000218,,CHEMBL617723,In vivo,,,,H,Autocuration,11454.0,6.0,,3196.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617724,In vivo,,,,H,Autocuration,11454.0,6.0,,3197.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617725,In vivo,,,,H,Autocuration,11454.0,6.0,,3198.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617726,In vivo,,,,H,Autocuration,11454.0,6.0,,3199.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617727,In vivo,,,,H,Autocuration,11454.0,6.0,,3200.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617728,In vivo,,,,H,Autocuration,11454.0,6.0,,3201.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617729,In vivo,,,,H,Autocuration,11454.0,6.0,,3202.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617730,In vivo,,,,H,Autocuration,11454.0,6.0,,3203.0,,,
,1.0,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617731,In vivo,,,,H,Autocuration,11454.0,6.0,,3204.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617732,In vivo,,,,H,Autocuration,11454.0,6.0,,3205.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617733,In vivo,,,,H,Autocuration,11454.0,6.0,,3206.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617734,In vivo,,,,H,Autocuration,11454.0,6.0,,3207.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,104698.0,BAO_0000218,,CHEMBL872874,In vivo,,,,H,Autocuration,11454.0,6.0,,3208.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,104698.0,BAO_0000218,,CHEMBL617735,In vivo,,,,H,Autocuration,11454.0,6.0,,3209.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,104698.0,BAO_0000218,,CHEMBL617736,In vivo,,,,H,Autocuration,11454.0,6.0,,3210.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,104698.0,BAO_0000218,,CHEMBL617737,In vivo,,,,H,Autocuration,11454.0,6.0,,3211.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,104698.0,BAO_0000218,,CHEMBL617738,In vivo,,,,H,Autocuration,11454.0,6.0,,3212.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617739,In vivo,,,,H,Autocuration,11454.0,6.0,,3213.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617740,In vivo,,,,H,Autocuration,11454.0,6.0,,3214.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617741,In vivo,,,,H,Autocuration,11454.0,6.0,,3215.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617742,In vivo,,,,H,Autocuration,11454.0,6.0,,3216.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617743,In vivo,,,,H,Autocuration,11454.0,6.0,,3217.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617744,In vivo,,,,H,Autocuration,11454.0,6.0,,3218.0,,,
,1.0,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,104698.0,BAO_0000218,,CHEMBL617745,In vivo,,,,H,Autocuration,11454.0,6.0,,3219.0,,,
,1.0,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,104698.0,BAO_0000218,,CHEMBL617746,,,,,H,Autocuration,670.0,6.0,,3220.0,,,
,1.0,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,104698.0,BAO_0000218,,CHEMBL617747,,,,,H,Autocuration,670.0,6.0,,3221.0,,,
,1.0,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,104698.0,BAO_0000218,,CHEMBL617748,In vivo,,,,H,Autocuration,10321.0,6.0,,3222.0,,,
,1.0,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,104698.0,BAO_0000218,,CHEMBL618909,In vivo,,,,H,Autocuration,10321.0,6.0,,3223.0,,,
,1.0,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,104698.0,BAO_0000218,,CHEMBL618910,In vivo,,,,H,Autocuration,10321.0,6.0,,3224.0,,,
,1.0,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,104698.0,BAO_0000218,,CHEMBL618911,In vivo,,,,H,Autocuration,10321.0,6.0,,3225.0,,,
,1.0,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,104698.0,BAO_0000218,,CHEMBL618912,In vivo,,,,H,Autocuration,10321.0,6.0,,3226.0,,,
,1.0,F,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,104698.0,BAO_0000218,,CHEMBL618913,In vivo,,,,H,Autocuration,10322.0,6.0,,3227.0,,,
,1.0,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698.0,BAO_0000019,,CHEMBL618914,,,,,H,Autocuration,15412.0,6.0,,3228.0,,,
,1.0,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,104698.0,BAO_0000019,,CHEMBL618915,,,,,H,Autocuration,15412.0,6.0,,3229.0,,,
,1.0,B,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL618916,,10116.0,,,D,Autocuration,15412.0,7.0,,3230.0,,,
,1.0,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,104698.0,BAO_0000019,,CHEMBL618917,,,,,H,Autocuration,15412.0,6.0,,3231.0,,,
Hippocampus,1.0,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,104698.0,BAO_0000221,,CHEMBL618918,,,10000000.0,,D,Intermediate,15412.0,7.0,,3232.0,,,
,1.0,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL618919,,10116.0,,,D,Autocuration,15412.0,7.0,,3233.0,,,
,1.0,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL618920,,10116.0,,,D,Autocuration,17394.0,7.0,,3234.0,,,
,1.0,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,,CHEMBL618921,,,,,H,Autocuration,12457.0,6.0,,3235.0,,,
,1.0,B,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,,CHEMBL618922,,,,,H,Autocuration,12457.0,6.0,,3236.0,,,
,1.0,B,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,104698.0,BAO_0000019,,CHEMBL618923,,,,,H,Autocuration,12205.0,6.0,,3237.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,104698.0,BAO_0000019,,CHEMBL618924,,,,,H,Autocuration,14532.0,6.0,,3238.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,104698.0,BAO_0000019,,CHEMBL618925,,,,,H,Autocuration,1122.0,6.0,,3239.0,,,
,1.0,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,104698.0,BAO_0000019,,CHEMBL618926,,,,,H,Autocuration,5094.0,6.0,,3240.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL618927,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3241.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL618928,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3242.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL618929,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3243.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL618930,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3244.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL618931,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3245.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619594,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3246.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619595,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3247.0,,,
Ileum,1.0,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619596,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3248.0,,,
Ileum,1.0,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619755,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3249.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619756,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3250.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619757,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3251.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619758,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3252.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619759,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3253.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619760,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3254.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619761,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3255.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619762,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3256.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619763,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3257.0,,,
Ileum,1.0,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL617868,,10141.0,2116.0,,D,Intermediate,14290.0,9.0,,3258.0,,,
,1.0,B,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617869,,10141.0,,,D,Intermediate,15034.0,9.0,,3259.0,,,
Striatum,1.0,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033.0,BAO_0000249,Cavia porcellus,CHEMBL882926,,10141.0,2435.0,,D,Intermediate,5094.0,9.0,,3260.0,,,
Striatum,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033.0,BAO_0000249,Cavia porcellus,CHEMBL617870,,10141.0,2435.0,,D,Intermediate,5094.0,9.0,,3261.0,,,
Striatum,1.0,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617871,,10141.0,2435.0,,D,Intermediate,5399.0,9.0,,3262.0,,,
Striatum,1.0,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617872,,10141.0,2435.0,,D,Intermediate,17394.0,9.0,,3263.0,,,
Striatum,1.0,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617873,,10141.0,2435.0,,D,Intermediate,17394.0,9.0,,3264.0,,,
Striatum,1.0,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL617874,,10141.0,2435.0,,D,Intermediate,17394.0,9.0,,3265.0,,,
Ileum,1.0,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619067,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3266.0,,,
Ileum,1.0,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619068,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3267.0,,,
Ileum,1.0,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619069,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3268.0,,,
,1.0,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619070,,10141.0,,,D,Intermediate,16946.0,9.0,,3269.0,,,
,1.0,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619071,,10141.0,,,D,Intermediate,16946.0,9.0,,3270.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619072,,10141.0,,,D,Intermediate,15034.0,9.0,,3271.0,,,
,1.0,F,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619073,,10141.0,,,D,Intermediate,15034.0,9.0,,3272.0,,,
,1.0,F,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619074,,10141.0,,,D,Intermediate,12918.0,9.0,,3273.0,,,
,1.0,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619075,,10141.0,,,D,Intermediate,16946.0,9.0,,3274.0,,,
Striatum,1.0,B,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619076,,10141.0,2435.0,,D,Intermediate,17394.0,9.0,,3275.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619077,,10141.0,2435.0,,D,Intermediate,15034.0,9.0,,3276.0,,,
Striatum,1.0,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033.0,BAO_0000249,Cavia porcellus,CHEMBL619078,,10141.0,2435.0,,D,Intermediate,5094.0,9.0,,3277.0,,,
Striatum,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,20033.0,BAO_0000249,Cavia porcellus,CHEMBL619079,,10141.0,2435.0,,D,Intermediate,5094.0,9.0,,3278.0,,,
Ileum,1.0,B,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619080,,10141.0,2116.0,,D,Intermediate,17358.0,9.0,,3279.0,,,
,1.0,B,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619081,,10141.0,,,D,Expert,12953.0,9.0,,3280.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619082,,10141.0,,,D,Intermediate,12953.0,9.0,,3281.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619083,,10141.0,,,D,Intermediate,12953.0,9.0,,3282.0,,,
,1.0,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619084,,10141.0,,,D,Intermediate,12953.0,9.0,,3283.0,,,
Ileum,1.0,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL859397,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,3284.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619085,,10141.0,2116.0,,D,Intermediate,12918.0,9.0,,3285.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619086,,10141.0,2116.0,,D,Intermediate,12919.0,9.0,,3286.0,,,
Ileum,1.0,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619087,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,3287.0,,,
Ileum,1.0,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619088,,10141.0,2116.0,,D,Intermediate,273.0,9.0,,3288.0,,,
,1.0,B,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619089,,10141.0,,,D,Intermediate,13181.0,9.0,,3289.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,168.0,BAO_0000357,Cavia porcellus,CHEMBL619090,,10141.0,,,H,Autocuration,13181.0,8.0,,3290.0,,,
,1.0,F,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619091,,10141.0,,,D,Intermediate,15034.0,9.0,,3291.0,,,
,1.0,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619092,,10141.0,,,D,Intermediate,5033.0,9.0,,3292.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619093,,10141.0,,,D,Intermediate,1980.0,9.0,,3293.0,,,
,1.0,B,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,HEK293,168.0,BAO_0000219,Cavia porcellus,CHEMBL619094,,10141.0,,,H,Autocuration,13181.0,8.0,722.0,3294.0,,,
,1.0,B,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619095,,10141.0,,,D,Intermediate,14287.0,9.0,,3295.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL857988,,10141.0,,,D,Intermediate,1317.0,9.0,,3296.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619096,,10141.0,,,D,Intermediate,15316.0,9.0,,3297.0,,,
Striatum,1.0,B,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619097,,10141.0,2435.0,,D,Intermediate,16429.0,9.0,,3298.0,,,
Hippocampus,1.0,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619098,,10141.0,10000000.0,,D,Intermediate,14818.0,9.0,,3299.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619751,,10141.0,,,D,Intermediate,15194.0,9.0,,3300.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619752,,10141.0,,,D,Intermediate,15194.0,9.0,,3301.0,,,
Ileum,1.0,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL875096,,10141.0,2116.0,,D,Intermediate,13961.0,9.0,,3302.0,,,
,1.0,B,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,108.0,BAO_0000357,,CHEMBL619004,,,,,H,Autocuration,5486.0,8.0,,3303.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,168.0,BAO_0000357,,CHEMBL619005,,,,,H,Autocuration,16209.0,8.0,,3304.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000019,,CHEMBL619006,,,,,H,Autocuration,17085.0,8.0,,3305.0,,,
,1.0,B,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,HeLa,168.0,BAO_0000219,,CHEMBL619007,,,,,H,Autocuration,4199.0,8.0,308.0,3306.0,,,
,1.0,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL619008,,,,,H,Autocuration,15146.0,8.0,,3307.0,,,
,1.0,B,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL619009,,,,,H,Autocuration,5213.0,8.0,,3308.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,HeLa,168.0,BAO_0000219,,CHEMBL619010,,,,,H,Autocuration,4829.0,8.0,308.0,3309.0,,,
,1.0,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,10622.0,BAO_0000357,,CHEMBL619011,,,,,H,Autocuration,17358.0,8.0,,3310.0,,,
,1.0,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,10622.0,BAO_0000357,,CHEMBL619012,,,,,H,Autocuration,17358.0,8.0,,3311.0,,,
,1.0,B,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,10622.0,BAO_0000219,,CHEMBL619013,,,,,H,Autocuration,16946.0,8.0,,3312.0,,,
,1.0,B,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,10622.0,BAO_0000357,,CHEMBL619014,,,,,H,Autocuration,17358.0,8.0,,3313.0,,,
Cardiac atrium,1.0,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,11249.0,BAO_0000019,,CHEMBL857503,,,2081.0,,H,Autocuration,268.0,8.0,,3314.0,,,
Cardiac atrium,1.0,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,11249.0,BAO_0000019,,CHEMBL619015,,,2081.0,,H,Autocuration,268.0,8.0,,3315.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,11249.0,BAO_0000357,,CHEMBL619016,,,,,H,Autocuration,15086.0,8.0,,3316.0,,,
Hippocampus,1.0,B,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,11249.0,BAO_0000221,,CHEMBL619017,,,10000000.0,,H,Autocuration,14875.0,8.0,,3317.0,,,
Hippocampus,1.0,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,168.0,BAO_0000221,Sus scrofa,CHEMBL619018,,9823.0,10000000.0,,H,Autocuration,13267.0,8.0,,3318.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,168.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL619019,,9986.0,,,H,Autocuration,13047.0,8.0,,3319.0,,,
,1.0,B,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,10623.0,BAO_0000357,Rattus norvegicus,CHEMBL619020,,10116.0,,,D,Expert,1650.0,9.0,,3320.0,,,
,1.0,F,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623.0,BAO_0000019,,CHEMBL619021,,,,,H,Autocuration,567.0,8.0,,3321.0,,,
,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,10623.0,BAO_0000357,,CHEMBL619022,,,,,H,Autocuration,17358.0,8.0,,3322.0,,,
,1.0,B,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,10623.0,BAO_0000357,,CHEMBL619023,,,,,H,Autocuration,188.0,8.0,,3323.0,,,
,1.0,F,lntrinsic activity relative to 5-HT receptor,,,10623.0,BAO_0000019,,CHEMBL619024,,,,,H,Autocuration,670.0,8.0,,3324.0,,,
,1.0,F,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,10623.0,BAO_0000019,,CHEMBL619025,,,,,H,Autocuration,204.0,8.0,,3325.0,,,
,1.0,F,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,10623.0,BAO_0000019,,CHEMBL619026,,,,,H,Expert,1946.0,8.0,,3326.0,,,
,1.0,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,10623.0,BAO_0000019,,CHEMBL619027,,,,,H,Autocuration,6398.0,8.0,,3327.0,,,
,1.0,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,10623.0,BAO_0000019,,CHEMBL619028,,,,,H,Autocuration,6398.0,8.0,,3328.0,,,
,1.0,F,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,10623.0,BAO_0000019,,CHEMBL619029,,,,,H,Autocuration,17358.0,8.0,,3329.0,,,
,1.0,F,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,10623.0,BAO_0000019,,CHEMBL619030,,,,,H,Autocuration,6398.0,8.0,,3330.0,,,
,1.0,B,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,10623.0,BAO_0000357,,CHEMBL619031,,,,,H,Expert,11752.0,8.0,,3331.0,,,
,1.0,F,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,10623.0,BAO_0000019,,CHEMBL619032,,,,,H,Autocuration,809.0,8.0,,3332.0,,,
,1.0,B,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,10623.0,BAO_0000357,Rattus norvegicus,CHEMBL619033,,10116.0,,,D,Expert,14178.0,9.0,,3333.0,,,
,1.0,B,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,10623.0,BAO_0000357,,CHEMBL619034,,,,,H,Autocuration,567.0,8.0,,3334.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,10623.0,BAO_0000357,,CHEMBL619035,,,,,H,Autocuration,1946.0,8.0,,3335.0,,,
,1.0,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,10623.0,BAO_0000357,,CHEMBL619036,,,,,H,Autocuration,1946.0,8.0,,3336.0,,,
,1.0,B,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,10623.0,BAO_0000019,Rattus norvegicus,CHEMBL619037,,10116.0,,,D,Expert,13961.0,9.0,,3337.0,,,
Striatum,1.0,B,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,10623.0,BAO_0000249,,CHEMBL619038,,,2435.0,,H,Autocuration,6238.0,8.0,,3338.0,,,
,1.0,B,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,10623.0,BAO_0000249,,CHEMBL619039,,,,,H,Autocuration,14290.0,8.0,,3339.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,10623.0,BAO_0000249,,CHEMBL619040,,,,,H,Expert,14290.0,8.0,,3340.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,10623.0,BAO_0000019,Rattus norvegicus,CHEMBL619041,,10116.0,2435.0,,D,Expert,809.0,9.0,,3341.0,,,
Striatum,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,10623.0,BAO_0000019,,CHEMBL619042,,,2435.0,,H,Autocuration,1578.0,8.0,,3342.0,,,
Striatum,1.0,B,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,10623.0,BAO_0000249,,CHEMBL619043,,,2435.0,,H,Expert,16709.0,8.0,,3343.0,,,
Striatum,1.0,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,10623.0,BAO_0000019,,CHEMBL619044,,,2435.0,,H,Expert,1946.0,8.0,,3344.0,,,
Striatum,1.0,B,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,10623.0,BAO_0000249,,CHEMBL619045,,,2435.0,,H,Expert,15253.0,8.0,,3345.0,,,
Striatum,1.0,B,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,10623.0,BAO_0000249,,CHEMBL619046,,,2435.0,,H,Expert,4535.0,8.0,,3346.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,10623.0,BAO_0000249,,CHEMBL619047,,,,,H,Expert,13961.0,8.0,,3347.0,,,
Brain,1.0,F,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,10623.0,BAO_0000221,,CHEMBL619048,,,955.0,,H,Autocuration,17358.0,8.0,,3348.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,10623.0,BAO_0000019,,CHEMBL859398,,,,,H,Autocuration,15847.0,8.0,,3349.0,,,
,1.0,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,10623.0,BAO_0000019,,CHEMBL619049,,,,,H,Autocuration,15847.0,8.0,,3350.0,,,
,1.0,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,10623.0,BAO_0000019,,CHEMBL857886,,,,,H,Autocuration,670.0,8.0,,3351.0,,,
,1.0,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,10623.0,BAO_0000019,,CHEMBL619050,,,,,H,Autocuration,670.0,8.0,,3352.0,,,
,1.0,F,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,10623.0,BAO_0000019,,CHEMBL620591,,,,,H,Autocuration,1317.0,8.0,,3353.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,10623.0,BAO_0000357,Rattus norvegicus,CHEMBL620592,,10116.0,,,D,Expert,12936.0,9.0,,3354.0,,,
Striatum,1.0,B,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,10623.0,BAO_0000249,,CHEMBL620593,,,2435.0,,H,Expert,4535.0,8.0,,3355.0,,,
,1.0,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,10623.0,BAO_0000019,Rattus norvegicus,CHEMBL620594,,10116.0,,,D,Expert,14424.0,9.0,,3356.0,,,
,1.0,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,10623.0,BAO_0000019,,CHEMBL875079,,,,,H,Expert,14424.0,8.0,,3357.0,,,
,1.0,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623.0,BAO_0000019,,CHEMBL620595,,,,,H,Expert,14424.0,8.0,,3358.0,,,
,1.0,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,10623.0,BAO_0000019,Rattus norvegicus,CHEMBL620596,,10116.0,,,D,Expert,14424.0,9.0,,3359.0,,,
,1.0,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,10623.0,BAO_0000019,,CHEMBL620597,,,,,H,Autocuration,14424.0,8.0,,3360.0,,,
,1.0,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,10623.0,BAO_0000019,,CHEMBL620598,,,,,H,Expert,14424.0,8.0,,3361.0,,,
,1.0,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,10623.0,BAO_0000218,,CHEMBL620599,,,,,H,Expert,14424.0,8.0,,3362.0,,,
,1.0,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,10623.0,BAO_0000019,,CHEMBL620600,,,,,H,Autocuration,14424.0,8.0,,3363.0,,,
,1.0,F,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,168.0,BAO_0000019,Rattus norvegicus,CHEMBL620601,,10116.0,,,H,Autocuration,1980.0,8.0,,3364.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,168.0,BAO_0000019,,CHEMBL620602,,,,,H,Autocuration,4639.0,8.0,,3365.0,,,
,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620603,,,,,H,Autocuration,17358.0,8.0,,3366.0,,,
,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,168.0,BAO_0000357,,CHEMBL620604,,,,,H,Autocuration,17358.0,8.0,,3367.0,,,
,1.0,B,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,168.0,BAO_0000357,,CHEMBL620605,,,,,H,Autocuration,17358.0,8.0,,3368.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620606,,,,,H,Autocuration,1558.0,8.0,,3369.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168.0,BAO_0000019,,CHEMBL620607,,,,,H,Autocuration,17358.0,8.0,,3370.0,,,
,1.0,B,In vitro binding affinity towards 5-HT4 receptor was determined,,,168.0,BAO_0000357,,CHEMBL620608,,,,,H,Autocuration,16117.0,8.0,,3371.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168.0,BAO_0000019,,CHEMBL620609,,,,,H,Autocuration,17358.0,8.0,,3372.0,,,
,1.0,F,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000019,,CHEMBL620610,,,,,H,Autocuration,17358.0,8.0,,3373.0,,,
,1.0,B,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620611,,,,,H,Autocuration,17358.0,8.0,,3374.0,,,
,1.0,B,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,168.0,BAO_0000357,,CHEMBL620612,,,,,H,Autocuration,17358.0,8.0,,3375.0,,,
,1.0,B,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,168.0,BAO_0000357,,CHEMBL620613,,,,,H,Autocuration,17358.0,8.0,,3376.0,,,
,1.0,B,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,168.0,BAO_0000357,,CHEMBL620614,,,,,H,Autocuration,17358.0,8.0,,3377.0,,,
,1.0,B,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620615,,,,,H,Expert,1274.0,8.0,,3378.0,,,
,1.0,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,104698.0,BAO_0000249,,CHEMBL857075,,,,,H,Autocuration,10728.0,6.0,,3379.0,Brain membranes,,
,1.0,B,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,104698.0,BAO_0000249,,CHEMBL620616,,,,,H,Autocuration,11695.0,6.0,,3380.0,Brain membranes,,
,1.0,B,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,104698.0,BAO_0000249,,CHEMBL619411,,,,,H,Autocuration,11695.0,6.0,,3381.0,Brain membranes,,
,1.0,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,104698.0,BAO_0000019,,CHEMBL619412,,,,,H,Autocuration,12490.0,6.0,,3382.0,,,
,1.0,B,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL619413,,10116.0,,,D,Autocuration,11828.0,7.0,,3383.0,,,
Hippocampus,1.0,B,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,104698.0,BAO_0000221,,CHEMBL619414,,,10000000.0,,H,Autocuration,12253.0,6.0,,3384.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,104698.0,BAO_0000019,,CHEMBL619415,,,,,H,Autocuration,10561.0,6.0,,3385.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,104698.0,BAO_0000019,,CHEMBL619416,,,,,H,Autocuration,10561.0,6.0,,3386.0,,,
,1.0,F,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,104698.0,BAO_0000019,,CHEMBL619417,,,,,H,Autocuration,14432.0,6.0,,3387.0,,,
,1.0,B,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL619418,,10116.0,,,D,Autocuration,12936.0,7.0,,3388.0,,,
,1.0,B,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL619419,,10116.0,,,D,Autocuration,1274.0,7.0,,3389.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,104698.0,BAO_0000019,,CHEMBL619420,,,,,H,Autocuration,1980.0,6.0,,3390.0,,,
,1.0,B,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,104698.0,BAO_0000249,,CHEMBL619421,,,,,H,Autocuration,670.0,6.0,,3391.0,,,
,1.0,B,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,104698.0,BAO_0000019,Rattus norvegicus,CHEMBL619422,,10116.0,,,D,Autocuration,968.0,7.0,,3392.0,,,
,1.0,B,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,104698.0,BAO_0000019,,CHEMBL619423,,,,,H,Autocuration,14287.0,6.0,,3393.0,,,
,1.0,B,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,104698.0,BAO_0000019,,CHEMBL875080,,,,,H,Autocuration,567.0,6.0,,3394.0,,,
,1.0,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,104698.0,BAO_0000019,,CHEMBL619424,,,,,H,Autocuration,13267.0,6.0,,3395.0,,,
,1.0,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,104698.0,BAO_0000249,,CHEMBL619425,,,,,H,Autocuration,14826.0,6.0,,3396.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,104698.0,BAO_0000223,,CHEMBL619426,,,,,H,Autocuration,15194.0,6.0,,3397.0,,,
,1.0,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,104698.0,BAO_0000223,,CHEMBL619427,,,,,H,Autocuration,15194.0,6.0,,3398.0,,,
,1.0,B,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,Rattus norvegicus,CHEMBL619645,,10116.0,,,D,Autocuration,10394.0,7.0,,3399.0,,,
,1.0,B,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,10576.0,BAO_0000249,,CHEMBL619646,,,,,D,Expert,13657.0,9.0,,3400.0,,,
Brain,1.0,F,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,12020.0,BAO_0000221,,CHEMBL619647,,,955.0,,H,Autocuration,1879.0,8.0,,3401.0,,,
,1.0,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,12020.0,BAO_0000019,,CHEMBL619648,,,,,H,Autocuration,1879.0,8.0,,3402.0,,,
,1.0,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,12020.0,BAO_0000019,,CHEMBL619165,,,,,H,Autocuration,1879.0,8.0,,3403.0,,,
,1.0,F,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,12020.0,BAO_0000218,,CHEMBL620719,In vivo,,,,H,Autocuration,204.0,8.0,,3404.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020.0,BAO_0000019,,CHEMBL872924,,,,,H,Autocuration,1879.0,8.0,,3405.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,12020.0,BAO_0000357,,CHEMBL620720,,,,,H,Autocuration,1879.0,8.0,,3406.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,12020.0,BAO_0000019,,CHEMBL620721,,,,,H,Autocuration,1879.0,8.0,,3407.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,12020.0,BAO_0000019,,CHEMBL620722,,,,,H,Autocuration,1879.0,8.0,,3408.0,,,
,1.0,B,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,104698.0,BAO_0000019,,CHEMBL620723,,,,,H,Autocuration,10641.0,6.0,,3409.0,,,
,1.0,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,12020.0,BAO_0000019,,CHEMBL620724,,,,,H,Autocuration,773.0,8.0,,3410.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,104698.0,BAO_0000249,,CHEMBL620725,,,,,H,Autocuration,11952.0,6.0,,3411.0,,,
,1.0,F,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,12020.0,BAO_0000019,Rattus norvegicus,CHEMBL620726,,10116.0,,,D,Autocuration,14145.0,9.0,,3412.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL620727,,,,,H,Expert,17066.0,8.0,,3413.0,,,
,1.0,B,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,104714.0,BAO_0000223,,CHEMBL620728,,,,,H,Autocuration,6398.0,4.0,,3414.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,22226.0,BAO_0000019,,CHEMBL620729,,,,,U,Autocuration,10321.0,0.0,,3415.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,104714.0,BAO_0000019,,CHEMBL858288,,,,,H,Autocuration,511.0,4.0,,3416.0,,,
,1.0,B,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL620730,,,,,H,Autocuration,4639.0,4.0,,3417.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL620731,,,,,H,Autocuration,4639.0,4.0,,3418.0,,,
,1.0,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL620732,,10141.0,,,H,Autocuration,4639.0,4.0,,3419.0,,,
,1.0,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618042,,10141.0,,,H,Autocuration,4639.0,4.0,,3420.0,,,
,1.0,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618043,,10141.0,,,H,Autocuration,4639.0,4.0,,3421.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL618044,,,,,H,Autocuration,1558.0,4.0,,3422.0,,,
,1.0,F,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,104714.0,BAO_0000019,,CHEMBL618045,,,,,H,Autocuration,268.0,4.0,,3423.0,,,
,1.0,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,104714.0,BAO_0000223,,CHEMBL618046,,,,,H,Autocuration,2474.0,4.0,,3424.0,,,
,1.0,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,104714.0,BAO_0000019,,CHEMBL618047,,,,,H,Autocuration,5067.0,4.0,,3425.0,,,
,1.0,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,104714.0,BAO_0000019,,CHEMBL875084,,,,,H,Autocuration,5067.0,4.0,,3426.0,,,
,1.0,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,104714.0,BAO_0000019,,CHEMBL618048,,,,,H,Autocuration,5067.0,4.0,,3427.0,,,
,1.0,B,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,104714.0,BAO_0000223,,CHEMBL618049,,,,,H,Autocuration,5067.0,4.0,,3428.0,,,
,1.0,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,104714.0,BAO_0000019,,CHEMBL619764,,,,,H,Autocuration,5067.0,4.0,,3429.0,,,
,1.0,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,104714.0,BAO_0000019,,CHEMBL619765,,,,,H,Autocuration,5067.0,4.0,,3430.0,,,
,1.0,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,104714.0,BAO_0000019,,CHEMBL619766,,,,,H,Autocuration,5067.0,4.0,,3431.0,,,
,1.0,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,104714.0,BAO_0000223,,CHEMBL619767,,,,,H,Autocuration,5067.0,4.0,,3432.0,,,
,1.0,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,104714.0,BAO_0000223,,CHEMBL619768,,,,,H,Autocuration,5067.0,4.0,,3433.0,,,
,1.0,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,104714.0,BAO_0000019,,CHEMBL619769,,,,,H,Autocuration,5067.0,4.0,,3434.0,,,
,1.0,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,104714.0,BAO_0000223,,CHEMBL619770,,,,,H,Autocuration,5067.0,4.0,,3435.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL619771,,,,,H,Autocuration,5067.0,4.0,,3436.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,104714.0,BAO_0000219,,CHEMBL619772,,,,,H,Autocuration,14331.0,4.0,,3437.0,,,
,1.0,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,104714.0,BAO_0000223,,CHEMBL619773,,,,,H,Autocuration,5067.0,4.0,,3438.0,,,
,1.0,B,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,NG108-15,104714.0,BAO_0000219,,CHEMBL619774,,,,,H,Autocuration,6179.0,4.0,433.0,3439.0,,,
,1.0,B,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,104714.0,BAO_0000019,,CHEMBL875083,,,,,H,Autocuration,4265.0,4.0,,3440.0,,,
,1.0,B,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,NG108-15,104714.0,BAO_0000219,,CHEMBL620718,,,,,H,Autocuration,4265.0,4.0,433.0,3441.0,,,
,1.0,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,104714.0,BAO_0000223,,CHEMBL618127,,,,,H,Autocuration,17358.0,4.0,,3442.0,,,
,1.0,B,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,104714.0,BAO_0000223,,CHEMBL618128,,,,,H,Autocuration,17358.0,4.0,,3443.0,,,
,1.0,B,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,104714.0,BAO_0000219,,CHEMBL618129,In vitro,,,,H,Autocuration,13628.0,4.0,,3444.0,,,
,1.0,B,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,104714.0,BAO_0000223,,CHEMBL618130,,,,,H,Autocuration,4612.0,4.0,,3445.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,104714.0,BAO_0000019,,CHEMBL618131,,,,,H,Autocuration,17358.0,4.0,,3446.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618132,,10141.0,,,H,Autocuration,4639.0,4.0,,3447.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618133,,10141.0,,,H,Autocuration,4639.0,4.0,,3448.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618134,,10141.0,,,H,Autocuration,4639.0,4.0,,3449.0,,,
,1.0,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618135,,10141.0,,,H,Autocuration,4639.0,4.0,,3450.0,,,
,1.0,B,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,104714.0,BAO_0000223,,CHEMBL618136,,,,,H,Autocuration,511.0,4.0,,3451.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL618137,,,,,H,Autocuration,1479.0,4.0,,3452.0,,,
,1.0,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,104714.0,BAO_0000223,,CHEMBL618138,,,,,H,Autocuration,1317.0,4.0,,3453.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,104714.0,BAO_0000223,,CHEMBL618139,,,,,H,Autocuration,12146.0,4.0,,3454.0,,,
,1.0,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,104714.0,BAO_0000223,,CHEMBL618140,,,,,H,Autocuration,12146.0,4.0,,3455.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,104714.0,BAO_0000223,,CHEMBL618141,,,,,H,Autocuration,13969.0,4.0,,3456.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,,108.0,BAO_0000357,,CHEMBL873478,,,,,H,Expert,13392.0,8.0,,3457.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,104698.0,BAO_0000223,,CHEMBL618142,,,,,H,Autocuration,13392.0,6.0,,3458.0,,,
,1.0,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL618143,,,,,H,Autocuration,14159.0,8.0,,3459.0,,,
,1.0,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL618144,,,,,H,Autocuration,1558.0,8.0,,3460.0,,,
,1.0,B,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL618145,,,,,H,Autocuration,16655.0,8.0,,3461.0,,,
,1.0,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714.0,BAO_0000223,,CHEMBL618146,,,,,H,Autocuration,13020.0,4.0,,3462.0,,,
,1.0,B,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,104714.0,BAO_0000223,,CHEMBL618147,,,,,H,Autocuration,13021.0,4.0,,3463.0,,,
,1.0,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,104714.0,BAO_0000223,,CHEMBL618148,,,,,H,Autocuration,13020.0,4.0,,3464.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,144.0,BAO_0000019,,CHEMBL618149,,,,,H,Autocuration,10321.0,8.0,,3465.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL872927,,,,,H,Autocuration,15818.0,8.0,,3466.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL618150,,,,,H,Autocuration,15818.0,8.0,,3467.0,,,
,1.0,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,144.0,BAO_0000357,,CHEMBL618151,,,,,H,Autocuration,17358.0,8.0,,3468.0,,,
,1.0,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,144.0,BAO_0000357,,CHEMBL875094,,,,,H,Autocuration,2222.0,8.0,,3469.0,,,
,1.0,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,144.0,BAO_0000019,,CHEMBL618152,,,,,H,Autocuration,10322.0,8.0,,3470.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,144.0,BAO_0000357,,CHEMBL618153,,,,,H,Autocuration,16117.0,8.0,,3471.0,,,
,1.0,B,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,144.0,BAO_0000357,,CHEMBL618888,,,,,H,Autocuration,17200.0,8.0,,3472.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,144.0,BAO_0000019,,CHEMBL618889,,,,,H,Autocuration,17358.0,8.0,,3473.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,144.0,BAO_0000357,,CHEMBL618890,,,,,H,Autocuration,16700.0,8.0,,3474.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,144.0,BAO_0000019,,CHEMBL618891,,,,,H,Autocuration,1980.0,8.0,,3475.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,144.0,BAO_0000019,,CHEMBL619054,,,,,H,Autocuration,1980.0,8.0,,3476.0,,,
,1.0,B,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,104714.0,BAO_0000223,,CHEMBL619055,,,,,H,Autocuration,12409.0,4.0,,3477.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144.0,BAO_0000357,,CHEMBL619056,,,,,H,Autocuration,4365.0,8.0,,3478.0,,,
,1.0,F,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,144.0,BAO_0000019,,CHEMBL619057,,,,,H,Autocuration,4365.0,8.0,,3479.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,144.0,BAO_0000357,,CHEMBL619058,,,,,H,Autocuration,4365.0,8.0,,3480.0,,,
,1.0,F,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Oocytes,12020.0,BAO_0000219,Rattus norvegicus,CHEMBL619059,,10116.0,,,D,Expert,6769.0,9.0,,3481.0,,,
,1.0,F,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Oocytes,12020.0,BAO_0000219,Rattus norvegicus,CHEMBL619060,,10116.0,,,D,Expert,6769.0,9.0,,3482.0,,,
,1.0,F,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Oocytes,12020.0,BAO_0000219,Rattus norvegicus,CHEMBL875095,,10116.0,,,D,Expert,6769.0,9.0,,3483.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619061,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3484.0,,,
Ileum,1.0,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619062,,10141.0,2116.0,,D,Intermediate,809.0,9.0,,3485.0,,,
,1.0,F,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,20033.0,BAO_0000019,Cavia porcellus,CHEMBL619063,,10141.0,,,D,Intermediate,14290.0,9.0,,3486.0,,,
Ileum,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619064,,10141.0,2116.0,,D,Intermediate,17358.0,9.0,,3487.0,,,
,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL619065,,10141.0,,,D,Intermediate,17358.0,9.0,,3488.0,,,
Ileum,1.0,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,20033.0,BAO_0000221,Cavia porcellus,CHEMBL619066,,10141.0,2116.0,,D,Intermediate,17358.0,9.0,,3489.0,,,
Ileum,1.0,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,10209.0,BAO_0000221,,CHEMBL619775,,,2116.0,,H,Autocuration,17386.0,8.0,,3490.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619776,,,,,H,Autocuration,3269.0,8.0,,3491.0,,,
,1.0,B,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841.0,BAO_0000224,Cavia porcellus,CHEMBL619777,,10141.0,,,H,Autocuration,7721.0,4.0,,3492.0,,,
,1.0,B,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,104841.0,BAO_0000224,Cavia porcellus,CHEMBL619778,,10141.0,,,H,Autocuration,7721.0,4.0,,3493.0,,,
Ileum,1.0,B,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,104841.0,BAO_0000221,Cavia porcellus,CHEMBL619779,,10141.0,2116.0,,H,Autocuration,9117.0,4.0,,3494.0,,,
,1.0,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841.0,BAO_0000224,Cavia porcellus,CHEMBL619780,,10141.0,,,H,Autocuration,7721.0,4.0,,3495.0,,,
,1.0,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,104841.0,BAO_0000224,Cavia porcellus,CHEMBL619166,,10141.0,,,H,Autocuration,7721.0,4.0,,3496.0,,,
,1.0,F,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841.0,BAO_0000019,Cavia porcellus,CHEMBL619167,,10141.0,,,H,Autocuration,15796.0,4.0,,3497.0,,,
,1.0,F,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,104841.0,BAO_0000019,Cavia porcellus,CHEMBL619168,,10141.0,,,H,Autocuration,15796.0,4.0,,3498.0,,,
Cardiac atrium,1.0,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,168.0,BAO_0000219,Homo sapiens,CHEMBL619169,,9606.0,2081.0,,D,Expert,15650.0,9.0,,3499.0,,,
Cardiac atrium,1.0,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,168.0,BAO_0000219,Homo sapiens,CHEMBL619170,,9606.0,2081.0,,D,Expert,15650.0,9.0,,3500.0,,,
,1.0,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,104841.0,BAO_0000019,Homo sapiens,CHEMBL619171,,9606.0,,,D,Autocuration,6866.0,5.0,,3501.0,,,
Cardiac atrium,1.0,F,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,168.0,BAO_0000219,Homo sapiens,CHEMBL619172,,9606.0,2081.0,,D,Expert,15650.0,9.0,,3502.0,,,
,1.0,B,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,22226.0,BAO_0000019,Mus musculus,CHEMBL619173,,10090.0,,,U,Autocuration,10063.0,0.0,,3503.0,,,
,1.0,B,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,22226.0,BAO_0000019,Mus musculus,CHEMBL619174,,10090.0,,,U,Autocuration,12665.0,0.0,,3504.0,,,
,1.0,B,5-hydroxytryptamine receptor binding affinity was determined in rats,,,104705.0,BAO_0000019,,CHEMBL619175,,,,,H,Autocuration,7504.0,4.0,,3505.0,,,
,1.0,B,Binding affinity at rat 5-hydroxytryptamine receptor.,,,104705.0,BAO_0000224,,CHEMBL619176,,,,,H,Autocuration,7504.0,4.0,,3506.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,104705.0,BAO_0000019,,CHEMBL619177,,,,,H,Autocuration,7038.0,4.0,,3507.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,104705.0,BAO_0000224,,CHEMBL619178,,,,,H,Autocuration,7626.0,4.0,,3508.0,,,
,1.0,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,104705.0,BAO_0000224,,CHEMBL619179,,,,,H,Autocuration,7626.0,4.0,,3509.0,,,
Stomach,1.0,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,104705.0,BAO_0000019,,CHEMBL619180,,,945.0,,H,Autocuration,7185.0,4.0,,3510.0,,,
Stomach,1.0,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,104705.0,BAO_0000019,,CHEMBL619181,,,945.0,,H,Autocuration,7185.0,4.0,,3511.0,,,
,1.0,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,104705.0,BAO_0000019,,CHEMBL619182,,,,,H,Autocuration,7185.0,4.0,,3512.0,,,
,1.0,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,104705.0,BAO_0000224,,CHEMBL619183,,,,,H,Autocuration,6960.0,4.0,,3513.0,,,
,1.0,B,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,104705.0,BAO_0000224,,CHEMBL619184,,,,,H,Autocuration,6960.0,4.0,,3514.0,,,
Hippocampus,1.0,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10576.0,BAO_0000221,,CHEMBL619185,,,10000000.0,,H,Autocuration,12416.0,8.0,,3515.0,,,
,1.0,B,Binding affinity for rat 5-hydroxytryptamine transporter.,,,12198.0,BAO_0000357,,CHEMBL619186,,,,,H,Expert,15753.0,8.0,,3516.0,,,
,1.0,B,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,104705.0,BAO_0000019,,CHEMBL619187,,,,,H,Autocuration,8062.0,4.0,,3517.0,,,
,1.0,B,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,104705.0,BAO_0000019,Rattus norvegicus,CHEMBL619188,,10116.0,,,D,Autocuration,9036.0,5.0,,3518.0,,,
,1.0,B,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,104705.0,BAO_0000224,Rattus norvegicus,CHEMBL619189,,10116.0,,,D,Autocuration,15067.0,5.0,,3519.0,,,
Brain,1.0,F,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,12198.0,BAO_0000019,Rattus norvegicus,CHEMBL619190,,10116.0,955.0,,D,Expert,15753.0,9.0,,3520.0,,,
Cerebellum,1.0,F,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,12198.0,BAO_0000221,Rattus norvegicus,CHEMBL619191,,10116.0,2037.0,,D,Expert,15753.0,9.0,,3521.0,,,
,1.0,B,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,104705.0,BAO_0000019,Rattus norvegicus,CHEMBL619192,,10116.0,,,D,Autocuration,15295.0,5.0,,3522.0,,,
,1.0,B,Percent binding affinity against 5-hydroxytryptamine receptor,,,104705.0,BAO_0000224,Rattus norvegicus,CHEMBL619193,,10116.0,,,D,Autocuration,6347.0,5.0,,3523.0,,,
,1.0,B,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,22226.0,BAO_0000019,,CHEMBL619194,,,,,U,Autocuration,6763.0,0.0,,3524.0,,,
,1.0,B,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,104705.0,BAO_0000224,Rattus norvegicus,CHEMBL619195,,10116.0,,,D,Autocuration,12092.0,5.0,,3525.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine receptor was determined,,,104705.0,BAO_0000224,Rattus norvegicus,CHEMBL619196,,10116.0,,,D,Autocuration,1579.0,5.0,,3526.0,,,
Stomach,1.0,B,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,104705.0,BAO_0000019,Rattus norvegicus,CHEMBL619197,,10116.0,945.0,,D,Autocuration,1579.0,5.0,,3527.0,,,
,1.0,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121.0,BAO_0000219,Homo sapiens,CHEMBL619198,In vitro,9606.0,,,D,Expert,5963.0,9.0,,3528.0,,,
,1.0,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,121.0,BAO_0000219,Homo sapiens,CHEMBL875081,In vitro,9606.0,,,D,Expert,5963.0,9.0,,3529.0,,,
,1.0,B,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,18065.0,BAO_0000357,,CHEMBL884712,,,,,H,Autocuration,5030.0,8.0,,3530.0,,,
,1.0,B,Inhibition of 5-hydroxytryptamine reuptake,,,121.0,BAO_0000357,,CHEMBL884710,,,,,H,Expert,15796.0,8.0,,3531.0,,,
,1.0,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,18065.0,BAO_0000019,,CHEMBL619199,,,,,H,Autocuration,15413.0,8.0,,3532.0,,,
,1.0,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,18065.0,BAO_0000019,,CHEMBL619200,,,,,H,Autocuration,15413.0,8.0,,3533.0,,,
,1.0,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,18065.0,BAO_0000019,,CHEMBL619201,,,,,H,Autocuration,15413.0,8.0,,3534.0,,,
,1.0,F,Tested for 5-hydroxytryptamine receptor uptake,,,18065.0,BAO_0000019,,CHEMBL619202,,,,,H,Autocuration,12409.0,8.0,,3535.0,,,
,1.0,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHO,51.0,BAO_0000219,Homo sapiens,CHEMBL619203,,9606.0,,,D,Expert,16909.0,9.0,449.0,3536.0,,,
,1.0,F,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,51.0,BAO_0000019,Homo sapiens,CHEMBL619204,,9606.0,,,D,Expert,16909.0,9.0,,3537.0,,,
,1.0,B,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,10576.0,BAO_0000249,Homo sapiens,CHEMBL619205,,9606.0,,,H,Autocuration,15629.0,8.0,,3538.0,,,
,1.0,B,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,10576.0,BAO_0000357,,CHEMBL619206,,,,,H,Autocuration,15629.0,8.0,,3539.0,,,
,1.0,B,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,10576.0,BAO_0000249,,CHEMBL619207,,,,,H,Expert,15629.0,8.0,,3540.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619208,,,2435.0,,H,Autocuration,10034.0,8.0,,3541.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619209,,,2435.0,,H,Autocuration,10034.0,8.0,,3542.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619210,,,2435.0,,H,Autocuration,10034.0,8.0,,3543.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619211,,,2435.0,,H,Autocuration,10034.0,8.0,,3544.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619212,,,2435.0,,H,Autocuration,10034.0,8.0,,3545.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620681,,,2435.0,,H,Autocuration,10034.0,8.0,,3546.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620682,,,2435.0,,H,Autocuration,10034.0,8.0,,3547.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620683,,,2435.0,,H,Autocuration,10034.0,8.0,,3548.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620684,,,2435.0,,H,Autocuration,10034.0,8.0,,3549.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620685,,,2435.0,,H,Autocuration,10034.0,8.0,,3550.0,,,
Striatum,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620686,,,2435.0,,H,Autocuration,10034.0,8.0,,3551.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620687,,,349.0,,H,Autocuration,10034.0,8.0,,3552.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620688,,,349.0,,H,Autocuration,10034.0,8.0,,3553.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620689,,,349.0,,H,Autocuration,10034.0,8.0,,3554.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620690,,,349.0,,H,Autocuration,10034.0,8.0,,3555.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620691,,,349.0,,H,Autocuration,10034.0,8.0,,3556.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620692,,,349.0,,H,Autocuration,10034.0,8.0,,3557.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,10825.0,BAO_0000019,,CHEMBL620693,,,349.0,,H,Autocuration,10034.0,8.0,,3558.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620694,,,,,H,Expert,1274.0,8.0,,3559.0,,,
,1.0,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,168.0,BAO_0000019,,CHEMBL857986,,,,,H,Autocuration,17358.0,8.0,,3560.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,168.0,BAO_0000357,,CHEMBL620695,,,,,H,Autocuration,14532.0,8.0,,3561.0,,,
,1.0,B,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620696,,,,,H,Expert,16989.0,8.0,,3562.0,,,
,1.0,B,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,168.0,BAO_0000357,,CHEMBL620697,,,,,H,Autocuration,17200.0,8.0,,3563.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,168.0,BAO_0000357,,CHEMBL620698,,,,,H,Autocuration,15779.0,8.0,,3564.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168.0,BAO_0000357,,CHEMBL620699,,,,,H,Autocuration,15779.0,8.0,,3565.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,168.0,BAO_0000357,,CHEMBL620700,,,,,H,Autocuration,15779.0,8.0,,3566.0,,,
,1.0,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,COS-7,168.0,BAO_0000219,,CHEMBL620701,,,,,H,Autocuration,15650.0,8.0,643.0,3567.0,,,
,1.0,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,COS-7,168.0,BAO_0000219,,CHEMBL875082,,,,,H,Autocuration,15650.0,8.0,643.0,3568.0,,,
,1.0,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,COS-7,168.0,BAO_0000219,,CHEMBL620702,,,,,H,Autocuration,15650.0,8.0,643.0,3569.0,,,
,1.0,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,COS-7,168.0,BAO_0000219,,CHEMBL620703,,,,,H,Autocuration,15650.0,8.0,643.0,3570.0,,,
,1.0,B,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,C6,168.0,BAO_0000219,,CHEMBL620704,,,,,H,Autocuration,17046.0,8.0,673.0,3571.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,C6,168.0,BAO_0000219,,CHEMBL620705,,,,,H,Expert,17046.0,8.0,673.0,3572.0,,,
,1.0,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,C6,168.0,BAO_0000219,,CHEMBL620706,,,,,H,Expert,15650.0,8.0,673.0,3573.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,C6,168.0,BAO_0000219,,CHEMBL620707,,,,,H,Expert,17046.0,8.0,673.0,3574.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,10624.0,BAO_0000357,,CHEMBL620708,,,,,H,Expert,17066.0,8.0,,3575.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,105.0,BAO_0000357,,CHEMBL620709,,,,,H,Autocuration,17200.0,8.0,,3576.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL620710,,9606.0,,,D,Expert,16146.0,9.0,,3577.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,CHO,10624.0,BAO_0000219,,CHEMBL620711,,,,,H,Autocuration,15250.0,8.0,449.0,3578.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL620712,,9606.0,,,D,Expert,6491.0,9.0,,3579.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL620713,,9606.0,,,D,Expert,17066.0,9.0,,3580.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL620714,,9606.0,,,D,Expert,17066.0,9.0,,3581.0,,,
,1.0,B,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL620715,,9606.0,,,D,Expert,4234.0,9.0,,3582.0,,,
,1.0,B,Binding affinity towards 5-HT5A receptor,,,10624.0,BAO_0000357,,CHEMBL620716,,,,,H,Autocuration,6013.0,8.0,,3583.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10624.0,BAO_0000357,,CHEMBL620717,,,,,H,Expert,17175.0,8.0,,3584.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,,CHEMBL618072,,,,,H,Autocuration,15818.0,8.0,,3585.0,,,
,1.0,B,Binding affinity towards cloned human 5-HT5A receptor was determined,,,10624.0,BAO_0000357,,CHEMBL857987,,,,,H,Autocuration,6166.0,8.0,,3586.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,10624.0,BAO_0000219,,CHEMBL618073,,,,,H,Autocuration,15779.0,8.0,722.0,3587.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,HEK293,10624.0,BAO_0000219,,CHEMBL618074,,,,,H,Autocuration,15779.0,8.0,722.0,3588.0,,,
,1.0,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,HEK293,10624.0,BAO_0000219,,CHEMBL618075,,,,,H,Autocuration,5213.0,8.0,722.0,3589.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,10625.0,BAO_0000357,Mus musculus,CHEMBL618076,,10090.0,,,D,Expert,17066.0,9.0,,3590.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10625.0,BAO_0000357,Mus musculus,CHEMBL618077,,10090.0,,,D,Expert,17066.0,9.0,,3591.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,10625.0,BAO_0000357,Mus musculus,CHEMBL618078,,10090.0,,,D,Expert,17066.0,9.0,,3592.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,10625.0,BAO_0000357,Mus musculus,CHEMBL881821,,10090.0,,,D,Expert,17066.0,9.0,,3593.0,,,
,1.0,B,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,10625.0,BAO_0000357,Mus musculus,CHEMBL618079,,10090.0,,,D,Expert,17066.0,9.0,,3594.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,10625.0,BAO_0000357,,CHEMBL618080,,,,,H,Expert,17175.0,8.0,,3595.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,HEK293,10576.0,BAO_0000219,,CHEMBL618081,,,,,H,Autocuration,16190.0,8.0,722.0,3596.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,HEK293,10626.0,BAO_0000219,,CHEMBL618082,,,,,H,Autocuration,16190.0,8.0,722.0,3597.0,,,
,1.0,B,Binding affinity towards 5-HT5a receptor,,,10624.0,BAO_0000357,,CHEMBL618083,,,,,H,Expert,4820.0,8.0,,3598.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,Homo sapiens,CHEMBL618084,,9606.0,,,D,Expert,17066.0,9.0,,3599.0,,,
,1.0,B,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,,CHEMBL618085,,,,,H,Expert,17066.0,8.0,,3600.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,10624.0,BAO_0000357,,CHEMBL618086,,,,,H,Expert,17175.0,8.0,,3601.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,,CHEMBL875092,,,,,H,Autocuration,16633.0,8.0,,3602.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,10624.0,BAO_0000357,,CHEMBL618087,,,,,H,Autocuration,16633.0,8.0,,3603.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,10624.0,BAO_0000357,,CHEMBL872926,,,,,H,Autocuration,16700.0,8.0,,3604.0,,,
,1.0,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,104714.0,BAO_0000019,Cavia porcellus,CHEMBL618088,,10141.0,,,H,Autocuration,4639.0,4.0,,3605.0,,,
,1.0,B,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,104714.0,BAO_0000223,,CHEMBL618089,,,,,H,Autocuration,5486.0,4.0,,3606.0,,,
,1.0,B,Inhibition of human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618090,,9606.0,,,D,Expert,16146.0,9.0,,3607.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618091,,9606.0,,,D,Expert,17273.0,9.0,,3608.0,,,
,1.0,B,Inhibition against human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL618092,,,,,H,Autocuration,17687.0,8.0,,3609.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618093,,9606.0,,,D,Expert,6491.0,9.0,,3610.0,,,
,1.0,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,HeLa,10627.0,BAO_0000219,,CHEMBL618094,,,,,H,Expert,16190.0,8.0,308.0,3611.0,,,
,1.0,B,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618095,,9606.0,,,D,Expert,17066.0,9.0,,3612.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL875093,,9606.0,,,D,Expert,17066.0,9.0,,3613.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618096,,9606.0,,,D,Expert,17066.0,9.0,,3614.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618118,,9606.0,,,D,Expert,17066.0,9.0,,3615.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618119,,9606.0,,,D,Expert,3555.0,9.0,,3616.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL618120,,,,,H,Expert,5808.0,8.0,,3617.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL618121,,,,,H,Autocuration,6013.0,8.0,,3618.0,,,
,1.0,B,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,HEK293,10627.0,BAO_0000219,,CHEMBL618122,,,,,H,Expert,15818.0,8.0,722.0,3619.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,10627.0,BAO_0000357,,CHEMBL618123,,,,,H,Autocuration,16209.0,8.0,,3620.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,HEK293,10627.0,BAO_0000219,,CHEMBL618124,,,,,H,Expert,3935.0,8.0,722.0,3621.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL618125,,,,,H,Autocuration,15818.0,8.0,,3622.0,,,
,1.0,B,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,HEK293,10627.0,BAO_0000219,Homo sapiens,CHEMBL618126,,9606.0,,,D,Expert,3805.0,9.0,722.0,3623.0,,,
,1.0,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,10627.0,BAO_0000019,,CHEMBL618236,,,,,H,Expert,16441.0,8.0,,3624.0,,,
,1.0,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10627.0,BAO_0000019,,CHEMBL618237,,,,,H,Expert,16441.0,8.0,,3625.0,,,
,1.0,B,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,COS-7,10627.0,BAO_0000219,,CHEMBL618238,,,,,H,Expert,6786.0,8.0,643.0,3626.0,,,
,1.0,B,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL618239,,9606.0,,,D,Expert,4234.0,9.0,,3627.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000019,,CHEMBL618240,,,,,H,Autocuration,17085.0,8.0,,3628.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,10627.0,BAO_0000357,,CHEMBL618241,,,,,H,Autocuration,17200.0,8.0,,3629.0,,,
,1.0,B,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,HEK293,10627.0,BAO_0000219,,CHEMBL859399,,,,,H,Autocuration,17451.0,8.0,722.0,3630.0,,,
,1.0,F,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,10627.0,BAO_0000019,,CHEMBL618242,,,,,H,Autocuration,3935.0,8.0,,3631.0,,,
,1.0,B,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL857991,,,,,H,Autocuration,5033.0,8.0,,3632.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL619951,,,,,H,Expert,4540.0,8.0,,3633.0,,,
,1.0,B,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,HeLa,10627.0,BAO_0000219,Homo sapiens,CHEMBL619952,,9606.0,,,D,Expert,4540.0,9.0,308.0,3634.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,HeLa,10627.0,BAO_0000219,Homo sapiens,CHEMBL619953,,9606.0,,,D,Expert,4540.0,9.0,308.0,3635.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,HeLa,10627.0,BAO_0000219,,CHEMBL619954,,,,,H,Autocuration,17296.0,8.0,308.0,3636.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,HeLa,10627.0,BAO_0000219,,CHEMBL619955,,,,,H,Autocuration,17296.0,8.0,308.0,3637.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,HeLa,10627.0,BAO_0000219,,CHEMBL619956,,,,,H,Autocuration,17296.0,8.0,308.0,3638.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHO,10627.0,BAO_0000219,,CHEMBL619957,,,,,H,Autocuration,15779.0,8.0,449.0,3639.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,HEK293,10627.0,BAO_0000219,,CHEMBL619958,,,,,H,Autocuration,15779.0,8.0,722.0,3640.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,HEK293,10627.0,BAO_0000219,,CHEMBL620627,,,,,H,Autocuration,15779.0,8.0,722.0,3641.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,HEK293,10627.0,BAO_0000219,,CHEMBL620628,,,,,H,Autocuration,15779.0,8.0,722.0,3642.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,HeLa,10627.0,BAO_0000219,,CHEMBL620629,,,,,H,Autocuration,15779.0,8.0,308.0,3643.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620630,,,,,H,Autocuration,6166.0,8.0,,3644.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,HeLa,10627.0,BAO_0000219,,CHEMBL620782,,,,,H,Autocuration,17451.0,8.0,308.0,3645.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620783,,,,,H,Autocuration,15316.0,8.0,,3646.0,,,
,1.0,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620784,,,,,H,Expert,4199.0,8.0,,3647.0,,,
,1.0,B,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,HeLa,10627.0,BAO_0000219,,CHEMBL620785,,,,,H,Expert,15146.0,8.0,308.0,3648.0,,,
,1.0,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,10627.0,BAO_0000357,,CHEMBL857992,,,,,H,Autocuration,5213.0,8.0,,3649.0,,,
,1.0,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,10627.0,BAO_0000219,,CHEMBL620786,,,,,H,Autocuration,16429.0,8.0,,3650.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,HeLa,10627.0,BAO_0000219,,CHEMBL620787,,,,,H,Autocuration,14818.0,8.0,308.0,3651.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,HeLa,10627.0,BAO_0000219,,CHEMBL620788,,,,,H,Autocuration,4829.0,8.0,308.0,3652.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,HeLa,10627.0,BAO_0000219,,CHEMBL620789,,,,,H,Autocuration,4829.0,8.0,308.0,3653.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,HeLa,10627.0,BAO_0000219,,CHEMBL620790,,,,,H,Autocuration,4829.0,8.0,308.0,3654.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,CHO,10628.0,BAO_0000219,,CHEMBL620791,,,,,H,Autocuration,15250.0,8.0,449.0,3655.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,10628.0,BAO_0000019,,CHEMBL620792,,,,,H,Autocuration,14423.0,8.0,,3656.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,10628.0,BAO_0000357,,CHEMBL620793,,,,,H,Autocuration,15086.0,8.0,,3657.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,10628.0,BAO_0000357,,CHEMBL620794,,,,,H,Autocuration,4342.0,8.0,,3658.0,,,
,1.0,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,HeLa,10627.0,BAO_0000219,Homo sapiens,CHEMBL620795,,9606.0,,,D,Autocuration,16190.0,9.0,308.0,3659.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620796,,,,,H,Expert,4820.0,8.0,,3660.0,,,
,1.0,B,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,10627.0,BAO_0000357,,CHEMBL620797,,,,,H,Autocuration,4639.0,8.0,,3661.0,,,
,1.0,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627.0,BAO_0000019,Homo sapiens,CHEMBL620798,,9606.0,,,D,Expert,17066.0,9.0,,3662.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,10627.0,BAO_0000357,,CHEMBL620799,,,,,H,Autocuration,6011.0,8.0,,3663.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620800,,,,,H,Expert,17066.0,8.0,,3664.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,10627.0,BAO_0000357,,CHEMBL620801,,,,,H,Autocuration,17515.0,8.0,,3665.0,,,
,1.0,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL875100,,,,,H,Autocuration,5014.0,8.0,,3666.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,10627.0,BAO_0000357,,CHEMBL620802,,,,,H,Autocuration,4373.0,8.0,,3667.0,,,
,1.0,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000019,,CHEMBL620803,,,,,H,Expert,17066.0,8.0,,3668.0,,,
,1.0,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,10627.0,BAO_0000019,,CHEMBL620804,,,,,H,Expert,17066.0,8.0,,3669.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,10627.0,BAO_0000357,,CHEMBL620805,,,,,H,Autocuration,4373.0,8.0,,3670.0,,,
,1.0,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620806,,,,,H,Autocuration,4687.0,8.0,,3671.0,,,
,1.0,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,10627.0,BAO_0000357,,CHEMBL620807,,,,,H,Autocuration,16946.0,8.0,,3672.0,,,
,1.0,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,10627.0,BAO_0000357,,CHEMBL620808,,,,,H,Autocuration,16946.0,8.0,,3673.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620809,,,,,H,Autocuration,16633.0,8.0,,3674.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620810,,,,,H,Autocuration,16633.0,8.0,,3675.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,Homo sapiens,CHEMBL620811,,9606.0,,,D,Expert,17066.0,9.0,,3676.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,10627.0,BAO_0000357,,CHEMBL620812,,,,,H,Autocuration,16700.0,8.0,,3677.0,,,
,1.0,B,Affinity against 5-hydroxytryptamine 6 receptor,,,10627.0,BAO_0000357,,CHEMBL620813,,,,,H,Autocuration,3269.0,8.0,,3678.0,,,
,1.0,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,10627.0,BAO_0000357,,CHEMBL620814,,,,,H,Autocuration,5486.0,8.0,,3679.0,,,
,1.0,B,Inhibition of human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620815,,9606.0,,,D,Expert,16146.0,9.0,,3680.0,,,
,1.0,B,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,HEK293,10209.0,BAO_0000219,,CHEMBL620816,,,,,H,Autocuration,5014.0,8.0,722.0,3681.0,,,
,1.0,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL620817,,,,,H,Autocuration,15463.0,8.0,,3682.0,,,
,1.0,B,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,10209.0,BAO_0000357,,CHEMBL620818,,,,,H,Autocuration,3805.0,8.0,,3683.0,,,
,1.0,B,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,HEK293,10209.0,BAO_0000219,,CHEMBL620819,,,,,H,Expert,5014.0,8.0,722.0,3684.0,,,
,1.0,B,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620820,,9606.0,,,D,Expert,6491.0,9.0,,3685.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,CHO,10209.0,BAO_0000219,,CHEMBL620821,,,,,H,Autocuration,16190.0,8.0,449.0,3686.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620822,,9606.0,,,D,Expert,17066.0,9.0,,3687.0,,,
,1.0,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620823,,9606.0,,,D,Expert,17066.0,9.0,,3688.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620824,,9606.0,,,D,Expert,3555.0,9.0,,3689.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,CHO,10209.0,BAO_0000219,,CHEMBL620825,,,,,H,Expert,6588.0,8.0,449.0,3690.0,,,
,1.0,B,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,10209.0,BAO_0000357,,CHEMBL872930,,,,,H,Autocuration,15463.0,8.0,,3691.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL620826,,,,,H,Autocuration,6013.0,8.0,,3692.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,10209.0,BAO_0000357,,CHEMBL620827,,,,,H,Autocuration,16209.0,8.0,,3693.0,,,
,1.0,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL620828,,,,,H,Autocuration,3935.0,8.0,,3694.0,,,
,1.0,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL620829,,,,,H,Autocuration,15818.0,8.0,,3695.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,HEK293,10209.0,BAO_0000219,,CHEMBL620830,,,,,H,Expert,5014.0,8.0,722.0,3696.0,,,
,1.0,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,10209.0,BAO_0000019,,CHEMBL620831,,,,,H,Expert,16441.0,8.0,,3697.0,,,
,1.0,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,10209.0,BAO_0000019,,CHEMBL620832,,,,,H,Expert,16441.0,8.0,,3698.0,,,
,1.0,B,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL621548,,9606.0,,,D,Expert,4234.0,9.0,,3699.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000019,,CHEMBL621549,,,,,H,Autocuration,17085.0,8.0,,3700.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,10209.0,BAO_0000357,,CHEMBL621550,,,,,H,Autocuration,17200.0,8.0,,3701.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,CHO,10209.0,BAO_0000219,,CHEMBL621551,,,,,H,Autocuration,17451.0,8.0,449.0,3702.0,,,
,1.0,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,10209.0,BAO_0000019,,CHEMBL621552,,,,,H,Autocuration,17085.0,8.0,,3703.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL857077,,,,,H,Autocuration,5104.0,8.0,,3704.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,10209.0,BAO_0000357,,CHEMBL618158,,,,,H,Autocuration,5104.0,8.0,,3705.0,,,
,1.0,B,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,COS-7,10209.0,BAO_0000219,Homo sapiens,CHEMBL618159,,9606.0,,,D,Expert,5033.0,9.0,643.0,3706.0,,,
,1.0,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,COS-7,10209.0,BAO_0000219,,CHEMBL875101,,,,,H,Autocuration,5486.0,8.0,643.0,3707.0,,,
,1.0,B,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,HEK293,10209.0,BAO_0000219,Homo sapiens,CHEMBL618160,,9606.0,,,D,Expert,4540.0,9.0,722.0,3708.0,,,
,1.0,B,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,10209.0,BAO_0000357,,CHEMBL618161,,,,,H,Expert,6166.0,8.0,,3709.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,HEK293,10209.0,BAO_0000219,,CHEMBL618162,,,,,H,Expert,17342.0,8.0,722.0,3710.0,,,
,1.0,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,10209.0,BAO_0000357,,CHEMBL618163,,,,,H,Expert,17342.0,8.0,,3711.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,10209.0,BAO_0000357,,CHEMBL618164,,,,,H,Autocuration,17296.0,8.0,,3712.0,,,
,1.0,B,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,10209.0,BAO_0000219,,CHEMBL618165,,,,,H,Expert,16429.0,8.0,,3713.0,,,
,1.0,B,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,HEK293,10209.0,BAO_0000219,,CHEMBL618166,,,,,H,Autocuration,15779.0,8.0,722.0,3714.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209.0,BAO_0000219,,CHEMBL857989,,,,,H,Autocuration,15779.0,8.0,722.0,3715.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209.0,BAO_0000219,,CHEMBL619888,,,,,H,Autocuration,15779.0,8.0,722.0,3716.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209.0,BAO_0000219,,CHEMBL619889,,,,,H,Autocuration,15779.0,8.0,722.0,3717.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,HEK293,10209.0,BAO_0000219,,CHEMBL619890,,,,,H,Autocuration,15779.0,8.0,722.0,3718.0,,,
,1.0,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,CHO,10209.0,BAO_0000219,,CHEMBL619891,,,,,H,Autocuration,17451.0,8.0,449.0,3719.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,HEK293,10209.0,BAO_0000219,,CHEMBL619892,,,,,H,Autocuration,4199.0,8.0,722.0,3720.0,,,
,1.0,B,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,HEK293,10209.0,BAO_0000219,,CHEMBL619893,,,,,D,Expert,4199.0,9.0,722.0,3721.0,,,
,1.0,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,HEK293,10209.0,BAO_0000219,,CHEMBL619894,,,,,H,Autocuration,4199.0,8.0,722.0,3722.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,HEK293,10209.0,BAO_0000219,,CHEMBL619895,,,,,D,Intermediate,3680.0,9.0,722.0,3723.0,,,
,1.0,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,10209.0,BAO_0000357,,CHEMBL619896,,,,,D,Intermediate,3680.0,9.0,,3724.0,,,
,1.0,B,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,COS-7,10209.0,BAO_0000219,,CHEMBL619897,,,,,H,Autocuration,15316.0,8.0,643.0,3725.0,,,
,1.0,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,HEK293,10209.0,BAO_0000219,,CHEMBL619898,,,,,H,Autocuration,15146.0,8.0,722.0,3726.0,,,
,1.0,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,HEK293,10209.0,BAO_0000219,,CHEMBL619899,,,,,H,Expert,5213.0,8.0,722.0,3727.0,,,
,1.0,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,HEK293,10209.0,BAO_0000219,,CHEMBL619900,,,,,H,Autocuration,5213.0,8.0,722.0,3728.0,,,
,1.0,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,HEK293,10209.0,BAO_0000219,Homo sapiens,CHEMBL619901,,9606.0,,,D,Expert,14818.0,9.0,722.0,3729.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,HEK293,10209.0,BAO_0000219,,CHEMBL620580,,,,,H,Autocuration,14818.0,8.0,722.0,3730.0,,,
,1.0,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,HEK293,10209.0,BAO_0000219,,CHEMBL620581,,,,,H,Autocuration,14818.0,8.0,722.0,3731.0,,,
,1.0,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,HEK293,10209.0,BAO_0000219,,CHEMBL620733,,,,,H,Autocuration,4829.0,8.0,722.0,3732.0,,,
,1.0,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL620734,,9606.0,,,D,Autocuration,17200.0,9.0,,3733.0,,,
,1.0,B,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,10022.0,BAO_0000357,Mus musculus,CHEMBL620735,,10090.0,,,D,Expert,17066.0,9.0,,3734.0,,,
,1.0,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,10209.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL620736,,9986.0,,,H,Autocuration,14025.0,8.0,,3735.0,,,
,1.0,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,CHO,11923.0,BAO_0000219,,CHEMBL620737,,,,,H,Autocuration,15250.0,8.0,449.0,3736.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620738,,,,,H,Autocuration,16372.0,8.0,449.0,3737.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620739,,,,,H,Autocuration,16372.0,8.0,449.0,3738.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620740,,,,,H,Autocuration,16372.0,8.0,449.0,3739.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,CHO,11923.0,BAO_0000219,,CHEMBL620741,,,,,H,Autocuration,16372.0,8.0,449.0,3740.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,CHO,11923.0,BAO_0000219,,CHEMBL620742,,,,,H,Autocuration,16372.0,8.0,449.0,3741.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,CHO,11923.0,BAO_0000219,,CHEMBL620743,,,,,H,Autocuration,16372.0,8.0,449.0,3742.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620744,,,,,H,Autocuration,16372.0,8.0,449.0,3743.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620745,,,,,H,Autocuration,16372.0,8.0,449.0,3744.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,CHO,11923.0,BAO_0000219,,CHEMBL620746,,,,,H,Autocuration,16372.0,8.0,449.0,3745.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,CHO,11923.0,BAO_0000219,,CHEMBL620747,,,,,H,Autocuration,16372.0,8.0,449.0,3746.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,CHO,11923.0,BAO_0000219,,CHEMBL620748,,,,,H,Autocuration,16372.0,8.0,449.0,3747.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,CHO,11923.0,BAO_0000219,,CHEMBL620749,,,,,H,Autocuration,16372.0,8.0,449.0,3748.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,11923.0,BAO_0000357,,CHEMBL620750,,,,,H,Expert,17066.0,8.0,,3749.0,,,
,1.0,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,11923.0,BAO_0000357,Rattus norvegicus,CHEMBL620751,,10116.0,,,D,Expert,17066.0,9.0,,3750.0,,,
,1.0,B,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,11923.0,BAO_0000357,,CHEMBL620752,,,,,H,Expert,17386.0,8.0,,3751.0,,,
,1.0,B,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,11923.0,BAO_0000019,,CHEMBL872929,,,,,H,Autocuration,14423.0,8.0,,3752.0,,,
,1.0,B,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,11923.0,BAO_0000357,Rattus norvegicus,CHEMBL620753,,10116.0,,,D,Expert,15874.0,9.0,,3753.0,,,
,1.0,B,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,11923.0,BAO_0000357,Rattus norvegicus,CHEMBL620754,,10116.0,,,D,Expert,15874.0,9.0,,3754.0,,,
,1.0,B,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,CHO,11923.0,BAO_0000219,Rattus norvegicus,CHEMBL620755,,10116.0,,,D,Expert,16372.0,9.0,449.0,3755.0,,,
,1.0,B,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,11923.0,BAO_0000357,,CHEMBL620756,,,,,H,Autocuration,4622.0,8.0,,3756.0,,,
,1.0,B,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,11923.0,BAO_0000357,,CHEMBL620757,,,,,H,Autocuration,15086.0,8.0,,3757.0,,,
,1.0,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,CHO,11923.0,BAO_0000219,,CHEMBL620758,,,,,H,Autocuration,16372.0,8.0,449.0,3758.0,,,
,1.0,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,CHO,11923.0,BAO_0000219,,CHEMBL620759,,,,,H,Autocuration,16372.0,8.0,449.0,3759.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,CHO,11923.0,BAO_0000219,,CHEMBL620760,,,,,H,Autocuration,16372.0,8.0,449.0,3760.0,,,
,1.0,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,CHO,11923.0,BAO_0000219,,CHEMBL620761,,,,,H,Autocuration,16372.0,8.0,449.0,3761.0,,,
Ileum,1.0,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,11923.0,BAO_0000221,,CHEMBL620762,,,2116.0,,H,Autocuration,17386.0,8.0,,3762.0,,,
Ileum,1.0,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,11923.0,BAO_0000221,,CHEMBL620763,,,2116.0,,H,Autocuration,17386.0,8.0,,3763.0,,,
Ileum,1.0,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,11923.0,BAO_0000221,,CHEMBL620764,,,2116.0,,H,Autocuration,17386.0,8.0,,3764.0,,,
,1.0,B,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,11923.0,BAO_0000249,Rattus norvegicus,CHEMBL857990,,10116.0,,,D,Expert,5831.0,9.0,,3765.0,Membranes,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,11923.0,BAO_0000357,,CHEMBL620765,,,,,H,Autocuration,4342.0,8.0,,3766.0,,,
,1.0,B,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,11923.0,BAO_0000357,,CHEMBL620766,,,,,H,Expert,17319.0,8.0,,3767.0,,,
Hypothalamus,1.0,B,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,11923.0,BAO_0000019,,CHEMBL620767,,,1898.0,,H,Expert,17342.0,8.0,,3768.0,,,
,1.0,B,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,11923.0,BAO_0000357,,CHEMBL620768,,,,,H,Autocuration,17342.0,8.0,,3769.0,,,
Hypothalamus,1.0,B,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,11923.0,BAO_0000249,,CHEMBL619051,,,1898.0,,H,Expert,3680.0,8.0,,3770.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,11923.0,BAO_0000357,,CHEMBL619052,,,,,H,Expert,3680.0,8.0,,3771.0,,,
,1.0,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,HEK293,11923.0,BAO_0000219,Rattus norvegicus,CHEMBL619053,,10116.0,,,D,Expert,17319.0,9.0,722.0,3772.0,,,
,1.0,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,HEK293,11923.0,BAO_0000219,Rattus norvegicus,CHEMBL619703,,10116.0,,,D,Expert,17319.0,9.0,722.0,3773.0,,,
,1.0,F,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,HEK293,11923.0,BAO_0000219,Rattus norvegicus,CHEMBL619704,,10116.0,,,D,Autocuration,17319.0,9.0,722.0,3774.0,,,
,1.0,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619851,,,,,H,Expert,4820.0,8.0,,3775.0,,,
,1.0,B,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,10209.0,BAO_0000357,,CHEMBL619852,,,,,H,Autocuration,4639.0,8.0,,3776.0,,,
,1.0,B,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,10209.0,BAO_0000357,,CHEMBL619853,,,,,H,Autocuration,6011.0,8.0,,3777.0,,,
,1.0,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,Homo sapiens,CHEMBL619854,,9606.0,,,D,Expert,17066.0,9.0,,3778.0,,,
,1.0,B,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619855,,,,,H,Expert,17066.0,8.0,,3779.0,,,
,1.0,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,10209.0,BAO_0000357,,CHEMBL619856,,,,,H,Autocuration,17515.0,8.0,,3780.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,10209.0,BAO_0000357,,CHEMBL619857,,,,,H,Autocuration,4373.0,8.0,,3781.0,,,
,1.0,F,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,10209.0,BAO_0000019,,CHEMBL619858,,,,,H,Expert,17066.0,8.0,,3782.0,,,
,1.0,B,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,10209.0,BAO_0000357,,CHEMBL619859,,,,,H,Autocuration,4373.0,8.0,,3783.0,,,
,1.0,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,10209.0,BAO_0000357,,CHEMBL619860,,,,,H,Autocuration,4373.0,8.0,,3784.0,,,
,1.0,B,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619861,,,,,H,Autocuration,4687.0,8.0,,3785.0,,,
,1.0,B,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619862,,,,,H,Expert,17342.0,8.0,,3786.0,,,
,1.0,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,10209.0,BAO_0000357,,CHEMBL619863,,,,,H,Autocuration,16946.0,8.0,,3787.0,,,
,1.0,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,10209.0,BAO_0000357,,CHEMBL619864,,,,,H,Autocuration,16946.0,8.0,,3788.0,,,
,1.0,B,Binding affinities against 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL872928,,,,,H,Autocuration,16633.0,8.0,,3789.0,,,
,1.0,B,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619865,,,,,H,Autocuration,16633.0,8.0,,3790.0,,,
,1.0,B,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,10209.0,BAO_0000357,,CHEMBL619866,,,,,H,Expert,17066.0,8.0,,3791.0,,,
,1.0,B,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,10209.0,BAO_0000357,,CHEMBL619867,,,,,H,Autocuration,16700.0,8.0,,3792.0,,,
Ileum,1.0,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,10209.0,BAO_0000221,,CHEMBL619868,,,2116.0,,H,Autocuration,17386.0,8.0,,3793.0,,,
,1.0,F,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,55.0,BAO_0000019,,CHEMBL619869,,,,,H,Autocuration,14080.0,8.0,,3794.0,,,
,1.0,F,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,55.0,BAO_0000019,Homo sapiens,CHEMBL619870,,9606.0,,,D,Expert,14080.0,9.0,,3795.0,,,
,1.0,B,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,55.0,BAO_0000357,,CHEMBL619871,,,,,H,Autocuration,409.0,8.0,,3796.0,,,
,1.0,B,In vitro inhibition of human recombinant lipoxygenase enzyme,,,55.0,BAO_0000357,,CHEMBL619872,,,,,H,Autocuration,409.0,8.0,,3797.0,,,
,1.0,B,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,55.0,BAO_0000357,,CHEMBL619873,,,,,H,Autocuration,409.0,8.0,,3798.0,,,
Blood,1.0,B,Inhibition of 5-lipoxygenase in human whole blood.,,,55.0,BAO_0000357,,CHEMBL619874,,,178.0,,H,Expert,11090.0,8.0,,3799.0,,,
Blood,1.0,B,Inhibition of 5-lipoxygenase in human whole blood.,,,55.0,BAO_0000357,,CHEMBL619875,,,178.0,,H,Expert,11090.0,8.0,,3800.0,,,
,1.0,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,55.0,BAO_0000357,,CHEMBL619876,,,,,H,Autocuration,948.0,8.0,,3801.0,,,
,1.0,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,55.0,BAO_0000357,,CHEMBL619877,,,,,H,Autocuration,948.0,8.0,,3802.0,,,
,1.0,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,55.0,BAO_0000219,,CHEMBL619878,,,,,H,Expert,13622.0,8.0,,3803.0,,,
Blood,1.0,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,55.0,BAO_0000019,,CHEMBL619879,,,178.0,,H,Autocuration,13622.0,8.0,,3804.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,55.0,BAO_0000357,,CHEMBL619880,,,,,H,Autocuration,9637.0,8.0,,3805.0,,,
,1.0,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,55.0,BAO_0000357,,CHEMBL619881,,,,,H,Autocuration,11320.0,8.0,,3806.0,,,
,1.0,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL619882,,,,,H,Expert,11320.0,8.0,,3807.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,55.0,BAO_0000357,,CHEMBL619883,,,,,H,Autocuration,6838.0,8.0,,3808.0,,,
Blood,1.0,B,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,55.0,BAO_0000357,Homo sapiens,CHEMBL619884,,9606.0,178.0,,D,Expert,17667.0,9.0,,3809.0,,,
,1.0,B,In vitro potency against human 5-Lipoxygenase,,,55.0,BAO_0000357,,CHEMBL619885,,,,,H,Autocuration,12703.0,8.0,,3810.0,,,
,1.0,F,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,55.0,BAO_0000019,Homo sapiens,CHEMBL619886,,9606.0,,,D,Expert,14312.0,9.0,,3811.0,,,
Blood,1.0,F,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,55.0,BAO_0000019,,CHEMBL619887,,,178.0,,H,Autocuration,14312.0,8.0,,3812.0,,,
,1.0,F,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,55.0,BAO_0000019,,CHEMBL875097,,,,,H,Autocuration,5364.0,8.0,,3813.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,55.0,BAO_0000219,,CHEMBL618001,,,,,H,Autocuration,951.0,8.0,,3814.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,55.0,BAO_0000219,,CHEMBL618002,,,,,H,Autocuration,951.0,8.0,,3815.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,55.0,BAO_0000219,,CHEMBL618003,,,,,H,Autocuration,951.0,8.0,,3816.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,55.0,BAO_0000219,,CHEMBL618004,,,,,H,Autocuration,951.0,8.0,,3817.0,,,
,1.0,B,Inhibition of human 5-lipoxygenase in human cells,,,55.0,BAO_0000219,,CHEMBL618005,,,,,H,Autocuration,12365.0,8.0,,3818.0,,,
,1.0,B,Inhibition of human neutrophil 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618006,,,,,H,Expert,10603.0,8.0,,3819.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,55.0,BAO_0000019,,CHEMBL875086,,,,,H,Autocuration,10501.0,8.0,,3820.0,,,
Blood,1.0,B,Inhibition of 5-lipoxygenase from human whole blood,,,55.0,BAO_0000357,,CHEMBL618007,,,178.0,,H,Expert,12281.0,8.0,,3821.0,,,
,1.0,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,55.0,BAO_0000357,,CHEMBL618008,,,,,H,Autocuration,2567.0,8.0,,3822.0,,,
,1.0,B,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,55.0,BAO_0000219,,CHEMBL618009,,,,,H,Autocuration,2567.0,8.0,,3823.0,,,
,1.0,B,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618010,,,,,H,Expert,10193.0,8.0,,3824.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55.0,BAO_0000357,,CHEMBL618011,,,,,H,Autocuration,10193.0,8.0,,3825.0,,,
,1.0,B,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618012,,,,,H,Expert,13623.0,8.0,,3826.0,,,
,1.0,B,Tested against 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL882927,,,,,H,Autocuration,12780.0,8.0,,3827.0,,,
,1.0,B,Tested for activity against 5-Lipoxygenase (5-LO),,,55.0,BAO_0000357,,CHEMBL618013,,,,,H,Autocuration,12780.0,8.0,,3828.0,,,
,1.0,B,Tested for activity against 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618014,,,,,H,Autocuration,12780.0,8.0,,3829.0,,,
,1.0,B,Tested for inhibition of 5-HPETE production by human 5-LO,,,55.0,BAO_0000357,,CHEMBL618015,,,,,H,Autocuration,11966.0,8.0,,3830.0,,,
,1.0,F,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,55.0,BAO_0000019,,CHEMBL618016,,,,,H,Autocuration,5364.0,8.0,,3831.0,,,
,1.0,B,Inhibition of Human 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618017,,,,,H,Expert,13165.0,8.0,,3832.0,,,
,1.0,B,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,55.0,BAO_0000019,,CHEMBL618018,,,,,H,Autocuration,5364.0,8.0,,3833.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,55.0,BAO_0000219,,CHEMBL875087,,,,,H,Autocuration,11311.0,8.0,,3834.0,,,
,1.0,B,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,55.0,BAO_0000219,,CHEMBL618019,,,,,H,Autocuration,11311.0,8.0,,3835.0,,,
,1.0,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,55.0,BAO_0000019,,CHEMBL618020,,,,,H,Autocuration,14863.0,8.0,,3836.0,,,
,1.0,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,55.0,BAO_0000019,,CHEMBL618021,,,,,H,Autocuration,14863.0,8.0,,3837.0,,,
Blood,1.0,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,55.0,BAO_0000357,,CHEMBL618022,,,178.0,,H,Autocuration,11087.0,8.0,,3838.0,,,
,1.0,B,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,55.0,BAO_0000357,,CHEMBL618023,,,,,H,Autocuration,455.0,8.0,,3839.0,,,
,1.0,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55.0,BAO_0000357,,CHEMBL618024,,,,,H,Autocuration,13183.0,8.0,,3840.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,55.0,BAO_0000019,,CHEMBL873950,,,,,H,Expert,10319.0,8.0,,3841.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55.0,BAO_0000357,,CHEMBL618025,,,,,H,Autocuration,10193.0,8.0,,3842.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,55.0,BAO_0000219,,CHEMBL618026,,,,,H,Autocuration,951.0,8.0,,3843.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,55.0,BAO_0000219,,CHEMBL618027,,,,,H,Autocuration,951.0,8.0,,3844.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,55.0,BAO_0000219,,CHEMBL618028,,,,,H,Autocuration,951.0,8.0,,3845.0,,,
,1.0,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,55.0,BAO_0000219,,CHEMBL618029,,,,,H,Autocuration,951.0,8.0,,3846.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,55.0,BAO_0000357,,CHEMBL618030,,,,,H,Expert,9859.0,8.0,,3847.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,55.0,BAO_0000357,,CHEMBL618031,,,,,H,Expert,9859.0,8.0,,3848.0,,,
,1.0,B,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,55.0,BAO_0000357,,CHEMBL618032,,,,,H,Autocuration,9859.0,8.0,,3849.0,,,
,1.0,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,55.0,BAO_0000357,,CHEMBL618033,,,,,H,Autocuration,2567.0,8.0,,3850.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,55.0,BAO_0000357,,CHEMBL618034,,,,,H,Autocuration,10193.0,8.0,,3851.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,55.0,BAO_0000357,,CHEMBL875088,,,,,H,Autocuration,10193.0,8.0,,3852.0,,,
,1.0,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,55.0,BAO_0000019,,CHEMBL618035,,,,,H,Autocuration,949.0,8.0,,3853.0,,,
,1.0,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,55.0,BAO_0000019,,CHEMBL618036,,,,,H,Autocuration,949.0,8.0,,3854.0,,,
,1.0,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,55.0,BAO_0000357,,CHEMBL618037,,,,,H,Expert,10603.0,8.0,,3855.0,,,
,1.0,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,55.0,BAO_0000357,,CHEMBL618038,,,,,H,Expert,10603.0,8.0,,3856.0,,,
,1.0,F,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,55.0,BAO_0000019,,CHEMBL618761,,,,,H,Autocuration,10603.0,8.0,,3857.0,,,
,1.0,B,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,55.0,BAO_0000357,,CHEMBL618762,,,,,H,Expert,10603.0,8.0,,3858.0,,,
,1.0,B,Inhibition of lipoxygenase at the concentration of 1 uM,,,55.0,BAO_0000357,,CHEMBL618763,,,,,H,Expert,10603.0,8.0,,3859.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,55.0,BAO_0000357,,CHEMBL618764,,,,,H,Autocuration,10193.0,8.0,,3860.0,,,
,1.0,B,Inhibition of 5-Lipoxygenase (5-LOX),,,55.0,BAO_0000357,Homo sapiens,CHEMBL618765,,9606.0,,,D,Expert,14580.0,9.0,,3861.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,,17087.0,BAO_0000357,,CHEMBL618766,,,,,H,Expert,11090.0,8.0,,3862.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,,17087.0,BAO_0000357,,CHEMBL618767,,,,,H,Expert,11090.0,8.0,,3863.0,,,
,1.0,B,Inhibitory activity against lipoxygenase-2 in mice,,,17087.0,BAO_0000357,,CHEMBL619380,,,,,H,Autocuration,6339.0,8.0,,3864.0,,,
,1.0,B,Inhibitory activity against murine lipoxygenase-2.,,,17087.0,BAO_0000357,,CHEMBL619381,,,,,H,Expert,6339.0,8.0,,3865.0,,,
,1.0,B,Inhibition of 5-lipoxygenase from mouse macrophage,,,17087.0,BAO_0000357,Mus musculus,CHEMBL619382,,10090.0,,,D,Expert,12281.0,9.0,,3866.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,17087.0,BAO_0000357,,CHEMBL619383,,,,,H,Autocuration,11311.0,8.0,,3867.0,,,
,1.0,B,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,55.0,BAO_0000019,Sus scrofa,CHEMBL619384,,9823.0,,,H,Autocuration,11089.0,8.0,,3868.0,,,
,1.0,B,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,55.0,BAO_0000019,Sus scrofa,CHEMBL619385,,9823.0,,,H,Autocuration,10091.0,8.0,,3869.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,55.0,BAO_0000019,Oryctolagus cuniculus,CHEMBL882928,,9986.0,,,H,Autocuration,14352.0,8.0,,3870.0,,,
,1.0,B,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,12166.0,BAO_0000019,Rattus norvegicus,CHEMBL619386,,10116.0,,,D,Expert,13329.0,9.0,,3871.0,,,
,1.0,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,12166.0,BAO_0000019,,CHEMBL619387,,,,,H,Autocuration,13329.0,8.0,,3872.0,,,
,1.0,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,12166.0,BAO_0000019,,CHEMBL619388,,,,,H,Autocuration,13329.0,8.0,,3873.0,,,
,1.0,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,12166.0,BAO_0000019,,CHEMBL619389,,,,,H,Autocuration,13329.0,8.0,,3874.0,,,
,1.0,B,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,12166.0,BAO_0000019,,CHEMBL619390,,,,,H,Expert,13329.0,8.0,,3875.0,,,
,1.0,B,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,12166.0,BAO_0000019,,CHEMBL619391,,,,,H,Expert,13329.0,8.0,,3876.0,,,
,1.0,B,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,12166.0,BAO_0000019,,CHEMBL619392,,,,,H,Autocuration,13329.0,8.0,,3877.0,,,
,1.0,B,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,12166.0,BAO_0000019,,CHEMBL619393,,,,,H,Autocuration,11311.0,8.0,,3878.0,,,
,1.0,B,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,12166.0,BAO_0000019,,CHEMBL619394,,,,,H,Autocuration,11311.0,8.0,,3879.0,,,
,1.0,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,RBL-1,12166.0,BAO_0000219,,CHEMBL619395,,,,,H,Autocuration,105.0,8.0,702.0,3880.0,,,
,1.0,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,RBL-1,12166.0,BAO_0000219,,CHEMBL619396,,,,,H,Autocuration,105.0,8.0,702.0,3881.0,,,
,1.0,B,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,12166.0,BAO_0000357,,CHEMBL619397,,,,,H,Autocuration,9138.0,8.0,,3882.0,,,
,1.0,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,12166.0,BAO_0000357,,CHEMBL619398,,,,,H,Autocuration,9138.0,8.0,,3883.0,,,
,1.0,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,12166.0,BAO_0000357,,CHEMBL619399,,,,,H,Autocuration,9138.0,8.0,,3884.0,,,
,1.0,B,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,12166.0,BAO_0000357,,CHEMBL619400,,,,,H,Autocuration,14427.0,8.0,,3885.0,,,
,1.0,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,12166.0,BAO_0000019,,CHEMBL619401,,,,,H,Autocuration,13329.0,8.0,,3886.0,,,
,1.0,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,12166.0,BAO_0000019,,CHEMBL619402,,,,,H,Autocuration,13329.0,8.0,,3887.0,,,
,1.0,B,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL619403,,10116.0,,,D,Expert,14427.0,9.0,663.0,3888.0,,,
,1.0,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,12166.0,BAO_0000357,,CHEMBL619404,,,,,H,Autocuration,14427.0,8.0,,3889.0,,,
,1.0,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,12166.0,BAO_0000357,,CHEMBL619405,,,,,H,Autocuration,14427.0,8.0,,3890.0,,,
,1.0,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,RBL-1,12166.0,BAO_0000219,,CHEMBL619406,,,,,H,Expert,10293.0,8.0,702.0,3891.0,,,
,1.0,B,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL619407,,10116.0,,,D,Expert,338.0,9.0,702.0,3892.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,12166.0,BAO_0000357,,CHEMBL619408,,,,,H,Autocuration,303.0,8.0,,3893.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,RBL-1,12166.0,BAO_0000219,,CHEMBL619409,,,,,H,Autocuration,303.0,8.0,702.0,3894.0,,,
,1.0,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,RBL-1,12166.0,BAO_0000219,,CHEMBL619410,,,,,H,Expert,9247.0,8.0,702.0,3895.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,RBL-1,12166.0,BAO_0000219,,CHEMBL619753,,,,,H,Autocuration,9247.0,8.0,702.0,3896.0,,,
,1.0,B,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,RBL-1,12166.0,BAO_0000219,,CHEMBL619754,,,,,H,Autocuration,137.0,8.0,702.0,3897.0,,,
,1.0,B,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619903,,,,,H,Expert,11481.0,8.0,,3898.0,,,
,1.0,B,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,12166.0,BAO_0000357,,CHEMBL619904,,,,,H,Expert,11481.0,8.0,,3899.0,,,
,1.0,B,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,12166.0,BAO_0000357,,CHEMBL619905,,,,,H,Expert,9029.0,8.0,,3900.0,,,
,1.0,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,12166.0,BAO_0000019,,CHEMBL619906,,,,,H,Autocuration,1701.0,8.0,,3901.0,,,
,1.0,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,12166.0,BAO_0000019,,CHEMBL619907,,,,,H,Autocuration,1701.0,8.0,,3902.0,,,
,1.0,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,12166.0,BAO_0000019,,CHEMBL619908,,,,,H,Autocuration,1701.0,8.0,,3903.0,,,
,1.0,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,12166.0,BAO_0000019,,CHEMBL619909,,,,,H,Autocuration,1701.0,8.0,,3904.0,,,
,1.0,F,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,RBL-1,12166.0,BAO_0000219,,CHEMBL619910,,,,,H,Expert,13358.0,8.0,702.0,3905.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL882929,,,,,H,Expert,1175.0,8.0,702.0,3906.0,,,
,1.0,B,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,RBL-1,12166.0,BAO_0000219,,CHEMBL619911,,,,,H,Expert,8797.0,8.0,702.0,3907.0,,,
,1.0,B,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,12166.0,BAO_0000019,,CHEMBL619912,,,,,H,Autocuration,8797.0,8.0,,3908.0,,,
,1.0,B,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,12166.0,BAO_0000357,Rattus norvegicus,CHEMBL619913,,10116.0,,,D,Expert,577.0,9.0,,3909.0,,,
,1.0,B,In vitro inhibitory activity against RBL-1 5-LO,,RBL-1,12166.0,BAO_0000219,,CHEMBL619914,,,,,H,Expert,9295.0,8.0,702.0,3910.0,,,
,1.0,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,RBL-1,12166.0,BAO_0000219,,CHEMBL619915,,,,,H,Autocuration,9295.0,8.0,702.0,3911.0,,,
,1.0,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,RBL-1,12166.0,BAO_0000219,,CHEMBL619916,,,,,H,Autocuration,9295.0,8.0,702.0,3912.0,,,
,1.0,B,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,12166.0,BAO_0000218,,CHEMBL619917,,,,,H,Autocuration,9295.0,8.0,,3913.0,,,
,1.0,B,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,12166.0,BAO_0000357,,CHEMBL619918,,,,,H,Autocuration,9295.0,8.0,,3914.0,,,
,1.0,B,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,12166.0,BAO_0000218,,CHEMBL619919,,,,,H,Autocuration,216.0,8.0,,3915.0,,,
,1.0,B,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,RBL-1,12166.0,BAO_0000219,,CHEMBL883710,,,,,H,Autocuration,11090.0,8.0,702.0,3916.0,,,
Blood,1.0,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,12166.0,BAO_0000019,,CHEMBL619920,,,178.0,,H,Autocuration,11090.0,8.0,,3917.0,,,
,1.0,B,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619921,,,,,H,Expert,10091.0,8.0,,3918.0,,,
,1.0,F,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,12166.0,BAO_0000019,,CHEMBL619922,,,,,H,Autocuration,10274.0,8.0,,3919.0,,,
,1.0,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,12166.0,BAO_0000219,,CHEMBL619923,,,,,H,Autocuration,13622.0,8.0,,3920.0,,,
,1.0,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,RBL-1,12166.0,BAO_0000219,,CHEMBL619924,,,,,H,Expert,12118.0,8.0,702.0,3921.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,12166.0,BAO_0000357,,CHEMBL619925,,,,,H,Expert,12576.0,8.0,,3922.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL619926,,,,,H,Expert,9546.0,8.0,702.0,3923.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL619927,,,,,H,Autocuration,9521.0,8.0,702.0,3924.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL619928,,,,,H,Expert,10626.0,8.0,702.0,3925.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase,,RBL-1,12166.0,BAO_0000219,,CHEMBL619929,,,,,H,Autocuration,9225.0,8.0,702.0,3926.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,RBL-1,12166.0,BAO_0000219,,CHEMBL875089,,,,,H,Autocuration,9225.0,8.0,702.0,3927.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,RBL-1,12166.0,BAO_0000219,,CHEMBL619930,,,,,H,Autocuration,9225.0,8.0,702.0,3928.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,RBL-1,12166.0,BAO_0000219,,CHEMBL619931,,,,,H,Autocuration,9225.0,8.0,702.0,3929.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,RBL-1,12166.0,BAO_0000219,,CHEMBL619932,,,,,H,Autocuration,9225.0,8.0,702.0,3930.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,RBL-1,12166.0,BAO_0000219,,CHEMBL619933,,,,,H,Autocuration,9225.0,8.0,702.0,3931.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,RBL-1,12166.0,BAO_0000219,,CHEMBL619934,,,,,H,Autocuration,9225.0,8.0,702.0,3932.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,RBL-1,12166.0,BAO_0000219,,CHEMBL619935,,,,,H,Autocuration,9225.0,8.0,702.0,3933.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,RBL-1,12166.0,BAO_0000219,,CHEMBL619936,,,,,H,Autocuration,9225.0,8.0,702.0,3934.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,RBL-1,12166.0,BAO_0000219,,CHEMBL619937,,,,,H,Autocuration,9225.0,8.0,702.0,3935.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,RBL-1,12166.0,BAO_0000219,,CHEMBL619938,,,,,H,Autocuration,9225.0,8.0,702.0,3936.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,RBL-1,12166.0,BAO_0000219,,CHEMBL619939,,,,,H,Autocuration,9225.0,8.0,702.0,3937.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,RBL-1,12166.0,BAO_0000219,,CHEMBL619940,,,,,H,Autocuration,9225.0,8.0,702.0,3938.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,RBL-1,12166.0,BAO_0000219,,CHEMBL875090,,,,,H,Autocuration,9225.0,8.0,702.0,3939.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,RBL-1,12166.0,BAO_0000219,,CHEMBL619941,,,,,H,Autocuration,9225.0,8.0,702.0,3940.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,RBL-1,12166.0,BAO_0000219,,CHEMBL619942,,,,,H,Autocuration,9225.0,8.0,702.0,3941.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,RBL-1,12166.0,BAO_0000219,,CHEMBL883711,,,,,H,Autocuration,9225.0,8.0,702.0,3942.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,RBL-1,12166.0,BAO_0000219,,CHEMBL619943,,,,,H,Autocuration,9225.0,8.0,702.0,3943.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,RBL-1,12166.0,BAO_0000219,,CHEMBL619944,,,,,H,Autocuration,9225.0,8.0,702.0,3944.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,RBL-1,12166.0,BAO_0000219,,CHEMBL619945,,,,,H,Autocuration,9225.0,8.0,702.0,3945.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,RBL-1,12166.0,BAO_0000219,,CHEMBL619946,,,,,H,Autocuration,9225.0,8.0,702.0,3946.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,RBL-1,12166.0,BAO_0000219,,CHEMBL619947,,,,,H,Autocuration,9225.0,8.0,702.0,3947.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,RBL-1,12166.0,BAO_0000219,,CHEMBL619948,,,,,H,Autocuration,9225.0,8.0,702.0,3948.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,RBL-1,12166.0,BAO_0000219,,CHEMBL619949,,,,,H,Autocuration,9225.0,8.0,702.0,3949.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,12166.0,BAO_0000019,,CHEMBL619950,,,,,H,Expert,9401.0,8.0,,3950.0,,,
,1.0,B,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,12166.0,BAO_0000019,,CHEMBL618050,,,,,H,Autocuration,10325.0,8.0,,3951.0,,,
,1.0,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL875091,,,,,H,Expert,1556.0,8.0,663.0,3952.0,,,
,1.0,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL618051,,,,,H,Expert,1556.0,8.0,663.0,3953.0,,,
,1.0,B,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618052,,10116.0,,,D,Expert,961.0,9.0,702.0,3954.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,12166.0,BAO_0000019,,CHEMBL618053,,,,,H,Autocuration,6838.0,8.0,,3955.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,12166.0,BAO_0000019,,CHEMBL618054,,,,,H,Expert,10325.0,8.0,,3956.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618055,,10116.0,,,D,Expert,9209.0,9.0,702.0,3957.0,,,
,1.0,B,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,RBL-1,12166.0,BAO_0000219,,CHEMBL618056,,,,,H,Expert,11520.0,8.0,702.0,3958.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase was determined,,,12166.0,BAO_0000357,,CHEMBL618057,,,,,H,Autocuration,137.0,8.0,,3959.0,,,
,1.0,B,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL618058,,,,,H,Autocuration,4717.0,8.0,702.0,3960.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,RBL-1,12166.0,BAO_0000219,,CHEMBL618059,,,,,H,Expert,10636.0,8.0,702.0,3961.0,,,
,1.0,F,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,12166.0,BAO_0000019,Rattus norvegicus,CHEMBL618060,,10116.0,,,D,Expert,14312.0,9.0,,3962.0,,,
,1.0,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL618061,,,,,H,Autocuration,1203.0,8.0,702.0,3963.0,,,
,1.0,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,12166.0,BAO_0000019,,CHEMBL618062,,,,,H,Autocuration,1203.0,8.0,,3964.0,,,
,1.0,B,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,RBL-1,12166.0,BAO_0000219,,CHEMBL618063,,,,,H,Expert,13622.0,8.0,702.0,3965.0,,,
,1.0,B,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,12166.0,BAO_0000357,,CHEMBL618064,,,,,H,Autocuration,9793.0,8.0,,3966.0,,,
,1.0,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618065,,10116.0,,,D,Expert,1143.0,9.0,702.0,3967.0,,,
,1.0,B,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618066,,10116.0,,,D,Expert,11854.0,9.0,702.0,3968.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL618067,,,,,H,Autocuration,3595.0,8.0,702.0,3969.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL618068,,,,,H,Autocuration,3595.0,8.0,702.0,3970.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618069,,10116.0,,,D,Expert,10501.0,9.0,702.0,3971.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166.0,BAO_0000219,,CHEMBL618070,,,,,H,Expert,12526.0,8.0,702.0,3972.0,,,
Limbic system,1.0,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,10825.0,BAO_0000019,,CHEMBL618071,,,349.0,,H,Autocuration,10034.0,8.0,,3973.0,,,
Limbic system,1.0,F,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,10825.0,BAO_0000019,,CHEMBL619247,,,349.0,,H,Autocuration,10034.0,8.0,,3974.0,,,
,1.0,F,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,10825.0,BAO_0000019,,CHEMBL619248,,,,,H,Autocuration,10034.0,8.0,,3975.0,,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576.0,BAO_0000221,,CHEMBL619249,,,10000000.0,,H,Autocuration,10046.0,8.0,,3976.0,,,
Hippocampus,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10576.0,BAO_0000221,,CHEMBL619250,,,10000000.0,,H,Autocuration,10046.0,8.0,,3977.0,,,
,1.0,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,10577.0,BAO_0000019,,CHEMBL619251,,,,,H,Autocuration,10046.0,8.0,,3978.0,,,
Blood,1.0,F,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,55.0,BAO_0000019,Canis lupus familiaris,CHEMBL619252,,9615.0,178.0,,H,Autocuration,12079.0,8.0,,3979.0,,,
Blood,1.0,F,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,55.0,BAO_0000019,,CHEMBL619253,,,178.0,,H,Autocuration,12079.0,8.0,,3980.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,12166.0,BAO_0000219,,CHEMBL619254,,,,,H,Autocuration,11311.0,8.0,,3981.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,17140.0,BAO_0000219,,CHEMBL619255,,,,,H,Expert,12338.0,8.0,,3982.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,17140.0,BAO_0000219,,CHEMBL619256,,,,,H,Expert,12143.0,8.0,,3983.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,17140.0,BAO_0000219,,CHEMBL875418,,,,,H,Autocuration,12143.0,8.0,,3984.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,17140.0,BAO_0000219,,CHEMBL619257,,,,,H,Expert,12143.0,8.0,,3985.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,17140.0,BAO_0000219,,CHEMBL619258,,,,,H,Autocuration,12143.0,8.0,,3986.0,,,
,1.0,B,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,17140.0,BAO_0000357,,CHEMBL619259,,,,,H,Expert,12365.0,8.0,,3987.0,,,
,1.0,B,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,17140.0,BAO_0000357,,CHEMBL619260,,,,,H,Expert,13500.0,8.0,,3988.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619261,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3989.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619263,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3990.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619264,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3991.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619265,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3992.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619266,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3993.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619902,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3994.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620058,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3995.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620059,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3996.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620060,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3997.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620061,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3998.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620062,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,3999.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620063,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4000.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620064,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4001.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620065,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4002.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620066,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4003.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620067,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4004.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620068,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4005.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620069,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4006.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620070,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4007.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620071,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4008.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620072,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4009.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620036,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4010.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL857702,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4011.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620037,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4012.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620038,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4013.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620039,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4014.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620040,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4015.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620041,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4016.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620042,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4017.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620043,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4018.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620044,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4019.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620045,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4020.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620046,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4021.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620047,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4022.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620048,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4023.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL857703,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4024.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620049,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4025.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620050,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4026.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620051,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4027.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619213,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4028.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619214,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4029.0,,,
Blood,1.0,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619804,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4030.0,,,
Blood,1.0,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619805,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4031.0,,,
Blood,1.0,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619806,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4032.0,,,
Blood,1.0,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619807,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4033.0,,,
Blood,1.0,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619808,In vivo,9615.0,178.0,,H,Autocuration,12832.0,8.0,,4034.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619809,,9615.0,,,H,Autocuration,3595.0,8.0,,4035.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619810,,9615.0,,,H,Autocuration,3595.0,8.0,,4036.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL619811,,9615.0,,,H,Autocuration,3595.0,8.0,,4037.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620769,,9615.0,,,H,Autocuration,3595.0,8.0,,4038.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620770,,9615.0,,,H,Autocuration,3595.0,8.0,,4039.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620771,,9615.0,,,H,Autocuration,3595.0,8.0,,4040.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620772,,9615.0,,,H,Autocuration,3595.0,8.0,,4041.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,55.0,BAO_0000218,Canis lupus familiaris,CHEMBL620773,,9615.0,,,H,Autocuration,3595.0,8.0,,4042.0,,,
,1.0,B,Ability to inhibit 5-lipoxygenase in guinea pig,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL620774,,10141.0,,,H,Autocuration,9203.0,8.0,,4043.0,,,
,1.0,B,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,55.0,BAO_0000357,Cavia porcellus,CHEMBL620775,,10141.0,,,H,Expert,82.0,8.0,,4044.0,,,
,1.0,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL620776,,10141.0,,,H,Autocuration,11090.0,8.0,,4045.0,,,
Blood,1.0,B,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,55.0,BAO_0000218,Cavia porcellus,CHEMBL620777,,10141.0,178.0,,H,Autocuration,12832.0,8.0,,4046.0,,,
,1.0,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL620778,,10141.0,,,H,Autocuration,1065.0,8.0,,4047.0,,,
,1.0,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL620779,,10141.0,,,H,Autocuration,1065.0,8.0,,4048.0,,,
,1.0,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL621500,,10141.0,,,H,Expert,12832.0,8.0,,4049.0,,,
,1.0,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL621501,,10141.0,,,H,Expert,12832.0,8.0,,4050.0,,,
,1.0,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL618098,,10141.0,,,H,Autocuration,12832.0,8.0,,4051.0,,,
,1.0,B,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL618099,,10141.0,,,H,Autocuration,10504.0,8.0,,4052.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618100,,10141.0,,,H,Autocuration,7788.0,8.0,,4053.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618101,,10141.0,,,H,Autocuration,10001.0,8.0,,4054.0,,,
,1.0,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618102,,10141.0,,,H,Autocuration,10193.0,8.0,,4055.0,,,
,1.0,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618103,,10141.0,,,H,Autocuration,13243.0,8.0,,4056.0,,,
,1.0,B,Inhibitory activity uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618104,,10141.0,,,H,Autocuration,13243.0,8.0,,4057.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,55.0,BAO_0000219,Cavia porcellus,CHEMBL883712,,10141.0,,,H,Autocuration,969.0,8.0,,4058.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618105,,10141.0,,,H,Autocuration,10001.0,8.0,,4059.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618106,,10141.0,,,H,Autocuration,7788.0,8.0,,4060.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618107,,10141.0,,,H,Autocuration,10001.0,8.0,,4061.0,,,
,1.0,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618108,,10141.0,,,H,Autocuration,10193.0,8.0,,4062.0,,,
,1.0,B,Inhibitory activity uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618109,,10141.0,,,H,Autocuration,13243.0,8.0,,4063.0,,,
,1.0,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618110,,10141.0,,,H,Autocuration,13243.0,8.0,,4064.0,,,
,1.0,B,Inhibitory activity uM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618111,,10141.0,,,H,Expert,13243.0,8.0,,4065.0,,,
,1.0,F,Inhibitory activity uM,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL618112,,10141.0,,,H,Autocuration,13243.0,8.0,,4066.0,,,
,1.0,B,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,55.0,BAO_0000019,Cavia porcellus,CHEMBL618113,,10141.0,,,H,Autocuration,10504.0,8.0,,4067.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,55.0,BAO_0000357,Cavia porcellus,CHEMBL618114,,10141.0,,,H,Autocuration,7788.0,8.0,,4068.0,,,
Ileum,1.0,F,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,55.0,BAO_0000221,Cavia porcellus,CHEMBL620871,,10141.0,2116.0,,H,Expert,10546.0,8.0,,4069.0,,,
,1.0,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55.0,BAO_0000357,,CHEMBL620872,,,,,H,Autocuration,13183.0,8.0,,4070.0,,,
,1.0,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,55.0,BAO_0000357,,CHEMBL620873,,,,,H,Autocuration,13183.0,8.0,,4071.0,,,
,1.0,B,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,55.0,BAO_0000357,,CHEMBL620874,,,,,H,Autocuration,2578.0,8.0,,4072.0,,,
,1.0,B,In vitro inhibition of human 5-Lipoxygenase.,,,55.0,BAO_0000357,,CHEMBL620875,,,,,H,Expert,12780.0,8.0,,4073.0,,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620876,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4074.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620877,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4075.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL857854,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4076.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620878,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4077.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620879,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4078.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620880,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4079.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620881,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4080.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620882,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4081.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620883,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4082.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620884,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4083.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620885,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4084.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620886,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4085.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620887,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4086.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618039,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4087.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618040,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4088.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618041,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4089.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618216,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4090.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618217,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4091.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618218,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4092.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618219,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4093.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618220,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4094.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618221,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4095.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618222,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4096.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618223,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4097.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618224,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4098.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618225,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4099.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618226,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4100.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618227,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4101.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618228,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4102.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618229,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4103.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618230,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4104.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618231,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4105.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618232,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4106.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618233,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4107.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618234,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4108.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618235,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4109.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618115,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4110.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618116,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4111.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL618117,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4112.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619968,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4113.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619969,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4114.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619970,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4115.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619971,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4116.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619972,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4117.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619973,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4118.0,Microsomes,,
Liver,1.0,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619974,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4119.0,Microsomes,,
Liver,1.0,B,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619975,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4120.0,Microsomes,,
,1.0,B,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619976,,10116.0,,,U,Autocuration,7411.0,0.0,,4121.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619977,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4122.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619978,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4123.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619979,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4124.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619980,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4125.0,Microsomes,,
Liver,1.0,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619981,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4126.0,Microsomes,,
,1.0,F,In vitro inhibition of 7226/S myeloma cancer cell line,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619982,,9606.0,,,N,Intermediate,10797.0,1.0,741.0,4127.0,,,
,1.0,F,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BEL-7404 tumor cell line,80698.0,BAO_0000219,Homo sapiens,CHEMBL619983,,9606.0,,,N,Intermediate,6881.0,1.0,993.0,4128.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL620031,,9606.0,,,N,Intermediate,3838.0,1.0,391.0,4129.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL620032,,9606.0,,,N,Intermediate,3838.0,1.0,391.0,4130.0,,,
,1.0,F,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,V79,81264.0,BAO_0000219,Cricetulus griseus,CHEMBL620033,,10029.0,,,N,Expert,12981.0,1.0,505.0,4131.0,,,
,1.0,F,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,V79,81264.0,BAO_0000219,Cricetulus griseus,CHEMBL620034,,10029.0,,,N,Expert,12981.0,1.0,505.0,4132.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL620035,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4133.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL618318,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4134.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL618319,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4135.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL618320,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4136.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL618321,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4137.0,,,
,1.0,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,7800C1 cell line,80635.0,BAO_0000219,Rattus norvegicus,CHEMBL883118,,10116.0,,,N,Intermediate,7653.0,1.0,1119.0,4138.0,,,
,1.0,F,In vitro antitumor activity against renal 786-0 tumor cell lines,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL883795,,9606.0,,,N,Intermediate,17229.0,1.0,391.0,4139.0,,,
,1.0,F,Cytotoxic activity against 786-0 Renal cancer cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618322,,9606.0,,,N,Intermediate,12858.0,1.0,391.0,4140.0,,,
,1.0,F,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618323,,9606.0,,,N,Intermediate,16325.0,1.0,391.0,4141.0,,,
,1.0,F,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618324,,9606.0,,,N,Intermediate,16325.0,1.0,391.0,4142.0,,,
,1.0,F,In vitro antitumor activity against human renal 786-0 cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618325,,9606.0,,,N,Intermediate,5858.0,1.0,391.0,4143.0,,,
,1.0,F,Inhibition of Renal cancer in 786-0 cancer cell lines,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL875416,,9606.0,,,N,Intermediate,16325.0,1.0,391.0,4144.0,,,
,1.0,F,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618326,,9606.0,,,N,Intermediate,14696.0,1.0,391.0,4145.0,,,
,1.0,F,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL618327,,9606.0,,,N,Intermediate,3786.0,1.0,391.0,4146.0,,,
,1.0,F,inhibition of the growth of renal cancer(786-0) cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619215,,9606.0,,,N,Intermediate,14696.0,1.0,391.0,4147.0,,,
,1.0,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619216,,9606.0,,,N,Intermediate,14769.0,1.0,391.0,4148.0,,,
,1.0,F,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619217,,9606.0,,,N,Intermediate,15354.0,1.0,391.0,4149.0,,,
,1.0,F,The IC50 value was measured on 786-0 cell line in ovarian tumor,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619218,,9606.0,,,N,Intermediate,14255.0,1.0,391.0,4150.0,,,
,1.0,F,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619219,,9606.0,,,N,Intermediate,14255.0,1.0,391.0,4151.0,,,
,1.0,F,The IC50 value was measured on 786-0 cell line in renal tumor type.,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619220,,9606.0,,,N,Intermediate,14255.0,1.0,391.0,4152.0,,,
,1.0,F,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619221,,9606.0,,,N,Intermediate,14696.0,1.0,391.0,4153.0,,,
,1.0,F,Tested for cytotoxic activity against renal cancer 786-0 cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619222,,9606.0,,,N,Intermediate,12016.0,1.0,391.0,4154.0,,,
,1.0,F,Compound was tested for growth inhibitory activity against 786-0 cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL857454,,9606.0,,,N,Intermediate,2597.0,1.0,391.0,4155.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL619223,,,,,H,Autocuration,12526.0,8.0,702.0,4156.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,RBL-1,12166.0,BAO_0000219,,CHEMBL619224,,,,,H,Autocuration,12526.0,8.0,702.0,4157.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,12166.0,BAO_0000019,,CHEMBL619225,,,,,H,Autocuration,14799.0,8.0,,4158.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL619226,,,,,H,Expert,3595.0,8.0,702.0,4159.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL619227,,,,,H,Expert,3595.0,8.0,702.0,4160.0,,,
,1.0,B,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619228,,,,,H,Autocuration,12767.0,8.0,,4161.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,12166.0,BAO_0000219,,CHEMBL619229,,,,,H,Autocuration,10997.0,8.0,,4162.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,RBL-1,12166.0,BAO_0000219,,CHEMBL619230,,,,,H,Autocuration,11388.0,8.0,702.0,4163.0,,,
,1.0,B,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,12166.0,BAO_0000357,,CHEMBL619231,,,,,H,Autocuration,167.0,8.0,,4164.0,,,
,1.0,B,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,12166.0,BAO_0000357,,CHEMBL619232,,,,,H,Autocuration,167.0,8.0,,4165.0,,,
,1.0,B,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,12166.0,BAO_0000357,,CHEMBL619233,,,,,H,Expert,13744.0,8.0,,4166.0,,,
,1.0,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619234,,,,,H,Autocuration,1630.0,8.0,,4167.0,,,
,1.0,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,12166.0,BAO_0000357,,CHEMBL619235,,,,,H,Autocuration,1630.0,8.0,,4168.0,,,
,1.0,B,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,12166.0,BAO_0000019,Rattus norvegicus,CHEMBL619236,,10116.0,,,D,Expert,969.0,9.0,,4169.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL619237,,,,,H,Autocuration,13621.0,8.0,702.0,4170.0,,,
,1.0,B,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,12166.0,BAO_0000357,,CHEMBL619238,,,,,H,Autocuration,10089.0,8.0,,4171.0,,,
,1.0,B,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619239,,,,,H,Expert,10193.0,8.0,,4172.0,,,
,1.0,B,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,12166.0,BAO_0000357,,CHEMBL619240,,,,,H,Autocuration,11966.0,8.0,,4173.0,,,
,1.0,B,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,12166.0,BAO_0000019,,CHEMBL875417,,,,,H,Autocuration,12251.0,8.0,,4174.0,,,
,1.0,B,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,RBL-1,12166.0,BAO_0000219,,CHEMBL619241,,,,,H,Autocuration,211.0,8.0,702.0,4175.0,,,
,1.0,F,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,12166.0,BAO_0000019,,CHEMBL619242,,,,,H,Expert,12251.0,8.0,,4176.0,,,
,1.0,B,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL883796,,,,,H,Autocuration,12495.0,8.0,702.0,4177.0,,,
,1.0,B,Tested for its inhibitory activity against 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL619243,,,,,H,Autocuration,414.0,8.0,,4178.0,,,
,1.0,B,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,12166.0,BAO_0000357,,CHEMBL619244,,,,,H,Autocuration,414.0,8.0,,4179.0,,,
,1.0,B,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,12166.0,BAO_0000019,,CHEMBL619245,,,,,H,Expert,10325.0,8.0,,4180.0,,,
,1.0,B,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,12166.0,BAO_0000019,,CHEMBL619246,,,,,H,Expert,11966.0,8.0,,4181.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166.0,BAO_0000219,,CHEMBL619984,,,,,H,Expert,165.0,8.0,702.0,4182.0,,,
,1.0,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL619985,,,,,H,Autocuration,165.0,8.0,702.0,4183.0,,,
,1.0,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166.0,BAO_0000219,,CHEMBL619986,,,,,H,Autocuration,165.0,8.0,702.0,4184.0,,,
,1.0,B,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,RBL-1,12166.0,BAO_0000219,,CHEMBL619987,,,,,H,Expert,165.0,8.0,702.0,4185.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,12166.0,BAO_0000218,,CHEMBL619988,,,,,H,Autocuration,11311.0,8.0,,4186.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,RBL-1,12166.0,BAO_0000219,,CHEMBL619989,,,,,H,Autocuration,11311.0,8.0,702.0,4187.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL619990,,,,,H,Autocuration,11311.0,8.0,702.0,4188.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,12166.0,BAO_0000219,,CHEMBL619991,,,,,H,Autocuration,11311.0,8.0,,4189.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,12166.0,BAO_0000219,,CHEMBL619992,,,,,H,Autocuration,11311.0,8.0,,4190.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,12166.0,BAO_0000218,,CHEMBL619993,In vivo,,,,H,Autocuration,11311.0,8.0,,4191.0,,,
,1.0,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL619994,,,,,H,Autocuration,11311.0,8.0,663.0,4192.0,,,
,1.0,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL619995,,,,,H,Autocuration,11311.0,8.0,663.0,4193.0,,,
,1.0,B,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,12166.0,BAO_0000019,,CHEMBL619996,,,,,H,Autocuration,11311.0,8.0,,4194.0,,,
,1.0,B,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,12166.0,BAO_0000019,,CHEMBL619997,,,,,H,Autocuration,11732.0,8.0,,4195.0,,,
,1.0,B,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,12166.0,BAO_0000019,,CHEMBL619998,,,,,H,Expert,11732.0,8.0,,4196.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,12166.0,BAO_0000019,,CHEMBL619999,,,,,H,Expert,11087.0,8.0,,4197.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,12166.0,BAO_0000019,,CHEMBL620000,,,,,H,Autocuration,11087.0,8.0,,4198.0,,,
,1.0,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL620001,,,,,H,Autocuration,11087.0,8.0,702.0,4199.0,,,
,1.0,B,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,12166.0,BAO_0000357,Rattus norvegicus,CHEMBL620002,,10116.0,,,D,Expert,11087.0,9.0,,4200.0,,,
,1.0,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,RBL-1,12166.0,BAO_0000219,,CHEMBL620003,,,,,H,Autocuration,496.0,8.0,702.0,4201.0,,,
,1.0,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,RBL-1,12166.0,BAO_0000219,,CHEMBL620004,,,,,H,Expert,13986.0,8.0,702.0,4202.0,,,
,1.0,B,Compound was evaluated for the inhibition of 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL874063,,,,,H,Autocuration,11520.0,8.0,,4203.0,,,
,1.0,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620005,,,,,H,Autocuration,10293.0,8.0,702.0,4204.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,RBL-1,12166.0,BAO_0000219,,CHEMBL620006,,,,,H,Autocuration,303.0,8.0,702.0,4205.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,RBL-1,12166.0,BAO_0000219,,CHEMBL620007,,,,,H,Autocuration,303.0,8.0,702.0,4206.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620008,,,,,H,Autocuration,9247.0,8.0,702.0,4207.0,,,
,1.0,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL620009,,10116.0,,,D,Expert,9247.0,9.0,702.0,4208.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,RBL-1,12166.0,BAO_0000219,,CHEMBL620010,,,,,H,Autocuration,9247.0,8.0,702.0,4209.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620011,,,,,H,Autocuration,9247.0,8.0,702.0,4210.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620677,,,,,H,Autocuration,9247.0,8.0,702.0,4211.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620678,,,,,H,Autocuration,9247.0,8.0,702.0,4212.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620679,,,,,H,Autocuration,9247.0,8.0,702.0,4213.0,,,
,1.0,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620680,,,,,H,Autocuration,9247.0,8.0,702.0,4214.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,,12166.0,BAO_0000357,Rattus norvegicus,CHEMBL620838,,10116.0,,,D,Expert,11481.0,9.0,,4215.0,,,
,1.0,B,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,12166.0,BAO_0000357,,CHEMBL620839,,,,,H,Autocuration,105.0,8.0,,4216.0,,,
,1.0,B,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,12166.0,BAO_0000357,,CHEMBL620840,,,,,H,Expert,9029.0,8.0,,4217.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620841,,,,,H,Expert,1175.0,8.0,702.0,4218.0,,,
,1.0,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620842,,,,,H,Autocuration,12118.0,8.0,702.0,4219.0,,,
,1.0,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,RBL-1,12166.0,BAO_0000219,,CHEMBL620843,,,,,H,Autocuration,12118.0,8.0,702.0,4220.0,,,
,1.0,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620844,,,,,H,Autocuration,12118.0,8.0,702.0,4221.0,,,
,1.0,B,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620845,,,,,H,Autocuration,9225.0,8.0,702.0,4222.0,,,
,1.0,B,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,12166.0,BAO_0000019,,CHEMBL620846,,,,,H,Autocuration,9401.0,8.0,,4223.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,12166.0,BAO_0000357,,CHEMBL873951,,,,,H,Autocuration,137.0,8.0,,4224.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,12166.0,BAO_0000357,,CHEMBL620847,,,,,H,Autocuration,137.0,8.0,,4225.0,,,
,1.0,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,RBL-1,12166.0,BAO_0000219,,CHEMBL620848,,,,,H,Autocuration,4717.0,8.0,702.0,4226.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620849,,,,,H,Autocuration,3595.0,8.0,702.0,4227.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,RBL-1,12166.0,BAO_0000219,,CHEMBL620850,,,,,H,Autocuration,10501.0,8.0,702.0,4228.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620851,,,,,H,Autocuration,10501.0,8.0,702.0,4229.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,RBL-1,12166.0,BAO_0000219,,CHEMBL620852,,,,,H,Autocuration,10501.0,8.0,702.0,4230.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166.0,BAO_0000219,,CHEMBL875098,,,,,H,Autocuration,12526.0,8.0,702.0,4231.0,,,
,1.0,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL620853,,10116.0,,,D,Expert,14799.0,9.0,702.0,4232.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,12166.0,BAO_0000019,,CHEMBL620854,,,,,H,Autocuration,14799.0,8.0,,4233.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620855,,,,,H,Autocuration,3595.0,8.0,702.0,4234.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL839884,,,,,H,Expert,3595.0,8.0,702.0,4235.0,,,
,1.0,B,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166.0,BAO_0000219,,CHEMBL620856,,,,,H,Autocuration,12526.0,8.0,702.0,4236.0,,,
,1.0,B,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,RBL-1,12166.0,BAO_0000219,,CHEMBL620857,,,,,H,Autocuration,12526.0,8.0,702.0,4237.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,12166.0,BAO_0000019,,CHEMBL620858,,,,,H,Autocuration,10193.0,8.0,,4238.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,12166.0,BAO_0000019,,CHEMBL620859,,,,,H,Autocuration,10193.0,8.0,,4239.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,12166.0,BAO_0000019,,CHEMBL620860,,,,,H,Autocuration,10193.0,8.0,,4240.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,12166.0,BAO_0000019,,CHEMBL620861,,,,,H,Autocuration,10193.0,8.0,,4241.0,,,
,1.0,B,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,12166.0,BAO_0000357,,CHEMBL620862,,,,,H,Expert,9138.0,8.0,,4242.0,,,
,1.0,B,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,12166.0,BAO_0000357,,CHEMBL620863,,,,,H,Autocuration,9138.0,8.0,,4243.0,,,
,1.0,B,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,12166.0,BAO_0000019,,CHEMBL620864,,,,,H,Autocuration,11966.0,8.0,,4244.0,,,
,1.0,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620865,,,,,H,Autocuration,165.0,8.0,702.0,4245.0,,,
,1.0,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620866,,,,,H,Autocuration,165.0,8.0,702.0,4246.0,,,
,1.0,B,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL620867,,,,,H,Autocuration,11311.0,8.0,663.0,4247.0,,,
,1.0,B,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL620868,,,,,H,Autocuration,11311.0,8.0,663.0,4248.0,,,
,1.0,F,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL620869,,,,,H,Autocuration,11311.0,8.0,663.0,4249.0,,,
,1.0,F,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,12166.0,BAO_0000019,,CHEMBL873952,,,,,H,Autocuration,11311.0,8.0,,4250.0,,,
,1.0,B,The compound was tested for inhibition of isolated 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL875099,,,,,H,Autocuration,11311.0,8.0,,4251.0,,,
,1.0,F,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,RBL-2H3,12166.0,BAO_0000219,,CHEMBL620870,,,,,H,Autocuration,11311.0,8.0,663.0,4252.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,12166.0,BAO_0000019,,CHEMBL618261,,,,,H,Autocuration,11087.0,8.0,,4253.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,12166.0,BAO_0000019,,CHEMBL618262,,,,,H,Autocuration,11087.0,8.0,,4254.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,12166.0,BAO_0000019,,CHEMBL619428,,,,,H,Autocuration,11087.0,8.0,,4255.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,12166.0,BAO_0000019,,CHEMBL619429,,,,,H,Autocuration,11087.0,8.0,,4256.0,,,
,1.0,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,12166.0,BAO_0000019,,CHEMBL619430,,,,,H,Autocuration,11087.0,8.0,,4257.0,,,
,1.0,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620017,,,,,H,Autocuration,496.0,8.0,702.0,4258.0,,,
,1.0,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620018,,,,,H,Autocuration,496.0,8.0,702.0,4259.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620019,,,,,H,Autocuration,13986.0,8.0,702.0,4260.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620020,,,,,H,Autocuration,13986.0,8.0,702.0,4261.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620021,,,,,H,Autocuration,13986.0,8.0,702.0,4262.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620022,,,,,H,Autocuration,13986.0,8.0,702.0,4263.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,RBL-1,12166.0,BAO_0000219,,CHEMBL620023,,,,,H,Autocuration,13986.0,8.0,702.0,4264.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620024,,,,,H,Autocuration,13986.0,8.0,702.0,4265.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620025,,,,,H,Autocuration,13986.0,8.0,702.0,4266.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620026,,,,,H,Autocuration,13986.0,8.0,702.0,4267.0,,,
,1.0,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL620027,,,,,H,Autocuration,13986.0,8.0,702.0,4268.0,,,
,1.0,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,12166.0,BAO_0000019,Rattus norvegicus,CHEMBL620028,,10116.0,,,D,Expert,13986.0,9.0,,4269.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,12166.0,BAO_0000357,,CHEMBL620029,,,,,H,Autocuration,10193.0,8.0,,4270.0,,,
,1.0,B,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,12166.0,BAO_0000357,,CHEMBL620030,,,,,H,Autocuration,9295.0,8.0,,4271.0,,,
,1.0,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,RBL-1,12166.0,BAO_0000219,,CHEMBL875415,,,,,H,Autocuration,4717.0,8.0,702.0,4272.0,,,
,1.0,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,RBL-1,12166.0,BAO_0000219,,CHEMBL618256,,,,,H,Autocuration,4717.0,8.0,702.0,4273.0,,,
,1.0,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,RBL-1,12166.0,BAO_0000219,,CHEMBL618257,,,,,H,Autocuration,11854.0,8.0,702.0,4274.0,,,
,1.0,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618258,,,,,H,Autocuration,11854.0,8.0,702.0,4275.0,,,
,1.0,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618259,,,,,H,Autocuration,11854.0,8.0,702.0,4276.0,,,
,1.0,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,12166.0,BAO_0000019,,CHEMBL618260,,,,,H,Autocuration,10193.0,8.0,,4277.0,,,
,1.0,B,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618215,,,,,H,Autocuration,9295.0,8.0,702.0,4278.0,,,
,1.0,B,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618390,,,,,H,Autocuration,9295.0,8.0,702.0,4279.0,,,
,1.0,B,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618391,,,,,H,Autocuration,9295.0,8.0,702.0,4280.0,,,
,1.0,B,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618392,,,,,H,Autocuration,9295.0,8.0,702.0,4281.0,,,
,1.0,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,RBL-1,12166.0,BAO_0000219,,CHEMBL618393,,,,,H,Autocuration,165.0,8.0,702.0,4282.0,,,
,1.0,B,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,12166.0,BAO_0000219,,CHEMBL618394,,,,,H,Autocuration,11311.0,8.0,,4283.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,RBL-1,12166.0,BAO_0000219,Homo sapiens,CHEMBL618395,,9606.0,,,H,Expert,10489.0,8.0,702.0,4284.0,,,
,1.0,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL618396,,10116.0,,,D,Expert,10489.0,9.0,702.0,4285.0,,,
,1.0,B,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,RBL-1,12166.0,BAO_0000219,Rattus norvegicus,CHEMBL858253,,10116.0,,,D,Expert,10489.0,9.0,702.0,4286.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,12166.0,BAO_0000019,Rattus norvegicus,CHEMBL618397,,10116.0,,,D,Autocuration,14799.0,9.0,,4287.0,,,
,1.0,B,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,12054.0,BAO_0000357,Glycine max,CHEMBL618398,,3847.0,,,H,Autocuration,9295.0,8.0,,4288.0,,,
,1.0,B,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,22226.0,BAO_0000019,,CHEMBL618399,,,,,U,Autocuration,16811.0,0.0,,4289.0,,,
,1.0,B,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,55.0,BAO_0000357,,CHEMBL618400,,,,,H,Expert,168.0,8.0,,4290.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,55.0,BAO_0000357,,CHEMBL618401,,,,,H,Autocuration,6309.0,8.0,,4291.0,,,
,1.0,B,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,55.0,BAO_0000357,,CHEMBL618402,,,,,H,Autocuration,6309.0,8.0,,4292.0,,,
,1.0,B,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,RBL-1,55.0,BAO_0000219,,CHEMBL876400,,,,,H,Autocuration,3092.0,8.0,702.0,4293.0,,,
,1.0,B,Inhibitory activity against 5-lipoxygenase.,,,55.0,BAO_0000357,,CHEMBL618403,,,,,H,Expert,168.0,8.0,,4294.0,,,
,1.0,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,55.0,BAO_0000357,,CHEMBL618404,,,,,H,Autocuration,168.0,8.0,,4295.0,,,
,1.0,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,55.0,BAO_0000357,,CHEMBL618405,,,,,H,Autocuration,168.0,8.0,,4296.0,,,
,1.0,B,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,55.0,BAO_0000357,,CHEMBL618406,,,,,H,Autocuration,168.0,8.0,,4297.0,,,
,1.0,F,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,55.0,BAO_0000019,,CHEMBL618407,,,,,H,Expert,12338.0,8.0,,4298.0,,,
,1.0,B,Tested for the inhibitory activity against 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618408,,,,,H,Autocuration,4501.0,8.0,,4299.0,,,
,1.0,B,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,55.0,BAO_0000357,,CHEMBL618409,,,,,H,Autocuration,1132.0,8.0,,4300.0,,,
,1.0,B,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,55.0,BAO_0000357,,CHEMBL618410,,,,,H,Autocuration,2117.0,8.0,,4301.0,,,
,1.0,B,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,55.0,BAO_0000357,,CHEMBL618411,,,,,H,Autocuration,168.0,8.0,,4302.0,,,
,1.0,B,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,55.0,BAO_0000357,,CHEMBL618412,,,,,H,Autocuration,168.0,8.0,,4303.0,,,
,1.0,B,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,RBL-1,12166.0,BAO_0000219,,CHEMBL618413,,,,,H,Autocuration,13575.0,8.0,702.0,4304.0,,,
,1.0,B,,,,12166.0,BAO_0000357,,CHEMBL618414,,,,,H,Autocuration,11089.0,8.0,,4305.0,,,
,1.0,B,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,10102.0,BAO_0000357,,CHEMBL618415,,,,,H,Autocuration,216.0,8.0,,4306.0,,,
,1.0,B,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,10102.0,BAO_0000019,,CHEMBL618416,,,,,H,Autocuration,13165.0,8.0,,4307.0,,,
,1.0,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,10102.0,BAO_0000357,,CHEMBL876401,,,,,H,Autocuration,3278.0,8.0,,4308.0,,,
,1.0,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,10102.0,BAO_0000357,,CHEMBL618417,,,,,H,Expert,3278.0,8.0,,4309.0,,,
,1.0,B,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,10102.0,BAO_0000357,,CHEMBL618418,,,,,H,Autocuration,11966.0,8.0,,4310.0,,,
,1.0,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,10102.0,BAO_0000357,,CHEMBL618419,,,,,H,Autocuration,175.0,8.0,,4311.0,,,
,1.0,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,10102.0,BAO_0000357,,CHEMBL618420,,,,,H,Autocuration,175.0,8.0,,4312.0,,,
,1.0,B,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,10102.0,BAO_0000357,,CHEMBL618421,,,,,H,Autocuration,13449.0,8.0,,4313.0,,,
,1.0,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,11238.0,BAO_0000019,,CHEMBL618422,,,,,H,Autocuration,12014.0,8.0,,4314.0,,,
,1.0,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,11238.0,BAO_0000019,,CHEMBL618423,,,,,H,Autocuration,12014.0,8.0,,4315.0,,,
,1.0,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,11238.0,BAO_0000019,,CHEMBL618424,,,,,H,Autocuration,12014.0,8.0,,4316.0,,,
,1.0,B,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,100284.0,BAO_0000220,,CHEMBL618425,,,,,S,Intermediate,99.0,2.0,,4317.0,,,
,1.0,F,The dark toxicity against 543 human galactophore carcinoma cells,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL618426,,9606.0,,,U,Autocuration,4349.0,0.0,,4318.0,,,
,1.0,F,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Panel (56 tumour cell lines),80623.0,BAO_0000219,Homo sapiens,CHEMBL618427,,9606.0,,,N,Expert,4071.0,1.0,390.0,4319.0,,,
,1.0,F,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618428,,9606.0,,,N,Expert,17589.0,1.0,345.0,4320.0,,,
,1.0,F,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618429,,9606.0,,,N,Intermediate,15002.0,1.0,345.0,4321.0,,,
,1.0,F,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618430,,9606.0,,,N,Intermediate,13958.0,1.0,345.0,4322.0,,,
,1.0,F,Growth inhibition against human 5637 cell lines,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618431,,9606.0,,,N,Expert,17589.0,1.0,345.0,4323.0,,,
,1.0,F,Antitumor activity against human bladder carcinoma 5637 cells.,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL883799,,9606.0,,,N,Expert,16748.0,1.0,345.0,4324.0,,,
,1.0,F,Antitumor activity against human bladder carcinoma 5637 cells,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618432,,9606.0,,,N,Intermediate,16747.0,1.0,345.0,4325.0,,,
,1.0,F,Antitumor activity against human bladder carcinoma 5637 cells,,5637,80008.0,BAO_0000219,Homo sapiens,CHEMBL618433,,9606.0,,,N,Intermediate,16747.0,1.0,345.0,4326.0,,,
,1.0,B,In vitro inhibition of bovine trypsin(Trp).,,,10443.0,BAO_0000357,Bos taurus,CHEMBL618434,,9913.0,,,D,Expert,15285.0,9.0,,4327.0,,,
,1.0,B,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,CV-1,240.0,BAO_0000219,Cercopithecidae,CHEMBL618435,,9527.0,,,H,Expert,3726.0,8.0,407.0,4328.0,,,
,1.0,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,10577.0,BAO_0000357,,CHEMBL876402,,,,,H,Autocuration,5033.0,8.0,,4329.0,,,
,1.0,F,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,104698.0,BAO_0000019,,CHEMBL618436,,,,,H,Autocuration,11756.0,6.0,,4330.0,,,
,1.0,F,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,22226.0,BAO_0000218,,CHEMBL618437,In vivo,,,,U,Autocuration,11953.0,0.0,,4331.0,,,
,1.0,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,20033.0,BAO_0000357,Cavia porcellus,CHEMBL618438,,10141.0,,,D,Intermediate,5033.0,9.0,,4332.0,,,
,1.0,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,17045.0,BAO_0000251,Rattus norvegicus,CHEMBL883800,,10116.0,,,H,Expert,11347.0,8.0,,4333.0,Microsomes,,
,1.0,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,17045.0,BAO_0000251,Rattus norvegicus,CHEMBL618439,,10116.0,,,H,Expert,11347.0,8.0,,4334.0,Microsomes,,
,1.0,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL618440,,,,,U,Intermediate,1229.0,0.0,,4335.0,,,
,1.0,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL618441,,,,,U,Intermediate,1229.0,0.0,,4336.0,,,
,1.0,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,11938.0,BAO_0000019,Trypanosoma brucei,CHEMBL618442,,5691.0,,,H,Expert,17588.0,8.0,,4337.0,,,
,1.0,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,11938.0,BAO_0000019,Trypanosoma brucei,CHEMBL618443,,5691.0,,,H,Autocuration,17588.0,8.0,,4338.0,,,
,1.0,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,11938.0,BAO_0000019,Ovis aries,CHEMBL619158,,9940.0,,,H,Expert,17588.0,8.0,,4339.0,,,
,1.0,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,11938.0,BAO_0000019,Ovis aries,CHEMBL620974,,9940.0,,,H,Autocuration,17588.0,8.0,,4340.0,,,
,1.0,B,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,11938.0,BAO_0000357,,CHEMBL620975,,,,,H,Autocuration,16485.0,8.0,,4341.0,,,
,1.0,F,Average inhibitory concentration against 60 human cell lines was reported,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL620976,,9606.0,,,U,Intermediate,4337.0,0.0,,4342.0,,,
,1.0,F,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,22226.0,BAO_0000019,Homo sapiens,CHEMBL620977,,9606.0,,,U,Expert,4112.0,0.0,,4343.0,,,
,1.0,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,Homo sapiens,CHEMBL620978,,9606.0,,,N,Intermediate,16160.0,1.0,542.0,4344.0,,,
,1.0,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,Homo sapiens,CHEMBL620979,,9606.0,,,N,Intermediate,16160.0,1.0,542.0,4345.0,,,
,1.0,F,In vitro mean growth inhibitory activity against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,,CHEMBL620980,,,,,N,Expert,17376.0,1.0,542.0,4346.0,,,
,1.0,F,In vitro mean growth lethal concentration against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,,CHEMBL620981,,,,,N,Expert,17376.0,1.0,542.0,4347.0,,,
,1.0,F,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,,CHEMBL620982,,,,,N,Expert,17376.0,1.0,542.0,4348.0,,,
,1.0,F,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,Panel NCI-60 (60 carcinoma cell lines),80315.0,BAO_0000219,,CHEMBL620983,,,,,N,Expert,17376.0,1.0,542.0,4349.0,,,
,1.0,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,104775.0,BAO_0000019,,CHEMBL620984,,,,,H,Autocuration,3241.0,4.0,,4350.0,,,
,1.0,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,104775.0,BAO_0000019,,CHEMBL620985,,,,,H,Autocuration,3241.0,4.0,,4351.0,,,
,1.0,B,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,275.0,BAO_0000357,,CHEMBL620986,,,,,H,Expert,3725.0,8.0,,4352.0,,,
,1.0,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,50425.0,BAO_0000218,Plasmodium falciparum,CHEMBL620987,,5833.0,,,N,Expert,10805.0,1.0,,4353.0,,,
,1.0,F,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,50425.0,BAO_0000218,Plasmodium falciparum,CHEMBL620988,,5833.0,,,N,Expert,10805.0,1.0,,4354.0,,,
,1.0,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,50425.0,BAO_0000218,Plasmodium falciparum,CHEMBL620989,,5833.0,,,N,Expert,10805.0,1.0,,4355.0,,,
,1.0,F,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,50425.0,BAO_0000218,Plasmodium falciparum,CHEMBL620990,,5833.0,,,N,Expert,10805.0,1.0,,4356.0,,,
,1.0,F,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,50425.0,BAO_0000218,Plasmodium falciparum,CHEMBL620991,,5833.0,,,N,Intermediate,10805.0,1.0,,4357.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL620992,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4358.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL620993,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4359.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL620994,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4360.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL620995,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4361.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL620996,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4362.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL875581,,10090.0,,,N,Intermediate,10144.0,1.0,850.0,4363.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL620997,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4364.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL620998,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4365.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,22224.0,BAO_0000218,Mus musculus,CHEMBL620999,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4366.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621000,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4367.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621001,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4368.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621002,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4369.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621003,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4370.0,,,
,1.0,F,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,22224.0,BAO_0000218,Mus musculus,CHEMBL621004,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4371.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,22224.0,BAO_0000218,Mus musculus,CHEMBL621005,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4372.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,22224.0,BAO_0000218,Mus musculus,CHEMBL621006,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4373.0,,,
,1.0,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621007,In vivo,10090.0,,,U,Autocuration,10685.0,0.0,,4374.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621008,,10090.0,,,U,Autocuration,10144.0,0.0,,4375.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,22224.0,BAO_0000218,Mus musculus,CHEMBL621009,,10090.0,,,U,Autocuration,10144.0,0.0,,4376.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,22224.0,BAO_0000218,Mus musculus,CHEMBL857705,,10090.0,,,U,Autocuration,10144.0,0.0,,4377.0,,,
,1.0,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619828,,10090.0,,,U,Autocuration,10144.0,0.0,,4378.0,,,
,1.0,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619829,,10090.0,,,U,Autocuration,10685.0,0.0,,4379.0,,,
,1.0,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619830,,10090.0,,,U,Autocuration,10685.0,0.0,,4380.0,,,
,1.0,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619831,,10090.0,,,U,Autocuration,10685.0,0.0,,4381.0,,,
,1.0,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619832,,10090.0,,,U,Autocuration,10685.0,0.0,,4382.0,,,
,1.0,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619833,,10090.0,,,U,Autocuration,10685.0,0.0,,4383.0,,,
,1.0,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619834,,10090.0,,,U,Autocuration,10685.0,0.0,,4384.0,,,
,1.0,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619835,,10090.0,,,U,Autocuration,10685.0,0.0,,4385.0,,,
,1.0,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,22224.0,BAO_0000218,Mus musculus,CHEMBL619836,,10090.0,,,U,Autocuration,10685.0,0.0,,4386.0,,,
,1.0,F,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL619837,,10090.0,,,N,Intermediate,8831.0,1.0,850.0,4387.0,,,
,1.0,F,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,22224.0,BAO_0000218,,CHEMBL619838,In vivo,,,,U,Autocuration,11704.0,0.0,,4388.0,,,
,1.0,A,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619839,,10090.0,,,N,Intermediate,11704.0,1.0,,4389.0,,,
,1.0,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL619840,In vivo,10090.0,,,N,Intermediate,10685.0,1.0,850.0,4390.0,,,
,1.0,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL619841,In vivo,10090.0,,,N,Intermediate,10685.0,1.0,850.0,4391.0,,,
,1.0,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL857704,,10090.0,,,N,Expert,11368.0,1.0,850.0,4392.0,,,
,1.0,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL619842,,10090.0,,,N,Intermediate,11368.0,1.0,850.0,4393.0,,,
,1.0,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,6C3HED,80628.0,BAO_0000218,Mus musculus,CHEMBL619843,,10090.0,,,N,Expert,11368.0,1.0,850.0,4394.0,,,
,1.0,B,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,22226.0,BAO_0000019,Staphylococcus aureus,CHEMBL619844,,1280.0,,,U,Autocuration,17763.0,0.0,,4395.0,,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL857855,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4396.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619845,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4397.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619846,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4398.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619847,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4399.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL619848,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4400.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620893,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4401.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620894,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4402.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620895,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4403.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620896,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4404.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620897,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4405.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620898,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4406.0,Microsomes,,
Liver,1.0,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,22226.0,BAO_0000251,Rattus norvegicus,CHEMBL620899,,10116.0,2107.0,,U,Autocuration,7411.0,0.0,,4407.0,Microsomes,,
Plasma,1.0,A,The apparent total plasma clearance in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620900,In vivo,9527.0,1969.0,,U,Autocuration,347.0,0.0,,4408.0,,,
,1.0,A,Compound was evaluated for Hepatic clearance in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620901,In vivo,9527.0,,,U,Autocuration,3341.0,0.0,,4409.0,,,
,1.0,A,Lower clearance in monkey (i.v.) at 0.5 mpk,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620902,In vivo,9527.0,,,U,Autocuration,17853.0,0.0,,4410.0,,,
,1.0,A,Plasma clearance in rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620903,In vivo,9527.0,,,U,Autocuration,4514.0,0.0,,4411.0,,,
,1.0,A,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620904,In vivo,9527.0,,,U,Autocuration,6062.0,0.0,,4412.0,,,
,1.0,A,Plasma clearance of compound was determined in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620905,In vivo,9527.0,,,U,Autocuration,6821.0,0.0,,4413.0,,,
,1.0,A,Plasma clearance was calculated in rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620906,In vivo,9527.0,,,U,Autocuration,6057.0,0.0,,4414.0,,,
,1.0,A,Plasma clearance in rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL875420,In vivo,9527.0,,,U,Autocuration,5145.0,0.0,,4415.0,,,
,1.0,A,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620907,In vivo,9527.0,,,U,Autocuration,6641.0,0.0,,4416.0,,,
,1.0,A,Plasma clearance was evaluated in rhesus,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620908,In vivo,9527.0,,,U,Autocuration,5472.0,0.0,,4417.0,,,
,1.0,A,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620909,In vivo,9527.0,,,U,Autocuration,4257.0,0.0,,4418.0,,,
,1.0,A,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620910,In vivo,9527.0,,,U,Autocuration,5546.0,0.0,,4419.0,,,
,1.0,A,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620911,In vivo,9527.0,,,U,Autocuration,5334.0,0.0,,4420.0,,,
,1.0,A,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620912,In vivo,9527.0,,,U,Autocuration,5334.0,0.0,,4421.0,,,
,1.0,A,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620913,In vivo,9527.0,,,U,Autocuration,17509.0,0.0,,4422.0,,,
,1.0,A,Cmax in monkey after administration of 1 mg/kg iv,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620914,In vivo,9527.0,,,U,Autocuration,6535.0,0.0,,4423.0,,,
,1.0,A,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620915,In vivo,9527.0,,,U,Autocuration,5668.0,0.0,,4424.0,,,
,1.0,A,Cmax in cynomolgus monkey by iv administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620916,In vivo,9527.0,,,U,Autocuration,5922.0,0.0,,4425.0,,,
,1.0,A,Cmax in cynomolgus monkey by po administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620917,In vivo,9527.0,,,U,Autocuration,5922.0,0.0,,4426.0,,,
,1.0,A,Cmax value evaluated in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620918,In vivo,9527.0,,,U,Autocuration,6078.0,0.0,,4427.0,,,
,1.0,A,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620919,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,4428.0,,,
Plasma,1.0,A,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620920,In vivo,9527.0,1969.0,,U,Autocuration,3249.0,0.0,,4429.0,,,
Plasma,1.0,A,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620921,In vivo,9527.0,1969.0,,U,Autocuration,3249.0,0.0,,4430.0,,,
Plasma,1.0,A,Maximal plasma concentration in squirrel monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620922,In vivo,9527.0,1969.0,,U,Autocuration,5553.0,0.0,,4431.0,,,
,1.0,A,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620923,In vivo,9527.0,,,U,Autocuration,1916.0,0.0,,4432.0,,,
Plasma,1.0,A,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620924,In vivo,9527.0,1969.0,,U,Autocuration,6227.0,0.0,,4433.0,,,
,1.0,A,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620925,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4434.0,,,
,1.0,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620926,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4435.0,,,
,1.0,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620927,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4436.0,,,
,1.0,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620928,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4437.0,,,
,1.0,A,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620929,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4438.0,,,
Plasma,1.0,A,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620930,In vivo,9527.0,1969.0,,U,Autocuration,6221.0,0.0,,4439.0,,,
,1.0,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620931,,9527.0,,,U,Autocuration,167.0,0.0,,4440.0,,,
,1.0,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620932,,9527.0,,,U,Autocuration,167.0,0.0,,4441.0,,,
,1.0,A,Absolute bioavailability was evaluated in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620933,In vivo,9443.0,,,U,Autocuration,4257.0,0.0,,4442.0,,,
,1.0,A,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,22224.0,BAO_0000218,monkey,CHEMBL620934,In vivo,9443.0,,,U,Autocuration,6221.0,0.0,,4443.0,,,
,1.0,A,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,22224.0,BAO_0000218,monkey,CHEMBL620935,In vivo,9443.0,,,U,Autocuration,17667.0,0.0,,4444.0,,,
,1.0,A,Bioavailability of compound was determined in rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620936,In vivo,9544.0,,,U,Autocuration,17267.0,0.0,,4445.0,,,
,1.0,A,Bioavailability determined after oral administration in marmoset,,,22224.0,BAO_0000218,marmosets,CHEMBL620937,In vivo,38020.0,,,U,Autocuration,4256.0,0.0,,4446.0,,,
,1.0,A,Oral bioavailability in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL620938,In vivo,9541.0,,,U,Autocuration,4256.0,0.0,,4447.0,,,
,1.0,A,Bioavailability in monkey (p.o.) at 2.0 mpk,,,22224.0,BAO_0000218,monkey,CHEMBL620939,In vivo,9443.0,,,U,Autocuration,17853.0,0.0,,4448.0,,,
,1.0,A,Bioavailability was evaluated after oral administration in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620940,In vivo,9443.0,,,U,Autocuration,16365.0,0.0,,4449.0,,,
,1.0,A,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL620941,In vivo,9541.0,,,U,Autocuration,1916.0,0.0,,4450.0,,,
,1.0,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620942,In vivo,9544.0,,,U,Autocuration,5334.0,0.0,,4451.0,,,
,1.0,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620943,In vivo,9544.0,,,U,Autocuration,5334.0,0.0,,4452.0,,,
,1.0,A,Bioavailability of the compound was determined in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620944,In vivo,9443.0,,,U,Autocuration,17592.0,0.0,,4453.0,,,
,1.0,A,Bioavailability in squirrel monkey (dose 5 mg/kg),,,22224.0,BAO_0000218,Saimiri sciureus,CHEMBL620945,In vivo,9521.0,,,U,Autocuration,1399.0,0.0,,4454.0,,,
,1.0,A,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224.0,BAO_0000218,monkey,CHEMBL620946,In vivo,9443.0,,,U,Autocuration,4809.0,0.0,,4455.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620947,In vivo,9443.0,,,U,Autocuration,3341.0,0.0,,4456.0,,,
,1.0,A,Compound was tested for bioavailability in squirrel monkey,,,22224.0,BAO_0000218,Saimiri sciureus,CHEMBL620948,In vivo,9521.0,,,U,Autocuration,64.0,0.0,,4457.0,,,
,1.0,A,Oral bioavailability in Rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620949,In vivo,9544.0,,,U,Autocuration,5005.0,0.0,,4458.0,,,
,1.0,A,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620950,In vivo,9544.0,,,U,Autocuration,5005.0,0.0,,4459.0,,,
,1.0,A,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL620951,In vivo,9541.0,,,U,Autocuration,5237.0,0.0,,4460.0,,,
,1.0,A,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL620952,In vivo,9541.0,,,U,Autocuration,5237.0,0.0,,4461.0,,,
,1.0,A,Oral bioavailability in monkey (dose 5 mg/kg),,,22224.0,BAO_0000218,monkey,CHEMBL875421,In vivo,9443.0,,,U,Autocuration,5302.0,0.0,,4462.0,,,
,1.0,A,Oral bioavailability of compound at 5 mg/kg in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620953,In vivo,9443.0,,,U,Autocuration,17667.0,0.0,,4463.0,,,
,1.0,A,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873491,In vivo,9615.0,,,N,Intermediate,6161.0,1.0,,4464.0,,,
,1.0,A,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620954,In vivo,9615.0,,,N,Intermediate,6161.0,1.0,,4465.0,,,
Plasma,1.0,A,Plasma half life determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620955,,9615.0,1969.0,,N,Intermediate,3854.0,1.0,,4466.0,,,
Plasma,1.0,A,Plasma half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618097,,9615.0,1969.0,,N,Intermediate,993.0,1.0,,4467.0,,,
Plasma,1.0,A,Plasma half-life in Beagle dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618268,,9615.0,1969.0,,N,Intermediate,4514.0,1.0,,4468.0,,,
Plasma,1.0,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618269,In vivo,9615.0,1969.0,,N,Intermediate,5334.0,1.0,,4469.0,,,
Plasma,1.0,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618270,In vivo,9615.0,1969.0,,N,Intermediate,5334.0,1.0,,4470.0,,,
,1.0,A,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618271,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,4471.0,,,
,1.0,A,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873493,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,4472.0,,,
,1.0,A,Tested for the half life period in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621031,,9615.0,,,N,Intermediate,5313.0,1.0,,4473.0,,,
,1.0,A,Tested for the half life period in dog at dosage of 10 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621032,In vivo,9615.0,,,N,Intermediate,5313.0,1.0,,4474.0,,,
,1.0,A,The compound was tested for half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621033,,9615.0,,,N,Intermediate,3880.0,1.0,,4475.0,,,
Plasma,1.0,A,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621034,,9615.0,1969.0,,N,Intermediate,3639.0,1.0,,4476.0,,,
,1.0,A,The half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621035,,9615.0,,,N,Intermediate,3880.0,1.0,,4477.0,,,
Plasma,1.0,A,The plasma half-life in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621036,,9615.0,1969.0,,N,Intermediate,3918.0,1.0,,4478.0,,,
Plasma,1.0,A,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621037,,9615.0,1969.0,,N,Intermediate,16452.0,1.0,,4479.0,,,
,1.0,A,Half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619812,,9615.0,,,N,Intermediate,17796.0,1.0,,4480.0,,,
,1.0,A,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619813,In vivo,9615.0,,,N,Intermediate,5983.0,1.0,,4481.0,,,
,1.0,A,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873335,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,4482.0,,,
,1.0,A,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619814,In vivo,9615.0,,,N,Intermediate,16456.0,1.0,,4483.0,,,
,1.0,A,Cmax in ferrets after 30 mg/kg oral dose,,,50506.0,BAO_0000218,Mustela putorius furo,CHEMBL619815,In vivo,9669.0,,,N,Expert,6113.0,1.0,,4484.0,,,
,1.0,F,Emesis in ferrets at 30 mg/kg oral dose,,,50506.0,BAO_0000218,Mustela putorius furo,CHEMBL619816,In vivo,9669.0,,,N,Expert,6113.0,1.0,,4485.0,,,
,1.0,A,Bioavailability in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL619817,In vivo,9541.0,,,U,Autocuration,17796.0,0.0,,4486.0,,,
,1.0,A,Volume of distribution in cynomolgus,,,100710.0,BAO_0000218,Macaca fascicularis,CHEMBL619818,In vivo,9541.0,,,N,Intermediate,17796.0,1.0,,4487.0,,,
Plasma,1.0,A,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619819,,10141.0,1969.0,,U,Autocuration,5308.0,0.0,,4488.0,,,
,1.0,A,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619820,,10141.0,,,U,Autocuration,4877.0,0.0,,4489.0,,,
,1.0,A,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL875419,,10141.0,,,U,Autocuration,4876.0,0.0,,4490.0,,,
Plasma,1.0,A,AUC in guinea pig after 3mg/kg oral dose,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619821,In vivo,10141.0,1969.0,,U,Autocuration,4878.0,0.0,,4491.0,,,
,1.0,A,Bioavailability in guinea pig was tested,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619822,In vivo,10141.0,,,U,Autocuration,5308.0,0.0,,4492.0,,,
,1.0,A,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619823,In vivo,10141.0,,,U,Autocuration,4877.0,0.0,,4493.0,,,
,1.0,A,Tested for the oral bioavailability of the compound,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619824,In vivo,10141.0,,,U,Autocuration,4876.0,0.0,,4494.0,,,
,1.0,A,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619825,In vivo,10141.0,,,U,Autocuration,4876.0,0.0,,4495.0,,,
,1.0,A,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619826,In vivo,10141.0,,,U,Autocuration,5308.0,0.0,,4496.0,,,
Lung,1.0,A,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL619827,In vivo,10141.0,2048.0,,U,Autocuration,4877.0,0.0,,4497.0,,,
,1.0,A,Cmax in guinea pig after 3mg/kg oral dose,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618167,In vivo,10141.0,,,U,Autocuration,4878.0,0.0,,4498.0,,,
Blood,1.0,A,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618168,,10141.0,178.0,,U,Autocuration,5689.0,0.0,,4499.0,,,
Brain,1.0,A,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618169,,10141.0,955.0,,U,Autocuration,5689.0,0.0,,4500.0,,,
,1.0,A,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618170,,10141.0,,,U,Autocuration,5689.0,0.0,,4501.0,,,
Intestine,1.0,A,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618171,,10141.0,160.0,,U,Autocuration,5689.0,0.0,,4502.0,,,
Kidney,1.0,A,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618172,,10141.0,2113.0,,U,Autocuration,5689.0,0.0,,4503.0,,,
Liver,1.0,A,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618173,,10141.0,2107.0,,U,Autocuration,5689.0,0.0,,4504.0,,,
,1.0,A,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618174,,10141.0,,,U,Autocuration,5689.0,0.0,,4505.0,,,
Spleen,1.0,A,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL875408,,10141.0,2106.0,,U,Autocuration,5689.0,0.0,,4506.0,,,
,1.0,A,Elimination T1/2 in Guinea pig (PO dose),,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL839827,In vivo,10141.0,,,U,Autocuration,14465.0,0.0,,4507.0,,,
,1.0,A,Partition coefficient was measured as -log (counts per min ),,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618175,,10141.0,,,U,Autocuration,5689.0,0.0,,4508.0,,,
,1.0,A,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618176,In vivo,10141.0,,,U,Autocuration,611.0,0.0,,4509.0,,,
,1.0,A,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618177,In vivo,10141.0,,,U,Autocuration,611.0,0.0,,4510.0,,,
,1.0,A,Elimination T1/2 in Guinea pig (PO dose),,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618178,In vivo,10141.0,,,U,Autocuration,14465.0,0.0,,4511.0,,,
,1.0,A,"Tested for the half life period of the compound, intravenously",,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618179,In vivo,10141.0,,,U,Autocuration,4876.0,0.0,,4512.0,,,
,1.0,A,Half-life was measured,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL873489,,10141.0,,,U,Autocuration,5689.0,0.0,,4513.0,,,
,1.0,A,The time required for onset of inotropy after addition of a single dose of delta F75,,,22224.0,BAO_0000019,Cavia porcellus,CHEMBL618180,,10141.0,,,U,Autocuration,7515.0,0.0,,4514.0,,,
,1.0,A,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618181,In vivo,10141.0,,,U,Autocuration,17667.0,0.0,,4515.0,,,
,1.0,A,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,22224.0,BAO_0000218,Cavia porcellus,CHEMBL618182,In vivo,10141.0,,,U,Autocuration,17667.0,0.0,,4516.0,,,
,1.0,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL618183,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4517.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618184,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4518.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618185,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4519.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618186,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4520.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618187,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4521.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618188,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4522.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875409,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4523.0,,,
,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618189,In vivo,10090.0,,,N,Intermediate,10107.0,1.0,,4524.0,,,
Blood,1.0,A,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618190,In vivo,10090.0,178.0,,N,Intermediate,3655.0,1.0,,4525.0,,,
Blood,1.0,A,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618191,In vivo,10090.0,178.0,,N,Intermediate,3655.0,1.0,,4526.0,,,
Blood,1.0,A,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618192,In vivo,10090.0,178.0,,N,Intermediate,3655.0,1.0,,4527.0,,,
Bone,1.0,A,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618193,In vivo,10090.0,10000001.0,,N,Intermediate,3655.0,1.0,,4528.0,,,
Bone,1.0,A,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618194,In vivo,10090.0,10000001.0,,N,Intermediate,3655.0,1.0,,4529.0,,,
Bone,1.0,A,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618195,In vivo,10090.0,10000001.0,,N,Intermediate,3655.0,1.0,,4530.0,,,
Brain,1.0,A,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618196,In vivo,10090.0,955.0,,N,Intermediate,3655.0,1.0,,4531.0,,,
Brain,1.0,A,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618197,In vivo,10090.0,955.0,,N,Intermediate,3655.0,1.0,,4532.0,,,
Brain,1.0,A,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618198,In vivo,10090.0,955.0,,N,Intermediate,3655.0,1.0,,4533.0,,,
Heart,1.0,A,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618199,In vivo,10090.0,948.0,,N,Intermediate,3655.0,1.0,,4534.0,,,
Heart,1.0,A,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618200,In vivo,10090.0,948.0,,N,Intermediate,3655.0,1.0,,4535.0,,,
Heart,1.0,A,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618201,In vivo,10090.0,948.0,,N,Intermediate,3655.0,1.0,,4536.0,,,
Intestine,1.0,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618202,In vivo,10090.0,160.0,,N,Intermediate,3655.0,1.0,,4537.0,,,
Intestine,1.0,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618203,In vivo,10090.0,160.0,,N,Intermediate,3655.0,1.0,,4538.0,,,
Intestine,1.0,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618204,In vivo,10090.0,160.0,,N,Intermediate,3655.0,1.0,,4539.0,,,
Kidney,1.0,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618205,In vivo,10090.0,2113.0,,N,Intermediate,3655.0,1.0,,4540.0,,,
Kidney,1.0,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618206,In vivo,10090.0,2113.0,,N,Intermediate,3655.0,1.0,,4541.0,,,
Kidney,1.0,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618207,In vivo,10090.0,2113.0,,N,Intermediate,3655.0,1.0,,4542.0,,,
Liver,1.0,A,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618208,In vivo,10090.0,2107.0,,N,Intermediate,3655.0,1.0,,4543.0,,,
Liver,1.0,A,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618932,In vivo,10090.0,2107.0,,N,Intermediate,3655.0,1.0,,4544.0,,,
Liver,1.0,A,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618933,In vivo,10090.0,2107.0,,N,Intermediate,3655.0,1.0,,4545.0,,,
Lung,1.0,A,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618934,In vivo,10090.0,2048.0,,N,Intermediate,3655.0,1.0,,4546.0,,,
Lung,1.0,A,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618935,In vivo,10090.0,2048.0,,N,Intermediate,3655.0,1.0,,4547.0,,,
Lung,1.0,A,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618936,In vivo,10090.0,2048.0,,N,Intermediate,3655.0,1.0,,4548.0,,,
Muscle tissue,1.0,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618937,In vivo,10090.0,2385.0,,N,Intermediate,3655.0,1.0,,4549.0,,,
Muscle tissue,1.0,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618938,In vivo,10090.0,2385.0,,N,Intermediate,3655.0,1.0,,4550.0,,,
Muscle tissue,1.0,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619104,In vivo,10090.0,2385.0,,N,Intermediate,3655.0,1.0,,4551.0,,,
Spleen,1.0,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619105,In vivo,10090.0,2106.0,,N,Intermediate,3655.0,1.0,,4552.0,,,
Spleen,1.0,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619106,In vivo,10090.0,2106.0,,N,Intermediate,3655.0,1.0,,4553.0,,,
Spleen,1.0,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619107,In vivo,10090.0,2106.0,,N,Intermediate,3655.0,1.0,,4554.0,,,
Stomach,1.0,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875410,In vivo,10090.0,945.0,,N,Intermediate,3655.0,1.0,,4555.0,,,
Stomach,1.0,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619108,In vivo,10090.0,945.0,,N,Intermediate,3655.0,1.0,,4556.0,,,
Stomach,1.0,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619109,In vivo,10090.0,945.0,,N,Intermediate,3655.0,1.0,,4557.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619110,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4558.0,,,
,1.0,F,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619111,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4559.0,,,
,1.0,A,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619112,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4560.0,,,
,1.0,A,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619113,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4561.0,,,
,1.0,A,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619114,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4562.0,,,
,1.0,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619115,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4563.0,,,
,1.0,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619116,,9606.0,,,N,Intermediate,3830.0,1.0,478.0,4564.0,,,
,1.0,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619117,,9606.0,,,N,Intermediate,3829.0,1.0,478.0,4565.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against A2780 cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619118,,9606.0,,,N,Intermediate,2040.0,1.0,478.0,4566.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619119,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4567.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619120,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4568.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619121,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4569.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619122,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4570.0,,,
,1.0,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619123,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4571.0,,,
,1.0,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619124,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4572.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619125,,9606.0,,,N,Intermediate,2859.0,1.0,478.0,4573.0,,,
,1.0,F,In vitro inhibitory activity against human tumor cell line A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL875411,,9606.0,,,N,Intermediate,5618.0,1.0,478.0,4574.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619126,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4575.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619127,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4576.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619128,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4577.0,,,
,1.0,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619129,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4578.0,,,
,1.0,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619130,,9606.0,,,N,Intermediate,2113.0,1.0,478.0,4579.0,,,
,1.0,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619131,,9606.0,,,N,Intermediate,2113.0,1.0,478.0,4580.0,,,
,1.0,F,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619132,,9606.0,,,N,Intermediate,16745.0,1.0,478.0,4581.0,,,
,1.0,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL619133,,9606.0,,,N,Expert,16597.0,1.0,478.0,4582.0,,,
,1.0,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619134,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4583.0,,,
,1.0,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619135,,9606.0,,,N,Intermediate,15684.0,1.0,478.0,4584.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619136,,9606.0,,,N,Intermediate,2040.0,1.0,478.0,4585.0,,,
,1.0,F,Relative resistance factor in A2780 cisplatin-resistant line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619137,,9606.0,,,N,Intermediate,2040.0,1.0,478.0,4586.0,,,
,1.0,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL883713,,9606.0,,,N,Intermediate,16165.0,1.0,478.0,4587.0,,,
,1.0,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL875412,,9606.0,,,N,Intermediate,16165.0,1.0,478.0,4588.0,,,
,1.0,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL619138,,9606.0,,,N,Expert,16597.0,1.0,478.0,4589.0,,,
,1.0,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL619262,,9606.0,,,N,Expert,16597.0,1.0,478.0,4590.0,,,
,1.0,F,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619139,,9606.0,,,N,Intermediate,3992.0,1.0,478.0,4591.0,,,
,1.0,F,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619140,,9606.0,,,N,Intermediate,10553.0,1.0,478.0,4592.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619141,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4593.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619142,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4594.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619143,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4595.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619144,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4596.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619145,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4597.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619146,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,4598.0,,,
,1.0,F,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619147,,9606.0,,,N,Intermediate,15569.0,1.0,478.0,4599.0,,,
,1.0,F,Antiproliferative effect of compound on A2780/DX cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619148,,9606.0,,,N,Intermediate,17420.0,1.0,478.0,4600.0,,,
,1.0,F,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619149,,9606.0,,,N,Intermediate,17420.0,1.0,478.0,4601.0,,,
,1.0,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619150,,9606.0,,,N,Intermediate,15099.0,1.0,478.0,4602.0,,,
,1.0,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619151,,9606.0,,,N,Intermediate,15099.0,1.0,478.0,4603.0,,,
,1.0,F,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL883794,,9606.0,,,N,Intermediate,17672.0,1.0,478.0,4604.0,,,
,1.0,F,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619152,,9606.0,,,N,Intermediate,17672.0,1.0,478.0,4605.0,,,
,1.0,F,In vitro cytotoxicity against A2780ADR cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619153,,9606.0,,,N,Intermediate,17270.0,1.0,478.0,4606.0,,,
,1.0,F,In vitro cytotoxicity against A2780CIS cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619154,,9606.0,,,N,Intermediate,17270.0,1.0,478.0,4607.0,,,
,1.0,F,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619155,,9606.0,,,N,Intermediate,5574.0,1.0,478.0,4608.0,,,
,1.0,F,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619156,,9606.0,,,N,Intermediate,2113.0,1.0,478.0,4609.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619157,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4610.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619797,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4611.0,,,
,1.0,A,Oral bioavailability of compound in rhesus macaques,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL619798,In vivo,9544.0,,,U,Autocuration,17839.0,0.0,,4612.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL619799,In vivo,9443.0,,,U,Autocuration,6821.0,0.0,,4613.0,,,
,1.0,A,Oral bioavailability evaluated in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL619800,In vivo,9443.0,,,U,Autocuration,6078.0,0.0,,4614.0,,,
,1.0,A,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,22224.0,BAO_0000218,monkey,CHEMBL619801,In vivo,9443.0,,,U,Autocuration,6535.0,0.0,,4615.0,,,
,1.0,A,Oral bioavailability in Rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL619802,In vivo,9544.0,,,U,Autocuration,4449.0,0.0,,4616.0,,,
,1.0,A,Oral bioavailability was calculated in rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL619803,In vivo,9544.0,,,U,Autocuration,6057.0,0.0,,4617.0,,,
,1.0,A,Oral bioavailability in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL619965,In vivo,9541.0,,,U,Autocuration,5922.0,0.0,,4618.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL619966,In vivo,9443.0,,,U,Autocuration,5940.0,0.0,,4619.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL619967,In vivo,9443.0,,,U,Autocuration,6265.0,0.0,,4620.0,,,
,1.0,A,Oral bioavailability in monkey (dose 1 mg/kg),,,22224.0,BAO_0000218,monkey,CHEMBL620073,In vivo,9443.0,,,U,Autocuration,6265.0,0.0,,4621.0,,,
,1.0,A,Oral bioavailability in monkey (dose 5 mg/kg),,,22224.0,BAO_0000218,monkey,CHEMBL620074,In vivo,9443.0,,,U,Autocuration,6265.0,0.0,,4622.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620075,In vivo,9443.0,,,U,Autocuration,5940.0,0.0,,4623.0,,,
,1.0,A,Oral bioavailability in monkey,,,22224.0,BAO_0000218,monkey,CHEMBL620076,In vivo,9443.0,,,U,Autocuration,5940.0,0.0,,4624.0,,,
,1.0,A,Oral bioavailability in rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620077,In vivo,9544.0,,,U,Autocuration,4514.0,0.0,,4625.0,,,
,1.0,A,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620078,In vivo,9544.0,,,U,Autocuration,5546.0,0.0,,4626.0,,,
,1.0,A,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,22224.0,BAO_0000218,Saimiri sciureus,CHEMBL620079,In vivo,9521.0,,,U,Autocuration,5553.0,0.0,,4627.0,,,
,1.0,A,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224.0,BAO_0000218,monkey,CHEMBL620080,In vivo,9443.0,,,U,Autocuration,6641.0,0.0,,4628.0,,,
,1.0,A,Oral bioavailability in Rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620081,In vivo,9544.0,,,U,Autocuration,5472.0,0.0,,4629.0,,,
,1.0,A,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620082,In vivo,9544.0,,,U,Autocuration,5668.0,0.0,,4630.0,,,
,1.0,A,Oral bioavailability in monkey at 10 mg/kg of the compound,,,22224.0,BAO_0000218,monkey,CHEMBL620083,In vivo,9443.0,,,U,Autocuration,5711.0,0.0,,4631.0,,,
,1.0,A,Bioavailability in Rhesus monkey,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL620084,In vivo,9544.0,,,U,Autocuration,5145.0,0.0,,4632.0,,,
,1.0,A,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620085,,9527.0,,,U,Autocuration,3443.0,0.0,,4633.0,,,
,1.0,A,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL874595,,9527.0,,,U,Autocuration,3443.0,0.0,,4634.0,,,
,1.0,A,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL873352,In vivo,9527.0,,,U,Autocuration,3249.0,0.0,,4635.0,,,
,1.0,A,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620086,In vivo,9527.0,,,U,Autocuration,3249.0,0.0,,4636.0,,,
,1.0,A,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620087,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4637.0,,,
,1.0,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620088,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4638.0,,,
,1.0,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620089,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4639.0,,,
,1.0,A,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620090,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4640.0,,,
,1.0,A,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620091,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4641.0,,,
,1.0,A,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,22224.0,BAO_0000251,Cercopithecidae,CHEMBL620092,,9527.0,,,U,Autocuration,14294.0,0.0,,4642.0,Microsomes,,
,1.0,A,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,22224.0,BAO_0000251,Cercopithecidae,CHEMBL620093,,9527.0,,,U,Autocuration,14294.0,0.0,,4643.0,Microsomes,,
,1.0,A,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,22224.0,BAO_0000251,Cercopithecidae,CHEMBL620094,,9527.0,,,U,Autocuration,14294.0,0.0,,4644.0,Microsomes,,
,1.0,A,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,22224.0,BAO_0000251,Cercopithecidae,CHEMBL620095,,9527.0,,,U,Autocuration,14294.0,0.0,,4645.0,Microsomes,,
,1.0,A,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620096,In vivo,9527.0,,,U,Autocuration,3443.0,0.0,,4646.0,,,
,1.0,A,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620097,In vivo,9527.0,,,U,Autocuration,3443.0,0.0,,4647.0,,,
,1.0,A,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL620098,,9527.0,,,U,Autocuration,11271.0,0.0,,4648.0,,,
,1.0,A,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620099,,9527.0,,,U,Autocuration,3443.0,0.0,,4649.0,,,
,1.0,A,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620100,,9527.0,,,U,Autocuration,3443.0,0.0,,4650.0,,,
,1.0,A,Elimination Half-life of compound was determined in monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL620101,,9527.0,,,U,Autocuration,6821.0,0.0,,4651.0,,,
,1.0,A,Half life of compound was determined in rhesus monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL620102,,9527.0,,,U,Autocuration,17267.0,0.0,,4652.0,,,
Plasma,1.0,A,Half life in monkey plasma,,,22224.0,BAO_0000366,Cercopithecidae,CHEMBL620103,,9527.0,1969.0,,U,Autocuration,5819.0,0.0,,4653.0,,,
Plasma,1.0,A,Half life in monkey plasma; Not detected,,,22224.0,BAO_0000366,Cercopithecidae,CHEMBL620104,,9527.0,1969.0,,U,Autocuration,5819.0,0.0,,4654.0,,,
,1.0,A,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL874596,In vivo,9527.0,,,U,Autocuration,1916.0,0.0,,4655.0,,,
,1.0,A,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL873490,In vivo,9527.0,,,U,Autocuration,17509.0,0.0,,4656.0,,,
,1.0,A,Terminal half life of the compound.,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL620105,,9527.0,,,U,Autocuration,1399.0,0.0,,4657.0,,,
,1.0,A,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620780,In vivo,9527.0,,,U,Autocuration,1916.0,0.0,,4658.0,,,
,1.0,A,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620781,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4659.0,,,
,1.0,A,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620956,,9527.0,,,U,Autocuration,5546.0,0.0,,4660.0,,,
Urine,1.0,A,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620957,,9527.0,1088.0,,U,Autocuration,3443.0,0.0,,4661.0,,,
Urine,1.0,A,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620958,,9527.0,1088.0,,U,Autocuration,3443.0,0.0,,4662.0,,,
,1.0,A,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620959,In vivo,9527.0,,,U,Autocuration,4257.0,0.0,,4663.0,,,
,1.0,A,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620960,In vivo,9527.0,,,U,Autocuration,6221.0,0.0,,4664.0,,,
,1.0,A,Volume of distribution was evaluated in rhesus,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL620961,In vivo,9527.0,,,U,Autocuration,5472.0,0.0,,4665.0,,,
,1.0,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL620962,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4666.0,,,
,1.0,A,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL620963,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4667.0,,,
,1.0,A,Bioavailability in hamster was determined,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL620964,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4668.0,,,
,1.0,A,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL620965,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4669.0,,,
,1.0,A,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL620966,In vivo,10029.0,,,U,Autocuration,4727.0,0.0,,4670.0,,,
Blood,1.0,A,Half life of compound was determined in hamster blood,,,22224.0,BAO_0000221,Cricetulus griseus,CHEMBL620967,,10029.0,178.0,,U,Autocuration,4727.0,0.0,,4671.0,,,
,1.0,A,Michaelis-Menten constant of the compound.,,,22224.0,BAO_0000019,Sus scrofa,CHEMBL620968,,9823.0,,,U,Autocuration,1452.0,0.0,,4672.0,,,
,1.0,A,Vmax value was measured at 0 uM concentration of silyl ether.,,,22224.0,BAO_0000019,Sus scrofa,CHEMBL874597,,9823.0,,,U,Autocuration,1452.0,0.0,,4673.0,,,
,1.0,A,Vmax value was measured at 10 uM concentration of silyl ether.,,,22224.0,BAO_0000019,Sus scrofa,CHEMBL620969,,9823.0,,,U,Autocuration,1452.0,0.0,,4674.0,,,
,1.0,A,Vmax value was measured at 5 uM concentration of silyl ether.,,,22224.0,BAO_0000019,Sus scrofa,CHEMBL620970,,9823.0,,,U,Autocuration,1452.0,0.0,,4675.0,,,
,1.0,B,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,235.0,BAO_0000357,Homo sapiens,CHEMBL620971,,9606.0,,,D,Expert,11706.0,9.0,,4676.0,,,
,1.0,A,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL620972,,9606.0,,,U,Autocuration,1916.0,0.0,,4677.0,,,
,1.0,A,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620973,,9606.0,,,U,Autocuration,17791.0,0.0,,4678.0,,,
,1.0,A,Active metabolite of ifosfamide determined in humans; A-Active,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618243,,9606.0,,,U,Autocuration,7766.0,0.0,,4679.0,,,
,1.0,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618244,,9606.0,,,U,Autocuration,6567.0,0.0,,4680.0,,,
,1.0,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618245,,9606.0,,,U,Autocuration,6567.0,0.0,,4681.0,,,
,1.0,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618246,,9606.0,,,U,Autocuration,6567.0,0.0,,4682.0,,,
,1.0,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618247,,9606.0,,,U,Autocuration,6567.0,0.0,,4683.0,,,
,1.0,A,Compound was evaluated for oral bioavailability in human,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL618248,,9606.0,,,U,Autocuration,17791.0,0.0,,4684.0,,,
Urine,1.0,A,Metabolite of ifosfamide determined in urine; NF-Not found,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618249,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4685.0,,,
,1.0,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618250,,9606.0,,,U,Autocuration,6852.0,0.0,,4686.0,,,
,1.0,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL874598,,9606.0,,,U,Autocuration,6852.0,0.0,,4687.0,,,
,1.0,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618251,,9606.0,,,U,Autocuration,6852.0,0.0,,4688.0,,,
,1.0,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618252,,9606.0,,,U,Autocuration,6852.0,0.0,,4689.0,,,
,1.0,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618253,,9606.0,,,U,Autocuration,6852.0,0.0,,4690.0,,,
,1.0,A,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618254,,9606.0,,,U,Autocuration,6852.0,0.0,,4691.0,,,
,1.0,A,Percent of compound in healthy individuals (Group D),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618255,,9606.0,,,U,Autocuration,6852.0,0.0,,4692.0,,,
Liver,1.0,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618983,,9606.0,2107.0,,U,Autocuration,4397.0,0.0,,4693.0,Microsomes,,
,1.0,A,Binding towards human plasma protein at 10 uM,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618984,,9606.0,,,U,Autocuration,17409.0,0.0,,4694.0,,,
,1.0,A,Binding towards human plasma protein at 100 uM,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618985,,9606.0,,,U,Autocuration,17409.0,0.0,,4695.0,,,
,1.0,A,Human plasma protein binding activity was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618986,,9606.0,,,U,Autocuration,17176.0,0.0,,4696.0,,,
,1.0,A,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618987,,9606.0,,,U,Autocuration,15444.0,0.0,,4697.0,,,
,1.0,A,Percent binding of compound towards human plasma protein was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618988,,9606.0,,,U,Autocuration,17267.0,0.0,,4698.0,,,
Liver,1.0,A,Plasma clearance in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618989,In vitro,9606.0,2107.0,,U,Autocuration,5944.0,0.0,,4699.0,Microsomes,,
Liver,1.0,A,In vitro intrinsic clearance in human liver microsome,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618990,In vitro,9606.0,2107.0,,U,Autocuration,5668.0,0.0,,4700.0,Microsomes,,
Liver,1.0,A,In vitro intrinsic clearance in human liver microsome,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618991,In vitro,9606.0,2107.0,,U,Autocuration,5669.0,0.0,,4701.0,Microsomes,,
,1.0,A,In vitro microsome metabolism clearance in human was determined,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL876725,In vitro,9606.0,,,U,Autocuration,5041.0,0.0,,4702.0,Microsomes,,
,1.0,A,In vitro microsome metabolism clearance in human was determined; High,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618992,In vitro,9606.0,,,U,Autocuration,5041.0,0.0,,4703.0,Microsomes,,
,1.0,A,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618993,In vitro,9606.0,,,U,Autocuration,5041.0,0.0,,4704.0,Microsomes,,
Liver,1.0,A,Pharmacokinetic property (clearance) in human liver microsome,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618994,In vitro,9606.0,2107.0,,U,Autocuration,5676.0,0.0,,4705.0,Microsomes,,
Liver,1.0,A,Plasma clearance in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618995,In vitro,9606.0,2107.0,,U,Autocuration,5944.0,0.0,,4706.0,Microsomes,,
Liver,1.0,A,In vitro clearance in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618996,In vitro,9606.0,2107.0,,U,Autocuration,17538.0,0.0,,4707.0,Microsomes,,
Liver,1.0,A,Intrinsic clearance in human liver microsomes was determined,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618997,In vitro,9606.0,2107.0,,U,Autocuration,6331.0,0.0,,4708.0,Microsomes,,
Liver,1.0,A,Intrinsic clearance in human liver microsomes was determined,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618998,In vitro,9606.0,2107.0,,U,Autocuration,5948.0,0.0,,4709.0,Microsomes,,
,1.0,A,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL618999,In vivo,9606.0,,,U,Autocuration,5965.0,0.0,,4710.0,,,
,1.0,A,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL620223,In vivo,9606.0,,,U,Autocuration,1916.0,0.0,,4711.0,,,
,1.0,A,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL620224,,9606.0,,,U,Autocuration,5965.0,0.0,,4712.0,,,
,1.0,A,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620225,,9606.0,,,U,Autocuration,1299.0,0.0,,4713.0,,,
,1.0,A,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620226,,9606.0,,,U,Autocuration,1299.0,0.0,,4714.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620227,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4715.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL876726,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4716.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620228,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4717.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620229,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4718.0,,,
,1.0,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620230,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4719.0,,,
,1.0,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620231,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4720.0,,,
,1.0,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620232,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4721.0,,,
,1.0,F,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620233,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4722.0,,,
,1.0,A,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620234,,10090.0,,,N,Intermediate,14294.0,1.0,,4723.0,,,
,1.0,A,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620235,,10090.0,,,N,Intermediate,14294.0,1.0,,4724.0,,,
,1.0,A,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620236,,10090.0,,,N,Intermediate,14294.0,1.0,,4725.0,,,
Liver,1.0,A,In vitro metabolic potential in mouse liver microsomes,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620237,,10090.0,2107.0,,N,Intermediate,6251.0,1.0,,4726.0,,,
,1.0,A,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620238,,10090.0,,,N,Intermediate,17582.0,1.0,,4727.0,,,
Adrenal gland,1.0,A,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620239,,10090.0,2369.0,,N,Intermediate,17811.0,1.0,,4728.0,,,
Brain,1.0,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620240,,10090.0,955.0,,N,Intermediate,17811.0,1.0,,4729.0,,,
Brain,1.0,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620241,,10090.0,955.0,,N,Intermediate,17811.0,1.0,,4730.0,,,
,1.0,A,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,50594.0,BAO_0000218,Mus musculus,CHEMBL876727,,10090.0,,,N,Intermediate,17811.0,1.0,,4731.0,,,
Kidney,1.0,A,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620242,,10090.0,2113.0,,N,Intermediate,17811.0,1.0,,4732.0,,,
,1.0,A,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620243,,10090.0,,,N,Intermediate,17811.0,1.0,,4733.0,,,
,1.0,A,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620244,,10090.0,,,N,Intermediate,5288.0,1.0,,4734.0,,,
Serum,1.0,A,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620245,,10090.0,1977.0,,N,Intermediate,2717.0,1.0,,4735.0,,,
Serum,1.0,A,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620246,,10090.0,1977.0,,N,Intermediate,2717.0,1.0,,4736.0,,,
Serum,1.0,A,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620247,,10090.0,1977.0,,N,Intermediate,2717.0,1.0,,4737.0,,,
Plasma,1.0,A,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620248,In vivo,10090.0,1969.0,,N,Intermediate,17753.0,1.0,,4738.0,,,
Plasma,1.0,A,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL873497,In vivo,10090.0,1969.0,,N,Intermediate,17753.0,1.0,,4739.0,,,
Plasma,1.0,A,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620249,In vivo,10090.0,1969.0,,N,Intermediate,17753.0,1.0,,4740.0,,,
,1.0,F,Half life after intraperitoneal administration in mice at 18 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620250,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4741.0,,,
,1.0,F,Half life after intraperitoneal administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620251,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4742.0,,,
,1.0,F,Half life after intraperitoneal administration in mice at 25 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620252,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4743.0,,,
,1.0,F,Half life after intraperitoneal administration in mice at 26 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620253,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4744.0,,,
,1.0,F,Half life after intravenous administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620254,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4745.0,,,
,1.0,A,Half life after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620255,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4746.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620256,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4747.0,,,
,1.0,A,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876728,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,4748.0,,,
,1.0,A,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620257,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,4749.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,50594.0,BAO_0000218,Mus musculus,CHEMBL620258,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4750.0,,,
,1.0,A,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,50594.0,BAO_0000218,Mus musculus,CHEMBL620259,In vivo,10090.0,,,N,Intermediate,4890.0,1.0,,4751.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620260,In vivo,10090.0,,,N,Intermediate,429.0,1.0,,4752.0,,,
Blood,1.0,A,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620261,In vivo,10090.0,178.0,,N,Intermediate,17837.0,1.0,,4753.0,,,
,1.0,A,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620262,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4754.0,,,
,1.0,A,Half life at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620263,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4755.0,,,
,1.0,A,Half life in ob/ob mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620264,,10090.0,,,N,Intermediate,6619.0,1.0,,4756.0,,,
,1.0,A,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620265,In vivo,10090.0,,,N,Intermediate,4066.0,1.0,,4757.0,,,
,1.0,A,Half-life was measured in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620266,,10090.0,,,N,Intermediate,4239.0,1.0,,4758.0,,,
,1.0,A,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620267,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4759.0,,,
,1.0,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619364,,10090.0,,,N,Intermediate,8999.0,1.0,,4760.0,,,
,1.0,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619365,,10090.0,,,N,Intermediate,8999.0,1.0,,4761.0,,,
Brain,1.0,A,T2 in brain of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619366,,10090.0,955.0,,N,Intermediate,17641.0,1.0,,4762.0,,,
Kidney,1.0,A,T2 in kidney of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619367,,10090.0,2113.0,,N,Intermediate,17641.0,1.0,,4763.0,,,
Liver,1.0,A,T2 in liver of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619368,,10090.0,2107.0,,N,Intermediate,17641.0,1.0,,4764.0,,,
Lung,1.0,A,T2 in lungs of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619369,,10090.0,2048.0,,N,Intermediate,17641.0,1.0,,4765.0,,,
Spleen,1.0,A,T2 in spleen of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876729,,10090.0,2106.0,,N,Intermediate,17641.0,1.0,,4766.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619370,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4767.0,,,
,1.0,A,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619371,In vivo,10090.0,,,N,Intermediate,4890.0,1.0,,4768.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619372,In vivo,10090.0,,,N,Intermediate,429.0,1.0,,4769.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620012,In vivo,10090.0,,,N,Intermediate,429.0,1.0,,4770.0,,,
,1.0,A,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620013,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4771.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL620014,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4772.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL620015,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4773.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621010,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4774.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621011,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4775.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621012,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4776.0,,,
,1.0,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621013,,9606.0,,,N,Intermediate,16913.0,1.0,478.0,4777.0,,,
,1.0,F,In vitro cytotoxicity against A2780TAX cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621014,,9606.0,,,N,Intermediate,17270.0,1.0,478.0,4778.0,,,
,1.0,F,In vitro inhibitory activity against human tumor cell line A2780cis,,A2780cisR,80017.0,BAO_0000219,Homo sapiens,CHEMBL618154,,9606.0,,,N,Intermediate,5618.0,1.0,481.0,4779.0,,,
,1.0,F,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618155,,9606.0,,,N,Expert,17777.0,1.0,478.0,4780.0,,,
,1.0,F,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,A2780cisR,80017.0,BAO_0000219,Homo sapiens,CHEMBL618156,,9606.0,,,N,Intermediate,16112.0,1.0,481.0,4781.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,A2780cisR,80017.0,BAO_0000219,Homo sapiens,CHEMBL618157,,9606.0,,,N,Intermediate,15748.0,1.0,481.0,4782.0,,,
,1.0,F,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618328,,9606.0,,,N,Intermediate,6633.0,1.0,478.0,4783.0,,,
,1.0,F,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618329,,9606.0,,,N,Intermediate,16930.0,1.0,478.0,4784.0,,,
,1.0,F,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618330,,9606.0,,,N,Intermediate,17496.0,1.0,478.0,4785.0,,,
,1.0,F,In vitro antitumor activity against A2780cisR cell line.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618331,,9606.0,,,N,Expert,12989.0,1.0,478.0,4786.0,,,
,1.0,F,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618332,,9606.0,,,N,Intermediate,4840.0,1.0,478.0,4787.0,,,
,1.0,F,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618333,,9606.0,,,N,Expert,12989.0,1.0,478.0,4788.0,,,
,1.0,F,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,A2780cisR,80017.0,BAO_0000219,Homo sapiens,CHEMBL618334,,9606.0,,,N,Intermediate,16745.0,1.0,481.0,4789.0,,,
,1.0,F,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618335,,9606.0,,,N,Expert,16597.0,1.0,478.0,4790.0,,,
,1.0,B,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,11736.0,BAO_0000019,Rattus norvegicus,CHEMBL618336,,10116.0,,,D,Expert,16547.0,9.0,,4791.0,,,
,1.0,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,11736.0,BAO_0000019,,CHEMBL618337,,,,,H,Expert,16547.0,8.0,,4792.0,,,
,1.0,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,11736.0,BAO_0000019,Rattus norvegicus,CHEMBL618338,,10116.0,,,D,Expert,16547.0,9.0,,4793.0,,,
,1.0,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,HEK293,278.0,BAO_0000219,Homo sapiens,CHEMBL618339,,9606.0,,,D,Expert,15856.0,9.0,722.0,4794.0,,,
,1.0,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,HEK293,278.0,BAO_0000219,Homo sapiens,CHEMBL618340,,9606.0,,,D,Expert,15856.0,9.0,722.0,4795.0,,,
,1.0,B,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,11831.0,BAO_0000019,Mus musculus,CHEMBL618341,,10090.0,,,D,Expert,16547.0,9.0,,4796.0,,,
,1.0,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,11831.0,BAO_0000019,,CHEMBL618342,,,,,H,Expert,16547.0,8.0,,4797.0,,,
,1.0,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,11831.0,BAO_0000019,Mus musculus,CHEMBL618343,,10090.0,,,D,Expert,16547.0,9.0,,4798.0,,,
,1.0,B,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,280.0,BAO_0000357,,CHEMBL621038,,,,,H,Expert,17402.0,8.0,,4799.0,,,
,1.0,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,T-cells,22226.0,BAO_0000219,Homo sapiens,CHEMBL621039,,9606.0,,,U,Autocuration,11746.0,0.0,574.0,4800.0,,,
,1.0,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,T-cells,22226.0,BAO_0000219,Homo sapiens,CHEMBL621040,,9606.0,,,U,Autocuration,11746.0,0.0,574.0,4801.0,,,
,1.0,F,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621041,,9606.0,,,N,Intermediate,5455.0,1.0,455.0,4802.0,,,
,1.0,F,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621042,,9606.0,,,N,Intermediate,2068.0,1.0,455.0,4803.0,,,
,1.0,F,In vitro antitumor activity against A375cell line extracted form melanoma,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621043,,9606.0,,,N,Intermediate,2683.0,1.0,455.0,4804.0,,,
,1.0,F,Inhibition of cell growth in (A375) melan cell line,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621044,,9606.0,,,N,Expert,15313.0,1.0,455.0,4805.0,,,
,1.0,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621045,,9606.0,,,N,Intermediate,13739.0,1.0,455.0,4806.0,,,
,1.0,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621046,,9606.0,,,N,Intermediate,13739.0,1.0,455.0,4807.0,,,
,1.0,F,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL621047,,9606.0,,,N,Intermediate,14750.0,1.0,455.0,4808.0,,,
,1.0,F,Antiproliferative activity measured against A427 human lung carcinoma,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621048,,9606.0,,,N,Intermediate,14777.0,1.0,797.0,4809.0,,,
,1.0,F,Antiproliferative activity measured against A427 human lung carcinoma,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL883798,,9606.0,,,N,Intermediate,14777.0,1.0,797.0,4810.0,,,
,1.0,F,Cytotoxicity against lung carcinoma A427 tumor cell lines,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621049,,9606.0,,,N,Intermediate,17672.0,1.0,797.0,4811.0,,,
,1.0,F,Inhibition of large cell lung carcinoma (A427),,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621050,,9606.0,,,N,Intermediate,14368.0,1.0,797.0,4812.0,,,
,1.0,F,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621051,,9606.0,,,N,Intermediate,14368.0,1.0,797.0,4813.0,,,
,1.0,F,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621052,,9606.0,,,N,Intermediate,13866.0,1.0,797.0,4814.0,,,
,1.0,F,Inhibitory concentration in human lung carcinoma A427 cell line,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621053,,9606.0,,,N,Intermediate,2545.0,1.0,797.0,4815.0,,,
,1.0,F,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL621054,,9606.0,,,N,Intermediate,2545.0,1.0,797.0,4816.0,,,
,1.0,A,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621055,In vivo,9527.0,,,U,Autocuration,6062.0,0.0,,4817.0,,,
,1.0,A,Tested for volume of distribution upon iv administration to african green monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL876398,In vivo,9527.0,,,U,Autocuration,4578.0,0.0,,4818.0,,,
,1.0,A,Volume of distribution in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621056,In vivo,9527.0,,,U,Autocuration,17592.0,0.0,,4819.0,,,
,1.0,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL621057,In vivo,9544.0,,,U,Autocuration,5005.0,0.0,,4820.0,,,
,1.0,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL621058,In vivo,9544.0,,,U,Autocuration,5005.0,0.0,,4821.0,,,
,1.0,A,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621059,In vivo,9527.0,,,U,Autocuration,5922.0,0.0,,4822.0,,,
,1.0,A,The distribution volume after intravenous administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621060,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4823.0,,,
,1.0,A,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621061,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4824.0,,,
,1.0,A,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621062,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4825.0,,,
,1.0,A,Volume displacement was calculated in rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621063,In vivo,9527.0,,,U,Autocuration,6057.0,0.0,,4826.0,,,
,1.0,A,Volume of distribution in steady state was determined in rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621064,In vivo,9527.0,,,U,Autocuration,5145.0,0.0,,4827.0,,,
,1.0,A,Volume of distribution of compound was determined in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621065,In vivo,9527.0,,,U,Autocuration,6821.0,0.0,,4828.0,,,
,1.0,A,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621066,In vivo,9527.0,,,U,Autocuration,5334.0,0.0,,4829.0,,,
,1.0,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621067,In vivo,9527.0,,,U,Autocuration,5334.0,0.0,,4830.0,,,
,1.0,A,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621068,In vivo,9527.0,,,U,Autocuration,6641.0,0.0,,4831.0,,,
,1.0,A,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL876399,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,4832.0,,,
,1.0,A,Volume distribution in monkey after administration of 1 mg/kg iv,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621069,In vivo,9527.0,,,U,Autocuration,6535.0,0.0,,4833.0,,,
,1.0,A,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621070,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4834.0,,,
,1.0,A,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621071,In vivo,9527.0,,,U,Autocuration,6062.0,0.0,,4835.0,,,
,1.0,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621072,In vivo,9527.0,,,U,Autocuration,3443.0,0.0,,4836.0,,,
,1.0,A,Oral systemic bioavailability upon iv administration to african green monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618209,In vivo,9527.0,,,U,Autocuration,4578.0,0.0,,4837.0,,,
,1.0,A,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618210,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4838.0,,,
,1.0,A,Baboon plasma free fraction. ,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618211,,9527.0,,,U,Autocuration,11271.0,0.0,,4839.0,,,
,1.0,A,Area under the curve was calculated in rhesus monkey after iv administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618212,,9527.0,,,U,Autocuration,6057.0,0.0,,4840.0,,,
,1.0,A,Area under the curve was calculated in rhesus monkey after peroral administration,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618213,,9527.0,,,U,Autocuration,6057.0,0.0,,4841.0,,,
,1.0,A,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618214,,9527.0,,,U,Autocuration,17853.0,0.0,,4842.0,,,
,1.0,A,Half life period in monkey after 5 mg/kg dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL873492,In vivo,9527.0,,,U,Autocuration,5302.0,0.0,,4843.0,,,
,1.0,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618272,In vivo,9527.0,,,U,Autocuration,4257.0,0.0,,4844.0,,,
,1.0,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618273,In vivo,9527.0,,,U,Autocuration,4257.0,0.0,,4845.0,,,
Plasma,1.0,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618274,In vivo,9527.0,1969.0,,U,Autocuration,13501.0,0.0,,4846.0,,,
,1.0,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618275,In vivo,9527.0,,,U,Autocuration,5394.0,0.0,,4847.0,,,
,1.0,A,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618276,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,4848.0,,,
,1.0,A,Compound was evaluated for terminal half life in monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618277,,9527.0,,,U,Autocuration,3341.0,0.0,,4849.0,,,
,1.0,A,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618278,In vivo,9527.0,,,U,Autocuration,3045.0,0.0,,4850.0,,,
Plasma,1.0,A,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL618279,In vivo,9544.0,1969.0,,U,Autocuration,5005.0,0.0,,4851.0,,,
,1.0,A,Half life of compound was determined in squirrel monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618280,,9527.0,,,U,Autocuration,4847.0,0.0,,4852.0,,,
,1.0,A,Half life after iv administration in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL618281,In vivo,9541.0,,,U,Autocuration,4256.0,0.0,,4853.0,,,
Plasma,1.0,A,Half life in monkey plasma after administration of 1 mg/kg iv,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618282,In vivo,9527.0,1969.0,,U,Autocuration,6535.0,0.0,,4854.0,,,
,1.0,A,Half life was calculated in rhesus monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618283,,9527.0,,,U,Autocuration,6057.0,0.0,,4855.0,,,
,1.0,A,Half life in monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618284,,9527.0,,,U,Autocuration,17592.0,0.0,,4856.0,,,
,1.0,A,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618285,In vivo,9527.0,,,U,Autocuration,6641.0,0.0,,4857.0,,,
,1.0,A,Half life was evaluated in rhesus,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618286,,9527.0,,,U,Autocuration,5472.0,0.0,,4858.0,,,
,1.0,A,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618287,In vivo,9527.0,,,U,Autocuration,6221.0,0.0,,4859.0,,,
,1.0,A,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618288,In vivo,9527.0,,,U,Autocuration,5668.0,0.0,,4860.0,,,
,1.0,A,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL876393,In vivo,9527.0,,,U,Autocuration,4809.0,0.0,,4861.0,,,
,1.0,A,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618289,In vivo,9527.0,,,U,Autocuration,5546.0,0.0,,4862.0,,,
,1.0,A,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618290,In vivo,9527.0,,,U,Autocuration,5553.0,0.0,,4863.0,,,
,1.0,A,Half-life was calculated in monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618291,,9527.0,,,U,Autocuration,6078.0,0.0,,4864.0,,,
,1.0,A,Half-life in Squirrel monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618292,,9527.0,,,U,Autocuration,5147.0,0.0,,4865.0,,,
,1.0,A,Half-life in rhesus monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618293,,9527.0,,,U,Autocuration,5145.0,0.0,,4866.0,,,
,1.0,A,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618294,In vivo,9527.0,,,U,Autocuration,6062.0,0.0,,4867.0,,,
,1.0,A,Half-life period after intravenous administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618295,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4868.0,,,
,1.0,A,Half-life period after oral administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618296,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4869.0,,,
,1.0,A,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618297,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,4870.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618298,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4871.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618299,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4872.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618300,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4873.0,,,
Urine,1.0,A,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618301,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4874.0,,,
Urine,1.0,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618302,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4875.0,,,
Urine,1.0,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL876394,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4876.0,,,
Urine,1.0,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618303,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4877.0,,,
Urine,1.0,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618304,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4878.0,,,
,1.0,A,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL618305,In vivo,9606.0,,,U,Autocuration,1916.0,0.0,,4879.0,,,
,1.0,A,Oral bioavailability in human,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL618306,In vivo,9606.0,,,U,Autocuration,16643.0,0.0,,4880.0,,,
,1.0,A,Compound was tested for human plasma protein binding,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618307,,9606.0,,,U,Autocuration,17248.0,0.0,,4881.0,,,
,1.0,A,Compound was tested for human plasma protein binding; Not determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618308,,9606.0,,,U,Autocuration,17248.0,0.0,,4882.0,,,
,1.0,A,Protein binding activity of compound in human plasma; % Free,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618309,,9606.0,,,U,Autocuration,6241.0,0.0,,4883.0,,,
,1.0,A,Unbound fraction (plasma),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618310,,9606.0,,,U,Autocuration,17716.0,0.0,,4884.0,,,
Plasma,1.0,A,Half life for the hydrolysis of compound in human blood serum,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL873353,,9606.0,1969.0,,U,Autocuration,17605.0,0.0,,4885.0,,,
Plasma,1.0,A,Half life period in human plasma using phosphate buffer (0.08 M),,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618311,,9606.0,1969.0,,U,Autocuration,17625.0,0.0,,4886.0,,,
Plasma,1.0,A,Half life period in human plasma using phosphate buffer (0.1 M),,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618312,,9606.0,1969.0,,U,Autocuration,17625.0,0.0,,4887.0,,,
Plasma,1.0,A,Half-life in human plasma was determined,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618313,,9606.0,1969.0,,U,Autocuration,17747.0,0.0,,4888.0,,,
,1.0,A,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618314,,9606.0,,,U,Autocuration,15613.0,0.0,,4889.0,,,
,1.0,A,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618315,,9606.0,,,U,Autocuration,354.0,0.0,,4890.0,,,
,1.0,A,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618316,,9606.0,,,U,Autocuration,3741.0,0.0,,4891.0,,,
,1.0,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618317,,9606.0,,,U,Autocuration,3741.0,0.0,,4892.0,,,
,1.0,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620138,,9606.0,,,U,Autocuration,3741.0,0.0,,4893.0,,,
,1.0,A,Partition coefficient (logP),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL858280,,9606.0,,,U,Autocuration,17599.0,0.0,,4894.0,,,
,1.0,A,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620139,,9606.0,,,U,Autocuration,5486.0,0.0,,4895.0,,,
,1.0,A,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620140,,9606.0,,,U,Autocuration,5600.0,0.0,,4896.0,Microsomes,,
,1.0,A,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620141,,9606.0,,,U,Autocuration,14294.0,0.0,,4897.0,,,
,1.0,A,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620142,,9606.0,,,U,Autocuration,14294.0,0.0,,4898.0,,,
,1.0,A,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL620143,,9606.0,,,U,Autocuration,14294.0,0.0,,4899.0,,,
,1.0,A,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620144,,9606.0,,,U,Autocuration,14294.0,0.0,,4900.0,Microsomes,,
,1.0,A,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620145,,9606.0,,,U,Autocuration,14294.0,0.0,,4901.0,Microsomes,,
,1.0,A,Metabolism of compound in human microsomes; Trace,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620146,,9606.0,,,U,Autocuration,14294.0,0.0,,4902.0,Microsomes,,
Liver,1.0,A,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620147,,9606.0,2107.0,,U,Autocuration,6260.0,0.0,,4903.0,Microsomes,,
,1.0,A,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620148,,9606.0,,,U,Autocuration,6187.0,0.0,,4904.0,Microsomes,,
Liver,1.0,A,In vitro metabolic potential in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL620149,,9606.0,2107.0,,U,Autocuration,6251.0,0.0,,4905.0,Microsomes,,
,1.0,A,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL876412,,9606.0,,,U,Autocuration,3246.0,0.0,,4906.0,,,
,1.0,A,Tested for human plasma protein binding of the compound; Not tested,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619352,,9606.0,,,U,Autocuration,17313.0,0.0,,4907.0,,,
,1.0,A,Compound was tested for percent protein binding (PB) in human,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619353,,9606.0,,,U,Autocuration,6227.0,0.0,,4908.0,,,
Plasma,1.0,A,Protein binding in human plasma,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619354,,9606.0,1969.0,,U,Autocuration,5530.0,0.0,,4909.0,,,
,1.0,A,Permeability coefficient (B to A) in Caco-2 cell,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619355,,9606.0,,,U,Autocuration,6108.0,0.0,,4910.0,,,
,1.0,A,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619356,,9606.0,,,U,Autocuration,6108.0,0.0,,4911.0,,,
,1.0,A,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619357,,9606.0,,,U,Autocuration,2774.0,0.0,,4912.0,,,
,1.0,A,In vitro rate of absorption observed as Caco-2 permeability in humans,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619358,,9606.0,,,U,Autocuration,16643.0,0.0,,4913.0,,,
,1.0,A,Cellular permeability of compound was determined in Caco-2 cells; High,,Caco-2,22224.0,BAO_0000219,Homo sapiens,CHEMBL619359,,9606.0,,,U,Autocuration,17582.0,0.0,495.0,4914.0,,,
,1.0,A,Permeability in Caco-2 cells of compound,,Caco-2,22224.0,BAO_0000219,Homo sapiens,CHEMBL619360,,9606.0,,,U,Autocuration,6838.0,0.0,495.0,4915.0,,,
,1.0,A,Permeability coefficient (A to B) in Caco-2 cell,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619361,,9606.0,,,U,Autocuration,6108.0,0.0,,4916.0,,,
,1.0,A,Permeability coefficient (B to A) in Caco-2 cell,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619362,,9606.0,,,U,Autocuration,6108.0,0.0,,4917.0,,,
,1.0,A,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619363,,9606.0,,,U,Autocuration,6108.0,0.0,,4918.0,,,
,1.0,A,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618942,,9606.0,,,U,Autocuration,2146.0,0.0,,4919.0,,,
,1.0,A,Compound was tested for protein binding in human plasma,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618943,,9606.0,,,U,Autocuration,4514.0,0.0,,4920.0,,,
,1.0,A,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618944,,9606.0,,,U,Autocuration,6108.0,0.0,,4921.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618945,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,4922.0,,,
,1.0,A,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618946,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4923.0,,,
,1.0,A,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594.0,BAO_0000218,Mus musculus,CHEMBL876413,In vivo,10090.0,,,N,Intermediate,3277.0,1.0,,4924.0,,,
,1.0,A,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618947,In vivo,10090.0,,,N,Intermediate,3802.0,1.0,,4925.0,,,
Plasma,1.0,A,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618948,In vivo,10090.0,1969.0,,N,Intermediate,2862.0,1.0,,4926.0,,,
Plasma,1.0,A,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618949,In vivo,10090.0,1969.0,,N,Intermediate,6348.0,1.0,,4927.0,,,
,1.0,F,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618950,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4928.0,,,
,1.0,A,Tmax after oral administration at 30 mg/kg in ICR mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618951,In vivo,10090.0,,,N,Intermediate,5781.0,1.0,,4929.0,,,
,1.0,A,Tmax after peroral administration in mice at 2.4 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618952,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4930.0,,,
,1.0,A,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618953,In vivo,10090.0,,,N,Intermediate,4066.0,1.0,,4931.0,,,
Brain,1.0,A,Tmax in brain of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618954,In vivo,10090.0,955.0,,N,Intermediate,17641.0,1.0,,4932.0,,,
Kidney,1.0,A,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618955,In vivo,10090.0,2113.0,,N,Intermediate,17641.0,1.0,,4933.0,,,
Liver,1.0,A,Tmax in liver of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618956,In vivo,10090.0,2107.0,,N,Intermediate,17641.0,1.0,,4934.0,,,
Lung,1.0,A,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618957,In vivo,10090.0,2048.0,,N,Intermediate,17641.0,1.0,,4935.0,,,
,1.0,F,Tmax in mice at 18 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618958,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4936.0,,,
,1.0,F,Tmax in mice at 23 uM/kg i.v. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618959,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4937.0,,,
,1.0,F,Tmax in mice at 25 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618960,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4938.0,,,
,1.0,F,Tmax in mice at 26 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876723,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4939.0,,,
Spleen,1.0,A,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618961,In vivo,10090.0,2106.0,,N,Intermediate,17641.0,1.0,,4940.0,,,
,1.0,A,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618962,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4941.0,,,
,1.0,A,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618963,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4942.0,,,
,1.0,A,Tmax value in IRC mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618964,,10090.0,,,N,Intermediate,5951.0,1.0,,4943.0,,,
,1.0,A,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618965,In vivo,10090.0,,,N,Intermediate,5506.0,1.0,,4944.0,,,
,1.0,A,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618966,In vivo,10090.0,,,N,Intermediate,5506.0,1.0,,4945.0,,,
Urine,1.0,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,50594.0,BAO_0000218,Mus musculus,CHEMBL618967,,10090.0,1088.0,,N,Intermediate,429.0,1.0,,4946.0,,,
Urine,1.0,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,50594.0,BAO_0000218,Mus musculus,CHEMBL618968,,10090.0,1088.0,,N,Intermediate,429.0,1.0,,4947.0,,,
Urine,1.0,A,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,50594.0,BAO_0000218,Mus musculus,CHEMBL618969,,10090.0,1088.0,,N,Intermediate,4066.0,1.0,,4948.0,,,
,1.0,A,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618970,,10090.0,,,N,Intermediate,17734.0,1.0,,4949.0,,,
,1.0,A,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618971,,10090.0,,,N,Intermediate,17734.0,1.0,,4950.0,,,
,1.0,A,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618972,In vivo,10090.0,,,N,Intermediate,6062.0,1.0,,4951.0,,,
,1.0,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618973,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4952.0,,,
,1.0,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618974,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4953.0,,,
,1.0,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618975,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,4954.0,,,
,1.0,A,Vd in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618976,In vivo,10090.0,,,N,Intermediate,5980.0,1.0,,4955.0,,,
,1.0,A,Volume of distribution in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618977,In vivo,10090.0,,,N,Intermediate,17592.0,1.0,,4956.0,,,
,1.0,A,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876724,In vivo,10090.0,,,N,Intermediate,6348.0,1.0,,4957.0,,,
,1.0,A,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618978,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,4958.0,,,
,1.0,A,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618979,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,4959.0,,,
,1.0,A,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618980,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,4960.0,,,
,1.0,A,Pharmacokinetic property (vdss) was measured in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618981,In vivo,10090.0,,,N,Intermediate,4239.0,1.0,,4961.0,,,
,1.0,A,Value distribution upon iv administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618982,In vivo,10090.0,,,N,Intermediate,2862.0,1.0,,4962.0,,,
,1.0,A,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620150,In vivo,10090.0,,,N,Intermediate,17734.0,1.0,,4963.0,,,
,1.0,A,Volume of distribution was evaluated in mice after intravenous administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620151,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,4964.0,,,
,1.0,A,Volume of distribution was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620152,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,4965.0,,,
,1.0,A,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620153,In vivo,10090.0,,,N,Intermediate,17837.0,1.0,,4966.0,,,
,1.0,A,Steady state volume of distribution was determined in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876395,In vivo,10090.0,,,N,Intermediate,5727.0,1.0,,4967.0,,,
,1.0,A,Volume distribution (steady state) of compound was determined in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620154,In vivo,10090.0,,,N,Intermediate,17852.0,1.0,,4968.0,,,
,1.0,A,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620155,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,4969.0,,,
,1.0,A,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620156,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,4970.0,,,
,1.0,A,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620157,In vivo,10090.0,,,N,Intermediate,6062.0,1.0,,4971.0,,,
Kidney,1.0,A,Biodistribution of compound (oxidized form) in in kidney tissue,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620158,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,4972.0,,,
Blood,1.0,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620159,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,4973.0,,,
Blood,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL620160,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,4974.0,,,
Blood,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL620161,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,4975.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL620162,,9606.0,,,N,Intermediate,10708.0,1.0,797.0,4976.0,,,
,1.0,F,Inhibition of A431 human squamous cell carcinoma cell proliferation,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620163,,9606.0,,,N,Expert,16597.0,1.0,500.0,4977.0,,,
,1.0,F,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620833,,9606.0,,,N,Expert,16062.0,1.0,500.0,4978.0,,,
,1.0,F,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL876396,,9606.0,,,N,Expert,16062.0,1.0,500.0,4979.0,,,
,1.0,F,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620834,,9606.0,,,N,Expert,16958.0,1.0,500.0,4980.0,,,
,1.0,F,Inhibition of A431 human carcinoma cell proliferation,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620835,,9606.0,,,N,Expert,6700.0,1.0,500.0,4981.0,,,
,1.0,F,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620836,,9606.0,,,N,Expert,17226.0,1.0,500.0,4982.0,,,
,1.0,F,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL620837,,9606.0,,,N,Intermediate,6828.0,1.0,500.0,4983.0,,,
,1.0,F,In vitro cytotoxicity against epidermoid carcinoma cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621017,,9606.0,,,N,Intermediate,12314.0,1.0,500.0,4984.0,,,
,1.0,F,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,A-431,9.0,BAO_0000218,Homo sapiens,CHEMBL621018,,9606.0,,,D,Expert,13412.0,9.0,500.0,4985.0,,,
,1.0,F,Antiproliferative activity of compound was measured on human tumor cell line A431.,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621019,,9606.0,,,N,Intermediate,13299.0,1.0,500.0,4986.0,,,
,1.0,F,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621020,,9606.0,,,N,Intermediate,17420.0,1.0,500.0,4987.0,,,
,1.0,F,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621021,,9606.0,,,N,Intermediate,13678.0,1.0,500.0,4988.0,,,
,1.0,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,A-431,9.0,BAO_0000219,,CHEMBL621022,,,,,H,Expert,14171.0,8.0,500.0,4989.0,,,
,1.0,F,Tested for antiproliferative activity against human A431 cells,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621023,,9606.0,,,N,Expert,6333.0,1.0,500.0,4990.0,,,
,1.0,F,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621024,,9606.0,,,D,Expert,2356.0,9.0,500.0,4991.0,,,
,1.0,F,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621025,,9606.0,,,N,Expert,15578.0,1.0,500.0,4992.0,,,
,1.0,F,Inhibition of A431 cell proliferation,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621026,,9606.0,,,N,Expert,5126.0,1.0,500.0,4993.0,,,
,1.0,F,Cytotoxic effect on A431 human epidermoid carcinoma cells,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621027,,9606.0,,,N,Expert,6844.0,1.0,500.0,4994.0,,,
,1.0,F,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL876397,,9606.0,,,N,Expert,6844.0,1.0,500.0,4995.0,,,
,1.0,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL883797,,9606.0,,,N,Intermediate,4925.0,1.0,500.0,4996.0,,,
,1.0,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621028,,9606.0,,,N,Intermediate,4925.0,1.0,500.0,4997.0,,,
,1.0,F,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621029,,9606.0,,,N,Intermediate,13978.0,1.0,500.0,4998.0,,,
,1.0,F,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621030,,9606.0,,,N,Intermediate,16786.0,1.0,500.0,4999.0,,,
,1.0,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9.0,BAO_0000219,,CHEMBL621147,,,,,H,Expert,13412.0,8.0,500.0,5000.0,,,
,1.0,F,In vivo antiproliferative activity against A431 cell line,,A-431,80852.0,BAO_0000218,Homo sapiens,CHEMBL621148,,9606.0,,,N,Intermediate,17824.0,1.0,500.0,5001.0,,,
,1.0,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621149,,9606.0,,,D,Expert,12751.0,9.0,500.0,5002.0,,,
,1.0,F,Inhibition of A431 human epidermoid carcinoma cell proliferation,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621150,,9606.0,,,N,Expert,12380.0,1.0,500.0,5003.0,,,
,1.0,F,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621151,,9606.0,,,D,Expert,4959.0,9.0,500.0,5004.0,,,
,1.0,F,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621152,,9606.0,,,N,Intermediate,6333.0,1.0,500.0,5005.0,,,
,1.0,F,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621153,,9606.0,,,N,Intermediate,6333.0,1.0,500.0,5006.0,,,
,1.0,F,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL884000,,9606.0,,,N,Intermediate,6333.0,1.0,500.0,5007.0,,,
,1.0,F,Inhibition of EGFR overexpressing A431 cell proliferation,,,9.0,BAO_0000019,Homo sapiens,CHEMBL621154,,9606.0,,,D,Expert,5296.0,9.0,,5008.0,,,
,1.0,F,Inhibition of A431 cell proliferation,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621155,,9606.0,,,N,Expert,12624.0,1.0,500.0,5009.0,,,
,1.0,F,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621156,,9606.0,,,D,Expert,14926.0,9.0,500.0,5010.0,,,
,1.0,F,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621157,,9606.0,,,D,Expert,14926.0,9.0,500.0,5011.0,,,
,1.0,F,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,A-431,9.0,BAO_0000219,,CHEMBL621158,,,,,H,Expert,14926.0,8.0,500.0,5012.0,,,
,1.0,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621159,,9606.0,,,N,Intermediate,15144.0,1.0,500.0,5013.0,,,
,1.0,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621160,,9606.0,,,N,Intermediate,15144.0,1.0,500.0,5014.0,,,
,1.0,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621161,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5015.0,,,
,1.0,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621162,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5016.0,,,
,1.0,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621163,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5017.0,,,
,1.0,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621164,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5018.0,,,
,1.0,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621165,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5019.0,,,
,1.0,A,Half-life period in cynomolgus monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619159,,9527.0,,,U,Autocuration,5922.0,0.0,,5020.0,,,
Plasma,1.0,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,22224.0,BAO_0000366,Cercopithecidae,CHEMBL619160,In vitro,9527.0,1969.0,,U,Autocuration,1116.0,0.0,,5021.0,,,
,1.0,A,Longer half-life in monkey (i.v.) at 0.5 mpk,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619161,In vivo,9527.0,,,U,Autocuration,17853.0,0.0,,5022.0,,,
Plasma,1.0,A,Plasma half life in monkey,,,22224.0,BAO_0000366,Cercopithecidae,CHEMBL619162,,9527.0,1969.0,,U,Autocuration,993.0,0.0,,5023.0,,,
Plasma,1.0,A,Plasma half-life in rhesus monkey,,,22224.0,BAO_0000366,Cercopithecidae,CHEMBL619163,,9527.0,1969.0,,U,Autocuration,4514.0,0.0,,5024.0,,,
Plasma,1.0,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619164,In vivo,9527.0,1969.0,,U,Autocuration,5334.0,0.0,,5025.0,,,
Plasma,1.0,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619320,In vivo,9527.0,1969.0,,U,Autocuration,5334.0,0.0,,5026.0,,,
,1.0,A,Tested for half life upon iv administration to african green monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619321,In vivo,9527.0,,,U,Autocuration,4578.0,0.0,,5027.0,,,
,1.0,A,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL873336,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,5028.0,,,
,1.0,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619322,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,5029.0,,,
,1.0,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619323,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,5030.0,,,
,1.0,A,The time for peak concentration value after oral administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL619324,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,5031.0,,,
,1.0,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619325,,9527.0,,,U,Autocuration,11271.0,0.0,,5032.0,,,
,1.0,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL876411,,9527.0,,,U,Autocuration,11271.0,0.0,,5033.0,,,
,1.0,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619326,,9527.0,,,U,Autocuration,11271.0,0.0,,5034.0,,,
,1.0,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619327,,9527.0,,,U,Autocuration,11271.0,0.0,,5035.0,,,
,1.0,A,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619328,,9527.0,,,U,Autocuration,11271.0,0.0,,5036.0,,,
,1.0,A,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619329,,9527.0,,,U,Autocuration,11271.0,0.0,,5037.0,,,
,1.0,A,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619330,,9527.0,,,U,Autocuration,11271.0,0.0,,5038.0,,,
,1.0,A,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619331,,9527.0,,,U,Autocuration,11271.0,0.0,,5039.0,,,
,1.0,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619332,,9527.0,,,U,Autocuration,11271.0,0.0,,5040.0,,,
,1.0,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619333,,9527.0,,,U,Autocuration,11271.0,0.0,,5041.0,,,
,1.0,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619334,,9527.0,,,U,Autocuration,11271.0,0.0,,5042.0,,,
,1.0,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619335,,9527.0,,,U,Autocuration,11271.0,0.0,,5043.0,,,
,1.0,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619336,,9527.0,,,U,Autocuration,11271.0,0.0,,5044.0,,,
,1.0,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619337,,9527.0,,,U,Autocuration,11271.0,0.0,,5045.0,,,
,1.0,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619338,,9527.0,,,U,Autocuration,11271.0,0.0,,5046.0,,,
,1.0,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL619339,,9527.0,,,U,Autocuration,11271.0,0.0,,5047.0,,,
,1.0,A,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619340,In vivo,10116.0,,,N,Intermediate,5809.0,1.0,,5048.0,,,
Plasma,1.0,A,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL873496,In vivo,10116.0,1969.0,,N,Intermediate,17720.0,1.0,,5049.0,,,
Plasma,1.0,A,AUC value in rat after IV administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619341,,10116.0,1969.0,,N,Intermediate,3546.0,1.0,,5050.0,,,
Plasma,1.0,A,AUC value in rat after oral administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619342,,10116.0,1969.0,,N,Intermediate,3546.0,1.0,,5051.0,,,
,1.0,A,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619343,In vivo,10116.0,,,N,Intermediate,3546.0,1.0,,5052.0,,,
,1.0,A,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619344,In vivo,10116.0,,,N,Intermediate,3546.0,1.0,,5053.0,,,
,1.0,A,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619345,In vivo,10116.0,,,N,Intermediate,3546.0,1.0,,5054.0,,,
,1.0,A,Vc value in rat after IV administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619346,,10116.0,,,N,Intermediate,3546.0,1.0,,5055.0,,,
,1.0,A,Half life period in rat after IV administration at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL619347,In vivo,10116.0,,,N,Intermediate,3546.0,1.0,,5056.0,,,
,1.0,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL619348,,9557.0,,,U,Autocuration,10625.0,0.0,,5057.0,,,
,1.0,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL619349,,9557.0,,,U,Autocuration,10625.0,0.0,,5058.0,,,
,1.0,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL619350,,9557.0,,,U,Autocuration,10625.0,0.0,,5059.0,,,
,1.0,A,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL619351,,9557.0,,,U,Autocuration,10625.0,0.0,,5060.0,,,
,1.0,A,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL875953,,9557.0,,,U,Autocuration,10625.0,0.0,,5061.0,,,
,1.0,A,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL621716,,9557.0,,,U,Autocuration,10625.0,0.0,,5062.0,,,
,1.0,A,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL621717,,9557.0,,,U,Autocuration,10625.0,0.0,,5063.0,,,
,1.0,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,22224.0,BAO_0000019,Papio hamadryas,CHEMBL621718,,9557.0,,,U,Autocuration,10625.0,0.0,,5064.0,,,
,1.0,A,Area under curve after 1 mpk peroral administration to beagles,,,22224.0,BAO_0000019,beagle,CHEMBL621719,,9615.0,,,U,Autocuration,3510.0,0.0,,5065.0,,,
,1.0,A,Area under curve after 2 mpk peroral administration to beagles,,,22224.0,BAO_0000019,beagle,CHEMBL621720,,9615.0,,,U,Autocuration,3510.0,0.0,,5066.0,,,
,1.0,A,Cmax value after 1 mpk peroral administration to beagles,,,22224.0,BAO_0000218,beagle,CHEMBL621721,In vivo,9615.0,,,U,Autocuration,3510.0,0.0,,5067.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL621722,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5068.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL621723,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5069.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL621724,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5070.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623443,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5071.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623444,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5072.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623445,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5073.0,,,
Urine,1.0,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623446,,9606.0,1088.0,,U,Autocuration,7766.0,0.0,,5074.0,,,
Liver,1.0,A,Metabolic stability observed at 30 min after administration in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL623447,,9606.0,2107.0,,U,Autocuration,16643.0,0.0,,5075.0,Microsomes,,
,1.0,A,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623448,,9606.0,,,U,Autocuration,6852.0,0.0,,5076.0,,,
,1.0,A,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623449,,9606.0,,,U,Autocuration,6852.0,0.0,,5077.0,,,
,1.0,A,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623450,,9606.0,,,U,Autocuration,6852.0,0.0,,5078.0,,,
Liver,1.0,A,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,22224.0,BAO_0000251,Homo sapiens,CHEMBL623451,,9606.0,2107.0,,U,Autocuration,6567.0,0.0,,5079.0,Microsomes,,
,1.0,A,Metabolic stability (% remaining at 30 mins) in human S9.,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623452,,9606.0,,,U,Autocuration,6570.0,0.0,,5080.0,,,
,1.0,A,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL623453,,9606.0,,,U,Autocuration,6570.0,0.0,,5081.0,,,
Liver,1.0,A,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL623454,,9606.0,2107.0,,U,Autocuration,5237.0,0.0,,5082.0,Microsomes,,
Liver,1.0,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL623455,,9606.0,2107.0,,U,Autocuration,5237.0,0.0,,5083.0,Microsomes,,
Liver,1.0,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624371,,9606.0,2107.0,,U,Autocuration,5237.0,0.0,,5084.0,Microsomes,,
,1.0,A,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL624372,,9606.0,,,U,Autocuration,5202.0,0.0,,5085.0,,,
,1.0,A,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624373,,9606.0,,,U,Autocuration,5481.0,0.0,,5086.0,,,
,1.0,A,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624374,,9606.0,,,U,Autocuration,5481.0,0.0,,5087.0,,,
,1.0,A,The percent remaining in human plasma after 30 min was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624556,,9606.0,,,U,Autocuration,3956.0,0.0,,5088.0,,,
Plasma,1.0,A,Conversion rate of the prodrug in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL624557,,9606.0,1969.0,,U,Autocuration,5074.0,0.0,,5089.0,,,
Plasma,1.0,A,Conversion rate of the prodrug in human plasma; ND means no data,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL624558,,9606.0,1969.0,,U,Autocuration,5074.0,0.0,,5090.0,,,
Blood,1.0,A,Half life of compound was determined in human blood,,,22224.0,BAO_0000221,Homo sapiens,CHEMBL624559,,9606.0,178.0,,U,Autocuration,4727.0,0.0,,5091.0,,,
,1.0,A,Half life of compound was determined in man with once daily dosing,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624560,,9606.0,,,U,Autocuration,5965.0,0.0,,5092.0,,,
,1.0,A,Half life in human microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624561,In vitro,9606.0,,,U,Autocuration,5732.0,0.0,,5093.0,Microsomes,,
Plasma,1.0,A,Half life in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL624562,,9606.0,1969.0,,U,Autocuration,5819.0,0.0,,5094.0,,,
Plasma,1.0,A,Half life in human plasma; Not detected,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL624563,,9606.0,1969.0,,U,Autocuration,5819.0,0.0,,5095.0,,,
,1.0,A,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL624564,In vivo,9606.0,,,U,Autocuration,1916.0,0.0,,5096.0,,,
Liver,1.0,A,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624565,In vitro,9606.0,2107.0,,U,Autocuration,6597.0,0.0,,5097.0,Microsomes,,
Plasma,1.0,A,Half-life in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL875152,,9606.0,1969.0,,U,Autocuration,5229.0,0.0,,5098.0,,,
Plasma,1.0,A,Half-life of the parent prodrug in plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL624566,,9606.0,1969.0,,U,Autocuration,5229.0,0.0,,5099.0,,,
Plasma,1.0,A,In vitro half life in human plasma was determined,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL873805,In vitro,9606.0,1969.0,,U,Autocuration,2192.0,0.0,,5100.0,,,
Liver,1.0,A,The compound was tested In Vitro for half life in human liver microsomes.,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624567,In vitro,9606.0,2107.0,,U,Autocuration,3032.0,0.0,,5101.0,Microsomes,,
,1.0,A,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL624568,In vivo,9606.0,,,U,Autocuration,1916.0,0.0,,5102.0,,,
,1.0,A,Observed volume of distribution,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL624569,In vivo,9606.0,,,U,Autocuration,17716.0,0.0,,5103.0,,,
,1.0,A,Oral bioavailability in human,,,22224.0,BAO_0000218,Homo sapiens,CHEMBL624570,In vivo,9606.0,,,U,Autocuration,15778.0,0.0,,5104.0,,,
,1.0,A,Tested for human plasma protein binding of the compound,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624571,,9606.0,,,U,Autocuration,17313.0,0.0,,5105.0,,,
,1.0,A,"First order rate constant, k was determined in human plasma",,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624572,,9606.0,,,U,Autocuration,4231.0,0.0,,5106.0,,,
,1.0,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624573,,9606.0,,,U,Autocuration,4755.0,0.0,,5107.0,,,
,1.0,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL875153,,9606.0,,,U,Autocuration,4755.0,0.0,,5108.0,,,
Liver,1.0,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624574,,9606.0,2107.0,,U,Autocuration,16907.0,0.0,,5109.0,Microsomes,,
,1.0,A,The compound was tested for the plasma binding in human,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624575,,9606.0,,,U,Autocuration,10839.0,0.0,,5110.0,,,
,1.0,A,Plasma protein binding (human),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL624576,,9606.0,,,U,Autocuration,10839.0,0.0,,5111.0,,,
Liver,1.0,A,Compound was evaluated for half-life in human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL624577,In vitro,9606.0,2107.0,,U,Autocuration,3199.0,0.0,,5112.0,Microsomes,,
Blood,1.0,A,Half life measured in vitro for its stability in human blood,,,22224.0,BAO_0000221,Homo sapiens,CHEMBL624578,In vitro,9606.0,178.0,,U,Autocuration,1345.0,0.0,,5113.0,,,
Serum,1.0,A,Half life in human serum,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL622796,,9606.0,1977.0,,U,Autocuration,4297.0,0.0,,5114.0,,,
Serum,1.0,A,Half life in human serum; ND=not determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL622797,,9606.0,1977.0,,U,Autocuration,4297.0,0.0,,5115.0,,,
,1.0,A,Half life were determined in CEM-SS cell extract in decomposition step 1,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL622798,,9606.0,,,U,Autocuration,4297.0,0.0,,5116.0,,,
,1.0,A,Half life were determined in CEM-SS cell extract in decomposition step 2,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL622799,,9606.0,,,U,Autocuration,4297.0,0.0,,5117.0,,,
Plasma,1.0,A,Half life of the in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL622800,,9606.0,1969.0,,U,Autocuration,4231.0,0.0,,5118.0,,,
,1.0,A,Half life period in human hepatic S9 fraction was determined,,,22224.0,BAO_0000220,Homo sapiens,CHEMBL622801,In vitro,9606.0,,,U,Autocuration,5633.0,0.0,,5119.0,S9,,
Liver,1.0,A,Half life period in human liver microsome was determined,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL622802,In vitro,9606.0,2107.0,,U,Autocuration,5633.0,0.0,,5120.0,Microsomes,,
,1.0,A,Half life period was determined; 6-7,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL622803,,9606.0,,,U,Autocuration,17791.0,0.0,,5121.0,,,
,1.0,A,Half life period was evaluated in human,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL875154,,9606.0,,,U,Autocuration,17791.0,0.0,,5122.0,,,
Plasma,1.0,A,Half life time in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL622804,,9606.0,1969.0,,U,Autocuration,3160.0,0.0,,5123.0,,,
Brain,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622805,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5124.0,,,
Heart,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622611,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5125.0,,,
Heart,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622612,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5126.0,,,
Kidney,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL875160,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5127.0,,,
Kidney,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622613,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5128.0,,,
Kidney,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622614,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5129.0,,,
Liver,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622615,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5130.0,,,
Liver,1.0,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622616,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5131.0,,,
Liver,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622617,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5132.0,,,
Spleen,1.0,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622618,In vivo,10090.0,2106.0,,N,Intermediate,16438.0,1.0,,5133.0,,,
Spleen,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622619,In vivo,10090.0,2106.0,,N,Intermediate,16438.0,1.0,,5134.0,,,
Spleen,1.0,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622620,In vivo,10090.0,2106.0,,N,Intermediate,16438.0,1.0,,5135.0,,,
Brain,1.0,A,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622621,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5136.0,,,
Blood,1.0,A,Biodistribution of compound (oxidized form) in blood tissue,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622622,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5137.0,,,
Blood,1.0,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622623,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5138.0,,,
Blood,1.0,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622624,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5139.0,,,
Blood,1.0,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622625,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5140.0,,,
Blood,1.0,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622626,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5141.0,,,
Blood,1.0,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622627,In vivo,10090.0,178.0,,N,Intermediate,16438.0,1.0,,5142.0,,,
Brain,1.0,A,Biodistribution of compound (oxidized form) in brain tissue of mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622628,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5143.0,,,
Brain,1.0,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622629,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5144.0,,,
Brain,1.0,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622630,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5145.0,,,
Brain,1.0,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622631,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5146.0,,,
Brain,1.0,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622632,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5147.0,,,
Brain,1.0,A,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622633,In vivo,10090.0,955.0,,N,Intermediate,16438.0,1.0,,5148.0,,,
Heart,1.0,A,Biodistribution of compound (oxidized form) in heart tissue of mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622634,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5149.0,,,
Heart,1.0,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622635,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5150.0,,,
Heart,1.0,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL875161,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5151.0,,,
Heart,1.0,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622636,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5152.0,,,
Heart,1.0,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623335,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5153.0,,,
Heart,1.0,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623336,In vivo,10090.0,948.0,,N,Intermediate,16438.0,1.0,,5154.0,,,
Kidney,1.0,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623337,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5155.0,,,
Kidney,1.0,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623338,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5156.0,,,
Kidney,1.0,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623339,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5157.0,,,
Kidney,1.0,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623524,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5158.0,,,
Kidney,1.0,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623525,In vivo,10090.0,2113.0,,N,Intermediate,16438.0,1.0,,5159.0,,,
Liver,1.0,A,Biodistribution of compound (oxidized form) in liver tissue,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623526,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5160.0,,,
Liver,1.0,A,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623527,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5161.0,,,
Liver,1.0,A,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,50594.0,BAO_0000218,Mus musculus,CHEMBL623528,In vivo,10090.0,2107.0,,N,Intermediate,16438.0,1.0,,5162.0,,,
,1.0,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL624615,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5163.0,,,
,1.0,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621672,,9606.0,,,N,Intermediate,5245.0,1.0,500.0,5164.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,A-431,80852.0,BAO_0000218,,CHEMBL621673,,,,,N,Expert,16289.0,1.0,500.0,5165.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,A-431,80852.0,BAO_0000218,,CHEMBL621674,,,,,N,Expert,16289.0,1.0,500.0,5166.0,,,
,1.0,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL884002,,9606.0,,,D,Expert,16093.0,9.0,500.0,5167.0,,,
,1.0,F,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621850,,9606.0,,,N,Intermediate,16825.0,1.0,500.0,5168.0,,,
,1.0,F,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL621851,,9606.0,,,N,Intermediate,4848.0,1.0,500.0,5169.0,,,
,1.0,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621852,,9606.0,,,D,Expert,14827.0,9.0,500.0,5170.0,,,
,1.0,F,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL621853,,9606.0,,,D,Expert,14827.0,9.0,500.0,5171.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,A-431,80852.0,BAO_0000218,,CHEMBL621854,,,,,N,Expert,16289.0,1.0,500.0,5172.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,A-431,80852.0,BAO_0000218,,CHEMBL621855,,,,,N,Expert,16289.0,1.0,500.0,5173.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,A-431,80852.0,BAO_0000218,,CHEMBL623724,,,,,N,Expert,16289.0,1.0,500.0,5174.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,A-431,80852.0,BAO_0000218,,CHEMBL623725,,,,,N,Expert,16289.0,1.0,500.0,5175.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,A-431,80852.0,BAO_0000218,,CHEMBL623726,,,,,N,Expert,16289.0,1.0,500.0,5176.0,,,
,1.0,F,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL623727,,9606.0,,,D,Expert,16289.0,9.0,500.0,5177.0,,,
,1.0,F,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,A-431,9.0,BAO_0000219,,CHEMBL623728,,,,,H,Expert,16289.0,8.0,500.0,5178.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,A-431,80852.0,BAO_0000218,,CHEMBL623729,,,,,N,Expert,16289.0,1.0,500.0,5179.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,A-431,80852.0,BAO_0000218,,CHEMBL623730,,,,,N,Expert,16289.0,1.0,500.0,5180.0,,,
,1.0,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,A-431,80852.0,BAO_0000218,,CHEMBL623731,,,,,N,Expert,16289.0,1.0,500.0,5181.0,,,
,1.0,F,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852.0,BAO_0000218,Mus musculus,CHEMBL623732,,10090.0,,,N,Expert,14555.0,1.0,500.0,5182.0,,,
,1.0,F,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852.0,BAO_0000218,Mus musculus,CHEMBL623733,,10090.0,,,N,Expert,14555.0,1.0,500.0,5183.0,,,
,1.0,F,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852.0,BAO_0000218,Mus musculus,CHEMBL623734,,10090.0,,,N,Expert,14555.0,1.0,500.0,5184.0,,,
,1.0,F,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,A-431,80852.0,BAO_0000218,Mus musculus,CHEMBL623735,,10090.0,,,N,Expert,14555.0,1.0,500.0,5185.0,,,
,1.0,F,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL623736,,9606.0,,,N,Expert,1937.0,1.0,500.0,5186.0,,,
,1.0,F,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL623737,,9606.0,,,N,Intermediate,13739.0,1.0,500.0,5187.0,,,
,1.0,F,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL623738,,9606.0,,,N,Intermediate,3558.0,1.0,500.0,5188.0,,,
,1.0,F,Dose giving a 50% decrease in the living cell number (A437 cells),,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL875168,,9606.0,,,N,Intermediate,3558.0,1.0,500.0,5189.0,,,
,1.0,F,In vitro inhibitory concentration against proliferation of A459 cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623739,,9606.0,,,N,Expert,17686.0,1.0,646.0,5190.0,,,
,1.0,F,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623740,,9606.0,,,N,Intermediate,5305.0,1.0,646.0,5191.0,,,
,1.0,F,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624424,,9606.0,,,N,Intermediate,3614.0,1.0,646.0,5192.0,,,
,1.0,F,In vitro antitumor activity against renal A498 tumor cell lines,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624425,,9606.0,,,N,Intermediate,17229.0,1.0,624.0,5193.0,,,
,1.0,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624426,,9606.0,,,N,Intermediate,15935.0,1.0,624.0,5194.0,,,
,1.0,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624427,,9606.0,,,N,Intermediate,15935.0,1.0,624.0,5195.0,,,
,1.0,F,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624428,,9606.0,,,N,Intermediate,15560.0,1.0,624.0,5196.0,,,
,1.0,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624429,,9606.0,,,N,Intermediate,13891.0,1.0,624.0,5197.0,,,
,1.0,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624620,,9606.0,,,N,Intermediate,13891.0,1.0,624.0,5198.0,,,
,1.0,F,Cytotoxicity on kidney carcinoma (A-498) cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624621,,9606.0,,,N,Intermediate,13788.0,1.0,624.0,5199.0,,,
,1.0,F,Compound was evaluated against Human cell line renal A498,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624622,,9606.0,,,N,Intermediate,15403.0,1.0,624.0,5200.0,,,
,1.0,F,Compound was tested for inhibition of A498 human renal cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624623,,9606.0,,,N,Intermediate,1009.0,1.0,624.0,5201.0,,,
,1.0,F,Growth inhibitory activity against A498 human cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL874365,,9606.0,,,N,Intermediate,1043.0,1.0,624.0,5202.0,,,
,1.0,F,In vitro antitumor activity against human renal A498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624624,,9606.0,,,N,Intermediate,5858.0,1.0,624.0,5203.0,,,
,1.0,F,In vitro cytotoxic activity against renal (A498) cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624625,,9606.0,,,N,Intermediate,5958.0,1.0,624.0,5204.0,,,
,1.0,F,In vitro cytotoxic activity against human renal cancer (A498) cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624626,,9606.0,,,N,Intermediate,5506.0,1.0,624.0,5205.0,,,
,1.0,F,Tested for cytostatic activity against renal A498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624627,,9606.0,,,N,Intermediate,12781.0,1.0,624.0,5206.0,,,
,1.0,F,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL883157,,9606.0,,,N,Intermediate,14399.0,1.0,624.0,5207.0,,,
,1.0,F,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624628,,9606.0,,,N,Expert,5958.0,1.0,624.0,5208.0,,,
,1.0,A,Cmax value after 2 mpk peroral administration to beagles,,,22224.0,BAO_0000218,beagle,CHEMBL624629,In vivo,9615.0,,,U,Autocuration,3510.0,0.0,,5209.0,,,
,1.0,A,Bioavailability,,,22224.0,BAO_0000218,Canis lupus familiaris,CHEMBL623551,In vivo,9615.0,,,U,Autocuration,3510.0,0.0,,5210.0,,beagle,
,1.0,A,Bioavailability after 1 mpk peroral administration to beagles,,,22224.0,BAO_0000218,Canis lupus familiaris,CHEMBL623552,In vivo,9615.0,,,U,Autocuration,3510.0,0.0,,5211.0,,beagle,
,1.0,A,Bioavailability after 2 mpk peroral administration to beagles,,,22224.0,BAO_0000218,Canis lupus familiaris,CHEMBL623553,In vivo,9615.0,,,U,Autocuration,3510.0,0.0,,5212.0,,beagle,
,1.0,A,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623554,,9913.0,,,U,Autocuration,3085.0,0.0,,5213.0,,,
,1.0,A,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623555,,9913.0,,,U,Autocuration,3085.0,0.0,,5214.0,,,
,1.0,A,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623556,,9913.0,,,U,Autocuration,3085.0,0.0,,5215.0,,,
,1.0,A,Solubility against bovine alpha-chymotrypsin,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623557,,9913.0,,,U,Autocuration,9372.0,0.0,,5216.0,,,
,1.0,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623558,,9913.0,,,U,Autocuration,3085.0,0.0,,5217.0,,,
,1.0,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623559,,9913.0,,,U,Autocuration,3085.0,0.0,,5218.0,,,
Spleen,1.0,A,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,22224.0,BAO_0000221,Bos taurus,CHEMBL623560,,9913.0,2106.0,,U,Autocuration,1469.0,0.0,,5219.0,,,
,1.0,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623561,,9913.0,,,U,Autocuration,4297.0,0.0,,5220.0,,,
,1.0,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623562,,9913.0,,,U,Autocuration,4297.0,0.0,,5221.0,,,
,1.0,A,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623563,,9913.0,,,U,Autocuration,17585.0,0.0,,5222.0,,,
Spleen,1.0,A,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,22224.0,BAO_0000221,Bos taurus,CHEMBL623564,,9913.0,2106.0,,U,Autocuration,1336.0,0.0,,5223.0,,,
,1.0,A,Half life in presence of 2 mg/mL BSA at pH 8.8,,,22224.0,BAO_0000019,Bos taurus,CHEMBL873806,,9913.0,,,U,Autocuration,3085.0,0.0,,5224.0,,,
,1.0,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623565,,9913.0,,,U,Autocuration,2857.0,0.0,,5225.0,,,
,1.0,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623566,,9913.0,,,U,Autocuration,2857.0,0.0,,5226.0,,,
,1.0,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,22224.0,BAO_0000019,Bos taurus,CHEMBL623567,,9913.0,,,U,Autocuration,2857.0,0.0,,5227.0,,,
,1.0,A,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,22224.0,BAO_0000019,Bos taurus,CHEMBL623568,,9913.0,,,U,Autocuration,1540.0,0.0,,5228.0,,,
Plasma,1.0,A,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623569,,9615.0,1969.0,,N,Intermediate,6316.0,1.0,,5229.0,,,
Plasma,1.0,A,AUC after administration at 100 mg/kg/day in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623570,,9615.0,1969.0,,N,Intermediate,17594.0,1.0,,5230.0,,,
Plasma,1.0,A,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624254,,9615.0,1969.0,,N,Intermediate,4953.0,1.0,,5231.0,,,
Plasma,1.0,A,AUC value after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624255,,9615.0,1969.0,,N,Intermediate,16907.0,1.0,,5232.0,,,
Plasma,1.0,A,AUC value after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624256,,9615.0,1969.0,,N,Intermediate,16907.0,1.0,,5233.0,,,
Plasma,1.0,A,AUC value after administration of 4 mg/Kg oral dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624257,,9615.0,1969.0,,N,Intermediate,2959.0,1.0,,5234.0,,,
Plasma,1.0,A,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624258,,9615.0,1969.0,,N,Intermediate,17594.0,1.0,,5235.0,,,
,1.0,A,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875277,,9615.0,,,N,Intermediate,5356.0,1.0,,5236.0,,,
,1.0,A,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622667,,9615.0,,,N,Intermediate,16807.0,1.0,,5237.0,,,
,1.0,A,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622668,,9615.0,,,N,Intermediate,4527.0,1.0,,5238.0,,,
,1.0,A,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622669,,9615.0,,,N,Intermediate,4527.0,1.0,,5239.0,,,
,1.0,A,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622670,,9615.0,,,N,Intermediate,15660.0,1.0,,5240.0,,,
,1.0,A,Area under curve determined in dogs after oral administration of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622671,,9615.0,,,N,Intermediate,15660.0,1.0,,5241.0,,,
,1.0,A,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622672,,9615.0,,,N,Intermediate,5802.0,1.0,,5242.0,,,
,1.0,A,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622673,,9615.0,,,N,Expert,3598.0,1.0,,5243.0,,,
,1.0,A,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622674,,9615.0,,,N,Expert,3598.0,1.0,,5244.0,,,
,1.0,A,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622675,,9615.0,,,N,Intermediate,5944.0,1.0,,5245.0,,,
,1.0,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622676,,9615.0,,,N,Intermediate,5944.0,1.0,,5246.0,,,
,1.0,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622677,,9615.0,,,N,Intermediate,5944.0,1.0,,5247.0,,,
,1.0,A,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622678,,9615.0,,,N,Intermediate,5944.0,1.0,,5248.0,,,
,1.0,A,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622679,,9615.0,,,N,Intermediate,4186.0,1.0,,5249.0,,,
,1.0,A,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622680,,9615.0,,,N,Intermediate,5007.0,1.0,,5250.0,,,
,1.0,A,Area under curve was determine after peroral administration at 10 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622681,,9615.0,,,N,Intermediate,5668.0,1.0,,5251.0,,,
,1.0,A,Area under curve was determine after peroral administration at 5 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875278,,9615.0,,,N,Intermediate,5668.0,1.0,,5252.0,,,
,1.0,A,Area under curve was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622682,,9615.0,,,N,Intermediate,5006.0,1.0,,5253.0,,,
,1.0,A,Area under curve in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622683,,9615.0,,,N,Intermediate,5006.0,1.0,,5254.0,,,
,1.0,A,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622684,,9615.0,,,N,Intermediate,3771.0,1.0,,5255.0,,,
,1.0,A,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622685,,9615.0,,,N,Intermediate,3771.0,1.0,,5256.0,,,
,1.0,A,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622686,,9615.0,,,N,Intermediate,3771.0,1.0,,5257.0,,,
,1.0,A,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618344,,9615.0,,,N,Intermediate,1916.0,1.0,,5258.0,,,
,1.0,A,Area under curve value in dog at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875582,,9615.0,,,N,Intermediate,5302.0,1.0,,5259.0,,,
,1.0,A,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618345,,9615.0,,,N,Intermediate,5600.0,1.0,,5260.0,,,
,1.0,A,Area under curve was determined after 0.3 mg/kg po administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618346,,9615.0,,,N,Intermediate,5600.0,1.0,,5261.0,,,
,1.0,A,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618347,,9615.0,,,N,Intermediate,17764.0,1.0,,5262.0,,,
,1.0,A,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618348,,9615.0,,,N,Intermediate,4368.0,1.0,,5263.0,,,
,1.0,A,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618349,,9606.0,,,U,Autocuration,5318.0,0.0,,5264.0,,,
,1.0,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618350,,9606.0,,,U,Autocuration,5318.0,0.0,,5265.0,,,
,1.0,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618351,,9606.0,,,U,Autocuration,5318.0,0.0,,5266.0,,,
,1.0,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618352,,9606.0,,,U,Autocuration,5318.0,0.0,,5267.0,,,
Blood,1.0,A,Time taken to reduce 50% of the concentration of compound in blood plasma,,,22224.0,BAO_0000221,Homo sapiens,CHEMBL873494,,9606.0,178.0,,U,Autocuration,14518.0,0.0,,5268.0,,,
Plasma,1.0,A,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618353,,9606.0,1969.0,,U,Autocuration,2209.0,0.0,,5269.0,,,
Plasma,1.0,A,Half life in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618354,,9606.0,1969.0,,U,Autocuration,6787.0,0.0,,5270.0,,,
Plasma,1.0,A,Half life in human plasma was reported,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL875583,,9606.0,1969.0,,U,Autocuration,4898.0,0.0,,5271.0,,,
Serum,1.0,A,Half life in human serum,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618355,,9606.0,1977.0,,U,Autocuration,6072.0,0.0,,5272.0,,,
Plasma,1.0,A,Half life upon exposure to human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618356,,9606.0,1969.0,,U,Autocuration,16907.0,0.0,,5273.0,,,
,1.0,A,t1/2 in human microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618357,In vitro,9606.0,,,U,Autocuration,5656.0,0.0,,5274.0,Microsomes,,
Plasma,1.0,A,Half life period in 80% human plasma at 37 degree Centigrade,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618358,,9606.0,1969.0,,U,Autocuration,4755.0,0.0,,5275.0,,,
Zone of skin,1.0,A,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,22224.0,BAO_0000221,Homo sapiens,CHEMBL618359,,9606.0,14.0,,U,Autocuration,17503.0,0.0,,5276.0,,,
Plasma,1.0,A,Half-life measured in in vitro Cathepsin B assay in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618360,In vitro,9606.0,1969.0,,U,Autocuration,12357.0,0.0,,5277.0,,,
,1.0,A,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618361,,9606.0,,,U,Autocuration,3076.0,0.0,,5278.0,,,
Liver,1.0,A,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618362,In vitro,9606.0,2107.0,,U,Autocuration,6410.0,0.0,,5279.0,Microsomes,,
Plasma,1.0,A,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618363,,9606.0,1969.0,,U,Autocuration,3741.0,0.0,,5280.0,,,
Plasma,1.0,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618364,,9606.0,1969.0,,U,Autocuration,3741.0,0.0,,5281.0,,,
Plasma,1.0,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL875584,,9606.0,1969.0,,U,Autocuration,3741.0,0.0,,5282.0,,,
,1.0,A,Half-life in the CEM cell extracts,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618365,,9606.0,,,U,Autocuration,1540.0,0.0,,5283.0,,,
Plasma,1.0,A,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL873495,,9606.0,1969.0,,U,Autocuration,2905.0,0.0,,5284.0,,,
Plasma,1.0,A,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618366,,9606.0,1969.0,,U,Autocuration,2905.0,0.0,,5285.0,,,
,1.0,A,Half-life was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618367,,9606.0,,,U,Autocuration,5523.0,0.0,,5286.0,,,
Blood,1.0,A,Half-life (human blood stability),,,22224.0,BAO_0000221,Homo sapiens,CHEMBL618368,,9606.0,178.0,,U,Autocuration,1499.0,0.0,,5287.0,,,
Blood,1.0,A,Half-life (human blood stability); no data,,,22224.0,BAO_0000221,Homo sapiens,CHEMBL618369,,9606.0,178.0,,U,Autocuration,1499.0,0.0,,5288.0,,,
Plasma,1.0,A,Half-life in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618370,,9606.0,1969.0,,U,Autocuration,17065.0,0.0,,5289.0,,,
,1.0,A,CYP3A4 metabolism half-life (t1/2),,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618371,,9606.0,,,U,Autocuration,6861.0,0.0,,5290.0,,,
Blood,1.0,A,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,22224.0,BAO_0000221,Homo sapiens,CHEMBL618372,,9606.0,178.0,,U,Autocuration,1499.0,0.0,,5291.0,,,
Plasma,1.0,A,In vitro half life in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618373,In vitro,9606.0,1969.0,,U,Autocuration,530.0,0.0,,5292.0,,,
Plasma,1.0,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618374,In vitro,9606.0,1969.0,,U,Autocuration,1116.0,0.0,,5293.0,,,
Plasma,1.0,A,In vitro hydrolysis in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618375,In vitro,9606.0,1969.0,,U,Autocuration,6695.0,0.0,,5294.0,,,
Plasma,1.0,A,In vitro hydrolysis in human plasma; no data,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618376,In vitro,9606.0,1969.0,,U,Autocuration,6695.0,0.0,,5295.0,,,
Liver,1.0,A,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL618377,In vitro,9606.0,2107.0,,U,Autocuration,10.0,0.0,,5296.0,Microsomes,,
Plasma,1.0,A,Plasma half life in human,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618378,,9606.0,1969.0,,U,Autocuration,993.0,0.0,,5297.0,,,
Plasma,1.0,A,Stability after incubation with human plasma (at 37 degree C),,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618379,,9606.0,1969.0,,U,Autocuration,15429.0,0.0,,5298.0,,,
Plasma,1.0,A,T1/2 was evaluated in human plasma,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618380,,9606.0,1969.0,,U,Autocuration,1675.0,0.0,,5299.0,,,
Plasma,1.0,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618381,,9606.0,1969.0,,U,Autocuration,2209.0,0.0,,5300.0,,,
Plasma,1.0,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,22224.0,BAO_0000366,Homo sapiens,CHEMBL618382,,9606.0,1969.0,,U,Autocuration,2209.0,0.0,,5301.0,,,
,1.0,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618383,,9606.0,,,U,Autocuration,5318.0,0.0,,5302.0,,,
,1.0,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618384,In vitro,9606.0,,,U,Autocuration,2412.0,0.0,,5303.0,,,
,1.0,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL618385,In vitro,9606.0,,,U,Autocuration,2412.0,0.0,,5304.0,,,
Plasma,1.0,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL619099,,9606.0,1969.0,,U,Autocuration,2906.0,0.0,,5305.0,,,
Plasma,1.0,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,22224.0,BAO_0000366,Homo sapiens,CHEMBL619100,,9606.0,1969.0,,U,Autocuration,2906.0,0.0,,5306.0,,,
,1.0,A,Time taken for 50% to be consumed by serum PON1 was determined,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619101,,9606.0,,,U,Autocuration,5495.0,0.0,,5307.0,,,
,1.0,A,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,22224.0,BAO_0000019,Homo sapiens,CHEMBL619102,,9606.0,,,U,Autocuration,5495.0,0.0,,5308.0,,,
Liver,1.0,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,22224.0,BAO_0000251,Homo sapiens,CHEMBL619103,,9606.0,2107.0,,U,Autocuration,4397.0,0.0,,5309.0,Microsomes,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL619268,,10095.0,,,U,Autocuration,2413.0,0.0,,5310.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL619269,,10095.0,,,U,Autocuration,2413.0,0.0,,5311.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL619270,,10095.0,,,U,Autocuration,2413.0,0.0,,5312.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL619271,,10095.0,,,U,Autocuration,2413.0,0.0,,5313.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL875585,,10095.0,,,U,Autocuration,2413.0,0.0,,5314.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL619272,,10095.0,,,U,Autocuration,2413.0,0.0,,5315.0,,,
,1.0,F,Compound tested for growth inhibition of renal cancer cell line 786-0,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619273,,9606.0,,,N,Intermediate,6058.0,1.0,391.0,5316.0,,,
,1.0,F,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619274,,9606.0,,,N,Intermediate,17708.0,1.0,391.0,5317.0,,,
,1.0,F,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619275,,9606.0,,,N,Expert,14017.0,1.0,391.0,5318.0,,,
,1.0,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619276,,9606.0,,,N,Intermediate,16818.0,1.0,391.0,5319.0,,,
,1.0,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619277,,9606.0,,,N,Intermediate,16818.0,1.0,391.0,5320.0,,,
,1.0,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619278,,9606.0,,,N,Intermediate,16818.0,1.0,391.0,5321.0,,,
,1.0,F,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619279,,9606.0,,,N,Intermediate,11970.0,1.0,391.0,5322.0,,,
,1.0,F,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL858458,,9606.0,,,N,Intermediate,12400.0,1.0,391.0,5323.0,,,
,1.0,F,Cytotoxic effect on renal cancer line 786-0,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619280,,9606.0,,,N,Expert,12888.0,1.0,391.0,5324.0,,,
,1.0,F,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619281,,9606.0,,,N,Intermediate,15300.0,1.0,391.0,5325.0,,,
,1.0,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619282,,9606.0,,,N,Intermediate,14769.0,1.0,391.0,5326.0,,,
,1.0,F,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619283,,9606.0,,,N,Intermediate,15895.0,1.0,391.0,5327.0,,,
,1.0,F,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619284,,9606.0,,,N,Intermediate,17376.0,1.0,391.0,5328.0,,,
,1.0,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619285,,9606.0,,,N,Intermediate,14882.0,1.0,391.0,5329.0,,,
,1.0,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619286,,9606.0,,,N,Intermediate,14882.0,1.0,391.0,5330.0,,,
,1.0,F,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619287,,9606.0,,,N,Intermediate,15176.0,1.0,391.0,5331.0,,,
,1.0,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL857455,,9606.0,,,N,Intermediate,12696.0,1.0,391.0,5332.0,,,
,1.0,F,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL883801,,9606.0,,,N,Intermediate,2496.0,1.0,391.0,5333.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619288,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5334.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619289,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5335.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619290,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5336.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619291,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5337.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619292,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5338.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619293,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5339.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619294,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5340.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619295,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5341.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619296,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5342.0,,,
,1.0,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,791T cell line,80641.0,BAO_0000219,Homo sapiens,CHEMBL619297,,9606.0,,,N,Intermediate,11831.0,1.0,972.0,5343.0,,,
,1.0,F,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,786-0,80640.0,BAO_0000219,Homo sapiens,CHEMBL619298,,9606.0,,,N,Intermediate,12782.0,1.0,391.0,5344.0,,,
,1.0,F,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL619299,,,,,U,Intermediate,1229.0,0.0,,5345.0,,,
,1.0,F,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619300,,9606.0,,,N,Expert,15313.0,1.0,741.0,5346.0,,,
,1.0,F,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619301,,9606.0,,,N,Expert,15313.0,1.0,741.0,5347.0,,,
,1.0,F,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619302,,9606.0,,,N,Intermediate,11544.0,1.0,741.0,5348.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619303,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5349.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619304,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5350.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL857706,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5351.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619305,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5352.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619306,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5353.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619307,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5354.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619308,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5355.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619309,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5356.0,,,
,1.0,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL619310,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5357.0,,,
,1.0,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619311,,9606.0,,,N,Intermediate,14769.0,1.0,624.0,5358.0,,,
,1.0,F,Compound was tested for the growth inhibition of A498 renal tumor cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619312,,9606.0,,,N,Intermediate,15354.0,1.0,624.0,5359.0,,,
,1.0,F,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619313,,9606.0,,,N,Intermediate,17445.0,1.0,624.0,5360.0,,,
,1.0,F,In vitro inhibitory concentration against renal cancer cell line A498,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619314,,9606.0,,,N,Intermediate,4337.0,1.0,624.0,5361.0,,,
,1.0,F,Cytotoxicity against A 498 tumor cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619959,,9606.0,,,N,Intermediate,15277.0,1.0,624.0,5362.0,,,
,1.0,F,In vitro antitumor activity against A498 human cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619960,,9606.0,,,N,Intermediate,4812.0,1.0,624.0,5363.0,,,
,1.0,F,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619961,,9606.0,,,N,Intermediate,4812.0,1.0,624.0,5364.0,,,
,1.0,F,Inhibitory dose required against A498 human tumor cell lines,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619962,,9606.0,,,N,Intermediate,4995.0,1.0,624.0,5365.0,,,
,1.0,F,Anticancer activity against one renal cancer (A498 cell line),,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL875586,,9606.0,,,N,Intermediate,5847.0,1.0,624.0,5366.0,,,
,1.0,F,In vitro cytotoxicity against melanoma A498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619963,,9606.0,,,N,Intermediate,6557.0,1.0,624.0,5367.0,,,
,1.0,F,Compound was tested for growth inhibitory activity against A498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619964,,9606.0,,,N,Intermediate,2597.0,1.0,624.0,5368.0,,,
,1.0,F,Compound tested for growth inhibition of renal cancer cell line A498,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620108,,9606.0,,,N,Intermediate,6058.0,1.0,624.0,5369.0,,,
,1.0,F,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620109,,9606.0,,,N,Intermediate,17708.0,1.0,624.0,5370.0,,,
,1.0,F,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620110,,9606.0,,,N,Intermediate,15176.0,1.0,624.0,5371.0,,,
,1.0,F,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620111,,9606.0,,,N,Intermediate,15300.0,1.0,624.0,5372.0,,,
,1.0,F,Tested for cytotoxicity against A498 cell lines in renal cancer,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620112,,9606.0,,,N,Intermediate,11970.0,1.0,624.0,5373.0,,,
,1.0,F,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620113,,9606.0,,,N,Intermediate,12400.0,1.0,624.0,5374.0,,,
,1.0,F,Cytotoxic effect on renal cancer lines A498,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620114,,9606.0,,,N,Expert,12888.0,1.0,624.0,5375.0,,,
,1.0,F,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620115,,9606.0,,,N,Intermediate,3030.0,1.0,624.0,5376.0,,,
,1.0,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620116,,9606.0,,,N,Intermediate,14769.0,1.0,624.0,5377.0,,,
,1.0,F,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620117,,9606.0,,,N,Intermediate,17376.0,1.0,624.0,5378.0,,,
,1.0,F,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620118,,9606.0,,,N,Intermediate,16558.0,1.0,624.0,5379.0,,,
,1.0,F,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620119,,9606.0,,,N,Intermediate,5194.0,1.0,624.0,5380.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620120,,9606.0,,,N,Intermediate,10708.0,1.0,624.0,5381.0,,,
,1.0,F,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620121,,9606.0,,,N,Expert,16880.0,1.0,646.0,5382.0,,,
,1.0,F,Antitumor activity against A549 human lung carcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620122,,9606.0,,,N,Intermediate,10196.0,1.0,646.0,5383.0,,,
,1.0,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620123,,9606.0,,,N,Intermediate,10196.0,1.0,646.0,5384.0,,,
,1.0,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620124,,9606.0,,,N,Intermediate,10196.0,1.0,646.0,5385.0,,,
,1.0,F,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620125,,9606.0,,,N,Intermediate,12083.0,1.0,646.0,5386.0,,,
,1.0,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620126,,9606.0,,,N,Expert,16464.0,1.0,646.0,5387.0,,,
,1.0,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL883027,,9606.0,,,N,Intermediate,16464.0,1.0,646.0,5388.0,,,
,1.0,F,In vitro cytotoxic activity against human lung A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620127,,9606.0,,,N,Expert,16470.0,1.0,646.0,5389.0,,,
,1.0,F,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620128,,9606.0,,,N,Intermediate,16470.0,1.0,646.0,5390.0,,,
,1.0,F,In vitro cytotoxic activity against human lung A549 cell line),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620129,,9606.0,,,N,Intermediate,16470.0,1.0,646.0,5391.0,,,
,1.0,F,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620130,,9606.0,,,N,Intermediate,16470.0,1.0,646.0,5392.0,,,
,1.0,F,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620131,,9606.0,,,N,Expert,16582.0,1.0,646.0,5393.0,,,
,1.0,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620132,,9606.0,,,N,Intermediate,15935.0,1.0,646.0,5394.0,,,
,1.0,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620133,,9606.0,,,N,Intermediate,15935.0,1.0,646.0,5395.0,,,
,1.0,F,Inhibition of A549 human lung carcinoma cell proliferation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620134,,9606.0,,,N,Expert,16597.0,1.0,646.0,5396.0,,,
,1.0,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620135,,9606.0,,,N,Intermediate,17376.0,1.0,646.0,5397.0,,,
,1.0,F,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620136,,9606.0,,,N,Intermediate,16496.0,1.0,646.0,5398.0,,,
,1.0,F,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620137,,9606.0,,,N,Intermediate,16152.0,1.0,646.0,5399.0,,,
,1.0,F,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620268,,9606.0,,,N,Intermediate,16152.0,1.0,646.0,5400.0,,,
,1.0,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620269,,9606.0,,,N,Intermediate,16464.0,1.0,646.0,5401.0,,,
,1.0,F,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620270,,9606.0,,,N,Intermediate,2288.0,1.0,646.0,5402.0,,,
,1.0,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620271,,9606.0,,,N,Intermediate,17350.0,1.0,646.0,5403.0,,,
,1.0,F,Inhibition of A549 cancer cell proliferation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620272,,9606.0,,,N,Expert,4090.0,1.0,646.0,5404.0,,,
,1.0,F,Inhibition of A549 cancer cell proliferation (Not tested),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620273,,9606.0,,,N,Expert,4090.0,1.0,646.0,5405.0,,,
,1.0,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620274,,9606.0,,,N,Intermediate,17350.0,1.0,646.0,5406.0,,,
,1.0,F,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620275,,9606.0,,,N,Intermediate,4197.0,1.0,646.0,5407.0,,,
,1.0,F,Antiproliferative potency determined as inhibitory concentration against A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620276,,9606.0,,,N,Intermediate,17072.0,1.0,646.0,5408.0,,,
,1.0,F,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620277,,9606.0,,,N,Intermediate,17072.0,1.0,646.0,5409.0,,,
,1.0,F,Cytotoxicity against Renal cell lines A549 was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620278,,9606.0,,,N,Intermediate,5194.0,1.0,646.0,5410.0,,,
,1.0,A,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620279,,9615.0,,,N,Intermediate,4257.0,1.0,,5411.0,,,
,1.0,A,Area under curve was determined in dog after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620280,,9615.0,,,N,Intermediate,6123.0,1.0,,5412.0,,,
,1.0,A,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620281,,9615.0,,,N,Intermediate,1337.0,1.0,,5413.0,,,
,1.0,A,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620282,,9615.0,,,N,Intermediate,1337.0,1.0,,5414.0,,,
,1.0,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621134,,9615.0,,,N,Intermediate,8833.0,1.0,,5415.0,,,
,1.0,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621135,,9615.0,,,N,Intermediate,8833.0,1.0,,5416.0,,,
,1.0,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621136,,9615.0,,,N,Intermediate,8833.0,1.0,,5417.0,,,
,1.0,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621137,,9615.0,,,N,Intermediate,8833.0,1.0,,5418.0,,,
Plasma,1.0,A,Area under plasma concentration time curve in dog upon oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621138,,9615.0,1969.0,,N,Intermediate,17657.0,1.0,,5419.0,,,
Plasma,1.0,A,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875587,,9615.0,1969.0,,N,Intermediate,17650.0,1.0,,5420.0,,,
,1.0,A,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621139,,9615.0,,,N,Intermediate,1977.0,1.0,,5421.0,,,
,1.0,A,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621140,,9615.0,,,N,Intermediate,1977.0,1.0,,5422.0,,,
,1.0,A,Area under the curve for the compound was obtained when tested in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621141,,9615.0,,,N,Intermediate,3132.0,1.0,,5423.0,,,
,1.0,A,Area under the curve at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621142,,9615.0,,,N,Intermediate,5473.0,1.0,,5424.0,,,
,1.0,A,Area under the curve at a dose of 1 mg/kg (oral),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621143,,9615.0,,,N,Intermediate,5474.0,1.0,,5425.0,,,
,1.0,A,Area under the curve at i.v. dose of 0.2 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621144,,9615.0,,,N,Intermediate,5474.0,1.0,,5426.0,,,
,1.0,A,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621145,,9615.0,,,N,Intermediate,6062.0,1.0,,5427.0,,,
,1.0,A,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621146,,9615.0,,,N,Intermediate,4709.0,1.0,,5428.0,,,
,1.0,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622567,,9615.0,,,N,Intermediate,2652.0,1.0,,5429.0,,,
,1.0,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622568,,9615.0,,,N,Intermediate,2652.0,1.0,,5430.0,,,
,1.0,A,Compound was evaluated for area under the curve in dog blood.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622569,,9615.0,,,N,Intermediate,2877.0,1.0,,5431.0,,,
,1.0,A,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622570,,9615.0,,,N,Intermediate,5444.0,1.0,,5432.0,,,
Plasma,1.0,A,AUC in dog after oral dose (1 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622571,,9615.0,1969.0,,N,Intermediate,5130.0,1.0,,5433.0,,,
,1.0,A,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622572,,9615.0,,,N,Intermediate,6265.0,1.0,,5434.0,,,
,1.0,A,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622573,,9615.0,,,N,Intermediate,4657.0,1.0,,5435.0,,,
,1.0,A,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622574,,9615.0,,,N,Intermediate,16367.0,1.0,,5436.0,,,
,1.0,A,Pharmacokinetic parameter AUC after oral administration to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622575,,9615.0,,,N,Intermediate,16367.0,1.0,,5437.0,,,
,1.0,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622576,,9615.0,,,N,Intermediate,9579.0,1.0,,5438.0,,,
,1.0,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622577,,9615.0,,,N,Intermediate,9579.0,1.0,,5439.0,,,
,1.0,A,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622578,,9615.0,,,N,Intermediate,5983.0,1.0,,5440.0,,,
,1.0,A,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622579,,9615.0,,,N,Intermediate,6241.0,1.0,,5441.0,,,
,1.0,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622580,,9615.0,,,N,Intermediate,5313.0,1.0,,5442.0,,,
,1.0,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622581,,9615.0,,,N,Intermediate,5313.0,1.0,,5443.0,,,
,1.0,A,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622582,,9615.0,,,N,Intermediate,6642.0,1.0,,5444.0,,,
,1.0,A,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622583,,9615.0,,,N,Intermediate,6642.0,1.0,,5445.0,,,
,1.0,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622584,,9615.0,,,N,Intermediate,6641.0,1.0,,5446.0,,,
,1.0,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622585,,9615.0,,,N,Intermediate,6642.0,1.0,,5447.0,,,
,1.0,A,Compound was evaluated for oral bioavailability in dog; 90-100,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622586,,9615.0,,,N,Intermediate,17791.0,1.0,,5448.0,,,
,1.0,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623281,,9615.0,,,N,Intermediate,17655.0,1.0,,5449.0,,,
,1.0,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623282,,9615.0,,,N,Intermediate,17655.0,1.0,,5450.0,,,
,1.0,A,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623283,,9615.0,,,N,Intermediate,6596.0,1.0,,5451.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623284,,9615.0,,,N,Intermediate,3880.0,1.0,,5452.0,,,
,1.0,A,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623285,,9615.0,,,N,Intermediate,16367.0,1.0,,5453.0,,,
Plasma,1.0,A,Plasma protein binding towards dog plasma at 10 uM,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623463,,9615.0,1969.0,,N,Intermediate,17409.0,1.0,,5454.0,,,
Plasma,1.0,A,Plasma protein binding towards dog plasma at 100 uM,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875952,,9615.0,1969.0,,N,Intermediate,17409.0,1.0,,5455.0,,,
,1.0,A,Bioavailability in dog (dose 4 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621705,In vivo,9615.0,,,N,Intermediate,2959.0,1.0,,5456.0,,,
,1.0,A,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621706,In vivo,9615.0,,,N,Intermediate,13501.0,1.0,,5457.0,,,
,1.0,A,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621707,In vivo,9615.0,,,N,Intermediate,4527.0,1.0,,5458.0,,,
,1.0,A,Bioavailability in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621708,In vivo,9615.0,,,N,Intermediate,15145.0,1.0,,5459.0,,,
,1.0,A,Bioavailability,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621709,In vivo,9615.0,,,N,Intermediate,4219.0,1.0,,5460.0,,,
,1.0,A,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621710,In vivo,9615.0,,,N,Intermediate,17538.0,1.0,,5461.0,,,
,1.0,A,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621711,In vivo,9615.0,,,N,Intermediate,17538.0,1.0,,5462.0,,,
,1.0,A,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621712,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,5463.0,,,
,1.0,A,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621713,In vivo,9615.0,,,N,Intermediate,17650.0,1.0,,5464.0,,,
,1.0,A,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621714,In vivo,9615.0,,,N,Intermediate,3132.0,1.0,,5465.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL621715,,10095.0,,,U,Autocuration,2413.0,0.0,,5466.0,,,
Liver,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623717,,10095.0,2107.0,,U,Autocuration,2413.0,0.0,,5467.0,,,
Liver,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623718,,10095.0,2107.0,,U,Autocuration,2413.0,0.0,,5468.0,,,
Liver,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623719,,10095.0,2107.0,,U,Autocuration,2413.0,0.0,,5469.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623720,,10095.0,,,U,Autocuration,2413.0,0.0,,5470.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623721,,10095.0,,,U,Autocuration,2413.0,0.0,,5471.0,,,
Muscle tissue,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623722,,10095.0,2385.0,,U,Autocuration,2413.0,0.0,,5472.0,,,
Muscle tissue,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623723,,10095.0,2385.0,,U,Autocuration,2413.0,0.0,,5473.0,,,
Muscle tissue,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL618543,,10095.0,2385.0,,U,Autocuration,2413.0,0.0,,5474.0,,,
Spleen,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL618544,,10095.0,2106.0,,U,Autocuration,2413.0,0.0,,5475.0,,,
Spleen,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL875155,,10095.0,2106.0,,U,Autocuration,2413.0,0.0,,5476.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL618545,,10095.0,,,U,Autocuration,2413.0,0.0,,5477.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL618546,,10095.0,,,U,Autocuration,2413.0,0.0,,5478.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623529,,10095.0,,,U,Autocuration,2413.0,0.0,,5479.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL623530,,10095.0,,,U,Autocuration,2413.0,0.0,,5480.0,,,
,1.0,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,22224.0,BAO_0000218,Mus sp.,CHEMBL621764,,10095.0,,,U,Autocuration,2413.0,0.0,,5481.0,,,
,1.0,A,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621765,,9527.0,,,U,Autocuration,17827.0,0.0,,5482.0,,,
Cerebellum,1.0,A,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621766,,9527.0,2037.0,,U,Autocuration,17827.0,0.0,,5483.0,,,
Frontal cortex,1.0,A,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621767,,9527.0,1870.0,,U,Autocuration,17827.0,0.0,,5484.0,,,
,1.0,A,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621768,,9527.0,,,U,Autocuration,17827.0,0.0,,5485.0,,,
Striatum,1.0,A,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621769,,9527.0,2435.0,,U,Autocuration,17827.0,0.0,,5486.0,,,
,1.0,A,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621770,,9527.0,,,U,Autocuration,17827.0,0.0,,5487.0,,,
Cerebellum,1.0,A,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621771,,9527.0,2037.0,,U,Autocuration,17827.0,0.0,,5488.0,,,
Frontal cortex,1.0,A,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621772,,9527.0,1870.0,,U,Autocuration,17827.0,0.0,,5489.0,,,
,1.0,A,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621773,,9527.0,,,U,Autocuration,17827.0,0.0,,5490.0,,,
Striatum,1.0,A,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621774,,9527.0,2435.0,,U,Autocuration,17827.0,0.0,,5491.0,,,
,1.0,A,Compound was evaluated for oral bioavailability in rats,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621775,,9527.0,,,U,Autocuration,17791.0,0.0,,5492.0,,,
Plasma,1.0,A,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621776,In vivo,9527.0,1969.0,,U,Autocuration,17667.0,0.0,,5493.0,,,
,1.0,A,Half life period was evaluated in monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621777,,9527.0,,,U,Autocuration,17791.0,0.0,,5494.0,,,
,1.0,A,Half-life in rhesus monkeys by intravenous administration of dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL875162,In vivo,9527.0,,,U,Autocuration,110.0,0.0,,5495.0,,,
Plasma,1.0,A,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621778,,10090.0,1969.0,,N,Intermediate,5781.0,1.0,,5496.0,,,
Plasma,1.0,A,AUC after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621779,,10090.0,1969.0,,N,Intermediate,17734.0,1.0,,5497.0,,,
Plasma,1.0,A,AUC value was determined after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622479,,10090.0,1969.0,,N,Intermediate,17718.0,1.0,,5498.0,,,
,1.0,A,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622480,,10090.0,,,N,Intermediate,4573.0,1.0,,5499.0,,,
,1.0,A,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594.0,BAO_0000218,Mus musculus,CHEMBL622481,,10090.0,,,N,Intermediate,3277.0,1.0,,5500.0,,,
,1.0,A,Area under curve by ioral administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622482,,10090.0,,,N,Intermediate,2862.0,1.0,,5501.0,,,
,1.0,A,Area under curve by iv administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622483,,10090.0,,,N,Intermediate,2862.0,1.0,,5502.0,,,
,1.0,A,Area under curve at 0-8 hr in IRC mice after peroral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622484,,10090.0,,,N,Intermediate,5951.0,1.0,,5503.0,,,
,1.0,A,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622641,,10090.0,,,N,Intermediate,17729.0,1.0,,5504.0,,,
,1.0,A,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622642,,10090.0,,,N,Intermediate,17728.0,1.0,,5505.0,,,
,1.0,A,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622643,,10090.0,,,N,Intermediate,17728.0,1.0,,5506.0,,,
,1.0,A,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622644,,10090.0,,,N,Intermediate,17729.0,1.0,,5507.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL622645,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5508.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL622646,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5509.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL621238,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5510.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL621239,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5511.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL621240,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5512.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL621241,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5513.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL621242,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5514.0,,,
,1.0,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620350,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5515.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620351,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5516.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620352,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5517.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620353,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5518.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620354,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5519.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620355,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5520.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620356,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5521.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620357,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5522.0,,,
,1.0,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620358,,9606.0,,,N,Intermediate,9424.0,1.0,741.0,5523.0,,,
,1.0,F,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620359,,9606.0,,,N,Expert,9424.0,1.0,741.0,5524.0,,,
,1.0,F,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620360,,9606.0,,,N,Intermediate,11544.0,1.0,741.0,5525.0,,,
,1.0,F,Cytotoxicity of compound against 8226/DOX1V cells,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620361,,9606.0,,,N,Intermediate,17378.0,1.0,741.0,5526.0,,,
,1.0,F,Cytotoxicity of compound against 8226/S cells,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620362,,9606.0,,,N,Intermediate,17378.0,1.0,741.0,5527.0,,,
,1.0,F,Inhibitory concentration against 8226 myeloma cancer cell line,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620363,,9606.0,,,N,Intermediate,17079.0,1.0,741.0,5528.0,,,
,1.0,F,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,RPMI-8226,80433.0,BAO_0000219,Homo sapiens,CHEMBL620364,,9606.0,,,N,Intermediate,17079.0,1.0,741.0,5529.0,,,
,1.0,F,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,833K,80647.0,BAO_0000219,Homo sapiens,CHEMBL620365,,9606.0,,,N,Intermediate,13466.0,1.0,854.0,5530.0,,,
,1.0,F,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,833K,80647.0,BAO_0000219,Homo sapiens,CHEMBL620366,,9606.0,,,N,Intermediate,13466.0,1.0,854.0,5531.0,,,
,1.0,F,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,833K,80647.0,BAO_0000219,Homo sapiens,CHEMBL620367,,9606.0,,,N,Expert,2392.0,1.0,854.0,5532.0,,,
,1.0,F,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,833K,80647.0,BAO_0000219,Homo sapiens,CHEMBL620368,,9606.0,,,N,Intermediate,2392.0,1.0,854.0,5533.0,,,
,1.0,B,Inhibitory activity against caspase-1,,,22226.0,BAO_0000019,,CHEMBL620369,,,,,U,Autocuration,6608.0,0.0,,5534.0,,,
,1.0,B,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,45.0,BAO_0000357,Enterococcus faecalis,CHEMBL620370,,1351.0,,,H,Autocuration,10199.0,8.0,,5535.0,,,
,1.0,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,8701-BC,80648.0,BAO_0000219,Homo sapiens,CHEMBL620371,,9606.0,,,N,Intermediate,17749.0,1.0,705.0,5536.0,,,
,1.0,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,8701-BC,80648.0,BAO_0000219,Homo sapiens,CHEMBL620372,,9606.0,,,N,Intermediate,17749.0,1.0,705.0,5537.0,,,
,1.0,F,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL876492,,,,,U,Intermediate,1229.0,0.0,,5538.0,,,
,1.0,F,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL620373,,,,,U,Intermediate,1229.0,0.0,,5539.0,,,
,1.0,F,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,22226.0,BAO_0000019,,CHEMBL620374,,,,,U,Intermediate,1229.0,0.0,,5540.0,,,
,1.0,B,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,22226.0,BAO_0000019,,CHEMBL620375,,,,,U,Autocuration,6390.0,0.0,,5541.0,,,
,1.0,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,22226.0,BAO_0000019,Streptococcus pyogenes,CHEMBL857902,,1314.0,,,U,Autocuration,16219.0,0.0,,5542.0,,,
,1.0,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,22226.0,BAO_0000019,Streptococcus pyogenes,CHEMBL620376,,1314.0,,,U,Autocuration,16219.0,0.0,,5543.0,,,
,1.0,B,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,11922.0,BAO_0000357,,CHEMBL620377,,,,,H,Autocuration,17043.0,8.0,,5544.0,,,
,1.0,F,Tested for in vitro cytotoxic potency of compound in 9KB assay,,KB ,81115.0,BAO_0000219,Homo sapiens,CHEMBL620378,,9606.0,,,N,Intermediate,6929.0,1.0,324.0,5545.0,,,
,1.0,A,Tested for in vitro cytotoxic potency of compound in 9KB assay,,KB ,81115.0,BAO_0000219,Homo sapiens,CHEMBL620379,,9606.0,,,N,Intermediate,6929.0,1.0,324.0,5546.0,,,
,1.0,F,In vitro cytotoxicity of compound was tested against 9KB cells.,,,22226.0,BAO_0000219,Homo sapiens,CHEMBL620380,,9606.0,,,U,Autocuration,7083.0,0.0,,5547.0,,,
,1.0,F,Cytotoxic concentration against 9L cells was determined on day 3,,9L,80653.0,BAO_0000219,Rattus norvegicus,CHEMBL884006,,10116.0,,,N,Intermediate,12446.0,1.0,392.0,5548.0,,,
,1.0,F,Tested in vitro for anticancer activity against 9L cells,,9L,80653.0,BAO_0000219,Rattus norvegicus,CHEMBL620381,,10116.0,,,N,Expert,15345.0,1.0,392.0,5549.0,,,
,1.0,F,Tested in vitro for anticancer activity against 9L cells; Not determined,,9L,80653.0,BAO_0000219,Rattus norvegicus,CHEMBL620382,,10116.0,,,N,Expert,15345.0,1.0,392.0,5550.0,,,
,1.0,F,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620383,,9606.0,,,N,Intermediate,6301.0,1.0,646.0,5551.0,,,
,1.0,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876493,,9606.0,,,N,Intermediate,4833.0,1.0,646.0,5552.0,,,
,1.0,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620384,,9606.0,,,N,Intermediate,4833.0,1.0,646.0,5553.0,,,
,1.0,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620385,,9606.0,,,N,Intermediate,4833.0,1.0,646.0,5554.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620386,,9606.0,,,N,Expert,13330.0,1.0,646.0,5555.0,,,
,1.0,F,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,A549,25.0,BAO_0000219,Homo sapiens,CHEMBL620387,,9606.0,,,D,Expert,17517.0,9.0,646.0,5556.0,,,
,1.0,F,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,A549,25.0,BAO_0000219,Homo sapiens,CHEMBL621404,,9606.0,,,D,Expert,17517.0,9.0,646.0,5557.0,,,
,1.0,F,"In vitro growth inhibition of A549, lung carcinoma",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621405,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5558.0,,,
,1.0,F,"In vitro growth inhibition of A549, lung carcinoma.",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621406,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5559.0,,,
,1.0,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621407,,9606.0,,,N,Expert,5228.0,1.0,646.0,5560.0,,,
,1.0,F,Cytotoxic activity against human lung cancer A549 cell line was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621408,,9606.0,,,N,Intermediate,5351.0,1.0,646.0,5561.0,,,
,1.0,F,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL885345,,9606.0,,,N,Expert,12198.0,1.0,646.0,5562.0,,,
,1.0,F,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621409,,9606.0,,,N,Intermediate,13891.0,1.0,646.0,5563.0,,,
,1.0,F,Cytotoxicity in A549 (human carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876034,,9606.0,,,N,Expert,5677.0,1.0,646.0,5564.0,,,
,1.0,F,Cytotoxicity on lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621410,,9606.0,,,N,Intermediate,13788.0,1.0,646.0,5565.0,,,
,1.0,F,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621411,,9606.0,,,N,Expert,13384.0,1.0,646.0,5566.0,,,
,1.0,F,Effective dose of compound against replication of A549 cell line was evaluated,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621412,,9606.0,,,N,Intermediate,6726.0,1.0,646.0,5567.0,,,
,1.0,F,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621413,,9606.0,,,N,Expert,3455.0,1.0,646.0,5568.0,,,
,1.0,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621414,,9606.0,,,N,Intermediate,5726.0,1.0,646.0,5569.0,,,
,1.0,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621415,,9606.0,,,N,Intermediate,5726.0,1.0,646.0,5570.0,,,
,1.0,F,The compound was evaluated for antiproliferative activity against A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621416,,9606.0,,,N,Intermediate,3936.0,1.0,646.0,5571.0,,,
,1.0,F,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621417,,9606.0,,,N,Intermediate,14991.0,1.0,646.0,5572.0,,,
,1.0,F,Concentration required for growth inhibition of human lung carcinoma cell line A549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621418,,9606.0,,,N,Intermediate,5243.0,1.0,646.0,5573.0,,,
,1.0,F,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621419,,9606.0,,,N,Intermediate,12858.0,1.0,646.0,5574.0,,,
,1.0,F,Growth inhibition against A549 cell line was evaluated,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621420,,9606.0,,,N,Intermediate,6776.0,1.0,646.0,5575.0,,,
,1.0,F,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL875823,,9606.0,,,N,Intermediate,16558.0,1.0,646.0,5576.0,,,
,1.0,F,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621421,,9606.0,,,N,Expert,4583.0,1.0,646.0,5577.0,,,
,1.0,F,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621422,,9606.0,,,N,Intermediate,13514.0,1.0,646.0,5578.0,,,
,1.0,F,Chemosensitivity against DT-diaphorase rich A549 cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884014,,9606.0,,,N,Expert,15166.0,1.0,646.0,5579.0,,,
,1.0,F,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621423,,9606.0,,,N,Intermediate,13873.0,1.0,646.0,5580.0,,,
,1.0,F,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621424,,9606.0,,,N,Expert,6447.0,1.0,646.0,5581.0,,,
,1.0,F,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621425,,9606.0,,,N,Intermediate,2068.0,1.0,646.0,5582.0,,,
,1.0,F,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621426,,9606.0,,,N,Expert,1863.0,1.0,646.0,5583.0,,,
,1.0,F,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621427,,9606.0,,,N,Intermediate,13873.0,1.0,646.0,5584.0,,,
,1.0,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621428,,9606.0,,,N,Intermediate,13873.0,1.0,646.0,5585.0,,,
,1.0,F,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621429,,9606.0,,,N,Expert,13873.0,1.0,646.0,5586.0,,,
,1.0,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621430,,9606.0,,,N,Intermediate,579.0,1.0,646.0,5587.0,,,
,1.0,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621431,,9606.0,,,N,Intermediate,579.0,1.0,646.0,5588.0,,,
,1.0,F,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621432,,9606.0,,,N,Intermediate,4584.0,1.0,646.0,5589.0,,,
,1.0,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621433,,9606.0,,,N,Expert,5421.0,1.0,646.0,5590.0,,,
,1.0,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL875824,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5591.0,,,
,1.0,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621434,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5592.0,,,
,1.0,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621435,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5593.0,,,
,1.0,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621436,,9606.0,,,N,Intermediate,14188.0,1.0,646.0,5594.0,,,
,1.0,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621437,,9606.0,,,N,Intermediate,14188.0,1.0,646.0,5595.0,,,
,1.0,F,Compound was tested for the growth inhibition of A549 lung tumor cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621438,,9606.0,,,N,Intermediate,15354.0,1.0,646.0,5596.0,,,
,1.0,F,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621439,,9606.0,,,N,Expert,14253.0,1.0,646.0,5597.0,,,
,1.0,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621440,,9606.0,,,N,Intermediate,13873.0,1.0,646.0,5598.0,,,
,1.0,A,Oral bioavailability in dog (conscious),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621441,In vivo,9615.0,,,N,Intermediate,3043.0,1.0,,5599.0,,,
,1.0,A,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621442,In vivo,9615.0,,,N,Intermediate,3045.0,1.0,,5600.0,,,
,1.0,A,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621443,In vivo,9615.0,,,N,Intermediate,3022.0,1.0,,5601.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621444,In vivo,9615.0,,,N,Intermediate,4453.0,1.0,,5602.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625133,In vivo,9615.0,,,N,Intermediate,1696.0,1.0,,5603.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625134,In vivo,9615.0,,,N,Intermediate,5045.0,1.0,,5604.0,,,
,1.0,A,Oral bioavailability in dog (fasted),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625135,In vivo,9615.0,,,N,Intermediate,5356.0,1.0,,5605.0,,,
,1.0,A,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625136,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,5606.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625137,In vivo,9615.0,,,N,Intermediate,6448.0,1.0,,5607.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625138,In vivo,9615.0,,,N,Intermediate,1475.0,1.0,,5608.0,,,
,1.0,A,Percent bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625139,In vivo,9615.0,,,N,Intermediate,3788.0,1.0,,5609.0,,,
,1.0,A,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL872264,In vivo,9615.0,,,N,Intermediate,3639.0,1.0,,5610.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625140,In vivo,9615.0,,,N,Intermediate,13397.0,1.0,,5611.0,,,
,1.0,A,The compound was evaluated for bioavailability in dogs; 34-44,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624436,In vivo,9615.0,,,N,Intermediate,2137.0,1.0,,5612.0,,,
,1.0,A,Bioavailability in dog (dose 4 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624437,In vivo,9615.0,,,N,Intermediate,2959.0,1.0,,5613.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL872261,In vivo,9615.0,,,N,Intermediate,6448.0,1.0,,5614.0,,,
,1.0,A,8 hour trough Blood level in dog was measured after administration of compound,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624438,,9615.0,,,N,Intermediate,6084.0,1.0,,5615.0,,,
Plasma,1.0,A,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624439,In vivo,9615.0,1969.0,,N,Intermediate,3639.0,1.0,,5616.0,,,
,1.0,A,C24 after oral administration at 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624440,,9615.0,,,N,Intermediate,6316.0,1.0,,5617.0,,,
,1.0,A,Clearance after oral and iv dosing in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624441,,9615.0,,,N,Intermediate,5238.0,1.0,,5618.0,,,
Plasma,1.0,A,Clearance of the drug was measured in the plasma of dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624442,,9615.0,1969.0,,N,Intermediate,17796.0,1.0,,5619.0,,,
,1.0,A,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624443,,9615.0,,,N,Intermediate,2652.0,1.0,,5620.0,,,
,1.0,A,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624444,In vivo,9615.0,,,N,Intermediate,5654.0,1.0,,5621.0,,,
,1.0,A,Clearance of compound was determined in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624445,In vivo,9615.0,,,N,Intermediate,6621.0,1.0,,5622.0,,,
,1.0,A,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624446,In vivo,9615.0,,,N,Intermediate,6505.0,1.0,,5623.0,,,
,1.0,A,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624447,In vivo,9615.0,,,N,Intermediate,5802.0,1.0,,5624.0,,,
,1.0,A,Plasma clearance in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624448,In vivo,9615.0,,,N,Intermediate,17267.0,1.0,,5625.0,,,
,1.0,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624449,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,5626.0,,,
,1.0,A,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624450,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,5627.0,,,
,1.0,A,Plasma clearance in dog after administration of 1 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875942,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,5628.0,,,
,1.0,A,Plasma clearance in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624451,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,5629.0,,,
,1.0,A,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624452,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,5630.0,,,
,1.0,A,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624453,In vivo,9615.0,,,N,Intermediate,5199.0,1.0,,5631.0,,,
,1.0,A,Plasma clearance after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624454,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,5632.0,,,
,1.0,A,Plasma clearance after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624455,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,5633.0,,,
,1.0,A,Plasma administration to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624456,In vivo,9615.0,,,N,Intermediate,16367.0,1.0,,5634.0,,,
,1.0,A,Plasma clearance was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624457,In vivo,9615.0,,,N,Intermediate,5505.0,1.0,,5635.0,,,
,1.0,A,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624458,In vivo,9615.0,,,N,Intermediate,6215.0,1.0,,5636.0,,,
,1.0,A,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624459,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,5637.0,,,
Liver,1.0,A,Intrinsic clearance in human liver microsomes,,,102164.0,BAO_0000251,Homo sapiens,CHEMBL624460,In vitro,9606.0,2107.0,,S,Intermediate,5007.0,2.0,,5638.0,Microsomes,,
Liver,1.0,A,Intrinsic clearance in human liver microsomes,,,102164.0,BAO_0000251,Homo sapiens,CHEMBL624461,In vitro,9606.0,2107.0,,S,Intermediate,5007.0,2.0,,5639.0,Microsomes,,
,1.0,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875943,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,5640.0,,,
,1.0,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624462,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,5641.0,,,
,1.0,A,Clearance in dog (dose 1 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624463,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,5642.0,,,
,1.0,A,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624464,In vivo,9615.0,,,N,Intermediate,6221.0,1.0,,5643.0,,,
,1.0,A,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624465,In vivo,9615.0,,,N,Intermediate,5007.0,1.0,,5644.0,,,
,1.0,A,Plasma clearance after peroral administration at 10 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624466,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5645.0,,,
,1.0,A,Plasma clearance after peroral administration at 5 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624467,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5646.0,,,
,1.0,A,Plasma clearance after peroral administration at 5 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624468,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5647.0,,,
,1.0,A,Plasma clearance was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624469,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,5648.0,,,
,1.0,A,Plasma clearance was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624470,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,5649.0,,,
,1.0,A,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624471,In vivo,9615.0,,,N,Intermediate,5983.0,1.0,,5650.0,,,
,1.0,A,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624472,In vivo,9615.0,,,N,Intermediate,5600.0,1.0,,5651.0,,,
,1.0,A,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622775,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,5652.0,,,
,1.0,A,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622776,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,5653.0,,,
,1.0,A,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622777,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,5654.0,,,
,1.0,A,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622778,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,5655.0,,,
,1.0,A,Clearance by intravenous administration of 1.2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622779,In vivo,9615.0,,,N,Intermediate,4368.0,1.0,,5656.0,,,
,1.0,A,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622780,In vivo,9615.0,,,N,Intermediate,4305.0,1.0,,5657.0,,,
Plasma,1.0,A,Clearance value was evaluated in dog plasma,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622781,In vivo,9615.0,1969.0,,N,Intermediate,1918.0,1.0,,5658.0,,,
,1.0,A,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622782,In vivo,9615.0,,,N,Intermediate,6005.0,1.0,,5659.0,,,
Plasma,1.0,A,Compound was tested for plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622783,In vivo,9615.0,1969.0,,N,Intermediate,4839.0,1.0,,5660.0,,,
,1.0,A,Pharmacokinetic property (Plasma clearance) was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622784,In vivo,9615.0,,,N,Intermediate,4239.0,1.0,,5661.0,,,
,1.0,A,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622785,,10090.0,,,N,Intermediate,17729.0,1.0,,5662.0,,,
,1.0,A,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622786,,10090.0,,,N,Intermediate,17728.0,1.0,,5663.0,,,
,1.0,A,Area under curve value in mouse at a dose of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622787,,10090.0,,,N,Intermediate,5302.0,1.0,,5664.0,,,
,1.0,A,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875949,,10090.0,,,N,Intermediate,5506.0,1.0,,5665.0,,,
,1.0,A,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622788,,10090.0,,,N,Intermediate,5506.0,1.0,,5666.0,,,
,1.0,F,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622789,,10090.0,,,N,Intermediate,17764.0,1.0,,5667.0,,,
,1.0,F,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622790,,10090.0,,,N,Intermediate,17764.0,1.0,,5668.0,,,
,1.0,F,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622791,,10090.0,,,N,Intermediate,17764.0,1.0,,5669.0,,,
,1.0,F,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622792,,10090.0,,,N,Intermediate,17764.0,1.0,,5670.0,,,
,1.0,A,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622793,,10090.0,,,N,Intermediate,17764.0,1.0,,5671.0,,,
,1.0,A,Area under curve was determined for the compound at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622794,,10090.0,,,N,Intermediate,17753.0,1.0,,5672.0,,,
,1.0,A,Area under curve was determined for the compound at 40 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622795,,10090.0,,,N,Intermediate,17753.0,1.0,,5673.0,,,
,1.0,A,Area under curve was determined for the compound at 5 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621803,,10090.0,,,N,Intermediate,17753.0,1.0,,5674.0,,,
,1.0,A,Area under the curve for the compound is obtained at dose 25 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621804,,10090.0,,,N,Intermediate,3132.0,1.0,,5675.0,,,
,1.0,A,Area under the curve for the compound was obtained when tested in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621805,,10090.0,,,N,Intermediate,3132.0,1.0,,5676.0,,,
,1.0,A,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621806,,10090.0,,,N,Intermediate,17837.0,1.0,,5677.0,,,
,1.0,A,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621807,,10090.0,,,N,Intermediate,17837.0,1.0,,5678.0,,,
,1.0,A,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621808,,10090.0,,,N,Intermediate,6062.0,1.0,,5679.0,,,
,1.0,A,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621809,,10090.0,,,N,Intermediate,4066.0,1.0,,5680.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,50594.0,BAO_0000218,Mus musculus,CHEMBL621810,,10090.0,,,N,Intermediate,16597.0,1.0,,5681.0,,,
,1.0,A,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875164,,10090.0,,,N,Intermediate,14239.0,1.0,,5682.0,,,
,1.0,A,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621811,,10090.0,,,N,Intermediate,14239.0,1.0,,5683.0,,,
,1.0,A,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,50594.0,BAO_0000218,Mus musculus,CHEMBL621812,,10090.0,,,N,Intermediate,4890.0,1.0,,5684.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,50594.0,BAO_0000218,Mus musculus,CHEMBL621813,,10090.0,,,N,Intermediate,429.0,1.0,,5685.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,50594.0,BAO_0000218,Mus musculus,CHEMBL621814,,10090.0,,,N,Intermediate,429.0,1.0,,5686.0,,,
,1.0,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621815,,10090.0,,,N,Intermediate,5969.0,1.0,,5687.0,,,
,1.0,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621816,,10090.0,,,N,Intermediate,5969.0,1.0,,5688.0,,,
,1.0,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621817,,10090.0,,,N,Intermediate,5969.0,1.0,,5689.0,,,
,1.0,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621818,,10090.0,,,N,Intermediate,6091.0,1.0,,5690.0,,,
,1.0,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621819,,10090.0,,,N,Intermediate,6091.0,1.0,,5691.0,,,
,1.0,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621820,,10090.0,,,N,Intermediate,6091.0,1.0,,5692.0,,,
,1.0,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621821,,10090.0,,,N,Intermediate,6091.0,1.0,,5693.0,,,
,1.0,A,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621822,,10090.0,,,N,Intermediate,6178.0,1.0,,5694.0,,,
,1.0,A,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619474,,10090.0,,,N,Intermediate,6178.0,1.0,,5695.0,,,
,1.0,A,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619475,,10090.0,,,N,Intermediate,6619.0,1.0,,5696.0,,,
,1.0,A,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619476,,10090.0,,,N,Intermediate,6619.0,1.0,,5697.0,,,
,1.0,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619477,,10090.0,,,N,Intermediate,3760.0,1.0,,5698.0,,,
,1.0,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619478,,10090.0,,,N,Intermediate,3760.0,1.0,,5699.0,,,
,1.0,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619479,,10090.0,,,N,Intermediate,3760.0,1.0,,5700.0,,,
,1.0,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,50594.0,BAO_0000218,Mus musculus,CHEMBL619480,,10090.0,,,N,Intermediate,3760.0,1.0,,5701.0,,,
,1.0,A,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619481,,10090.0,,,N,Intermediate,3192.0,1.0,,5702.0,,,
,1.0,A,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619482,,10090.0,,,N,Intermediate,3192.0,1.0,,5703.0,,,
,1.0,A,Area under the curve was evaluated in mice after intravenous administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619483,,10090.0,,,N,Intermediate,2675.0,1.0,,5704.0,,,
,1.0,A,Area under the curve was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619484,,10090.0,,,N,Intermediate,2675.0,1.0,,5705.0,,,
Plasma,1.0,A,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619485,,10090.0,1969.0,,N,Intermediate,16597.0,1.0,,5706.0,,,
Plasma,1.0,A,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619486,,10090.0,1969.0,,N,Intermediate,16597.0,1.0,,5707.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,50594.0,BAO_0000218,Mus musculus,CHEMBL619487,,10090.0,,,N,Intermediate,16597.0,1.0,,5708.0,,,
,1.0,A,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619488,,10090.0,,,N,Intermediate,17734.0,1.0,,5709.0,,,
Blood,1.0,A,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620106,In vivo,10090.0,178.0,,N,Intermediate,7767.0,1.0,,5710.0,,,
,1.0,F,The compound was tested in vitro for anticancer activity against 9L cells,,9L,80653.0,BAO_0000219,,CHEMBL620107,,,,,N,Intermediate,15345.0,1.0,392.0,5711.0,,,
,1.0,F,Anti proliferation activity determined; Weak effect,,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL620283,,10116.0,,,U,Autocuration,2181.0,0.0,,5712.0,,,
,1.0,F,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL875176,,10116.0,,,U,Autocuration,2181.0,0.0,,5713.0,,,
,1.0,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL620284,,10116.0,,,U,Autocuration,2181.0,0.0,,5714.0,,,
,1.0,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL623515,,10116.0,,,U,Autocuration,2181.0,0.0,,5715.0,,,
,1.0,F,The cytotoxic activity was in vitro tested by 9PS assay method,,,22226.0,BAO_0000019,Mus musculus,CHEMBL623516,,10090.0,,,U,Autocuration,10486.0,0.0,,5716.0,,,
,1.0,F,The cytotoxic activity was in vitro tested by 9PS assay method.,,,22226.0,BAO_0000019,Mus musculus,CHEMBL623517,,10090.0,,,U,Autocuration,10486.0,0.0,,5717.0,,,
,1.0,A,Partition coefficient (logD6.5),,,22224.0,BAO_0000019,,CHEMBL857878,,,,,U,Autocuration,15508.0,0.0,,5718.0,,,
,1.0,F,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623518,,9606.0,,,N,Expert,5242.0,1.0,478.0,5719.0,,,
,1.0,F,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL624195,,9606.0,,,N,Intermediate,16167.0,1.0,455.0,5720.0,,,
,1.0,F,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL624196,,9606.0,,,N,Expert,4782.0,1.0,500.0,5721.0,,,
,1.0,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,A-431,9.0,BAO_0000219,Homo sapiens,CHEMBL624197,,9606.0,,,D,Expert,16093.0,9.0,500.0,5722.0,,,
,1.0,F,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL624198,,9606.0,,,N,Intermediate,2596.0,1.0,624.0,5723.0,,,
,1.0,F,in vitro cytotoxicity against A 498 cancer cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL621287,,9606.0,,,N,Intermediate,2596.0,1.0,624.0,5724.0,,,
,1.0,F,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL621288,,9606.0,,,N,Intermediate,3239.0,1.0,624.0,5725.0,,,
,1.0,F,Cytotoxic activity against A 498 renal cancer cell lines.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL876496,,9606.0,,,N,Intermediate,1847.0,1.0,624.0,5726.0,,,
,1.0,F,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL621289,,9606.0,,,N,Intermediate,10553.0,1.0,624.0,5727.0,,,
,1.0,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,22226.0,BAO_0000019,Staphylococcus aureus,CHEMBL621290,,1280.0,,,U,Autocuration,16219.0,0.0,,5728.0,,,
,1.0,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,22226.0,BAO_0000019,Staphylococcus aureus,CHEMBL621291,,1280.0,,,U,Autocuration,16219.0,0.0,,5729.0,,,
,1.0,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,22226.0,BAO_0000019,Staphylococcus aureus,CHEMBL621292,,1280.0,,,U,Autocuration,16219.0,0.0,,5730.0,,,
,1.0,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,22226.0,BAO_0000019,Staphylococcus aureus,CHEMBL621293,,1280.0,,,U,Autocuration,16219.0,0.0,,5731.0,,,
,1.0,F,Inhibitory concentration required against A 549 lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621294,,9606.0,,,N,Intermediate,4782.0,1.0,646.0,5732.0,,,
,1.0,F,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621295,,9606.0,,,N,Intermediate,11805.0,1.0,646.0,5733.0,,,
,1.0,F,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884007,,9606.0,,,N,Intermediate,11805.0,1.0,646.0,5734.0,,,
,1.0,F,In vitro cytotoxicity against lung cancer A 549 cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621296,,9606.0,,,N,Intermediate,2007.0,1.0,646.0,5735.0,,,
,1.0,F,Compound was tested for its cytotoxicity against A 549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621297,,9606.0,,,N,Intermediate,4594.0,1.0,646.0,5736.0,,,
,1.0,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL839828,,9606.0,,,N,Expert,6018.0,1.0,646.0,5737.0,,,
,1.0,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620397,,9606.0,,,N,Intermediate,6018.0,1.0,646.0,5738.0,,,
,1.0,F,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620398,,9606.0,,,N,Expert,3599.0,1.0,646.0,5739.0,,,
,1.0,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620399,,9606.0,,,N,Intermediate,2551.0,1.0,646.0,5740.0,,,
,1.0,F,In vitro inhibition of A549 (human lung cancer) cell growth.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620400,,9606.0,,,N,Expert,16132.0,1.0,646.0,5741.0,,,
,1.0,F,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620401,,9606.0,,,N,Intermediate,16132.0,1.0,646.0,5742.0,,,
,1.0,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620402,,9606.0,,,N,Expert,2551.0,1.0,646.0,5743.0,,,
,1.0,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620403,,9606.0,,,N,Expert,2551.0,1.0,646.0,5744.0,,,
,1.0,F,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,22226.0,BAO_0000218,,CHEMBL620404,,,,,U,Autocuration,11913.0,0.0,,5745.0,,,
,1.0,F,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,104694.0,BAO_0000218,,CHEMBL620405,In vivo,,,,H,Autocuration,12621.0,4.0,,5746.0,,,
,1.0,F,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,104694.0,BAO_0000218,,CHEMBL620406,In vivo,,,,H,Autocuration,12621.0,4.0,,5747.0,,,
,1.0,F,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,104694.0,BAO_0000218,,CHEMBL620407,In vivo,,,,H,Autocuration,12621.0,4.0,,5748.0,,,
,1.0,F,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,104694.0,BAO_0000218,,CHEMBL620408,In vivo,,,,H,Autocuration,12621.0,4.0,,5749.0,,,
,1.0,F,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,104694.0,BAO_0000218,,CHEMBL620409,In vivo,,,,H,Autocuration,12621.0,4.0,,5750.0,,,
,1.0,F,Inhibition of A-498 human Renal cell proliferation,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL620410,,9606.0,,,N,Expert,3600.0,1.0,624.0,5751.0,,,
,1.0,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL620411,,10116.0,,,U,Autocuration,1796.0,0.0,,5752.0,,,
,1.0,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL620412,,10116.0,,,U,Autocuration,1796.0,0.0,,5753.0,,,
,1.0,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,22226.0,BAO_0000019,Rattus norvegicus,CHEMBL876596,,10116.0,,,U,Autocuration,1796.0,0.0,,5754.0,,,
,1.0,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL620413,,9606.0,,,N,Expert,16464.0,1.0,622.0,5755.0,,,
,1.0,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL620414,,9606.0,,,N,Intermediate,16464.0,1.0,622.0,5756.0,,,
,1.0,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL620415,,9606.0,,,N,Intermediate,16464.0,1.0,622.0,5757.0,,,
,1.0,F,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620416,,9606.0,,,N,Expert,13617.0,1.0,646.0,5758.0,,,
,1.0,F,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620417,,9606.0,,,N,Intermediate,4584.0,1.0,646.0,5759.0,,,
,1.0,F,Cytotoxic activity evaluated against A549 tumor cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620418,,9606.0,,,N,Expert,13799.0,1.0,646.0,5760.0,,,
,1.0,F,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620419,,9606.0,,,N,Intermediate,16726.0,1.0,646.0,5761.0,,,
,1.0,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620420,,9606.0,,,N,Intermediate,16109.0,1.0,646.0,5762.0,,,
,1.0,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620421,,9606.0,,,N,Intermediate,16109.0,1.0,646.0,5763.0,,,
,1.0,F,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620422,,9606.0,,,N,Intermediate,15474.0,1.0,646.0,5764.0,,,
,1.0,F,Cytotoxicity of compound against A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620423,,9606.0,,,N,Intermediate,6851.0,1.0,646.0,5765.0,,,
,1.0,F,Cytotoxicity against human lung cell carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620424,,9606.0,,,N,Expert,17534.0,1.0,646.0,5766.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620425,,9606.0,,,N,Intermediate,2621.0,1.0,646.0,5767.0,,,
,1.0,F,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620426,,9606.0,,,N,Intermediate,830.0,1.0,646.0,5768.0,,,
,1.0,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620427,,9606.0,,,N,Intermediate,14255.0,1.0,646.0,5769.0,,,
,1.0,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620428,,9606.0,,,N,Intermediate,14255.0,1.0,646.0,5770.0,,,
,1.0,F,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620429,,9606.0,,,N,Intermediate,1590.0,1.0,646.0,5771.0,,,
,1.0,F,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620430,,9606.0,,,N,Expert,6146.0,1.0,646.0,5772.0,,,
,1.0,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL839887,,9606.0,,,N,Expert,17427.0,1.0,646.0,5773.0,,,
,1.0,F,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620431,,9606.0,,,N,Intermediate,5280.0,1.0,646.0,5774.0,,,
,1.0,F,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884010,,9606.0,,,N,Intermediate,16786.0,1.0,646.0,5775.0,,,
,1.0,F,In vitro cytotoxicity against A549 (human lung cancer),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620538,,9606.0,,,N,Intermediate,5895.0,1.0,646.0,5776.0,,,
,1.0,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620539,,9606.0,,,N,Expert,14297.0,1.0,646.0,5777.0,,,
,1.0,F,In vivo antiproliferative activity against A549 cell line,,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL623373,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5778.0,,,
,1.0,F,Inhibition of non-small-cell lung adenocarcinoma (A549),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623374,,9606.0,,,N,Intermediate,14368.0,1.0,646.0,5779.0,,,
,1.0,F,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623375,,9606.0,,,N,Intermediate,14368.0,1.0,646.0,5780.0,,,
,1.0,F,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623376,,9606.0,,,N,Intermediate,14254.0,1.0,646.0,5781.0,,,
,1.0,F,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623377,,9606.0,,,N,Intermediate,15897.0,1.0,646.0,5782.0,,,
,1.0,F,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623378,,9606.0,,,N,Intermediate,13866.0,1.0,646.0,5783.0,,,
,1.0,F,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623379,,9606.0,,,N,Intermediate,13370.0,1.0,646.0,5784.0,,,
,1.0,F,Inhibitory activity against A549 lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623380,,9606.0,,,N,Intermediate,4862.0,1.0,646.0,5785.0,,,
,1.0,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623381,,9606.0,,,N,Intermediate,4862.0,1.0,646.0,5786.0,,,
,1.0,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623382,,9606.0,,,N,Intermediate,4862.0,1.0,646.0,5787.0,,,
,1.0,F,Inhibitory concentration against A549 (lung cancer) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623383,,9606.0,,,N,Intermediate,15970.0,1.0,646.0,5788.0,,,
,1.0,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623384,,9606.0,,,N,Expert,17713.0,1.0,646.0,5789.0,,,
,1.0,F,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623385,,9606.0,,,N,Intermediate,4833.0,1.0,646.0,5790.0,,,
,1.0,F,Activity against A549 cancer cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623386,,9606.0,,,N,Expert,13736.0,1.0,646.0,5791.0,,,
,1.0,F,The compound was evaluated for cytotoxicity against A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884105,,9606.0,,,N,Intermediate,4312.0,1.0,646.0,5792.0,,,
,1.0,F,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623387,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5793.0,,,
,1.0,F,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621568,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5794.0,,,
,1.0,F,Growth inhibitory activity was measured for human A549 tumor cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621569,,9606.0,,,N,Intermediate,14717.0,1.0,646.0,5795.0,,,
,1.0,F,Inhibitory activity against A549 lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621570,,9606.0,,,N,Intermediate,4634.0,1.0,646.0,5796.0,,,
,1.0,F,Inhibitory activity against A549 cell line; inactive,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621571,,9606.0,,,N,Intermediate,1149.0,1.0,646.0,5797.0,,,
,1.0,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621572,,9606.0,,,N,Expert,5421.0,1.0,646.0,5798.0,,,
,1.0,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621573,,9606.0,,,N,Expert,5421.0,1.0,646.0,5799.0,,,
,1.0,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621574,,9606.0,,,N,Intermediate,5421.0,1.0,646.0,5800.0,,,
,1.0,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621575,,9606.0,,,N,Intermediate,3320.0,1.0,646.0,5801.0,,,
,1.0,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621576,,9606.0,,,N,Intermediate,3320.0,1.0,646.0,5802.0,,,
,1.0,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621577,,9606.0,,,N,Intermediate,3320.0,1.0,646.0,5803.0,,,
,1.0,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621578,,9606.0,,,N,Intermediate,3320.0,1.0,646.0,5804.0,,,
,1.0,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621579,,9606.0,,,N,Intermediate,3320.0,1.0,646.0,5805.0,,,
,1.0,F,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621580,,9606.0,,,N,Intermediate,5726.0,1.0,646.0,5806.0,,,
,1.0,A,Plasma clearance (in vivo) in mongrel dogs was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621581,In vivo,9615.0,,,N,Intermediate,17800.0,1.0,,5807.0,,,
,1.0,A,Plasma clearance was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621582,In vivo,9615.0,,,N,Intermediate,5985.0,1.0,,5808.0,,,
,1.0,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621583,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,5809.0,,,
,1.0,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621584,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,5810.0,,,
Plasma,1.0,A,Tested for plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621585,In vivo,9615.0,1969.0,,N,Intermediate,4839.0,1.0,,5811.0,,,
,1.0,A,The compound was tested for clearance in dog plasma.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621586,In vivo,9615.0,,,N,Intermediate,3639.0,1.0,,5812.0,,,
,1.0,A,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875835,In vivo,9615.0,,,N,Intermediate,4838.0,1.0,,5813.0,,,
,1.0,A,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621587,In vivo,9615.0,,,N,Intermediate,4137.0,1.0,,5814.0,,,
Plasma,1.0,A,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621588,In vivo,9615.0,1969.0,,N,Intermediate,5017.0,1.0,,5815.0,,,
Liver,1.0,A,In vitro clearance in dog liver microsomes,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621589,In vitro,9615.0,2107.0,,N,Intermediate,17538.0,1.0,,5816.0,Microsomes,,
,1.0,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621590,In vivo,9615.0,,,N,Intermediate,6161.0,1.0,,5817.0,,,
,1.0,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621591,In vivo,9615.0,,,N,Intermediate,6161.0,1.0,,5818.0,,,
,1.0,A,Plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621592,In vivo,9615.0,,,N,Intermediate,1696.0,1.0,,5819.0,,,
,1.0,A,Clearance rate in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621593,In vivo,9615.0,,,N,Intermediate,6762.0,1.0,,5820.0,,,
Plasma,1.0,A,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621594,In vivo,9615.0,1969.0,,N,Intermediate,5932.0,1.0,,5821.0,,,
,1.0,A,Clearance in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621595,In vivo,9615.0,,,N,Intermediate,6305.0,1.0,,5822.0,,,
,1.0,A,Plasma clearance in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621596,In vivo,9615.0,,,N,Intermediate,4942.0,1.0,,5823.0,,,
,1.0,A,Plasma clearance was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621597,In vivo,9615.0,,,N,Intermediate,4219.0,1.0,,5824.0,,,
,1.0,A,Lower clearance in dog (i.v.) at 0.5 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621598,In vivo,9615.0,,,N,Intermediate,17853.0,1.0,,5825.0,,,
,1.0,A,Plasma clearance in Beagle dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621599,In vivo,9615.0,,,N,Intermediate,4514.0,1.0,,5826.0,,,
,1.0,A,Plasma clearance (Clp) in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875836,In vivo,9615.0,,,N,Intermediate,6448.0,1.0,,5827.0,,,
,1.0,A,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621600,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,5828.0,,,
,1.0,A,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621601,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,5829.0,,,
,1.0,A,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618474,In vivo,9615.0,,,N,Intermediate,6062.0,1.0,,5830.0,,,
,1.0,A,Plasma clearance of compound was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618475,In vivo,9615.0,,,N,Intermediate,6821.0,1.0,,5831.0,,,
,1.0,A,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624524,In vivo,9615.0,,,N,Intermediate,4709.0,1.0,,5832.0,,,
,1.0,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624525,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,5833.0,,,
,1.0,A,Plasma clearance in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624526,In vivo,9615.0,,,N,Intermediate,5374.0,1.0,,5834.0,,,
,1.0,A,Plasma clearance was calculated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624527,In vivo,9615.0,,,N,Intermediate,6057.0,1.0,,5835.0,,,
,1.0,A,Plasma clearance at the dose of 2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624528,In vivo,9615.0,,,N,Intermediate,4727.0,1.0,,5836.0,,,
,1.0,A,Plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624529,In vivo,9615.0,,,N,Intermediate,5145.0,1.0,,5837.0,,,
,1.0,A,Plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624530,In vivo,9615.0,,,N,Intermediate,17657.0,1.0,,5838.0,,,
,1.0,A,Plasma clearance in dog; Unable to calculate,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624531,In vivo,9615.0,,,N,Intermediate,17657.0,1.0,,5839.0,,,
,1.0,A,Plasma clearance in rhesus monkey,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624532,In vivo,9615.0,,,N,Intermediate,5145.0,1.0,,5840.0,,,
,1.0,A,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624533,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,5841.0,,,
,1.0,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624534,In vivo,9615.0,,,N,Intermediate,6641.0,1.0,,5842.0,,,
,1.0,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624535,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,5843.0,,,
,1.0,A,Plasma clearance was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624536,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,5844.0,,,
,1.0,A,Plasma clearance was evaluated in dog; Not tested,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624537,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,5845.0,,,
,1.0,A,Plasma clearance was evaluated in rhesus,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624538,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,5846.0,,,
,1.0,A,Plasma clearance was evaluated in rhesus; Not tested,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624539,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,5847.0,,,
,1.0,A,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624540,In vivo,9615.0,,,N,Intermediate,4257.0,1.0,,5848.0,,,
,1.0,A,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624541,In vivo,9615.0,,,N,Intermediate,6679.0,1.0,,5849.0,,,
,1.0,A,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624542,In vivo,9615.0,,,N,Intermediate,5546.0,1.0,,5850.0,,,
,1.0,A,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624543,In vivo,9615.0,,,N,Intermediate,6348.0,1.0,,5851.0,,,
,1.0,A,Clearance value at a dose of 0.2 mg/kg i.v.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624544,In vivo,9615.0,,,N,Intermediate,5474.0,1.0,,5852.0,,,
Plasma,1.0,A,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624545,In vivo,9615.0,1969.0,,N,Intermediate,6316.0,1.0,,5853.0,,,
,1.0,A,Cmax after oral dose of compound at 3 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624546,In vivo,9615.0,,,N,Intermediate,17594.0,1.0,,5854.0,,,
,1.0,A,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875957,In vivo,9615.0,,,N,Intermediate,17594.0,1.0,,5855.0,,,
,1.0,A,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624547,In vivo,9615.0,,,N,Intermediate,5802.0,1.0,,5856.0,,,
,1.0,A,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624548,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,5857.0,,,
,1.0,A,Cmax in dog after administration of 1 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624549,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,5858.0,,,
Plasma,1.0,A,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624550,In vivo,9615.0,1969.0,,N,Intermediate,1466.0,1.0,,5859.0,,,
,1.0,A,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621613,In vivo,9615.0,,,N,Intermediate,6505.0,1.0,,5860.0,,,
,1.0,A,Cmax was determine after peroral administration at 10 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621614,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5861.0,,,
,1.0,A,Cmax was determine after peroral administration at 5 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623431,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5862.0,,,
,1.0,A,Cmax was determine after peroral administration at 5 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623432,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,5863.0,,,
,1.0,A,Cmax after 0.3 mg/kg po administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623433,In vivo,9615.0,,,N,Intermediate,5600.0,1.0,,5864.0,,,
,1.0,A,Cmax after peroral administration in dogs at 2.4 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623434,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,5865.0,,,
,1.0,A,Cmax in dog after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623435,In vivo,9615.0,,,N,Intermediate,6123.0,1.0,,5866.0,,,
,1.0,A,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623436,In vivo,9615.0,,,N,Intermediate,6123.0,1.0,,5867.0,,,
,1.0,A,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875958,In vivo,9615.0,,,N,Intermediate,6757.0,1.0,,5868.0,,,
,1.0,A,Cmax value after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623437,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,5869.0,,,
Blood,1.0,A,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623438,In vivo,10090.0,178.0,,N,Intermediate,7767.0,1.0,,5870.0,,,
Blood,1.0,A,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623439,In vivo,10090.0,178.0,,N,Intermediate,7767.0,1.0,,5871.0,,,
Bone,1.0,A,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623440,In vivo,10090.0,10000001.0,,N,Intermediate,7767.0,1.0,,5872.0,,,
Bone,1.0,A,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623441,In vivo,10090.0,10000001.0,,N,Intermediate,7767.0,1.0,,5873.0,,,
Bone,1.0,A,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623442,In vivo,10090.0,10000001.0,,N,Intermediate,7767.0,1.0,,5874.0,,,
,1.0,A,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623469,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5875.0,,,
,1.0,A,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623470,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5876.0,,,
,1.0,A,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623471,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5877.0,,,
Heart,1.0,A,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623472,In vivo,10090.0,948.0,,N,Intermediate,7767.0,1.0,,5878.0,,,
Heart,1.0,A,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623473,In vivo,10090.0,948.0,,N,Intermediate,7767.0,1.0,,5879.0,,,
Heart,1.0,A,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623474,In vivo,10090.0,948.0,,N,Intermediate,7767.0,1.0,,5880.0,,,
Kidney,1.0,A,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623475,In vivo,10090.0,2113.0,,N,Intermediate,7767.0,1.0,,5881.0,,,
Kidney,1.0,A,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623476,In vivo,10090.0,2113.0,,N,Intermediate,7767.0,1.0,,5882.0,,,
Kidney,1.0,A,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623477,In vivo,10090.0,2113.0,,N,Intermediate,7767.0,1.0,,5883.0,,,
Intestine,1.0,A,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621896,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5884.0,,,
Intestine,1.0,A,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621897,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5885.0,,,
Intestine,1.0,A,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621898,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5886.0,,,
Liver,1.0,A,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621899,In vivo,10090.0,2107.0,,N,Intermediate,7767.0,1.0,,5887.0,,,
Liver,1.0,A,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621900,In vivo,10090.0,2107.0,,N,Intermediate,7767.0,1.0,,5888.0,,,
Liver,1.0,A,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621901,In vivo,10090.0,2107.0,,N,Intermediate,7767.0,1.0,,5889.0,,,
Lung,1.0,A,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621902,In vivo,10090.0,2048.0,,N,Intermediate,7767.0,1.0,,5890.0,,,
Lung,1.0,A,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621903,In vivo,10090.0,2048.0,,N,Intermediate,7767.0,1.0,,5891.0,,,
Lung,1.0,A,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622587,In vivo,10090.0,2048.0,,N,Intermediate,7767.0,1.0,,5892.0,,,
Muscle tissue,1.0,A,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620285,In vivo,10090.0,2385.0,,N,Intermediate,7767.0,1.0,,5893.0,,,
Muscle tissue,1.0,A,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875285,In vivo,10090.0,2385.0,,N,Intermediate,7767.0,1.0,,5894.0,,,
Muscle tissue,1.0,A,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620286,In vivo,10090.0,2385.0,,N,Intermediate,7767.0,1.0,,5895.0,,,
,1.0,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620287,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5896.0,,,
,1.0,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620288,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5897.0,,,
,1.0,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620289,In vivo,10090.0,,,N,Intermediate,7767.0,1.0,,5898.0,,,
Intestine,1.0,A,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620290,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5899.0,,,
Intestine,1.0,A,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620291,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5900.0,,,
Intestine,1.0,A,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620292,In vivo,10090.0,160.0,,N,Intermediate,7767.0,1.0,,5901.0,,,
Spleen,1.0,A,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620293,In vivo,10090.0,2106.0,,N,Intermediate,7767.0,1.0,,5902.0,,,
Spleen,1.0,A,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL620294,In vivo,10090.0,2106.0,,N,Intermediate,7767.0,1.0,,5903.0,,,
Spleen,1.0,A,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618614,In vivo,10090.0,2106.0,,N,Intermediate,7767.0,1.0,,5904.0,,,
Stomach,1.0,A,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618615,In vivo,10090.0,945.0,,N,Intermediate,7767.0,1.0,,5905.0,,,
Stomach,1.0,A,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618616,In vivo,10090.0,945.0,,N,Intermediate,7767.0,1.0,,5906.0,,,
,1.0,F,Cytotoxicity against A-172 human tumor cell lines,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL618617,,9606.0,,,N,Expert,2036.0,1.0,622.0,5907.0,,,
,1.0,F,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL618618,,9606.0,,,N,Intermediate,2357.0,1.0,622.0,5908.0,,,
,1.0,F,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,A204,80014.0,BAO_0000219,Homo sapiens,CHEMBL618619,,9606.0,,,N,Intermediate,1457.0,1.0,623.0,5909.0,,,
,1.0,F,Tested for antiproliferative activity against A-2780 tumoral cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618620,,9606.0,,,N,Intermediate,4379.0,1.0,478.0,5910.0,,,
,1.0,F,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL618621,,9606.0,,,N,Intermediate,1093.0,1.0,455.0,5911.0,,,
,1.0,F,Tested in vitro against A-375 cell line human melanoma,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL618622,,9606.0,,,N,Intermediate,12152.0,1.0,455.0,5912.0,,,
,1.0,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618623,,9606.0,,,N,Expert,16464.0,1.0,797.0,5913.0,,,
,1.0,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618624,,9606.0,,,N,Intermediate,16464.0,1.0,797.0,5914.0,,,
,1.0,F,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618625,,9606.0,,,N,Expert,16582.0,1.0,797.0,5915.0,,,
,1.0,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618626,,9606.0,,,N,Intermediate,16464.0,1.0,797.0,5916.0,,,
,1.0,F,Antitumor activity on A-427 lung carcinoma cell lines,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618627,,9606.0,,,N,Intermediate,10413.0,1.0,797.0,5917.0,,,
,1.0,F,Cytotoxic activity against human A-427 lung tumor cell line,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618628,,9606.0,,,N,Intermediate,6418.0,1.0,797.0,5918.0,,,
,1.0,F,In vitro antitumor effects against human A-427 cell lines.,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618629,,9606.0,,,N,Expert,17134.0,1.0,797.0,5919.0,,,
,1.0,F,In vitro inhibition of A-427 (human lung cancer) cell growth.,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618630,,9606.0,,,N,Expert,16132.0,1.0,797.0,5920.0,,,
,1.0,F,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618631,,9606.0,,,N,Intermediate,16132.0,1.0,797.0,5921.0,,,
,1.0,F,Cytotoxic activity of compound against A-427 lung human tumor cell line,,A-427,80019.0,BAO_0000219,Homo sapiens,CHEMBL618632,,9606.0,,,N,Intermediate,16780.0,1.0,797.0,5922.0,,,
,1.0,F,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,A-431,80852.0,BAO_0000219,Homo sapiens,CHEMBL618633,,9606.0,,,N,Expert,4085.0,1.0,500.0,5923.0,,,
,1.0,F,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619315,,9606.0,,,N,Intermediate,1276.0,1.0,624.0,5924.0,,,
,1.0,F,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619316,,9606.0,,,N,Expert,3498.0,1.0,624.0,5925.0,,,
,1.0,F,Cytotoxicity against human kidney carcinoma A-498cell lines,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619317,,9606.0,,,N,Intermediate,1169.0,1.0,624.0,5926.0,,,
,1.0,F,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619318,,9606.0,,,N,Intermediate,4450.0,1.0,624.0,5927.0,,,
,1.0,F,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619319,,9606.0,,,N,Intermediate,3311.0,1.0,624.0,5928.0,,,
,1.0,F,Antitumor cytotoxic activity against A-498 cell line was determined,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619739,,9606.0,,,N,Intermediate,4461.0,1.0,624.0,5929.0,,,
,1.0,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619740,,9606.0,,,N,Intermediate,3311.0,1.0,624.0,5930.0,,,
,1.0,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL883158,,9606.0,,,N,Intermediate,3311.0,1.0,624.0,5931.0,,,
,1.0,F,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL884012,,9606.0,,,N,Intermediate,1457.0,1.0,624.0,5932.0,,,
,1.0,F,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619741,,9606.0,,,N,Intermediate,3664.0,1.0,624.0,5933.0,,,
,1.0,F,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,A498,80021.0,BAO_0000219,Homo sapiens,CHEMBL619742,,9606.0,,,N,Intermediate,15895.0,1.0,624.0,5934.0,,,
,1.0,F,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876610,,9606.0,,,N,Intermediate,11843.0,1.0,646.0,5935.0,,,
,1.0,F,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619743,,9606.0,,,N,Intermediate,11843.0,1.0,646.0,5936.0,,,
,1.0,F,In vitro antiproliferative activity against human A-549 NSCL cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619744,,9606.0,,,N,Intermediate,17705.0,1.0,646.0,5937.0,,,
,1.0,F,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619745,,9606.0,,,N,Intermediate,17705.0,1.0,646.0,5938.0,,,
,1.0,F,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619746,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5939.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619747,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5940.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619748,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5941.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619749,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5942.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619750,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5943.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624014,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5944.0,,,
,1.0,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624015,,9606.0,,,N,Intermediate,4369.0,1.0,646.0,5945.0,,,
,1.0,F,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL885344,,9606.0,,,N,Expert,4787.0,1.0,646.0,5946.0,,,
,1.0,F,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623224,,9606.0,,,N,Intermediate,4787.0,1.0,646.0,5947.0,,,
,1.0,F,Cytotoxic activity against A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL623225,,9606.0,,,N,Intermediate,6513.0,1.0,646.0,5948.0,,,
,1.0,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622698,,9606.0,,,N,Intermediate,6690.0,1.0,646.0,5949.0,,,
,1.0,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622699,,9606.0,,,N,Intermediate,6690.0,1.0,646.0,5950.0,,,
,1.0,F,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622700,,9606.0,,,N,Expert,12263.0,1.0,646.0,5951.0,,,
,1.0,F,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622701,,9606.0,,,N,Intermediate,1054.0,1.0,646.0,5952.0,,,
,1.0,F,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622702,,9606.0,,,N,Intermediate,1359.0,1.0,646.0,5953.0,,,
,1.0,F,Cytotoxic activity against human lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622703,,9606.0,,,N,Intermediate,3547.0,1.0,646.0,5954.0,,,
,1.0,F,Cytotoxic activity towards A-549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622704,,9606.0,,,N,Expert,5771.0,1.0,646.0,5955.0,,,
,1.0,F,"In vitro percent inhibition of A549, lung carcinoma.",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622705,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5956.0,,,
,1.0,F,"In vitro percent inhibition of A549, lung carcinoma",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622706,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5957.0,,,
,1.0,F,"In vitro percent inhibition of A549, lung carcinoma.",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622707,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5958.0,,,
,1.0,F,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622708,,9606.0,,,N,Intermediate,14425.0,1.0,646.0,5959.0,,,
,1.0,F,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622709,,9606.0,,,N,Intermediate,5280.0,1.0,646.0,5960.0,,,
,1.0,F,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622710,,9606.0,,,N,Intermediate,15176.0,1.0,646.0,5961.0,,,
,1.0,F,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622711,,9606.0,,,N,Intermediate,15300.0,1.0,646.0,5962.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622712,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5963.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622713,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5964.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622714,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5965.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622715,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5966.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622716,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5967.0,,,
,1.0,F,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622717,,9606.0,,,N,Intermediate,17824.0,1.0,646.0,5968.0,,,
,1.0,F,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL622718,,9606.0,,,N,Intermediate,17528.0,1.0,646.0,5969.0,,,
,1.0,F,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622719,,9606.0,,,N,Expert,6870.0,1.0,646.0,5970.0,,,
,1.0,F,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622720,,9606.0,,,N,Intermediate,6870.0,1.0,646.0,5971.0,,,
,1.0,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622721,,9606.0,,,N,Intermediate,6870.0,1.0,646.0,5972.0,,,
,1.0,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622722,,9606.0,,,N,Intermediate,6870.0,1.0,646.0,5973.0,,,
,1.0,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876030,,9606.0,,,N,Intermediate,16726.0,1.0,646.0,5974.0,,,
,1.0,F,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620206,,9606.0,,,N,Intermediate,6170.0,1.0,646.0,5975.0,,,
,1.0,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620207,,9606.0,,,N,Expert,6583.0,1.0,646.0,5976.0,,,
,1.0,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620208,,9606.0,,,N,Expert,6583.0,1.0,646.0,5977.0,,,
,1.0,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620209,,9606.0,,,N,Expert,6583.0,1.0,646.0,5978.0,,,
,1.0,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620210,,9606.0,,,N,Expert,6583.0,1.0,646.0,5979.0,,,
,1.0,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621639,,9606.0,,,N,Expert,6583.0,1.0,646.0,5980.0,,,
,1.0,F,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621640,,9606.0,,,N,Intermediate,17321.0,1.0,646.0,5981.0,,,
,1.0,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621641,,9606.0,,,N,Expert,17528.0,1.0,646.0,5982.0,,,
,1.0,F,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621642,,9606.0,,,N,Expert,12888.0,1.0,646.0,5983.0,,,
,1.0,F,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621643,,9606.0,,,N,Intermediate,4312.0,1.0,646.0,5984.0,,,
,1.0,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621644,,9606.0,,,N,Intermediate,4312.0,1.0,646.0,5985.0,,,
,1.0,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL621645,,9606.0,,,N,Intermediate,4312.0,1.0,646.0,5986.0,,,
,1.0,F,In vitro antiproliferative activity against A549 cell line,,A549,80682.0,BAO_0000219,Mus musculus,CHEMBL621646,,10090.0,,,N,Intermediate,17737.0,1.0,646.0,5987.0,,,
,1.0,F,Synergism with indomethacin in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621647,,,,,N,Intermediate,6630.0,1.0,646.0,5988.0,,,
,1.0,F,Synergism with tolmetin in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621648,,,,,N,Intermediate,6630.0,1.0,646.0,5989.0,,,
,1.0,F,Synergism with sulindac in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621649,,,,,N,Intermediate,6630.0,1.0,646.0,5990.0,,,
,1.0,F,Antagonism of indomethacin in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621650,,,,,N,Intermediate,6630.0,1.0,646.0,5991.0,,,
,1.0,F,Antagonism of sulindac in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621651,,,,,N,Intermediate,6630.0,1.0,646.0,5992.0,,,
,1.0,F,Antagonism of tolmetin in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621652,,,,,N,Intermediate,6630.0,1.0,646.0,5993.0,,,
,1.0,F,Synergism with indomethacin in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621653,,,,,N,Intermediate,6630.0,1.0,646.0,5994.0,,,
,1.0,F,Synergism with sulindac in A549 cells,,A549,80682.0,BAO_0000219,,CHEMBL621654,,,,,N,Intermediate,6630.0,1.0,646.0,5995.0,,,
,1.0,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,A549,80682.0,BAO_0000219,,CHEMBL621655,,,,,N,Intermediate,6630.0,1.0,646.0,5996.0,,,
,1.0,A,Cmax value after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621656,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,5997.0,,,
,1.0,A,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621657,In vivo,9615.0,,,N,Intermediate,5944.0,1.0,,5998.0,,,
,1.0,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621658,In vivo,9615.0,,,N,Intermediate,5944.0,1.0,,5999.0,,,
,1.0,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621659,In vivo,9615.0,,,N,Intermediate,5944.0,1.0,,6000.0,,,
,1.0,A,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621660,In vivo,9615.0,,,N,Intermediate,5944.0,1.0,,6001.0,,,
,1.0,A,Cmax value after administration of 4 mg/Kg oral dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621661,In vivo,9615.0,,,N,Intermediate,2959.0,1.0,,6002.0,,,
,1.0,A,Cmax value in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621662,In vivo,9615.0,,,N,Intermediate,6241.0,1.0,,6003.0,,,
,1.0,A,Cmax value in dogs after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621663,In vivo,9615.0,,,N,Intermediate,6241.0,1.0,,6004.0,,,
,1.0,A,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621664,In vivo,9615.0,,,N,Intermediate,2652.0,1.0,,6005.0,,,
Plasma,1.0,A,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621665,In vivo,9615.0,1969.0,,N,Intermediate,1806.0,1.0,,6006.0,,,
Plasma,1.0,A,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621666,In vivo,9615.0,1969.0,,N,Intermediate,1806.0,1.0,,6007.0,,,
,1.0,A,Concentration maxima after oral dosing in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621667,In vivo,9615.0,,,N,Intermediate,1021.0,1.0,,6008.0,,,
,1.0,A,Concentration maxima after oral dosing in dogs; not available,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876738,In vivo,9615.0,,,N,Intermediate,1021.0,1.0,,6009.0,,,
,1.0,A,Concentration maxima after oral dosing in dogs; not available,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621668,In vivo,9615.0,,,N,Intermediate,1021.0,1.0,,6010.0,,,
,1.0,A,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621669,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,6011.0,,,
,1.0,A,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621670,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,6012.0,,,
,1.0,A,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621671,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,6013.0,,,
,1.0,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622360,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,6014.0,,,
,1.0,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622361,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,6015.0,,,
Plasma,1.0,A,Cmax in dog plasma after oral dose (1 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622362,In vivo,9615.0,1969.0,,N,Intermediate,5130.0,1.0,,6016.0,,,
Plasma,1.0,A,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622363,In vivo,9615.0,1969.0,,N,Intermediate,3249.0,1.0,,6017.0,,,
Plasma,1.0,A,Maximal plasma concentration at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622364,In vivo,9615.0,1969.0,,N,Intermediate,5473.0,1.0,,6018.0,,,
Plasma,1.0,A,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622365,In vivo,9615.0,1969.0,,N,Intermediate,5474.0,1.0,,6019.0,,,
Plasma,1.0,A,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622533,In vivo,9615.0,1969.0,,N,Intermediate,4657.0,1.0,,6020.0,,,
,1.0,A,Maximum concentration of compound in dog was evaluated.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622534,In vivo,9615.0,,,N,Intermediate,3031.0,1.0,,6021.0,,,
,1.0,A,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622535,In vivo,9615.0,,,N,Intermediate,4527.0,1.0,,6022.0,,,
,1.0,A,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876739,In vivo,9615.0,,,N,Intermediate,4186.0,1.0,,6023.0,,,
,1.0,A,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622536,In vivo,9615.0,,,N,Intermediate,5007.0,1.0,,6024.0,,,
Plasma,1.0,A,Maximum concentration obtained in dog plasma was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622537,In vivo,9615.0,1969.0,,N,Intermediate,3132.0,1.0,,6025.0,,,
,1.0,A,Maximum concentration was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622538,In vivo,9615.0,,,N,Intermediate,5006.0,1.0,,6026.0,,,
,1.0,A,Maximum concentration at the dose of 2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627867,In vivo,9615.0,,,N,Intermediate,4727.0,1.0,,6027.0,,,
,1.0,A,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627868,In vivo,9615.0,,,N,Intermediate,1916.0,1.0,,6028.0,,,
Plasma,1.0,A,Maximum concentration was evaluated in dog plasma,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627869,In vivo,9615.0,1969.0,,N,Intermediate,1918.0,1.0,,6029.0,,,
,1.0,A,Maximum concentration was evaluated after 75 min after administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627870,In vivo,9615.0,,,N,Intermediate,3045.0,1.0,,6030.0,,,
Plasma,1.0,A,Maximum plasma concentration determined in dog after oral administration of 17b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627871,In vivo,9615.0,1969.0,,N,Intermediate,9579.0,1.0,,6031.0,,,
Plasma,1.0,A,Maximum plasma concentration determined in dog after oral administration of 2b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627872,In vivo,9615.0,1969.0,,N,Intermediate,9579.0,1.0,,6032.0,,,
Plasma,1.0,A,Maximum plasma concentration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627873,In vivo,9615.0,1969.0,,N,Intermediate,933.0,1.0,,6033.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627874,In vivo,9615.0,1969.0,,N,Intermediate,17839.0,1.0,,6034.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627875,In vivo,9615.0,1969.0,,N,Intermediate,17839.0,1.0,,6035.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627876,In vivo,9615.0,1969.0,,N,Intermediate,17839.0,1.0,,6036.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627877,In vivo,9615.0,1969.0,,N,Intermediate,17839.0,1.0,,6037.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627878,In vivo,9615.0,1969.0,,N,Intermediate,6348.0,1.0,,6038.0,,,
Plasma,1.0,A,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627879,In vivo,9615.0,1969.0,,N,Intermediate,16367.0,1.0,,6039.0,,,
Plasma,1.0,A,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875355,In vivo,9615.0,1969.0,,N,Intermediate,1337.0,1.0,,6040.0,,,
Plasma,1.0,A,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627880,In vivo,9615.0,1969.0,,N,Intermediate,1337.0,1.0,,6041.0,,,
Plasma,1.0,A,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627881,In vivo,9615.0,1969.0,,N,Intermediate,5199.0,1.0,,6042.0,,,
Plasma,1.0,A,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627882,In vivo,9615.0,1969.0,,N,Intermediate,17650.0,1.0,,6043.0,,,
Plasma,1.0,A,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL627883,In vivo,9615.0,1969.0,,N,Intermediate,6679.0,1.0,,6044.0,,,
Plasma,1.0,A,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL628526,In vivo,9615.0,1969.0,,N,Intermediate,5356.0,1.0,,6045.0,,,
Plasma,1.0,A,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL628527,In vivo,9615.0,1969.0,,N,Intermediate,5356.0,1.0,,6046.0,,,
Plasma,1.0,A,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL628528,In vivo,9615.0,1969.0,,N,Intermediate,6227.0,1.0,,6047.0,,,
Plasma,1.0,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL628529,In vivo,9615.0,1969.0,,N,Intermediate,6227.0,1.0,,6048.0,,,
Plasma,1.0,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL628530,In vivo,9615.0,1969.0,,N,Intermediate,6227.0,1.0,,6049.0,,,
Plasma,1.0,A,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625243,In vivo,9615.0,1969.0,,N,Intermediate,6227.0,1.0,,6050.0,,,
Plasma,1.0,A,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625244,In vivo,9615.0,1969.0,,N,Expert,3598.0,1.0,,6051.0,,,
,1.0,A,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625245,In vivo,9615.0,,,N,Intermediate,4368.0,1.0,,6052.0,,,
,1.0,A,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625246,In vivo,9615.0,,,N,Intermediate,6265.0,1.0,,6053.0,,,
Stomach,1.0,A,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625247,In vivo,10090.0,945.0,,N,Intermediate,7767.0,1.0,,6054.0,,,
Urine,1.0,A,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625248,In vivo,10090.0,1088.0,,N,Intermediate,7767.0,1.0,,6055.0,,,
Urine,1.0,A,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625249,In vivo,10090.0,1088.0,,N,Intermediate,7767.0,1.0,,6056.0,,,
Urine,1.0,A,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625250,In vivo,10090.0,1088.0,,N,Intermediate,7767.0,1.0,,6057.0,,,
,1.0,A,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625251,,10090.0,,,N,Intermediate,17811.0,1.0,,6058.0,,,
,1.0,A,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875356,,10090.0,,,N,Intermediate,17811.0,1.0,,6059.0,,,
,1.0,A,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625252,,10090.0,,,N,Intermediate,17827.0,1.0,,6060.0,,,
Blood,1.0,A,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625253,,10090.0,178.0,,N,Intermediate,17827.0,1.0,,6061.0,,,
,1.0,A,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625254,,10090.0,,,N,Intermediate,17827.0,1.0,,6062.0,,,
,1.0,A,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625255,,10090.0,,,N,Intermediate,17827.0,1.0,,6063.0,,,
,1.0,A,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625256,,10090.0,,,N,Intermediate,17827.0,1.0,,6064.0,,,
Blood,1.0,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625257,,10090.0,178.0,,N,Intermediate,17827.0,1.0,,6065.0,,,
Blood,1.0,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625258,,10090.0,178.0,,N,Intermediate,17827.0,1.0,,6066.0,,,
,1.0,A,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL625259,,10090.0,,,N,Intermediate,17827.0,1.0,,6067.0,,,
,1.0,A,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625260,,10090.0,,,N,Intermediate,17827.0,1.0,,6068.0,,,
,1.0,A,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594.0,BAO_0000218,Mus musculus,CHEMBL625261,,10090.0,,,N,Intermediate,17827.0,1.0,,6069.0,,,
,1.0,A,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594.0,BAO_0000218,Mus musculus,CHEMBL625262,,10090.0,,,N,Intermediate,17827.0,1.0,,6070.0,,,
,1.0,A,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,50594.0,BAO_0000218,Mus musculus,CHEMBL622639,,10090.0,,,N,Intermediate,17827.0,1.0,,6071.0,,,
,1.0,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622640,,10090.0,,,N,Intermediate,17257.0,1.0,,6072.0,,,
,1.0,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622812,,10090.0,,,N,Intermediate,17257.0,1.0,,6073.0,,,
,1.0,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622813,,10090.0,,,N,Intermediate,17257.0,1.0,,6074.0,,,
,1.0,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622814,,10090.0,,,N,Intermediate,17257.0,1.0,,6075.0,,,
,1.0,A,Time at maximum activity in mice (Radiolabeled compound),,,50594.0,BAO_0000218,Mus musculus,CHEMBL622815,,10090.0,,,N,Intermediate,17827.0,1.0,,6076.0,,,
,1.0,A,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625342,,10090.0,,,N,Intermediate,3760.0,1.0,,6077.0,,,
,1.0,A,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625343,,10090.0,,,N,Intermediate,3760.0,1.0,,6078.0,,,
,1.0,A,Binding towards mouse plasma protein at 10 uM,,,50594.0,BAO_0000218,Mus musculus,CHEMBL877591,,10090.0,,,N,Intermediate,17409.0,1.0,,6079.0,,,
,1.0,A,Binding towards mouse plasma protein at 100 uM,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625344,,10090.0,,,N,Intermediate,17409.0,1.0,,6080.0,,,
,1.0,A,Bioavailability was evaluated in mice after intravenous administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625345,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,6081.0,,,
,1.0,A,Bioavailability was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625346,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,6082.0,,,
,1.0,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625347,In vivo,10090.0,,,N,Intermediate,3132.0,1.0,,6083.0,,,
,1.0,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625348,In vivo,10090.0,,,N,Intermediate,3132.0,1.0,,6084.0,,,
,1.0,A,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625349,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,6085.0,,,
,1.0,A,Oral bioavailability in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625350,In vivo,10090.0,,,N,Intermediate,2862.0,1.0,,6086.0,,,
,1.0,A,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL882952,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6087.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625351,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6088.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625352,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6089.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL877592,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6090.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625353,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6091.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL625354,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6092.0,,,
Brain,1.0,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL626019,In vivo,10090.0,955.0,,N,Intermediate,846.0,1.0,,6093.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL626020,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6094.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL626021,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6095.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL626022,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6096.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL626192,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6097.0,,,
,1.0,F,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626193,,9606.0,,,N,Intermediate,1276.0,1.0,646.0,6098.0,,,
,1.0,F,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626194,,9606.0,,,N,Expert,3498.0,1.0,646.0,6099.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma A-549 cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626195,,9606.0,,,N,Intermediate,1169.0,1.0,646.0,6100.0,,,
,1.0,F,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626196,,9606.0,,,N,Intermediate,4450.0,1.0,646.0,6101.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626197,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6102.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626198,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6103.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626199,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6104.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626200,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6105.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626201,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6106.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626202,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6107.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626203,,9606.0,,,N,Intermediate,358.0,1.0,646.0,6108.0,,,
,1.0,F,In vitro cytotoxicity against A-549 human lung cancer cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL626204,,9606.0,,,N,Intermediate,15167.0,1.0,646.0,6109.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624701,,9606.0,,,N,Intermediate,4139.0,1.0,646.0,6110.0,,,
,1.0,F,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624702,,9606.0,,,N,Intermediate,833.0,1.0,646.0,6111.0,,,
,1.0,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624703,,9606.0,,,N,Expert,15718.0,1.0,646.0,6112.0,,,
,1.0,F,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624704,,9606.0,,,N,Intermediate,12373.0,1.0,646.0,6113.0,,,
,1.0,F,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624705,,9606.0,,,N,Intermediate,637.0,1.0,646.0,6114.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624706,,9606.0,,,N,Expert,14867.0,1.0,646.0,6115.0,,,
,1.0,F,Antitumor cytotoxic activity against A-549 cell line was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624707,,9606.0,,,N,Intermediate,4461.0,1.0,646.0,6116.0,,,
,1.0,F,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624708,,9606.0,,,N,Intermediate,5406.0,1.0,646.0,6117.0,,,
,1.0,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624709,,9606.0,,,N,Intermediate,4457.0,1.0,646.0,6118.0,,,
,1.0,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884107,,9606.0,,,N,Expert,1386.0,1.0,646.0,6119.0,,,
,1.0,F,Antitumoral activity was assayed against A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624710,,9606.0,,,N,Intermediate,3265.0,1.0,646.0,6120.0,,,
,1.0,F,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624711,,9606.0,,,N,Intermediate,2359.0,1.0,646.0,6121.0,,,
,1.0,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624712,,9606.0,,,N,Intermediate,4457.0,1.0,646.0,6122.0,,,
,1.0,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624713,,9606.0,,,N,Expert,12454.0,1.0,646.0,6123.0,,,
,1.0,F,Compound was tested for inhibition of cell growth of A-549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624714,,9606.0,,,N,Intermediate,1481.0,1.0,646.0,6124.0,,,
,1.0,F,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624715,,9606.0,,,N,Intermediate,1750.0,1.0,646.0,6125.0,,,
,1.0,F,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624716,,9606.0,,,N,Intermediate,5065.0,1.0,646.0,6126.0,,,
,1.0,F,In vitro cytotoxicity against A549-human lung carcinoma cells.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619505,,9606.0,,,N,Expert,808.0,1.0,646.0,6127.0,,,
,1.0,F,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619506,,9606.0,,,N,Expert,16364.0,1.0,646.0,6128.0,,,
,1.0,F,Cytotoxic activity against A-549 cell lines.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619507,,9606.0,,,N,Intermediate,1847.0,1.0,646.0,6129.0,,,
,1.0,F,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619508,,9606.0,,,N,Expert,1747.0,1.0,646.0,6130.0,,,
,1.0,F,Cytotoxicity against human A549 non small cell lung cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619509,,9606.0,,,N,Intermediate,1003.0,1.0,646.0,6131.0,,,
,1.0,F,Inhibition of cell growth in (A-549) lung cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619510,,9606.0,,,N,Expert,15313.0,1.0,646.0,6132.0,,,
,1.0,F,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619511,,9606.0,,,N,Intermediate,3122.0,1.0,646.0,6133.0,,,
,1.0,F,In vitro antitumor activity against A-549 tumor cells.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619512,,9606.0,,,N,Intermediate,16049.0,1.0,646.0,6134.0,,,
,1.0,F,In vitro antitumor effects against human A-549 cell lines.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619513,,9606.0,,,N,Expert,17134.0,1.0,646.0,6135.0,,,
,1.0,F,In vitro cytotoxic activity of compound against A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619514,,9606.0,,,N,Intermediate,6406.0,1.0,646.0,6136.0,,,
,1.0,F,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619515,,9606.0,,,N,Intermediate,627.0,1.0,646.0,6137.0,,,
,1.0,F,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619516,,9606.0,,,N,Intermediate,12307.0,1.0,646.0,6138.0,,,
,1.0,F,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884005,,9606.0,,,N,Intermediate,17861.0,1.0,646.0,6139.0,,,
,1.0,F,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619517,,9606.0,,,N,Expert,6682.0,1.0,646.0,6140.0,,,
,1.0,F,Inhibitory concentration of compound against A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619518,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6141.0,,,
,1.0,F,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619519,,9606.0,,,N,Intermediate,2454.0,1.0,646.0,6142.0,,,
,1.0,F,cytotoxic activity against leukemia (A-549) cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876489,,9606.0,,,N,Intermediate,14709.0,1.0,646.0,6143.0,,,
,1.0,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619520,,9606.0,,,N,Expert,15718.0,1.0,646.0,6144.0,,,
,1.0,F,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619521,,9606.0,,,N,Intermediate,15718.0,1.0,646.0,6145.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619522,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6146.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619523,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6147.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619524,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6148.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619525,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6149.0,,,
,1.0,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,A549,80682.0,BAO_0000219,,CHEMBL619526,,,,,N,Intermediate,6630.0,1.0,646.0,6150.0,,,
,1.0,F,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619527,,9606.0,,,N,Intermediate,16726.0,1.0,646.0,6151.0,,,
,1.0,F,Cytotoxicity against A549 cells; No cytotoxicity,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619528,,9606.0,,,N,Intermediate,17846.0,1.0,646.0,6152.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma (A549) cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619529,,9606.0,,,N,Expert,3415.0,1.0,646.0,6153.0,,,
,1.0,F,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619530,,9606.0,,,N,Expert,3415.0,1.0,646.0,6154.0,,,
,1.0,F,In vitro anticancer activity against human lung (A549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876490,,9606.0,,,N,Intermediate,5609.0,1.0,646.0,6155.0,,,
,1.0,F,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619531,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6156.0,,,
,1.0,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619532,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6157.0,,,
,1.0,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619533,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6158.0,,,
,1.0,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619534,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6159.0,,,
,1.0,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620164,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6160.0,,,
,1.0,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620165,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6161.0,,,
,1.0,F,Inhibition of A549 human lung tumor cell proliferation,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620166,,9606.0,,,N,Expert,16295.0,1.0,646.0,6162.0,,,
,1.0,F,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620167,,9606.0,,,N,Intermediate,16825.0,1.0,646.0,6163.0,,,
,1.0,F,In vitro cytotoxicity against human tumor cell line A549,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620168,,9606.0,,,N,Expert,3439.0,1.0,646.0,6164.0,,,
,1.0,F,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620338,,9606.0,,,N,Intermediate,10870.0,1.0,646.0,6165.0,,,
,1.0,F,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620339,,9606.0,,,N,Intermediate,4845.0,1.0,646.0,6166.0,,,
,1.0,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620340,,9606.0,,,N,Intermediate,5822.0,1.0,646.0,6167.0,,,
,1.0,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620341,,9606.0,,,N,Intermediate,5822.0,1.0,646.0,6168.0,,,
,1.0,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876491,,9606.0,,,N,Intermediate,5822.0,1.0,646.0,6169.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620342,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6170.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620343,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6171.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620344,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6172.0,,,
,1.0,F,In vitro anticancer activity against human lung (A549) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620345,,9606.0,,,N,Intermediate,5609.0,1.0,646.0,6173.0,,,
,1.0,F,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620346,,9606.0,,,N,Intermediate,4644.0,1.0,646.0,6174.0,,,
,1.0,F,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620347,,9606.0,,,N,Intermediate,4644.0,1.0,646.0,6175.0,,,
,1.0,F,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620348,,9606.0,,,N,Intermediate,4644.0,1.0,646.0,6176.0,,,
,1.0,F,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620349,,9606.0,,,N,Intermediate,4644.0,1.0,646.0,6177.0,,,
,1.0,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL618667,,9606.0,,,N,Intermediate,5822.0,1.0,646.0,6178.0,,,
,1.0,F,Percentage inhibition of human lung carcinoma (A549) cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL618668,,9606.0,,,N,Expert,3415.0,1.0,646.0,6179.0,,,
,1.0,F,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876031,,9606.0,,,N,Intermediate,16726.0,1.0,646.0,6180.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL618759,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6181.0,,,
,1.0,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL618760,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6182.0,,,
,1.0,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619000,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6183.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619001,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6184.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619002,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6185.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619003,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6186.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619597,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6187.0,,,
,1.0,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619598,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6188.0,,,
,1.0,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619599,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6189.0,,,
,1.0,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619600,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6190.0,,,
,1.0,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619601,,9606.0,,,N,Intermediate,16726.0,1.0,646.0,6191.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619602,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6192.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619603,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6193.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619604,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6194.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619605,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6195.0,,,
,1.0,A,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619606,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6196.0,,,
,1.0,A,Pharmacokinetic activity (Cmax) in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876032,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6197.0,,,
,1.0,A,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619607,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,6198.0,,,
,1.0,A,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619608,In vivo,9615.0,,,N,Intermediate,5983.0,1.0,,6199.0,,,
,1.0,A,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619609,In vivo,9615.0,,,N,Intermediate,6251.0,1.0,,6200.0,,,
Plasma,1.0,A,Cmax in dog plasma after 30mg/kg oral dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619610,In vivo,9615.0,1969.0,,N,Intermediate,5932.0,1.0,,6201.0,,,
Blood,1.0,A,Tested for the peak blood level in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619611,In vivo,9615.0,178.0,,N,Intermediate,4273.0,1.0,,6202.0,,,
,1.0,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619612,In vivo,9615.0,,,N,Intermediate,5313.0,1.0,,6203.0,,,
,1.0,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619613,In vivo,9615.0,,,N,Intermediate,5313.0,1.0,,6204.0,,,
Blood,1.0,A,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619614,In vivo,9615.0,178.0,,N,Intermediate,6221.0,1.0,,6205.0,,,
,1.0,A,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619615,,9615.0,,,N,Intermediate,4709.0,1.0,,6206.0,,,
,1.0,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619616,,9615.0,,,N,Intermediate,167.0,1.0,,6207.0,,,
Plasma,1.0,A,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619617,,9615.0,1969.0,,N,Intermediate,6241.0,1.0,,6208.0,,,
,1.0,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619618,,9615.0,,,N,Intermediate,344.0,1.0,,6209.0,,,
,1.0,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876033,,9615.0,,,N,Intermediate,344.0,1.0,,6210.0,,,
,1.0,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619619,,9615.0,,,N,Intermediate,344.0,1.0,,6211.0,,,
,1.0,A,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619620,,9615.0,,,N,Intermediate,2189.0,1.0,,6212.0,,,
Urine,1.0,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619621,,9615.0,1088.0,,N,Intermediate,2189.0,1.0,,6213.0,,,
Urine,1.0,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619622,,9615.0,1088.0,,N,Intermediate,2189.0,1.0,,6214.0,,,
Urine,1.0,A,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618874,,9615.0,1088.0,,N,Intermediate,2189.0,1.0,,6215.0,,,
,1.0,A,Absolute bioavailability was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618875,In vivo,9615.0,,,N,Intermediate,4257.0,1.0,,6216.0,,,
,1.0,A,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618876,In vivo,9615.0,,,N,Intermediate,6221.0,1.0,,6217.0,,,
,1.0,A,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618877,In vivo,9615.0,,,N,Intermediate,6215.0,1.0,,6218.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618878,In vivo,9615.0,,,N,Intermediate,17267.0,1.0,,6219.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618879,In vivo,9615.0,,,N,Intermediate,6621.0,1.0,,6220.0,,,
,1.0,A,Bioavailability after intravenous administration in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618880,In vivo,9615.0,,,N,Intermediate,3854.0,1.0,,6221.0,,,
,1.0,A,Bioavailability after peroral administration in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618881,In vivo,9615.0,,,N,Intermediate,3854.0,1.0,,6222.0,,,
,1.0,A,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618882,In vivo,9615.0,,,N,Intermediate,5007.0,1.0,,6223.0,,,
,1.0,A,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624226,In vivo,9615.0,,,N,Intermediate,4333.0,1.0,,6224.0,,,
Plasma,1.0,A,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624227,In vivo,9615.0,1969.0,,N,Intermediate,4333.0,1.0,,6225.0,,,
,1.0,A,Bioavailability,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624228,In vivo,9615.0,,,N,Intermediate,5006.0,1.0,,6226.0,,,
,1.0,A,Bioavailability,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624229,In vivo,9615.0,,,N,Intermediate,5199.0,1.0,,6227.0,,,
,1.0,A,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624230,In vivo,9615.0,,,N,Intermediate,4368.0,1.0,,6228.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624231,In vivo,9615.0,,,N,Intermediate,3771.0,1.0,,6229.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624232,In vivo,9615.0,,,N,Intermediate,4953.0,1.0,,6230.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625127,In vivo,9615.0,,,N,Intermediate,5064.0,1.0,,6231.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625128,In vivo,9615.0,,,N,Intermediate,17657.0,1.0,,6232.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621675,In vivo,9615.0,,,N,Intermediate,17796.0,1.0,,6233.0,,,
,1.0,A,Bioavailability in dog (p.o.) at 2.0 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621676,In vivo,9615.0,,,N,Intermediate,17853.0,1.0,,6234.0,,,
,1.0,A,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621677,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,6235.0,,,
,1.0,A,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621678,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,6236.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621679,In vivo,9615.0,,,N,Intermediate,5006.0,1.0,,6237.0,,,
,1.0,A,Bioavailability was evaluated after oral administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621680,In vivo,9615.0,,,N,Intermediate,16365.0,1.0,,6238.0,,,
,1.0,A,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621681,In vivo,9615.0,,,N,Intermediate,1916.0,1.0,,6239.0,,,
,1.0,A,Bioavailability was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876740,In vivo,9615.0,,,N,Intermediate,1918.0,1.0,,6240.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621682,In vivo,9615.0,,,N,Intermediate,4239.0,1.0,,6241.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621683,In vivo,9615.0,,,N,Intermediate,6505.0,1.0,,6242.0,,,
,1.0,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621684,In vivo,9615.0,,,N,Intermediate,5334.0,1.0,,6243.0,,,
,1.0,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621685,In vivo,9615.0,,,N,Intermediate,5334.0,1.0,,6244.0,,,
,1.0,A,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621686,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,6245.0,,,
,1.0,A,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621687,In vivo,9615.0,,,N,Intermediate,6348.0,1.0,,6246.0,,,
,1.0,A,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621688,In vivo,9615.0,,,N,Intermediate,6005.0,1.0,,6247.0,,,
,1.0,A,Bioavailability of compound in dog was determined after peroral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621689,In vivo,9615.0,,,N,Intermediate,17804.0,1.0,,6248.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621690,In vivo,9615.0,,,N,Intermediate,3184.0,1.0,,6249.0,,,
,1.0,A,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621691,In vivo,9615.0,,,N,Intermediate,1806.0,1.0,,6250.0,,,
,1.0,A,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875941,In vivo,9615.0,,,N,Intermediate,1806.0,1.0,,6251.0,,,
,1.0,A,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621692,In vivo,9615.0,,,N,Intermediate,1806.0,1.0,,6252.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621693,In vivo,9615.0,,,N,Intermediate,4839.0,1.0,,6253.0,,,
,1.0,A,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621694,In vivo,9615.0,,,N,Intermediate,5017.0,1.0,,6254.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621695,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6255.0,,,
Heart,1.0,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621696,In vivo,10090.0,948.0,,N,Intermediate,846.0,1.0,,6256.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621697,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6257.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621698,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6258.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623420,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6259.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623421,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6260.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623422,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6261.0,,,
Kidney,1.0,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623423,In vivo,10090.0,2113.0,,N,Intermediate,846.0,1.0,,6262.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623424,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6263.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623425,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6264.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623426,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6265.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623427,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6266.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623428,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6267.0,,,
Liver,1.0,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875947,In vivo,10090.0,2107.0,,N,Intermediate,846.0,1.0,,6268.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623429,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6269.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623430,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6270.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622588,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6271.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622589,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6272.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622751,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6273.0,,,
Lung,1.0,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622752,In vivo,10090.0,2048.0,,N,Intermediate,846.0,1.0,,6274.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622753,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6275.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622647,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6276.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL875163,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6277.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622648,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6278.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622649,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6279.0,,,
Brain,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622650,,10090.0,955.0,,N,Intermediate,6599.0,1.0,42.0,6280.0,,,
Brain,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622651,,10090.0,955.0,,N,Intermediate,6599.0,1.0,42.0,6281.0,,,
Brain,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622652,,10090.0,955.0,,N,Intermediate,6599.0,1.0,42.0,6282.0,,,
Brain,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622653,,10090.0,955.0,,N,Intermediate,6599.0,1.0,42.0,6283.0,,,
Brain,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622654,,10090.0,955.0,,N,Intermediate,6599.0,1.0,42.0,6284.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622655,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6285.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622656,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6286.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622657,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6287.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622658,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6288.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL622659,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6289.0,,,
Kidney,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624630,,10090.0,2113.0,,N,Intermediate,6599.0,1.0,42.0,6290.0,,,
Kidney,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624631,,10090.0,2113.0,,N,Intermediate,6599.0,1.0,42.0,6291.0,,,
Kidney,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624632,,10090.0,2113.0,,N,Intermediate,6599.0,1.0,42.0,6292.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624633,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6293.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624634,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6294.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624635,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6295.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624636,,9606.0,,,N,Intermediate,17130.0,1.0,646.0,6296.0,,,
,1.0,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL857055,,9606.0,,,N,Expert,3263.0,1.0,646.0,6297.0,,,
,1.0,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624637,,9606.0,,,N,Expert,6663.0,1.0,646.0,6298.0,,,
,1.0,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624638,,9606.0,,,N,Expert,6663.0,1.0,646.0,6299.0,,,
,1.0,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL874366,,9606.0,,,N,Expert,6663.0,1.0,646.0,6300.0,,,
,1.0,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624639,,9606.0,,,N,Expert,6663.0,1.0,646.0,6301.0,,,
,1.0,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624640,,9606.0,,,N,Expert,6663.0,1.0,646.0,6302.0,,,
,1.0,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624641,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6303.0,,,
,1.0,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624642,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6304.0,,,
,1.0,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624643,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6305.0,,,
,1.0,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624644,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6306.0,,,
,1.0,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL624645,,9606.0,,,N,Intermediate,6663.0,1.0,646.0,6307.0,,,
,1.0,F,The compound was evaluated for its cytotoxic potency against A-549 cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619445,,9606.0,,,N,Intermediate,3983.0,1.0,646.0,6308.0,,,
,1.0,F,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL839886,,9606.0,,,N,Expert,11141.0,1.0,646.0,6309.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 tumor cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619446,,9606.0,,,N,Intermediate,5076.0,1.0,646.0,6310.0,,,
,1.0,F,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619447,,9606.0,,,N,Intermediate,3311.0,1.0,646.0,6311.0,,,
,1.0,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619448,,9606.0,,,N,Intermediate,3311.0,1.0,646.0,6312.0,,,
,1.0,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619449,,9606.0,,,N,Intermediate,3311.0,1.0,646.0,6313.0,,,
,1.0,F,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619450,,9606.0,,,N,Intermediate,5076.0,1.0,646.0,6314.0,,,
,1.0,F,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619451,,9606.0,,,N,Intermediate,4150.0,1.0,646.0,6315.0,,,
,1.0,F,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619452,,9606.0,,,N,Expert,2150.0,1.0,646.0,6316.0,,,
,1.0,F,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619453,,9606.0,,,N,Intermediate,4644.0,1.0,646.0,6317.0,,,
,1.0,F,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL874367,,9606.0,,,N,Intermediate,263.0,1.0,646.0,6318.0,,,
,1.0,F,Cytotoxic concentration against A-549 tumor cells.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619454,,9606.0,,,N,Intermediate,11333.0,1.0,646.0,6319.0,,,
,1.0,F,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619455,,9606.0,,,N,Intermediate,11333.0,1.0,646.0,6320.0,,,
,1.0,F,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619456,,9606.0,,,N,Intermediate,15895.0,1.0,646.0,6321.0,,,
,1.0,F,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,50191.0,BAO_0000218,Acinetobacter baumannii,CHEMBL619457,,470.0,,,N,Expert,16677.0,1.0,,6322.0,,,
,1.0,F,Activity against Acinetobacter calcoaceticus (AC54),,,50192.0,BAO_0000218,Acinetobacter calcoaceticus,CHEMBL619458,,471.0,,,N,Intermediate,10624.0,1.0,,6323.0,,,
,1.0,F,In vitro antifungal activity against Aspergillus flavus CM74,,,50274.0,BAO_0000218,Aspergillus flavus,CHEMBL619459,,5059.0,,,N,Expert,16717.0,1.0,,6324.0,,,
,1.0,F,In vitro antifungal activity against Aspergillus flavus CM74,,,50274.0,BAO_0000218,Aspergillus flavus,CHEMBL619460,,5059.0,,,N,Expert,16717.0,1.0,,6325.0,,,
,1.0,F,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL619461,,746128.0,,,N,Intermediate,5513.0,1.0,,6326.0,,,
,1.0,F,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL619462,,746128.0,,,N,Intermediate,15962.0,1.0,,6327.0,,,
,1.0,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL620388,,746128.0,,,N,Intermediate,15962.0,1.0,,6328.0,,,
,1.0,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL620389,,746128.0,,,N,Intermediate,15962.0,1.0,,6329.0,,,
,1.0,F,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL620390,,746128.0,,,N,Intermediate,15962.0,1.0,,6330.0,,,
,1.0,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL620391,,746128.0,,,N,Expert,16717.0,1.0,,6331.0,,,
,1.0,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,50416.0,BAO_0000218,Aspergillus fumigatus,CHEMBL621073,,746128.0,,,N,Expert,16717.0,1.0,,6332.0,,,
,1.0,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL621074,,1655.0,,,N,Intermediate,8117.0,1.0,,6333.0,,,
,1.0,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL621075,,1656.0,,,N,Intermediate,8117.0,1.0,,6334.0,,,
,1.0,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL619554,,6277.0,,,N,Intermediate,15472.0,1.0,,6335.0,,,
,1.0,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL619555,,6277.0,,,N,Intermediate,15472.0,1.0,,6336.0,,,
,1.0,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,50169.0,BAO_0000218,Aggregatibacter actinomycetemcomitans,CHEMBL619556,,714.0,,,N,Intermediate,16443.0,1.0,,6337.0,,,
,1.0,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,50169.0,BAO_0000218,Aggregatibacter actinomycetemcomitans,CHEMBL619557,,714.0,,,N,Intermediate,16443.0,1.0,,6338.0,,,
,1.0,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,50169.0,BAO_0000218,Aggregatibacter actinomycetemcomitans,CHEMBL619558,,714.0,,,N,Intermediate,16443.0,1.0,,6339.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619559,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6340.0,,,
,1.0,F,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619560,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6341.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619561,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6342.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619562,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6343.0,,,
,1.0,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619563,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6344.0,,,
,1.0,F,GI values against A549 cells (lung cancer),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL857457,,9606.0,,,N,Intermediate,16381.0,1.0,646.0,6345.0,,,
,1.0,F,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619564,,9606.0,,,N,Intermediate,17206.0,1.0,646.0,6346.0,,,
,1.0,F,Inhibitory activity against A549 human adenocarcinoma,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619565,,9606.0,,,N,Intermediate,16325.0,1.0,646.0,6347.0,,,
,1.0,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL619566,,9606.0,,,N,Intermediate,10708.0,1.0,646.0,6348.0,,,
,1.0,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL619567,,9606.0,,,N,Intermediate,10708.0,1.0,646.0,6349.0,,,
,1.0,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619568,,9606.0,,,N,Intermediate,17376.0,1.0,646.0,6350.0,,,
,1.0,F,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619569,,9606.0,,,N,Intermediate,17376.0,1.0,646.0,6351.0,,,
,1.0,F,Cytotoxicity against human A549 lung cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619570,,9606.0,,,N,Intermediate,17488.0,1.0,646.0,6352.0,,,
,1.0,F,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,A549,80682.0,BAO_0000218,Homo sapiens,CHEMBL619571,,9606.0,,,N,Intermediate,17404.0,1.0,646.0,6353.0,,,
,1.0,F,Growth inhibition of A549 (human lung carcinoma) cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619572,,9606.0,,,N,Expert,10958.0,1.0,646.0,6354.0,,,
,1.0,F,Effective dose required for inhibitory activity against A549 human tumor cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619573,,9606.0,,,N,Expert,17099.0,1.0,646.0,6355.0,,,
,1.0,F,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619574,,9606.0,,,N,Intermediate,17099.0,1.0,646.0,6356.0,,,
,1.0,F,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619575,,9606.0,,,N,Intermediate,4096.0,1.0,646.0,6357.0,,,
,1.0,F,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619576,,9606.0,,,N,Expert,4096.0,1.0,646.0,6358.0,,,
,1.0,F,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619577,,9606.0,,,N,Intermediate,4096.0,1.0,646.0,6359.0,,,
,1.0,F,In vitro inhibitory activity against A549 tumor cell culture,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619578,,9606.0,,,N,Intermediate,2525.0,1.0,646.0,6360.0,,,
,1.0,F,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884009,,9606.0,,,N,Intermediate,2525.0,1.0,646.0,6361.0,,,
,1.0,F,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619579,,9606.0,,,N,Intermediate,5302.0,1.0,646.0,6362.0,,,
,1.0,F,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619580,,9606.0,,,N,Intermediate,16325.0,1.0,646.0,6363.0,,,
,1.0,F,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619581,,9606.0,,,N,Intermediate,16939.0,1.0,646.0,6364.0,,,
,1.0,F,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619582,,9606.0,,,N,Intermediate,17229.0,1.0,646.0,6365.0,,,
,1.0,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619583,,9606.0,,,N,Intermediate,17380.0,1.0,646.0,6366.0,,,
,1.0,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL876502,,9606.0,,,N,Intermediate,17380.0,1.0,646.0,6367.0,,,
,1.0,F,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619584,,9606.0,,,N,Intermediate,1903.0,1.0,646.0,6368.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619585,,9606.0,,,N,Intermediate,3838.0,1.0,646.0,6369.0,,,
,1.0,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619586,,9606.0,,,N,Intermediate,14696.0,1.0,646.0,6370.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619587,,9606.0,,,N,Intermediate,3838.0,1.0,646.0,6371.0,,,
,1.0,F,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619588,,9606.0,,,N,Intermediate,1522.0,1.0,646.0,6372.0,,,
,1.0,F,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619589,,9606.0,,,N,Intermediate,12400.0,1.0,646.0,6373.0,,,
,1.0,F,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619590,,9606.0,,,N,Intermediate,14696.0,1.0,646.0,6374.0,,,
,1.0,F,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619591,,9606.0,,,N,Intermediate,14769.0,1.0,646.0,6375.0,,,
,1.0,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619592,,9606.0,,,N,Intermediate,14696.0,1.0,646.0,6376.0,,,
,1.0,F,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL619593,,9606.0,,,N,Intermediate,1888.0,1.0,646.0,6377.0,,,
,1.0,F,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620217,,9606.0,,,N,Intermediate,12016.0,1.0,646.0,6378.0,,,
,1.0,F,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620218,,9606.0,,,N,Intermediate,6058.0,1.0,646.0,6379.0,,,
,1.0,F,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620219,,9606.0,,,N,Intermediate,17708.0,1.0,646.0,6380.0,,,
,1.0,F,Antitumor activity against A549/ATCC cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL620220,,9606.0,,,N,Intermediate,12301.0,1.0,646.0,6381.0,,,
,1.0,F,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL625141,,9606.0,,,N,Intermediate,11970.0,1.0,646.0,6382.0,,,
,1.0,F,In vitro cytotoxicity against A549/ATCC cell line.,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL625142,,9606.0,,,N,Expert,11818.0,1.0,646.0,6383.0,,,
,1.0,F,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL625143,,9606.0,,,N,Intermediate,12400.0,1.0,646.0,6384.0,,,
,1.0,F,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL625144,,9606.0,,,N,Intermediate,3381.0,1.0,646.0,6385.0,,,
,1.0,F,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL622474,,9606.0,,,N,Intermediate,17376.0,1.0,646.0,6386.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,A549,80682.0,BAO_0000219,Homo sapiens,CHEMBL884104,,9606.0,,,N,Intermediate,10708.0,1.0,646.0,6387.0,,,
,1.0,F,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,22226.0,BAO_0000219,Homo sapiens,CHEMBL622475,,9606.0,,,U,Autocuration,2964.0,0.0,,6388.0,,,
,1.0,A,Compound was tested for oral bioavailability in dogs,,,22224.0,BAO_0000218,Canis lupus familiaris,CHEMBL622476,In vivo,9615.0,,,U,Intermediate,5005.0,0.0,,6389.0,,,
,1.0,A,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875831,In vivo,9615.0,,,N,Intermediate,6229.0,1.0,,6390.0,,,
,1.0,A,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622477,In vivo,9615.0,,,N,Intermediate,6229.0,1.0,,6391.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622478,In vivo,9615.0,,,N,Intermediate,5374.0,1.0,,6392.0,,,
,1.0,A,Compound was tested for the oral bioavailability in dog; No availability,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623172,In vivo,9615.0,,,N,Intermediate,5374.0,1.0,,6393.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623173,In vivo,9615.0,,,N,Intermediate,6265.0,1.0,,6394.0,,,
,1.0,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623174,In vivo,9615.0,,,N,Intermediate,5654.0,1.0,,6395.0,,,
,1.0,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623175,In vivo,9615.0,,,N,Intermediate,5654.0,1.0,,6396.0,,,
,1.0,A,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623340,In vivo,9615.0,,,N,Intermediate,16456.0,1.0,,6397.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623341,In vivo,9615.0,,,N,Intermediate,5302.0,1.0,,6398.0,,,
,1.0,A,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623342,In vivo,9615.0,,,N,Intermediate,3624.0,1.0,,6399.0,,,
,1.0,A,Oral bioavailability of active FTIs in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623343,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,6400.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623344,In vivo,9615.0,,,N,Intermediate,5802.0,1.0,,6401.0,,,
,1.0,A,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623345,In vivo,9615.0,,,N,Expert,3598.0,1.0,,6402.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875832,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,6403.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623346,In vivo,9615.0,,,N,Intermediate,6762.0,1.0,,6404.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623347,In vivo,9615.0,,,N,Intermediate,6821.0,1.0,,6405.0,,,
,1.0,A,Oral bioavailability of compound was determined in dog; Not tested,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623348,In vivo,9615.0,,,N,Intermediate,6821.0,1.0,,6406.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623349,In vivo,9615.0,,,N,Intermediate,5210.0,1.0,,6407.0,,,
,1.0,A,Oral bioavailability (10 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623350,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,6408.0,,,
,1.0,A,Oral bioavailability,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623351,In vivo,9615.0,,,N,Intermediate,761.0,1.0,,6409.0,,,
,1.0,A,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623352,In vivo,9615.0,,,N,Intermediate,761.0,1.0,,6410.0,,,
,1.0,A,Oral bioavailability administered in solution in rats,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623353,In vivo,9615.0,,,N,Intermediate,761.0,1.0,,6411.0,,,
,1.0,A,Oral bioavailability after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875833,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6412.0,,,
,1.0,A,Oral bioavailability at a dose of 1 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623354,In vivo,9615.0,,,N,Intermediate,5474.0,1.0,,6413.0,,,
,1.0,A,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623355,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,6414.0,,,
,1.0,A,Oral bioavailability in Dog; ND = not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623356,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,6415.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623357,In vivo,9615.0,,,N,Intermediate,3352.0,1.0,,6416.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623358,In vivo,9615.0,,,N,Intermediate,6168.0,1.0,,6417.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623359,In vivo,9615.0,,,N,Intermediate,5988.0,1.0,,6418.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623360,In vivo,9615.0,,,N,Intermediate,4942.0,1.0,,6419.0,,,
,1.0,A,Oral bioavailability in dogs; No data,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623361,In vivo,9615.0,,,N,Intermediate,4942.0,1.0,,6420.0,,,
,1.0,A,Oral bioavailability measured in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623362,In vivo,9615.0,,,N,Intermediate,14541.0,1.0,,6421.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623363,In vivo,9615.0,,,N,Intermediate,4449.0,1.0,,6422.0,,,
,1.0,A,Oral bioavailability was calculated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623364,In vivo,9615.0,,,N,Intermediate,6057.0,1.0,,6423.0,,,
,1.0,A,Oral bioavailability after 0.3 mg/kg po administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875834,In vivo,9615.0,,,N,Intermediate,5600.0,1.0,,6424.0,,,
,1.0,A,Oral bioavailability in dog (i.v. dosing),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623365,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,6425.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623366,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,6426.0,,,
,1.0,A,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623367,In vivo,9615.0,,,N,Intermediate,5546.0,1.0,,6427.0,,,
,1.0,A,Oral bioavailability in Beagle dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623368,In vivo,9615.0,,,N,Intermediate,4514.0,1.0,,6428.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623369,In vivo,9615.0,,,N,Intermediate,3624.0,1.0,,6429.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623370,In vivo,9615.0,,,N,Intermediate,3854.0,1.0,,6430.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623371,In vivo,9615.0,,,N,Intermediate,5836.0,1.0,,6431.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623372,In vivo,9615.0,,,N,Intermediate,5940.0,1.0,,6432.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621351,In vivo,9615.0,,,N,Intermediate,6168.0,1.0,,6433.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621352,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,6434.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621353,In vivo,9615.0,,,N,Intermediate,6251.0,1.0,,6435.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621354,In vivo,9615.0,,,N,Intermediate,6448.0,1.0,,6436.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621355,In vivo,9615.0,,,N,Intermediate,6647.0,1.0,,6437.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621356,In vivo,9615.0,,,N,Intermediate,5940.0,1.0,,6438.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621357,In vivo,9615.0,,,N,Intermediate,933.0,1.0,,6439.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621358,In vivo,9615.0,,,N,Intermediate,5210.0,1.0,,6440.0,,,
,1.0,A,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621359,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,6441.0,,,
,1.0,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621360,In vivo,9615.0,,,N,Intermediate,6641.0,1.0,,6442.0,,,
,1.0,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621361,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,6443.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621362,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,6444.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621363,In vivo,9615.0,,,N,Intermediate,5985.0,1.0,,6445.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621364,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,6446.0,,,
,1.0,A,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621166,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,6447.0,,,
,1.0,A,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621167,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,6448.0,,,
,1.0,A,Oral bioavailability (F) in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621168,In vivo,9615.0,,,N,Intermediate,6305.0,1.0,,6449.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621169,In vivo,9615.0,,,N,Intermediate,5210.0,1.0,,6450.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875950,In vivo,9615.0,,,N,Intermediate,5238.0,1.0,,6451.0,,,
,1.0,A,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621170,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,6452.0,,,
,1.0,A,Oral bioavailability after peroral administration at 5 mpk in Dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621171,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,6453.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621172,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,6454.0,,,
,1.0,A,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621173,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6455.0,,,
Kidney,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621174,,10090.0,2113.0,,N,Intermediate,6599.0,1.0,42.0,6456.0,,,
Kidney,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621175,,10090.0,2113.0,,N,Intermediate,6599.0,1.0,42.0,6457.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621176,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6458.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621177,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6459.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621178,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6460.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621179,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6461.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621180,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6462.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL875951,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6463.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621181,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6464.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621182,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6465.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621183,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6466.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621184,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6467.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621185,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6468.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621186,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6469.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621187,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6470.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621188,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6471.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621189,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6472.0,,,
Spleen,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621190,,10090.0,2106.0,,N,Intermediate,6599.0,1.0,42.0,6473.0,,,
Spleen,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL618520,,10090.0,2106.0,,N,Intermediate,6599.0,1.0,42.0,6474.0,,,
Spleen,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621739,,10090.0,2106.0,,N,Intermediate,6599.0,1.0,42.0,6475.0,,,
Spleen,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621740,,10090.0,2106.0,,N,Intermediate,6599.0,1.0,42.0,6476.0,,,
Spleen,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621741,,10090.0,2106.0,,N,Intermediate,6599.0,1.0,42.0,6477.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621742,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6478.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621743,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6479.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621744,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6480.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621745,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6481.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621746,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6482.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621747,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6483.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621748,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6484.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621749,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6485.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621750,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6486.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621751,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6487.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621752,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6488.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621753,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6489.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL875955,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6490.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621754,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6491.0,,,
Heart,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621755,,10090.0,948.0,,N,Intermediate,6599.0,1.0,42.0,6492.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL621756,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6493.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624199,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6494.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624200,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6495.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624375,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6496.0,,,
Liver,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624376,,10090.0,2107.0,,N,Intermediate,6599.0,1.0,42.0,6497.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624377,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6498.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624378,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6499.0,,,
,1.0,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067.0,BAO_0000218,aeinetobacter anitrotap,CHEMBL857901,,107673.0,,,N,Intermediate,12269.0,1.0,,6500.0,,,
,1.0,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067.0,BAO_0000218,Acinetobacter calcoaceticus subsp. anitratus,CHEMBL875274,,107673.0,,,N,Intermediate,12269.0,1.0,,6501.0,,,
,1.0,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067.0,BAO_0000218,Acinetobacter calcoaceticus subsp. anitratus,CHEMBL624379,,107673.0,,,N,Intermediate,12269.0,1.0,,6502.0,,,
,1.0,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,50067.0,BAO_0000218,aeinetobacter anitrotap,CHEMBL624380,,107673.0,,,N,Intermediate,12269.0,1.0,,6503.0,,,
,1.0,F,Activity against Acinetobacter calcoaceticus (AC54),,,50192.0,BAO_0000218,Acinetobacter calcoaceticus,CHEMBL624381,,471.0,,,N,Intermediate,10624.0,1.0,,6504.0,,,
,1.0,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,50714.0,BAO_0000218,Anolis carolinensis,CHEMBL624382,,28377.0,,,N,Intermediate,17216.0,1.0,,6505.0,,,
,1.0,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,50714.0,BAO_0000218,Anolis carolinensis,CHEMBL624383,,28377.0,,,N,Intermediate,17216.0,1.0,,6506.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624384,,1655.0,,,N,Intermediate,9560.0,1.0,,6507.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624385,,1655.0,,,N,Intermediate,9560.0,1.0,,6508.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624386,,1655.0,,,N,Intermediate,9560.0,1.0,,6509.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624387,,1655.0,,,N,Intermediate,9560.0,1.0,,6510.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces naeslundii 631,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624388,,1655.0,,,N,Intermediate,9560.0,1.0,,6511.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces naeslundii N/9,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624389,,1655.0,,,N,Intermediate,9560.0,1.0,,6512.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces naeslundii B74,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL624390,,1655.0,,,N,Intermediate,9560.0,1.0,,6513.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces naeslundii N/3,,,50296.0,BAO_0000218,Actinomyces naeslundii,CHEMBL875275,,1655.0,,,N,Intermediate,9560.0,1.0,,6514.0,,,
,1.0,F,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,50056.0,BAO_0000218,Artemia salina,CHEMBL624391,,85549.0,,,N,Intermediate,114.0,1.0,,6515.0,,,
,1.0,F,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,50056.0,BAO_0000218,Artemia salina,CHEMBL623636,,85549.0,,,N,Intermediate,114.0,1.0,,6516.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623637,,6253.0,,,N,Intermediate,10841.0,1.0,,6517.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623638,,6253.0,,,N,Intermediate,10841.0,1.0,,6518.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623639,,6253.0,,,N,Intermediate,10841.0,1.0,,6519.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623640,,6253.0,,,N,Intermediate,10841.0,1.0,,6520.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623641,,6253.0,,,N,Intermediate,10841.0,1.0,,6521.0,,,
,1.0,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623642,,6253.0,,,N,Intermediate,10841.0,1.0,,6522.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623643,,6253.0,,,N,Intermediate,10841.0,1.0,,6523.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623644,,6253.0,,,N,Intermediate,10841.0,1.0,,6524.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623645,,6253.0,,,N,Intermediate,10841.0,1.0,,6525.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623646,,6253.0,,,N,Intermediate,10841.0,1.0,,6526.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623647,,6253.0,,,N,Intermediate,10841.0,1.0,,6527.0,,,
,1.0,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,50532.0,BAO_0000218,Ascaris suum,CHEMBL623648,,6253.0,,,N,Intermediate,10841.0,1.0,,6528.0,,,
,1.0,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623649,,1656.0,,,N,Intermediate,8117.0,1.0,,6529.0,,,
,1.0,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623650,,1656.0,,,N,Intermediate,8117.0,1.0,,6530.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623651,,1656.0,,,N,Intermediate,9560.0,1.0,,6531.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623652,,1656.0,,,N,Expert,9560.0,1.0,,6532.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623653,,1656.0,,,N,Intermediate,9560.0,1.0,,6533.0,,,
,1.0,F,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623654,,1656.0,,,N,Intermediate,9560.0,1.0,,6534.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces viscosus 8A06,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623655,,1656.0,,,N,Intermediate,9560.0,1.0,,6535.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces viscosus M-100,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623656,,1656.0,,,N,Intermediate,9560.0,1.0,,6536.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623657,,1656.0,,,N,Expert,9560.0,1.0,,6537.0,,,
,1.0,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623658,,1656.0,,,N,Intermediate,9560.0,1.0,,6538.0,,,
,1.0,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623659,,1656.0,,,N,Intermediate,9560.0,1.0,,6539.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces viscosus 626,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623660,,1656.0,,,N,Intermediate,9560.0,1.0,,6540.0,,,
,1.0,F,Plaque bactericidal index against Actinomyces viscosus T14V,,,50366.0,BAO_0000218,Actinomyces viscosus,CHEMBL623661,,1656.0,,,N,Intermediate,9560.0,1.0,,6541.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL875281,,6277.0,,,N,Intermediate,10986.0,1.0,,6542.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL623662,,6277.0,,,N,Intermediate,10986.0,1.0,,6543.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL623663,,6277.0,,,N,Intermediate,10986.0,1.0,,6544.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL623664,,6277.0,,,N,Intermediate,10986.0,1.0,,6545.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL623665,,6277.0,,,N,Intermediate,10986.0,1.0,,6546.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,A673,80023.0,BAO_0000219,Homo sapiens,CHEMBL621856,,9606.0,,,N,Intermediate,10708.0,1.0,165.0,6547.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,A704,80661.0,BAO_0000219,Homo sapiens,CHEMBL620432,,9606.0,,,N,Intermediate,10708.0,1.0,645.0,6548.0,,,
,1.0,F,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL620433,,10116.0,,,U,Autocuration,416.0,0.0,,6549.0,,,
,1.0,F,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL620434,,10090.0,,,N,Intermediate,14354.0,1.0,625.0,6550.0,,,
,1.0,F,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL620435,,10090.0,,,N,Intermediate,14354.0,1.0,625.0,6551.0,,,
,1.0,F,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,A9,80024.0,BAO_0000219,Homo sapiens,CHEMBL620436,,9606.0,,,N,Intermediate,5116.0,1.0,625.0,6552.0,,,
,1.0,F,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,A9,80024.0,BAO_0000219,Homo sapiens,CHEMBL876597,,9606.0,,,N,Intermediate,5116.0,1.0,625.0,6553.0,,,
,1.0,F,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Human ovarian carcinoma cell line,81037.0,BAO_0000219,Homo sapiens,CHEMBL620437,,9606.0,,,N,Expert,15694.0,1.0,874.0,6554.0,,,
,1.0,F,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL620438,,10090.0,,,N,Expert,13038.0,1.0,625.0,6555.0,,,
,1.0,F,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL620439,,10090.0,,,N,Expert,13038.0,1.0,625.0,6556.0,,,
,1.0,F,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL619657,,10090.0,,,N,Expert,10923.0,1.0,625.0,6557.0,,,
,1.0,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL619658,,10090.0,,,N,Intermediate,10923.0,1.0,625.0,6558.0,,,
,1.0,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL619659,,10090.0,,,N,Intermediate,10923.0,1.0,625.0,6559.0,,,
,1.0,F,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,10649.0,BAO_0000019,,CHEMBL619660,,,,,H,Expert,10923.0,8.0,,6560.0,,,
,1.0,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL619661,,10090.0,,,N,Intermediate,10923.0,1.0,625.0,6561.0,,,
,1.0,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,A9,80024.0,BAO_0000219,Mus musculus,CHEMBL619662,,10090.0,,,N,Intermediate,10923.0,1.0,625.0,6562.0,,,
,1.0,F,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,AA6,80663.0,BAO_0000219,Cricetulus griseus,CHEMBL619663,,10029.0,,,N,Intermediate,8158.0,1.0,975.0,6563.0,,,
,1.0,F,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,22226.0,BAO_0000219,Homo sapiens,CHEMBL619664,,9606.0,,,U,Autocuration,15494.0,0.0,,6564.0,,,
,1.0,F,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,22226.0,BAO_0000219,Homo sapiens,CHEMBL619665,,9606.0,,,U,Autocuration,15494.0,0.0,,6565.0,,,
,1.0,F,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,AA5,80662.0,BAO_0000219,Homo sapiens,CHEMBL883244,,9606.0,,,N,Intermediate,12348.0,1.0,974.0,6566.0,,,
,1.0,F,Cytotoxicity was measured against AA5/HIV-1(IIIB),,AA5,80662.0,BAO_0000219,Homo sapiens,CHEMBL884011,,9606.0,,,N,Intermediate,12348.0,1.0,974.0,6567.0,,,
,1.0,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,AA5,80662.0,BAO_0000219,Homo sapiens,CHEMBL619666,,9606.0,,,N,Intermediate,2726.0,1.0,974.0,6568.0,,,
,1.0,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,U-937,80566.0,BAO_0000219,Homo sapiens,CHEMBL619667,,9606.0,,,N,Intermediate,2726.0,1.0,379.0,6569.0,,,
,1.0,F,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,UV4,80578.0,BAO_0000219,Cricetulus griseus,CHEMBL619668,,10029.0,,,N,Intermediate,10747.0,1.0,274.0,6570.0,,,
,1.0,F,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619669,,10029.0,,,N,Expert,11005.0,1.0,185.0,6571.0,,,
,1.0,F,Average intracellular compound concentration when the hypoxic SER=1.6,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL876608,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6572.0,,,
,1.0,F,Average intracellular compound concentration when the hypoxic SER=1.6.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619670,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6573.0,,,
,1.0,F,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619671,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6574.0,,,
,1.0,F,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619672,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6575.0,,,
,1.0,F,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619673,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6576.0,,,
,1.0,F,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619674,,10029.0,,,N,Intermediate,13436.0,1.0,185.0,6577.0,,,
,1.0,F,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619675,,10029.0,,,N,Intermediate,13435.0,1.0,185.0,6578.0,,,
,1.0,F,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619676,,10029.0,,,N,Intermediate,13302.0,1.0,185.0,6579.0,,,
,1.0,F,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619677,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6580.0,,,
,1.0,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619678,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6581.0,,,
,1.0,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619679,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6582.0,,,
,1.0,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL619680,,10029.0,,,N,Expert,12878.0,1.0,185.0,6583.0,,,
,1.0,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL621457,,10029.0,,,N,Intermediate,12878.0,1.0,185.0,6584.0,,,
,1.0,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL876609,,10029.0,,,N,Expert,14367.0,1.0,185.0,6585.0,,,
,1.0,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL621458,,10029.0,,,N,Intermediate,14367.0,1.0,185.0,6586.0,,,
,1.0,F,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,CHO-AA8,80089.0,BAO_0000219,hampster,CHEMBL621459,,36483.0,,,N,Expert,12398.0,1.0,185.0,6587.0,,,
,1.0,F,Aerobic growth inhibition in Chinese hamster cell line AA8,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL621460,,10029.0,,,N,Expert,12878.0,1.0,185.0,6588.0,,,
,1.0,F,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL621461,,10029.0,,,N,Expert,13820.0,1.0,185.0,6589.0,,,
,1.0,F,Inhibition of growth under aerobic conditions in AA8 cells,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL621462,,10029.0,,,N,Expert,13436.0,1.0,185.0,6590.0,,,
,1.0,A,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621463,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6591.0,,,
,1.0,A,Oral bioavailability in dog at 10 mg/kg of the compound,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621464,In vivo,9615.0,,,N,Intermediate,5711.0,1.0,,6592.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621465,In vivo,9615.0,,,N,Intermediate,4353.0,1.0,,6593.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621466,In vivo,9615.0,,,N,Intermediate,4353.0,1.0,,6594.0,,,
,1.0,A,Oral bioavailability in dog (mongrel),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621467,In vivo,9615.0,,,N,Intermediate,17800.0,1.0,,6595.0,,,
,1.0,A,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621468,In vivo,9615.0,,,N,Intermediate,3994.0,1.0,,6596.0,,,
,1.0,F,Oral bioavailability in dog (dose 10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876734,In vivo,9615.0,,,N,Intermediate,3994.0,1.0,,6597.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618476,In vivo,9615.0,,,N,Intermediate,5145.0,1.0,,6598.0,,,
,1.0,A,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618477,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,6599.0,,,
,1.0,A,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618478,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,6600.0,,,
,1.0,A,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618479,In vivo,9615.0,,,N,Intermediate,5983.0,1.0,,6601.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618480,In vivo,9615.0,,,N,Intermediate,4273.0,1.0,,6602.0,,,
,1.0,A,Bioavailability in dog (dose 3-10 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618481,In vivo,9615.0,,,N,Intermediate,12500.0,1.0,,6603.0,,,
Plasma,1.0,A,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618482,In vivo,9615.0,1969.0,,N,Intermediate,12500.0,1.0,,6604.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618483,In vivo,9615.0,,,N,Intermediate,3639.0,1.0,,6605.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618484,In vivo,9615.0,,,N,Intermediate,3880.0,1.0,,6606.0,,,
,1.0,A,Bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618485,In vivo,9615.0,,,N,Intermediate,4838.0,1.0,,6607.0,,,
,1.0,A,oral bioavailability was measured in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618486,In vivo,9615.0,,,N,Intermediate,15600.0,1.0,,6608.0,,,
,1.0,A,Compound was tested for plasma protein binding in dog; Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618487,,9615.0,,,N,Intermediate,17248.0,1.0,,6609.0,,,
,1.0,A,Compound was tested for plasma protein binding of dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618488,,9615.0,,,N,Intermediate,17248.0,1.0,,6610.0,,,
,1.0,A,Compound was tested for plasma protein binding of dog; Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876735,,9615.0,,,N,Intermediate,17248.0,1.0,,6611.0,,,
,1.0,A,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618489,,9615.0,,,N,Intermediate,17443.0,1.0,,6612.0,,,
,1.0,A,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618490,In vivo,9615.0,,,N,Intermediate,4186.0,1.0,,6613.0,,,
,1.0,A,Half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618491,,9615.0,,,N,Intermediate,3749.0,1.0,,6614.0,,,
,1.0,A,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618492,In vivo,9615.0,,,N,Intermediate,3249.0,1.0,,6615.0,,,
,1.0,A,Half life was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873354,,9615.0,,,N,Intermediate,3022.0,1.0,,6616.0,,,
,1.0,A,Half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618493,,9615.0,,,N,Intermediate,3749.0,1.0,,6617.0,,,
,1.0,A,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618494,In vivo,9615.0,,,N,Intermediate,2517.0,1.0,,6618.0,,,
Heart,1.0,A,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618495,In vivo,9615.0,948.0,,N,Intermediate,2517.0,1.0,,6619.0,,,
Kidney,1.0,A,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618496,In vivo,9615.0,2113.0,,N,Intermediate,2517.0,1.0,,6620.0,,,
Liver,1.0,A,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618497,In vivo,9615.0,2107.0,,N,Intermediate,2517.0,1.0,,6621.0,,,
Lung,1.0,A,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618498,In vivo,9615.0,2048.0,,N,Intermediate,2517.0,1.0,,6622.0,,,
Spleen,1.0,A,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618499,In vivo,9615.0,2106.0,,N,Intermediate,2517.0,1.0,,6623.0,,,
,1.0,A,LogP in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876736,,9615.0,,,N,Intermediate,3639.0,1.0,,6624.0,,,
,1.0,A,Partition coefficient (logP),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618500,,9615.0,,,N,Intermediate,6227.0,1.0,,6625.0,,,
,1.0,A,Partition coefficient in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL857831,,9615.0,,,N,Intermediate,6227.0,1.0,,6626.0,,,
,1.0,A,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618501,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,6627.0,,,
,1.0,A,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618502,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,6628.0,,,
,1.0,A,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618503,,9615.0,,,N,Intermediate,5600.0,1.0,,6629.0,,,
,1.0,A,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618504,,9615.0,,,N,Intermediate,14294.0,1.0,,6630.0,,,
,1.0,A,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618505,,9615.0,,,N,Intermediate,14294.0,1.0,,6631.0,,,
,1.0,A,Metabolism of compound in dog S9 microsomes; Trace,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618506,,9615.0,,,N,Intermediate,14294.0,1.0,,6632.0,,,
Liver,1.0,A,In vitro metabolic potential in dog liver microsomes,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618507,,9615.0,2107.0,,N,Intermediate,6251.0,1.0,,6633.0,,,
,1.0,A,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876737,In vivo,9615.0,,,N,Intermediate,3748.0,1.0,,6634.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618508,In vivo,9615.0,,,N,Intermediate,2713.0,1.0,,6635.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618509,In vivo,9615.0,,,N,Intermediate,6512.0,1.0,,6636.0,,,
,1.0,A,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618510,In vivo,9615.0,,,N,Intermediate,6679.0,1.0,,6637.0,,,
,1.0,A,The compound was tested for bioavailability in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618511,In vivo,9615.0,,,N,Intermediate,3749.0,1.0,,6638.0,,,
,1.0,A,The compound was tested for oral bioavailability in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618512,In vivo,9615.0,,,N,Intermediate,3749.0,1.0,,6639.0,,,
,1.0,A,Oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618513,In vivo,9615.0,,,N,Intermediate,6742.0,1.0,,6640.0,,,
,1.0,A,Compound was tested for percent protein binding (PB) in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618514,,9615.0,,,N,Intermediate,6227.0,1.0,,6641.0,,,
,1.0,A,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620052,,9615.0,,,N,Intermediate,6874.0,1.0,,6642.0,,,
Plasma,1.0,A,Compound was evaluated for plasma clearance.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620053,In vivo,9615.0,1969.0,,N,Intermediate,2877.0,1.0,,6643.0,,,
Plasma,1.0,A,The compound was tested for plasma clearance in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620054,In vivo,9615.0,1969.0,,N,Intermediate,12500.0,1.0,,6644.0,,,
Plasma,1.0,A,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620055,In vivo,9615.0,1969.0,,N,Intermediate,12500.0,1.0,,6645.0,,,
,1.0,A,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620056,,9615.0,,,N,Intermediate,4709.0,1.0,,6646.0,,,
Liver,1.0,A,In vitro relative rate of metabolism was determined in dog liver microsomes,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620057,,9615.0,2107.0,,N,Intermediate,5542.0,1.0,,6647.0,,,
,1.0,A,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618939,In vivo,9615.0,,,N,Intermediate,17594.0,1.0,,6648.0,,,
,1.0,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618940,In vivo,9615.0,,,N,Intermediate,2652.0,1.0,,6649.0,,,
,1.0,A,Half life after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618941,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,6650.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624473,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6651.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624474,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6652.0,,,
Lung,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624475,,10090.0,2048.0,,N,Intermediate,6599.0,1.0,42.0,6653.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL624476,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6654.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL623478,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6655.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL623479,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6656.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL623480,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6657.0,,,
,1.0,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,CCRF S-180,50594.0,BAO_0000218,Mus musculus,CHEMBL623481,,10090.0,,,N,Intermediate,6599.0,1.0,42.0,6658.0,,,
Brain,1.0,A,C2 in brain of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623482,,10090.0,955.0,,N,Intermediate,17641.0,1.0,,6659.0,,,
Kidney,1.0,A,C2 in kidney of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623483,,10090.0,2113.0,,N,Intermediate,17641.0,1.0,,6660.0,,,
Liver,1.0,A,C2 in liver of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623484,,10090.0,2107.0,,N,Intermediate,17641.0,1.0,,6661.0,,,
Lung,1.0,A,C2 in lungs of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623485,,10090.0,2048.0,,N,Intermediate,17641.0,1.0,,6662.0,,,
Spleen,1.0,A,C2 in spleen of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623486,,10090.0,2106.0,,N,Intermediate,17641.0,1.0,,6663.0,,,
,1.0,A,Plasma clearance in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623487,In vivo,10090.0,,,N,Intermediate,17852.0,1.0,,6664.0,,,
,1.0,A,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623488,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6665.0,,,
,1.0,A,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623489,In vivo,10090.0,,,N,Intermediate,17837.0,1.0,,6666.0,,,
,1.0,A,Clearance was evaluated in mice after intravenous administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875157,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,6667.0,,,
,1.0,A,Clearance was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623490,In vivo,10090.0,,,N,Intermediate,2675.0,1.0,,6668.0,,,
,1.0,A,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623491,In vivo,10090.0,,,N,Intermediate,4239.0,1.0,,6669.0,,,
,1.0,A,Plasma clearance of compound was determined at 40 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623492,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,6670.0,,,
,1.0,A,Plasma clearance of at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623493,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,6671.0,,,
,1.0,A,Plasma clearance at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623494,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,6672.0,,,
,1.0,A,Plasma clearance at 5 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623495,In vivo,10090.0,,,N,Intermediate,17753.0,1.0,,6673.0,,,
,1.0,A,Plasma clearance in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623496,In vivo,10090.0,,,N,Intermediate,5727.0,1.0,,6674.0,,,
,1.0,A,Plasma clearance value upon iv administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623497,In vivo,10090.0,,,N,Intermediate,2862.0,1.0,,6675.0,,,
Plasma,1.0,A,Total plasma clearance in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623498,In vivo,10090.0,1969.0,,N,Intermediate,5980.0,1.0,,6676.0,,,
,1.0,A,Clearance in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623499,In vivo,10090.0,,,N,Intermediate,17592.0,1.0,,6677.0,,,
,1.0,A,Clearance value was determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623500,In vivo,10090.0,,,N,Intermediate,17718.0,1.0,,6678.0,,,
,1.0,A,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623501,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,6679.0,,,
,1.0,P,Calculated partition coefficient (clogP),,,22229.0,BAO_0000100,,CHEMBL875158,,,,,U,Intermediate,17384.0,0.0,,6680.0,,,
,1.0,A,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623502,In vivo,10090.0,,,N,Intermediate,6062.0,1.0,,6681.0,,,
,1.0,A,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623503,In vivo,10090.0,,,N,Intermediate,17734.0,1.0,,6682.0,,,
,1.0,A,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623504,In vivo,10090.0,,,N,Intermediate,6348.0,1.0,,6683.0,,,
,1.0,A,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623505,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,6684.0,,,
,1.0,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623506,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,6685.0,,,
,1.0,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623507,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,6686.0,,,
,1.0,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623508,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,6687.0,,,
,1.0,A,Cmax after oral administration at 30 mg/kg in ICR mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623509,In vivo,10090.0,,,N,Intermediate,5781.0,1.0,,6688.0,,,
,1.0,A,Cmax after peroral administration in mice at 2.4 uM/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875159,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6689.0,,,
Brain,1.0,A,Cmax in brain of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623510,In vivo,10090.0,955.0,,N,Intermediate,17641.0,1.0,,6690.0,,,
Kidney,1.0,A,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623511,In vivo,10090.0,2113.0,,N,Intermediate,17641.0,1.0,,6691.0,,,
Liver,1.0,A,Cmax in liver of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623512,In vivo,10090.0,2107.0,,N,Intermediate,17641.0,1.0,,6692.0,,,
Lung,1.0,A,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623513,In vivo,10090.0,2048.0,,N,Intermediate,17641.0,1.0,,6693.0,,,
,1.0,F,Cmax in mice at 18 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623514,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6694.0,,,
,1.0,F,Cmax in mice at 23 uM/kg i.v. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622609,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6695.0,,,
,1.0,F,Cmax in mice at 24 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622610,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6696.0,,,
,1.0,F,Cmax in mice at 25 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621823,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6697.0,,,
,1.0,F,Cmax in mice at 26 uM/kg i.p. administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621824,In vivo,10090.0,,,N,Intermediate,17764.0,1.0,,6698.0,,,
Spleen,1.0,A,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621825,In vivo,10090.0,2106.0,,N,Intermediate,17641.0,1.0,,6699.0,,,
,1.0,A,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621826,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,6700.0,,,
,1.0,A,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621827,In vivo,10090.0,,,N,Intermediate,16597.0,1.0,,6701.0,,,
,1.0,A,Cmax value was determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621828,In vivo,10090.0,,,N,Intermediate,5727.0,1.0,,6702.0,,,
,1.0,A,Cmax value in IRC mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621829,In vivo,10090.0,,,N,Intermediate,5951.0,1.0,,6703.0,,,
,1.0,A,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621830,In vivo,10090.0,,,N,Intermediate,5506.0,1.0,,6704.0,,,
,1.0,A,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621831,In vivo,10090.0,,,N,Intermediate,5506.0,1.0,,6705.0,,,
Plasma,1.0,A,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621832,In vivo,10090.0,1969.0,,N,Intermediate,14239.0,1.0,,6706.0,,,
Plasma,1.0,A,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,50594.0,BAO_0000218,Mus musculus,CHEMBL624579,In vivo,10090.0,1969.0,,N,Intermediate,4890.0,1.0,,6707.0,,,
,1.0,A,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624580,In vivo,10090.0,,,N,Intermediate,429.0,1.0,,6708.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL624581,,6277.0,,,N,Intermediate,10986.0,1.0,,6709.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL624582,,6277.0,,,N,Intermediate,10986.0,1.0,,6710.0,,,
,1.0,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,50535.0,BAO_0000218,Acanthocheilonema viteae,CHEMBL624583,,6277.0,,,N,Intermediate,10986.0,1.0,,6711.0,,,
,1.0,F,Inhibitory activity against human tumor cell line A0375 melanoma.,,A-375,80018.0,BAO_0000219,Homo sapiens,CHEMBL624584,,9606.0,,,N,Intermediate,13227.0,1.0,455.0,6712.0,,,
,1.0,B,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,12512.0,BAO_0000249,Rattus norvegicus,CHEMBL624585,,10116.0,,,D,Expert,4481.0,9.0,,6713.0,Brain membranes,,
,1.0,F,Forskolin-induced cAMP production at human A1 adenosine receptor,,,114.0,BAO_0000019,Homo sapiens,CHEMBL875165,,9606.0,,,D,Expert,16931.0,9.0,,6714.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL619490,,,,,H,Autocuration,3850.0,8.0,449.0,6715.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL619491,,,,,H,Autocuration,3850.0,8.0,449.0,6716.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,CHO,114.0,BAO_0000219,,CHEMBL619492,,,,,H,Expert,3850.0,8.0,449.0,6717.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,CHO,114.0,BAO_0000219,,CHEMBL619493,,,,,H,Expert,3850.0,8.0,449.0,6718.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL619494,,,,,H,Autocuration,3850.0,8.0,449.0,6719.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,CHO,114.0,BAO_0000219,,CHEMBL619495,,,,,H,Autocuration,3850.0,8.0,449.0,6720.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL619496,,,,,H,Autocuration,3850.0,8.0,449.0,6721.0,,,
,1.0,F,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,Homo sapiens,CHEMBL619497,,9606.0,,,D,Expert,3850.0,9.0,449.0,6722.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,CHO,114.0,BAO_0000219,,CHEMBL619498,,,,,H,Autocuration,3850.0,8.0,449.0,6723.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL619499,,,,,H,Autocuration,3850.0,8.0,449.0,6724.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,CHO,114.0,BAO_0000219,,CHEMBL619500,,,,,H,Expert,3850.0,8.0,449.0,6725.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL619501,,,,,H,Autocuration,3850.0,8.0,449.0,6726.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL619502,,,,,H,Expert,3850.0,8.0,449.0,6727.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,CHO,114.0,BAO_0000219,,CHEMBL619503,,,,,H,Autocuration,3850.0,8.0,449.0,6728.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL619504,,,,,H,Autocuration,3850.0,8.0,449.0,6729.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL621298,,,,,H,Autocuration,3850.0,8.0,449.0,6730.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,CHO,114.0,BAO_0000219,,CHEMBL621299,,,,,H,Expert,3850.0,8.0,449.0,6731.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL621300,,,,,H,Autocuration,3850.0,8.0,449.0,6732.0,,,
,1.0,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,CHO,114.0,BAO_0000219,,CHEMBL621301,,,,,H,Autocuration,3850.0,8.0,449.0,6733.0,,,
,1.0,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHO,114.0,BAO_0000219,,CHEMBL621302,,,,,H,Expert,3850.0,8.0,449.0,6734.0,,,
,1.0,F,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,A10,80013.0,BAO_0000219,Oryctolagus cuniculus,CHEMBL621303,,9986.0,,,N,Intermediate,12680.0,1.0,164.0,6735.0,,,
,1.0,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,A10,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL621304,,10116.0,,,U,Autocuration,1313.0,0.0,164.0,6736.0,,,
,1.0,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,A10,22226.0,BAO_0000219,Rattus norvegicus,CHEMBL621305,,10116.0,,,U,Autocuration,1313.0,0.0,164.0,6737.0,,,
,1.0,F,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL621306,,10116.0,,,N,Intermediate,17567.0,1.0,164.0,6738.0,,,
,1.0,F,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL618444,,10116.0,,,N,Intermediate,17567.0,1.0,164.0,6739.0,,,
,1.0,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL618445,,10116.0,,,N,Intermediate,11819.0,1.0,164.0,6740.0,,,
,1.0,F,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618446,,10029.0,,,N,Intermediate,13436.0,1.0,185.0,6741.0,,,
,1.0,F,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618447,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6742.0,,,
,1.0,F,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618448,,10029.0,,,N,Intermediate,12651.0,1.0,185.0,6743.0,,,
,1.0,F,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618449,,10029.0,,,N,Intermediate,13300.0,1.0,185.0,6744.0,,,
,1.0,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618637,,10029.0,,,N,Intermediate,15296.0,1.0,185.0,6745.0,,,
,1.0,F,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618638,,10029.0,,,N,Intermediate,15328.0,1.0,185.0,6746.0,,,
,1.0,F,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618639,,10029.0,,,N,Intermediate,13302.0,1.0,185.0,6747.0,,,
,1.0,F,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618640,,10029.0,,,N,Expert,14367.0,1.0,185.0,6748.0,,,
,1.0,F,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618641,,10029.0,,,N,Expert,17002.0,1.0,185.0,6749.0,,,
,1.0,F,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618642,,10029.0,,,N,Intermediate,13436.0,1.0,185.0,6750.0,,,
,1.0,F,Inhibitory activity against aerobic growth of AA8 cells.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618643,,10029.0,,,N,Intermediate,13435.0,1.0,185.0,6751.0,,,
,1.0,A,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL884013,,10029.0,,,N,Intermediate,10503.0,1.0,185.0,6752.0,,,
,1.0,F,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622723,,10029.0,,,N,Expert,10503.0,1.0,185.0,6753.0,,,
,1.0,F,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622724,,10029.0,,,N,Intermediate,10503.0,1.0,185.0,6754.0,,,
,1.0,F,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622725,,10029.0,,,N,Expert,15090.0,1.0,185.0,6755.0,,,
,1.0,F,Cytotoxicity against AA8 cell line,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622726,,10029.0,,,N,Expert,10368.0,1.0,185.0,6756.0,,,
,1.0,F,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622727,,10029.0,,,N,Intermediate,12651.0,1.0,185.0,6757.0,,,
,1.0,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622728,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6758.0,,,
,1.0,F,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622729,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6759.0,,,
,1.0,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622730,,10029.0,,,N,Intermediate,12687.0,1.0,185.0,6760.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622731,,10029.0,,,N,Intermediate,1890.0,1.0,185.0,6761.0,,,
,1.0,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622732,,10029.0,,,N,Intermediate,10747.0,1.0,185.0,6762.0,,,
,1.0,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622733,,10029.0,,,N,Intermediate,10747.0,1.0,185.0,6763.0,,,
,1.0,F,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,22224.0,BAO_0000218,Cricetulus griseus,CHEMBL622734,,10029.0,,,U,Autocuration,11616.0,0.0,,6764.0,,,
,1.0,F,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL622735,,10029.0,,,N,Expert,11616.0,1.0,185.0,6765.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618746,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6766.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618747,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6767.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL620540,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6768.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL620541,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6769.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL620542,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6770.0,,,
,1.0,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL620543,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6771.0,,,
,1.0,F,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618832,,10029.0,,,U,Autocuration,3471.0,0.0,185.0,6772.0,,,
,1.0,F,Concentration required to reduce AA8 cell survival by 10%,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL618833,,10029.0,,,N,Expert,11616.0,1.0,185.0,6773.0,,,
,1.0,F,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618834,,10029.0,,,U,Autocuration,2656.0,0.0,185.0,6774.0,,,
,1.0,F,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618835,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6775.0,,,
,1.0,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618836,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6776.0,,,
,1.0,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618837,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6777.0,,,
,1.0,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618838,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6778.0,,,
,1.0,F,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618839,,10029.0,,,U,Autocuration,16156.0,0.0,185.0,6779.0,,,
,1.0,F,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618840,,10029.0,,,U,Autocuration,2656.0,0.0,185.0,6780.0,,,
,1.0,F,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,22224.0,BAO_0000019,Cricetulus griseus,CHEMBL618841,,10029.0,,,U,Autocuration,11005.0,0.0,,6781.0,,,
,1.0,F,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618842,,10029.0,,,U,Autocuration,11942.0,0.0,185.0,6782.0,,,
,1.0,F,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL618843,,10029.0,,,U,Autocuration,2128.0,0.0,185.0,6783.0,,,
,1.0,A,Half life period after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618844,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6784.0,,,
,1.0,A,Half life period after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618845,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6785.0,,,
,1.0,A,Half life was measured after oral 2b administration (tested in 6 dogs),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618846,In vivo,9615.0,,,N,Intermediate,9579.0,1.0,,6786.0,,,
,1.0,A,Half life was measured in dog after oral 17b administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618847,In vivo,9615.0,,,N,Intermediate,9579.0,1.0,,6787.0,,,
,1.0,A,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618848,In vivo,9615.0,,,N,Intermediate,9579.0,1.0,,6788.0,,,
,1.0,A,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618849,In vivo,9615.0,,,N,Intermediate,9579.0,1.0,,6789.0,,,
,1.0,A,Tmax value after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618850,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6790.0,,,
,1.0,A,Tmax value after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618851,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6791.0,,,
,1.0,A,Compound was evaluated for its half life when administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873815,In vivo,9615.0,,,N,Intermediate,3184.0,1.0,,6792.0,,,
Plasma,1.0,A,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618852,In vivo,9615.0,1969.0,,N,Intermediate,5017.0,1.0,,6793.0,,,
,1.0,A,Elimination Half-life of compound was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618853,,9615.0,,,N,Intermediate,6821.0,1.0,,6794.0,,,
,1.0,A,Half life of compound in dog following oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618854,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,6795.0,,,
,1.0,A,Half life of compound was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618855,,9615.0,,,N,Intermediate,17267.0,1.0,,6796.0,,,
Blood,1.0,A,Half life of compound was determined in dog blood,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618856,,9615.0,178.0,,N,Intermediate,4727.0,1.0,,6797.0,,,
,1.0,A,Half life after oral and iv dosing in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875827,In vivo,9615.0,,,N,Intermediate,5238.0,1.0,,6798.0,,,
,1.0,A,Half life in dogs in hours,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618857,,9615.0,,,N,Intermediate,4942.0,1.0,,6799.0,,,
,1.0,A,Half life on i.v. administration of 2 mg/kg was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618858,In vivo,9615.0,,,N,Intermediate,6505.0,1.0,,6800.0,,,
,1.0,A,t1/2 in dog after oral dose (1 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618859,In vivo,9615.0,,,N,Intermediate,5130.0,1.0,,6801.0,,,
,1.0,A,Half life was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618860,,9615.0,,,N,Intermediate,1475.0,1.0,,6802.0,,,
,1.0,A,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618861,In vivo,9615.0,,,N,Intermediate,17804.0,1.0,,6803.0,,,
,1.0,A,Half life period of compound was determined after peroral administration at 2 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622539,In vivo,9615.0,,,N,Intermediate,17804.0,1.0,,6804.0,,,
,1.0,A,Half life period (10 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622540,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6805.0,,,
,1.0,A,Half life period (10 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873803,In vivo,9615.0,,,N,Intermediate,6084.0,1.0,,6806.0,,,
,1.0,A,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873804,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,6807.0,,,
,1.0,A,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624311,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,6808.0,,,
,1.0,A,Half life period in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624312,,9615.0,,,N,Intermediate,6084.0,1.0,,6809.0,,,
,1.0,A,Half life period in dogs after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624313,In vivo,9615.0,,,N,Intermediate,6241.0,1.0,,6810.0,,,
,1.0,A,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624314,In vivo,9615.0,,,N,Intermediate,1916.0,1.0,,6811.0,,,
,1.0,A,Half-life of compound was determined in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624315,,9615.0,,,N,Intermediate,6621.0,1.0,,6812.0,,,
Plasma,1.0,A,Half-life in dog plasma,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624316,,9615.0,1969.0,,N,Intermediate,1696.0,1.0,,6813.0,,,
,1.0,A,Half-life in mongrel dogs was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624317,,9615.0,,,N,Intermediate,17800.0,1.0,,6814.0,,,
,1.0,A,Half-life in dog upon oral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624318,In vivo,9615.0,,,N,Intermediate,17657.0,1.0,,6815.0,,,
,1.0,A,Half-life in dog upon oral administration; Unable to calculate,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624319,In vivo,9615.0,,,N,Intermediate,17657.0,1.0,,6816.0,,,
,1.0,A,Half-life was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624496,,9615.0,,,N,Intermediate,4239.0,1.0,,6817.0,,,
,1.0,A,Half-life was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624497,,9615.0,,,N,Intermediate,5985.0,1.0,,6818.0,,,
,1.0,A,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624498,,9615.0,,,N,Intermediate,9932.0,1.0,,6819.0,,,
,1.0,A,Oral half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624499,In vivo,9615.0,,,N,Intermediate,5199.0,1.0,,6820.0,,,
Plasma,1.0,A,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624500,In vivo,9615.0,1969.0,,N,Intermediate,5199.0,1.0,,6821.0,,,
Plasma,1.0,A,Plasma half life was evaluated,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624501,,9615.0,1969.0,,N,Intermediate,1475.0,1.0,,6822.0,,,
Plasma,1.0,A,Plasma half life was evaluated in Dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623666,,9615.0,1969.0,,N,Intermediate,1475.0,1.0,,6823.0,,,
Plasma,1.0,A,Plasma half life was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623667,,9615.0,1969.0,,N,Intermediate,1475.0,1.0,,6824.0,,,
,1.0,A,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623668,In vivo,9615.0,,,N,Intermediate,6316.0,1.0,,6825.0,,,
,1.0,A,Tested for the half life value in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623669,,9615.0,,,N,Intermediate,4883.0,1.0,,6826.0,,,
,1.0,A,Maximum time at the dose of 2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623670,In vivo,9615.0,,,N,Intermediate,4727.0,1.0,,6827.0,,,
,1.0,A,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623671,In vivo,9615.0,,,N,Intermediate,1916.0,1.0,,6828.0,,,
Blood,1.0,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875945,In vivo,9615.0,178.0,,N,Intermediate,1337.0,1.0,,6829.0,,,
Blood,1.0,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623672,In vivo,9615.0,178.0,,N,Intermediate,1337.0,1.0,,6830.0,,,
,1.0,A,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623673,In vivo,9615.0,,,N,Intermediate,6265.0,1.0,,6831.0,,,
,1.0,A,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623674,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,6832.0,,,
,1.0,A,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623675,In vivo,9615.0,,,N,Intermediate,5983.0,1.0,,6833.0,,,
,1.0,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL872526,,9615.0,,,N,Intermediate,5313.0,1.0,,6834.0,,,
,1.0,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623676,In vivo,9615.0,,,N,Intermediate,5313.0,1.0,,6835.0,,,
Plasma,1.0,A,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623677,In vivo,9615.0,1969.0,,N,Intermediate,17650.0,1.0,,6836.0,,,
Plasma,1.0,A,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623678,In vivo,9615.0,1969.0,,N,Intermediate,5199.0,1.0,,6837.0,,,
Plasma,1.0,A,Time taken for maximum plasma concentration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623679,,9615.0,1969.0,,N,Intermediate,933.0,1.0,,6838.0,,,
,1.0,A,Time to reach Cmax after oral administration to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623680,In vivo,9615.0,,,N,Intermediate,16367.0,1.0,,6839.0,,,
Plasma,1.0,A,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623681,In vivo,9615.0,1969.0,,N,Intermediate,6348.0,1.0,,6840.0,,,
,1.0,A,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623682,In vivo,9615.0,,,N,Intermediate,6316.0,1.0,,6841.0,,,
,1.0,A,Tmax after peroral administration (1 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623683,In vivo,9615.0,,,N,Intermediate,6215.0,1.0,,6842.0,,,
,1.0,A,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623684,In vivo,9615.0,,,N,Expert,3598.0,1.0,,6843.0,,,
,1.0,A,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622745,In vivo,9615.0,,,N,Intermediate,4527.0,1.0,,6844.0,,,
,1.0,A,Tmax after peroral administration in dogs at 2.4 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622746,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,6845.0,,,
,1.0,A,In vivo Cmax in mice at dose of 100 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622747,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,6846.0,,,
,1.0,A,In vivo Cmax in mice at dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622748,In vivo,10090.0,,,N,Intermediate,5969.0,1.0,,6847.0,,,
,1.0,A,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622749,In vivo,10090.0,,,N,Intermediate,4573.0,1.0,,6848.0,,,
Plasma,1.0,A,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,50594.0,BAO_0000218,Mus musculus,CHEMBL622750,In vivo,10090.0,1969.0,,N,Intermediate,3277.0,1.0,,6849.0,,,
Plasma,1.0,A,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623411,In vivo,10090.0,1969.0,,N,Intermediate,17734.0,1.0,,6850.0,,,
Plasma,1.0,A,Maximum concentration obtained in mouse plasma was determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875946,In vivo,10090.0,1969.0,,N,Intermediate,3132.0,1.0,,6851.0,,,
Plasma,1.0,A,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623412,In vivo,10090.0,1969.0,,N,Intermediate,3132.0,1.0,,6852.0,,,
Plasma,1.0,A,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623413,In vivo,10090.0,1969.0,,N,Intermediate,6348.0,1.0,,6853.0,,,
Plasma,1.0,A,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623414,In vivo,10090.0,1969.0,,N,Intermediate,17729.0,1.0,,6854.0,,,
Plasma,1.0,A,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623415,In vivo,10090.0,1969.0,,N,Intermediate,17729.0,1.0,,6855.0,,,
Plasma,1.0,A,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623416,In vivo,10090.0,1969.0,,N,Intermediate,17729.0,1.0,,6856.0,,,
Plasma,1.0,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623417,In vivo,10090.0,1969.0,,N,Intermediate,17728.0,1.0,,6857.0,,,
Plasma,1.0,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623418,In vivo,10090.0,1969.0,,N,Intermediate,17728.0,1.0,,6858.0,,,
Plasma,1.0,A,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623419,In vivo,10090.0,1969.0,,N,Intermediate,17728.0,1.0,,6859.0,,,
,1.0,A,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622816,In vivo,10090.0,,,N,Intermediate,4066.0,1.0,,6860.0,,,
,1.0,A,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623313,In vivo,10090.0,,,N,Intermediate,6178.0,1.0,,6861.0,,,
,1.0,A,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623314,In vivo,10090.0,,,N,Intermediate,6178.0,1.0,,6862.0,,,
,1.0,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876788,In vivo,10090.0,,,N,Intermediate,3760.0,1.0,,6863.0,,,
,1.0,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623315,In vivo,10090.0,,,N,Intermediate,3760.0,1.0,,6864.0,,,
,1.0,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623316,In vivo,10090.0,,,N,Intermediate,3760.0,1.0,,6865.0,,,
,1.0,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623317,In vivo,10090.0,,,N,Intermediate,3760.0,1.0,,6866.0,,,
,1.0,A,Cmax in male mice after 2 mg/kg oral dose,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623319,In vivo,10090.0,,,N,Intermediate,5961.0,1.0,,6868.0,,,
,1.0,A,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623320,In vivo,10090.0,,,N,Intermediate,6137.0,1.0,,6869.0,,,
,1.0,A,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623321,In vivo,10090.0,,,N,Intermediate,3802.0,1.0,,6870.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623322,,10090.0,,,N,Intermediate,3535.0,1.0,,6871.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623323,,10090.0,,,N,Intermediate,3535.0,1.0,,6872.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623324,,10090.0,,,N,Intermediate,3535.0,1.0,,6873.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623325,,10090.0,,,N,Intermediate,3535.0,1.0,,6874.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623326,,10090.0,,,N,Intermediate,3535.0,1.0,,6875.0,,,
,1.0,A,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623327,,10090.0,,,N,Intermediate,3535.0,1.0,,6876.0,,,
Plasma,1.0,A,Maximum concentration in plasma upon oral administration in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623328,,10090.0,1969.0,,N,Intermediate,2862.0,1.0,,6877.0,,,
Plasma,1.0,A,Maximum plasma concentration was evaluated in mice after oral administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623329,,10090.0,1969.0,,N,Intermediate,2675.0,1.0,,6878.0,,,
Plasma,1.0,A,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623330,In vivo,10090.0,1969.0,,N,Intermediate,2675.0,1.0,,6879.0,,,
,1.0,A,Dose at which the compound induced fecal excretion in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL876789,,10090.0,,,N,Intermediate,5399.0,1.0,,6880.0,,,
,1.0,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL623333,,10116.0,,,N,Expert,11819.0,1.0,164.0,6893.0,,,
,1.0,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL623334,,10116.0,,,N,Expert,11819.0,1.0,164.0,6894.0,,,
,1.0,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL627536,,10116.0,,,N,Expert,11819.0,1.0,164.0,6895.0,,,
,1.0,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL627537,,10116.0,,,N,Expert,11819.0,1.0,164.0,6896.0,,,
,1.0,F,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,A10,80013.0,BAO_0000219,Rattus norvegicus,CHEMBL627538,,10116.0,,,N,Intermediate,16361.0,1.0,164.0,6897.0,,,
,1.0,F,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL884106,,9606.0,,,N,Intermediate,2288.0,1.0,393.0,6898.0,,,
,1.0,F,Anticancer activity against human ovarian carcinoma A121 cells,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625294,,9606.0,,,N,Intermediate,10404.0,1.0,393.0,6899.0,,,
,1.0,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625295,,9606.0,,,N,Intermediate,14790.0,1.0,393.0,6900.0,,,
,1.0,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625296,,9606.0,,,N,Intermediate,14790.0,1.0,393.0,6901.0,,,
,1.0,F,Growth inhibition of human ovarian carcinoma (A121) cell line,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625297,,9606.0,,,N,Expert,14253.0,1.0,393.0,6902.0,,,
,1.0,F,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625298,,9606.0,,,N,Expert,13617.0,1.0,393.0,6903.0,,,
,1.0,F,Cytotoxicity against human A121 ovarian cells,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625960,,9606.0,,,N,Intermediate,1003.0,1.0,393.0,6904.0,,,
,1.0,F,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625961,,9606.0,,,N,Intermediate,830.0,1.0,393.0,6905.0,,,
,1.0,F,In vitro cytotoxicity against human ovarian carcinoma A21,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL625962,,9606.0,,,N,Intermediate,12307.0,1.0,393.0,6906.0,,,
,1.0,F,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL624717,,9606.0,,,N,Intermediate,14254.0,1.0,393.0,6907.0,,,
,1.0,F,Inhibitory activity of compound against human A121 ovarian cell line.,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL624718,,9606.0,,,N,Intermediate,13370.0,1.0,393.0,6908.0,,,
,1.0,F,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL624719,,9606.0,,,N,Intermediate,14790.0,1.0,393.0,6909.0,,,
,1.0,F,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,A121,80655.0,BAO_0000219,Homo sapiens,CHEMBL624720,,9606.0,,,N,Intermediate,3614.0,1.0,393.0,6910.0,,,
,1.0,F,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL624721,,9606.0,,,N,Intermediate,2664.0,1.0,622.0,6911.0,,,
,1.0,F,In vitro cytotoxicity against A172 human tumor cell lines.,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL624722,,9606.0,,,N,Expert,2037.0,1.0,622.0,6912.0,,,
,1.0,F,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL877597,,9606.0,,,N,Intermediate,14539.0,1.0,622.0,6913.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL624723,,9606.0,,,N,Intermediate,2836.0,1.0,622.0,6914.0,,,
,1.0,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,A 172,80012.0,BAO_0000219,Homo sapiens,CHEMBL624724,,9606.0,,,N,Intermediate,10708.0,1.0,622.0,6915.0,,,
,1.0,B,Association constant against A2 adenosine receptor,,,104729.0,BAO_0000224,Canis lupus familiaris,CHEMBL624725,,9615.0,,,H,Autocuration,8975.0,4.0,,6916.0,,,
,1.0,F,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,A2,80656.0,BAO_0000219,fish,CHEMBL624726,,,,,N,Intermediate,7645.0,1.0,1085.0,6917.0,,,
,1.0,B,Ratio of Ki for adenosine A2 and A1 receptor binding,,,104713.0,BAO_0000224,Rattus norvegicus,CHEMBL857535,,10116.0,,,D,Autocuration,11377.0,5.0,,6918.0,,,
,1.0,F,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,A204,80014.0,BAO_0000219,Homo sapiens,CHEMBL624727,,9606.0,,,N,Expert,13528.0,1.0,623.0,6919.0,,,
,1.0,F,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,A204,80014.0,BAO_0000219,Homo sapiens,CHEMBL624728,,9606.0,,,N,Expert,10160.0,1.0,623.0,6920.0,,,
,1.0,F,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,A2058,80015.0,BAO_0000219,Homo sapiens,CHEMBL624729,,9606.0,,,N,Intermediate,15144.0,1.0,404.0,6921.0,,,
,1.0,F,Growth inhibition against Human squamous cell line(A 253),,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624730,,9606.0,,,N,Intermediate,13160.0,1.0,973.0,6922.0,,,
,1.0,F,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624731,,9606.0,,,N,Intermediate,12898.0,1.0,973.0,6923.0,,,
,1.0,F,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624732,,9606.0,,,N,Intermediate,13069.0,1.0,973.0,6924.0,,,
,1.0,F,Growth inhibition of A253 cell lines.,,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL883245,,9606.0,,,N,Intermediate,15984.0,1.0,973.0,6925.0,,,
,1.0,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624733,,9606.0,,,N,Intermediate,15564.0,1.0,973.0,6926.0,,,
,1.0,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624734,,9606.0,,,N,Intermediate,15564.0,1.0,973.0,6927.0,,,
,1.0,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,A253 cell line,80657.0,BAO_0000219,Homo sapiens,CHEMBL624735,,9606.0,,,N,Intermediate,15564.0,1.0,973.0,6928.0,,,
,1.0,F,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621780,,9606.0,,,N,Intermediate,4720.0,1.0,478.0,6929.0,,,
,1.0,F,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL877598,,9606.0,,,N,Intermediate,16112.0,1.0,478.0,6930.0,,,
,1.0,F,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621781,,9606.0,,,N,Expert,16597.0,1.0,478.0,6931.0,,,
,1.0,F,Cytotoxicity against human cancer cell lines A2780 (ovarian),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621782,,9606.0,,,N,Intermediate,16378.0,1.0,478.0,6932.0,,,
,1.0,F,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621783,,9606.0,,,N,Expert,16085.0,1.0,478.0,6933.0,,,
,1.0,F,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621784,,9606.0,,,N,Intermediate,16317.0,1.0,478.0,6934.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621785,,9606.0,,,N,Intermediate,15748.0,1.0,478.0,6935.0,,,
,1.0,F,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621968,,9606.0,,,N,Expert,16597.0,1.0,478.0,6936.0,,,
,1.0,F,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621969,,9606.0,,,N,Expert,16597.0,1.0,478.0,6937.0,,,
,1.0,F,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621970,,9606.0,,,N,Expert,16597.0,1.0,478.0,6938.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621971,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,6939.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621972,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,6940.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL884108,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,6941.0,,,
,1.0,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,22224.0,BAO_0000019,Cricetulus griseus,CHEMBL623826,,10029.0,,,U,Autocuration,15296.0,0.0,,6942.0,,,
,1.0,A,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623827,,10029.0,,,U,Autocuration,10251.0,0.0,185.0,6943.0,,,
,1.0,F,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623828,,10029.0,,,U,Autocuration,10251.0,0.0,185.0,6944.0,,,
,1.0,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623829,,10029.0,,,U,Autocuration,10251.0,0.0,185.0,6945.0,,,
,1.0,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623830,,10029.0,,,U,Autocuration,10251.0,0.0,185.0,6946.0,,,
,1.0,F,Growth inhibition against CHO-derived cell line AA8,,,22224.0,BAO_0000019,Cricetulus griseus,CHEMBL623831,,10029.0,,,U,Autocuration,11858.0,0.0,,6947.0,,,
,1.0,F,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623832,,10029.0,,,U,Autocuration,11858.0,0.0,185.0,6948.0,,,
,1.0,F,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,CHO-AA8,80089.0,BAO_0000219,hampster,CHEMBL623833,,36483.0,,,N,Expert,11616.0,1.0,185.0,6949.0,,,
,1.0,F,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL623834,,10029.0,,,N,Expert,11616.0,1.0,185.0,6950.0,,,
,1.0,F,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623835,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6951.0,,,
,1.0,F,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623836,,10029.0,,,U,Autocuration,11396.0,0.0,185.0,6952.0,,,
,1.0,F,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,CHO-AA8,22224.0,BAO_0000219,Cricetulus griseus,CHEMBL623837,,10029.0,,,U,Autocuration,10518.0,0.0,185.0,6953.0,,,
,1.0,F,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,CHO-AA8,80089.0,BAO_0000219,Cricetulus griseus,CHEMBL623838,,10029.0,,,N,Expert,11616.0,1.0,185.0,6954.0,,,
,1.0,F,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,12675.0,BAO_0000019,,CHEMBL623839,,,,,H,Autocuration,14837.0,8.0,,6955.0,,,
,1.0,F,Number of binding sites (n) of isolated serum protein AAG,,,12675.0,BAO_0000019,,CHEMBL623840,,,,,H,Autocuration,14837.0,8.0,,6956.0,,,
,1.0,B,Association constant for binding to AATT duplex,,,22222.0,BAO_0000225,,CHEMBL623841,,,,,M,Intermediate,16037.0,3.0,,6957.0,,,
,1.0,F,Inhibition of ABAE human fibroblast cell proliferation,,ABAE,100090.0,BAO_0000219,Homo sapiens,CHEMBL623842,,9606.0,,,N,Expert,16597.0,1.0,416.0,6958.0,,,
,1.0,F,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,AC755,80668.0,BAO_0000218,Mus musculus,CHEMBL623843,,10090.0,,,N,Intermediate,8831.0,1.0,1064.0,6959.0,,,
,1.0,F,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,102444.0,BAO_0000218,Oryctolagus cuniculus,CHEMBL618669,,9986.0,,,D,Expert,13419.0,9.0,,6960.0,,,
,1.0,F,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,102444.0,BAO_0000218,Oryctolagus cuniculus,CHEMBL618670,In vivo,9986.0,,,D,Expert,13419.0,9.0,,6961.0,,,
,1.0,B,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,69.0,BAO_0000357,,CHEMBL618671,,,,,H,Autocuration,15778.0,8.0,,6962.0,,,
,1.0,B,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,69.0,BAO_0000357,,CHEMBL618672,,,,,H,Autocuration,15778.0,8.0,,6963.0,,,
,1.0,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,ACH-2 cell line,80669.0,BAO_0000219,Homo sapiens,CHEMBL618673,,9606.0,,,N,Intermediate,12988.0,1.0,978.0,6964.0,,,
,1.0,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,ACH-2 cell line,80669.0,BAO_0000219,Homo sapiens,CHEMBL618674,,9606.0,,,N,Intermediate,12988.0,1.0,978.0,6965.0,,,
,1.0,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,T cell line,22224.0,BAO_0000219,Human immunodeficiency virus 1,CHEMBL618675,,11676.0,,,U,Autocuration,12988.0,0.0,998.0,6966.0,,,
,1.0,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,T cell line,22224.0,BAO_0000219,Human immunodeficiency virus 1,CHEMBL618676,,11676.0,,,U,Autocuration,12988.0,0.0,998.0,6967.0,,,
,1.0,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,T cell line,22224.0,BAO_0000219,Human immunodeficiency virus 1,CHEMBL618677,,11676.0,,,U,Autocuration,12988.0,0.0,998.0,6968.0,,,
,1.0,F,Inhibition of growth of renal cancer ACHN cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618678,,9606.0,,,N,Intermediate,11843.0,1.0,626.0,6969.0,,,
,1.0,F,Inhibition of growth of ACHN renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618679,,9606.0,,,N,Intermediate,16939.0,1.0,626.0,6970.0,,,
,1.0,F,Inhibitory concentration required against ACHN renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618680,,9606.0,,,N,Intermediate,4782.0,1.0,626.0,6971.0,,,
,1.0,F,Concentration required to inhibit growth of human renal (ACHN) cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618681,,9606.0,,,N,Expert,6310.0,1.0,626.0,6972.0,,,
,1.0,F,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618682,,9606.0,,,N,Intermediate,6310.0,1.0,626.0,6973.0,,,
,1.0,F,Cytotoxic activity against ACHN Renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618683,,9606.0,,,N,Intermediate,12858.0,1.0,626.0,6974.0,,,
,1.0,F,Cytotoxicity evaluation against ACHN renal cancer cells,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618684,,9606.0,,,N,Intermediate,17380.0,1.0,626.0,6975.0,,,
,1.0,F,In vitro antitumor activity against human renal ACHN cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618685,,9606.0,,,N,Intermediate,5858.0,1.0,626.0,6976.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL876499,,9606.0,,,N,Intermediate,3838.0,1.0,626.0,6977.0,,,
,1.0,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618686,,9606.0,,,N,Intermediate,3838.0,1.0,626.0,6978.0,,,
,1.0,F,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618687,,9606.0,,,N,Intermediate,5406.0,1.0,626.0,6979.0,,,
,1.0,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618688,,9606.0,,,N,Intermediate,4071.0,1.0,626.0,6980.0,,,
,1.0,F,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618689,,9606.0,,,N,Expert,4071.0,1.0,626.0,6981.0,,,
,1.0,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618690,,9606.0,,,N,Intermediate,4071.0,1.0,626.0,6982.0,,,
,1.0,F,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL618691,,9606.0,,,N,Intermediate,15002.0,1.0,626.0,6983.0,,,
,1.0,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619373,,9606.0,,,N,Intermediate,14769.0,1.0,626.0,6984.0,,,
,1.0,F,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL884008,,9606.0,,,N,Intermediate,13958.0,1.0,626.0,6985.0,,,
,1.0,F,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619374,,9606.0,,,N,Intermediate,1665.0,1.0,626.0,6986.0,,,
,1.0,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619375,,9606.0,,,N,Intermediate,15354.0,1.0,626.0,6987.0,,,
,1.0,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619376,,9606.0,,,N,Intermediate,15354.0,1.0,626.0,6988.0,,,
,1.0,F,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619377,,9606.0,,,N,Intermediate,13978.0,1.0,626.0,6989.0,,,
,1.0,F,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL619378,,9606.0,,,N,Intermediate,6798.0,1.0,626.0,6990.0,,,
,1.0,A,Tmax value after administration of 4 mg/Kg oral dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL872527,In vivo,9615.0,,,N,Intermediate,2959.0,1.0,,6991.0,,,
,1.0,A,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876500,,9615.0,,,N,Intermediate,9932.0,1.0,,6992.0,,,
,1.0,A,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619379,,9615.0,,,N,Intermediate,5546.0,1.0,,6993.0,,,
,1.0,A,Volume distribution after 15 mg/kg iv dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619538,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6994.0,,,
,1.0,A,Volume distribution after 30 mg/kg po dose in Dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619539,In vivo,9615.0,,,N,Intermediate,16907.0,1.0,,6995.0,,,
,1.0,A,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619540,In vivo,9615.0,,,N,Intermediate,4257.0,1.0,,6996.0,,,
,1.0,A,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619541,In vivo,9615.0,,,N,Intermediate,4305.0,1.0,,6997.0,,,
,1.0,A,Volume of distribution was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619542,In vivo,9615.0,,,N,Intermediate,5472.0,1.0,,6998.0,,,
,1.0,A,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619543,In vivo,9615.0,,,N,Intermediate,6062.0,1.0,,6999.0,,,
,1.0,A,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619544,,9615.0,,,N,Expert,3598.0,1.0,,7000.0,,,
,1.0,A,The compound was tested for volume of distribution in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619545,In vivo,9615.0,,,N,Intermediate,12500.0,1.0,,7001.0,,,
,1.0,A,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619546,In vivo,9615.0,,,N,Intermediate,12500.0,1.0,,7002.0,,,
,1.0,A,Vd (1 mg/kg) was determined in dog (in vivo),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619547,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,7003.0,,,
,1.0,A,Vd in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619548,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,7004.0,,,
,1.0,A,Volume distribution was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619549,In vivo,9615.0,,,N,Intermediate,4219.0,1.0,,7005.0,,,
,1.0,A,Volume of distribution in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619550,In vivo,9615.0,,,N,Intermediate,1696.0,1.0,,7006.0,,,
,1.0,A,Volume of distribution by as 4 fold increase by iv administration in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876501,In vivo,9615.0,,,N,Intermediate,5542.0,1.0,,7007.0,,,
,1.0,A,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619551,In vivo,9615.0,,,N,Intermediate,5199.0,1.0,,7008.0,,,
,1.0,A,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619552,In vivo,9615.0,,,N,Intermediate,6348.0,1.0,,7009.0,,,
,1.0,A,Volume distribution at the dose of 2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619553,In vivo,9615.0,,,N,Intermediate,4727.0,1.0,,7010.0,,,
,1.0,A,Steady state volume of distribution was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618722,In vivo,9615.0,,,N,Intermediate,16367.0,1.0,,7011.0,,,
,1.0,A,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618723,In vivo,9615.0,,,N,Intermediate,2652.0,1.0,,7012.0,,,
,1.0,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618724,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7013.0,,,
,1.0,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618725,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7014.0,,,
,1.0,A,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618726,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7015.0,,,
,1.0,A,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618727,In vivo,9615.0,,,N,Intermediate,5334.0,1.0,,7016.0,,,
,1.0,A,Pharmacokinetic property (vdss) was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624233,In vivo,9615.0,,,N,Intermediate,4239.0,1.0,,7017.0,,,
,1.0,A,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624234,In vivo,9615.0,,,N,Intermediate,4709.0,1.0,,7018.0,,,
,1.0,A,Vdss was determined after iv 0.1 mg/kg administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624235,In vivo,9615.0,,,N,Intermediate,5600.0,1.0,,7019.0,,,
,1.0,A,Volume displacement was calculated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624236,In vivo,9615.0,,,N,Intermediate,6057.0,1.0,,7020.0,,,
,1.0,A,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624237,In vivo,9615.0,,,N,Intermediate,5654.0,1.0,,7021.0,,,
,1.0,A,Volume distribution constant was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624238,In vivo,9615.0,,,N,Intermediate,5505.0,1.0,,7022.0,,,
,1.0,A,Volume distribution at a dose of 1 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624239,In vivo,9615.0,,,N,Intermediate,4527.0,1.0,,7023.0,,,
,1.0,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875829,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,7024.0,,,
,1.0,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624240,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,7025.0,,,
,1.0,A,Volume distribution (Vdss) was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624241,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,7026.0,,,
,1.0,A,Volume distribution (Vdss) was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624242,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,7027.0,,,
,1.0,A,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624243,In vivo,9615.0,,,N,Intermediate,6679.0,1.0,,7028.0,,,
,1.0,A,Volume of distribution in steady state was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624244,In vivo,9615.0,,,N,Intermediate,5145.0,1.0,,7029.0,,,
,1.0,A,Volume of distribution of compound was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624245,In vivo,9615.0,,,N,Intermediate,6821.0,1.0,,7030.0,,,
,1.0,A,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624246,In vivo,9615.0,,,N,Intermediate,4137.0,1.0,,7031.0,,,
,1.0,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624247,In vivo,9615.0,,,N,Intermediate,5334.0,1.0,,7032.0,,,
,1.0,A,Volume of distribution (Vdss) was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624248,In vivo,9615.0,,,N,Intermediate,15660.0,1.0,,7033.0,,,
,1.0,A,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624249,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,7034.0,,,
,1.0,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624250,In vivo,9615.0,,,N,Intermediate,6641.0,1.0,,7035.0,,,
,1.0,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624251,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,7036.0,,,
,1.0,A,Maximum rate of depolarization of the upstroke of the action potential,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624252,,9615.0,,,N,Intermediate,11659.0,1.0,,7037.0,,,
,1.0,A,Steady state volume distribution in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624253,In vivo,9615.0,,,N,Intermediate,6448.0,1.0,,7038.0,,,
,1.0,A,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624950,In vivo,9615.0,,,N,Intermediate,5474.0,1.0,,7039.0,,,
,1.0,A,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624951,In vivo,9615.0,,,N,Intermediate,1466.0,1.0,,7040.0,,,
,1.0,A,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875830,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,7041.0,,,
,1.0,A,Volume distribution in dog after administration of 1 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624952,In vivo,9615.0,,,N,Intermediate,6535.0,1.0,,7042.0,,,
,1.0,A,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624953,In vivo,9615.0,,,N,Intermediate,17764.0,1.0,,7043.0,,,
,1.0,A,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624954,In vivo,9615.0,,,N,Intermediate,6215.0,1.0,,7044.0,,,
,1.0,A,Vss on i.v. administration of 2 mg/kg was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624955,In vivo,9615.0,,,N,Intermediate,6505.0,1.0,,7045.0,,,
,1.0,A,Vss was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624956,,9615.0,,,N,Intermediate,3639.0,1.0,,7046.0,,,
,1.0,A,Vss in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625129,,9615.0,,,N,Intermediate,3639.0,1.0,,7047.0,,,
,1.0,A,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625130,In vivo,9615.0,,,N,Intermediate,6062.0,1.0,,7048.0,,,
,1.0,A,Volume distribution in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625131,In vivo,9615.0,,,N,Intermediate,4942.0,1.0,,7049.0,,,
,1.0,A,Volume of distribution in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625132,In vivo,9615.0,,,N,Intermediate,17796.0,1.0,,7050.0,,,
,1.0,A,Tested for the oral bioavailability in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL872263,In vivo,9615.0,,,N,Intermediate,4883.0,1.0,,7051.0,,,
,1.0,A,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624336,In vivo,10090.0,,,N,Intermediate,17837.0,1.0,,7060.0,,,
,1.0,A,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624337,In vivo,10090.0,,,N,Intermediate,17729.0,1.0,,7061.0,,,
,1.0,A,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624338,In vivo,10090.0,,,N,Intermediate,17729.0,1.0,,7062.0,,,
,1.0,A,Bioavailability was measured in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624339,In vivo,10090.0,,,N,Intermediate,4239.0,1.0,,7063.0,,,
,1.0,A,Bioavailability in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624340,In vivo,10090.0,,,N,Intermediate,17592.0,1.0,,7064.0,,,
,1.0,A,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624341,In vivo,10090.0,,,N,Intermediate,6348.0,1.0,,7065.0,,,
,1.0,A,Bioavailability in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624342,In vivo,10090.0,,,N,Intermediate,2801.0,1.0,,7066.0,,,
,1.0,A,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624343,In vivo,10090.0,,,N,Intermediate,2801.0,1.0,,7067.0,,,
,1.0,A,Oral bioavailability in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624344,In vivo,10090.0,,,N,Intermediate,17718.0,1.0,,7068.0,,,
,1.0,A,Oral availability at 50 mg/kg po in male mice,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624345,In vivo,10090.0,,,N,Intermediate,5727.0,1.0,,7069.0,,,
,1.0,A,Oral bioavailability in mouse (dose 10 mg/kg),,,50594.0,BAO_0000218,Mus musculus,CHEMBL624346,In vivo,10090.0,,,N,Intermediate,5302.0,1.0,,7070.0,,,
,1.0,A,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624347,In vivo,10090.0,,,N,Expert,3598.0,1.0,,7071.0,,,
,1.0,A,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,50594.0,BAO_0000218,Mus musculus,CHEMBL624348,In vivo,10090.0,,,N,Intermediate,5961.0,1.0,,7072.0,,,
,1.0,A,Oral bioavailability in mouse,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622754,In vivo,10090.0,,,N,Intermediate,6091.0,1.0,,7074.0,,,
,1.0,A,Oral bioavailability in vivo in mice;ND=Not determined,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622755,In vivo,10090.0,,,N,Intermediate,6091.0,1.0,,7075.0,,,
,1.0,A,Oral bioavailability in mouse at 10 mg/kg of the compound,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622756,In vivo,10090.0,,,N,Intermediate,5711.0,1.0,,7076.0,,,
,1.0,A,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,50594.0,BAO_0000218,Mus musculus,CHEMBL622757,In vivo,10090.0,,,N,Intermediate,17728.0,1.0,,7077.0,,,
,1.0,A,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,50594.0,BAO_0000218,Mus musculus,CHEMBL622758,In vivo,10090.0,,,N,Intermediate,17728.0,1.0,,7078.0,,,
,1.0,A,Tested for bioavailability of the compound,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622759,In vivo,10090.0,,,N,Intermediate,3802.0,1.0,,7079.0,,,
,1.0,A,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622760,In vivo,10090.0,,,N,Intermediate,3802.0,1.0,,7080.0,,,
Plasma,1.0,A,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622761,,10090.0,1969.0,,N,Intermediate,14029.0,1.0,,7081.0,,,
Plasma,1.0,A,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622762,,10090.0,1969.0,,N,Intermediate,14029.0,1.0,,7082.0,,,
Plasma,1.0,A,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622763,,10090.0,1969.0,,N,Intermediate,14029.0,1.0,,7083.0,,,
Plasma,1.0,A,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622764,,10090.0,1969.0,,N,Intermediate,14029.0,1.0,,7084.0,,,
Plasma,1.0,A,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622765,,10090.0,1969.0,,N,Intermediate,14029.0,1.0,,7085.0,,,
,1.0,F,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622766,,10090.0,,,N,Intermediate,17753.0,1.0,,7086.0,,,
,1.0,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622767,,10090.0,,,N,Intermediate,17753.0,1.0,,7087.0,,,
,1.0,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622768,,10090.0,,,N,Intermediate,17753.0,1.0,,7088.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875948,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7089.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622769,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7090.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622770,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7091.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622771,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7092.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622772,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7093.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622773,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7094.0,,,
Blood,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL622774,In vivo,10090.0,178.0,,N,Intermediate,10107.0,1.0,,7095.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621725,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7096.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621726,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7097.0,,,
,1.0,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621727,,9606.0,,,N,Intermediate,15608.0,1.0,478.0,7098.0,,,
,1.0,F,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622413,,9606.0,,,N,Expert,3290.0,1.0,478.0,7099.0,,,
,1.0,F,Compound was evaluated for cytotoxicity against A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622414,,9606.0,,,N,Intermediate,2859.0,1.0,478.0,7100.0,,,
,1.0,F,Inhibition of A2780 cell clonogenic assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622415,,9606.0,,,N,Expert,15688.0,1.0,478.0,7101.0,,,
,1.0,F,Cytotoxic effect on ovarian cancer cell line (A2780),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL884001,,9606.0,,,N,Expert,5642.0,1.0,478.0,7102.0,,,
,1.0,F,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622416,,9606.0,,,N,Intermediate,6633.0,1.0,478.0,7103.0,,,
,1.0,F,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622417,,9606.0,,,N,Intermediate,3906.0,1.0,478.0,7104.0,,,
,1.0,F,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622590,,9606.0,,,N,Expert,6788.0,1.0,478.0,7105.0,,,
,1.0,F,Antiproliferative activity against human A2780 cells,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622591,,9606.0,,,N,Expert,17582.0,1.0,478.0,7106.0,,,
,1.0,F,Inhibition of human A2780 cell proliferation,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622592,,9606.0,,,N,Expert,17764.0,1.0,478.0,7107.0,,,
,1.0,F,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622593,,9606.0,,,N,Expert,17764.0,1.0,478.0,7108.0,,,
,1.0,F,Inhibition of human A2780 cell proliferation (No data),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622594,,9606.0,,,N,Expert,17764.0,1.0,478.0,7109.0,,,
,1.0,F,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622595,,9606.0,,,N,Intermediate,2815.0,1.0,478.0,7110.0,,,
,1.0,F,Compound was evaluated against human Ovarian carcinoma cell line A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622596,,9606.0,,,N,Intermediate,16930.0,1.0,478.0,7111.0,,,
,1.0,F,Growth inhibition against A2780 wild-type ovarian cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622597,,9606.0,,,N,Expert,17777.0,1.0,478.0,7112.0,,,
,1.0,F,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622598,,9606.0,,,N,Intermediate,17777.0,1.0,478.0,7113.0,,,
,1.0,F,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,104766.0,BAO_0000019,Homo sapiens,CHEMBL622599,,9606.0,,,D,Autocuration,16936.0,5.0,,7114.0,,,
,1.0,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622600,,9606.0,,,N,Intermediate,13759.0,1.0,478.0,7115.0,,,
,1.0,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622601,,9606.0,,,N,Intermediate,13759.0,1.0,478.0,7116.0,,,
,1.0,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622602,,9606.0,,,N,Intermediate,13759.0,1.0,478.0,7117.0,,,
,1.0,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622603,,9606.0,,,N,Intermediate,13759.0,1.0,478.0,7118.0,,,
,1.0,F,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622604,,9606.0,,,N,Intermediate,15292.0,1.0,478.0,7119.0,,,
,1.0,F,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622605,,9606.0,,,N,Intermediate,15292.0,1.0,478.0,7120.0,,,
,1.0,F,In vitro inhibition of human ovarian cell line A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622606,,9606.0,,,N,Expert,15069.0,1.0,478.0,7121.0,,,
,1.0,F,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619463,,9606.0,,,N,Expert,15069.0,1.0,478.0,7122.0,,,
,1.0,F,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619464,,9606.0,,,N,Intermediate,14073.0,1.0,478.0,7123.0,,,
,1.0,F,Concentration required to inhibit A2780-cell growth by 50%,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619465,,9606.0,,,N,Expert,14553.0,1.0,478.0,7124.0,,,
,1.0,F,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619466,,9606.0,,,N,Expert,13040.0,1.0,478.0,7125.0,,,
,1.0,F,Cytotoxic effect on human ovarian (A2780) cancer cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619467,,9606.0,,,N,Expert,6891.0,1.0,478.0,7126.0,,,
,1.0,F,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619468,,9606.0,,,N,Intermediate,15569.0,1.0,478.0,7127.0,,,
,1.0,F,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619469,,9606.0,,,N,Expert,14190.0,1.0,478.0,7128.0,,,
,1.0,F,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619470,,9606.0,,,N,Expert,15014.0,1.0,478.0,7129.0,,,
,1.0,F,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619471,,9606.0,,,N,Intermediate,15014.0,1.0,478.0,7130.0,,,
,1.0,F,Cytotoxicity against human ovarian carcinoma A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619472,,9606.0,,,N,Intermediate,17496.0,1.0,478.0,7131.0,,,
,1.0,F,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL619473,,9606.0,,,N,Intermediate,13617.0,1.0,478.0,7132.0,,,
,1.0,F,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL874368,,9606.0,,,N,Intermediate,13617.0,1.0,478.0,7133.0,,,
,1.0,F,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL884003,,9606.0,,,N,Intermediate,13617.0,1.0,478.0,7134.0,,,
,1.0,F,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622690,,9606.0,,,N,Intermediate,13617.0,1.0,478.0,7135.0,,,
,1.0,F,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622691,,9606.0,,,N,Intermediate,17672.0,1.0,478.0,7136.0,,,
,1.0,F,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL622692,,9606.0,,,N,Intermediate,4544.0,1.0,478.0,7137.0,,,
,1.0,F,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623406,,9606.0,,,N,Intermediate,4544.0,1.0,478.0,7138.0,,,
,1.0,F,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL884004,,9606.0,,,N,Intermediate,16317.0,1.0,478.0,7139.0,,,
,1.0,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623407,,9606.0,,,N,Intermediate,15099.0,1.0,478.0,7140.0,,,
,1.0,F,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623408,,9606.0,,,N,Intermediate,13978.0,1.0,478.0,7141.0,,,
,1.0,F,In vitro antitumor activity against A2780 cell line.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623409,,9606.0,,,N,Expert,12989.0,1.0,478.0,7142.0,,,
,1.0,F,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623410,,9606.0,,,N,Intermediate,5574.0,1.0,478.0,7143.0,,,
,1.0,F,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL623576,,9606.0,,,N,Expert,13528.0,1.0,478.0,7144.0,,,
,1.0,F,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623577,,9606.0,,,N,Intermediate,12782.0,1.0,626.0,7145.0,,,
,1.0,F,The IC50 value was measured on ACHN cell line in renal tumor type.,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623578,,9606.0,,,N,Intermediate,14255.0,1.0,626.0,7146.0,,,
,1.0,F,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623579,,9606.0,,,N,Intermediate,16364.0,1.0,626.0,7147.0,,,
,1.0,F,In vitro lethal concentration against most sensitive ACHN cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623580,,9606.0,,,N,Expert,17376.0,1.0,626.0,7148.0,,,
,1.0,F,Tested for cytotoxic activity against renal cancer ACHN cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623581,,9606.0,,,N,Intermediate,12016.0,1.0,626.0,7149.0,,,
,1.0,F,Compound tested for growth inhibition of renal cancer cell line ACHN,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL857456,,9606.0,,,N,Intermediate,6058.0,1.0,626.0,7150.0,,,
,1.0,F,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623582,,9606.0,,,N,Intermediate,17708.0,1.0,626.0,7151.0,,,
,1.0,F,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623583,,9606.0,,,N,Intermediate,15176.0,1.0,626.0,7152.0,,,
,1.0,F,In vitro anticancer activity against ACHN renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623584,,9606.0,,,N,Intermediate,2806.0,1.0,626.0,7153.0,,,
,1.0,F,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623585,,9606.0,,,N,Intermediate,15300.0,1.0,626.0,7154.0,,,
,1.0,F,Percent selectivity was evaluated in renal ACHN cell lines,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623586,,9606.0,,,N,Intermediate,16364.0,1.0,626.0,7155.0,,,
,1.0,F,In vitro inhibitory activity against renal ACHN cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623587,,9606.0,,,N,Intermediate,13859.0,1.0,626.0,7156.0,,,
,1.0,F,Tested for cytotoxicity against ACHN cell lines in renal cancer,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL875279,,9606.0,,,N,Intermediate,11970.0,1.0,626.0,7157.0,,,
,1.0,F,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623588,,9606.0,,,N,Intermediate,2450.0,1.0,626.0,7158.0,,,
,1.0,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623589,,9606.0,,,N,Intermediate,12696.0,1.0,626.0,7159.0,,,
,1.0,F,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623590,,9606.0,,,N,Intermediate,12400.0,1.0,626.0,7160.0,,,
,1.0,F,Cytotoxic effect on renal cancer line ACHN,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623591,,9606.0,,,N,Expert,12888.0,1.0,626.0,7161.0,,,
,1.0,F,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623592,,9606.0,,,N,Intermediate,3156.0,1.0,626.0,7162.0,,,
,1.0,F,In vitro inhibition of Renal Cancer ACHN cell lines,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623593,,9606.0,,,N,Intermediate,3381.0,1.0,626.0,7163.0,,,
,1.0,F,Antitumor activity against human renal adenocarcinoma ACHN cells,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL623594,,9606.0,,,N,Intermediate,16747.0,1.0,626.0,7164.0,,,
,1.0,F,Antitumor activity against human renal adenocarcinoma ACHN cells.,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621833,,9606.0,,,N,Expert,16748.0,1.0,626.0,7165.0,,,
,1.0,F,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621834,,9606.0,,,N,Intermediate,12062.0,1.0,626.0,7166.0,,,
,1.0,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621835,,9606.0,,,N,Intermediate,14769.0,1.0,626.0,7167.0,,,
,1.0,F,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621836,,9606.0,,,N,Intermediate,15895.0,1.0,626.0,7168.0,,,
,1.0,F,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621837,,9606.0,,,N,Intermediate,17376.0,1.0,626.0,7169.0,,,
,1.0,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL875280,,9606.0,,,N,Intermediate,14882.0,1.0,626.0,7170.0,,,
,1.0,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621838,,9606.0,,,N,Intermediate,14882.0,1.0,626.0,7171.0,,,
,1.0,F,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,ACHN,80025.0,BAO_0000219,Homo sapiens,CHEMBL621839,,9606.0,,,N,Intermediate,15661.0,1.0,626.0,7172.0,,,
,1.0,A,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,22224.0,BAO_0000019,,CHEMBL621840,,,,,U,Autocuration,9680.0,0.0,,7173.0,,,
,1.0,F,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,10647.0,BAO_0000019,,CHEMBL621841,,,,,H,Autocuration,14579.0,8.0,,7174.0,,,
,1.0,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,HEL,50529.0,BAO_0000218,Cytomegalovirus,CHEMBL622979,,10358.0,,,N,Expert,17290.0,1.0,468.0,7175.0,,,
,1.0,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,50529.0,BAO_0000218,Cytomegalovirus,CHEMBL876595,,10358.0,,,N,Intermediate,17290.0,1.0,,7176.0,,,
,1.0,B,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,12159.0,BAO_0000357,,CHEMBL620221,,,,,H,Autocuration,15891.0,8.0,,7177.0,,,
,1.0,B,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,12159.0,BAO_0000357,,CHEMBL620222,,,,,H,Autocuration,15890.0,8.0,,7178.0,,,
,1.0,F,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,ADDP cell line,80670.0,BAO_0000219,Bos taurus,CHEMBL620506,,9913.0,,,N,Intermediate,3801.0,1.0,979.0,7179.0,,,
,1.0,F,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620507,,10090.0,,,N,Intermediate,9222.0,1.0,980.0,7180.0,,,
,1.0,F,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620508,,10090.0,,,N,Intermediate,9222.0,1.0,980.0,7181.0,,,
,1.0,F,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620509,,10090.0,,,N,Intermediate,7257.0,1.0,980.0,7182.0,,,
,1.0,F,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620510,,10090.0,,,N,Intermediate,7257.0,1.0,980.0,7183.0,,,
,1.0,A,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620511,,10090.0,,,N,Intermediate,7257.0,1.0,980.0,7184.0,,,
,1.0,F,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,ADJ/PC6,80671.0,BAO_0000219,Mus musculus,CHEMBL620512,,10090.0,,,N,Intermediate,8084.0,1.0,980.0,7185.0,,,
,1.0,F,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,22224.0,BAO_0000019,Mus musculus,CHEMBL620513,,10090.0,,,U,Autocuration,14943.0,0.0,,7186.0,,,
,1.0,F,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,22224.0,BAO_0000019,Mus musculus,CHEMBL620514,,10090.0,,,U,Autocuration,14943.0,0.0,,7187.0,,,
,1.0,F,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,22224.0,BAO_0000019,Mus musculus,CHEMBL620515,,10090.0,,,U,Autocuration,14943.0,0.0,,7188.0,,,
,1.0,A,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,22224.0,BAO_0000218,Bacillus subtilis,CHEMBL620516,In vivo,1423.0,,,U,Autocuration,10524.0,0.0,,7189.0,,,
Plasma,1.0,A,AUC value in dog after IV administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620517,,9615.0,1969.0,,N,Intermediate,3546.0,1.0,,7190.0,,,
Plasma,1.0,A,AUC value in dog after oral administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620518,,9615.0,1969.0,,N,Intermediate,3546.0,1.0,,7191.0,,,
,1.0,A,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL620519,In vivo,9615.0,,,N,Intermediate,3546.0,1.0,,7192.0,,,
,1.0,A,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621386,In vivo,9615.0,,,N,Intermediate,3546.0,1.0,,7193.0,,,
,1.0,A,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621387,In vivo,9615.0,,,N,Intermediate,3546.0,1.0,,7194.0,,,
,1.0,A,Compound was evaluated for its clearance when administered intravenously in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621388,In vivo,9615.0,,,N,Intermediate,3184.0,1.0,,7195.0,,,
,1.0,A,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621389,In vivo,9615.0,,,N,Intermediate,16456.0,1.0,,7196.0,,,
,1.0,A,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621390,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,7197.0,,,
,1.0,P,Calculated partition coefficient (clogP),,,22229.0,BAO_0000100,,CHEMBL621391,,,,,U,Intermediate,4219.0,0.0,,7198.0,,,
,1.0,A,Half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621392,,9615.0,,,N,Intermediate,3748.0,1.0,,7199.0,,,
,1.0,A,Time taken for EC90 was determined when tested in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621393,,9615.0,,,N,Intermediate,3132.0,1.0,,7200.0,,,
,1.0,A,Half life (iv) was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621394,,9615.0,,,N,Intermediate,4219.0,1.0,,7201.0,,,
Liver,1.0,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621395,,9615.0,2107.0,,N,Intermediate,16907.0,1.0,,7202.0,,,
,1.0,A,Area under the curve was calculated in dog after iv administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621396,,9615.0,,,N,Intermediate,6057.0,1.0,,7203.0,,,
,1.0,A,Area under the curve was calculated in dog after peroral administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621397,,9615.0,,,N,Intermediate,6057.0,1.0,,7204.0,,,
,1.0,A,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621398,,9615.0,,,N,Intermediate,17853.0,1.0,,7205.0,,,
,1.0,A,pKa was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618818,,9615.0,,,N,Intermediate,3639.0,1.0,,7206.0,,,
,1.0,A,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618819,,9615.0,,,N,Intermediate,14541.0,1.0,,7207.0,,,
,1.0,A,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618820,In vivo,9615.0,,,N,Intermediate,16456.0,1.0,,7208.0,,,
,1.0,A,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873810,In vivo,9615.0,,,N,Intermediate,16456.0,1.0,,7209.0,,,
,1.0,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876606,In vivo,9615.0,,,N,Intermediate,2652.0,1.0,,7210.0,,,
,1.0,A,Compound was evaluated for the half-life (t 1/2) in hours,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618821,,9615.0,,,N,Intermediate,3624.0,1.0,,7211.0,,,
Blood,1.0,A,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618822,In vivo,9615.0,178.0,,N,Intermediate,1337.0,1.0,,7212.0,,,
Blood,1.0,A,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618823,In vivo,9615.0,178.0,,N,Intermediate,1337.0,1.0,,7213.0,,,
,1.0,A,Half life after intravenous administration of 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618824,In vivo,9615.0,,,N,Intermediate,4709.0,1.0,,7214.0,,,
,1.0,A,Half life was measured in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618825,,9615.0,,,N,Intermediate,15660.0,1.0,,7215.0,,,
,1.0,A,Half life period in dog after 5 mg/kg dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618826,In vivo,9615.0,,,N,Intermediate,5302.0,1.0,,7216.0,,,
,1.0,A,Half life period was evaluated in dog; 4-4.8,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618827,,9615.0,,,N,Intermediate,17791.0,1.0,,7217.0,,,
,1.0,A,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618828,In vivo,9615.0,,,N,Intermediate,6348.0,1.0,,7218.0,,,
,1.0,A,Half-life was determined in dog after a3 mg/kg of iv dose,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618829,In vivo,9615.0,,,N,Intermediate,4257.0,1.0,,7219.0,,,
,1.0,A,Half-life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618830,,9615.0,,,N,Intermediate,3771.0,1.0,,7220.0,,,
,1.0,A,Half life in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL618831,,9615.0,,,N,Intermediate,6305.0,1.0,,7221.0,,,
Plasma,1.0,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619489,In vivo,9615.0,1969.0,,N,Intermediate,13501.0,1.0,,7222.0,,,
,1.0,A,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619649,In vivo,9615.0,,,N,Intermediate,17594.0,1.0,,7223.0,,,
,1.0,A,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876607,In vivo,9615.0,,,N,Intermediate,3045.0,1.0,,7224.0,,,
,1.0,A,Compound was evaluated for the half life period after oral administration in conscious dog.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619650,In vivo,9615.0,,,N,Intermediate,3043.0,1.0,,7225.0,,,
,1.0,A,Compound was tested for half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619651,,9615.0,,,N,Intermediate,4839.0,1.0,,7226.0,,,
,1.0,A,Compound was tested for its half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619652,,9615.0,,,N,Intermediate,4839.0,1.0,,7227.0,,,
,1.0,A,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619653,In vivo,9615.0,,,N,Intermediate,5802.0,1.0,,7228.0,,,
,1.0,A,Half life of compound in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619654,,9615.0,,,N,Intermediate,17839.0,1.0,,7229.0,,,
,1.0,A,Half life (iv) was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619655,In vivo,9615.0,,,N,Intermediate,4219.0,1.0,,7230.0,,,
Blood,1.0,A,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619656,,9615.0,178.0,,N,Intermediate,13966.0,1.0,,7231.0,,,
Plasma,1.0,A,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873812,In vivo,9615.0,1969.0,,N,Intermediate,3994.0,1.0,,7232.0,,,
Plasma,1.0,F,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621365,In vivo,9615.0,1969.0,,N,Intermediate,3994.0,1.0,,7233.0,,,
,1.0,A,Half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621366,,9615.0,,,N,Intermediate,4453.0,1.0,,7234.0,,,
Plasma,1.0,A,Half life in dog plasma,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621367,,9615.0,1969.0,,N,Intermediate,6535.0,1.0,,7235.0,,,
Plasma,1.0,A,Half life in dog plasma after administration of 0.25 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621368,In vivo,9615.0,1969.0,,N,Intermediate,6535.0,1.0,,7236.0,,,
Plasma,1.0,A,Half life in dog plasma after administration of 1 mg/kg iv,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621369,In vivo,9615.0,1969.0,,N,Intermediate,6535.0,1.0,,7237.0,,,
Plasma,1.0,A,Half life in dog plasma was determined at dose 10 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621370,In vivo,9615.0,1969.0,,N,Intermediate,3132.0,1.0,,7238.0,,,
,1.0,A,Half life in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621371,,9615.0,,,N,Intermediate,5374.0,1.0,,7239.0,,,
,1.0,A,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621372,In vivo,9615.0,,,N,Intermediate,5007.0,1.0,,7240.0,,,
Plasma,1.0,A,Half life upon exposure to human plasma,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621373,,9615.0,1969.0,,N,Intermediate,16907.0,1.0,,7241.0,,,
,1.0,A,Half life was calculated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621374,,9615.0,,,N,Intermediate,6057.0,1.0,,7242.0,,,
,1.0,A,Half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621375,,9615.0,,,N,Intermediate,5006.0,1.0,,7243.0,,,
,1.0,A,Half life was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621376,,9615.0,,,N,Intermediate,5473.0,1.0,,7244.0,,,
,1.0,A,Half life by intravenous administration of 1.2 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619624,In vivo,9615.0,,,N,Intermediate,4368.0,1.0,,7245.0,,,
,1.0,A,Half life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL875840,,9615.0,,,N,Intermediate,6448.0,1.0,,7246.0,,,
,1.0,A,Half life in dog after intra venous administration of the compound,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619625,,9615.0,,,N,Intermediate,4353.0,1.0,,7247.0,,,
,1.0,A,Half life in dog after intra venous administration of the compound; ND means Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619626,,9615.0,,,N,Intermediate,4353.0,1.0,,7248.0,,,
,1.0,A,Half life in dog after po administration of the compound,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619627,In vivo,9615.0,,,N,Intermediate,4353.0,1.0,,7249.0,,,
,1.0,A,Half life in dog after po administration of the compound; ND means Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873817,In vivo,9615.0,,,N,Intermediate,4353.0,1.0,,7250.0,,,
,1.0,A,Half life in dog at the single oral dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619628,In vivo,9615.0,,,N,Intermediate,6265.0,1.0,,7251.0,,,
,1.0,A,Half life in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619629,,9615.0,,,N,Intermediate,5006.0,1.0,,7252.0,,,
,1.0,A,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619630,In vivo,9615.0,,,N,Intermediate,5356.0,1.0,,7253.0,,,
,1.0,A,Half life in rat,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619631,,9615.0,,,N,Intermediate,405.0,1.0,,7254.0,,,
,1.0,A,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL619632,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,7255.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619633,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7256.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875841,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7257.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619634,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7258.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619635,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7259.0,,,
Bone,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619636,In vivo,10090.0,10000001.0,,N,Intermediate,10107.0,1.0,,7260.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619637,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7261.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619638,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7262.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619639,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7263.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619640,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7264.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619641,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7265.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619642,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7266.0,,,
Gut,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619643,In vivo,10090.0,10000004.0,,N,Intermediate,10107.0,1.0,,7267.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL619644,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7268.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621112,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7269.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621113,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7270.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621114,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7271.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621115,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7272.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621116,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7273.0,,,
Heart,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621117,In vivo,10090.0,948.0,,N,Intermediate,10107.0,1.0,,7274.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621118,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7275.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621119,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7276.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621120,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7277.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621757,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7278.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621758,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7279.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621759,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7280.0,,,
Kidney,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621760,In vivo,10090.0,2113.0,,N,Intermediate,10107.0,1.0,,7281.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621761,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7282.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621762,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7283.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL621763,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7284.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624502,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7285.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624503,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7286.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624504,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7287.0,,,
Liver,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624505,In vivo,10090.0,2107.0,,N,Intermediate,10107.0,1.0,,7288.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624506,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7289.0,,,
,1.0,F,In vitro cytotoxicity against A2780 (human ovarian cancer),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624507,,9606.0,,,N,Intermediate,5895.0,1.0,478.0,7290.0,,,
,1.0,F,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624508,,9606.0,,,N,Intermediate,6338.0,1.0,478.0,7291.0,,,
,1.0,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624509,,9606.0,,,N,Intermediate,15163.0,1.0,478.0,7292.0,,,
,1.0,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624510,,9606.0,,,N,Intermediate,15163.0,1.0,478.0,7293.0,,,
,1.0,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL875956,,9606.0,,,N,Expert,15000.0,1.0,478.0,7294.0,,,
,1.0,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL839885,,9606.0,,,N,Expert,15000.0,1.0,478.0,7295.0,,,
,1.0,F,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624511,,9606.0,,,N,Expert,14729.0,1.0,478.0,7296.0,,,
,1.0,F,In vitro cytotoxicity against A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624512,,9606.0,,,N,Intermediate,17270.0,1.0,478.0,7297.0,,,
,1.0,F,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624513,,9606.0,,,N,Intermediate,5685.0,1.0,478.0,7298.0,,,
,1.0,F,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL624514,,9606.0,,,N,Intermediate,3563.0,1.0,478.0,7299.0,,,
,1.0,F,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL618547,,9606.0,,,N,Intermediate,17753.0,1.0,478.0,7300.0,,,
,1.0,F,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618548,,9606.0,,,N,Intermediate,16317.0,1.0,478.0,7301.0,,,
,1.0,F,Inhibition of tubulin polymerization in analogy of ca.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618549,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7302.0,,,
,1.0,F,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618550,,9606.0,,,N,Intermediate,3801.0,1.0,478.0,7303.0,,,
,1.0,F,Cytotoxic effect in ovarian cancer cell line (A2780),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618551,,9606.0,,,N,Expert,6181.0,1.0,478.0,7304.0,,,
,1.0,F,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618552,,9606.0,,,N,Intermediate,5318.0,1.0,478.0,7305.0,,,
,1.0,F,Tested for the cytotoxicity in A2780 ovarian cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618553,,9606.0,,,N,Intermediate,4840.0,1.0,478.0,7306.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618554,,9606.0,,,N,Intermediate,15748.0,1.0,478.0,7307.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618555,,9606.0,,,N,Intermediate,15748.0,1.0,478.0,7308.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,A2780cisR,80017.0,BAO_0000219,,CHEMBL618556,,,,,N,Intermediate,15748.0,1.0,481.0,7309.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,A2780cisR,80017.0,BAO_0000219,,CHEMBL618557,,,,,N,Intermediate,15748.0,1.0,481.0,7310.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,A2780cisR,80017.0,BAO_0000219,,CHEMBL618558,,,,,N,Intermediate,15748.0,1.0,481.0,7311.0,,,
,1.0,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,A2780cisR,80017.0,BAO_0000219,,CHEMBL618559,,,,,N,Intermediate,15748.0,1.0,481.0,7312.0,,,
,1.0,F,In vivo log of cells killed after administration of compound in A2780 cell line,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL618560,,9606.0,,,N,Intermediate,17753.0,1.0,478.0,7313.0,,,
,1.0,F,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL618561,In vivo,9606.0,,,N,Intermediate,17753.0,1.0,478.0,7314.0,,,
,1.0,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618562,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7315.0,,,
,1.0,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618563,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7316.0,,,
,1.0,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618564,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7317.0,,,
,1.0,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618565,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7318.0,,,
,1.0,F,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,A2780,81034.0,BAO_0000218,Homo sapiens,CHEMBL618566,,9606.0,,,N,Intermediate,17528.0,1.0,478.0,7319.0,,,
,1.0,F,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618567,,9606.0,,,N,Intermediate,6633.0,1.0,478.0,7320.0,,,
,1.0,F,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618568,,9606.0,,,N,Expert,15000.0,1.0,478.0,7321.0,,,
,1.0,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL618569,,9606.0,,,N,Expert,17528.0,1.0,478.0,7322.0,,,
,1.0,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621857,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7323.0,,,
,1.0,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621858,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7324.0,,,
,1.0,F,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621859,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7325.0,,,
,1.0,F,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621860,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7326.0,,,
,1.0,F,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621861,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7327.0,,,
,1.0,F,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621862,,9606.0,,,N,Expert,16936.0,1.0,478.0,7328.0,,,
,1.0,F,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621863,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7329.0,,,
,1.0,F,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621864,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7330.0,,,
,1.0,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621865,,9606.0,,,N,Intermediate,16936.0,1.0,478.0,7331.0,,,
,1.0,F,In vitro antiproliferative activity against A2780 cell line,,A2780,81034.0,BAO_0000219,Mus musculus,CHEMBL621866,,10090.0,,,N,Intermediate,17737.0,1.0,478.0,7332.0,,,
,1.0,F,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,A2780,81034.0,BAO_0000219,Mus musculus,CHEMBL621867,,10090.0,,,N,Expert,17764.0,1.0,478.0,7333.0,,,
,1.0,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL621868,,9606.0,,,N,Intermediate,3830.0,1.0,478.0,7334.0,,,
,1.0,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,A2780,81034.0,BAO_0000219,Homo sapiens,CHEMBL875282,,9606.0,,,N,Intermediate,3829.0,1.0,478.0,7335.0,,,
,1.0,A,Vc value in dog after IV administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621869,,9615.0,,,N,Intermediate,3546.0,1.0,,7336.0,,,
,1.0,A,Half life period in dog after IV administration at a dose of 5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621870,In vivo,9615.0,,,N,Intermediate,3546.0,1.0,,7337.0,,,
,1.0,A,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621871,,9527.0,,,U,Autocuration,5668.0,0.0,,7338.0,,,
Plasma,1.0,A,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621243,,9527.0,1969.0,,U,Autocuration,3443.0,0.0,,7339.0,,,
Plasma,1.0,A,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621244,,9527.0,1969.0,,U,Autocuration,3443.0,0.0,,7340.0,,,
,1.0,A,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL621245,In vivo,9541.0,,,U,Autocuration,4256.0,0.0,,7341.0,,,
,1.0,A,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL621246,In vivo,9541.0,,,U,Autocuration,4256.0,0.0,,7342.0,,,
,1.0,A,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,22224.0,BAO_0000218,Macaca fascicularis,CHEMBL621247,In vivo,9541.0,,,U,Autocuration,4256.0,0.0,,7343.0,,,
,1.0,A,Oral Bioavailability in rat,,,22224.0,BAO_0000218,Rattus norvegicus,CHEMBL618386,In vivo,10116.0,,,U,Autocuration,4256.0,0.0,,7344.0,,,
,1.0,A,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618387,,9527.0,,,U,Autocuration,1916.0,0.0,,7345.0,,,
,1.0,A,Area under curve value in monkey at a dose of 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618388,,9527.0,,,U,Autocuration,5302.0,0.0,,7346.0,,,
,1.0,A,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618389,,9527.0,,,U,Autocuration,4257.0,0.0,,7347.0,,,
,1.0,A,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618574,,9527.0,,,U,Autocuration,5355.0,0.0,,7348.0,,,
,1.0,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618575,,9527.0,,,U,Autocuration,5355.0,0.0,,7349.0,,,
,1.0,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618576,,9527.0,,,U,Autocuration,5355.0,0.0,,7350.0,,,
,1.0,A,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618577,,9527.0,,,U,Autocuration,6078.0,0.0,,7351.0,,,
,1.0,A,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL876487,,9527.0,,,U,Autocuration,6078.0,0.0,,7352.0,,,
,1.0,A,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618578,,9527.0,,,U,Autocuration,6062.0,0.0,,7353.0,,,
,1.0,A,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618579,,9527.0,,,U,Autocuration,2661.0,0.0,,7354.0,,,
,1.0,A,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618580,,9527.0,,,U,Autocuration,2661.0,0.0,,7355.0,,,
,1.0,A,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618581,,9527.0,,,U,Autocuration,5394.0,0.0,,7356.0,,,
,1.0,A,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618582,,9527.0,,,U,Autocuration,4397.0,0.0,,7357.0,,,
,1.0,A,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618583,,9527.0,,,U,Autocuration,17509.0,0.0,,7358.0,,,
,1.0,A,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618584,,9527.0,,,U,Autocuration,17509.0,0.0,,7359.0,,,
,1.0,A,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618585,In vivo,9527.0,,,U,Autocuration,6641.0,0.0,,7360.0,,,
,1.0,A,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618586,,9527.0,,,U,Autocuration,5355.0,0.0,,7361.0,,,
,1.0,A,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618587,In vivo,9527.0,,,U,Autocuration,3443.0,0.0,,7362.0,,,
,1.0,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618588,In vivo,9527.0,,,U,Autocuration,3443.0,0.0,,7363.0,,,
,1.0,A,Binding towards monkey plasma protein at 10 uM,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618589,,9527.0,,,U,Autocuration,17409.0,0.0,,7364.0,,,
,1.0,A,Binding towards monkey plasma protein at 100 uM,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL618590,,9527.0,,,U,Autocuration,17409.0,0.0,,7365.0,,,
,1.0,A,Apparent bioavailability in squirrel monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL872262,In vivo,9527.0,,,U,Autocuration,1052.0,0.0,,7366.0,,,
,1.0,A,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618591,In vivo,9527.0,,,U,Autocuration,13501.0,0.0,,7367.0,,,
,1.0,A,Bioavailability in monkey (dose 2 mg/kg),,,22224.0,BAO_0000218,monkey,CHEMBL618592,In vivo,9443.0,,,U,Autocuration,17509.0,0.0,,7368.0,,,
,1.0,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL876488,In vivo,9527.0,,,U,Autocuration,5394.0,0.0,,7369.0,,,
,1.0,A,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618593,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,7370.0,,,
,1.0,A,Bioavailability in monkey (i.d. dosing),,,22224.0,BAO_0000218,monkey,CHEMBL618594,In vivo,9443.0,,,U,Autocuration,11219.0,0.0,,7371.0,,,
,1.0,A,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL618595,In vivo,9527.0,,,U,Autocuration,3045.0,0.0,,7372.0,,,
,1.0,A,Clearance of the drug was measured in cynomolgus,,,22224.0,BAO_0000019,Cercopithecidae,CHEMBL621469,,9527.0,,,U,Autocuration,17796.0,0.0,,7373.0,,,
,1.0,A,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621470,In vivo,9527.0,,,U,Autocuration,1399.0,0.0,,7374.0,,,
,1.0,A,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621471,In vivo,9527.0,,,U,Autocuration,2661.0,0.0,,7375.0,,,
Plasma,1.0,A,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,22224.0,BAO_0000218,Macaca mulatta,CHEMBL621472,In vivo,9544.0,1969.0,,U,Autocuration,5005.0,0.0,,7376.0,,,
,1.0,A,Plasma clearance in rhesus monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621473,In vivo,9527.0,,,U,Autocuration,17267.0,0.0,,7377.0,,,
,1.0,A,Plasma clearance in monkey after administration of 1 mg/kg iv,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621474,In vivo,9527.0,,,U,Autocuration,6535.0,0.0,,7378.0,,,
,1.0,A,Plasma clearance in cynomolgus monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621475,In vivo,9527.0,,,U,Autocuration,5922.0,0.0,,7379.0,,,
,1.0,A,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL621476,In vivo,9527.0,,,U,Autocuration,6221.0,0.0,,7380.0,,,
,1.0,A,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624290,In vivo,9527.0,,,U,Autocuration,5668.0,0.0,,7381.0,,,
,1.0,A,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624291,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,7382.0,,,
,1.0,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624292,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,7383.0,,,
,1.0,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624293,In vivo,9527.0,,,U,Autocuration,5355.0,0.0,,7384.0,,,
,1.0,A,Tested for Clearance upon iv administration to african green monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624294,In vivo,9527.0,,,U,Autocuration,4578.0,0.0,,7385.0,,,
,1.0,A,Clearance in monkey,,,22224.0,BAO_0000218,Cercopithecidae,CHEMBL624295,In vivo,9527.0,,,U,Autocuration,17592.0,0.0,,7386.0,,,
,1.0,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624296,In vivo,9615.0,,,N,Intermediate,6641.0,1.0,,7387.0,,,
,1.0,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624297,In vivo,9615.0,,,N,Intermediate,6642.0,1.0,,7388.0,,,
,1.0,A,Half life was evaluated after intravenous administration to dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624298,In vivo,9615.0,,,N,Intermediate,16367.0,1.0,,7389.0,,,
,1.0,A,Half life was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624299,,9615.0,,,N,Intermediate,5472.0,1.0,,7390.0,,,
,1.0,A,Half life was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624300,,9615.0,,,N,Intermediate,5474.0,1.0,,7391.0,,,
,1.0,A,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624301,In vivo,9615.0,,,N,Intermediate,5654.0,1.0,,7392.0,,,
,1.0,A,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624302,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,7393.0,,,
,1.0,A,Half life period after intravenous administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876026,In vivo,9615.0,,,N,Intermediate,6227.0,1.0,,7394.0,,,
,1.0,A,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624303,In vivo,9615.0,,,N,Intermediate,6221.0,1.0,,7395.0,,,
,1.0,A,Half life period at a dose of 1 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624304,,9615.0,,,N,Intermediate,4527.0,1.0,,7396.0,,,
,1.0,A,Half life period was determine after peroral administration at 10 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624305,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,7397.0,,,
,1.0,A,Half life period was determine after peroral administration at 5 mpk in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624306,In vivo,9615.0,,,N,Intermediate,5668.0,1.0,,7398.0,,,
,1.0,A,Half life period was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624307,,9615.0,,,N,Intermediate,3854.0,1.0,,7399.0,,,
,1.0,A,Half life period was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624308,,9615.0,,,N,Intermediate,5505.0,1.0,,7400.0,,,
,1.0,A,Half life period by iv administration in dog at a dose of 6 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624309,In vivo,9615.0,,,N,Intermediate,6251.0,1.0,,7401.0,,,
,1.0,A,Half life period was evaluated in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624310,,9615.0,,,N,Intermediate,1918.0,1.0,,7402.0,,,
,1.0,A,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625003,In vivo,9615.0,,,N,Intermediate,5546.0,1.0,,7403.0,,,
,1.0,A,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625004,In vivo,9615.0,,,N,Intermediate,4809.0,1.0,,7404.0,,,
,1.0,A,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625005,In vivo,9615.0,,,N,Intermediate,6215.0,1.0,,7405.0,,,
,1.0,A,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873813,In vivo,9615.0,,,N,Intermediate,4527.0,1.0,,7406.0,,,
,1.0,A,Half-life after oral dose of compound at 3 mg/kg in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625006,In vivo,9615.0,,,N,Intermediate,17594.0,1.0,,7407.0,,,
,1.0,A,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625007,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,7408.0,,,
,1.0,A,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876027,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,7409.0,,,
,1.0,A,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625008,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,7410.0,,,
,1.0,A,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625009,In vivo,9615.0,,,N,Intermediate,17839.0,1.0,,7411.0,,,
Plasma,1.0,A,Half-life of compound in plasma of dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625010,,9615.0,1969.0,,N,Intermediate,5210.0,1.0,,7412.0,,,
,1.0,A,Half-life of compound was determined in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL625011,,9615.0,,,N,Intermediate,5210.0,1.0,,7413.0,,,
,1.0,A,Half-life after administration of 4 mg/Kg oral dose in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621553,In vivo,9615.0,,,N,Intermediate,2959.0,1.0,,7414.0,,,
,1.0,A,Half-life after intravenous administration of 1 mg/kg/h in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621554,In vivo,9615.0,,,N,Intermediate,4137.0,1.0,,7415.0,,,
,1.0,A,Half-life in Dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621555,,9615.0,,,N,Intermediate,5064.0,1.0,,7416.0,,,
,1.0,A,Half-life in Dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621556,,9615.0,,,N,Intermediate,5147.0,1.0,,7417.0,,,
,1.0,A,Half-life in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621557,,9615.0,,,N,Intermediate,5145.0,1.0,,7418.0,,,
,1.0,A,Half-life in dog after oral administration at 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621558,In vivo,9615.0,,,N,Intermediate,6123.0,1.0,,7419.0,,,
,1.0,A,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621559,In vivo,9615.0,,,N,Intermediate,6123.0,1.0,,7420.0,,,
,1.0,A,Half-life in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621560,,9615.0,,,N,Intermediate,4333.0,1.0,,7421.0,,,
,1.0,A,Half-life in dogs; ND indicates not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL876028,,9615.0,,,N,Intermediate,4333.0,1.0,,7422.0,,,
Plasma,1.0,A,Half-life in plasma of dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621561,,9615.0,1969.0,,N,Intermediate,12500.0,1.0,,7423.0,,,
Plasma,1.0,A,Half-life in plasma of dog at dose of 3-10 mgkg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621562,,9615.0,1969.0,,N,Intermediate,12500.0,1.0,,7424.0,,,
,1.0,A,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621563,In vivo,9615.0,,,N,Intermediate,6005.0,1.0,,7425.0,,,
,1.0,A,Half-life was measured in dog after an iv dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621564,In vivo,9615.0,,,N,Intermediate,6062.0,1.0,,7426.0,,,
,1.0,A,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621565,In vivo,9615.0,,,N,Intermediate,17650.0,1.0,,7427.0,,,
,1.0,A,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621566,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,7428.0,,,
,1.0,A,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL621567,In vivo,9615.0,,,N,Intermediate,5530.0,1.0,,7429.0,,,
,1.0,A,Half-life of the compound after 0.3 mg/kg po administration in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL622978,In vivo,9615.0,,,N,Intermediate,5600.0,1.0,,7430.0,,,
,1.0,A,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL873814,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,7431.0,,,
,1.0,A,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623219,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,7432.0,,,
,1.0,A,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624477,In vivo,9615.0,,,N,Intermediate,6039.0,1.0,,7433.0,,,
,1.0,A,t1/2 in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624478,,9615.0,,,N,Intermediate,6227.0,1.0,,7434.0,,,
,1.0,A,Half-life period measured in dogs,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624479,,9615.0,,,N,Intermediate,14541.0,1.0,,7435.0,,,
,1.0,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL624480,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,7436.0,,,
,1.0,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623595,In vivo,9615.0,,,N,Intermediate,4521.0,1.0,,7437.0,,,
,1.0,A,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623596,In vivo,9615.0,,,N,Intermediate,6679.0,1.0,,7438.0,,,
Plasma,1.0,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623597,In vitro,9615.0,1969.0,,N,Intermediate,1116.0,1.0,,7439.0,,,
,1.0,A,In vivo half life period was calculated at 1 mg/kg in dog,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623598,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,7440.0,,,
,1.0,A,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623599,In vivo,9615.0,,,N,Intermediate,5444.0,1.0,,7441.0,,,
,1.0,A,Longer half-life in dog (i.v.) at 0.5 mpk,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623600,In vivo,9615.0,,,N,Intermediate,17853.0,1.0,,7442.0,,,
,1.0,A,Oral bioavailability in dog (dose 5 uM/kg),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623601,In vivo,9615.0,,,N,Intermediate,4353.0,1.0,,7443.0,,,
,1.0,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623602,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7444.0,,,
,1.0,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623603,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7445.0,,,
,1.0,A,Bioavailability in dog (dose 1 mg/kg i.v.),,,50588.0,BAO_0000218,Canis lupus familiaris,CHEMBL623604,In vivo,9615.0,,,N,Intermediate,16452.0,1.0,,7446.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623605,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7447.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623606,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7448.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623607,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7449.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623608,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7450.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623609,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7451.0,,,
Lung,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623610,In vivo,10090.0,2048.0,,N,Intermediate,10107.0,1.0,,7452.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623611,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7453.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623612,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7454.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623613,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7455.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623614,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7456.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623615,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7457.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623616,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7458.0,,,
Muscle tissue,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623617,In vivo,10090.0,2385.0,,N,Intermediate,10107.0,1.0,,7459.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL875944,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7460.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623618,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7461.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623619,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7462.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623620,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7463.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623621,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7464.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623622,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7465.0,,,
Zone of skin,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623623,In vivo,10090.0,14.0,,N,Intermediate,10107.0,1.0,,7466.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL623624,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7467.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618521,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7468.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618522,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7469.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618523,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7470.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618524,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7471.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL618525,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7472.0,,,
Spleen,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624586,In vivo,10090.0,2106.0,,N,Intermediate,10107.0,1.0,,7473.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624587,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7474.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624588,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7475.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624589,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7476.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624590,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7477.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624591,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7478.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624592,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7479.0,,,
Stomach,1.0,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,50594.0,BAO_0000218,Mus musculus,CHEMBL624593,In vivo,10090.0,945.0,,N,Intermediate,10107.0,1.0,,7480.0,,,
,1.0,A,Oral bioavailability in rat,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624594,In vivo,10116.0,,,N,Intermediate,4689.0,1.0,,7481.0,,,
,1.0,A,Tested for the bioavailability in rat,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624595,In vivo,10116.0,,,N,Intermediate,4950.0,1.0,,7482.0,,,
,1.0,A,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624596,In vivo,10116.0,,,N,Intermediate,5328.0,1.0,,7483.0,,,
,1.0,A,Bioavailability in rat,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624597,In vivo,10116.0,,,N,Intermediate,406.0,1.0,,7484.0,,,
,1.0,A,Bioavailability in rat,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624598,In vivo,10116.0,,,N,Intermediate,12500.0,1.0,,7485.0,,,
,1.0,A,Bioavailability in rat (dose 3-10 mg/kg),,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624599,In vivo,10116.0,,,N,Intermediate,12500.0,1.0,,7486.0,,,
,1.0,A,Bioavailability in rat,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL875166,In vivo,10116.0,,,N,Intermediate,5247.0,1.0,,7487.0,,,
Plasma,1.0,A,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624600,In vivo,10116.0,1969.0,,N,Intermediate,4186.0,1.0,,7488.0,,,
Plasma,1.0,A,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624601,In vivo,10116.0,1969.0,,N,Intermediate,4186.0,1.0,,7489.0,,,
,1.0,A,Half life after oral administration was determined in rats at 6 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624602,In vivo,10116.0,,,N,Intermediate,6647.0,1.0,,7490.0,,,
,1.0,A,Half life was determined,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624603,,10116.0,,,N,Intermediate,6484.0,1.0,,7491.0,,,
,1.0,A,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624604,In vivo,10116.0,,,N,Intermediate,3249.0,1.0,,7492.0,,,
Plasma,1.0,A,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624605,In vivo,10116.0,1969.0,,N,Intermediate,6281.0,1.0,,7493.0,,,
,1.0,A,Half life in rats,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624606,,10116.0,,,N,Intermediate,3307.0,1.0,,7494.0,,,
Blood,1.0,A,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624607,In vivo,10116.0,178.0,,N,Intermediate,12058.0,1.0,,7495.0,,,
,1.0,A,Hill coefficient of the compound,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624608,,10116.0,,,N,Intermediate,8833.0,1.0,,7496.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624609,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7497.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624610,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7498.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624611,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7499.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624612,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7500.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL875167,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7501.0,,,
Blood,1.0,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624613,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7502.0,,,
Blood,1.0,A,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624614,,10116.0,178.0,,N,Intermediate,3193.0,1.0,,7503.0,,,
,1.0,A,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624392,,10116.0,,,N,Intermediate,5960.0,1.0,,7504.0,,,
Brain,1.0,A,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624393,In vivo,10116.0,955.0,,N,Intermediate,13950.0,1.0,,7505.0,,,
Brain,1.0,A,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624394,In vivo,10116.0,955.0,,N,Intermediate,13950.0,1.0,,7506.0,,,
Brain,1.0,A,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624395,In vivo,10116.0,955.0,,N,Intermediate,13950.0,1.0,,7507.0,,,
Brain,1.0,A,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624396,In vivo,10116.0,955.0,,N,Intermediate,13950.0,1.0,,7508.0,,,
Brain,1.0,A,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624397,In vivo,10116.0,955.0,,N,Intermediate,13950.0,1.0,,7509.0,,,
Thyroid gland,1.0,A,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624398,In vivo,10116.0,2046.0,,N,Intermediate,13950.0,1.0,,7510.0,,,
Thyroid gland,1.0,A,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624399,In vivo,10116.0,2046.0,,N,Intermediate,13950.0,1.0,,7511.0,,,
Thyroid gland,1.0,A,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624400,In vivo,10116.0,2046.0,,N,Intermediate,13950.0,1.0,,7512.0,,,
Thyroid gland,1.0,A,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624401,In vivo,10116.0,2046.0,,N,Intermediate,13950.0,1.0,,7513.0,,,
Thyroid gland,1.0,A,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624402,In vivo,10116.0,2046.0,,N,Intermediate,13950.0,1.0,,7514.0,,,
Blood,1.0,A,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624403,In vivo,10116.0,178.0,,N,Intermediate,9866.0,1.0,,7515.0,,,
Blood,1.0,A,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624404,In vivo,10116.0,178.0,,N,Intermediate,9866.0,1.0,,7516.0,,,
Blood,1.0,A,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624405,In vivo,10116.0,178.0,,N,Intermediate,9866.0,1.0,,7517.0,,,
Bone,1.0,A,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624406,In vivo,10116.0,10000001.0,,N,Intermediate,9866.0,1.0,,7518.0,,,
Bone,1.0,A,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624407,In vivo,10116.0,10000001.0,,N,Intermediate,9866.0,1.0,,7519.0,,,
Bone,1.0,A,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL624408,In vivo,10116.0,10000001.0,,N,Intermediate,9866.0,1.0,,7520.0,,,
Heart,1.0,A,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL618644,In vivo,10116.0,948.0,,N,Intermediate,9866.0,1.0,,7521.0,,,
Heart,1.0,A,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL618645,In vivo,10116.0,948.0,,N,Intermediate,9866.0,1.0,,7522.0,,,
Heart,1.0,A,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,50597.0,BAO_0000218,Rattus norvegicus,CHEMBL618646,In vivo,10116.0,948.0,,N,Intermediate,9866.0,1.0,,7523.0,,,
